PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Beard, BL; Johnson, CM; Cox, L; Sun, H; Nealson, KH; Aguilar, C				Beard, BL; Johnson, CM; Cox, L; Sun, H; Nealson, KH; Aguilar, C			Iron isotope biosignatures	SCIENCE			English	Article								The Fe-56/Fe-54 of Fe-bearing phases precipitated in sedimentary environments varies by 2.5 per mil (delta(56)Fe values of +0.9 to -1.6 per mil). In contrast, the Fe-56/Fe-54 of Fe-bearing phases in igneous rocks from Earth and the moon does not vary measurably (delta(56)Fe = 0.0 +/- 0.3 per mil). Experiments with dissimilatory Fe-reducing bacteria of the genus Shewanella algae grown on a ferrihydrite substrate indicate that the delta(56)Fe of ferrous Fe in solution is isotopically Lighter than the ferrihydrite substrate by 1.3 per mil. Therefore, the range in delta(56)Fe values of sedimentary rocks may reflect biogenic fractionation, and the isotopic composition of Fe may be used to trace the distribution of microorganisms in modern and ancient Earth.	Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Wisconsin, Inst Great Lakes Study, Milwaukee, WI 53204 USA	University of Wisconsin System; University of Wisconsin Madison; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Wisconsin System; University of Wisconsin Milwaukee	Beard, BL (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.							BEARD BL, IN PRESS GEOCHIM COS; Bullen T.D., 1998, MINERAL MAG A, V62, P255; Bullen T. D., 1997, EOS, V78, pS173; CALDEIRA K, 1990, EXTINCTION EVENTS EA, P333, DOI DOI 10.1007/BFB0011156; Cornell RM., 1991, IRON OXIDES LAB PREP; DIXON PR, 1992, WATER ROCK INTERACTI, V2, P915; Friedman I., 1977, 440KK US GEOL SURV; JOHNSON CM, 1999, INT J MASS SPECTROM, V63, P1653; LIN CF, 1990, ENVIRON SCI TECHNOL, V24, P126, DOI 10.1021/es00071a016; LITTLE B, 1997, CORROSION 97; Marechal CN, 1999, CHEM GEOL, V156, P251, DOI 10.1016/S0009-2541(98)00191-0; Morgan E. H., 1994, IRON METABOLISM HLTH, P63; MYERS CR, 1994, J APPL BACTERIOL, V76, P253, DOI 10.1111/j.1365-2672.1994.tb01624.x; NEALSON KH, 1990, AM J SCI, V290A, P35; Schidlowski M., 1983, P149; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016	16	303	333	7	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1889	1892		10.1126/science.285.5435.1889	http://dx.doi.org/10.1126/science.285.5435.1889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489362				2022-12-01	WOS:000082638300042
J	Miralles, R; Gerrish, PJ; Moya, A; Elena, SF				Miralles, R; Gerrish, PJ; Moya, A; Elena, SF			Clonal interference and the evolution of RNA viruses	SCIENCE			English	Article							SPONTANEOUS MUTATION; FITNESS; POPULATIONS; ADAPTATION; RATES	In asexual populations, beneficial mutations that occur in different lineages compete with one another. This phenomenon, known as clonal interference, ensures that those beneficial mutations that do achieve fixation are of Large effect. Clonal interference also increases the time between fixations, thereby stowing the adaptation of asexual populations. The effects of clonal interference were measured in the asexual RNA virus vesicular stomatitis virus; rates and average effects of beneficial mutations were quantified.	Univ Valencia, Inst Cavanilles Biodiversitat & Biol Evolut, Valencia 46071, Spain; Univ Valencia, Dept Genet, Valencia 46071, Spain; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	University of Valencia; University of Valencia; Centers for Disease Control & Prevention - USA	Elena, SF (corresponding author), Univ Valencia, Inst Cavanilles Biodiversitat & Biol Evolut, Apartado 22085, Valencia 46071, Spain.		Gerrish, Philip/AAE-7346-2019; Elena, Santiago F./A-4191-2011; Moya, Andrés/A-8190-2008	Elena, Santiago F./0000-0001-8249-5593; Moya, Andrés/0000-0002-2867-1119; Gerrish, Philip/0000-0001-6393-0553				Burch CL, 1999, GENETICS, V151, P921; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; DELATORRE JC, 1990, J VIROL, V64, P6278, DOI 10.1128/JVI.64.12.6278-6281.1990; Drake JW, 1998, GENETICS, V148, P1667; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; Elena SF, 1998, EVOLUTION, V52, P309, DOI 10.1111/j.1558-5646.1998.tb01633.x; Escarmis C, 1999, J MOL BIOL, V285, P495, DOI 10.1006/jmbi.1998.2366; Fisher R.A., 1930, GENETICAL THEORY NAT; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Gillespie J.H., 1991, CAUSES MOL EVOLUTION; Hogg R.V., 1995, INTRO MATH STAT; HOLLAND JJ, 1991, J VIROL, V65, P2960, DOI 10.1128/JVI.65.6.2960-2967.1991; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Miralles R, 1999, J GEN VIROL, V80, P2051, DOI 10.1099/0022-1317-80-8-2051; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Novella IS, 1996, MOL GEN GENET, V252, P733, DOI 10.1007/BF02173980; Novella IS, 1999, J VIROL, V73, P1668, DOI 10.1128/JVI.73.2.1668-1671.1999; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; NOVELLA IS, 1995, J VIROL, V69, P2869, DOI 10.1128/JVI.69.5.2869-2872.1995; Orr HA, 1998, EVOLUTION, V52, P935, DOI 10.1111/j.1558-5646.1998.tb01823.x; Otto SP, 1997, GENETICS, V147, P879; VANDEPOL SB, 1986, VIROLOGY, V148, P312, DOI 10.1016/0042-6822(86)90328-4	23	207	208	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1745	1747		10.1126/science.285.5434.1745	http://dx.doi.org/10.1126/science.285.5434.1745			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481012				2022-12-01	WOS:000082472600038
J	Peters, M; Petros, A; Dixon, G; Inwald, D; Klein, N				Peters, M; Petros, A; Dixon, G; Inwald, D; Klein, N			Acquired immunoparalysis in paediatric intensive care: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							MONOCYTE		Inst Child Hlth, Portex Dept Anaesthesia Intens Therapy & Resp Med, London WC1N 3EH, England; Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, London WC1N 3JH, England; Inst Child Hlth, Immunobiol Unit, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Peters, M (corresponding author), Inst Child Hlth, Portex Dept Anaesthesia Intens Therapy & Resp Med, London WC1N 3EH, England.			Inwald, David/0000-0001-9518-7821; Klein, Nigel/0000-0003-3925-9258; Peters, Mark/0000-0003-3653-4808; Dixon, Garth/0000-0001-8165-3094				ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Schinkel C, 1998, J TRAUMA, V44, P743, DOI 10.1097/00005373-199805000-00001; WILKINSON JD, 1986, CRIT CARE MED, V14, P271, DOI 10.1097/00003246-198604000-00002; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609	5	20	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					609	610		10.1136/bmj.319.7210.609	http://dx.doi.org/10.1136/bmj.319.7210.609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473475	Bronze, Green Published			2022-12-01	WOS:000082460300019
J	Richards, AM; Nicholls, MG				Richards, AM; Nicholls, MG			Aldosterone antagonism in heart failure	LANCET			English	Editorial Material							SECONDARY		Christchurch Sch Med, Cardioendocrine Res Grp, Christchurch, New Zealand	University of Otago	Richards, AM (corresponding author), Christchurch Sch Med, Cardioendocrine Res Grp, POB 4345, Christchurch, New Zealand.							BARR CS, 1995, AM J CARDIOL, V76, P1259, DOI 10.1016/S0002-9149(99)80353-1; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; Hjalmarson A, 1999, LANCET, V353, P2001; Lechat P, 1999, LANCET, V353, P9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pitt B, 1996, AM J CARDIOL, V78, P902; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Struthers A D, 1996, J Card Fail, V2, P47, DOI 10.1016/S1071-9164(96)80009-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Volpe M, 1997, HYPERTENSION, V30, P168, DOI 10.1161/01.HYP.30.2.168	11	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					789	790						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485716				2022-12-01	WOS:000082400700003
J	Jomaa, H; Wiesner, J; Sanderbrand, S; Altincicek, B; Weidemeyer, C; Hintz, M; Turbachova, I; Eberl, M; Zeidler, J; Lichtenthaler, HK; Soldati, D; Beck, E				Jomaa, H; Wiesner, J; Sanderbrand, S; Altincicek, B; Weidemeyer, C; Hintz, M; Turbachova, I; Eberl, M; Zeidler, J; Lichtenthaler, HK; Soldati, D; Beck, E			Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs	SCIENCE			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; MEVALONATE-INDEPENDENT PATHWAY; PARASITE TOXOPLASMA-GONDII; TERPENOID BIOSYNTHESIS; HIGHER-PLANTS; ISOPENTENYL DIPHOSPHATE; APICOMPLEXAN PARASITES; PLASMODIUM-FALCIPARUM; ERYTHROCYTES; FOSMIDOMYCIN	A mevalonate-independent pathway of isoprenoid biosynthesis present in Plasmodium falciparum was shown to represent an effective target for chemotherapy of malaria. This pathway includes 1-deoxy-D-xylulose 5-phosphate (DOXP) as a key metabolite. The presence of two genes encoding the enzymes DOXP synthase and DOXP reductoisomerase suggests that isoprenoid biosynthesis in P. falciparum depends on the DOXP pathway. This pathway is probably Located in the apicoplast. The recombinant P, falciparum DOXP reductoisomerase was inhibited by fosmidomycin and its derivative, FR-900098. Both drugs suppressed the in vitro growth of multidrug-resistant P. falciparum strains. After therapy with these drugs, mice infected with the rodent malaria parasite P. vinckei were cured.	Univ Giessen, Acad Hosp Ctr, Inst Biochem, D-35392 Giessen, Germany; Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Karlsruhe, Inst Bot 1, D-76128 Karlsruhe, Germany	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology	Jomaa, H (corresponding author), Univ Giessen, Acad Hosp Ctr, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	hassan.jomaa@biochemie.med.uni-giessen.de	Eberl, Matthias/A-5970-2009; Soldati-Favre, Dominique/A-2999-2009; Altincicek, Boran/C-1191-2009	Eberl, Matthias/0000-0002-9390-5348; Altincicek, Boran/0000-0003-2019-452X				Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; Disch A, 1998, BIOCHEM J, V333, P381, DOI 10.1042/bj3330381; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; GRELLIER P, 1994, ANTIMICROB AGENTS CH, V38, P1144, DOI 10.1128/AAC.38.5.1144; KAMIYA T, 1980, Patent No. 4206156; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KUEMMERLE HP, 1987, CHEMIOTERAPIA, V6, P113; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lichtenthaler HK, 1997, PHYSIOL PLANTARUM, V101, P643, DOI 10.1111/j.1399-3054.1997.tb01049.x; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Lichtenthaler HK, 1997, FEBS LETT, V400, P271, DOI 10.1016/S0014-5793(96)01404-4; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MURAKAWA T, 1982, ANTIMICROB AGENTS CH, V21, P224, DOI 10.1128/AAC.21.2.224; OHLER E, 1995, SYNTHESIS-STUTTGART, P539; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; PETERS W, 1980, MALARIA, V1, P160; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Schwender J, 1997, FEBS LETT, V414, P129, DOI 10.1016/S0014-5793(97)01002-8; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VACEROAKBANI A, IN PRESS METHODS EN; VIAL HJ, 1984, MOL BIOCHEM PARASIT, V13, P53, DOI 10.1016/0166-6851(84)90101-4; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	33	940	983	2	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1573	1576		10.1126/science.285.5433.1573	http://dx.doi.org/10.1126/science.285.5433.1573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477522				2022-12-01	WOS:000082359500067
J	Suh, YA; Arnold, RS; Lassegue, B; Shi, J; Xu, XX; Sorescu, D; Chung, AB; Griendling, KK; Lambeth, JD				Suh, YA; Arnold, RS; Lassegue, B; Shi, J; Xu, XX; Sorescu, D; Chung, AB; Griendling, KK; Lambeth, JD			Cell transformation by the superoxide-generating oxidase Mox1	NATURE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; MAMMALIAN-CELLS; ANION; CYTOCHROME-B558; HYPERTROPHY; FIBROBLASTS; EXPRESSION	Reactive oxygen species (ROS) generated in some non-phagocytic cells are implicated in mitogenic signalling and cancer(1-6). Many cancer cells show increased production of ROS7, and normal cells exposed to hydrogen peroxide or superoxide show increased proliferations and express growth-related genes(9-11). ROS are generated in response to growth factors, and may affect cell growth(2,3,12,13), for example in vascular smooth-muscle cells(6,13-15) Increased ROS in Ras-transformed fibroblasts correlates with increased mitogenic rate(16). Here we describe the cloning of mox1, which encodes a homologue of the catalytic subunit of the superoxide-generating NADPH oxidase of phagocytes(17,18), gp91phox. mox1 messenger RNA is expressed in colon, prostate, uterus and vascular smooth muscle, but not in peripheral blood leukocytes. In smooth-muscle cells, platelet-derived growth factor induces mox1 mRNA production, while antisense mox1 mRNA decreases superoxide generation and serum-stimulated growth. Overexpression of mox1 in NIH3T3 cells increases superoxide generation and cell growth, Cells expressing mox1 have a transformed appearance, show,anchorage-independent growth and produce tumours in athymic mice. These data link ROS production by Mox1 to growth control in non-phagocytic cells.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582; Lassegue, Bernard/0000-0003-4924-6506				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERK BC, 1990, J BIOL CHEM, V265, P19632; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CRAWFORD D, 1988, ONCOGENE, V3, P27; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; FLINT DH, 1994, ARCH BIOCHEM BIOPHYS, V311, P509, DOI 10.1006/abbi.1994.1269; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WOLIN MS, 1991, KLIN WOCHENSCHR, V69, P1046, DOI 10.1007/BF01645156; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	29	1226	1289	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					79	82		10.1038/43459	http://dx.doi.org/10.1038/43459			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485709				2022-12-01	WOS:000082374400045
J	Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, B				Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, B			Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODERATE HYPOGLYCEMIA; AWARENESS; ADULTS; IDDM	Context Laboratory studies have shown impairments in driving performance among subjects with type 1 diabetes mellitus when their blood glucose (BG) level is between 2.6 and 3.6 mmol/L (47-65 mg/dL), However, to our knowledge, no data exist examining subjects' decisions to drive at various BC levels during their daily routine, Objective To examine type 1 diabetic subjects' decisions to drive during their daily routine based on perception of BG levels compared with actual measured BC; levels. Design and Setting Two separate groups of patients were recruited 2 years apart from 4 academic medical centers. Participants All subjects were adults with type 1 diabetes who were drivers and who performed at least 2 BC tests per day. Group 1 (initial) subjects (n = 65) had a mean (SD) age of 38.6 (8.9) years with a mean (SD) diabetes duration of 20.5 (10.6) years, were taking 38.8 (16.8) U/d of insulin, and had a mean (SD) glycosylated hemoglobin (HbA(1)) level of 10.0% (1.9%), Group 2 (replication) subjects (n = 93) were 35.8 (8.0) years old with a mean diabetes duration of 17.0 (10.6) years, were taking 40.0 (15.5) U/d of insulin, and had a mean (SD) HbA(1) level of 8.5% (1.6%). Each subject used a handheld computer to record data on symptoms, cognitive function, insulin dosage, food, activity, estimated and actual BC levels, and whether he/she would drive. Data were entered 3 to 6 times per day for a total of 50 to 70 collections per subject during a 3- to 4-week period. Main outcome Measures Decisions to drive when subjects estimated their BC level to be less than 2.2 mmol/L (40 mg/dL), 2.2 to 2.8 mmol/L (40-50 mg/dL), 2.8 to 3.3 mmol/L (50-60 mg/dL), 3.3 to 3.9 mmol/L (60-70 mg/dL), 3.9 to 10 mmol/L (70-180 mg/dL), and more than 10 mmol/L (>180 mg/dL), and driving decisions when actual BG levels were in these ranges. Results Subjects stated they would drive 43% to 44% of the time when they estimated their BG level to be 3.3 to 3.9 mmol/L (60-70 mg/dL), and 38% to 47% of the time when their actual BC level was less than 2.2 mmol/L (40 mg/dL), Logistic regression analysis demonstrated that number of autonomic symptoms, degree of impairment on cognitive function tests, and BC level estimate predicted 76% to 80% of decisions to drive (P < .01 for all). Approximately 50% of subjects in each group decided to drive at least 50% of the time when their BG level was less than 3.9 mmol/L (70 mg/dL), Conclusions Our data suggest that persons with type 1 diabetes may not judge correctly when their BC level is too low to permit safe driving and may consider driving with a low BC level even when they are aware of the low level. Health care professionals should counsel their patients about the risk of driving with hypoglycemia and the importance of measuring BG level before driving.	Univ Virginia, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Psychiat Med, Behav Med Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Clarke, WL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Box 386, Charlottesville, VA 22908 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028288] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00847] Funding Source: Medline; NIDDK NIH HHS [R01-DK-28288] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM DIAB ASS NAT C, 1996, PROV REC PROGR; Clarke WL, 1997, DIABETES EDUCATOR, V23, P55, DOI 10.1177/014572179702300107; COX D, 1995, DIABETES CARE, V18, P523, DOI 10.2337/diacare.18.4.523; COX D, IN PRESS DIABETES CA; COX DJ, 1993, DIABETES CARE, V16, P519, DOI 10.2337/diacare.16.2.519; COX DJ, 1993, DIABETES, V42, P239, DOI 10.2337/diabetes.42.2.239; COX DJ, 1994, DIABETES CARE, V17, P1, DOI 10.2337/diacare.17.1.1; Kovatchev B, 1998, HEALTH PSYCHOL, V17, P277, DOI 10.1037/0278-6133.17.3.277; QUILLIAN WC, 1994, DIABETES CARE, V17, P1367, DOI 10.2337/diacare.17.11.1367	9	50	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					750	754		10.1001/jama.282.8.750	http://dx.doi.org/10.1001/jama.282.8.750			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463710				2022-12-01	WOS:000082118800026
J	Whitehouse, I; Flaus, A; Cairns, BR; White, MF; Workman, JL; Owen-Hughes, T				Whitehouse, I; Flaus, A; Cairns, BR; White, MF; Workman, JL; Owen-Hughes, T			Nucleosome mobilization catalysed by the yeast SWI/SNF complex	NATURE			English	Article							REMODELING FACTOR; HOLLIDAY JUNCTION; MOBILITY; BINDING; TRANSCRIPTION; RESOLUTION; ISWI; RSC; DNA	The generation of a local chromatin topology conducive to transcription is a key step in gene regulation(1). The yeast SWI/SNF complex is the founding member of a family of ATP-dependent remodelling activities capable of altering chromatin structure both in vitro and in vivo(2). Despite its importance, the pathway by which the SWI/SNF complex disrupts chromatin structure is unknown. Here we use a model system to demonstrate that the yeast SWI/SNF complex can reposition nucleosomes in an ATP-dependent reaction that favours attachment of the histone octamer to an acceptor site on the same molecule of DNA (in cis), We show that SWI/SNF-mediated displacement of the histone octamer is effectively blocked by a barrier introduced into the DNA, suggesting that this redistribution involves sliding or tracking of nucleosomes along DNA, and that it is achieved by a catalytic mechanism. We conclude that SWI/SNF catalyses the redistribution of nucleosomes along DNA in cis, which may represent a general mechanism by which ATP-dependent chromatin remodelling occurs.	Univ Dundee, Div Gene Regulat, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Huntsman Canc Inst, Salt Lake City, UT 84108 USA; Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Dundee; University of Dundee; Huntsman Cancer Institute; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Owen-Hughes, T (corresponding author), Univ Dundee, Div Gene Regulat, Wellcome Trust Bldg, Dundee DD1 5EH, Scotland.		White, Malcolm F/A-6055-2010; Flaus, Andrew/D-5076-2011	White, Malcolm F/0000-0003-1543-9342; Flaus, Andrew/0000-0002-5720-7139; Whitehouse, Iestyn/0000-0003-0385-3116; Owen-Hughes, Tom/0000-0002-0618-8185	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Grigoriev M, 1997, MOL CELL BIOL, V17, P7139, DOI 10.1128/MCB.17.12.7139; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; van Holde KE, 1985, STRUCTURE FUNCTION G, P35, DOI DOI 10.1007/978-1-4684-5024-8_4; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	29	268	275	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					784	787		10.1038/23506	http://dx.doi.org/10.1038/23506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466730				2022-12-01	WOS:000082131100055
J	Stein, R; Sherrill, D; Morgan, WJ; Holberg, CJ; Halonen, M; Taussig, LM; Wright, AL; Martinez, FD				Stein, R; Sherrill, D; Morgan, WJ; Holberg, CJ; Halonen, M; Taussig, LM; Wright, AL; Martinez, FD			Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years	LANCET			English	Article							LUNG-FUNCTION; EARLY-CHILDHOOD; 1ST YEAR; AIRWAY RESPONSIVENESS; TRACT ILLNESS; SERUM IGE; ASTHMA; BRONCHIOLITIS; CHILDREN; RESPONSES	Background The relation between lower respiratory tract illnesses in early life caused by the respiratory syncytial virus (RSV) and the subsequent development of wheezing acid atopy in childhood is not well understood. We studied this relation in children who had lower respiratory tract illnesses that occurred before 3 years of age. Methods Children were enrolled at birth and cases of lower respiratory tract illness were ascertained by a physician. Viral tests were done for specimens collected at the time of the illness. Children were classified into five groups according to type and cause of lower respiratory tract illness. Children were then followed prospectively up to age 13, and we measured frequency of wheezing, pulmonary function, and atopic status (allergy skin-prick tests, serum IgE concentrations). Findings RSV lower respiratory tract illnesses were associated with an increased risk of infrequent wheeze (odds ratio 3.2 [95% CI 2.0-5.0], p<0.001), and an increased risk of frequent wheeze (4.3 [2.2-8.7], p less than or equal to 0.001) by age 6, Risk decreased markedly with age and was not significant by age 13. There was no association between RSV lower respiratory tract illnesses and subsequent atopic status. RSV lower respiratory tract illnesses were associated with significantly lower measurements of forced expiratory volume (2.11 [2.05-2.15], p less than or equal to 0.001) when compared with those of children with no lower respiratory tract illnesses, but there was no difference in forced expiratory volume after inhalation of salbutamol. Interpretation RSV lower respiratory tract illnesses in early childhood are an independent risk factor for the subsequent development of wheezing up to age 11 years but not at ape 13. This association is not caused by an increased risk of allergic sensitisation.	Pontiflcia Univ Catolica RS, Dept Pediat, Pediat Pulm Sect, Porto Alegre, RS, Brazil; Univ Arizona, Resp Sci Ctr, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Arizona; National Jewish Health	Martinez, FD (corresponding author), POB 245030, Tucson, AZ 85724 USA.		Stein, Renato Tetelbom/K-2568-2014; Stein, Renato T/G-2975-2012	Halonen, Marilyn/0000-0001-9606-935X; STEIN, RENATO/0000-0003-0269-0757	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03154, R01 HL-56177] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1302, DOI 10.1164/ajrccm.152.4.7551386; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Colasurdo GN, 1998, AM J RESP CRIT CARE, V157, P1506, DOI 10.1164/ajrccm.157.5.9705026; COLASURDO GN, 1995, AM J PHYSIOL-LUNG C, V268, pL1006, DOI 10.1152/ajplung.1995.268.6.L1006; GLEZEN WP, 1981, J PEDIATR, V98, P702; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HALONEN M, 1999, IN PRESS AM J RESP C; Hanrahan JP, 1996, AM J RESP CRIT CARE, V154, P670, DOI 10.1164/ajrccm.154.3.8810604; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Larsen GL., 1998, RSV ASTHMA IS THERE, P17; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MCCONNOCHIE KM, 1985, AM J DIS CHILD, V139, P625, DOI 10.1001/archpedi.1985.02140080095042; MURRAY M, 1992, ARCH DIS CHILD, V67, P482, DOI 10.1136/adc.67.4.482; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PULLAN CR, 1982, BRIT MED J, V284, P165; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SIGURS N, 1995, PEDIATRICS, V95, P500; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; STROPE GL, 1991, AM REV RESPIR DIS, V144, P655, DOI 10.1164/ajrccm/144.3_Pt_1.655; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TAUSSIG LM, 1993, AM REV RESPIR DIS, V147, pA375; TEPPER RS, 1992, PEDIATR PULM, V13, P6, DOI 10.1002/ppul.1950130104; VOTER KZ, 1988, AM REV RESPIR DIS, V137, P302, DOI 10.1164/ajrccm/137.2.302; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WELLIVER RC, 1998, RSV ASTHMA IS THERE, P21; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	34	1104	1149	1	54	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					541	545		10.1016/S0140-6736(98)10321-5	http://dx.doi.org/10.1016/S0140-6736(98)10321-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470697				2022-12-01	WOS:000081991000010
J	Musaro, A; McCullagh, KJA; Naya, FJ; Olson, EN; Rosenthal, N				Musaro, A; McCullagh, KJA; Naya, FJ; Olson, EN; Rosenthal, N			IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1	NATURE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; NF-AT; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; TRANSGENIC MICE; GROWTH-FACTORS; MUSCLE-CELLS; ACTIVATION; MORPHOGENESIS	Localized synthesis of insulin-like growth factors (IGFs) has been broadly implicated in skeletal muscle growth, hypertrophy and regeneration(1). Virally delivered IGF-1 genes induce local skeletal muscle hypertrophy and attenuate age-related skeletal muscle atrophy, restoring and improving muscle mass and strength in mice(2), Here we show that the molecular pathways underlying the hypertrophic action of IGF-1 in skeletal muscle are similar to those responsible for cardiac hypertrophy, Transfected IGF-1 gene expression in postmitotic skeletal myocytes activates calcineurin-mediated calcium signalling by inducing calcineurin transcripts and nuclear localization of calcineurin protein. Expression of activated calcineurin mimics the effects of IGF-1, whereas expression of a dominant-negative calcineurin mutant or addition of cyclosporin, a calcineurin inhibitor, represses myocyte differentiation and hypertrophy. Either IGF-1 or activated calcineurin induces expression of the transcription factor GATA-2, which accumulates in a subset of myocyte nuclei, where it associates with calcineurin and a specific dephosphorylated isoform of the transcription factor NF-ATc1. Thus, IGF-1 induces calcineurin-mediated signalling and activation of GATA-2, a marker of skeletal muscle hypertrophy, which cooperates with selected NF-ATc isoforms to activate gene expression programs.	Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75225 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosenthal, N (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Musaro, Antonio/P-2953-2019; Musarò, Antonio/K-9598-2016	Musaro, Antonio/0000-0002-2944-9739; Musarò, Antonio/0000-0002-2944-9739; Rosenthal, Nadia/0000-0002-7599-7365				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MITSUMOTO Y, 1992, FEBS LETT, V301, P94, DOI 10.1016/0014-5793(92)80217-5; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Muramatsu T, 1996, BIOCHEM BIOPH RES CO, V218, P466, DOI 10.1006/bbrc.1996.0083; Musaro A, 1999, MOL CELL BIOL, V19, P3115; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	30	529	546	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					581	585		10.1038/23060	http://dx.doi.org/10.1038/23060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448862				2022-12-01	WOS:000081854800060
J	Norman, TC; Smith, DL; Sorger, PK; Drees, BL; O'Rourke, SM; Hughes, TR; Roberts, CJ; Friend, SH; Fields, S; Murray, AW				Norman, TC; Smith, DL; Sorger, PK; Drees, BL; O'Rourke, SM; Hughes, TR; Roberts, CJ; Friend, SH; Fields, S; Murray, AW			Genetic selection of peptide inhibitors of biological pathways	SCIENCE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; STAPHYLOCOCCAL NUCLEASE; RESPONSE PATHWAY; PROTEIN; KINASE; IDENTIFICATION; ACTIVATION; PHEROMONE	Genetic selections were used to find peptides that inhibit biological pathways in budding yeast. The peptides were presented inside cells as peptamers, surface loops on a highly expressed and biologically inert carrier protein, a catalytically inactive derivative of staphylococcal nuclease, Peptamers that inhibited the pheromone signaling pathway, transcriptional silencing, and the spindle checkpoint were isolated. Putative targets for the inhibitors were identified by a combination of two-hybrid analysis and genetic dissection of the target pathways. This analysis identified Ydr517w as a component of the spindle checkpoint and reinforced earlier indications that Ste50 has both positive and negative roles in pheromone signaling. Analysis of transcript arrays showed that the peptamers were highly specific in their effects, which suggests that they may be useful reagents in organisms that lack sophisticated genetics as well as for identifying components of existing biological pathways that are potential targets for drug discovery.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Rosetta Pharmaceut, Kirkland, WA 98034 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Norman, TC (corresponding author), Microbia Inc, 840 Mem Dr, Cambridge, MA 02139 USA.			Sorger, Peter/0000-0002-3364-1838	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR11823] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; CHAMBERS A, 1988, NUCLEIC ACIDS RES, V16, P8245, DOI 10.1093/nar/16.17.8245; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; James P, 1996, GENETICS, V144, P1425; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; NORMAN TC, UNPUB; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; RAD MR, 1992, MOL GEN GENET, V236, P145; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Singer MS, 1998, GENETICS, V150, P613; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75	36	153	170	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					591	595		10.1126/science.285.5427.591	http://dx.doi.org/10.1126/science.285.5427.591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417390				2022-12-01	WOS:000081609500040
J	Weliky, M; Katz, LC				Weliky, M; Katz, LC			Correlational structure of spontaneous neuronal activity in the developing lateral geniculate nucleus in vivo	SCIENCE			English	Article							ORIENTATION PREFERENCE MAPS; OCULAR DOMINANCE COLUMNS; RETINAL GANGLION-CELLS; CAT VISUAL-CORTEX; STRIATE CORTEX; IN-VITRO; PERIGENICULATE NUCLEUS; ORDERED ARRANGEMENT; BURSTING ACTIVITY; MAMMALIAN RETINA	The properties of spontaneous activity in the developing visual pathway beyond the retina are unknown. Multielectrode recordings in the lateral geniculate nucleus (LGN) of awake behaving ferrets, before eye opening, revealed patterns of spontaneous activity that reflect a reshaping of retinal drive within higher visual stages. Significant binocular correlations were present only when corticothalamic feedback was intact. In the absence of retinal drive, cortico-thalamic feedback was required to sustain correlated LGN bursting. Activity originating from the contralateral eye drove thalamic activity far more strongly than that originating from the ipsilateral eye. Thus, in vivo patterns of LGN spontaneous activity emerge from interactions between retina, thalamus, and cortex.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Weliky, M (corresponding author), Univ Rochester, Dept Brain & Cognit Sci, Meljora Hall, Rochester, NY 14627 USA.							BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Contreras D, 1996, SCIENCE, V274, P771, DOI 10.1126/science.274.5288.771; COULTER DA, 1993, BRAIN RES, V631, P137, DOI 10.1016/0006-8993(93)91199-3; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Erwin E, 1998, J NEUROSCI, V18, P9870; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Godwin DW, 1996, J NEUROSCI, V16, P8181; HOLLANDER H, 1972, BRAIN RES, V41, P464, DOI 10.1016/0006-8993(72)90516-1; Horton JC, 1996, J NEUROSCI, V16, P1791; HU B, 1989, NEUROSCIENCE, V31, P13, DOI 10.1016/0306-4522(89)90027-4; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; Kao CQ, 1997, J NEUROPHYSIOL, V77, P2661, DOI 10.1152/jn.1997.77.5.2661; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; LO FS, 1994, EXP BRAIN RES, V100, P365; LU SM, 1993, VISUAL NEUROSCI, V10, P631, DOI 10.1017/S0952523800005332; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1994, J NEUROSCI, V14, P409; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Murphy PC, 1996, J NEUROSCI, V16, P1180; MURPHY PC, 1994, VISUAL NEUROSCI, V11, P781, DOI 10.1017/S0952523800003084; PETTIGREW JD, 1974, J PHYSIOL-LONDON, V237, P49, DOI 10.1113/jphysiol.1974.sp010469; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SWINDALE NV, 1980, PROC R SOC SER B-BIO, V208, P243, DOI 10.1098/rspb.1980.0051; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	37	207	210	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					599	604		10.1126/science.285.5427.599	http://dx.doi.org/10.1126/science.285.5427.599			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417392				2022-12-01	WOS:000081609500042
J	Stapleton, JA; Lowin, A; Russell, MAH				Stapleton, JA; Lowin, A; Russell, MAH			Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness	LANCET			English	Article							RANDOMIZED TRIAL; ADJUNCT	Background The 1998 UK government White Paper Smoking Kills emphasises that normal practice should be for general practitioners (GPs), practice nurses, and others to offer advice and support to smokers in their efforts to stop. However, GPs are not allowed to write NHS prescriptions for nicotine-replacement therapy, even though this is the only effective pharmceutical treatment available in the UK. We estimated the cost-effectiveness, for the NHS, of allowing GPs to prescribe transdermal nicotine patches for up to 12 weeks. Methods We used data from a randomised, placebo-controlled efficacy trial of nicotine patches and a survey of associated resource use in 30 GP surgeries in 15 English counties. We calculated the health benefit of nicotine-patch treatment in number of life years that would be saved by stopping smoking at various ages, and used an abstinence-contingent treatment model to calculate the incremental cost per life year saved by GP counselling with nicotine-patch treatment over GP counselling alone. Cost effectiveness was assessed on the basis that GPs would provide repeat NHS prescriptions for up to 12 weeks if the treatment was proving successful. Findings If GPs were allowed to prescribe transdermal nicotine patches on the NHS, for up to 12 weeks, the incremental cost per life year saved would be: pound 398 per person younger than 35 years; pound 345 for those aged 35-44 years; pound 432 for those aged 45-54 years; and pound 785 for those aged 55-65 years. Interpretation The low cost per life year saved would make GP intervention against smoking a cost-effective life-saving treatment. The priniciples of the government White Paper could be cost-effectively extended into general practice to reduce smoking and smoking-related illnesses.	Inst Psychiat, Tobacco Res Sect, London SE5 8AF, England; Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; Univ Sydney, Ctr Hlth Econ & Evaluat, Sydney, NSW 2006, Australia	University of London; King's College London; University of London; King's College London; University of Sydney	Stapleton, JA (corresponding author), Inst Psychiat, Tobacco Res Sect, London SE5 8AF, England.		Stapleton, John A/I-6550-2012					Akehurst R, 1994, BR J MED EC, V7, P115; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; BURKE P, 1994, BRIT MED J, V308, P1476; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; *DEP HLTH, 1995, HLTH NAT POL APPR HL; Department of Health, 1998, SMOK KILLS WHIT PAP; Department of Physical Education Teaching Materials Compilation Committee the writing group calisthenics teaching, 1990, BLOOD CHOL TEST COST, P1; Dey P, 1999, BRIT J GEN PRACT, V49, P127; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Fiscella K, 1996, JAMA-J AM MED ASSOC, V275, P1247, DOI 10.1001/jama.275.16.1247; HAM C, 1995, BR J HLTH CARE MANAG, V1, P27; JARVIS M, 1988, BRIT J ADDICT, V83, P323; JARVIS MJ, 1996, COMMUNICATION; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; Mikkelsen K, 1994, J SMOK REL DIS, V5, P95; Netten A, 1998, UNIT COSTS HLTH SOCI; *OFF NAT STAT, 1998, LIV BRIT RES 1996 GE; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PARROTS S, 1999, THORAX S5, V53, pS1; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1994, MORTALITY TOBACCO DE; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SILAGY C, 1999, COCHRANE LIBRARY; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; Stapleton JA, 1998, BRIT MED J, V316, P830, DOI 10.1136/bmj.316.7134.830; Tonnesen P, 1999, EUR RESPIR J, V13, P238, DOI 10.1034/j.1399-3003.1999.13b04.x; Torrance GW, 1987, METHODS EC EVALUATIO; Wasley MA, 1997, PREV MED, V26, P264, DOI 10.1006/pmed.1996.0127; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; Yudkin PL, 1996, BRIT J GEN PRACT, V46, P145	30	64	64	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					210	215		10.1016/S0140-6736(99)90001-6	http://dx.doi.org/10.1016/S0140-6736(99)90001-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421303				2022-12-01	WOS:000081504200013
J	Kosunen, E; Vikat, A; Rimpela, M; Rimpela, A; Huhtala, H				Kosunen, E; Vikat, A; Rimpela, M; Rimpela, A; Huhtala, H			Questionnaire study of use of emergency contraception among teenagers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							KNOWLEDGE	Easy accessibility and availability of emergency contraception raises contradictory opinions. Education about emergency contraception is resisted because of a fear that it might lead to irresponsible sexual behaviour and repeated use of emergency contraception instead of regular contraception.(1) In Finland, sales of emergency contraception (the Yuzpe method) increased 10-fold from 1987 to the mid-1990s. In 1994 a national survey among 18-44 year old women showed that knowledge and use of the method was concentrated in the youngest respondents.(2) Reports from other countries confirm that young women and even teenagers are well aware of the method.(3) (4) However, only a few reports have been published on use of emergency contraception among adolescents. We studied knowledge of emergency contraception and frequency of use among teenagers.	Tampere Univ, Sch Med, Dept Gen Practice, FIN-33101 Tampere, Finland; Tampere Univ, Sch Publ Hlth, FIN-33101 Tampere, Finland; Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland	Tampere University; Tampere University	Kosunen, E (corresponding author), Tampere Univ, Sch Med, Dept Gen Practice, POB 607, FIN-33101 Tampere, Finland.	meelko@uta.fi	Rimpela, Arja/J-3910-2014					Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; Kosunen E, 1997, CONTRACEPTION, V55, P153, DOI 10.1016/S0010-7824(97)00022-X; RIMPELA M, 1996, INT J HLTH PROMOTION, V3, P28; Smith BH, 1996, BRIT J OBSTET GYNAEC, V103, P1109, DOI 10.1111/j.1471-0528.1996.tb09592.x; Stubblefield P, 1998, NEW ENGL J MED, V339, P41, DOI 10.1056/NEJM199807023390108	5	25	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					91	91		10.1136/bmj.319.7202.91	http://dx.doi.org/10.1136/bmj.319.7202.91			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398631	Bronze, Green Published			2022-12-01	WOS:000081438200030
J	Jimenez, GS; Bryntesson, F; Torres-Arzayus, MI; Priestley, A; Beeche, M; Saito, S; Sakaguchi, K; Appella, E; Jeggo, PA; Taccioli, GE; Wahl, GM; Hubank, M				Jimenez, GS; Bryntesson, F; Torres-Arzayus, MI; Priestley, A; Beeche, M; Saito, S; Sakaguchi, K; Appella, E; Jeggo, PA; Taccioli, GE; Wahl, GM; Hubank, M			DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL-CYCLE ARREST; V(D)J RECOMBINATION; P53; GROWTH; MICE; GENE; PK	Damage to DNA in the cell activates the tumour-suppressor protein p53 (ref. 1), and failure of this activation leads to genetic instability and a predisposition to cancer, It is therefore crucial to understand the signal transduction mechanisms that connect DNA damage with p53 activation. The enzyme known as DNA-dependent protein kinase (DNA-PK) has been proposed to be an essential activator of p53 (refs 2, 3), but the evidence for its involvement in this pathway is controversial(3,4). We now show that the p53 response is fully functional in primary mouse embryonic fibroblasts lacking DNA-PK: irradiation-induced DNA damage in these defective fibroblasts induces a normal response of p53 accumulation, phosphorylation of a p53 serine residue at position 15, nuclear localization and binding to DNA of p53. The upregulation of p53-target genes and cell-cycle arrest also occur normally. The DNA-PR-deficient cell line SCGR11 contains a homozygous mutation in the DNA-binding domain of p53, which may explain the defective response by p53 reported in this line(3), Our results indicate that DNA-PK activity is not required for cells to mount a p53-dependent response to DNA damage.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Sussex, Trafford Ctr, Brighton BN1 9RY, E Sussex, England; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Salk Institute; University of Brighton; University of Sussex; Boston University; University of Sussex; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Hubank, Michael JF/C-1837-2008	Hubank, Michael JF/0000-0002-2901-0742; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Huang LC, 1996, CANCER RES, V56, P2940; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jongmans W, 1996, ONCOGENE, V13, P1133; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rathmell WK, 1997, CANCER RES, V57, P68; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	19	113	116	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					81	83		10.1038/21913	http://dx.doi.org/10.1038/21913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403253				2022-12-01	WOS:000081255700055
J	Bohni, R; Riesgo-Escovar, J; Oldham, S; Brogiolo, W; Stocker, H; Andruss, BF; Beckingham, K; Hafen, E				Bohni, R; Riesgo-Escovar, J; Oldham, S; Brogiolo, W; Stocker, H; Andruss, BF; Beckingham, K; Hafen, E			Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4	CELL			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASE; GROWTH-FACTORS; C-ELEGANS; LIFE-SPAN; MICE; GENE; CYCLE; DIVISION	The control of growth is fundamental to the developing metazoan. Here, we show that CHICO, a Drosophila homolog of vertebrate IRS1-4, plays an essential role in the control of cell size and growth. Animals mutant for chico are less than half the size of wild-type flies, owing to fewer and smaller cells. In mosaic animals, chico homozygous cells grow slower than their heterozygous siblings, show an autonomous reduction in cell size, and form organs of reduced size. Although chico flies are smaller, they show an almost P-fold increase in lipid levels. The similarities of the growth defects caused by mutations in chico and the insulin receptor gene in Drosophila and by perturbations of the insulin/IGF1 signaling pathway in vertebrates suggest that this pathway plays a conserved role in the regulation of overall growth by controling cell size, cell number, and metabolism.	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich	Hafen, E (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hafen@zool.unizh.ch	Stoecker, Horst/F-8382-2012	Stoecker, Horst/0000-0002-3282-3664				Abe H, 1998, J CLIN INVEST, V101, P1784, DOI 10.1172/JCI1594; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASLER K, 1988, CELL, V54, P299; BERG CA, 1991, GENETICS, V127, P515; Britton JS, 1998, DEVELOPMENT, V125, P2149; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Chou TB, 1996, GENETICS, V144, P1673; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Ilic D, 1998, J CELL BIOL, V143, P547; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MINARI O, 1963, ANAL BIOCHEM, V6, P320, DOI 10.1016/0003-2697(63)90156-8; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nurse P., 1985, P185; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; ROBERTSON FW, 1963, GENET RES, V4, P74, DOI 10.1017/S001667230000344X; SANTAMARIA P, 1983, DEV BIOL, V96, P285, DOI 10.1016/0012-1606(83)90165-3; SCHMIDT A, 1998, EMBO J, V17, P101; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stern DL, 1999, DEVELOPMENT, V126, P1091; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANHANDEL E, 1988, J AM MOSQUITO CONTR, V4, P549; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1997, J BIOL CHEM, V272, P14606, DOI 10.1074/jbc.272.23.14606; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XU T, 1993, DEVELOPMENT, V117, P1223; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yenush L, 1996, MOL CELL BIOL, V16, P2509; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	655	668	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					865	875		10.1016/S0092-8674(00)80799-0	http://dx.doi.org/10.1016/S0092-8674(00)80799-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399915	Bronze			2022-12-01	WOS:000081162800008
J	Tai, AW; Chuang, JZ; Bode, C; Wolfrum, U; Sung, CH				Tai, AW; Chuang, JZ; Bode, C; Wolfrum, U; Sung, CH			Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1	CELL			English	Article							DOMINANT RETINITIS-PIGMENTOSA; PHOTORECEPTOR CELLS; ROD PHOTORECEPTORS; VESICLE TRANSPORT; OUTER SEGMENT; RETINAL RODS; IN-VIVO; COMPLEX; LOCALIZATION; GENE	The interaction of cytoplasmic dynein with its cargoes is thought to be indirectly mediated by dynactin, a complex that binds to the dynein intermediate chain. However, the roles of other dynein subunits in cargo binding have been unknown. Here we demonstrate that dynein translocates rhodopsin-bearing vesicles along microtubules. This interaction occurs directly between the C-terminal cytoplasmic tail of rhodopsin and Tctex-1, a dynein light chain. C-terminal rhodopsin mutations responsible for retinitis pigmentosa inhibit this interaction. Our results point to an alternative docking mechanism for cytoplasmic dynein, provide novel insights into the role of motor proteins in the polarized transport of post-Golgi vesicles, and shed light on the molecular basis of retinitis pigmentosa.	Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Ophthalmol, Margaret M Dyson Vis Res Inst, New York, NY 10021 USA; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Cornell University; Cornell University; Johannes Gutenberg University of Mainz	Sung, CH (corresponding author), Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA.	chsung@mail.med.cornell.edu	Tai, Andrew W./M-8380-2017	Tai, Andrew W./0000-0002-6877-450X	NATIONAL EYE INSTITUTE [R01EY011307] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011307, EY11307] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, Peptide Research, V1, P42; Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; Beech PL, 1996, J CELL SCI, V109, P889; BESHARSE JC, 1995, J NEUROCYTOL, V24, P371, DOI 10.1007/BF01189064; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Campbell KS, 1998, J IMMUNOL, V161, P1728; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DEETIC D, 1998, P NATL ACAD SCI USA, V95, P10620; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HARGRAVE PA, 1982, METHOD ENZYMOL, V81, P251; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HYMAN AA, 1991, J CELL SCI, P125; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; KREBS W, 1977, EXP EYE RES, V25, P511, DOI 10.1016/0014-4835(77)90180-4; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; MACKE JP, 1993, AM J HUM GENET, V53, P80; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mou T, 1998, FEBS LETT, V435, P275, DOI 10.1016/S0014-5793(98)01069-2; Muresan V, 1996, J CELL BIOL, V135, P383, DOI 10.1083/jcb.135.2.383; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; PAPERMASTER DS, 1986, J HISTOCHEM CYTOCHEM, V34, P5, DOI 10.1177/34.1.2934469; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; ROHLICH P, 1975, CELL TISSUE RES, V161, P421; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; SPENCER M, 1988, INVEST OPHTH VIS SCI, V29, P1012; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; TROUTT LL, 1988, J NEUROSCI, V8, P2371; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P153, DOI 10.1159/000134329; WEISS ER, 1995, BIOCHEM BIOPH RES CO, V216, P755, DOI 10.1006/bbrc.1995.2686; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	62	388	398	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					877	887		10.1016/S0092-8674(00)80800-4	http://dx.doi.org/10.1016/S0092-8674(00)80800-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399916	Bronze			2022-12-01	WOS:000081162800009
J	Hussein, WI; Green, R; Jacobsen, DW; Faiman, C				Hussein, WI; Green, R; Jacobsen, DW; Faiman, C			Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Clinical-Endocrinology	1998	ORLANDO, FL	Amer Assoc Clin Endocrinol			VASCULAR-DISEASE; RISK FACTOR; PLASMA HOMOCYSTEINE; HYPERTENSION	Background: Hyperhomocysteinemia is an independent risk factor for coronary, peripheral, and cerebrovascular disease. Elevated plasma homocysteine levels were described in a preliminary report on primary hypothyroidism. Objective: To determine whether restoration of euthyroidism by L-thyroxine replacement therapy would reduce or normalize plasma homocysteine levels. Design: Prospective cohort study. Setting: Outpatient endocrinology department of a tertiary center. Patients: 14 patients (10 women and 4 men; 25 to 77 years of age): 4 with newly diagnosed chronic (Hashimoto) hypothyroidism and 10 who had been rendered acutely hypothyroid (thyroid-stimulating hormone level > 25 mU/L) by total thyroidectomy for thyroid carcinoma. Measurements: Total plasma homocysteine levels were measured at baseline and 3 to 9 months later, after euthyroidism had been attained by L-thyroxine replacement therapy. Results: Median baseline plasma homocysteine levels in both sexes (women, 11.65 mu mol/L [range, 7.2 to 26.5 mu mol/ L]; men, 15.1 mu mol/L [range, 14.1 to 16.3 mu mol/L]) were higher (P = 0.002) than those in healthy female (n = 35) and male (n = 36) volunteers (women, 7.52 mu mol/L [range, 4.3 to 14.0 mu mol/L]; men, 8.72 mu mol/L [range, 5.94 to 14.98 mu mol/L]). Eight patients (57%) had baseline plasma homocysteine levels that exceeded the upper limit of sex-specific reference ranges. Upon attainment of euthyroidism, all patients had a diminution in plasma homocysteine levels. The median overall change of -5.5 mu mol/L (range, -15.4 to -1.8 mu mol/L) corresponds to a difference of -44% (range, -58% to -13%) (P < 0.001). Homocysteine levels returned to normal in 7 of the 8 patients with elevated pretreatment values. Conclusions: Hypothyroidism may be a treatable cause of hyperhomocysteinemia, and elevated plasma homocysteine levels may be an independent risk factor for the accelerated atherosclerosis seen in primary hypothyroidism.	Cleveland Clin Fdn, Dept Endocrinol, Cleveland, OH 44195 USA; Univ Calif Davis, Davis, CA 95616 USA	Cleveland Clinic Foundation; University of California System; University of California Davis	Faiman, C (corresponding author), Cleveland Clin Fdn, Dept Endocrinol, 9500 Euclid Ave,Desk A30, Cleveland, OH 44195 USA.	faimancl@cesmtp.ccf.org		Hussein, Wiam/0000-0002-7416-4521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GREEN R, 1995, IRISH J MED SCI S15, V164, P27; GRYTTING G, 1957, ACTA MED SCAND, V157, P169; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; LINDENBAUM J, 1964, J CLIN PATHOL, V17, P666, DOI 10.1136/jcp.17.6.666; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; NAIR CPP, 1994, METABOLISM, V43, P1575, DOI 10.1016/0026-0495(94)90019-1; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; SAITO I, 1994, ENDOCRIN METAB CLIN, V23, P379, DOI 10.1016/S0889-8529(18)30103-8; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; STREETEN DHP, 1988, HYPERTENSION, V11, P78, DOI 10.1161/01.HYP.11.1.78; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; WILLIAMS GH, 1984, HEART DISEASE TXB CA, P1722	20	72	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					348	351		10.7326/0003-4819-131-5-199909070-00005	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	234AC	10475887				2022-12-01	WOS:000082458500004
J	Kinrade, SD; Del Nin, JW; Schach, AS; Sloan, TA; Wilson, KL; Knight, CTG				Kinrade, SD; Del Nin, JW; Schach, AS; Sloan, TA; Wilson, KL; Knight, CTG			Stable five- and six-coordinated silicate anions in aqueous solution	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SI-29 NMR; PENTACOORDINATE; SILICON(IV); ALUMINUM(III); EQUILIBRIUM; COMPLEXES; SIO2; ACID	Addition of aliphatic polyols to aqueous silicate solutions is shown to yield high concentrations of stable polyolate complexes containing five- or six-coordinated silicon. Coordinating polyols require at Least four hydroxy groups, two of which must be in three configuration, and coordinate to silicon via hydroxy oxygens at chain positions on either side of the threo pair. The remarkable ease by which these simple sugar-like molecules react to form hypervalent silicon complexes in aqueous solution supports a long-standing supposition that such species play a significant role in the biological uptake and transport of silicon and in mineral diagenesis.	Lakehead Univ, Dept Chem, Thunder Bay, ON P7B 5E1, Canada; Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA	Lakehead University; University of Illinois System; University of Illinois Urbana-Champaign	Kinrade, SD (corresponding author), Lakehead Univ, Dept Chem, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.				NCRR NIH HHS [RR 01811, 1 S10 RR 10444-01] Funding Source: Medline; NIGMS NIH HHS [GM-42208] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042208] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRCHALL JD, 1995, CHEM SOC REV, V24, P351, DOI 10.1039/cs9952400351; BLOHOWIAK KY, 1994, CHEM MATER, V6, P2177, DOI 10.1021/cm00047a045; CHUIT C, 1993, CHEM REV, V93, P1371, DOI 10.1021/cr00020a003; EVANS DF, 1992, POLYHEDRON, V11, P567, DOI 10.1016/S0277-5387(00)83306-9; GAINSFORD GJ, 1995, ACTA CRYSTALLOGR C, V51, P8, DOI 10.1107/S010827019400702X; HERREROS B, 1994, SCIENCE, V263, P1585, DOI 10.1126/science.263.5153.1585; HOPPE ML, 1993, ANGEW CHEM INT EDIT, V32, P287, DOI 10.1002/anie.199302871; Iler R., 1979, CHEM SILICA; KEMMITT T, 1995, AUST J CHEM, V48, P93, DOI 10.1071/CH9950093; Kinrade SD, 1998, INORG CHEM, V37, P4278, DOI 10.1021/ic971630d; Kinrade SD, 1998, INORG CHEM, V37, P4272, DOI 10.1021/ic971629e; Kinrade SD, 1996, J PHYS CHEM-US, V100, P4760, DOI 10.1021/jp952683o; KINRADE SD, IN PRESS J CHEM S DA; KNIGHT CTG, 1989, ZEOLITES, V9, P448, DOI 10.1016/0144-2449(89)90103-6; LAINE RM, 1991, NATURE, V353, P642, DOI 10.1038/353642a0; Laine RM, 1996, J MATER CHEM, V6, P1441, DOI 10.1039/jm9960601441; Liebau F, 2012, STRUCTURAL CHEM SILI; MUNOZ A, 1991, CARBOHYD RES, V225, P113; Rosenheim A, 1931, Z ANORG ALLG CHEM, V196, P160, DOI 10.1002/zaac.19311960117; SEDEH IF, 1993, J INORG BIOCHEM, V50, P119, DOI 10.1016/0162-0134(93)80019-6; SEDEH IF, 1992, ACTA CHEM SCAND, V46, P933, DOI 10.3891/acta.chem.scand.46-0933; SJOBERG S, 1985, J INORG BIOCHEM, V24, P267, DOI 10.1016/0162-0134(85)85055-8; SMALL JH, 1995, ACS SYM SER, V585, P248; STEBBINS JF, 1993, J NON-CRYST SOLIDS, V160, P116, DOI 10.1016/0022-3093(93)90292-6; STEBBINS JF, 1989, AM MINERAL, V74, P965; SVENSSON IL, 1989, J CHEM SOC FARADAY T, V31, P4558; Weiss A., 1964, ANGEW CHEM, V76, P818; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	28	156	168	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1542	1545		10.1126/science.285.5433.1542	http://dx.doi.org/10.1126/science.285.5433.1542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477513				2022-12-01	WOS:000082359500058
J	Ziegler, BL; Valtieri, M; Porada, GA; De Maria, R; Muller, R; Masella, B; Gabbianelli, M; Casella, I; Pelosi, E; Bock, T; Zanjani, ED; Peschle, C				Ziegler, BL; Valtieri, M; Porada, GA; De Maria, R; Muller, R; Masella, B; Gabbianelli, M; Casella, I; Pelosi, E; Bock, T; Zanjani, ED; Peschle, C			KDR receptor: A key marker defining hematopoietic stem cells	SCIENCE			English	Article							HUMAN BONE-MARROW; LONG-TERM CULTURE; GROWTH-FACTOR; IN-VIVO; REPOPULATING ACTIVITY; ENDOTHELIAL-CELLS; COMMON PRECURSOR; EXPRESSION; DIFFERENTIATION; IDENTIFICATION	Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR). Pluripotent HSCs were restricted to the CD34(+)KDR(+) cell fraction. Conversely, Lineage-committed HPCs were in the CD34(+)KDR(-) subset. On the basis of Limiting dilution analysis, the HSC frequency in the CD34(+)KDR(+) fraction was 20 percent in bone marrow (BM) by mouse xenograft assay and 25 to 42 percent in BM, peripheral blood, and cord blood by 12-week long-term culture (LTC) assay. The latter values rose to 53 to 63 percent in LTC supplemented with VEGF and to greater than 95 percent, for the cell subfraction resistant to growth factor starvation. Thus, KDR is a positive functional marker defining stem cells and distinguishing them from progenitors.	Univ Tubingen, Dept Hematol & Oncol, D-72076 Tubingen, Germany; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ Nevada, Dept Vet Affairs, Reno, NV 89520 USA	Eberhard Karls University of Tubingen; Jefferson University; Istituto Superiore di Sanita (ISS); Nevada System of Higher Education (NSHE); University of Nevada Reno	Peschle, C (corresponding author), Univ Tubingen, Dept Hematol & Oncol, Otfried Muller Str 10, D-72076 Tubingen, Germany.	cesare.peschle@mail.tju.edu	Gabbianelli, Marco/O-1210-2017; De Maria, Ruggero/S-6385-2019; valtieri, mauro/H-1044-2016; pelosi, elvira/J-7298-2016	Gabbianelli, Marco/0000-0002-7824-780X; De Maria, Ruggero/0000-0003-2255-0583; valtieri, mauro/0000-0002-9139-6754; pelosi, elvira/0000-0002-3043-6249; Casella, Ida/0000-0002-3358-4976				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; BRANDT J, 1990, J CLIN INVEST, V86, P932, DOI 10.1172/JCI114795; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Choi K, 1998, DEVELOPMENT, V125, P725; Civin CI, 1996, BLOOD, V88, P4102, DOI 10.1182/blood.V88.11.4102.bloodjournal88114102; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Garcia-Ojeda ME, 1998, J EXP MED, V187, P1813, DOI 10.1084/jem.187.11.1813; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KATOH O, 1995, CANCER RES, V55, P5687; Kawashima I, 1996, BLOOD, V87, P4136, DOI 10.1182/blood.V87.10.4136.bloodjournal87104136; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; OGAWA M, 1993, BLOOD, V81, P2844; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Sutherland DR, 1996, EXP HEMATOL, V24, P795; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; TERMAN BI, 1991, ONCOGENE, V6, P1677; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Uchida N, 1996, BLOOD, V88, P1297, DOI 10.1182/blood.V88.4.1297.bloodjournal8841297; VANDERLOO JCM, 1995, BLOOD, V85, P2598, DOI 10.1182/blood.V85.9.2598.bloodjournal8592598; Verstegen MMA, 1998, BLOOD, V91, P1966, DOI 10.1182/blood.V91.6.1966.1966_1966_1976; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; Zanjani ED, 1998, EXP HEMATOL, V26, P353	34	368	419	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1553	1558		10.1126/science.285.5433.1553	http://dx.doi.org/10.1126/science.285.5433.1553			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477517				2022-12-01	WOS:000082359500062
J	Slifka, MK; Rodriguez, F; Whitton, JL				Slifka, MK; Rodriguez, F; Whitton, JL			Rapid on/off cycling of cytokine production by virus-specific CD8(+) T cells	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TUMOR-NECROSIS-FACTOR; VIRAL-INFECTION; MESSENGER-RNA; HOST-DEFENSE; MICE; PERFORIN; CYTOTOXICITY; ACTIVATION; CLEARANCE	CD8-positive T cells protect the body against viral pathogens by two important mechanisms: production of antiviral cytokines(1,2) and lysis of infected cells(3,4). Cytokine production can have both local and systemic consequences(5,6), whereas cytolytic activity is limited to infected cells that are in direct contact with T cells(7-9). Here we analyse activated CD8-positive T cells from mice infected with lymphocytic choriomeningitis virus and find that cytokines are not produced ex vivo in the absence of peptide stimulation, but that they are rapidly generated after T cells encounter viral peptides bound to the major histocompatibility complex. Remarkably, cytokine production ceases immediately upon dissociation of the T cells from their targets and resumes when antigenic contact is restored. In contrast to the 'on/off/on' cycling of cytokines, the pore-forming cytotoxic protein perforin is constitutively maintained. Our results indicate that there is differential expression of effector molecules according to whether the antiviral product is secreted (like cytokines) or stored inside the cell (like perforin). The ability to turn cytokines on and off while maintaining intracellular stores of perforin shows the versatility of the cellular immune response and provides a mechanism for maintaining effective immune surveillance while reducing systemic immunopathology.	Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Slifka, MK (corresponding author), Scripps Res Inst, Dept Neuropharmacol, CVN-9,10550 N torrey Pines Rd, La Jolla, CA 92037 USA.		Rodriguez, Fernando/C-3972-2011; Rodriguez, Fernando/GLN-3947-2022	Rodriguez, Fernando/0000-0001-7361-8408				AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CAMPBELL IL, 1995, INT J DEV NEUROSCI, V13, P275, DOI 10.1016/0736-5748(94)00073-C; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Guidotti LG, 1996, CURR OPIN IMMUNOL, V8, P478, DOI 10.1016/S0952-7915(96)80034-3; HAHN K, 1994, VIROLOGY, V201, P330, DOI 10.1006/viro.1994.1298; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Masuda N, 1998, BRIT J CANCER, V78, P388, DOI 10.1038/bjc.1998.504; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; TRACEY KJ, 1992, P SOC EXP BIOL MED, V200, P233; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WHITTON JL, 1990, SEMIN VIROL, V1, P257; WHITTON JL, 1996, FIELDS VIROLOGY, V3, P345; Yang Y, 1998, J EXP MED, V188, P247, DOI 10.1084/jem.188.2.247	26	216	220	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					76	79		10.1038/43454	http://dx.doi.org/10.1038/43454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485708				2022-12-01	WOS:000082374400044
J	Apse, MP; Aharon, GS; Snedden, WA; Blumwald, E				Apse, MP; Aharon, GS; Snedden, WA; Blumwald, E			Salt tolerance conferred by overexpression of a vacuolar Na+/H+ antiport in Arabidopsis	SCIENCE			English	Article							ION-TRANSPORT; TONOPLAST VESICLES; EXCHANGER; MEMBRANE; YEAST	Agricultural productivity is severely affected by soil salinity, One possible mechanism by which plants could survive salt stress is to compartmentalize sodium ions away from the cytosol. Overexpression of a vacuolar Na+/H+ antiport from Arabidopsis thaliana in Arabidopsis plants promotes sustained growth and development in soil watered with up to 200 millimolar sodium chloride. This salinity tolerance was correlated with higher-than-normal levels of AtNHX1 transcripts, protein, and vacuolar Na+/H+ (sodium/proton) antiport activity, These results demonstrate the feasibility of engineering salt tolerance in plants.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of Toronto	Blumwald, E (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.		Blumwald, Eduardo/Y-2751-2019					APSE MP, 1998, P 11 INT WORKSH PLAN, P84; Barkla BJ, 1996, ANNU REV PLANT PHYS, V47, P159, DOI 10.1146/annurev.arplant.47.1.159; BLUMWALD E, 1985, PLANT PHYSIOL, V78, P163, DOI 10.1104/pp.78.1.163; Blumwald E, 1997, ADV BOT RES, V25, P401, DOI 10.1016/S0065-2296(08)60159-7; BLUMWALD E, 1987, PLANT PHYSIOL, V85, P30, DOI 10.1104/pp.85.1.30; BLUMWALD E, 1987, PHYSIOL PLANTARUM, V69, P731, DOI 10.1111/j.1399-3054.1987.tb01993.x; DARLEY CP, 1998, P 11 INT WORKSH PLAN, P8; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Glenn EP, 1999, CRIT REV PLANT SCI, V18, P227, DOI 10.1016/S0735-2689(99)00388-3; HARLOW E, 1988, ANTIBODIES LAB MANUA, P498; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Johnson C.B., 1981, PHYSL PROCESSES LIMI, P271; Narasimhulu SB, 1996, PLANT CELL, V8, P873, DOI 10.1105/tpc.8.5.873; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; PLANT PJ, 1994, J MEMBRANE BIOL, V140, P1; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998	18	1379	1655	13	347	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1256	1258		10.1126/science.285.5431.1256	http://dx.doi.org/10.1126/science.285.5431.1256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455050				2022-12-01	WOS:000082130200040
J	Wald, NJ; Watt, HC; Hackshaw, AK				Wald, NJ; Watt, HC; Hackshaw, AK			Integrated screening for Down's syndrome based on tests performed during the first and second trimesters	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCHAL-TRANSLUCENCY THICKNESS; MATERNAL SERUM; FETAL TRISOMIES; INHIBIN-A; PREGNANCY; RISK; AGE; TRISOMY-21; GESTATION; MARKER	Background Both first-trimester screening and second-trimester screening for Down's syndrome are effective means of selecting women for chorionic-villus sampling or amniocentesis, but there is uncertainty about which screening method should be used in practice. We propose a new screening method in which measurements obtained during both trimesters are integrated to provide a single estimate of a woman's risk of having a pregnancy affected by Down's syndrome. Methods We used data from published studies of various screening methods employed during the first and second trimesters. The first-trimester screening consisted of measurement of serum pregnancy-associated plasma protein A in 77 pregnancies affected by Down's syndrome and 383 unaffected pregnancies and measurements of nuchal translucency obtained by ultrasonography in 326 affected and 95,476 unaffected pregnancies. The second-trimester tests were various combinations of measurements of serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin, and inhibin A in 77 affected and 385 unaffected pregnancies. Results When we used a risk of 1 in 120 or greater as the cutoff to define a positive result on the integrated screening test, the rate of detection of Down's syndrome was 85 percent, with a false positive rate of 0.9 percent. To achieve the same rate of detection, current screening tests would have higher false positive rates (5 to 22 percent). If the integrated test were to replace the triple test (measurements of serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin), currently used with a 5 percent false positive rate, for screening during the second trimester, the detection rate would be higher (85 percent vs. 69 percent), with a reduction of four fifths in the number of invasive diagnostic procedures and consequent losses of normal fetuses. Conclusions The integrated test detects more cases of Down's syndrome with a much lower false positive rate than the best currently available test. (N Engl J Med 1999;341:461-7.) (C) 1999, Massachusetts Medical Society.	St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, Charterhouse Sq, London EC1M 6BQ, England.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BRIZOT ML, 1995, BRIT J OBSTET GYNAEC, V102, P127, DOI 10.1111/j.1471-0528.1995.tb09065.x; BRIZOT ML, 1994, OBSTET GYNECOL, V84, P918; Canick JA, 1998, PRENATAL DIAG, V18, P413; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; De Biasio P, 1999, PRENATAL DIAG, V19, P360, DOI 10.1002/(SICI)1097-0223(199904)19:4<360::AID-PD556>3.0.CO;2-U; Hackshaw AK, 1996, LANCET, V348, P1740, DOI 10.1016/S0140-6736(05)65871-0; Haddow JE, 1998, LANCET, V352, P336, DOI 10.1016/S0140-6736(98)22031-9; Haddow JE, 1998, J MED SCREEN, V5, P115, DOI 10.1136/jms.5.3.115; Haddow JE, 1998, NEW ENGL J MED, V338, P955, DOI 10.1056/NEJM199804023381404; LAM YH, 1998, ULTRASOUND OBSTET S1, V12, pA62; Nicolaides KH, 1998, PRENATAL DIAG, V18, P519, DOI 10.1002/(SICI)1097-0223(199805)18:5<519::AID-PD398>3.0.CO;2-U; Nicolaides KH, 1996, LANCET, V347, P906, DOI 10.1016/S0140-6736(96)91391-4; NIELSON JP, 1997, LANCET, V350, P754; Noble PL, 1995, ULTRASOUND OBST GYN, V6, P390, DOI 10.1046/j.1469-0705.1995.06060390.x; Onda T, 1998, PRENATAL DIAG, V18, P956, DOI 10.1002/(SICI)1097-0223(199809)18:9<956::AID-PD370>3.3.CO;2-I; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; ROYSTON P, 1992, STAT MED, V11, P257, DOI 10.1002/sim.4780110211; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Wald N J, 1996, J Med Screen, V3, P185; Wald N J, 1997, J Med Screen, V4, P181; WALD NJ, 1988, BRIT MED J, V297, P1029; Wald NJ, 1997, PRENATAL DIAG, V17, P821, DOI 10.1002/(SICI)1097-0223(199709)17:9<821::AID-PD154>3.3.CO;2-X; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; Wald NJ, 1996, PRENATAL DIAG, V16, P143, DOI 10.1002/(SICI)1097-0223(199602)16:2<143::AID-PD825>3.0.CO;2-F; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; Wald NJ, 1997, PRENATAL DIAG, V17, P285, DOI 10.1002/(SICI)1097-0223(199703)17:3<285::AID-PD71>3.0.CO;2-A; WALD NJ, 1994, PRENATAL DIAG, V14, P707, DOI 10.1002/pd.1970140810; Wald NJ, 1998, J MED SCREEN, V5, P110; Wald NJ, 1998, J MED SCREEN, V5, P166	30	377	396	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					461	467		10.1056/NEJM199908123410701	http://dx.doi.org/10.1056/NEJM199908123410701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441601				2022-12-01	WOS:000081962600001
J	Seder, RA; Gurunathan, S				Seder, RA; Gurunathan, S			DNA vaccines - Designer vaccines for the 21st Century	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LYMPHOCYTES		NIAID, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476	5	42	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					277	278		10.1056/NEJM199907223410410	http://dx.doi.org/10.1056/NEJM199907223410410			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413742				2022-12-01	WOS:000081528800010
J	Poulin, JF; Sekaly, RP				Poulin, JF; Sekaly, RP			Function of the thymus in HIV-infected adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Clin Res Inst Montreal, Immunol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Poulin, JF (corresponding author), Clin Res Inst Montreal, Immunol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FRANCIS IR, 1985, AM J ROENTGENOL, V145, P249, DOI 10.2214/ajr.145.2.249; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; PICKER LJ, 1993, J IMMUNOL, V150, P1105; STEINMANN GG, 1986, HUMAN THYMUS HISTOPA, P43; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	7	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					219	219		10.1001/jama.282.3.219	http://dx.doi.org/10.1001/jama.282.3.219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422975				2022-12-01	WOS:000081504400002
J	Giuffrida, A; Gravelle, H; Roland, M				Giuffrida, A; Gravelle, H; Roland, M			Measuring quality of care with routine data: avoiding confusion between performance indicators and health outcomes	BRITISH MEDICAL JOURNAL			English	Article							PREVENTABLE HOSPITALIZATIONS; ACCESS; RATES; POPULATION; ADMISSIONS; CHILDREN	Objective To investigate the impact of factors outside the control of primary care on performance indicators proposed as measures of the quality of primary care. Design Multiple regression analysis relating admission rates standardised for age and sex for asthma, diabetes, and epilepsy to socioeconomic population characteristics and to the supply of secondary care resources. Setting 90 family health services authorities in England, 1989-90 to 1994-5. Results At health authority level socioeconomic characteristics, health status, and secondary care supply factors explained 45% of the variation in admission rates for asthma, 33% for diabetes, and 55% for epilepsy. When health authorities were ranked, only four of the 10 with the highest age-sex standardised admission rates for asthma in 1994-5 remained in the top 10 when allowance was made for socioeconomic characteristics, health status, and secondary care supply factors. There was also substantial year to year variation in the rates. Conclusion Health outcomes should relate to crude rates of adverse events in the population. These give the best indication of the size of a health problem. Performance indicators, however, should relate to those aspects of care which can be altered by the staff whose performance is being measured.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO10 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.			Gravelle, Hugh/0000-0002-7753-4233				ARNOLD J, 1989, USING HLTH OUTCOMES; Aveyard P, 1997, J Eval Clin Pract, V3, P275, DOI 10.1046/j.1365-2753.1997.t01-1-00004.x; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BEGLEY CE, 1994, J COMMUN HEALTH, V19, P377, DOI 10.1007/BF02260406; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; Billings J, 1989, USE SMALL AREA ANAL; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; DUROJAIYE LIA, 1989, PUBLIC HEALTH, V103, P181, DOI 10.1016/S0033-3506(89)80073-3; FARMER A, 1990, BRIT J GEN PRACT, V40, P56; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Lambrew JM, 1996, MED CARE, V34, P138, DOI 10.1097/00005650-199602000-00006; *MA DIV HLTH CAR F, 1995, IMPR PRIM CAR US PRE; MACKINNON JG, 1983, J ECONOMETRICS, V21, P53, DOI 10.1016/0304-4076(83)90119-7; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; *NHS EX, 1998, NEW NHS NAT FRAM ASS; *NHS EX, 1994, HLTH SERV IND HDB 19; *SECR STAT HLTH, 1997, CM3807; Smith P., 1994, FORMULA DISTRIBUTING; WATTS JP, 1996, EUR RESPIR J, V9, P2087; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITE H, 1978, ECONOMETRICA, V46, P817	24	118	121	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					94	98		10.1136/bmj.319.7202.94	http://dx.doi.org/10.1136/bmj.319.7202.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	216JD	10398635	Bronze, Green Published, Green Accepted			2022-12-01	WOS:000081438200034
J	Philips, DP; Christenfeld, N; Ryan, NM				Philips, DP; Christenfeld, N; Ryan, NM			An increase in the number of deaths in the United States in the first week of the month - An association with substance abuse and other causes of death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; ALCOHOL-CONSUMPTION; EMERGENCY ROOM; DISABILITY; MORTALITY; WORKING; INCOME	Background and Methods There are regular changes in mortality rates, such as increased rates of death from influenza in the winter and from motor vehicle accidents on long holiday weekends. Previous research has shown that among persons with schizophrenia, the rates of cocaine use and hospital admissions increase at the beginning of the month, after the receipt of disability payments, Using computerized data from all death certificates in the United States between 1973 and 1988, we compared the number of deaths in the fi rst week of the month with the number of deaths in the last week of the preceding month. Results The average number of deaths was about 5500 per day, or about 165,000 in a 30-day month. There were 100.9 deaths (95 percent confidence interval, 100.8 to 101.0) in the first week of the month for every 100 deaths in the last week of the preceding month, This was equivalent to about 4320 more deaths in the first week of each month than in the last week of the preceding month in an average year. Between 1983 and 1988, for deaths involving substance abuse and an external cause (such as suicides, accidents, and homicides), there were 114.2 deaths (95 percent confidence interval, 110.5 to 117.9) in the first week of the month for every 100 in the last week of the preceding month. There were significant increases in the number of deaths in the first week of the month for many causes of death, including substance abuse, natural causes, homicides, suicides, and motor vehicle accidents. Conclusions In the United States, the number of deaths is higher in the first week of the month than in the last week of the preceding month. The increase at the beginning of the month is associated with substance abuse and other causes of death. (N Engl J Med 1999;341:93-8.) (C) 1999, Massachusetts Medical Society.	Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Philips, DP (corresponding author), Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA.							Borges G, 1996, J STUD ALCOHOL, V57, P543, DOI 10.15288/jsa.1996.57.543; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; Chou SP, 1996, ALCOHOL CLIN EXP RES, V20, P1423, DOI 10.1111/j.1530-0277.1996.tb01144.x; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; Cornelius JR, 1996, ALCOHOL CLIN EXP RES, V20, P1451, DOI 10.1111/j.1530-0277.1996.tb01148.x; *DEP COMM, 1998, STAT ABSTR US 1998; *DEP COMM, 1998, STAT ABSTR US 1988; DUFFY JC, 1995, INT J EPIDEMIOL, V24, P100, DOI 10.1093/ije/24.1.100; Durkheim E, 1897, SUICIDE; Gardner M. J., 1989, STAT CONFIDENCE; Gresenz CR, 1998, COMMUNITY MENT HLT J, V34, P337, DOI 10.1023/A:1018779805833; *NAT CTR HLTH STAT, 1977, VIT STAT US 1973 1 A, V2; *NAT CTR HLTH STAT, 1985, MULT CAUS DEATH 1983; *NAT CTR HLTH STAT, 1991, VIT STAT US 1973 1 A, V2; *NAT CTR HLTH STAT, 1984, MORT DET FIL 1973 19; *NAT CTR HLTH STAT, 1984, VIT STAT US 1979 1 A, V2; PHILLIPS DP, 1988, LANCET, V2, P728; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS DP, 1992, PSYCHOSOM MED, V54, P532, DOI 10.1097/00006842-199209000-00001; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; POIKOLAINEN K, 1995, J CIN EPIDEMIOL, V48, P1; Rosenheck R, 1997, PSYCHIATR SERV, V48, P789; SATEL SL, 1995, NEW ENGL J MED, V333, P794, DOI 10.1056/NEJM199509213331210; SHANER A, 1995, NEW ENGL J MED, V333, P777, DOI 10.1056/NEJM199509213331207; Spielberg C, 1996, AM HEART J, V132, P579, DOI 10.1016/S0002-8703(96)90241-0; VANDERPALEN J, 1995, NEW ZEAL MED J, V108, P332; WILLICH SN, 1994, CIRCULATION, V90, P87, DOI 10.1161/01.CIR.90.1.87	27	97	98	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					93	98		10.1056/NEJM199907083410206	http://dx.doi.org/10.1056/NEJM199907083410206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214ET	10395634	Bronze			2022-12-01	WOS:000081316200006
J	Schenk, D; Barbour, R; Dunn, W; Gordon, G; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Liao, ZM; Lieberburg, I; Motter, R; Mutter, L; Soriano, F; Shopp, G; Vasquez, N; Vandevert, C; Walker, S; Wogulis, M; Yednock, T; Games, D; Seubert, P				Schenk, D; Barbour, R; Dunn, W; Gordon, G; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Liao, ZM; Lieberburg, I; Motter, R; Mutter, L; Soriano, F; Shopp, G; Vasquez, N; Vandevert, C; Walker, S; Wogulis, M; Yednock, T; Games, D; Seubert, P			Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse	NATURE			English	Article							PRECURSOR PROTEIN; TRANSGENIC MICE; SENILE PLAQUES; IN-VIVO; PRESENILIN-1; DEPOSITION; PEPTIDE	Amyloid-beta peptide (A beta) seems to have a central role in the neuropathology of Alzheimer's disease (AD)(1). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes(2,3). Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (A beta(42))(4-8), which is the predominant form found in the amyloid plaques of Alzheimer's disease(9,10). The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner(11,12). In the present study, transgenic animals were immunized with A beta(42), either before the onset of AD-type neuropathologies (at 6 weeks of age) or at an older age (11 months), when amyloid-beta deposition and several of the subsequent neuropathological changes were well established. We report that immunization of the young animals essentially prevented the development of beta-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-beta may be effective in preventing and treating Alzheimer's disease.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Schenk, D (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hardy J, 1996, ANN MED, V28, P255, DOI 10.3109/07853899609033127; Hyman BT, 1998, ARCH NEUROL-CHICAGO, V55, P1174, DOI 10.1001/archneur.55.9.1174; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; Lippa CF, 1998, LANCET, V352, P1117, DOI 10.1016/S0140-6736(05)79757-9; McGeer EG, 1997, MOVEMENT DISORD, V12, P855, DOI 10.1002/mds.870120604; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016	16	2595	2985	2	321	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					173	177		10.1038/22124	http://dx.doi.org/10.1038/22124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408445				2022-12-01	WOS:000081324900056
J	Chowdhury, AMR				Chowdhury, AMR			Success with the DOTS strategy	LANCET			English	Article									BRAC, Dhaka 1212, Bangladesh	Bangladesh Rural Advancement Committee BRAC	Chowdhury, AMR (corresponding author), BRAC, 75 Mohakhall, Dhaka 1212, Bangladesh.							Chowdhury A.M.R., 1996, SIMPLE SOLUTION TEAC; Chowdhury AMR, 1997, LANCET, V350, P169, DOI 10.1016/S0140-6736(96)11311-8; CHOWDHURY AMR, 1991, IUATLD NEWSLETTER, P1; CHOWDHURY AMR, IN PRESS TUBERCULOSI; GRANGE JM, 1997, LANCET, V350, P158; LOVELL CH, 1992, BREAKING CYCLE PROVE	6	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1003	1004		10.1016/S0140-6736(99)02119-4	http://dx.doi.org/10.1016/S0140-6736(99)02119-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459928				2022-12-01	WOS:000079421600049
J	Grange, JM; Zumla, A				Grange, JM; Zumla, A			Paradox of the global emergency of tuberculosis	LANCET			English	Article									UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis, London W1P 6DB, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England	University of London; University College London; UCL Medical School; Imperial College London	Zumla, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis, 46 Cleveland St, London W1P 6DB, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				Department for International Development, 1997, WHIT PAP INT DEV; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; Kochi A, 1997, WORLD HEALTH FORUM, V18, P225; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; 1998, INT J TUBERC LUNG DI, V2, P1044	5	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					996	996		10.1016/S0140-6736(99)01196-4	http://dx.doi.org/10.1016/S0140-6736(99)01196-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459922				2022-12-01	WOS:000079421600043
J	Kelly, TR; De Silva, H; Silva, RA				Kelly, TR; De Silva, H; Silva, RA			Unidirectional rotary motion in a molecular system	NATURE			English	Article							MOTORS; MUSCLE; F1-ATPASE; MACHINES; SHUTTLE; COMPLEX; RATCHET; SEARCH; WORK	The conversion of energy into controlled motion plays an important role in both man-made devices and biological systems. The principles of operation of conventional motors are well established, but the molecular processes used by 'biological motors' such as muscle fibres, flagella and cilia(1-9) to convert chemical energy into co-ordinated movement remain poorly understood(10-12). Although Brownian ratchets'(13-16) are known to permit thermally activated motion in one direction only, the concept of channelling random thermal energy into controlled motion has not pet been extended to the molecular level. Here we describe a molecule that uses chemical energy to activate and bias a thermally induced isomerization reaction, and thereby achieve unidirectional intramolecular rotary motion. The motion consists of a 120 degrees rotation around a single bond connecting a three-bladed subunit to the bulky remainder of the molecule, and unidirectional motion is achieved by reversibly introducing a tether between the two units to energetically favour one of the two possible rotation directions. Although our system does not achieve continuous and fast rotation, the design principles that we have used may prove relevant for a better understanding of biological and synthetic molecular motors producing unidirectional rotary motion.	Boston Coll, Dept Chem, EF Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Kelly, TR (corresponding author), Boston Coll, Dept Chem, EF Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BENNISTON AC, 1993, ANGEW CHEM INT EDIT, V32, P1459, DOI 10.1002/anie.199314591; Berg HC, 1998, NATURE, V394, P324, DOI 10.1038/28506; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Block SM, 1997, NATURE, V386, P217, DOI 10.1038/386217a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Huxley A, 1998, NATURE, V391, P239, DOI 10.1038/34567; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; KELLY TR, 1994, J AM CHEM SOC, V116, P3657, DOI 10.1021/ja00087a085; Kelly TR, 1998, J ORG CHEM, V63, P3655, DOI 10.1021/jo9723218; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Mislow K, 1988, CHEMTRACTS ORG CHEM, V2, P151; Musser G, 1999, SCI AM, V280, P24; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; STRYER L, 1995, BIOCHEMISTRY-US, pCH15; TRAVIS J, 1995, SCIENCE, V267, P1593, DOI 10.1126/science.267.5204.1593; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I	28	679	691	1	200	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					150	152		10.1038/43639	http://dx.doi.org/10.1038/43639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490021				2022-12-01	WOS:000082458800049
J	Koumura, N; Zijlstra, RWJ; van Delden, RA; Harada, N; Feringa, BL				Koumura, N; Zijlstra, RWJ; van Delden, RA; Harada, N; Feringa, BL			Light-driven monodirectional molecular rotor	NATURE			English	Article							UNIQUE CHIRAL OLEFINS; ABSOLUTE STEREOCHEMISTRY; ROTATION; TRANS-1,1',2,2',3,3',4,4'-OCTAHYDRO-3,3'-DIMETHYL-4,4'-BIPHENANTHRYLIDENE; CIS-1,1',2,2',3,3',4,4'-OCTAHYDRO-3,3'-DIMETHYL-4,4'-BIPHENANTHRYLIDENE; MACHINES	Attempts to fabricate mechanical devices on the molecular level(1,2) have yielded analogues of rotors(3), gears(4) switches(5), shuttles(6,7), turnstiles(8) and ratchets(9). Molecular motors, however, have not yet been made, even though they are common in biological systems(10) Rotary motion as such has been induced in interlocked systems(11-13) and directly visualized for single molecules(14), but the controlled conversion of energy into unidirectional rotary motion has remained difficult to achieve. Here we report repetitive, monodirectional rotation around a central carbon-carbon double bond in a chiral, helical alkene, with each 360 degrees rotation involving four discrete isomerization steps activated by ultraviolet light or a change in the temperature of the system. We find that axial chirality and the presence of two chiral centres are essential for the observed monodirectional behaviour of the molecular motor. Two light-induced cis-trans isomerizations are each associated with a 180 degrees rotation around the carbon-carbon double bond and are each followed by thermally controlled helicity inversions, which effectively block reverse rotation and thus ensure that the four individual steps add up to one full rotation in one direction only. As the energy barriers of the helicity inversion steps can be adjusted by structural modifications, chiral alkenes based on our system may find use as basic components for 'molecular machinery' driven by light.	Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, NL-9747 AG Groningen, Netherlands; Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	University of Groningen; Tohoku University	Feringa, BL (corresponding author), Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Koumura, Nagatoshi/M-4947-2018; Feringa, Ben L./C-1665-2013	Koumura, Nagatoshi/0000-0002-2141-0741; 				Armaroli N, 1999, J AM CHEM SOC, V121, P4397, DOI 10.1021/ja984051w; Ashton PR, 1998, J AM CHEM SOC, V120, P11932, DOI 10.1021/ja982167m; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Clayden J, 1998, ANGEW CHEM INT EDIT, V37, P1937, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14<1937::AID-ANIE1937>3.0.CO;2-4; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Drexler KE, 1992, NANOSYSTEMS MOL MACH; Feynman RP, 1961, MINIATURIZATION; Gimzewski JK, 1998, SCIENCE, V281, P531, DOI 10.1126/science.281.5376.531; Harada N, 1997, J AM CHEM SOC, V119, P7256, DOI 10.1021/ja970669e; Huck NPM, 1996, SCIENCE, V273, P1686, DOI 10.1126/science.273.5282.1686; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; Koumura N, 1998, CHEM LETT, P1151, DOI 10.1246/cl.1998.1151; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Schoevaars AM, 1997, J ORG CHEM, V62, P4943, DOI 10.1021/jo962210t	17	1381	1395	25	922	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					152	155		10.1038/43646	http://dx.doi.org/10.1038/43646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490022	Green Submitted			2022-12-01	WOS:000082458800050
J	Grum, VL; Li, DN; MacDonald, RI; Mondragon, A				Grum, VL; Li, DN; MacDonald, RI; Mondragon, A			Structures of two repeats of spectrin suggest models of flexibility	CELL			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; MEMBRANE SKELETON; CRYSTAL-STRUCTURE; ALPHA-SPECTRIN; TEMPERATURE-DEPENDENCE; CONFORMATIONAL UNIT; MOLECULAR-STRUCTURE; PLASMA-MEMBRANE; CELL MEMBRANE; SITE	Spectrin is a vital component of the cytoskeleton, conferring flexibility on cells and providing a scaffold for a variety of proteins. It is composed of tandem, antiparallel coiled-coil repeats. We report four related crystal structures at 1.45 Angstrom, 2.0 Angstrom 3.1 Angstrom and 4.0 Angstrom resolution of two connected repeats of chicken brain a-spectrin. In all of the structures, the linker region between adjacent units is or-helical without breaks, kinks, or obvious boundaries. Two features observed in the structures are (1) conformational rearrangement in one repeat, resulting in movement of the position of a loop, and (2) varying degrees of bending at the linker region. These features form the basis of two different models of flexibility: a conformational rearrangement and a bending model. These models provide novel atomic details of spectrin flexibility.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	a-mondragon@nwu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057692, R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51350, GM57692] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BABCOCK MS, 1994, J MOL BIOL, V237, P125, DOI 10.1006/jmbi.1994.1213; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cb.09.110193.000331; BLOCH R J, 1992, Trends in Cell Biology, V2, P186, DOI 10.1016/0962-8924(92)90231-B; Brown JH, 1996, PROTEINS, V26, P134; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P3898, DOI 10.1021/bi00468a016; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DeSilva TM, 1997, BIOCHEMISTRY-US, V36, P3991, DOI 10.1021/bi962412j; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dubreuil RR, 1996, CURR TOP MEMBR, V43, P147; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUNG LWM, 1989, LIFE SCI, V44, P735, DOI 10.1016/0024-3205(89)90385-8; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GRUM VL, 1998, THESIS NW U EVANSTON; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEARMONTH RP, 1989, BIOCHIM BIOPHYS ACTA, V987, P124, DOI 10.1016/0005-2736(89)90463-X; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; Lusitani D, 1998, BIOCHEMISTRY-US, V37, P16546, DOI 10.1021/bi9811462; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MARCHESI SL, 1991, CURR TOP MEMBR, V38, P155; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKKELSEN A, 1981, BIOCHIM BIOPHYS ACTA, V668, P74, DOI 10.1016/0005-2795(81)90150-1; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 1998, BIOCHEM J, V332, P81, DOI 10.1042/bj3320081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantazatos DP, 1997, J BIOL CHEM, V272, P21052, DOI 10.1074/jbc.272.34.21052; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Repasky EA, 1996, CURR TOP MEMBR, V43, P313; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Steck T. L., 1989, CELL SHAPE DETERMINA, P205; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P111, DOI 10.1016/0005-2736(85)90399-2; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P102, DOI 10.1016/0005-2736(85)90398-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WAUGH RE, 1982, BIOPHYS J, V39, P273, DOI 10.1016/S0006-3495(82)84517-7; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	72	212	213	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					523	535		10.1016/S0092-8674(00)81980-7	http://dx.doi.org/10.1016/S0092-8674(00)81980-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481916	Bronze			2022-12-01	WOS:000082174900012
J	Alter, MJ; Kruszon-Moran, D; Nainan, OV; McQuillan, GM; Gao, FX; Moyer, LA; Kaslow, RA; Margolis, HS				Alter, MJ; Kruszon-Moran, D; Nainan, OV; McQuillan, GM; Gao, FX; Moyer, LA; Kaslow, RA; Margolis, HS			The prevalence of hepatitis C virus infection in the United States, 1988 through 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	IX Triennial International Symposium on Viral Hepatitis and Liver Disease	APR 21-25, 1996	ROME, ITALY				NON-B-HEPATITIS; SEXUALLY-TRANSMITTED DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-A; RISK-FACTORS; VIRAL-HEPATITIS; LIVER-DISEASE; BLOOD-DONORS; EPIDEMIOLOGY; TRANSFUSION	Background Because many persons with chronic hepatitis C virus (HCV) infection are asymptomatic, population-based serologic studies are needed to estimate the prevalence of the infection and to develop and evaluate prevention efforts. Methods We performed tests for antibody to HCV (anti-HCV) on serum samples from 21,241 persons six years old or older who participated in the third National Health and Nutrition Examination Survey, conducted during 1988 through 1994. We determined the prevalence of HCV RNA by means of nucleic acid amplification and the genotype by means of sequencing. Results The overall prevalence of anti-HCV was 1.8 percent, corresponding to an estimated 3.9 million persons nationwide (95 percent confidence interval, 3.1 million to 4.8 million) with HCV infection. Sixty-five percent of the persons with HCV infection were 30 to 49 years old. Seventy-four percent were positive for HCV RNA, indicating that an estimated 2.7 million persons in the United States (95 percent confidence interval, 2.4 million to 3.0 million) were chronically infected, of whom 73.7 percent were infected with genotype 1 (56.7 percent with genotype la, and 17.0 percent with genotype Ib). Among subjects 17 to 59 years of age, the strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior. Other factors independently associated with infection included poverty, having had 12 or fewer years of education, and having been divorced or separated. Neither sex nor racial-ethnic group was independently associated with HCV infection. Conclusions In the United States, about 2.7 million persons are chronically infected with HCV. People who use illegal drugs or engage in high-risk sexual behavior account for most persons with HCV infection. (N Engl J Med 1999;341:556-62.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; NIAID, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Alter, MJ (corresponding author), Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mailstop G37, Atlanta, GA 30333 USA.							ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; EZZATI T, 1993, 1992 P SURV RES METH, P339; FRANCIS DP, 1984, AM J MED, V76, P69, DOI 10.1016/0002-9343(84)90752-6; Kahn HA., 1989, STAT METHODS EPIDEMI; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANPHEAR BP, 1994, INFECT CONT HOSP EP, V15, P745; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MANSELL CJ, 1995, SEMIN LIVER DIS, V15, P15, DOI 10.1055/s-2007-1007260; Mast EE, 1997, SEMIN PEDIAT INFECT, V8, P17; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; Mosley J W, 1965, Tech Bull Regist Med Technol, V35, P183; Nainan OV, 1996, J VIROL METHODS, V61, P127, DOI 10.1016/0166-0934(96)02077-0; National Center for Health Statistics, 1994, VITAL HLTH STAT, V1; *NIH CONS DEV C PA, 1997, HEPATOLOGY S1, V26, P25; PANLILIO AL, 1995, J AM COLL SURGEONS, V180, P16; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SEEFF LB, 1975, AM J MED SCI, V270, P355, DOI 10.1097/00000441-197509000-00018; SHAH BV, 1991, SUDAAN USERS MANUAL; Shapiro CN, 1996, J BONE JOINT SURG AM, V78A, P1791, DOI 10.2106/00004623-199612000-00001; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; THOMAS DL, 1994, J INFECT DIS, V169, P990, DOI 10.1093/infdis/169.5.990; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; Thomas SL, 1997, EUR J CLIN MICROBIOL, V16, P711, DOI 10.1007/BF01709250; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x	41	2099	2157	0	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					556	562		10.1056/NEJM199908193410802	http://dx.doi.org/10.1056/NEJM199908193410802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	227CV	10451460				2022-12-01	WOS:000082061500002
J	Choudhury, D; Thompson, A; Stojanoff, V; Langermann, S; Pinkner, J; Hultgren, SJ; Knight, SD				Choudhury, D; Thompson, A; Stojanoff, V; Langermann, S; Pinkner, J; Hultgren, SJ; Knight, SD			X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli	SCIENCE			English	Article							MACROMOLECULAR STRUCTURES; ANOMALOUS DIFFRACTION; PROTEIN STRUCTURES; TYPE-1 FIMBRIAE; PILUS; ENTEROBACTERIACEAE; RECOGNITION; REFINEMENT; ALIGNMENT	Type 1 pili-adhesive fibers expressed in most members of the Enterobacteriaceae family-mediate binding to mannose receptors on host cells through the FimH adhesin. Pilus biogenesis proceeds by way of the chaperone/usher pathway. The x-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli at 2.5 angstrom resolution reveals the basis for carbohydrate recognition and for pilus assembly. The carboxyl-terminal pilin domain of FimH has an immunoglobulin-like fold, except that the seventh strand is missing, leaving part of the hydrophobic core exposed. A donor strand complementation mechanism in which the chaperone donates a strand to complete the pilin domain explains the basis for both chaperone function and pilus biogenesis.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Mol Biol, S-75324 Uppsala, Sweden; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France; European Synchrotron Radiat Facil, F-38400 Grenoble, France; Medimmune Inc, Gaithersburg, MD 20878 USA	Washington University (WUSTL); Swedish University of Agricultural Sciences; European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF); AstraZeneca; Medimmune	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	hullgren@borcim.wustl.edu; stefan@xray.bmc.uu.se	stojanoff, vivian/I-7290-2012; Knight, Stefan/D-4315-2015	stojanoff, vivian/0000-0002-6650-512X; Pinkner, Jerome/0000-0002-7389-7440; Knight, Stefan/0000-0002-7180-8758	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; Brunger A. T, 1993, XPLOR MANUAL VERSION; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; HANSON MS, 1988, J BACTERIOL, V170, P3350, DOI 10.1128/jb.170.8.3350-3358.1988; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Knight S, 1997, ACTA CRYSTALLOGR D, V53, P207, DOI 10.1107/S0907444996011511; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KNIGHT SD, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LANGERMANN S, UNPUB; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellecchia M, 1998, NAT STRUCT BIOL, V5, P885, DOI 10.1038/2325; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Schembri MA, 1996, FEMS MICROBIOL LETT, V137, P257, DOI 10.1016/0378-1097(96)00067-5; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	37	504	525	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1061	1066		10.1126/science.285.5430.1061	http://dx.doi.org/10.1126/science.285.5430.1061			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446051				2022-12-01	WOS:000082033100044
J	Maekawa, M; Ishizaki, T; Boku, S; Watanabe, N; Fujita, A; Iwamatsu, A; Obinata, T; Ohashi, K; Mizuno, K; Narumiya, S				Maekawa, M; Ishizaki, T; Boku, S; Watanabe, N; Fujita, A; Iwamatsu, A; Obinata, T; Ohashi, K; Mizuno, K; Narumiya, S			Signaling from rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase	SCIENCE			English	Article							DEPOLYMERIZING FACTOR; MYOSIN PHOSPHATASE; FILAMENT TURNOVER; IN-VIVO; COFILIN; PHOSPHORYLATION; DYNAMICS; IDENTIFICATION; ASSOCIATION; MUSCLE	The actin cytoskeleton undergoes extensive remodeling during cell morphogenesis and motility. The small guanosine triphosphatase Rho regulates such remodeling, but the underlying mechanisms of this regulation remain unclear. Cofilin exhibits actin-depolymerizing activity that is inhibited as a result of its phosphorylation by LIM-kinase. Cofilin was phosphorylated in N1E-115 neuroblastoma cells during lysophosphatidic acid-induced, Rho-mediated neurite retraction. This phosphorylation was sensitive to Y-27632, a specific inhibitor of the Rho-associated kinase ROCK. ROCK, which is a downstream effector of Rho, did not phosphorylate cofilin directly but phosphorylated LIM-kinase, which in turn was activated to phosphorylate cofilin, Overexpression of LIM-kinase in HeLa cells induced the formation of actin stress fibers in a Y-27632-sensitive manner. These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan; Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan	Kyoto University; Kirin Brewery Company Limited; Chiba University; Tohoku University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.		Boku, Shuken/H-2776-2017; Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Maekawa M, UNPUB; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ONO S, 1994, J BIOL CHEM, V269, P15280; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WATANABE N, 1997, EMBO J, V16, P1307; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	25	1238	1272	3	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					895	898		10.1126/science.285.5429.895	http://dx.doi.org/10.1126/science.285.5429.895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436159				2022-12-01	WOS:000081860900051
J	Semsarian, C; Wu, MJ; Ju, YK; Marciniec, T; Yeoh, T; Allen, DG; Harvey, RP; Graham, RM				Semsarian, C; Wu, MJ; Ju, YK; Marciniec, T; Yeoh, T; Allen, DG; Harvey, RP; Graham, RM			Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway	NATURE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; FIBER-TYPE; GROWTH; PROLIFERATION; ACTIVATION; CELLS	Skeletal muscle hypertrophy and regeneration are important adaptive responses to both physical activity and pathological stimuli(1). Failure to maintain these processes underlies the loss of skeletal muscle mass and strength that occurs with ageing and in myopathies(2). Here we show that stable expression of a gene encoding insulin-like growth factor 1 (IGF-1) in C2C12 skeletal muscle cells, or treatment of these cells with recombinant IGF-1 or with insulin and dexamethasone, results in hypertrophy of differentiated myotubes and a switch to glycolytic metabolism. Treatment with IGF-1 or insulin and dexamethasone mobilizes intracellular calcium, activates the Ca2+/calmodulin-dependent phosphatase calcineurin, and induces the nuclear translocation of the transcription factor NF-ATc1. Hypertrophy is suppressed by the calcineurin inhibitors cyclosporin A or FK506, but not by inhibitors of the MAP-kinase or phosphatidylinositol-3-OH kinase pathways. Injecting rat latissimus dorsi muscle with a plasmid encoding IGF-1 also activates calcineurin, mobilizes satellite cells and causes a switch to glycolytic metabolism. We propose that growth-factor-induced skeletal-muscle hypertrophy and changes in myofibre phenotype are mediated by calcium mobilization and are critically regulated by the calcineurin/NF-ATc1 signalling pathway.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2033, Australia	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of Sydney; University of New South Wales Sydney	Graham, RM (corresponding author), St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia.	b.graham@victorchang.unsw.edu.au		Harvey, Richard/0000-0002-9950-9792				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; Ju YK, 1998, J PHYSIOL-LONDON, V508, P153, DOI 10.1111/j.1469-7793.1998.153br.x; KAZAKI M, 1997, J BIOL CHEM, V272, P4964; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montano MM, 1997, ENDOCR RES, V23, P37, DOI 10.1080/07435809709031841; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Renganathan M, 1998, J BIOL CHEM, V273, P28845, DOI 10.1074/jbc.273.44.28845; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; Semsarian C, 1999, BIOCHEM J, V339, P443, DOI 10.1042/0264-6021:3390443; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TESCH PA, 1984, J APPL PHYSIOL, V56, P35, DOI 10.1152/jappl.1984.56.1.35; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	30	359	378	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					576	581		10.1038/23054	http://dx.doi.org/10.1038/23054			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448861				2022-12-01	WOS:000081854800059
J	Augustin, I; Rosenmund, C; Sudhof, TC; Brose, N				Augustin, I; Rosenmund, C; Sudhof, TC; Brose, N			Munc13-1 is essential for fusion competence of glutamatergic synoptic vesicles	NATURE			English	Article							TRANSMITTER RELEASE; CENTRAL SYNAPSE; RECEPTOR; PROBABILITY; EXOCYTOSIS; CULTURE; FAMILY; POOL	Neurotransmitter release at synapses between nerve cells is mediated by calcium-triggered exocytotic fusion of synaptic vesicles'. Before fusion, vesicles dock at the presynaptic release site where they mature to a fusion-competent state(1,2). Here we identify Munc13-1, a brain-specific presynaptic phorbol ester receptor(3,4), as an essential protein for synaptic vesicle maturation. We show that glutamatergic hippocampal neurons from mice lacking Munc13-1 form ultrastructurally normal synapses whose synaptic-vesicle cycle is arrested at the maturation step. Transmitter release from mutant synapses cannot be triggered by action potentials, calcium-ionophores or hypertonic sucrose solution. In contrast, release evoked by alpha-latrotolrin is indistinguishable from wild-type controls, indicating that the toxin can bypass Munc13-1-mediated vesicle maturation. A small subpopulation of synapses of any given glutamatergic neuron as well as all synapses of GABA (gamma-aminobutyric acid)-containing neurons are unaffected by Munc13-1 loss, demonstrating the existence of multiple and transmitter-specific synaptic vesicle maturation processes in synapses.	Max Planck Inst Expt Med, AG Mol Neurobiol, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Membranbiophys, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, Dallas, TX 75235 USA	Max Planck Society; Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brose, N (corresponding author), Max Planck Inst Expt Med, AG Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444				BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Boyer C, 1998, J NEUROSCI, V18, P5294, DOI 10.1523/JNEUROSCI.18-14-05294.1998; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Martin TFJ, 1998, VITAM HORM, V54, P207, DOI 10.1016/S0083-6729(08)60926-7; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	17	532	549	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					457	461		10.1038/22768	http://dx.doi.org/10.1038/22768			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440375				2022-12-01	WOS:000081715000052
J	Einsle, O; Messerschmidt, A; Stach, P; Bourenkov, GP; Bartunik, HD; Huber, R; Kroneck, PMH				Einsle, O; Messerschmidt, A; Stach, P; Bourenkov, GP; Bartunik, HD; Huber, R; Kroneck, PMH			Structure of cytochrome c nitrite reductase	NATURE			English	Article							WOLINELLA-SUCCINOGENES; DESULFOVIBRIO-DESULFURICANS; NITROSOMONAS-EUROPAEA; ENTERIC BACTERIA; ESCHERICHIA-COLI; NITROGEN-CYCLE; AMMONIA; PURIFICATION; OXYGEN; ENZYME	The enzyme cytochrome c nitrite reductase catalyses the six-electron reduction of nitrite to ammonia as one of the key steps in the biological nitrogen cycle(1), where it participates in the anaerobic energy metabolism of dissimilatory nitrate ammonification(2). Here we report on the crystal structure of this enzyme from the microorganism Sulfurospirillum deleyianum, which we solved by multiwavelength anomalous dispersion methods. We propose a reaction scheme for the transformation of nitrite based on structural and spectroscopic information. Cytochrome c nitrite reductase is a functional dimer, with 10 dose-packed haem groups of type c and an unusual lysine-coordinated high-spin haem at the active site. By comparing the haem arrangement of this nitrite reductase with that of other multihaem cytochromes, we have been able to identify a family of proteins in which the orientation of haem groups is conserved whereas structure and function are not.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; DESY, Arbeitsgrp Prot Dynam, MPG ASMB, D-22603 Hamburg, Germany	University of Konstanz; Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Kroneck, PMH (corresponding author), Univ Konstanz, Fak Biol, D-78457 Constance, Germany.	einsle@biochem.mpg.de	Messerschmidt, Albrecht/A-8337-2008; Bourenkov, Gleb P/C-7794-2017	Bourenkov, Gleb P/0000-0002-2617-5920; Einsle, Oliver/0000-0001-8722-2893				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; COLE JA, 1980, FEMS MICROBIOL LETT, V7, P65, DOI 10.1111/j.1574-6941.1980.tb01578.x; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; LAFORTELLE ED, 1997, CRYSTALLOGR COMPUT, V7, P1; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; MORENO C, 1993, EUR J BIOCHEM, V212, P79, DOI 10.1111/j.1432-1033.1993.tb17635.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHRODER I, 1985, ARCH MICROBIOL, V140, P380, DOI 10.1007/BF00446982; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751; Schumacher W, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P329; SCHUMACHER W, 1991, ARCH MICROBIOL, V156, P70, DOI 10.1007/BF00418190; Strehlitz B, 1996, ANAL CHEM, V68, P807, DOI 10.1021/ac950692n; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Vijgenboom, 1998, BIOL ELECT TRANSFER, P197, DOI 10.1007/978-94-011-5133-7_14; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	30	274	283	4	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					476	480		10.1038/22802	http://dx.doi.org/10.1038/22802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440380				2022-12-01	WOS:000081715000057
J	Kume, K; Zylka, MJ; Sriram, S; Shearman, LP; Weaver, DR; Jin, XW; Maywood, ES; Hastings, MH; Reppert, SM				Kume, K; Zylka, MJ; Sriram, S; Shearman, LP; Weaver, DR; Jin, XW; Maywood, ES; Hastings, MH; Reppert, SM			mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop	CELL			English	Article							DROSOPHILA PERIOD GENE; SUPRACHIASMATIC NUCLEUS; MESSENGER-RNA; LIGHT; PROTEIN; MOUSE; EXPRESSION; TRANSCRIPTION; CRYPTOCHROME; TIMELESS	We determined that two mouse cryptochrome genes, mCry1 and mCry2, act in the negative limb of the clock feedback loop. In cell lines, mPER proteins (alone or in combination) have modest effects on their cellular location and ability to inhibit CLOCK:BMAL1-mediated transcription. This suggested cryptochrome involvement in the negative limb of the feedback loop. Indeed, mCry1 and mCry2 RNA levels are reduced in the central and peripheral clocks of Clock/Clock mutant mice. mCRY1 and mCRY2 are nuclear proteins that interact with each of the mPER proteins, translocate each mPER protein from cytoplasm to nucleus, and are rhythmically expressed in the suprachiasmatic circadian clock. Luciferase reporter gene assays show that mCRY1 or mCRY2 alone abrogates CLOCK:BMAL1-E box-mediated transcription. The mPER and mCRY proteins appear to inhibit the transcriptional complex differentially.	Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Cambridge	Kume, K (corresponding author), Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA.	reppert@helix.mgh.harvard.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Weaver, David/0000-0001-7941-6719; Hastings, Michael Harvey/0000-0001-8576-6651; Kume, Kazuhiko/0000-0003-4232-1657	NICHD NIH HHS [R37 HD14427] Funding Source: Medline; NIMH NIH HHS [MH12067, MH11547] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011547, F32MH012067] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hastings M.H., 1999, J NEUROSCI, V11, P1; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	44	1227	1264	6	109	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					193	205		10.1016/S0092-8674(00)81014-4	http://dx.doi.org/10.1016/S0092-8674(00)81014-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428031	Bronze			2022-12-01	WOS:000081632300009
J	Cheng, KH; Leung, SL; Hoekman, HW; Beekhuis, WH; Mulder, PGH; Geerards, AJM; Kijlstra, A				Cheng, KH; Leung, SL; Hoekman, HW; Beekhuis, WH; Mulder, PGH; Geerards, AJM; Kijlstra, A			Incidence of contact-lens-associated microbial keratitis and its related morbidity	LANCET			English	Article							ULCERATIVE KERATITIS; EXTENDED-WEAR; ACANTHAMOEBA-KERATITIS; PSEUDOMONAS-AERUGINOSA; CORNEAL ULCERS; OVERNIGHT WEAR; RISK-FACTORS; USERS; CONTAMINATION; ENGLAND	Background The incidence of contact-lens-associated microbial keratitis is uncertain and its related morbidity in the general population of contact-lens wearers is not known. We examined these issues in a prospective epidemiological study. Methods We surveyed all practising ophthalmologists in the Netherlands to identify all new cases of microbial keratitis reported during a 3-month period in 1996. Follow-up telephone calls were made to examine ocular morbidity. We undertook annual nationwide telephone surveys between 1994 and 1997 to estimate the prevalence of contact-lens wear. Findings Of 440 ophthalmologists contacted, 379 provided information. There were 92 cases of microbial keratitis; 17 used daily-wear rigid gas-permeable lenses, 63 daily-wear soft lenses, and 12 extended-wear soft lenses. The estimated annualised incidence of microbial keratitis was 1.1 per 10 000 (95% CI 0.6-1.7) users of daily-wear rigid gas-permeable lenses, 3.5 per 10 000 (2.7-4.5) users of daily-wear soft lenses, and 20.0 per 10 000 (10.3-35.0) users of extended-wear soft lenses (p<0.00001 for comparison between all groups), Five of the 92 patients achieved a final visual acuity of 20/70 or less. Pseudomonas and Serratia sop were the organisms most commonly isolated, Pseudomonas keratitis accounted for the largest mean diameter of corneal ulcers, the highest mean number of days in hospital, the greatest number of mean outpatients visits, and the poorest visual acuity outcome. Interpretation The incidence of microbial keratitis among users of extended-wear soft contact lenses in the Netherlands is similar to that reported in the USA during 1989. Awareness of risk factors and improvement in contact-lens materials have not led to a decrease in incidence. Overnight wear should be strongly discouraged.	Netherlands Ophthalm Res Inst, Dept Ophthalmoimmunol, NL-1100 AC Amsterdam, Netherlands; Univ Amsterdam, Dept Ophthalmol, Amsterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Coll Econ, Drenthe, Netherlands; Rotterdam Eye Hosp, Rotterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Erasmus University Rotterdam; Rotterdam Eye Hospital	Kijlstra, A (corresponding author), Netherlands Ophthalm Res Inst, Dept Ophthalmoimmunol, POB 12141, NL-1100 AC Amsterdam, Netherlands.							BATES A K, 1989, Eye (London), V3, P803; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; COSTER DJ, 1987, BRIT J OPHTHALMOL, V71, P96, DOI 10.1136/bjo.71.2.96; DART JKG, 1988, BRIT J OPHTHALMOL, V72, P926, DOI 10.1136/bjo.72.12.926; DART JKG, 1991, LANCET, V338, P650, DOI 10.1016/0140-6736(91)91231-I; DONZIS PB, 1987, AM J OPHTHALMOL, V104, P325, DOI 10.1016/0002-9394(87)90219-4; ERIE JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1665, DOI 10.1001/archopht.1993.01090120087027; GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P104, DOI 10.1001/archopht.1991.01080010106041; IMAYASU M, 1994, OPHTHALMOLOGY, V101, P371; KAMATA R, 1985, OPHTHALMOLOGY, V92, P1452; KOCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1453, DOI 10.1001/archopht.1990.01070120101038; KOIDOUTSILIGIANNI A, 1989, AM J OPHTHALMOL, V108, P64, DOI 10.1016/S0002-9394(14)73262-3; LASS JH, 1981, AM J OPHTHALMOL, V92, P384, DOI 10.1016/0002-9394(81)90529-8; LAZACHEK GW, 1971, ARCH OPHTHALMOL-CHIC, V86, P599, DOI 10.1001/archopht.1971.01000010601020; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; Lim-Bon-Siong R, 1998, AM J OPHTHALMOL, V125, P169, DOI 10.1016/S0002-9394(99)80087-7; Mathers WD, 1996, AM J OPHTHALMOL, V121, P129, DOI 10.1016/S0002-9394(14)70577-X; MAYO MS, 1987, J CLIN MICROBIOL, V25, P1398, DOI 10.1128/JCM.25.8.1398-1400.1987; MUMMERT R, 1994, BAUSCH LOMB ANN REPO, P2; Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225; ORMEROD LD, 1986, ARCH OPHTHALMOL-CHIC, V104, P79; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; RADFORD CF, 1995, BRIT MED J, V310, P1567, DOI 10.1136/bmj.310.6994.1567; Radford CF, 1998, BRIT J OPHTHALMOL, V82, P1387, DOI 10.1136/bjo.82.12.1387; Rapuano CJ, 1999, OPHTHALMOLOGY, V106, P422; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; STEIN RM, 1988, AM J OPHTHALMOL, V105, P632, DOI 10.1016/0002-9394(88)90056-6; Taylor HR, 1996, ARCH OPHTHALMOL-CHIC, V114, P248, DOI 10.1001/archopht.1996.01100130244001; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; 1988, LANCET, V1, P1437	32	372	384	0	42	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					181	185		10.1016/S0140-6736(98)09385-4	http://dx.doi.org/10.1016/S0140-6736(98)09385-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421298				2022-12-01	WOS:000081504200008
J	Jamora, C; Yamanouye, N; Van Lint, J; Laudenslager, J; Vandenheede, JR; Faulkner, DJ; Malhotra, V				Jamora, C; Yamanouye, N; Van Lint, J; Laudenslager, J; Vandenheede, JR; Faulkner, DJ; Malhotra, V			G beta gamma-mediated regulation of Golgi organization is through the direct activation of protein kinase D	CELL			English	Article							HETEROTRIMERIC-G-PROTEINS; CONSTITUTIVE TRANSPORT VESICLES; C-MU; DOMAIN; RECEPTOR; BINDING; EPSILON	We have shown previously that the py subunits of the heterotrimeric G proteins regulate the organization of the pericentriolarly localized Golgi stacks. In this report, evidence is presented that the downstream target of G beta gamma is protein kinase D (PKD), an isoform of protein kinase C. PKD, unlike other members of this class of serine/threonine kinases, contains a pleckstrin homology (PH) domain. Our results demonstrate that G beta gamma directly activates PKD by interacting with its PH domain. Inhibition of PKD activity through the use of pharmacological agents, synthetic peptide substrates, and, more specifically, the PH domain of PKD prevents G beta gamma-mediated Golgi breakdown. Our findings suggest a possible mechanism by which the direct interaction of G beta gamma with PKD regulates the dynamics of Golgi membranes and protein secretion.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA; Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; Salk Institute; Universite Catholique Louvain	Malhotra, V (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Yamanouye, Norma/I-3348-2013; Malhotra, Vivek/O-9811-2014; Van Lint, Johan/P-9073-2019	Yamanouye, Norma/0000-0001-6007-0199; Malhotra, Vivek/0000-0001-6198-7943; Van Lint, Johan/0000-0002-0275-571X				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Gschwendt M, 1998, FEBS LETT, V421, P165, DOI 10.1016/S0014-5793(97)01530-5; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Westermann P, 1996, BIOCHEM J, V320, P651, DOI 10.1042/bj3200651	28	233	236	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					59	68		10.1016/S0092-8674(00)80606-6	http://dx.doi.org/10.1016/S0092-8674(00)80606-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412981	Bronze			2022-12-01	WOS:000081451000008
J	Wu, ZD; Puigserver, P; Andersson, U; Zhang, CY; Adelmant, G; Mootha, V; Troy, A; Cinti, S; Lowell, B; Scarpulla, RC; Spiegelman, BM				Wu, ZD; Puigserver, P; Andersson, U; Zhang, CY; Adelmant, G; Mootha, V; Troy, A; Cinti, S; Lowell, B; Scarpulla, RC; Spiegelman, BM			Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1	CELL			English	Article							BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN HOMOLOG; DIET-INDUCED THERMOGENESIS; ACTIVATED RECEPTOR-GAMMA; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; DNA-BINDING; GENE-EXPRESSION; NUCLEAR; OBESITY	Mitochondrial number and function are altered in response to external stimuli in eukaryotes. While several transcription/replication factors directly regulate mitochondrial genes, the coordination of these factors into a program responsive to the environment is not understood. We show here that PGC-1, a cold-inducible coactivator of nuclear receptors, stimulates mitochondrial biogenesis and respiration in muscle cells through an induction of uncoupling protein 2 (UCP-2) and through regulation of the nuclear respiratory factors (NRFs). PGC-1 stimulates a powerful induction of NRF-1 and NRF-5 gene expression; in addition, PGC-1 binds to and coactivates the transcriptional function of NRF-1 on the promoter for mitochondrial transcription factor A (mtTFA), a direct regulator of mitochondrial DNA replication/transcription. These data elucidate a pathway that directly links external physiological stimuli to the regulation of mitochondrial biogenesis and function.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02115 USA; Univ Ancona, Fac Med & Chirurg, Ist Morfol Umana Normale Anat, I-60020 Ancona, Italy	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Marche Polytechnic University	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Andersson, Ulf/ABD-5162-2021	Andersson, Ulf/0000-0003-0316-3860; Wu, Zhidan/0000-0001-7289-9420; CINTI, Saverio/0000-0003-0362-5017	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054477, R01DK054477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54477] Funding Source: Medline; NIGMS NIH HHS [GM32525] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BROOKS SL, 1980, NATURE, V286, P274, DOI 10.1038/286274a0; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Maniatis T., 1989, LAB MANUAL, Vsecond; NELSON BD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P275, DOI 10.1016/0005-2728(90)90266-7; NICHOLLS D, 1986, BIOCHEM SOC T, V14, P223, DOI 10.1042/bst0140223; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ricquier D, 1997, PROG NUCLEIC ACID RE, V56, P83, DOI 10.1016/S0079-6603(08)61003-X; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V251, P374, DOI 10.1006/bbrc.1998.9479; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089	44	2983	3113	6	249	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					115	124		10.1016/S0092-8674(00)80611-X	http://dx.doi.org/10.1016/S0092-8674(00)80611-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412986	Bronze			2022-12-01	WOS:000081451000013
J	Rowland-Jones, S				Rowland-Jones, S			HIV infection: where have all the T cells gone?	LANCET			English	Editorial Material							CD4(+); REPERTOIRE; TURNOVER; THERAPY; AIDS		John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England	University of Oxford	Rowland-Jones, S (corresponding author), John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Haynes BF, 1999, J CLIN INVEST, V103, P921, DOI 10.1172/JCI5201E1; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543	17	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					5	7		10.1016/S0140-6736(99)90017-X	http://dx.doi.org/10.1016/S0140-6736(99)90017-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406356				2022-12-01	WOS:000081243200005
J	Graves, LE; Segal, S; Goodwin, EB				Graves, LE; Segal, S; Goodwin, EB			TRA-1 regulates the cellular distribution of the tra-2 mRNA in C. elegans	NATURE			English	Article							SEX-DETERMINING GENE; NEMATODE CAENORHABDITIS-ELEGANS; ZINC FINGER PROTEINS; MOLECULAR ANALYSIS; TRANSFORMATION; HEDGEHOG; MEMBER; FAMILY	The GLI protein family is involved in several key developmental processes in both vertebrates and invertebrates, The Drosophila GLI protein, Cubitus interuptus (Ci), regulates segment polarity and wing and leg development. In vertebrates, the GLI proteins control neural, lung, bone and gut development(1), In the nematode Caenorhabditis elegans, the GLI family member TRA-1 is necessary for normal sexual development(2,3). GLI, Ci and TRA-1 each contain five zinc-finger domains and bind the identical DNA sequence. Previous analyses are consistent with these proteins being transcription factors(4,5). Here we show that TRA-1 can act post-transcriptionally to govern gene activity. Our results indicate that the binding of TRA-1 to the 3' untranslated region of tra-2 regulates the export of tra-2 messenger RNA from the nucleus. The fact that TRA-1 is part of a conserved family of proteins raises the possibility that GLI family members are both transcriptional and post-transcriptional regulators of gene expression.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Goodwin, EB (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.	ebg778@nwu.edu						Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BRENNER S, 1974, GENETICS, V77, P71; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; Goodwin EB, 1997, DEVELOPMENT, V124, P749; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HODGKIN J, 1993, GENETICS, V133, P543; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1986, GENETICS, V114, P15; HODGKIN JA, 1977, GENETICS, V86, P275; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; Kuwabara PE, 1998, DEV BIOL, V204, P251, DOI 10.1006/dbio.1998.9062; KUWAMURA S, 1992, P ESO C HIGH RESOLUT, V2, P461; Mello C, 1995, METHOD CELL BIOL, V48, P451; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Weed M, 1997, MATRIX BIOL, V16, P53, DOI 10.1016/S0945-053X(97)90072-X; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	22	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					802	805						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391248				2022-12-01	WOS:000081101600058
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Test tube kidneys	SCIENCE			English	Article									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Sikorski, R (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Humes HD, 1999, NAT BIOTECHNOL, V17, P451, DOI 10.1038/8626	1	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1952	1952						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10400538				2022-12-01	WOS:000080932700034
J	Farrell, AM				Farrell, AM			Staphylococcal scalded-skin syndrome	LANCET			English	Editorial Material							EXFOLIATIVE TOXIN; EPIDERMOLYTIC TOXIN; SERINE-PROTEASE; AUREUS		John Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England	University of Oxford	Farrell, AM (corresponding author), John Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England.							Acland KM, 1999, BRIT J DERMATOL, V140, P518; CRIBIER B, 1994, J AM ACAD DERMATOL, V30, P319, DOI 10.1016/S0190-9622(94)70032-X; DANCER SJ, 1990, FEBS LETT, V268, P129, DOI 10.1016/0014-5793(90)80990-Z; ELSNER P, 1988, ZBL BAKT-INT J MED M, V268, P534; Farrell AM, 1996, BRIT J DERMATOL, V134, P962, DOI 10.1111/j.1365-2133.1996.tb06337.x; Kawabata A, 1997, J CLIN MICROBIOL, V35, P1984, DOI 10.1128/JCM.35.8.1984-1987.1997; Lina G, 1997, CLIN INFECT DIS, V25, P1369, DOI 10.1086/516129; Melish M.E., 1981, ZBL BAKT S, V10, P287; MELISH ME, 1972, J INFECT DIS, V125, P129, DOI 10.1093/infdis/125.2.129; Qasim W, 1998, ARCH DIS CHILD, V79, P290, DOI 10.1136/adc.79.3.290a; REDPATH MB, 1991, FEMS MICROBIOL LETT, V81, P151; SMITH TP, 1987, HISTOCHEM J, V19, P137, DOI 10.1007/BF01695138; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; WILEY BB, 1974, INFECT IMMUN, V9, P636, DOI 10.1128/IAI.9.4.636-640.1974	14	24	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					880	881		10.1016/S0140-6736(99)90120-4	http://dx.doi.org/10.1016/S0140-6736(99)90120-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489941				2022-12-01	WOS:000082511800004
J	Yeung, K; Seitz, T; Li, SF; Janosch, P; McFerran, B; Kaiser, C; Fee, F; Katsanakis, KD; Rose, DW; Mischak, H; Sedivy, JM; Kolch, W				Yeung, K; Seitz, T; Li, SF; Janosch, P; McFerran, B; Kaiser, C; Fee, F; Katsanakis, KD; Rose, DW; Mischak, H; Sedivy, JM; Kolch, W			Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP	NATURE			English	Article							CELL-CYCLE ARREST; DNA-SYNTHESIS; C-FOS; ACTIVATION; INHIBITION; BINDING; TRANSFORMATION; EXPRESSION; CASCADE; PURIFICATION	Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK), This kinase cascade controls the proliferation and differentiation of different cell types(1,2). Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein). In vitro, RKIP binds to Raf-1, MEK and ERK, but not to pas, RKIP co-immunoprecipitates with Raf-1 and MEK from cell lysates and colocalizes with Raf-1 when examined by confocal microscopy, RKIP is not a substrate for Raf-1 or MEK, but competitively disrupts the interaction between these kinases, RKIP overexpression interferes with the activation of MEK and ERK, induction of AP-1-dependent reporter genes and transformation elicited by an oncogenically activated Raf-1 kinase, Downregulation of endogenous RKIP by expression of antisense RNA or antibody microinjection induces the activation of MEK-, ERK- and AP-1-dependent transcription. RKIP represents a new class of protein-kinase-inhibitor protein that regulates the activity of the Raf/MEK/ERK module.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Richmond, RI 02912 USA; GSF Munich, Res Ctr Hlth & Environm, Inst Clin Mol Biol, D-81377 Munich, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Whittier Diabet Program, La Jolla, CA 92093 USA; Franz Volhard Klinikum, Max Delbruck Ctr, D-13122 Berlin, Germany	Beatson Institute; Brown University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of California System; University of California San Diego; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kolch, W (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	john_sedivy@brown.edu; wkolch@beatson.gla.ac.uk	Mischak, Harald/E-8685-2011; Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306				BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Kolch W, 1996, ONCOGENE, V13, P1305; KOLCH W, 1993, ONCOGENE, V8, P361; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RAPP UR, 1994, ONCOGENE, V9, P3493; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Tombes RM, 1998, BIOCHEM J, V330, P1451; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	26	674	739	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					173	177		10.1038/43686	http://dx.doi.org/10.1038/43686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490027	Green Accepted			2022-12-01	WOS:000082458800056
J	Lee, CK; Klopp, RG; Weindruch, R; Prolla, TA				Lee, CK; Klopp, RG; Weindruch, R; Prolla, TA			Gene expression profile of aging and its retardation by caloric restriction	SCIENCE			English	Article							MESSENGER-RNA EXPRESSION; CAENORHABDITIS-ELEGANS; LIFE-SPAN; TRANSCRIPTION FACTOR; PROTEIN; MUSCLE; STRESS; LONGEVITY; EXTENSION; DAF-16	The gene expression profile of the aging process was analyzed in skeletal muscle of mice. Use of high-density oligonucleotide arrays representing 6347 genes revealed that aging resulted in a differential gene expression pattern indicative of a marked stress response and Lower expression of metabolic and biosynthetic genes. Most alterations were either completely or partially prevented by caloric restriction, the only intervention known to retard aging in mammals. Transcriptional patterns of calorie-restricted animals suggest that caloric restriction retards the aging process by causing a metabolic shift toward increased protein turnover and decreased macromolecular damage.	VA Hosp, Dept Med, GRECC 4D, Madison, WI 53705 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Inst Aging, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Weindruch, R (corresponding author), VA Hosp, Dept Med, GRECC 4D, 2500 Overlook Terrace, Madison, WI 53705 USA.	rhweindr@facstaff.wisc.edu; taprolla@facstaff.wisc.edu	Lee, Cheol-Koo/F-2103-2013	Lee, Cheol-Koo/0000-0003-3927-9195	NCI NIH HHS [R01 CA78723] Funding Source: Medline; NIA NIH HHS [P01 AG11915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Copray JCVM, 1997, NEUROSCI LETT, V236, P41, DOI 10.1016/S0304-3940(97)00747-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dutta C, 1997, MUSCLE NERVE, V5, P55; Goyns MH, 1998, MECH AGEING DEV, V101, P73, DOI 10.1016/S0047-6374(97)00166-8; HOEK JB, 1988, BIOCHEM J, V254, P1; JACKMAN J, 1994, CANCER RES, V54, P5656; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91; Lexell J, 1997, J NUTR, V127, pS1011, DOI 10.1093/jn/127.5.1011S; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LISOWSKY T, 1994, CURR GENET, V26, P15, DOI 10.1007/BF00326299; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luciakova K, 1999, FEBS LETT, V444, P186, DOI 10.1016/S0014-5793(99)00058-7; LUDATSCHER R, 1983, EXP GERONTOL, V18, P113, DOI 10.1016/0531-5565(83)90004-9; MARAZZI G, 1993, DEV DYNAM, V197, P115, DOI 10.1002/aja.1001970205; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peterson CA, 1997, J NUTR, V127, pS1007; Pugh TD, 1999, CANCER RES, V59, P1642; Schwartz AL, 1999, ANNU REV MED, V50, P57; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Tissenbaum HA, 1998, GENETICS, V148, P703; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Wang S, 1996, MECH AGEING DEV, V92, P121, DOI 10.1016/S0047-6374(96)01814-3; Weindruch R., 1988, RETARDATION AGING DI; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.micro.47.1.321; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	40	1187	1251	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	1999	285	5432					1390	1393		10.1126/science.285.5432.1390	http://dx.doi.org/10.1126/science.285.5432.1390			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464095				2022-12-01	WOS:000082233500039
J	Lindegren, ML; Byers, RH; Thomas, P; Davis, SF; Caldwell, B; Rogers, M; Gwinn, M; Ward, JW; Fleming, PL				Lindegren, ML; Byers, RH; Thomas, P; Davis, SF; Caldwell, B; Rogers, M; Gwinn, M; Ward, JW; Fleming, PL			Trends in perinatal transmission of HIV/AIDS in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTION; PREGNANT-WOMEN; VERTICAL TRANSMISSION; ZIDOVUDINE TREATMENT; CHILDREN; AIDS; PREVALENCE; REDUCTION; TYPE-1	Context Since 1994, the US Public Health Service (PHS) has recommended routine, voluntary prenatal human immunodeficiency virus (HIV)testing and zidovudine therapy to reduce perinatal HIV transmission. Objective To describe trends in incidence of perinatal AIDS and factors contributing to these trends, particularly the effect of PHS perinatal HIV recommendations. Design, Setting, and Participants Analysis of nationwide AIDS surveillance data and data from HIV-reporting states through June 1998. Main Outcome Measures Trends in AIDS by year of diagnosis, incidence rates of AIDS and Pneumocystis carinii pneumonia (PCP) among infants younger than 1 year from US natality data for birth cohorts 1988 to 1996; expected number of infants with AIDS from national serosurvey data; and zidovudine use data from selected HIV-reporting states. Results Perinatal AIDS cases peaked in 1992 and then declined 67% from 1992 through 1997, including an 80% decline in infants and a 66% decline in children aged 1 to 5 years. Rates of AIDS among infants (per 100 000 births) declined 69%, from 8.9 in 1992 to 2.8 in 1996 compared with a 17% decline in births to HIV-infected women from 1992 (n = 6990) to 1995 (n = 5797). Among infants, PCP rates per 100 000 declined 67% (from 4.5 in 1992 to 1,5 in 1996), similar to the decline in other AIDS conditions. The percentage of perinatally exposed children born from 1993 through 1997 whose mothers were tested for HIV before giving birth increased from 70% to 94%; the percentage who received zidovudine increased from 7% to 91%. Conclusions According to these data, substantial declines in AIDS incidence were temporally associated with an increase in zidovudine use to reduce perinatal HIV transmission, demonstrating substantial success in implementing PHS guidelines. Reductions in the numbers of births and effects of therapy in delaying AIDS do not explain the decline.	New York City Dept Hlth, New York, NY 10013 USA; Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Atlanta, GA USA; Ctr Dis Control & Prevent, Program Epidemiol, Off Sci & Hlth Commun, Atlanta, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Lindegren, ML (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Sueveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Mailstop E-47,1600 Clifton Rd, Atlanta, GA 30333 USA.	mll3@cdc.gov						Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; Barnhart HX, 1996, PEDIATRICS, V97, P710; Blanche S, 1997, J ACQ IMMUN DEF SYND, V14, P442, DOI 10.1097/00042560-199704150-00008; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; Byers RH, 1998, STAT MED, V17, P169, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;169::AID-SIM759&gt;3.0.CO;2-8; BYERS RH, 1993, 9 INT AIDS C JUN 6 1; *CDCP, 1985, MMWR-MORBID MORTAL W, V34, P731; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P43; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P688; Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, p1S; Centers for Disease Control (CDC), 1985, MMWR Morb Mortal Wkly Rep, V34, P721; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR EM, 1993, PEDIATR INFECT DIS J, V12, P513, DOI 10.1097/00006454-199306000-00011; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Green TA, 1998, STAT MED, V17, P143, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;143::AID-SIM757&gt;3.0.CO;2-Y; *I MED NAT RES COU, 1999, RED ODDS PREV PER TR; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KARON JM, 1989, LECTURE NOTES BIOMAT, V83, P58; KROGSTAD P, 1998, 5 C RETR OPP INF FEB; Lansky A, 1998, J ACQ IMMUN DEF SYND, V18, P289, DOI 10.1097/00042560-199807010-00014; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; MUELLER BU, 1997, 4 C RETR OPP INF JAN; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SIMONDS RJ, 1995, NEW ENGL J MED, V332, P786, DOI 10.1056/NEJM199503233321206; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Simpson BJ, 1997, J ACQ IMMUN DEF SYND, V14, P145, DOI 10.1097/00042560-199702010-00007; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; WANG MC, 1992, J AM STAT ASSOC, V87, P397, DOI 10.2307/2290270; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilfert C, 1998, PEDIATRICS, V101, P315, DOI 10.1542/peds.101.2.315; WORTLEY P, 1997, JAMA-J AM MED ASSOC, V298, P911	48	197	204	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					531	538		10.1001/jama.282.6.531	http://dx.doi.org/10.1001/jama.282.6.531			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450714	Bronze			2022-12-01	WOS:000081919100026
J	Rustin, P; von Kleist-Retzow, JC; Chantrel-Groussard, K; Sidi, D; Munnich, A; Rotig, A				Rustin, P; von Kleist-Retzow, JC; Chantrel-Groussard, K; Sidi, D; Munnich, A; Rotig, A			Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study	LANCET			English	Article							MITOCHONDRIAL-FUNCTION; IRON ACCUMULATION; OXIDATIVE STRESS; FRATAXIN; HOMOLOG; DEFICIENCY; ACONITASE; CHAIN; GENE	Background Friedreich's ataxia is caused by a deficiency of frataxin, a protein involved in regulation of mitochondrial iron content. We have reported a combined deficiency of a Krebs-cycle enzyme, aconitase, and three mitochondrial respiratory-chain complexes in endomyocardial biopsy samples from patients with this disorder. All four enzymes share iron-sulphur cluster-containing proteins that are damaged by iron overload through generation of oxygen free radicals. We used an in-vitro system to elucidate the mechanism of iron-induced injury and to test the protective effects of various substances. On the basis of these results, we assessed the effect of idebenone (a free-radical scavenger) in three patients with Friedreich's ataxia. Methods Heart homogenates from patients with valvular stenosis were tested for respiratory-chain complex II activity, lipoperoxidation, and aconitase activity by spectrophotometric assays, in the presence of reduced iron (Fe2+), oxidised iron (Fe3+), desferrioxamine, ascorbic acid, and idebenone. The Friedreich's ataxia patients (aged 11 years, 19 years, and 21 years) underwent ultrasonographic heart measurements at baseline and after 4-9 months of idebenone (5 mg/kg daily). Findings Fe2+ (but not Fe3+) decreased complex II activity and increased lipoperoxidation in heart homogenate. Addition of ascorbate or desferrioxamine increased some of the iron-induced adverse effects. Idebenone protected against these effects. In the three patients, left-ventricular mass index decreased from baseline to 4-9 months of idebenone treatment (patient 1, 145 g to 114 g; patient 2, 215 g to 151 g; patient 3, 408 g to 279 g). Interpretation Our in-vitro data suggest that both iron chelators and antioxidant drugs that may reduce iron are potentially harmful in patients with Friedreich's ataxia. Conversely, our preliminary findings in patients suggest that idebenone protects heart muscle from iron-induced injury.	Hop Necker Enfants Malad, INSERM, U393,, F-75743 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Munnich, A (corresponding author), Hop Necker Enfants Malad, INSERM, U393,, Tour Lavoisler,149 Rue Sevres, F-75743 Paris, France.		Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHAMBERLAIN S, 1989, AM J HUM GENET, V44, P518; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; GILLIS JC, 1994, DRUG AGING, V5, P133, DOI 10.2165/00002512-199405020-00007; HARDING AE, 1981, BRAIN, V104, P598; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; NIENHUIS AW, 1981, NEW ENGL J MED, V304, P170, DOI 10.1056/NEJM198101153040311; NZNAGY I, 1990, ARCH GERONTOL GERIAT, V11, P177; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SANCHEZCASIS G, 1977, CAN J NEUROL SCI, V3, P349; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352	18	284	301	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					477	479		10.1016/S0140-6736(99)01341-0	http://dx.doi.org/10.1016/S0140-6736(99)01341-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465173				2022-12-01	WOS:000081896100013
J	Geissler, PE; McEwen, AS; Ip, W; Belton, MJS; Johnson, TV; Smyth, WH; Ingersoll, AP				Geissler, PE; McEwen, AS; Ip, W; Belton, MJS; Johnson, TV; Smyth, WH; Ingersoll, AP			Galileo imaging of atmospheric emissions from Io	SCIENCE			English	Article							PLASMA TORUS; ELECTRON-IMPACT; ULTRAVIOLET; JUPITER; TEMPERATURE; VOLCANISM; SO2	The Galileo spacecraft has detected diffuse optical emissions from to in high-resolution images acquired while the satellite was eclipsed by Jupiter. Three distinct components make up lo's visible emissions. Bright blue glows of more than 300 kilorayleighs emanate from volcanic plumes, probably due to electron impact on molecular sulfur dioxide. Weaker red emissions, possibly due to atomic oxygen, are seen along the Limbs, brighter on the pole closest to the plasma torus. A faint green glow appears concentrated on the night side of to, possibly produced by atomic sodium. to's disk-averaged emission diminishes with time after entering eclipse, whereas the localized blue glows brighten instead.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA; Natl Cent Univ, Astron Inst, Chungli 320, Taiwan; Natl Opt Astron Observ, Tucson, AZ 85719 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Atmospher & Environm Res Inc, Cambridge, MA 02139 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	University of Arizona; National Central University; National Optical Astronomy Observatory; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Atmospheric & Environmental Research; California Institute of Technology	Geissler, PE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA.							AJELLO JM, 1992, J GEOPHYS RES-SPACE, V97, P10501, DOI 10.1029/92JA00295; AUSTIN JV, 1998, B AM ASTRON SOC, V30, P1121; BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; BALLESTER GE, 1997, B AM ASTRON SOC, V29, P980; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BRENEMAN H, 1993, D5880 JET PROP LAB; BROWN MA, UNPUB; Brown R. A., 1974, EXPLORATION PLANETAR, P527; BROWN RA, 1981, ASTROPHYS J, V244, P1072, DOI 10.1086/158777; CLARK REH, 1982, ASTROPHYS J, V254, P412, DOI 10.1086/159746; CLARKE JT, 1994, J GEOPHYS RES-PLANET, V99, P8387, DOI 10.1029/93JE02547; Combi MR, 1998, J GEOPHYS RES-SPACE, V103, P9071, DOI 10.1029/98JA00073; COOK AF, 1981, SCIENCE, V211, P1419, DOI 10.1126/science.211.4489.1419; DURRANCE ST, 1983, ASTROPHYS J, V267, pL125, DOI 10.1086/184016; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; Gold T, 1979, Science, V206, P1071, DOI 10.1126/science.206.4422.1071; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; Gurnett DA, 1996, SCIENCE, V274, P391, DOI 10.1126/science.274.5286.391; Hendrix AR, 1999, J GEOPHYS RES-PLANET, V104, P11817, DOI 10.1029/1999JE900009; Ingersoll AP, 1998, ICARUS, V135, P251, DOI 10.1006/icar.1998.5971; Klaasen KP, 1997, OPT ENG, V36, P3001, DOI 10.1117/1.601525; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; Linker JA, 1998, J GEOPHYS RES-PLANET, V103, P19867, DOI 10.1029/98JE00632; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; MILLER K, 1987, CAN J PHYS, V65, P530, DOI 10.1139/p87-074; PEARL J, 1979, NATURE, V280, P757; PERATT AL, 1988, ASTROPHYS SPACE SCI, V144, P451; Roesler FL, 1999, SCIENCE, V283, P353, DOI 10.1126/science.283.5400.353; SAUER J, IN PRESS J GEOPHYS R; SCHERB F, 1993, J GEOPHYS RES-PLANET, V98, P18729, DOI 10.1029/93JE00539; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; STROM RG, 1982, SATELLITES JUPITER, pCH16; TRAFTON L, 1975, NATURE, V258, P690, DOI 10.1038/258690a0; TRAUGER JT, 1976, B AM ASTRON SOC, V8, P468; TRAUGER JT, 1997, B AM ASTRON SOC, V29, P1002; Volwerk M, 1997, GEOPHYS RES LETT, V24, P1147, DOI 10.1029/97GL00966; WONG MC, 1998, B AM ASTRON SOC, V30, P1117	38	63	63	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					870	874		10.1126/science.285.5429.870	http://dx.doi.org/10.1126/science.285.5429.870			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436151				2022-12-01	WOS:000081860900043
J	Best, D; Noble, A; Finch, E; Gossop, M; Sidwell, C; Strang, J				Best, D; Noble, A; Finch, E; Gossop, M; Sidwell, C; Strang, J			Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USERS; VIRUS-INFECTION; RISK		Maudsley Hosp, Natl Addict Ctr, London SE5 8AF, England; Inst Psychiat, London SE5 8AF, England	South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London	Best, D (corresponding author), Maudsley Hosp, Natl Addict Ctr, London SE5 8AF, England.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Best, David/0000-0002-6792-916X				Crofts N, 1997, ADDICTION, V92, P999, DOI 10.1111/j.1360-0443.1997.tb02979.x; DOW BC, 1993, J MED VIROL, V41, P215, DOI 10.1002/jmv.1890410309; MAJID A, 1995, J MED VIROL, V46, P48, DOI 10.1002/jmv.1890460111; Rhodes T, 1996, ADDICTION, V91, P1457, DOI 10.1111/j.1360-0443.1996.tb02250.x; Serfaty MA, 1997, DRUG ALCOHOL REV, V16, P339, DOI 10.1080/09595239700186721	5	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					290	291		10.1136/bmj.319.7205.290	http://dx.doi.org/10.1136/bmj.319.7205.290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	224QE	10426739	Bronze, Green Published			2022-12-01	WOS:000081909100023
J	Aliprantis, AO; Yang, RB; Mark, MR; Suggett, S; Devaux, B; Radolf, JD; Klimpel, GR; Godowski, P; Zychlinsky, A				Aliprantis, AO; Yang, RB; Mark, MR; Suggett, S; Devaux, B; Radolf, JD; Klimpel, GR; Godowski, P; Zychlinsky, A			Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2	SCIENCE			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; SYNTHETIC LIPOPEPTIDE ANALOGS; TREPONEMA-PALLIDUM; CYTOKINE PRODUCTION; PATHWAY DISTINCT; MONOCYTIC CELLS; LIPOPOLYSACCHARIDE; GENE; FAMILY	Apoptosis is implicated in the generation and resolution of inflammation in response to bacterial pathogens. All bacterial pathogens produce lipoproteins (BLPs), which trigger the innate immune response. BLPs were found to induce apoptosis in THP-1 monocytic cells through human Toll-like receptor-2 (hTLR2). BLPs also initiated apoptosis in an epithelial cell line transfected with hTLR2. In addition, BLPs stimulated nuclear factor-kappa B, a transcriptional activator of multiple host defense genes, and activated the respiratory burst through hTLR2. Thus, hTLR2 is a molecular link between microbial products, apoptosis, and host defense mechanisms.	NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Genentech Inc, Antibody Technol Grp, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	New York University; New York University; Roche Holding; Genentech; Roche Holding; Genentech; University of Connecticut; University of Texas System; University of Texas Medical Branch Galveston	Zychlinsky, A (corresponding author), NYU, Sch Med, Skirball Inst, 540 1st Ave, New York, NY 10016 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714	NIAID NIH HHS [AI 37720-04, AI-38894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIPRANTIS AO, UNPUB; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bessler WG, 1997, INT J IMMUNOPHARMACO, V19, P547, DOI 10.1016/S0192-0561(97)00054-4; BESSLER WG, 1985, J IMMUNOL, V135, P1900; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Moss JE, 1999, INT REV CYTOL, V187, P203, DOI 10.1016/S0074-7696(08)62419-5; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Vidal V, 1998, NAT MED, V4, P1416, DOI 10.1038/4007; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG RG, UNPUB; Zhang HW, 1997, J IMMUNOL, V159, P4868; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	29	1228	1287	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					736	739		10.1126/science.285.5428.736	http://dx.doi.org/10.1126/science.285.5428.736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426996				2022-12-01	WOS:000081765100055
J	Edmonds, ME				Edmonds, ME			Progress in care of the diabetic foot	LANCET			English	Editorial Material							ULCERS		Univ London Kings Coll Hosp, Kings Diabet Ctr, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Edmonds, ME (corresponding author), Univ London Kings Coll Hosp, Kings Diabet Ctr, Denmark Hill, London SE5 9RS, England.							APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong D G, 1998, Clin Podiatr Med Surg, V15, P95; Edmonds M, 1994, FOOT DIABETES; EMBONDS M, 1996, DIABET MED S4, V13, pS27; Eneroth M, 1997, FOOT ANKLE INT, V18, P716, DOI 10.1177/107110079701801107; LARSSON J, 1995, DIABETIC MED, V12, P770, DOI 10.1111/j.1464-5491.1995.tb02078.x; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; Naughton G, 1997, ARTIF ORGANS, V21, P1203; PAPA J, 1993, J BONE JOINT SURG AM, V75A, P1056, DOI 10.2106/00004623-199307000-00012; POMPOSELLI FB, 1995, J VASC SURG, V21, P375, DOI 10.1016/S0741-5214(95)70279-2; Wieman TJ, 1998, AM J SURG, V176, P436, DOI 10.1016/S0002-9610(98)00235-9	11	35	35	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					270	272		10.1016/S0140-6736(99)90012-0	http://dx.doi.org/10.1016/S0140-6736(99)90012-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440300				2022-12-01	WOS:000081646000006
J	Yang, YM; Bauer, C; Strasser, G; Wollman, R; Julien, JP; Fuchs, E				Yang, YM; Bauer, C; Strasser, G; Wollman, R; Julien, JP; Fuchs, E			Integrators of the cytoskeleton that stabilize microtubules	CELL			English	Article							NEUROLOGIC DEGENERATION; INTERMEDIATE FILAMENTS; NERVOUS-SYSTEM; LIVING CELLS; MUTANT MICE; TAU-PROTEIN; ORGANIZATION; GENE; EXPRESSION; PLECTIN	Sensory neurodegeneration occurs in mice defective in BPAG1, a gene encoding cytoskeletal linker proteins capable of anchoring neuronal intermediate filaments to actin cytoskeleton. While BPAG1 null mice fail to anchor neurofilaments (NFs), BPAG1/NF null mice still degenerate in the absence of NFs. We report a novel neural splice form that lacks the actin-binding domain and instead binds and stabilizes microtubules. This interaction is functionally important; in mice and in vitro, neurons lacking BPAG1 display short, disorganized, and unstable microtubules defective in axonal transport. Ironically, BPAG1 neural isoforms represent microtubule-associated proteins that when absent lead to devastating consequences. Moreover, BPAG1 can functionally account for the extraordinary stability of axonal microtubules necessary for transport over long distances. Its isoforms interconnect all three cytoskeletal networks, a feature apparently central to neuronal survival.	Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Neurol, Chicago, IL 60637 USA; McGill Univ, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago; McGill University	Fuchs, E (corresponding author), Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA.	nliptak@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR27883] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; BAAS PW, 1994, J CELL SCI, V107, P135; BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; Bernier G, 1995, MOL CELL NEUROSCI, V6, P509, DOI 10.1006/mcne.1995.0003; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dalpe G, 1998, MOL CELL NEUROSCI, V10, P243, DOI 10.1006/mcne.1997.0660; Dowling J, 1997, DEV BIOL, V187, P131, DOI 10.1006/dbio.1997.8567; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Eyer J, 1998, NATURE, V391, P584, DOI 10.1038/35378; Gimona M, 1998, CURR BIOL, V8, pR674; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MORRIS JR, 1982, J CELL BIOL, V92, P192, DOI 10.1083/jcb.92.1.192; NAGELE RG, 1988, BRAIN RES, V474, P279, DOI 10.1016/0006-8993(88)90441-6; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Strumpf D, 1998, J CELL BIOL, V143, P1259, DOI 10.1083/jcb.143.5.1259; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WEBB BC, 1980, BIOCHEMISTRY-US, V19, P1993, DOI 10.1021/bi00550a041; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	36	157	162	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					229	238		10.1016/S0092-8674(00)81017-X	http://dx.doi.org/10.1016/S0092-8674(00)81017-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428034	Bronze			2022-12-01	WOS:000081632300012
J	Huang, JT; Welch, JS; Ricote, M; Binder, CJ; Willson, TM; Kelly, C; Witztum, JL; Funk, CD; Conrad, D; Glass, CK				Huang, JT; Welch, JS; Ricote, M; Binder, CJ; Willson, TM; Kelly, C; Witztum, JL; Funk, CD; Conrad, D; Glass, CK			Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; LOW-DENSITY-LIPOPROTEIN; MAMMALIAN LIPOXYGENASES; PERITONEAL-MACROPHAGES; HUMAN 15-LIPOXYGENASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; OXIDIZED LDL; CD36; FIBROBLASTS	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-dependent nuclear receptor that has been implicated in the modulation of critical aspects of development and homeostasis, including adipocyte differentiation(1), glucose metabolism(2,3) and macrophage development and function(4-6). PPAR-gamma is activated by a range of synthetic and naturally occurring substances, including antidiabetic thiazolidinediones(2,3), polyunsaturated fatty acids(7), 15-deoxy-Delta(12,14)prostaglandin J(2) (refs 8, 9) and components of oxidized low-density lipoprotein, such as 13-hydroxyoctadecadienoic acid (13-HODE) and 15-hydroxyeicosatetraenoic acid (15-HETE)(10), However, the identities of endogenous ligands for PPAR-gamma and their means of production in vivo have not been established. In monocytes and macrophages, 13-HODE and 15-HETE can be generated from linoleic and arachidonic acids, respectively, by a 12/15-lipoxygenase that is upregulated by the T(H)2-derived cytokine interleukin-4 (ref. 11). Here we show that interleukin-4 also induces the expression of PPAR-gamma and provide evidence that the coordinate induction of PPAR-gamma and 12/15-lipoxygenase mediates interleukin-4-dependent transcription of the CD36 gene in macrophages. These findings reveal a physiological role of 12/15-lipoxygenase in the generation of endogenous ligands for PPAR-gamma, and suggest a paradigm for the regulation of nuclear receptor function by cytokines.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Nephrol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; GlaxoSmithKline; University of Pennsylvania	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.		feinstein, doug/M-9414-2019; Ricote, Mercedes/L-4615-2014; Funk, Colin D/A-9518-2010; Glass, Christopher/AAI-3933-2021	Ricote, Mercedes/0000-0002-8090-8902; Glass, Christopher/0000-0003-4344-3592; Binder, Christoph J./0000-0001-8313-7050; Funk, Colin/0000-0001-7029-4233				BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KILEWER SA, 1995, CELL, V83, P813; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; RANKIN SM, 1991, J LIPID RES, V32, P449; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	30	739	772	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					378	382		10.1038/22572	http://dx.doi.org/10.1038/22572			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432118				2022-12-01	WOS:000081590000054
J	Lowrie, DB; Tascon, RE; Bonato, VLD; Lima, VMF; Faccioli, LH; Stavropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K; Silva, CL				Lowrie, DB; Tascon, RE; Bonato, VLD; Lima, VMF; Faccioli, LH; Stavropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K; Silva, CL			Therapy of tuberculosis in mice by DNA vaccination	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; INTERLEUKIN-12; EXPRESSION; INFECTION; IMMUNITY; IL-12; RESISTANCE; ANTIGEN; MPT70	Mycobacterium tuberculosis continues to kill about 3 million people every year(1), more than any other single infectious agent, This is attributed primarily to an inadequate immune response towards infecting bacteria, which suffer growth inhibition rather than death and subsequently multiply catastrophically. Although the bacillus Calmette-Guerin (BCG) vaccine is widely used, it has major limitations as a preventative measure(2), In addition, effective treatment requires that patients take large doses of antibacterial drug combinations for at least 6 months after diagnosis(3), which is difficult to achieve in many parts of the world and is further restricted by the emergence of multidrug-resistant strains of M. tuberculosis, In these circumstances, immunotherapy to boost the efficiency of the immune system in infected patients could be a valuable adjunct to antibacterial chemotherapy(4), Here we show in mice that DNA vaccines, initially designed to prevent infection, can also have a pronounced therapeutic action, In heavily infected mice, DNA vaccinations can switch the immune response from one that is relatively inefficient and gives bacterial stasis to one that kills bacteria, Application of such immunotherapy in conjunction with conventional chemotherapeutic antibacterial drugs might result in faster or more certain cure of the disease in humans.	Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, BR-14049900 Ribeirao Preto, SP, Brazil; Natl Inst Med Res, Mycobacteriol Res Lab, London NW7 1AA, England; Cent Vet Lab, Addlestone KT15 3NB, Surrey, England; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Universidade de Sao Paulo; Universidade de Sao Paulo; MRC National Institute for Medical Research; University of Zurich	Silva, CL (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, BR-14049900 Ribeirao Preto, SP, Brazil.	clsilva@beverly.fmrp.usp.br	Hewinson, Glyn/J-1902-2014; Hewinson, Glyn/F-7077-2010; Silva, Celio/C-4639-2012; Lucia, Faccioli/G-8976-2015; Hewinson, Glyn/AAA-2364-2019; Bonato, Vania LD/C-3509-2015; Faccioli, Lúcia Helena/AGH-5297-2022; de Lima, Valéria M.F./B-7867-2013; Lowrie, Douglas/B-8151-2013	Silva, Celio/0000-0002-0043-4568; Lucia, Faccioli/0000-0002-4999-8305; Bonato, Vania LD/0000-0003-4189-2685; Faccioli, Lúcia Helena/0000-0002-4999-8305; de Lima, Valéria M.F./0000-0002-0954-5045; Lowrie, Douglas/0000-0003-2689-9627; Hewinson, Glyn/0000-0002-5517-4281				ALLAN WGL, 1982, TUBERCLE, V63, P89; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Bloom Barry R., 1994, P531; Bonato VLD, 1998, INFECT IMMUN, V66, P169, DOI 10.1128/IAI.66.1.169-175.1998; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; de Jong R, 1998, SCIENCE, V280, P1435; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; FLYNN JL, 1995, J IMMUNOL, V155, P2515; Hewinson RG, 1996, SCAND J IMMUNOL, V43, P490, DOI 10.1046/j.1365-3083.1996.d01-78.x; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Johnston SA, 1997, VACCINE, V15, P808, DOI 10.1016/S0264-410X(96)00276-9; KOCHI A, 1994, LANCET, V344, P608; Krieg AM, 1998, J IMMUNOL, V161, P2428; Lai WC, 1997, J IMMUNOL, V158, P2513; Lowrie DB, 1997, VACCINE, V15, P834, DOI 10.1016/S0264-410X(97)00073-X; MATSUMOTO S, 1995, SCAND J IMMUNOL, V41, P281, DOI 10.1111/j.1365-3083.1995.tb03565.x; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; ORME IM, 1993, J IMMUNOL, V151, P518; SCHULTZ J, IN PRESS HUM GENE TH; Smith P. G., 1994, P47; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tascon RE, 1997, NATO ADV SCI I A-LIF, V293, P181; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; WIEGESHAUS E, 1989, INFECT IMMUN, V57, P3671, DOI 10.1128/IAI.57.12.3671-3676.1989; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; ZHANG M, 1995, INFECT IMMUN, V63, P3231, DOI 10.1128/IAI.63.8.3231-3234.1995; Zhu XJ, 1997, J IMMUNOL, V158, P5921	30	372	425	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					269	271		10.1038/22326	http://dx.doi.org/10.1038/22326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421369				2022-12-01	WOS:000081503800045
J	Kadir, RA; Sabin, C; Whitlow, B; Brockbank, E; Economides, D				Kadir, RA; Sabin, C; Whitlow, B; Brockbank, E; Economides, D			Neural tube defects and periconceptional folic acid in England and Wales: retrospective study	BRITISH MEDICAL JOURNAL			English	Article								The risks of a first occurrence and a recurrence of neural tube defects have been shown to be reduced by periconceptional folic acid supplementation-that is by taking folic acid from 3 months before conception to 3 months after conception.(1 2) The Expert Advisory Group in the United Kingdom recommended in 1992 that women who were trying to conceive should take 0.4 mg folic acid per day.(3) We assessed whether there had been any change in the incidence of neural tube defects since this recommendation was made.	UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, London NW3 2QG, England; UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Populat Sci, London, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Economides, D (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, London NW3 2QG, England.		Abdulkadir, Rezan/C-5589-2008; Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; *DEP HLTH SCOTT OF, 1992, REP EXP ADV GROUP FO; McGovern E, 1997, BRIT J GEN PRACT, V47, P635; WALD N, 1991, LANCET, V338, P131	4	40	40	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					92	93		10.1136/bmj.319.7202.92	http://dx.doi.org/10.1136/bmj.319.7202.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398632	Green Published, Bronze			2022-12-01	WOS:000081438200031
J	Nightingale, SL				Nightingale, SL			Trovafloxacin public health advisory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					19	19		10.1001/jama.282.1.19	http://dx.doi.org/10.1001/jama.282.1.19			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404896				2022-12-01	WOS:000081195800007
J	Todd, JA				Todd, JA			Interpretation of results from genetic studies of multifactorial diseases	LANCET			English	Article							ALZHEIMER-DISEASE; INSULIN GENE		Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England	University of Cambridge	Todd, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust-MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Todd, John/A-3542-2010	Todd, John/0000-0003-2740-8148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altshuler D, 1998, NEW ENGL J MED, V338, P1626, DOI 10.1056/NEJM199805283382214; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Blacker D, 1998, ARCH NEUROL-CHICAGO, V55, P294, DOI 10.1001/archneur.55.3.294; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Bonn D, 1999, LANCET, V353, P1684, DOI 10.1016/S0140-6736(05)76995-6; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; CUCCA F, 1996, HLA MHC GENES MOL FU, P3483; DAY N, IN PRESS BR J CANC S; Dow DJ, 1999, NAT GENET, V22, P16, DOI 10.1038/8724; Golding J, 1990, West Engl Med J, V105, P80; Rogaeva EA, 1999, NAT GENET, V22, P19, DOI 10.1038/8729; Rudrasingham V, 1999, NAT GENET, V22, P17, DOI 10.1038/8726; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; TODD JA, IN PRESS METABOLIC M; 1999, NAT GENET, V22, P1	17	21	21	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI15	SI16						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437850				2022-12-01	WOS:000081825900005
J	Rzany, B; Correia, O; Kelly, JP; Naldi, L; Auquier, A; Stern, R				Rzany, B; Correia, O; Kelly, JP; Naldi, L; Auquier, A; Stern, R		Study Grp Int Case-Control Study Sever	Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study	LANCET			English	Article							ERYTHEMA MULTIFORME; LAMOTRIGINE; APOPTOSIS; RADIATION; GERMANY; DEATH	Background There is still controversy about whether all antiepileptic drugs are associated with the severe cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We have studied the role of antiepileptic drugs in SJS and TEN, taking into account potential cofactors that might confound or modify the risk. Methods The case-control study in France, Italy, Germany, and Portugal identified cases of SJS/TEN that developed when the patient was not in hospital and were validated by an expert committee. Controls were patients admitted to the same hospital as the case for an acute illness or an elective procedure. Findings 73 (21%) of the 352 SJS/TEN cases and 28 (2%) of the 1579 controls reported intake of antiepileptic drugs. Among the 73 exposed SJS and TEN patients, 36 reported intake of phenobarbital, 14 of phenytoin, 21 of carbamazepine, 13 of valproic acid, and three of lamotrigine. Risk was highest in the first 8 weeks after onset of treatment. For individual antiepileptic drugs the univariate relative risk of SJS/TEN for 8 weeks or less of use was 57 (95% CI 16-360; multivariate risk 59 [12-302]) for phenobarbital; 91(26-infinity) for phenytoin; 120 (34-infinity) for carbamazepine; 25 (5.6-infinity) for lamotrigine, and 24 (5.9-infinity) for valproic acid. The result for valproic acid was based on four case users, all of whom reported concurrent use of other associate drugs. The univariate relative risk for more than 8 weeks of use was 6.2 (2.4-17.0; multivariate risk 2.1 [0.5-9.3]) for phenobarbital, 1.2 (0-5.4) for phenytoin, 0.4 (0.02-2.1) for carbamazepine, and 7.0 (2.4-21.0; multivariate risk 2.0 [0.3-15.0]) for valproic acid. Interpretation SJS and TEN are associated with short-term therapy with phenytoin, phenobarbital, and carbamazepine. The association with valproic acid seems to be confounded by concomitant short-term therapy with other causal drugs. Lamotrigine also has the potential for severe skin reactions. The period of increased risk is largely confined to the first 8 weeks of treatment.	Univ Heidelberg, Fak Klin Med Mannheim, Dept Dermatol, D-6800 Mannheim, Germany; Fac Med, Inst Portugues Oncol & Immunol, Dept Dermatol & Immunol, Porto, Portugal; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Milan, Osped Riuniti, Dept Dermatol, Bergamo, Italy; Inst Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France; Harvard Univ, Sch Med, Beth Israel Deaconess Med CTr, Dept Dermatol, Boston, MA USA	Ruprecht Karls University Heidelberg; Universidade do Porto; Boston University; Ospedali Riuniti di Bergamo; University of Milan; UNICANCER; Gustave Roussy; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rzany, B (corresponding author), Univ Heidelberg, Klinikum Mannheim gGmbH, Fak Klin Med Mannheim, Hautklin, Theodor Kutzer Ufer, D-68135 Mannheim, Germany.		Naldi, Luigi/AFM-8982-2022; Naldi, Luigi/K-6343-2016	Naldi, Luigi/0000-0002-3160-2835; Naldi, Luigi/0000-0002-3160-2835				ASMARK H, 1990, ACTA NEUROL SCAND, V81, P131; BASTUJI S, 1993, ARCH DERMATOL, V125, P92; Borg M F, 1995, Australas Radiol, V39, P42, DOI 10.1111/j.1440-1673.1995.tb00230.x; Chaffin JJ, 1997, ANN PHARMACOTHER, V31, P720, DOI 10.1177/106002809703100609; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; CHEN M, 1995, CANCER RES, V55, P991; DELATTRE JY, 1988, NEUROLOGY, V38, P194, DOI 10.1212/WNL.38.2.194; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DUVAL X, 1995, LANCET, V345, P1301; Fogh K, 1997, SEIZURE, V6, P63, DOI 10.1016/S1059-1311(97)80055-6; GOODMAN LS, 1985, PHARMACOL BASIS THER, P446; Inachi S, 1997, ARCH DERMATOL, V133, P845, DOI 10.1001/archderm.133.7.845; KELLY JP, 1995, J CLIN EPIDEMIOL, V48, P1099, DOI 10.1016/0895-4356(95)00004-N; LEENUTAPHONG V, 1993, INT J DERMATOL, V32, P428, DOI 10.1111/j.1365-4362.1993.tb02814.x; MAICHE A, 1985, LANCET, V2, P45; MIETTINEN OS, 1976, AM J EPIDEMIOL, V109, P226; NAWALKHA PL, 1972, BRIT J RADIOL, V45, P768, DOI 10.1259/0007-1285-45-538-768; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; RUIZMALDONADO R, 1985, J AM ACAD DERMATOL, V13, P623, DOI 10.1016/S0190-9622(85)70207-1; Rzany B, 1996, J CLIN EPIDEMIOL, V49, P769, DOI 10.1016/0895-4356(96)00035-2; Sachs B, 1996, LANCET, V348, P1597, DOI 10.1016/S0140-6736(05)66227-7; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; STERKER M, 1995, INT J CLIN PHARM TH, V33, P595; STERN RS, 1989, J AM ACAD DERMATOL, V21, P317, DOI 10.1016/S0190-9622(89)70176-6; Sullivan J R, 1996, Australas J Dermatol, V37, P208, DOI 10.1111/j.1440-0960.1996.tb01057.x; Tennis P, 1997, NEUROLOGY, V49, P542, DOI 10.1212/WNL.49.2.542; Wadelius M, 1996, LANCET, V348, P1041, DOI 10.1016/S0140-6736(05)64979-3	29	222	226	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2190	2194		10.1016/S0140-6736(98)05418-X	http://dx.doi.org/10.1016/S0140-6736(98)05418-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392983				2022-12-01	WOS:000081091300011
J	Hong, KS; Hinck, L; Nishiyama, M; Poo, MM; Tessier-Lavigne, M; Stein, E				Hong, KS; Hinck, L; Nishiyama, M; Poo, MM; Tessier-Lavigne, M; Stein, E			A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion	CELL			English	Article							C-ELEGANS; COLORECTAL-CANCER; AXON GUIDANCE; ENCODES; PROTEIN; GENES; IMMUNOGLOBULIN; EXPRESSION; MIGRATIONS; RESPONSES	Netrins are bifunctional: they attract some axons and repel others. Netrin receptors of the Deleted in Colorectal Cancer (DCC) family are implicated in attraction and those of the UNC5 family in repulsion, but genetic evidence also suggests involvement of the DCC protein UNC-40 in some cases of repulsion. To test whether these proteins form a receptor complex for repulsion, we studied the attractive responses of Xenopus spinal axons to netrin-1, which are mediated by DCC. Vie show that attraction is converted to repulsion by expression of UNC5 proteins in these cells, that this repulsion requires DCC function, that the UNC5 cytoplasmic domain is sufficient to effect the conversion, and that repulsion can be initiated by netrin-1 binding to either UNC5 or DCC. The isolated cytoplasmic domains of DCC and UNC5 proteins interact directly, but this interaction is repressed in the context of the full-length proteins. We provide evidence that netrin-1 triggers the formation of a receptor complex of DCC: and UNC5 proteins and simultaneously derepresses the interaction between their cytoplasmic domains, thereby converting DCC-mediated attraction to UNC5/DCC-mediated repulsion.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692; Hinck, Lindsay/0000-0002-4009-3913	NINDS NIH HHS [NS22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Gong QZ, 1999, DEVELOPMENT, V126, P1451; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Przyborski SA, 1998, DEVELOPMENT, V125, P41; Rose M, 1990, LAB COURSE MANUAL ME; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tabti N., 1991, CULTURING NERVE CELL, P137; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Van Vactor D, 1999, NEURON, V22, P649, DOI 10.1016/S0896-6273(00)80723-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wadsworth WG, 1996, BIOESSAYS, V18, P355, DOI 10.1002/bies.950180505; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; ZHANG JQ, 1994, NATURE, V368, P140	37	545	568	1	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					927	941		10.1016/S0092-8674(00)80804-1	http://dx.doi.org/10.1016/S0092-8674(00)80804-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399920	Bronze			2022-12-01	WOS:000081162800013
J	Romashkova, JA; Makarov, SS				Romashkova, JA; Makarov, SS			NF-kappa B is a target of AKT in anti-apoptotic PDGF signalling	NATURE			English	Article							KINASE-C-ZETA; GROWTH-FACTOR; CELL-DEATH; PROTEIN; ACTIVATION; PHOSPHORYLATION; FIBROBLASTS; INDUCTION; RAS; TRANSDUCTION	The mechanisms of cell proliferation and transformation are intrinsically linked to the process of apoptosis: the default of proliferating cells is to die unless specific survival signals are provided(1,2). Platelet-derived growth factor (PDGF) is a principal survival factor that inhibits apoptosis and promotes proliferation(1), but the mechanisms mediating its anti-apoptotic properties are not completely understood. Here we show that the transcription factor NF-kappa B3-5 is important in PDGF signalling. NF-kappa B transmits two signals: one is required for the induction of proto-oncogene c-myc and proliferation, and the second, an anti-apoptotic signal, counterbalances c-Myc cytotoxicity. We have traced a putative pathway whereby PDGF activates NF-kappa B through pas and phospatidylinositol-3-kinase (PI(3)K) to the PKB/Akt protein kinase and the I kappa B kinase (IKK); NF-kappa B thus appears to be a target of the anti-apoptotic Ras/PI(3)K/Akt pathway(6,7). We show that, upon PDGF stimulation, Akt transiently associates in vivo with IKK and induces IKK activation. These findings establish a role for NF-kappa B in growth factor signalling and define an anti-apoptotic Ras/PI(3)K/Akt/IKK/NF-kappa B pathway, thus linking anti-apoptotic signalling with transcription machinery.	Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Makarov, SS (corresponding author), Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Firestein GS, 1999, ARTHRITIS RHEUM-US, V42, P609, DOI 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I; Foo SY, 1999, TRENDS GENET, V15, P229; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARRIS CC, 1994, CANCER EPIDEM BIOMAR, V3, P1; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Makarov SS, 1996, P NATL ACAD SCI USA, V93, P402, DOI 10.1073/pnas.93.1.402; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296	30	1619	1671	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					86	90		10.1038/43474	http://dx.doi.org/10.1038/43474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485711				2022-12-01	WOS:000082374400047
J	Haddow, JE; Palomaki, GE; Allan, WC; Williams, JR; Knight, GJ; Gagnon, J; O'Heir, CE; Mitchell, ML; Hermos, RJ; Waisbren, SE; Faix, JD; Klein, RZ				Haddow, JE; Palomaki, GE; Allan, WC; Williams, JR; Knight, GJ; Gagnon, J; O'Heir, CE; Mitchell, ML; Hermos, RJ; Waisbren, SE; Faix, JD; Klein, RZ			Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOTHYROIDISM; IMMUNOGLOBULINS; BINDING; WOMEN	Background When thyroid deficiency occurs simultaneously in a pregnant woman and her fetus, the child's neuropsychological development is adversely affected. Whether developmental problems occur when only the mother has hypothyroidism during pregnancy is not known. Methods In 1996 and 1997,we measured thyrotropin in stored serum samples collected from 25,216 pregnant women between January 1987 and March 1990. We then located 47 women with serum thyrotropin concentrations at or above the 99.7th percentile of the values for all the pregnant women, 15 women with values between the 98th and 99.6th percentiles, inclusive, in combination with low thyroxine levels, and 124 matched women with normal values. Their seven-to-nine-year-old children, none of whom had hypothyroidism as newborns, underwent 15 tests relating to intelligence, attention, language, reading ability, school performance, and visual-motor performance. Results The children of the 62 women with high serum thyrotropin concentrations performed slightly less well on all 15 tests. Their full-scale IQ scares on the Wechsler Intelligence Scale for Children, third edition, averaged 4 points lower than those of the children of the 124 matched control women (P=0.06); 15 percent had scores of 85 or less, as compared with 5 percent of the matched control children. Of the 62 women with thyroid deficiency, 48 were not treated for the condition during the pregnancy under study. The full-scale IQ scores of their children averaged 7 points lower than those of the 124 matched control children (P=0.005); 19 percent had scores of 85 or less. Eleven years after the pregnancy under study, 64 percent of the untreated women and 4 percent of the matched control women had confirmed hypothyroidism. Conclusions Undiagnosed hypothyroidism in pregnant women may adversely affect their fetuses; therefore, screening for thyroid deficiency during pregnancy may be warranted. (N Engl J Med 1999;341:549-55.) (C)1999, Massachusetts Medical Society.	Fdn Blood Res, Scarborough, ME 04074 USA; New England Newborn Screening Program, Jamaica Plain, MA USA; Childrens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA USA; Dartmouth Med Sch, Hanover, NH USA	Foundation for Blood Research (FBR); Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	Haddow, JE (corresponding author), Fdn Blood Res, 69 US Rte 1, Scarborough, ME 04074 USA.		Fahimifar, Sepideh/M-5303-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031183] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD31183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; CHO BY, 1988, ENDOCRINOL JAPON, V35, P819; CONNERS CK, 1994, CPT COMPUTER PROGRAM; CONNORS MH, 1986, PEDIATRICS, V78, P287; Dussault JH, 1999, OBSTET GYNECOL, V93, P15, DOI 10.1016/S0029-7844(98)00369-X; FORT P, 1988, J CLIN ENDOCR METAB, V66, P645, DOI 10.1210/jcem-66-3-645; Gardner LI, 1975, ENDOCRINE GENETIC DI, P234; GOLDSMITH RE, 1973, J CLIN ENDOCR METAB, V37, P265, DOI 10.1210/jcem-37-2-265; HADDOW JE, 1983, OBSTET GYNECOL, V62, P556; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KLEIN RZ, 1991, CLIN ENDOCRINOL, V35, P41, DOI 10.1111/j.1365-2265.1991.tb03494.x; MAN EB, 1969, AM J OBSTET GYNECOL, V104, P898, DOI 10.1016/0002-9378(69)90644-9; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MARKWARDT F, 1989, PEABODY INDIVIDUAL A; MATSUURA N, 1990, ENDOCRINOL JAPON, V37, P369; MATSUURA N, 1990, ENDOCRINOL JAPON, V37, pA767; MITCHELL ML, 1976, CLIN CHEM, V22, P1912; NEWCOMER P, 1991, TEST LANGUAGE DEV, V2; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; SUTHERLAND JM, 1960, NEW ENGL J MED, V263, P336, DOI 10.1056/NEJM196008182630703; Trites R., 1989, GROOVED PEGBOARD TES; Volpe J., 1995, NEUROLOGY NEWBORN, P43; Wechsler D, 1991, WECHSLER INTELLIGENC, V3rd	26	1585	1714	3	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					549	555		10.1056/NEJM199908193410801	http://dx.doi.org/10.1056/NEJM199908193410801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451459				2022-12-01	WOS:000082061500001
J	Gardner, K; Chapple, A				Gardner, K; Chapple, A			Barriers to referral in patients with angina: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY; REVASCULARIZATION; ACCESS; RATES; CARE; UK	Objectives To explore barriers to patients being referred for possible revascularisation. Design Qualitative study using semi-structured interviews. Participants 16 patients aged under 75 years with stable angina and their doctors. Setting General practice in Toxteth, Liverpool. Results Fear of both hospitals and medical tests was common and largely hidden from the doctors. Patients felt they were old, had low expectations of treatment, viewed angina as a chronic illness, and knew little about new developments in angina treatment Patients and doctors had difficulty in recognising angina symptoms that were not textbook definitions amid multiple comorbidity. Patients saw doctors as busy and did not want to bother them with their condition. Cultural gaps and communication difficulties existed despite all but one patient having English as their first language. Conclusions Listening to patients is vital to address inequitable access to health services: how patients are treated by doctors today affects acceptability of referral tomorrow. Primary care groups in deprived areas should work With communities to address local fears. This will involve collaboration between primary, secondary, and tertiary care. Cultural gaps exist between patients and doctors in deprived areas, and diagnostic confusion can occur particularly in die presence of other psychological and physical morbidity. Adequate time and resources-for example, education for doctors and patients and provision of interpreters-need to he provided if inequitable access to revascularisation procedures is to be addressed.	Princes Pk Hlth Ctr, Liverpool L8 OSY, Merseyside, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Gardner, K (corresponding author), Princes Pk Hlth Ctr, Liverpool L8 OSY, Merseyside, England.							ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; BEERY TA, 1995, HEART LUNG, V24, P427, DOI 10.1016/S0147-9563(95)80020-4; BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; BLACK N, 1995, J EPIDEMIOL COMMUN H, V49, P408, DOI 10.1136/jech.49.4.408; Chapple A, 1998, J Health Serv Res Policy, V3, P153; FORREST D, 1995, HEART DIS PREVENTION; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; Kee F, 1993, Qual Health Care, V2, P87, DOI 10.1136/qshc.2.2.87; LEAR JT, 1994, J R SOC MED, V84, P661; Morse JM, 1999, QUAL HEALTH RES, V9, P5, DOI 10.1177/104973299129121622; Morse JM, 1997, QUAL HEALTH RES, V7, P445, DOI 10.1177/104973239700700401; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; PENDLETON D, 1984, CONSULTATOIN APPROAC; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; Popay J, 1996, SOC SCI MED, V42, P759, DOI 10.1016/0277-9536(95)00341-X; Ruston A, 1998, BRIT MED J, V316, P1060; SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717; Tesch R, 1990, ANAL TYPES SOFTWARE	19	59	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					418	421		10.1136/bmj.319.7207.418	http://dx.doi.org/10.1136/bmj.319.7207.418			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445924	Bronze, Green Published			2022-12-01	WOS:000082098900018
J	Hermans, PWM; Hibberd, ML; Booy, R; Daramola, O; Hazelzet, JA; de Groot, R; Levin, M				Hermans, PWM; Hibberd, ML; Booy, R; Daramola, O; Hazelzet, JA; de Groot, R; Levin, M		Meningococcal Res Grp	4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; PROTEIN-C; PURPURA FULMINANS; SEPTIC SHOCK; PLASMA ENDOTOXIN; ASSOCIATION; COAGULATION; CHILDREN; INTERLEUKIN-1; ANTITHROMBIN	Background Intravascular coagulation with infarction of skin, digits, and limbs is a characteristic feature of meningococcal sepsis. Children with meningococcal sepsis have higher than normal concentrations of plasminogen activator inhibitor 1 (PAI-1) in plasma. Combined with the widespread venous thrombosis, this finding suggests an impairment of fibrinolysis. A common functional insertion/deletion (4G/5G) polymorphism exists in the promoter region of the PAI-1. gene. We tested the hypothesis that children with the 4G/4G genotype produce higher concentrations of PAI-1, develop more severe coagulopathy, and are at greater risk of death during meningococcal sepsis. Methods The relation between meningococcal disease outcome, PAI-1 concentration, ana PAI-1 genotype was investigated in 175 children with meningococcal disease (37 from Rotterdam, the Netherlands, and 138 from London, UK) and 226 controls (137 from Rotterdam, 89 from London). PAI-1 concentrations in plasma were measured by ELISA, and the 4G/5G PAI-1 polymorphism was detected by PCR and hybridisation. Findings Concentrations of PAI-1 on admission correlated with presentation (sepsis or meningitis) and outcome. The median PAI-1 concentration in children who died was substantially higher than that in survivors (2448 [IQR 1115-3191] vs 370 [146-914] ng/mL; p<0.0001). Patients with the 4G/4G genotype had significantly higher PAI-1 concentrations than those with the 4G/5G or 5G/5G genotype (1051 [550-2440] vs 436 [198-1225] ng/mL; p=0.03), and had an increased risk of death (relative risk 2.0 [1.0-3.8] for the two cohorts combined, and 4.8 [1.8-13] for the London cohort). Interpretation A genetic predisposition to produce high concentrations of PAI-1 is associated with poor outcome of meningococcal sepsis. This finding suggests that impaired fibrinolysis is an important factor in the pathophysiology of meningococcal sepsis.	Erasmus Univ, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat, London, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Imperial College London; University of London; University College London	Hermans, PWM (corresponding author), Erasmus Univ, Lab Paediat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Hazelzet, Jan A/L-2888-2015; Hermans, Peter W.M./H-8042-2014; Hermans, Peter P.W.M./F-4655-2010; Hibberd, Martin L/D-5050-2009	Hazelzet, Jan/0000-0002-9414-5539; Hibberd, Martin/0000-0001-8587-1849; Levin, Michael/0000-0003-2767-6919	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achtman M, 1995, MENINGOCOCCAL DIS, P159; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZAEG P, 1989, J INFECT DIS, V160, P58, DOI 10.1093/infdis/160.1.58; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; DAY KC, 1990, BLOOD, V76, P1538; Derkx B, 1999, CLIN INFECT DIS, V28, P770, DOI 10.1086/515184; DRAPKIN MS, 1989, PEDIATR INFECT DIS J, V8, P399, DOI 10.1097/00006454-198906000-00015; Duncan A, 1997, LANCET, V350, P1565, DOI 10.1016/S0140-6736(05)64007-X; ENGEBRETSEN LF, 1986, THROMB RES, V42, P713, DOI 10.1016/0049-3848(86)90351-8; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; FOURRIER F, 1990, INTENS CARE MED, V16, P121, DOI 10.1007/BF01699858; GLADSON CL, 1989, BLOOD, V74, P173; Hazelzet JA, 1996, THROMB HAEMOSTASIS, V76, P932; HEYDERMAN RS, 1991, ARCH DIS CHILD, V66, P1296, DOI 10.1136/adc.66.11.1296; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; KUPPERMANN N, 1994, PEDIATR INFECT DIS J, V13, P867, DOI 10.1097/00006454-199410000-00004; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NADEL S, 1995, MENINGOCOCCAL DIS, P207; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; POWARS DR, 1987, NEW ENGL J MED, V317, P571; Ryan MP, 1996, BIOCHEM J, V314, P1041, DOI 10.1042/bj3141041; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; SPEER CP, 1987, J PEDIATR-US, V111, P667, DOI 10.1016/S0022-3476(87)80240-8; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; ZENZ W, 1995, PEDIATRICS, V96, P144	30	218	226	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					556	560		10.1016/S0140-6736(99)02220-5	http://dx.doi.org/10.1016/S0140-6736(99)02220-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470700				2022-12-01	WOS:000081991000013
J	Conradt, B; Horvitz, HR				Conradt, B; Horvitz, HR			The TRA-1A sex determination protein of C. elegans regulates sexually dimorphic cell deaths by repressing the egl-1 cell death activator gene	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REGULATION; CUBITUS INTERRUPTUS; SIGNALING PATHWAY; IN-VITRO; APOPTOSIS; DROSOPHILA; NUCLEUS; FAMILY; DIFFERENTIATION	The hermaphrodite-specific neurons (HSNs) of the nematode Caenorhabditis elegans are generated embryonically in both hermaphrodites and males but undergo programmed cell death in males. The gene egl-1 encodes a BH3-containing cell death activator that is required for programmed cell death in C. elegans. Gain-of-function (gf) mutations in egl-1 cause the inappropriate programmed cell death of the HSNs in hermaphrodites. These mutations lie 5.6 kb downstream of the egl-1 transcription unit and disrupt the binding of the TRA-1A zinc finger protein, the terminal global regulator of somatic sexual fate. This disruption results in the activation of the egl-1 gene in the HSNs not only in males but also in hermaphrodites. Our findings suggest that in hermaphrodites TRA-1A represses egl-1 transcription in the HSNs to prevent these neurons from undergoing programmed cell death.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02319 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), Max Planck Inst Neurobiol, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	horvitz@mit.edu	Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BREEDLOVE SM, 1986, J NEUROBIOL, V17, P157, DOI 10.1002/neu.480170304; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CLARK SG, 1994, GENETICS, V137, P987; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/0006-8993(96)00298-3; DEBONO M, 1995, GENE DEV, V9, P155, DOI 10.1101/gad.9.2.155; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; DESAI C, 1989, GENETICS, V121, P703; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KIM RJ, 1989, J NEUROSCI, V9, P3176; KONISHI M, 1985, NATURE, V315, P145, DOI 10.1038/315145a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MEYER BJ, 1997, C ELEGANS, V2, P209; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NORDEEN EJ, 1985, SCIENCE, V229, P671, DOI 10.1126/science.4023706; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PERRY MD, 1994, GENETICS, V138, P317; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Priess J. R., 1997, C ELEGANS 2; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Sasaki H, 1997, DEVELOPMENT, V124, P1313; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORN RS, 1994, J NEUROBIOL, V25, P1039, DOI 10.1002/neu.480250902; TRENT C, 1983, GENETICS, V104, P619; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRUMAN JW, 1984, ANNU REV NEUROSCI, V7, P171; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	55	171	185	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					317	327		10.1016/S0092-8674(00)81961-3	http://dx.doi.org/10.1016/S0092-8674(00)81961-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458607	Bronze			2022-12-01	WOS:000081950300007
J	Ritchie, ME; Olff, H				Ritchie, ME; Olff, H			Spatial scaling laws yield a synthetic theory of biodiversity	NATURE			English	Article							BODY-SIZE; FRACTAL LANDSCAPES; DIVERSITY; ABUNDANCE; PLANT	Ecologists still search for common principles that predict well-known responses of biological diversity to different factors(1-4) Such factors include the number of available niches in space(5-7), productivity(8-10), area(10), species' body size(11-14) and habitat fragmentation. Here we show that all these patterns can arise from simple constraints on how organisms acquire resources in space. We use spatial scaling laws to describe how species of different sizes find food in patches of varying size and resource concentration. We then derive a mathematical rule for the minimum similarity in size of species that share these resources. This packing rule yields a theory of species diversity that predicts relations between diversity and productivity more effectively than previous models(8-10). Size and diversity patterns for locally coexisting East African grazing mammals and North American savanna plants strongly support these predictions. The theory also predicts relations between diversity and area and between diversity and habitat fragmentation. Thus, spatial scaling laws provide potentially unifying first principles that may explain many important patterns of species diversity.	Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA; Agr Univ Wageningen, Dept Environm Sci, Trop Nat Conservat & Vertebrate Ecol Grp, NL-6708 PD Wageningen, Netherlands	Utah System of Higher Education; Utah State University; Wageningen University & Research	Ritchie, ME (corresponding author), Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA.	ritchie@cc.usu.edu	Olff, Han/A-8516-2008	Olff, Han/0000-0003-2154-3576				[Anonymous], 1979, PLANT STRATEGIES VEG; Belovsky GE, 1997, EVOL ECOL, V11, P641, DOI 10.1023/A:1018430201230; BROWN JH, 1993, AM NAT, V142, P573, DOI 10.1086/285558; BROWN JH, 1981, AM ZOOL, V21, P877; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; Hubbell SP, 1997, CORAL REEFS, V16, pS9, DOI 10.1007/s003380050237; HUTCHINSON GE, 1959, AM NAT, V93, P117, DOI 10.1086/282063; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; JONES CG, 1991, J ANIM ECOL, V60, P767, DOI 10.2307/5413; KINGDON J, 1979, E AFRICAN MAMMALS AT, V1; MACARTHUR RH, 1964, AM NAT, V98, P387, DOI 10.1086/282334; Magurran A.E, 1995, BIOL DIVERSITY, V32, P668, DOI 10.2307/2404662; Mandelbrot B.B., 1983, FRACTAL GEOMETRY NAT; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; MILNE BT, 1992, AM NAT, V139, P32, DOI 10.1086/285312; Milne BT, 1997, WILDLIFE AND LANDSCAPE ECOLOGY, P32; MORSE DR, 1985, NATURE, V314, P731, DOI 10.1038/314731a0; O'Neill RV, 1988, LANDSCAPE ECOL, V2, P63, DOI 10.1007/BF00138908; PALMER MW, 1992, AM NAT, V139, P375, DOI 10.1086/285332; Prins H.H.T., 1998, P449; Ritchie ME, 1998, ECOLOGY, V79, P165, DOI 10.1890/0012-9658(1998)079[0165:HEOPAN]2.0.CO;2; Ritchie ME, 1998, EVOL ECOL, V12, P309, DOI 10.1023/A:1006552200746; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG ML, 1994, SPECIES DIVERSITY EC, P52; SCHLUTER D, 1994, SPECIES DIVERSITY EC; SCHOENER TW, 1974, THEOR POPUL BIOL, V6, P265, DOI 10.1016/0040-5809(74)90013-6; Siemann E, 1996, NATURE, V380, P704, DOI 10.1038/380704a0; SINCLAIR ARE, 1979, SERENGCTI DYNAMICS E; TILMAN D, 1994, SPECIES DIVERSITY EC, P13; WRIGHT DH, 1983, OIKOS, V41, P496, DOI 10.2307/3544109	30	290	301	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					557	560		10.1038/23010	http://dx.doi.org/10.1038/23010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448857	Green Published			2022-12-01	WOS:000081854800053
J	Amado, RG; Chen, ISY				Amado, RG; Chen, ISY			Biomedicine - Lentiviral vectors - the promise of gene therapy within reach?	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; NONDIVIDING CELLS; IN-VIVO; TRANSDUCTION; INTEGRATION; EXPRESSION; DELIVERY; HIV		Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Amado, RG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Hematol Oncol, Los Angeles, CA 90095 USA.	ramado@ucla.edu						Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; AN DS, IN PRESS J VIROL; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; DONAHUE RE, 1998, BLOOD S1, V92; Herzog RW, 1999, NAT MED, V5, P56, DOI 10.1038/4743; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Kim VN, 1998, J VIROL, V72, P811, DOI 10.1128/JVI.72.1.811-816.1998; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Poeschla EM, 1998, NAT MED, V4, P354, DOI 10.1038/nm0398-354; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; TAKAHASHI M, IN PRESS J VIROL; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	21	132	163	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					674	676		10.1126/science.285.5428.674	http://dx.doi.org/10.1126/science.285.5428.674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454923				2022-12-01	WOS:000081765100031
J	Tyler, CW				Tyler, CW			Neuroscience - Is art lawful?	SCIENCE			English	Editorial Material									Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Tyler, CW (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							Arnheim R., 1988, POWER CTR STUDY COMP; BRENNAN SE, 1985, LEONARDO, V18, P170, DOI 10.2307/1578048; HANSON HM, 1959, J EXP PSYCHOL, V58, P321, DOI 10.1037/h0042606; Kandinsky W., 1947, POINT LINE PLANE; Martindale C., 1990, CLOCKWORK MUSE PREDI; Ramachandran V.S., 1999, J CONSCIOUSNESS STUD, V6, P15, DOI DOI 10.1179/174327908X392906	6	13	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					673	674		10.1126/science.285.5428.673	http://dx.doi.org/10.1126/science.285.5428.673			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454922				2022-12-01	WOS:000081765100030
J	Kimura, K; Rybenkov, VV; Crisona, NJ; Hirano, T; Cozzarelli, NR				Kimura, K; Rybenkov, VV; Crisona, NJ; Hirano, T; Cozzarelli, NR			13S condensin actively reconfigures DNA by introducing global positive writhe: Implications for chromosome condensation	CELL			English	Article							TOPOISOMERASE-II; SUPERCOILED DNA; PROTEIN FAMILY; IN-VITRO; SMC; SEGREGATION; MECHANISM; BINDING; RECOMBINATION; REPLICATION	Xenopus 13S condensin converts interphase chromatin into mitotic-like chromosomes, and, in the presence of ATP and a type I topoisomerase, introduces (+) supercoils into DNA. The specific production of (+) trefoil knots in the presence of condensin and a type II topoisomerase shows that condensin reconfigures DNA by introducing an ordered, global, (+) writhe. Knotting required ATP hydrolysis and cell cycle-specific phosphorylation of condensin. Condensin bound preferentially to (+) supercoiled DNA in the presence of ATP but not in its absence. Our results suggest a mechanism for the compaction of chromatin by condensin during mitosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California Berkeley; Cold Spring Harbor Laboratory	Kimura, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NIGMS NIH HHS [GM 31655, GM 53926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926, R01GM031655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; DARCY LD, 1997, KNOTS 96, P267; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1978, COLD SPRING HARB SYM, V42, P351; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	37	264	275	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					239	248		10.1016/S0092-8674(00)81018-1	http://dx.doi.org/10.1016/S0092-8674(00)81018-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428035	Bronze			2022-12-01	WOS:000081632300013
J	Dieckmann, U; Doebeli, M				Dieckmann, U; Doebeli, M			On the origin of species by sympatric speciation	NATURE			English	Article							ADAPTIVE RADIATION; NATURAL-SELECTION; SEXUAL SELECTION; MODEL; DYNAMICS; ANIMALS	Understanding speciation is a fundamental biological problem. It is believed that many species originated through allopatric divergence, where new species arise from geographically isolated populations of the same ancestral species(1-3). In contrast, the possibility of sympatric speciation (in which new species arise without geographical isolation) has often been dismissed, partly because of theoretical difficulties(2,3). Most previous models analysing sympatric speciation concentrated on particular aspects of the problem while neglecting others(4-10). Here we present a model that integrates a novel combination of different features and show that sympatric speciation is a likely outcome of competition for resources. We use multilocus genetics to describe sexual reproduction in an individual-based model, and we consider the evolution of assortative mating (where individuals mate preferentially with like individuals) depending either on an ecological character affecting resource use or on a selectively neutral marker trait. In both cases, evolution of assortative mating often leads to reproductive isolation between ecologically diverging subpopulations. When assortative mating depends on a marker trait, and is therefore not directly linked to resource competition, speciation occurs when genetic drift breaks the linkage equilibrium between the marker and the ecological trait. Our theory conforms well with mounting empirical evidence for the-sympatric origin of many species(10-18).	Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria; Univ Basel, Inst Zool, CH-4051 Basel, Switzerland	International Institute for Applied Systems Analysis (IIASA); University of Basel	Dieckmann, U (corresponding author), Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria.		Dieckmann, Ulf/E-1424-2011; Gilbert, Marcus TP/A-8936-2013; Doebeli, Michael/D-5391-2012	Dieckmann, Ulf/0000-0001-7089-0393; Gilbert, Marcus TP/0000-0002-5805-7195; 				BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Dieckmann U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751; Dieckmann U, 1997, TRENDS ECOL EVOL, V12, P128, DOI 10.1016/S0169-5347(97)01004-5; Doebeli M, 1997, EVOLUTION, V51, P1730, DOI 10.1111/j.1558-5646.1997.tb05097.x; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Geritz SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681; Johannesson K, 1995, EVOLUTION, V49, P1180, DOI 10.1111/j.1558-5646.1995.tb04445.x; Johnson PA, 1996, EVOL ECOL, V10, P187, DOI 10.1007/BF01241784; KNOX EB, 1995, P NATL ACAD SCI USA, V92, P10349, DOI 10.1073/pnas.92.22.10349; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; KONDRASHOV AS, 1986, THEOR POPUL BIOL, V29, P1, DOI 10.1016/0040-5809(86)90002-X; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; Mayr E, 1963, ANIMAL SPECIES EVOLU; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MEZ JAJ, 1996, STOCHASTIC SPATIAL S, P183; Nagel L, 1998, EVOLUTION, V52, P209, DOI 10.1111/j.1558-5646.1998.tb05154.x; Orr MR, 1998, TRENDS ECOL EVOL, V13, P502, DOI 10.1016/S0169-5347(98)01511-0; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; ROSENZWEIG ML, 1978, BIOL J LINN SOC, V10, P275, DOI 10.1111/j.1095-8312.1978.tb00016.x; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; SCHLUTER D, 1993, TRENDS ECOL EVOL, V8, P197, DOI 10.1016/0169-5347(93)90098-A; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; SEGER J, 1985, EVOLUTOIN ESSAYS HON; Taylor EB, 1999, BIOL J LINN SOC, V66, P271, DOI 10.1111/j.1095-8312.1999.tb01891.x; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093	30	1197	1232	4	627	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					354	357		10.1038/22521	http://dx.doi.org/10.1038/22521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432112	Green Submitted			2022-12-01	WOS:000081590000047
J	Selam, JL				Selam, JL			Implantable insulin pumps	LANCET			English	Editorial Material							INTRAPERITONEAL; MULTICENTER; INFUSION; GLUCOSE		Univ Paris 06, CHU Broussais Hotel Dieu, INSERM,U341, Serv Diabetol, F-75181 Paris 04, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Selam, JL (corresponding author), Univ Paris 06, CHU Broussais Hotel Dieu, INSERM,U341, Serv Diabetol, F-75181 Paris 04, France.							ABRAIRA C, 1995, DIABETES CARE, V18, P1112; ALBISSER AM, 1974, DIABETES, V23, P397, DOI 10.2337/diab.23.5.397; BLACKSHEAR P J, 1970, Surgical Forum (Chicago), V21, P136; BLACKSHEAR PJ, 1979, DIABETES, V28, P634, DOI 10.2337/diabetes.28.7.634; BROUSSOLLE C, 1994, LANCET, V343, P514, DOI 10.1016/S0140-6736(94)91462-1; Duckworth WC, 1998, DIABETES CARE, V21, P1596, DOI 10.2337/diacare.21.10.1596; DUCKWORTH WC, 1992, DIABETES, V41, P657, DOI 10.2337/diabetes.41.6.657; HAARDT MJ, 1994, DIABETES CARE, V17, P847, DOI 10.2337/diacare.17.8.847; HANAIREBROUTIN H, 1995, DIABETES CARE, V18, P388, DOI 10.2337/diacare.18.3.388; LassmannVague V, 1997, DIABETES METAB, V23, P234; Laube BL, 1998, CHEST, V114, P1734, DOI 10.1378/chest.114.6.1734; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; Selam JL, 1995, DIABETIC MED, V12, P1102, DOI 10.1111/j.1464-5491.1995.tb00428.x	13	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					178	179		10.1016/S0140-6736(99)90034-X	http://dx.doi.org/10.1016/S0140-6736(99)90034-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421296				2022-12-01	WOS:000081504200006
J	Shlomchik, WD; Couzens, MS; Tang, CB; McNiff, J; Robert, ME; Liu, JL; Shlomchik, MJ; Emerson, SG				Shlomchik, WD; Couzens, MS; Tang, CB; McNiff, J; Robert, ME; Liu, JL; Shlomchik, MJ; Emerson, SG			Prevention of graft versus host disease by inactivation of host antigen-presenting cells	SCIENCE			English	Article							BONE-MARROW TRANSPLANTATION; CD8+ T-CELLS; HISTOCOMPATIBILITY ANTIGEN; DENDRITIC CELLS; LYMPHOCYTES; DEFICIENT; TOLERANCE; PROTEINS; MICE	Craft versus host disease, an alloimmune attack on host tissues mounted by donor T cells, is the most important toxicity of allogeneic bone marrow transplantation. The mechanism by which allogeneic T cells are initially stimulated is unknown. In a murine allogeneic bone marrow transplantation model it was found that, despite the presence of numerous donor antigen-presenting cells, only host-derived antigen-presenting cells initiated graft versus host disease. Thus, strategies for preventing graft versus host disease could be developed that are based on inactivating host antigen-presenting cells. Such strategies could expand the safety and application of allogeneic bone marrow transplantation in treatment of common genetic and neoplastic diseases.	Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	University of Pennsylvania; University of Pennsylvania; Yale University; Yale University; Yale University; Yale University	Emerson, SG (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054516] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50HL-54516] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BEVAN MJ, 1995, J EXP MED, V182, P639, DOI 10.1084/jem.182.3.639; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CHAO NJ, 1996, GRAFT VS HOST DIS, P639; DEEG HJ, 1996, GRAFT VS HOST DIS, P311; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; FERRARA JLM, 1994, BONE MARROW TRANSPL, V14, P183; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HOROWITZ MM, 1990, BLOOD, V75, P555; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORNGOLD R, 1982, J EXP MED, V155, P872, DOI 10.1084/jem.155.3.872; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; MAIER T, 1996, GRAFT VS HOST DIS, P75; MATZINGER P, 1977, CELL IMMUNOL, V33, P92, DOI 10.1016/0008-8749(77)90137-X; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; STREILEIN JW, 1970, J EXP MED, V132, P163, DOI 10.1084/jem.132.1.163; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TRUITT RL, 1991, BLOOD, V77, P2515; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; WEIDEN PL, 1976, J IMMUNOL, V116, P1212	23	955	986	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					412	415		10.1126/science.285.5426.412	http://dx.doi.org/10.1126/science.285.5426.412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411505				2022-12-01	WOS:000081465900056
J	Martinez-Menarguez, JA; Geuze, HJ; Slot, JW; Klumperman, J				Martinez-Menarguez, JA; Geuze, HJ; Slot, JW; Klumperman, J			Vesicular tubular clusters between the ER and Golgi mediate concentration of soluble secretory proteins by exclusion front COPI-coated vesicles	CELL			English	Article							PANCREATIC ACINAR CELL; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; INTERMEDIATE COMPARTMENT; SELECTIVE TRANSPORT; EXOCRINE PANCREAS; THIN-SECTIONS; LIVING CELLS; BULK FLOW; CARGO	We have determined the concentrations of the secretory proteins amylase and chymotrypsinogen and the membrane proteins KDELr and rBet1 in COPII- and COPI-coated pre-Golgi compartments of pancreatic cells by quantitative immunoelectron microscopy. COPII was confined to ER membrane buds and adjacent vesicles. COPI occurred on vesicular tubular clusters (VTCs), Golgi cisternae, the trans-Golgi network, and immature secretory granules. Both secretory proteins exhibited a first, significant concentration step in noncoated segments of VTC tubules and were excluded from COPI-coated tips. By contrast, KDELr and rBet1 showed a first, significant concentration in COPII-coated ER buds and vesicles and were prominently present in COPI-coated tips of VTC tubules. These data suggest an important role of VTCs in soluble cargo concentration by exclusion from COPI-coated domains.	Univ Utrecht, Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Klumperman, J (corresponding author), Univ Utrecht, Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.							Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1998, HISTOCHEM CELL BIOL, V109, P463, DOI 10.1007/s004180050248; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENDAYAN M, 1984, HISTOCHEM J, V16, P85, DOI 10.1007/BF01003438; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; DIJKHOF J, 1978, BIOCHIM BIOPHYS ACTA, V543, P167, DOI 10.1016/0304-4165(78)90062-4; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; FARQUHAR MG, 1997, GOLGI APPARATUS, P63; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GEUZE HJ, 1980, EUR J CELL BIOL, V21, P93; GEUZE JJ, 1979, J CELL BIOL, V82, P697, DOI 10.1083/jcb.82.3.697; GRIFFITHS G, 1995, TRENDS CELL BIOL, V5, P9, DOI 10.1016/S0962-8924(00)88926-6; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; MartinezMenarguez JA, 1996, EUR J CELL BIOL, V71, P137; Nickel W, 1998, J CELL SCI, V111, P3081; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; POSTHUMA G, 1987, J HISTOCHEM CYTOCHEM, V35, P405, DOI 10.1177/35.4.2434559; POSTHUMA G, 1984, J HISTOCHEM CYTOCHEM, V32, P1028, DOI 10.1177/32.10.6207220; POSTHUMA G, 1988, EUR J CELL BIOL, V46, P327; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHEELE G, 1985, J BIOL CHEM, V260, P926; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SESSO A, 1994, J CELL SCI, V107, P517; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	55	247	251	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					81	90		10.1016/S0092-8674(00)80608-X	http://dx.doi.org/10.1016/S0092-8674(00)80608-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412983	Bronze			2022-12-01	WOS:000081451000010
J	Sadetzki, S; Modan, B				Sadetzki, S; Modan, B			Epidemiology as a basis for legislation: how far should epidemiology go?	LANCET			English	Editorial Material							RADIATION		Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Stanley Steyer Inst Canc Epidemiol, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University	Modan, B (corresponding author), Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel.							BROWN WMC, 1955, LANCET, V1, P1283; CRAWFORD GM, 1951, NEW ENGL J MED, V245, P726, DOI 10.1056/NEJM195111082451904; DAMESHEK W, 1957, JAMA-J AM MED ASSOC, V163, P838, DOI 10.1001/jama.1957.02970450040010; HARDER D, 1995, DIGNITY DISCOVERY RA; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; *ICRP, 1992, ICRP PUBL, V59; KAPLAN I I, 1957, Can Med Assoc J, V76, P43; LANGE RD, 1954, BLOOD, V9, P574, DOI 10.1182/blood.V9.6.574.574; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; MARCH HC, 1950, AM J MED SCI, V220, P282, DOI 10.1097/00000441-195022030-00007; March HC., 1944, RADIOLOGY, V43, P275, DOI DOI 10.1148/43.3.275; Modan B, 1975, Harefuah, V88, P541; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1987, MED ONCOL TUMOR PHAR, V4, P141; MOLONEY WC, 1995, SCIENCE, V121, P308; RON E, 1984, ISRAEL J MED SCI, V20, P1164; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; RON E, 1982, AM J EPIDEMIOL, V16, P149; *US DHEW, 1964, PHS PUBL; VETTER RJ, 1993, HEALTH PHYS, V64, P115; WERNER A, 1968, PHYS MED BIOL, V13, P247, DOI 10.1088/0031-9155/13/2/310; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P320	22	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2238	2239		10.1016/S0140-6736(98)12327-9	http://dx.doi.org/10.1016/S0140-6736(98)12327-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10393003				2022-12-01	WOS:000081091300045
J	Harnden, P; Mahmood, N; Southgate, J				Harnden, P; Mahmood, N; Southgate, J			Expression of cytokeratin 20 redefines urothelial papillomas of the bladder	LANCET			English	Article							CARCINOMA; CANCER	Background Most non-invasive urothelial tumours of the bladder are diagnosed as papillary carcinomas in accordance with the WHO classification and because the identification of papillomas is difficult by routine histology; some patients are therefore misdiagnosed. This practice is associated with psychological morbidity for the patient and may also skew cancer statistics. Cytokeratin 20 (CK20) is a sensitive marker of urothelial differentiation. We investigated whether this marker could be used in the identification of urothelial papillomas and used the rate of recurrence as an indicator to assess the biological behaviour of such tumours. Methods In a prospective study, immunocytochemistry for CK20 was done on tumours of all patients who presented for the first time with non-invasive papillary bladder tumours. We classified the expression pattern of CK20 as normal or abnormal at the time of initial diagnosis. We recorded time to first biopsy-proven recurrence or length of follow-up when no recurrence was observed. Findings Of 58 consecutive patients, ten had tumours with a normal pattern of CK20 expression. No patients developed further tumours during the follow-up (median 18 [range 13-28] months). By contrast, 30 (73%) of the 41 evaluable patients with tumours that showed abnormal CK20 expression developed further tumours; the median time to a second tumour was 6 (2-24) months. The only factor that had a significant effect on the outcome of patients in terms of recurrence was expression of CK20 (p<0.0001). Interpretation Normal urothelial differentiation, as evidenced by a normal pattern of CK20 expression, is retained in a proportion of non-invasive papillary urothelial tumours and thus justifies use of the term urothelial papilloma. A large-scale study is needed to investigate the outcome of patients with such tumours.	Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England	Leeds General Infirmary; Saint James's University Hospital	Harnden, P (corresponding author), St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England.		Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X				DEMING CL, 1950, J UROLOGY, V63, P815, DOI 10.1016/S0022-5347(17)68833-5; GREENE LF, 1973, J UROLOGY, V110, P205, DOI 10.1016/S0022-5347(17)60161-7; HALL RR, 1994, BMJ-BRIT MED J, V308, P257, DOI 10.1136/bmj.308.6923.257; Harnden P, 1996, BRIT J UROL, V78, P870, DOI 10.1046/j.1464-410X.1996.23511.x; HARNDEN P, 1996, CURR DIAGN PATHOL, V3, P109; HARNDEN P, 1995, HISTOPATHOLOGY, V27, P167; JORDAN AM, 1987, CANCER, V60, P2766, DOI 10.1002/1097-0142(19871201)60:11<2766::AID-CNCR2820601129>3.0.CO;2-0; KIEMENEY LALM, 1994, EUR J CANCER, V30A, P1134, DOI 10.1016/0959-8049(94)90472-3; KURTH KH, 1995, EUR J CANCER, V31A, P1840, DOI 10.1016/0959-8049(95)00287-S; Murphy WM, 1994, TUMORS KIDNEY BLADDE; OOMS ECM, 1983, HUM PATHOL, V14, P140, DOI 10.1016/S0046-8177(83)80242-1; PROUT GR, 1992, J UROLOGY, V148, P1413, DOI 10.1016/S0022-5347(17)36924-0; READING J, 1995, BRIT J UROL, V75, P604, DOI 10.1111/j.1464-410X.1995.tb07417.x; REUTER VE, 1994, DIAGNOSTIC SURG PATH; *WHO, 1973, HIST TYP UR BLADD TU, V10; [No title captured]	16	95	98	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					974	977		10.1016/S0140-6736(98)05383-5	http://dx.doi.org/10.1016/S0140-6736(98)05383-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459907				2022-12-01	WOS:000079421600013
J	Mofenson, LM				Mofenson, LM			Short-course zidovudine for prevention of perinatal infection	LANCET			English	Editorial Material							CLINICAL-TRIAL; TRANSMISSION; AFRICA		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; MOFENSON LM, IN PRESS AIDS; Rouse DJ, 1997, AM J OBSTET GYNECOL, V176, P617, DOI 10.1016/S0002-9378(97)70557-X; Scholl TO, 1997, AM J EPIDEMIOL, V146, P134, DOI 10.1093/oxfordjournals.aje.a009244; SEMBA R, 1998, 3 INT S GLOB STRAT P; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; World Health Organization, 1997, COV MAT CAR LIST AV	16	50	51	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					766	767		10.1016/S0140-6736(99)90028-4	http://dx.doi.org/10.1016/S0140-6736(99)90028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459952				2022-12-01	WOS:000079089100002
J	Moore, T				Moore, T			Shape representations and visual guidance sf saccadic eye movements	SCIENCE			English	Article							CORTEX; MACAQUE; CONNECTIONS; POSITION; FIELD	One hallmark of primate vision is that the direction of gaze is constantly shifting to position objects of interest appropriately on the fovea, where visual acuity is greatest. This process most involve the close cooperation of oculomotor and Visual recognition mechanisms because visual details must be translated into specific motor commands. This paper describes the correspondence between the presaccadic activity of V4 neurons and the degree of visual guidance of saccadic eye movements to objects of different form. The results suggest that neurons that participate in coding visual stimuli are also involved in guiding the eyes to prominent features of objects.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Moore, T (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	tirin@princeton.edu			NEI NIH HHS [EY0067] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1980, BRAIN RES, V184, P41, DOI 10.1016/0006-8993(80)90586-7; FISCHER B, 1981, EXP BRAIN RES, V44, P129; FRIES W, 1984, J COMP NEUROL, V230, P55, DOI 10.1002/cne.902300106; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Groh JM, 1997, J NEUROSCI, V17, P4312; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Moore T, 1998, P NATL ACAD SCI USA, V95, P8981, DOI 10.1073/pnas.95.15.8981; ROBINSON DA, 1964, J PHYSIOL-LONDON, V174, P245, DOI 10.1113/jphysiol.1964.sp007485; SCHALL JD, 1995, J NEUROSCI, V15, P4464; Thier P, 1998, J NEUROPHYSIOL, V80, P1713, DOI 10.1152/jn.1998.80.4.1713; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; VITU F, 1990, PERCEPT PSYCHOPHYS, V47, P583, DOI 10.3758/BF03203111; Yarbus Alfred L, 1967, EYE MOVEMENTS VISION, P171, DOI [10.1007/978-1-4899-5379-7_8, DOI 10.1007/978-1-4899-5379-7, 10.1007/978-1-4899-5379-7]; Zipser K, 1996, J NEUROSCI, V16, P7376	18	67	67	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1914	1917		10.1126/science.285.5435.1914	http://dx.doi.org/10.1126/science.285.5435.1914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489371				2022-12-01	WOS:000082638300051
J	Pietrangelo, A; Montosi, G; Totaro, A; Garuti, C; Conte, D; Cassanelli, S; Fraquelli, M; Sardini, C; Vasta, F; Gasparini, P				Pietrangelo, A; Montosi, G; Totaro, A; Garuti, C; Conte, D; Cassanelli, S; Fraquelli, M; Sardini, C; Vasta, F; Gasparini, P			Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IRON OVERLOAD	Background and Methods Hereditary hemochromatosis in adults is usually characterized by mutations in the hemochromatosis (HFE) gene on the short arm of chromosome 6. Most patients have a substitution of tyrosine for cysteine at position 282 (C282Y). We studied a large family from Italy that includes persons who have a hereditary iron-overload condition indistinguishable from hemochromatosis but without apparent pathogenic mutations in the HFE gene. We performed biochemical, histologic, and genetic studies of 53 living members of the family, including microsatellite analysis of chromosome 6 and direct sequencing of the HFE gene, Results Of the 53 family members, 15 had abnormal serum ferritin levels, values for transferrin saturation that were higher than 50 percent, or both. Thirteen of the 15 had elevated body iron levels, diagnosed on the basis of the clinical evaluation and liver biopsy, and underwent iron-removal therapy. The other two, both children, did not undergo liver biopsy or iron-removal therapy. None of the 15 members had the C282Y mutation of the HFE gene; 5 of the 15 (as well as 5 healthy relatives) had another mutation of this gene, a substitution of aspartate for histidine at position 63, but none were homozygous for it. No other mutations were found after sequencing of the entire HFE gene for all family members. Microsatellite analysis showed no linkage of the hemochromatosis phenotype with the short arm of chromosome 6, the site of the HFE gene. Conclusions Hereditary hemochromatosis can occur in adults who do not have pathogenic mutations in the hemochromatosis gene. (N Engl J Med 1999;341:725-32,) (C)1999, Massachusetts Medical Society.	Univ Modena, Policlin, Dept Internal Med, I-41100 Modena, Italy; Osped San Giovanni Rotondo, Foggia, Italy; Univ Milan, Dept Gastroenterol, Milan, Italy	Universita di Modena e Reggio Emilia; University of Milan	Pietrangelo, A (corresponding author), Univ Modena, Policlin, Dept Internal Med, Via Pozzo 71, I-41100 Modena, Italy.		Gasparini, Paolo/B-6173-2014; Cassanelli, Stefano/D-7631-2015; Pietrangelo, Antonello/K-1517-2016	Cassanelli, Stefano/0000-0001-5929-4689; Pietrangelo, Antonello/0000-0002-7411-935X; Gasparini, Paolo/0000-0002-0859-0856	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Beutler E, 1997, AM J HUM GENET, V61, P762; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509; Carella M, 1997, AM J HUM GENET, V60, P828; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; McNamara L, 1998, BRIT J HAEMATOL, V102, P1176; PERKINS KW, 1965, AM J MED, V39, P118, DOI 10.1016/0002-9343(65)90251-2; Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1; ROCCHI E, 1986, J LAB CLIN MED, V107, P36; Sanchez M, 1998, GENE, V225, P77, DOI 10.1016/S0378-1119(98)00519-8; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; VONRECKLINGHAUS.FD, 1889, HAEMOCHROMATOSE, P324	16	209	220	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					725	732		10.1056/NEJM199909023411003	http://dx.doi.org/10.1056/NEJM199909023411003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471458				2022-12-01	WOS:000082291900003
J	Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH				Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH			Mice with reduced NMDA receptor expression display behaviors related to schizophrenia	CELL			English	Article							DOPAMINE-RECEPTORS; ANTIPSYCHOTIC AGENTS; TARGETED DISRUPTION; LOCOMOTOR-ACTIVITY; NUCLEUS-ACCUMBENS; NEONATAL DEATH; PCP SITE-2; PHENCYCLIDINE; AMPHETAMINE; SUBUNIT	N-methyl-D-aspartate receptors (NMDARs) represent a subclass of glutamate receptors that play a critical role in neuronal development and physiology. We report here the generation of mice expressing only 5% of normal levels of the essential NMDAR1 (NR1) subunit. Unlike NR1 null mice, these mice survive to adulthood and display behavioral abnormalities, including increased motor activity and stereotypy and deficits in social and sexual interactions. These behavioral alterations are similar to those observed in pharmacologically induced animal models of schizophrenia and can be ameliorated by treatment with haloperidol or clozapine, antipsychotic drugs that antagonize dopaminergic and serotonergic receptors. These findings support a model in which reduced NMDA receptor activity results in schizophrenic-like behavior and reveals how pharmacological manipulation of monoaminergic pathways can affect this phenotype.	Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol & Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Koller, BH (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.	treawouns@aol.com	Gainetdinov, Raul R/G-5875-2011	Gainetdinov, Raul R/0000-0003-2951-6038; Ramsey, Amy/0000-0002-2717-5279	NIGMS NIH HHS [T32GM07092] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abi-Saab WM, 1998, PHARMACOPSYCHIATRY, V31, P104, DOI 10.1055/s-2007-979354; AKUNNE HC, 1992, NEUROCHEM RES, V17, P261, DOI 10.1007/BF00966668; ANDEN NE, 1970, EUR J PHARMACOL, V11, P303, DOI 10.1016/0014-2999(70)90006-3; ANGRIST B, 1974, J PSYCHIAT RES, V11, P13, DOI 10.1016/0022-3956(74)90064-8; BAN TA, 1984, PSYCHIAT DEV, V2, P179; *BRANB C GEN BACKG, 1997, NEURON, V20, P755; Carlsson A, 1997, LIFE SCI, V61, P75, DOI 10.1016/S0024-3205(97)00228-2; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; CORBETT R, 1995, PSYCHOPHARMACOLOGY, V120, P67, DOI 10.1007/BF02246146; CORBETT R, 1993, PHARMACOL BIOCHEM BE, V45, P9, DOI 10.1016/0091-3057(93)90079-9; Coyle JT, 1996, HARVARD REV PSYCHIAT, V3, P241, DOI 10.3109/10673229609017192; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; DIXON AK, 1994, J CLIN PSYCHIAT, V55, P4; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Druhan JP, 1996, SYNAPSE, V24, P135, DOI 10.1002/(SICI)1098-2396(199610)24:2<135::AID-SYN5>3.0.CO;2-G; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; ELLISON G, 1995, BRAIN RES REV, V20, P250, DOI 10.1016/0165-0173(94)00014-G; ERESHEFSKY L, 1989, CLIN PHARMACY, V8, P691; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Franklin K., 1996, MOUSE BRAIN STEREOTA; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gleason SD, 1997, PSYCHOPHARMACOLOGY, V129, P79, DOI 10.1007/s002130050165; Goff DC, 1997, SCHIZOPHR RES, V27, P157, DOI 10.1016/S0920-9964(97)00079-0; GRIFFITH JD, 1972, ARCH GEN PSYCHIAT, V26, P97; HOFFMAN DC, 1995, PSYCHOPHARMACOLOGY, V120, P128, DOI 10.1007/BF02246184; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HYTTEL J, 1978, PSYCHOPHARMACOLOGY, V59, P211, DOI 10.1007/BF00426624; IKEDA K, 1995, MOL BRAIN RES, V33, P61, DOI 10.1016/0169-328X(95)00107-4; IMPERATO A, 1990, EUR J PHARMACOL, V187, P555, DOI 10.1016/0014-2999(90)90387-L; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Kelly MA, 1998, J NEUROSCI, V18, P3470; KNABLE MB, 1994, BIOL PSYCHIAT, V36, P827, DOI 10.1016/0006-3223(94)90593-2; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lahti RA, 1996, NEUROREPORT, V7, P1945, DOI 10.1097/00001756-199608120-00016; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Martin P, 1998, J NEURAL TRANSM, V105, P365, DOI 10.1007/s007020050064; Masters WG, 1996, LAB ANIM SCI, V46, P663; MELTZER HY, 1991, SCHIZOPHRENIA BULL, V17, P263, DOI 10.1093/schbul/17.2.263; Miller DW, 1996, BRAIN RES BULL, V40, P57, DOI 10.1016/0361-9230(95)02144-2; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; MOHN AR, 1995, DNA CLONING, V4, P141; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nankai M, 1996, NEUROCHEM INT, V29, P529, DOI 10.1016/0197-0186(96)00010-1; Nieoullon A., 1983, EXP BRAIN RES S, V7, P54; Nimgaonkar VL, 1997, ACTA PSYCHIAT SCAND, V95, P364, DOI 10.1111/j.1600-0447.1997.tb09647.x; ODEGARD O, 1980, ACTA PSYCHIAT SCAND, V62, P212, DOI 10.1111/j.1600-0447.1980.tb00609.x; Pierce RC, 1997, PSYCHOPHARMACOLOGY, V133, P188, DOI 10.1007/s002130050390; ROSENBAUER K A, 1980, Folia Morphologica (Prague), V28, P126; ROTHMAN RB, 1994, NEUROTOXICOL TERATOL, V16, P343, DOI 10.1016/0892-0362(94)90022-1; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SAUGSTAD LF, 1989, SCHIZOPHRENIA BULL, V15, P9, DOI 10.1093/schbul/15.1.9; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5	62	823	866	0	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					427	436		10.1016/S0092-8674(00)81972-8	http://dx.doi.org/10.1016/S0092-8674(00)81972-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481908	Bronze			2022-12-01	WOS:000082174900004
J	Mathews, F; Yudkin, P; Neil, A				Mathews, F; Yudkin, P; Neil, A			Influence of maternal nutrition on outcome of pregnancy: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; DIET; WOMEN	Objective To investigate the relations of maternal diet and smoking during pregnancy to placental and birth weights at term. Design Prospective cohort study. Setting District general hospital in the south of England. Participants 693 pregnant nulliparous white women with singleton pregnancies who were selected from antenatal booking clinics with stratified random sampling. Main outcome measures Birth and placental weights at term. Results Placental and birth weights were unrelated to the intake of any macronutrient Early in pregnancy, vitamin C was the only micronutrient independently associated with birth weight after adjustment for maternal height and smoking. Each In mg increase in vitamin C was associated with a 50.8 g (95% confidence interval 4.6 g to 97.0 g) increase in birth weight Vitamin C, vitamin E, and folate were each associated with placental weight after adjustment for maternal characteristics. In simultaneous regression, however, vitamin C was the only nutrient predictive of placental weight: each In mg increase in vitamin C was associated with a 3.2% (0.4 to 6.1) rise in placental weight No nutrient late in pregnancy was associated with either placental or birth weight. Conclusions Concern over the impact of maternal nutrition on the health of the infant has been premature, Maternal nutrition, at least in industrialised populations, seems to have only a small effect on placental and birth weights. Other possible determinants of fetal and placental growth should be investigated.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Mathews, F (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		li, tao/B-2402-2008					ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barker DJP, 1992, FETAL INFANT ORIGINS; Bingham SA, 1997, EUR J CANCER PREV, V6, P118; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; BINGHAM SA, 1991, DESIGN CONCEPTS NUTR, P151; BOLLING K, 1997, SMOKING PREGNANCY SU; BOTTING B, 1993, POPULATION TRENDS, V74, P27; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; Foster K, 1997, INFANT FEEDING 1995; Fraser R, 1997, BRIT J OBSTET GYNAEC, V104, P645, DOI 10.1111/j.1471-0528.1997.tb11972.x; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; Godfrey KM, 1997, BRIT J OBSTET GYNAEC, V104, P663, DOI 10.1111/j.1471-0528.1997.tb11975.x; Gregory J., 1990, DIETARY NUTR SURVEY; HASTE FM, 1991, BRIT J NUTR, V65, P347, DOI 10.1079/BJN19910095; KNIGHT GJ, 1985, CLIN CHEM, V31, P118; KRAMER MS, 1994, COCHRANE LIB; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V43, P461; MAHOMED K, 1993, COCHRANE LIB; Mathews F, 1996, NUTR RES REV, V9, P175, DOI 10.1079/NRR19960011; Mathews F, 1998, J HUM NUTR DIET, V11, P151, DOI 10.1046/j.1365-277X.1998.00085.x; MATHEWS F, IN PRESS ANN CLIN BI; Office of Population Censuses and Surveys, 1980, CLASS OCC; Robinson S, 1996, EUR J CLIN NUTR, V50, P302; RUSH D, 1989, EFFECTIVE CARE PREGN, P255; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Willett W, 1990, NUTR EPIDEMIOLOGY, P92	27	233	237	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					339	343		10.1136/bmj.319.7206.339	http://dx.doi.org/10.1136/bmj.319.7206.339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435950	Green Published, Bronze			2022-12-01	WOS:000082001700014
J	Tsevat, J; Sherman, SN; McElwee, JA; Mandell, KL; Simbartl, LA; Sonnenberg, FA; Fowler, FJ				Tsevat, J; Sherman, SN; McElwee, JA; Mandell, KL; Simbartl, LA; Sonnenberg, FA; Fowler, FJ			The will to live among HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the Society-for-Medical-Decision-Making	OCT 25-29, 1997	HOUSTON, TX	Soc Med Decis Making			QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH STATES; VALUES; OUTCOMES; UTILITIES	Background: Patients infected with HIV value both longevity and health, Objective: To understand how HIV-infected patients value their health. Design: Interview study. Setting: Regional treatment center for HIV. Patients: 51 patients with HIV infection. Measurements: Life-satisfaction, health rating, time-tradeoff, and standard-gamble scores. Results: Of the 51 patients, 49% (95% CI, 35% to 63%) said that their life was better currently than it was before they contracted HIV infection; only 29% said that life was currently worse. The mean (+/- SD) time-tradeoff score was 0.95 +/- 0.10, indicating that, on average, patients would give up no more than 5% of their remaining life expectancy in their current state of health in exchange for a shorter but healthy life. The average health rating score was 71.0 +/- 18.7 on a scale of 0 to 100, and the average standard-gamble score was 0.80 +/- 0.27. Factors contributing to life satisfaction and time-tradeoff scores included spirituality and having children. Conclusion: Many patients with HIV have a strong will to live, and many feel that life with HIV is better than it was before they became infected.	Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res,Infect Dis Ctr, Cincinnati, OH 45267 USA; SNS Res, Cincinnati, OH 45241 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Gen Internal Med, New Brunswick, NJ 08903 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	University System of Ohio; University of Cincinnati; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Massachusetts System; University of Massachusetts Boston	Tsevat, J (corresponding author), Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res,Infect Dis Ctr, Box 670535, Cincinnati, OH 45267 USA.	Joel.Tsevat@uc.edu			AHRQ HHS [1 R01 HS 09103-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andrews FM, 1976, SOCIAL INDICATORS WE; Carson V B, 1993, J Assoc Nurses AIDS Care, V4, P18; CLEARY PD, 1993, MED CARE, V31, P569, DOI 10.1097/00005650-199307000-00001; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Klitzman R., 1997, BEING POSITIVE LIVES; LAMPING DL, 1994, PSYCHOL HEALTH, V9, P31, DOI 10.1080/08870449408407458; OLEARY JF, 1995, MED DECIS MAKING, V15, P132, DOI 10.1177/0272989X9501500205; Owens DK, 1997, QUAL LIFE RES, V6, P77, DOI 10.1023/A:1026473613487; PEARSON SD, 1995, J GEN INTERN MED, V10, P557, DOI 10.1007/BF02640365; REVICKI DA, 1995, MED CARE, V33, pAS173; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; Wu AW, 1997, QUAL LIFE RES, V6, P531, DOI 10.1023/A:1018460132567	18	83	83	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					194	198		10.7326/0003-4819-131-3-199908030-00006	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	222ME	10428736				2022-12-01	WOS:000081788700005
J	Singh, A; Crockard, HA				Singh, A; Crockard, HA			Quantitative assessment of cervical spondylotic myelopathy by a simple walking test	LANCET			English	Article							SPINAL-CORD INJURY; RHEUMATOID-ARTHRITIS	Background We developed a 30 m walking test as a quantifiable measure of severity of cervical spondylotic myelopathy (CSM), which will be of use in determining the effects of decompressive surgical treatment. Methods Preoperative measurements were made in 41 patients with CSM of 30 m walking times, number of steps taken over this distance, myelopathy disability index (MDI), and Nurick scores. The walking factors were compared with a similar number of age-matched and sex-matched controls. The individuals in the study were patients with CSM and no other relevant pathology consecutively referred for decompressive surgery to the National Hospital for Neurology and Neurosurgery. Findings Both walking time and the number of steps taken were significantly worse in pre-operative patients than in controls. The walking data were highly reproducible over three trials. Postoperatively, there was a significant improvement in walking time (p=0.0018) and number of steps taken (p=5.87x10(-6)). Only two of 41 patients were worse postoperatively. There was also a significant improvement in MDI (two-tailed Wilcoxon, related samples; p<0.0001) and Nurick scores (two-tailed Wilcoxon p<0.0001) postoperatively. The preoperative and postoperative walking scores were significantly and equally correlated with the MDI and Nurick scores. Interpretation Timed walks are an easily performed, quantitative, and valid means of assessing CSM and the effects of surgery.	UCL Natl Hosp Neurol & Neurosurg, Dept Neurol Surg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Crockard, HA (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurol Surg, Queen Sq, London WC1N 3BG, England.	A.Crockard@ion.uci.ac.uk						ALLEN KL, 1952, J NEUROL NEUROSUR PS, V15, P20, DOI 10.1136/jnnp.15.1.20; BAKAY L, 1970, J NEUROL NEUROSUR PS, V33, P20; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Casey ATH, 1996, ANN RHEUM DIS, V55, P901, DOI 10.1136/ard.55.12.901; CLARKE E, 1956, BRAIN, V79, P483, DOI 10.1093/brain/79.3.483; DITUNNO JF, 1992, PARAPLEGIA, V30, P90, DOI 10.1038/sc.1992.31; DONOVAN WH, 1990, J NEURO REHAB, V4, P39; Dun-Rankin P., 1983, SCALING METHODS; GONZALEZFERIA L, 1975, ACTA NEUROCHIR, V31, P185, DOI 10.1007/BF01406291; HADLEY MN, 1995, PRINCIPLES SPINAL SU, P531; HERMANN J, 1994, ADV NEUROSURG, P266; HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; LINDSAY KW, 1991, NEUROLOGY NEUROSURGE, P373; NURICK S, 1972, BRAIN, V95, P87; RANAWAT CS, 1979, J BONE JOINT SURG AM, V61, P1003, DOI 10.2106/00004623-197961070-00006; ROGERS L, 1961, J NEUROSURG, V18, P490, DOI 10.3171/jns.1961.18.4.0490; ROGERS L, 1961, J BONE JOINT SURG BR, V43, P3, DOI 10.1302/0301-620X.43B1.3; SCOVILLE WB, 1961, J NEUROSURG, V18, P423, DOI 10.3171/jns.1961.18.4.0423; STREINER DI, 1996, MEASURING CHANGE HLT, P163; SYPERT GW, 1992, DISORDERS CERVICAL S, P407; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WATERS RL, 1991, PARAPLEGIA, V29, P573, DOI 10.1038/sc.1991.85	23	94	99	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					370	373		10.1016/S0140-6736(98)10199-X	http://dx.doi.org/10.1016/S0140-6736(98)10199-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437865				2022-12-01	WOS:000081764900011
J	Hahn, WC; Counter, CM; Lundberg, AS; Beijersbergen, RL; Brooks, MW; Weinberg, RA				Hahn, WC; Counter, CM; Lundberg, AS; Beijersbergen, RL; Brooks, MW; Weinberg, RA			Creation of human tumour cells with defined genetic elements	NATURE			English	Article							LARGE T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; HUMAN-FIBROBLASTS; TRANSFORMATION; EXPRESSION; SENESCENCE; ONCOGENE; SARCOMA; CANCER	During malignant transformation, cancer cells acquire genetic mutations that override the normal mechanisms controlling: cellular proliferation. Primary rodent cells are efficiently converted into tumorigenic cells by the coexpression of cooperating oncogenes(1,2). However, similar experiments with human cells have consistently failed to yield tumorigenic transformants(3-5), indicating a fundamental difference in the biology of human and rodent cells. The few reported successes in the creation of human tumour cells have depended on the use of chemical or physical agents to achieve immortalization(6), the selection of rare, spontaneously arising immortalized cells(7-10), or the use of an entire viral genome(11). We show here that the ectopic expression of the telomerase catalytic subunit (hTERT)(12) in combination with two oncogenes (the simian virus 40 large-T oncoprotein and an oncogenic allele of H-ras) results in direct tumorigenic conversion of normal human epithelial and fibroblast cells. These results demonstrate that disruption of the intracellular pathways regulated by large-T, oncogenic ras and telomerase suffices to create a human tumor cell.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu		Beijersbergen, Roderick/0000-0003-0116-4130; Counter, Christopher M/0000-0003-0748-3079				Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Burger AM, 1998, INT J ONCOL, V13, P1043; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kang KS, 1998, MOL CARCINOGEN, V21, P225, DOI 10.1002/(SICI)1098-2744(199804)21:4<225::AID-MC1>3.0.CO;2-J; Kim JW, 1997, INFORM SYST RES, V8, P25, DOI 10.1287/isre.8.1.25; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kipling D, 1997, EUR J CANCER, V33, P792, DOI 10.1016/S0959-8049(97)00060-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	30	1866	1948	1	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					464	468		10.1038/22780	http://dx.doi.org/10.1038/22780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440377				2022-12-01	WOS:000081715000054
J	Strous, M; Fuerst, JA; Kramer, EHM; Logemann, S; Muyzer, G; van de Pas-Schoonen, KT; Webb, R; Kuenen, JG; Jetten, MSM				Strous, M; Fuerst, JA; Kramer, EHM; Logemann, S; Muyzer, G; van de Pas-Schoonen, KT; Webb, R; Kuenen, JG; Jetten, MSM			Missing lithotroph identified as new planctomycete	NATURE			English	Article							ANAEROBIC AMMONIUM OXIDATION; ORDER PLANCTOMYCETALES; BUDDING BACTERIA; REACTOR; DIVERSITY; EVOLUTION; PIRELLA	With the increased use of chemical fertilizers in agriculture, many densely populated countries face environmental problems associated with high ammonia emissions. The process of anaerobic ammonia oxidation ('anammox') is one of the most innovative technological advances in the removal of ammonia nitrogen from waste water(1,2). This new process combines ammonia and nitrite directly into dinitrogen gas(3). Until now, bacteria capable of anaerobically oxidizing ammonia had never been found and were known as "lithotrophs missing from nature"(4). Here we report the discovery of this missing lithotroph and its identification as a new, autotrophic member of the order Planctomycetales, one of the major distinct divisions of the Bacteria(5). The new planctomycete grows extremely slowly, dividing only once every two weeks. At present, it cannot be cultivated by conventional microbiological techniques. The identification of this bacterium as the one responsible for anaerobic oxidation of ammonia makes an important contribution to the problem of unculturability.	Delft Univ Technol, Dept Biotechnol, NL-2628 BC Delft, Netherlands; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Netherlands Inst Sea Res, NL-1790 AB Den Burg, Netherlands	Delft University of Technology; University of Queensland; University of Queensland; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Jetten, MSM (corresponding author), Delft Univ Technol, Dept Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.		Jetten, Mike/B-8834-2011; Muyzer, Gerard/ABE-5834-2020; Muyzer, Gerard/A-3161-2013; Curto, Ana Q/O-6849-2015; Fuerst, John/I-8649-2012; Strous, Marc/B-4064-2017	Jetten, Mike/0000-0002-4691-7039; Muyzer, Gerard/0000-0002-2422-0732; Curto, Ana Q/0000-0003-3568-9322; Strous, Marc/0000-0001-9600-3828; Fuerst, John/0000-0002-6451-8533				BRODA E, 1977, Z ALLG MIKROBIOL, V17, P491, DOI 10.1002/jobm.3630170611; Byers HK, 1998, FEMS MICROBIOL ECOL, V25, P391, DOI 10.1111/j.1574-6941.1998.tb00491.x; DELONG EF, 1993, LIMNOL OCEANOGR, V38, P924, DOI 10.4319/lo.1993.38.5.0924; FUERST JA, 1995, MICROBIOL-UK, V141, P1493, DOI 10.1099/13500872-141-7-1493; FUERST JA, 1991, P NATL ACAD SCI USA, V88, P8184, DOI 10.1073/pnas.88.18.8184; Fuerst JA, 1997, APPL ENVIRON MICROB, V63, P254, DOI 10.1128/AEM.63.1.254-262.1997; Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Jetten MSM, 1997, WATER SCI TECHNOL, V35, P171, DOI 10.1016/S0273-1223(97)00195-9; KONIG E, 1984, ARCH MICROBIOL, V138, P200, DOI 10.1007/BF00402120; LIESACK W, 1986, ARCH MICROBIOL, V145, P361, DOI 10.1007/BF00470872; Lindsay MR, 1997, MICROBIOL-UK, V143, P739, DOI 10.1099/00221287-143-3-739; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Neef A, 1998, MICROBIOL-UK, V144, P3257, DOI 10.1099/00221287-144-12-3257; SCHLESNER H, 1986, SYST APPL MICROBIOL, V8, P174, DOI 10.1016/S0723-2020(86)80072-8; Strous M, 1997, WATER RES, V31, P1955, DOI 10.1016/S0043-1354(97)00055-9; Strous M, 1998, APPL MICROBIOL BIOT, V50, P589, DOI 10.1007/s002530051340; Van De Graaf Astrid A., 1996, Microbiology (Reading), V142, P2187; vandeGraaf AA, 1997, MICROBIOL-SGM, V143, P2415, DOI 10.1099/00221287-143-7-2415; Vergin KL, 1998, APPL ENVIRON MICROB, V64, P3075; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Zarda B, 1997, ARCH MICROBIOL, V168, P185, DOI 10.1007/s002030050486	22	1100	1297	42	771	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					446	449		10.1038/22749	http://dx.doi.org/10.1038/22749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440372				2022-12-01	WOS:000081715000049
J	Greenough, A				Greenough, A			Chronic lung disease of prematurity - prevention by inhaled corticosteroids?	LANCET			English	Editorial Material							METERED-DOSE INHALER; PRETERM; INFANTS; DEXAMETHASONE; STEROIDS; DELIVERY; AEROSOL		Univ London Kings Coll Hosp, Sch Med & Dent, Dept Child Hlth, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Greenough, A (corresponding author), Univ London Kings Coll Hosp, Sch Med & Dent, Dept Child Hlth, Denmark Hill, London SE5 9RS, England.							Arnon S, 1996, PEDIATR PULM, V21, P231; Bhuta T, 1998, ARCH DIS CHILD-FETAL, V79, pF26, DOI 10.1136/fn.79.1.F26; Cole CH, 1999, NEW ENGL J MED, V340, P1005, DOI 10.1056/NEJM199904013401304; Dimitriou G, 1997, EUR J PEDIATR, V156, P51; Fok TF, 1999, ARCH DIS CHILD-FETAL, V80, pF203, DOI 10.1136/fn.80.3.F203; Fok TF, 1997, PEDIATR PULM, V24, P204; Giep T, 1996, AM J PERINAT, V13, P5, DOI 10.1055/s-2007-994193; Greenough A, 1998, LANCET, V352, P835, DOI 10.1016/S0140-6736(05)60002-5; Groneck P, 1999, PEDIATR PULM, V27, P383, DOI 10.1002/(SICI)1099-0496(199906)27:6<383::AID-PPUL4>3.0.CO;2-V; HALLIDAY HL, DELAYED GREATER 3 WE; Kovacs L, 1998, ACTA PAEDIATR, V87, P792, DOI 10.1080/080352598750013905; Ng PC, 1998, J CLIN ENDOCR METAB, V83, P2390, DOI 10.1210/jc.83.7.2390; OCALLAGHAN C, 1992, ARCH DIS CHILD-FETAL, V67, P20, DOI 10.1136/adc.67.1_Spec_No.20	13	5	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					266	267		10.1016/S0140-6736(99)00176-2	http://dx.doi.org/10.1016/S0140-6736(99)00176-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440296				2022-12-01	WOS:000081646000002
J	Sotiropoulos, A; Gineitis, D; Copeland, J; Treisman, R				Sotiropoulos, A; Gineitis, D; Copeland, J; Treisman, R			Signal-regulated activation of serum response factor is mediated by changes in actin dynamics	CELL			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; FILAMENT TURNOVER; SWINHOLIDE-A; ZINC-FINGER; BINDING; VINCULIN; COFILIN; PROTEIN; KINASE	Serum response factor (SRF) regulates transcription of many serum-inducible and muscle-specific genes. Using a functional screen, we identified LIM kinase-l as a potent activator of SRF. We show that SRF activation by LIM kinase-l is dependent on its ability to regulate actin treadmilling. LIM kinase activity is not essential for SRF activation by serum, but signals depend on alterations in actin dynamics. Studies with actin-binding drugs, the actin-specific C2 toxin, and actin overexpression demonstrate that G-actin level controls SRF. Regulation of actin dynamics is necessary for serum induction of a subset of SRF target genes, including vinculin, cytoskeletal actin, and srf itself, and also suffices for their activation. Actin treadmilling provides a convergence point for both serum- and LIM kinase-1-induced signaling to SRF.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	treisman@icrf.icnet.uk	Sotiropoulos, Athanassia/P-4269-2017	Sotiropoulos, Athanassia/0000-0002-7265-1473; Treisman, Richard/0000-0002-9658-0067				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Lyubimova A, 1997, J CELL BIOCHEM, V65, P469, DOI 10.1002/(SICI)1097-4644(19970615)65:4<469::AID-JCB3>3.3.CO;2-O; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.tb20530.x; Reuner KH, 1996, BIOCHEM J, V319, P843, DOI 10.1042/bj3190843; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Saito S, 1998, J BIOCHEM-TOKYO, V123, P571; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHEVZOV G, 1995, DNA CELL BIOL, V14, P689, DOI 10.1089/dna.1995.14.689; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	53	558	566	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					159	169		10.1016/S0092-8674(00)81011-9	http://dx.doi.org/10.1016/S0092-8674(00)81011-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428028	Bronze			2022-12-01	WOS:000081632300006
J	Lucas, GM; Chaisson, RE; Moore, RD				Lucas, GM; Chaisson, RE; Moore, RD			Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions	ANNALS OF INTERNAL MEDICINE			English	Article						anti-HIV agents; protease inhibitors; RNA, viral; CD4 lymphocytecount; urban health services	HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA HIV-1 RNA; PROTEASE INHIBITORS; TYPE-1 RNA; INFECTION; PROGRESSION; DISEASE; PREDICTORS; INDINAVIR; ADHERENCE	Background: In clinical trials, highly active antiretroviral therapy (HAART) reduces plasma HIV-1 RNA levels to less than 500 copies/mL in 60% to 90% of patients with HIV-1 infection. The performance of such therapy outside of the clinical trial setting is unclear. Objective: To determine factors associated with failure to suppress HIV-1 RNA levels and adverse drug reactions in a cohort of patients in whom protease inhibitor-containing therapy was begun in a large urban clinic. Design: Retrospective cohort study. Setting: Johns Hopkins HIV Clinic in Baltimore, Maryland. Patients: 273 protease inhibitor-naive patients began taking a protease inhibitor regimen containing at least one other antiretroviral drug to which the patients had not previously been exposed. Measurements: Demographic variables, plasma HIV-1 RNA levels, CD4(+) lymphocyte counts, and adverse drug reactions. Results: Levels of HIV-1 RNA were undetectable in 42% of the cohort at 1 to 90 days, in 44% at 3 to 7 months, and in 37% at 7 to 14 months. Factors associated with failure to suppress viral load at two or more time points included higher rates of missed clinic appointments, nonwhite ethnicity, age 40 years or younger, injection drug use, lower baseline CD4(+) lymphocyte count, and higher baseline viral load. In a multivariate model, only higher rates of missed clinic appointments were independently associated with viral suppression at 1 year. Ritonavir was associated with adverse drug reactions about twice as frequently as indinavir or nelfinavir, and women experienced significantly more adverse effects than men. Conclusions: Unselected patients in whom HAART is started in a clinic setting achieve viral suppression substantially less frequently than do patients in controlled clinical trials. Missed clinic visits were the most important risk factor for failure to suppress HIV-l RNA levels. Studies are needed to identify interventions that maximize the performance of HAART in inner-city clinics.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University	Moore, RD (corresponding author), 1830 E Monument St,Room 8059, Baltimore, MD 21205 USA.				NIDA NIH HHS [R01-DA11602] Funding Source: Medline; PHS HHS [R01-H507809] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; CLUMECK N, 1998, 5 C RETR OPP INF FEB, P386; Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DEEKS S, 1998, 5 C RETR OPP INF FEB, P419; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Drusano GL, 1998, J INFECT DIS, V178, P360, DOI 10.1086/515631; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; KAHN J, 1998, 5 C RETR OPP INF CHI, P208; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KISSINGER P, 1995, J NATL MED ASSOC, V87, P19; LEVINE AM, 1987, J CLIN ONCOL, V5, P1469, DOI 10.1200/JCO.1987.5.9.1469; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Moore RD, 1996, AM J MED, V101, P34, DOI 10.1016/S0002-9343(96)00077-0; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *ROCH LAB, 1997, INV SAQ MES CAPS PRO; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAG M, 1997, INF DIS SOC AM 35 AN, P112; TURNER J, 1995, CHEST, V108, P394, DOI 10.1378/chest.108.2.394; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; WOOD PR, 1985, ANN ALLERGY, V54, P400	31	688	712	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					81	+		10.7326/0003-4819-131-2-199907200-00002	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419445				2022-12-01	WOS:000081509700001
J	Meyers, EN; Martin, GR				Meyers, EN; Martin, GR			Differences in left-right axis pathways in mouse and chick: Functions of FGF8 and SHH	SCIENCE			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; PITX2; EMBRYOGENESIS; EXPRESSION; XENOPUS; EMBRYOS; GENE; MORPHOGENESIS	A molecular pathway leading to left-right asymmetry in the chick embryo has been described, in which FGF8 is a right determinant and Sonic Hedgehog a left determinant. Here evidence is presented that the Fgf8 and Sonic Hedgehog genes are required for left-right axis determination in the mouse embryo, but that they have different functions from those previously reported in the chick. In the mouse FGF8 is a left determinant and Sonic Hedgehog is required to prevent left determinants from being expressed on the right.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.	gmartin@itsa.ucsf.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001216, R01HD034380] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01216, R01 HD34380] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Campione M, 1999, DEVELOPMENT, V126, P1225; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Dufort D, 1998, DEVELOPMENT, V125, P3015; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MEYERS EN, UNPUB; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; STURM K, 1993, METHOD ENZYMOL, V225, P164; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	30	252	256	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					403	406		10.1126/science.285.5426.403	http://dx.doi.org/10.1126/science.285.5426.403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411502				2022-12-01	WOS:000081465900053
J	Platt, ML; Glimcher, PW				Platt, ML; Glimcher, PW			Neural correlates of decision variables in parietal cortex	NATURE			English	Article							REPRESENTATION; INTENTION; SELECTION; MEMORY; MONKEY	Decision theory proposes that humans and animals decide what to do in a given situation by assessing the relative value of each possible response, This assessment can be computed, in part, from the probability that each action will result In a gain and the magnitude of the gain expected, Here we show that the gain (or reward) a monkey can expect to realize from an eye-movement response modulates the activity of neurons in the lateral intraparietal area, an area of primate cortex that is thought to transform visual signals into eye-movement commands, We also show that the activity of these neurons is sensitive to the probability that a particular response will result in a gain, When animals can choose freely between two alternative responses, the choices subjects make and neuronal activation in this area are both correlated with the relative amount of gain that the animal can expect from each response. Our data indicate that a decision-theoretic model may provide a powerful new framework for studying the neural processes that intervene between sensation and action.	NYU, Ctr Neural Sci, New York, NY 10003 USA	New York University	Platt, ML (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	mplatt@cns.nyu.edu						ARNAULD A, 1982, ART THINKING PORT RO; ASANUMA H, 1967, J NEUROPHYSIOL, V30, P35, DOI 10.1152/jn.1967.30.1.35; Basso MA, 1997, NATURE, V389, P66, DOI 10.1038/37975; Bechara A, 1998, J NEUROSCI, V18, P428; BERNOULLI D, 1982, WORKS; Bernstein Nikolai, 1984, HUMAN MOTOR ACTIONS, P77, DOI DOI 10.1016/S0166-4115(08)61370-9; Bracewell RM, 1996, J NEUROPHYSIOL, V76, P1457, DOI 10.1152/jn.1996.76.3.1457; CATANIA AC, 1963, J EXP ANAL BEHAV, V6, P299, DOI 10.1901/jeab.1963.6-299; DAVENPORT JW, 1966, PSYCHON SCI, V4, P187; Descartes R., 1972, TREATISE MAN; DEVILLIERS PA, 1976, PSYCHOL BULL, V83, P1131, DOI DOI 10.1037/0033-2909.83.6.1131; Dorris MC, 1998, J NEUROSCI, V18, P7015; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1990, COLD SPRING HARB SYM, V55, P729; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; HERRNSTEIN RJ, 1961, J EXP ANAL BEHAV, V4, P267, DOI 10.1901/jeab.1961.4-267; HERRNSTEIN RJ, 1980, ALLOCATION INDIVIDUA, P143; Kahneman D., 1982, JUDGEMENT UNCERTAINT; KREBS JR, 1978, NATURE, V275, P27, DOI 10.1038/275027a0; Pavlov IP, 1927, CONDITIONED REFLEXES; Penfield W., 1975, MYSTERY MIND CRITICA; Platt M. L., 1997, Society for Neuroscience Abstracts, V23, P16; Platt ML, 1997, J NEUROPHYSIOL, V78, P1574, DOI 10.1152/jn.1997.78.3.1574; PLATT ML, 1998, INVEST OPHTH VIS SCI, V39, P326; PYKE GH, 1977, Q REV BIOL, V52, P137, DOI 10.1086/409852; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; Schoener T. W., 1971, A Rev Ecol Syst, V2, P369, DOI 10.1146/annurev.es.02.110171.002101; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Sherrington CS., 1906, INTEGRATIVE ACTION N; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STADDON JER, 1978, PSYCHOL REV, V85, P436, DOI 10.1037/0033-295X.85.5.436; Stephens D.W., 1986, pi; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; von Holst E., 1973, BEHAV PHYSL ANIMALS; WEISS PAUL, 1941, COMPAR PSYCHOL MONOGR, V17, P1	37	1138	1150	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					233	238		10.1038/22268	http://dx.doi.org/10.1038/22268			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	217MP	10421364				2022-12-01	WOS:000081503800035
J	Rochon, PA; Gurwitz, JH				Rochon, PA; Gurwitz, JH			Prescribing for seniors - Neither too much nor too little	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; REPLACEMENT; WOMEN		Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; Univ Toronto, Dept Med, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	University of Toronto; Baycrest; University of Toronto; University of Toronto; University of Toronto	Rochon, PA (corresponding author), Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.157.21.2413; Barakat K, 1999, LANCET, V353, P955, DOI 10.1016/S0140-6736(98)07114-1; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Handa VL, 1996, J AM GERIATR SOC, V44, P1; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Josse R, 1996, CAN MED ASSOC J, V155, P1113; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MYERS MG, 1995, GUIDELINES TREATMENT; *NAT OST FDN, 1998, PHYS GUID PREV TREAT; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spurgeon D, 1999, BRIT MED J, V318, P961, DOI 10.1136/bmj.318.7189.961b; Steinbrook R, 1998, NEW ENGL J MED, V338, P1541, DOI 10.1056/NEJM199805213382111; TAMBLYN R, 1999, EVALUATION IMPACT RE	24	90	94	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					113	115		10.1001/jama.282.2.113	http://dx.doi.org/10.1001/jama.282.2.113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411177				2022-12-01	WOS:000081376800002
J	Alberman, E; Noble, JM				Alberman, E; Noble, JM			Commentary: Food should be fortified with folic acid	BRITISH MEDICAL JOURNAL			English	Editorial Material							NEURAL-TUBE DEFECTS; PREVENTION		St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Alberman, E (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.							DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Mathews F, 1998, BRIT J OBSTET GYNAEC, V105, P954, DOI 10.1111/j.1471-0528.1998.tb10257.x; Murphy M, 1996, ARCH DIS CHILD-FETAL, V75, pF133, DOI 10.1136/fn.75.2.F133; Wald NJ, 1998, LANCET, V351, P834, DOI 10.1016/S0140-6736(05)78966-2; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Wild J, 1997, LANCET, V350, P30, DOI 10.1016/S0140-6736(05)66239-3	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					93	93						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398634				2022-12-01	WOS:000081438200032
J	Wolf, SG; Frenkiel, D; Arad, T; Finkel, SE; Kolter, R; Minsky, A				Wolf, SG; Frenkiel, D; Arad, T; Finkel, SE; Kolter, R; Minsky, A			DNA protection by stress-induced biocrystallization	NATURE			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; STATIONARY-PHASE; OXIDATIVE-STRESS; BINDING PROTEIN; NONHEME IRON; DPS; FERRITIN; COMPLEXES	The crystalline state is considered to be incompatible with life. However, in living systems exposed to severe environmental assaults, the sequestration of vital macromolecules in intracellular crystalline assemblies may provide an efficient means for protection. Here we report a generic defence strategy found in Escherichia coli, involving co-crystallization of its DNA with the stress-induced protein Dps(1,2). We show that when purified Dps and DNA interact, extremely stable crystals form almost instantaneously, within which DNA is sequestered and effectively protected against varied assaults. Crystalline structures with similar lattice spacings are formed in E. coli in which Dps is slightly over expressed, as well as in starved wild-type bacteria. Hence, DNA-Dps co-crystallization is proposed to represent a binding mode that provides wide-range protection of DNA by sequestration. The rapid induction and large-scale production of Dps in response to stress, as well as the presence of Dps homologues in many distantly related bacteria, indicate that DNA protection by biocrystallization may be crucial and widespread in prokaryotes.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Weizmann Institute of Science; Weizmann Institute of Science; Harvard University; Harvard Medical School	Minsky, A (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; BERNARDIN WD, 1986, J MOL BIOL, V189, P503; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FLARDH K, 1992, J BACTERIOL, V174, P6780, DOI 10.1128/JB.174.21.6780-6788.1992; FRAZIER BA, 1993, J BACTERIOL, V175, P966, DOI 10.1128/JB.175.4.966-972.1993; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; HOBOT JA, 1985, J BACTERIOL, V162, P960, DOI 10.1128/JB.162.3.960-971.1985; KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.mi.47.100193.004231; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; PENA MMO, 1995, ARCH MICROBIOL, V163, P337, DOI 10.1007/BF00404206; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; PINSINCE JM, 1992, J MOL BIOL, V228, P409, DOI 10.1016/0022-2836(92)90830-D; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; ROBINOW C, 1994, MICROBIOL REV, V58, P211, DOI 10.1128/MMBR.58.2.211-232.1994; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Wai SN, 1997, MICROBIOL IMMUNOL, V41, P461, DOI 10.1111/j.1348-0421.1997.tb01879.x	22	280	294	0	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					83	85		10.1038/21918	http://dx.doi.org/10.1038/21918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403254				2022-12-01	WOS:000081255700056
J	Coninx, R; Mathieu, C; Debacker, M; Mirzoev, F; Ismaelov, A; de Haller, R; Meddings, DR				Coninx, R; Mathieu, C; Debacker, M; Mirzoev, F; Ismaelov, A; de Haller, R; Meddings, DR			First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons	LANCET			English	Article							HIV-INFECTION	Background We assessed a programme of tuberculosis control in a prison setting in Baku, Azerbaijan. The programme used first-line therapy and DOTS (directly observed treatment, short course). Methods 467 patients had sputum-positive tuberculosis. Their treatment regimens followed WHO guidelines, and they had regular clinical examinations and dietary supplements. Isolates were tested by standard methods for resistance to isoniazid, rifampicin, ethambutol, and streptomycin in three laboratories. Treatment success was defined as three consecutive negative sputum smears at end of treatment. Factors independently associated with treatment failure were estimated by logistic regression. Findings Drug-resistance data on admission were available for 131 patients. 55% of patients had strains of Mycobacterium tuberculosis resistant to two or more antibiotics. Mortality during treatment was 11%, and 13% of patients defaulted. Overall, treatment was successful in 54% of patients, and in 71% of those completing treatment. 104 patients completed a full treatment regimen and remained sputum-positive. Resistance to two or more antibiotics, a positive sputum result at the end of initial treatment, cavitary disease, and poor compliance were independently associated with treatment failure. Interpretation The effectiveness of a DOTS programme with first-line therapy fell short of the 85% target set by WHO. First-line therapy may not be sufficient in settings with a high degree of resistance to antibiotics.	Int Comm Red Cross, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Republ Stadyum, Baku, Azerbaijan		Coninx, R (corresponding author), Int Comm Red Cross, 19 Ave Paix, CH-1202 Geneva, Switzerland.	rconinx@icrc.org		Mirzayev, Fuad/0000-0001-6658-0325				BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; Coninx R, 1998, BRIT MED J, V316, P1423, DOI 10.1136/bmj.316.7142.1423; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; *EUR CTR EP MON AI, 1996, 52 EUR CTR EP MON AI, P11; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Siddiqi SH, 1989, BACTEC TB SYSTEM PRO; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; *WHO, 1997, GLOB TUB CONTR, P66; *WHO, 1995, WKLY EPIDEMIOL REC, V70, P21; *WHO, 1997, ANT DRUG RES WORLD W, P117; *WHO, 1997, TUB CONTR REF SIT; *WHO, 1997, TREATM TUB DISTR LEV; World Health Organization, 1995, WHO REP TUB EP 1995	16	90	99	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					969	973		10.1016/S0140-6736(98)08341-X	http://dx.doi.org/10.1016/S0140-6736(98)08341-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459906				2022-12-01	WOS:000079421600012
J	Kirkpatrick, PJ				Kirkpatrick, PJ			Time to reconsider treatment options for intracranial aneurysms	LANCET			English	Editorial Material									Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Kirkpatrick, PJ (corresponding author), Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 2QQ, England.							INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	4	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					942	943		10.1016/S0140-6736(98)00278-5	http://dx.doi.org/10.1016/S0140-6736(98)00278-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459898				2022-12-01	WOS:000079421600004
J	Valverde, MA; Rojas, P; Amigo, J; Cosmelli, D; Orio, P; Bahamonde, MI; Mann, GE; Vergara, C; Latorre, R				Valverde, MA; Rojas, P; Amigo, J; Cosmelli, D; Orio, P; Bahamonde, MI; Mann, GE; Vergara, C; Latorre, R			Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit	SCIENCE			English	Article							VASCULAR SMOOTH-MUSCLE; POTASSIUM CHANNELS; CA2+ CURRENTS; CELL-LINE; ESTROGEN; MEMBRANE; 17-BETA-ESTRADIOL; RECEPTOR; INHIBITION; RELAXATION	Maxi-K channels consist of a pore-forming alpha subunit and a regulatory beta subunit, which confers the channel with a higher Ca2+ sensitivity. Estradiol bound to the beta subunit and activated the Maxi-K channel (hSlo) only when both a and beta subunits were present. This activation was independent of the generation of intracellular signals and could be triggered by estradiol conjugated to a membrane-impenetrable carrier protein. This study documents the direct interaction of a hormone with a voltage-gated channel subunit and provides the molecular mechanism for the modulation of vascular smooth muscle Maxi-K channels by estrogens.	Univ Pompeu Fabra, Dept Ciencias Expt & Salut, Barcelona 08003, Spain; Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Ctr Estudios Cient, Valdivia 9, Chile; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Kings Coll London, Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 9RT, England	Pompeu Fabra University; Universidad de Chile; University of California System; University of California Los Angeles; University of London; King's College London	Valverde, MA (corresponding author), Univ Pompeu Fabra, Dept Ciencias Expt & Salut, C-Doctor Aiguader 80, Barcelona 08003, Spain.	miguel.valverde@cexs.upf.es	Orio, Patricio/F-6207-2010; Vergara, Cecilia/H-6964-2014	Orio, Patricio/0000-0003-0332-8098; Vergara, Cecilia/0000-0002-4015-7438; Valverde, Miguel A./0000-0002-6961-3361; ROZALI, ZALNIATI FONNA/0000-0003-2242-5125	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Clark AG, 1999, J PHYSIOL-LONDON, V516, P45, DOI 10.1111/j.1469-7793.1999.045aa.x; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; JIANG C, 1994, BRIT J PHARMACOL, V104, P1033; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Moats RK, 1998, BIOL REPROD, V58, P531, DOI 10.1095/biolreprod58.2.531; MOCZYDLOWSKI EG, 1983, BIOCHIM BIOPHYS ACTA, V732, P412, DOI 10.1016/0005-2736(83)90058-5; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nakajima T, 1995, EUR J PHARMACOL, V294, P625, DOI 10.1016/0014-2999(95)00602-8; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Ogata R, 1996, BRIT J PHARMACOL, V117, P351, DOI 10.1111/j.1476-5381.1996.tb15198.x; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Russell KS, 1997, CIRCULATION, V96, P256; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TAGLIALATELA M, 1993, P NATL ACAD SCI USA, V90, P4758, DOI 10.1073/pnas.90.10.4758; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wetzel CHR, 1998, MOL ENDOCRINOL, V12, P1441, DOI 10.1210/me.12.9.1441; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	38	429	447	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1929	1931		10.1126/science.285.5435.1929	http://dx.doi.org/10.1126/science.285.5435.1929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489376				2022-12-01	WOS:000082638300056
J	Larkin, M				Larkin, M			US online pharmacies strive for respectability	LANCET			English	Editorial Material																		1999, LANCET, V354, P138	1	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					782	782		10.1016/S0140-6736(05)76034-7	http://dx.doi.org/10.1016/S0140-6736(05)76034-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475233				2022-12-01	WOS:000082233000077
J	Schwaiger, M; Melin, J				Schwaiger, M; Melin, J			Cardiological applications of nuclear medicine	LANCET			English	Article							CORONARY-ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; ISCHEMIC-HEART-DISEASE; MYOCARDIAL BLOOD-FLOW; PROGNOSTIC VALUE; VENTRICULAR DYSFUNCTION; VIABILITY ASSESSMENT; TL-201; REVASCULARIZATION; CARDIOMYOPATHY	Cardiovascular mortality is falling in most industrialised nations. Primarily responsible for this encouraging trend are preventive measures such as risk-factor modification but improved medical and surgical management have helped too. Clinical decision making in the patient with coronary heart disease demands techniques that not only describe coronary anatomy but also provide functional indices for early detection and to monitor the severity and extent of disease. Nuclear medicine methods can characterise non-invasively myocardial function, perfusion, and metabolism. Novel radiopharmaceuticals, improvements in imaging equipment, and extensive validation have contributed to the growing clinical acceptance of these techniques and to their cost-effective integration in the workup of patients with cardiovascular disease.	Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, D-81675 Munich, Germany; Catholic Univ Louvain, Clin Univ St Luc, Dept Internal Med, Div Nucl Med, Brussels, Belgium	Technical University of Munich; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwaiger, M (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, Ismaninger Str 22, D-81675 Munich, Germany.	M.Schwaiger@lrz.tu-muenchen.de		schwaiger, markus/0000-0002-2305-7144				Bax JJ, 1997, J AM COLL CARDIOL, V30, P1451, DOI 10.1016/S0735-1097(97)00352-5; Beller GA, 1998, J AM COLL CARDIOL, V31, P1286; BERGMANN SR, 1989, J AM COLL CARDIOL, V14, P639, DOI 10.1016/0735-1097(89)90105-8; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BROWN KA, 1993, AM J CARDIOL, V71, P865, DOI 10.1016/0002-9149(93)90840-9; Campisi R, 1999, CIRCULATION, V99, P491, DOI 10.1161/01.CIR.99.4.491; Carrio I, 1998, J NUCL CARDIOL, V5, P551, DOI 10.1016/S1071-3581(98)90108-8; DICARLI MF, 1995, CIRCULATION, V92, P3436, DOI 10.1161/01.CIR.92.12.3436; DREYFUS GD, 1994, ANN THORAC SURG, V57, P1402, DOI 10.1016/0003-4975(94)90091-4; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; EITZMAN D, 1992, J AM COLL CARDIOL, V20, P559, DOI 10.1016/0735-1097(92)90008-B; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; Garber AM, 1999, ANN INTERN MED, V130, P719, DOI 10.7326/0003-4819-130-9-199905040-00003; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GOULD KL, 1978, AM J CARDIOL, V41, P267, DOI 10.1016/0002-9149(78)90165-0; Guethlin M, 1999, CIRCULATION, V99, P475, DOI 10.1161/01.CIR.99.4.475; Haas F, 1997, J AM COLL CARDIOL, V30, P1693, DOI 10.1016/S0735-1097(97)00375-6; Hachamovitch R, 1998, CIRCULATION, V97, P535; Iskander S, 1998, J AM COLL CARDIOL, V32, P57, DOI 10.1016/S0735-1097(98)00177-6; KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Laine M, 1998, J CLIN INVEST, V101, P1156, DOI 10.1172/JCI1065; MACHECOURT J, 1994, J AM COLL CARDIOL, V23, P1096, DOI 10.1016/0735-1097(94)90597-5; MAISEY MN, 1990, EUR J NUCL MED, V16, P869, DOI 10.1007/BF01280254; MELIN JA, 1986, J NUCL MED, V27, P641; OHTANI H, 1990, AM J CARDIOL, V66, P394, DOI 10.1016/0002-9149(90)90692-T; Pagley PR, 1997, CIRCULATION, V96, P793; Pennell DJ, 1998, HEART, V80, P296, DOI 10.1136/hrt.80.3.296; POHOST GM, 1977, CIRCULATION, V55, P294, DOI 10.1161/01.CIR.55.2.294; PORT SC, 1995, J NUCL CARDIOL, V2, P551, DOI 10.1016/S1071-3581(05)80049-2; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; Shaw LJ, 1999, J AM COLL CARDIOL, V33, P661, DOI 10.1016/S0735-1097(98)00606-8; SILSIZIAN V, 1996, J AM COLL CARDIOL, V27, P910; Stollfuss JC, 1998, EUR J NUCL MED, V25, P522, DOI 10.1007/s002590050253; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; UDELSON JE, 1994, CIRCULATION, V89, P2552, DOI 10.1161/01.CIR.89.6.2552; Underwood SR, 1999, EUR HEART J, V20, P157, DOI 10.1053/euhj.1998.1196; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; Wijns W, 1998, NEW ENGL J MED, V339, P173, DOI 10.1056/NEJM199807163390307; ZARET BL, 1973, NEW ENGL J MED, V288, P809, DOI 10.1056/NEJM197304192881602; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313	43	59	61	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					661	666		10.1016/S0140-6736(99)06057-2	http://dx.doi.org/10.1016/S0140-6736(99)06057-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466685				2022-12-01	WOS:000082214500045
J	Michael, M; Meddings, DR; Ramez, S; Gutierrez-Fisac, JL				Michael, M; Meddings, DR; Ramez, S; Gutierrez-Fisac, JL			Incidence of weapon injuries not related to interfactional combat in Afghanistan in 1996: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FIREARM	Objective To examine the descriptive epidemiology of weapon injuries not directly attributable to combat during armed conflict Design Prospective cohort study. Setting Nangarhar region of Afghanistan, which experienced effective peace, intense fighting, and then peace over six months in 1996, Subjects 608 people admitted to Jalalabad hospital because of weapon injuries. Main outcome measures Estimated incidence of injuries from combat or otherwise (non-combat injury) before, during, and after the fall of Kabul. Results Incidence of non-combat injury was initially 65 per 100 000, During the intense military campaign for Kabul the incidence declined dramatically and then differentially increased dependent on injury subcategory-that is, whether injuries were accidental or intentional and whether they were inflicted by firearms or fragmenting munitions. Non-combat injuries accounted for 51% of weapon injuries observed over the study period. Civilians were more likely to have non-combat injuries than combat injuries. Conclusions Weapon injuries that are not attributable to combat are common. Social changes accompanying conflict and widespread availability of weapons may be predictive of use of weapons that persists independently of conflict.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Hlth Operat Div, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Peshawar, Pakistan; Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain	Autonomous University of Madrid	Meddings, DR (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.	dmeddings@icrc.org		Michael, Markus/0000-0003-0482-4325				ADENIJI O, 1998, MORATORIUM LIGHT WEA, P85; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Bellah RN, 1995, BOST THEO I, V4, P1; BERMAN E, 1996, MANAGING ARMS PEACE, P57; CHACHIUA M, 1999, ARMS MANAGEMENT PROG; Coupland R. M., 1996, MED GLOBAL SURVIVAL, V3, P1; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Cukier W, 1998, Chronic Dis Can, V19, P25; HIGDON S, 1996, ANGOLA CONFLICT RESO; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Klare M. T., 1995, LETHAL COMMERCE GLOB; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; Smith C., 1995, LETHAL COMMERCE GLOB, P61; Williams P., 1997, SOC SIEGE CRIME VIOL, P11; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	16	19	20	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					415	417		10.1136/bmj.319.7207.415	http://dx.doi.org/10.1136/bmj.319.7207.415			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445923	Bronze, Green Published			2022-12-01	WOS:000082098900017
J	Peters, C; Andrews, PD; Stark, MJR; Cesaro-Tadic, S; Glatz, A; Podtelejnikov, A; Mann, M; Mayer, A				Peters, C; Andrews, PD; Stark, MJR; Cesaro-Tadic, S; Glatz, A; Podtelejnikov, A; Mann, M; Mayer, A			Control of the terminal step of intracellular membrane fusion by protein phosphatase 1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE PHOSPHATASES; YEAST VACUOLES; SEC18P NSF; T-SNARE; DOCKING; DISTINCT; KINASE; BINDS; ROLES	Intracellular membrane fusion is crucial for the biogenesis and maintenance of cellular compartments, for vesicular traffic between them, and for exo- and endocytosis. Parts of the molecular machinery underlying this process have been identified, but most of these components operate in mutual recognition of the membranes. Here it is shown that protein phosphatase 1 (PP1) is essential for bilayer mixing, the last step of membrane fusion, PP1 was also identified in a complex that contained calmodulin, the second known factor implicated in the regulation of bilayer mixing. The PP1-calmodulin complex was required at multiple sites of intracellular trafficking; hence, PP1 may be a general factor controlling membrane bilayer mixing.	Friedrich Miescher Lab, D-72076 Tubingen, Germany; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Univ So Denmark, Dept Mol Biol, Prot Interact Lab, DK-5230 Odense M, Denmark	Eberhard Karls University of Tubingen; University of Dundee; University of Southern Denmark	Mayer, A (corresponding author), Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.	andreas.mayer@tuebingen.mpg.de	Podtelejnikov, Alexandre/B-6120-2017; Mayer, Andreas/AAE-4315-2020; Mann, Matthias/A-3454-2013; Stark, Michael J. R./B-2815-2014	Podtelejnikov, Alexandre/0000-0002-8124-6584; Mayer, Andreas/0000-0001-6131-313X; Mann, Matthias/0000-0003-1292-4799; Stark, Michael J. R./0000-0001-9086-191X; Andrews, Paul/0000-0001-7699-5604	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS PD, UNPUB; Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JONES EW, 1977, GENETICS, V85, P23; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MAYER A, IN PRESS CURR OPIN C; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	29	138	142	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1084	1087		10.1126/science.285.5430.1084	http://dx.doi.org/10.1126/science.285.5430.1084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446058				2022-12-01	WOS:000082033100051
J	Wichman, HA; Badgett, MR; Scott, LA; Boulianne, CM; Bull, JJ				Wichman, HA; Badgett, MR; Scott, LA; Boulianne, CM; Bull, JJ			Different trajectories of parallel evolution during viral adaptation	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESISTANCE MUTATIONS; BENEFICIAL MUTATIONS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SELECTION; FITNESS; POPULATION; DRUG; DNA	The molecular basis of adaptation is a major focus of evolutionary biology, yet the dynamic process of adaptation has been explored only piecemeal. Experimental evolution of two bacteriophage lines under strong selection led to over a dozen nucleotide changes genomewide in each replicate. At Least 96 percent of the amino acid substitutions appeared to be adaptive, and half the changes in one line also occurred in the other. However, the order of these changes differed between replicates, and parallel substitutions did not reflect the changes with the largest beneficial effects or indicate a common trajectory of adaptation.	Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Idaho; University of Idaho; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Wichman, HA (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA.	hwichman@uidaho.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057756, R01GM057755] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057756, GM57755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; Boyd EF, 1998, J MOL EVOL, V47, P258, DOI 10.1007/PL00006383; Bull JJ, 1997, GENETICS, V147, P1497; Canica MMM, 1997, J MOL EVOL, V44, P57, DOI 10.1007/PL00006121; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Elena SF, 1996, GENETICS, V142, P673; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; HOLLAND JJ, 1979, CELL, V16, P495, DOI 10.1016/0092-8674(79)90024-2; KELLAM P, 1994, J GEN VIROL, V75, P341, DOI 10.1099/0022-1317-75-2-341; LAU PCK, 1985, GENE, V40, P273, DOI 10.1016/0378-1119(85)90050-2; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Li W.H., 1997, MOL EVOLUTION; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Nijhuis M, 1998, P NATL ACAD SCI USA, V95, P14441, DOI 10.1073/pnas.95.24.14441; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SPENCER JH, 1978, SINGLE STRANDED DNA, P87; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497; WARNER JC, 1978, SINGLE STRANDED DNA, P417	28	273	274	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					422	424		10.1126/science.285.5426.422	http://dx.doi.org/10.1126/science.285.5426.422			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411508				2022-12-01	WOS:000081465900059
J	Kovacs, A; Schluchter, M; Easley, K; Demmler, G; Shearer, W; La Russa, P; Pitt, J; Cooper, E; Goldfarb, J; Hodes, D; Kattan, M; McIntosh, K				Kovacs, A; Schluchter, M; Easley, K; Demmler, G; Shearer, W; La Russa, P; Pitt, J; Cooper, E; Goldfarb, J; Hodes, D; Kattan, M; McIntosh, K		Pediat Pulmonary Cardiovascular Complications	Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	XIth International Conference on AIDS	JUL 07-13, 1996	VANCOUVER, CANADA				HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; HOMOSEXUAL MEN; MULTIPLE IMPUTATION; AIDS PATIENTS; CMV DISEASE; TYPE-1; DNA; CHILDREN; MONONUCLEOSIS	Background and Methods Cytomegalovirus (CMV) has been implicated as a cofactor in the progression of human immunodeficiency virus type 1 (HIV-1) disease. We assessed 440 infants (75 of whom were HIV-1-infected and 365 of whom were not) whose CMV status was known, who were born to HIV-1-infected women, and who were followed prospectively. HIV-1 disease progression was defined as the presence of class C symptoms (according to the criteria of the Centers for Disease Control and Prevention [CDC]) or CD4 counts of less than 750 cells per cubic millimeter by 1 year of age and less than 500 cells per cubic millimeter by 18 months of age. Results At birth the frequency of CMV infection was similar in the HIV-1-infected and HIV-1-uninfected infants (4.3 percent and 4.5 percent, respectively), but the HIV-1-infected infants had a higher rate of CMV infection at six months of age (39.9 percent vs. 15.3 percent, P=0.001) and continued to have a higher rate of CMV infection through four years of age (P=0.04). By 18 months of age, the infants with both infections had higher rates of HIV-1 disease progression (70.0 percent vs. 30.4 percent, P=0.001), CDC class C symptoms or death (52.5 percent vs. 21.7 percent, P=0.008), and impaired brain growth or progressive motor deficits (35.6 percent vs. 8.7 percent, P=0.005) than infants infected only with HIV-1. In a Cox regression analysis, CMV infection was associated with an increased risk of HIV-1 disease progression (relative risk, 2.59; 95 percent confidence interval, 1.13 to 5.95). Among children infected with HIV-1 alone, but not among those infected with both viruses, children with rapid progression of HIV-1 disease had higher mean levels of HIV-1 RNA than those with slower or no progression of disease. Conclusions HIV-1-infected infants who acquire CMV infection in the first 18 months of life have a significantly higher rate of disease progression and central nervous system disease than those infected with HIV-1 alone. (N Engl J Med 1999;341:77-84.) (C) 1999, Massachusetts Medical Society.	Univ So Calif, Los Angeles Cty Med Ctr, Maternal Child HIV Management & Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Div Pediat Invect Dis, Los Angeles, CA USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Div Pediat & Adolescent Med, Cleveland, OH 44195 USA; Baylor Coll Med, Dept Pediat, Sect Infect Dis, Houston, TX 77030 USA; Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA; Columbia Presbyterian Med Ctr, Dept Pediat, New York, NY 10032 USA; Bolston Med Ctr, Dept Pediat, Boston, MA USA; Mt Sinai Sch Med, Pediat Pulm & Crit Care Div, New York, NY USA; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Infect Dis, New York, NY USA	University of Southern California; University of Southern California; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Baylor College of Medicine; Baylor College of Medicine; Columbia University; NewYork-Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital; Icahn School of Medicine at Mount Sinai	Kovacs, A (corresponding author), Hlth Res Associates Bldg,1640 Marengo St,3rd Fl, Los Angeles, CA 90033 USA.		Easley, Kirk A/K-6910-2015	Easley, Kirk A/0000-0003-4419-2617; Shearer, William/0000-0002-2483-2130	DIVISION OF LUNG DISEASES [N01HR096039, N01HR096038, N01HR096037, N01HR096043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533, M01RR002172, M01RR000043, M01RR000645, M01RR000865, M01RR000071, M01RR000188, K01RR000188] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000533, M01 RR002172, M01 RR000645, M01 RR000188, M01 RR000071, M01 RR000865, K01 RR000188, M01 RR000043] Funding Source: Medline; NHLBI NIH HHS [N01-HR-96038, N01 HR096043, N01-HR-96039, N01 HR096037] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; BELMAN AL, 1988, AM J DIS CHILD, V142, P29, DOI 10.1001/archpedi.1988.02150010039017; BELMAN AL, 1988, AM J DIS CHILD, V142, P507; Carcaba V, 1991, An Med Interna, V8, P243; CARNEY WP, 1983, J IMMUNOL, V130, P390; Chandwani S, 1996, PEDIATR INFECT DIS J, V15, P310, DOI 10.1097/00006454-199604000-00006; COLLIER AC, 1987, AM J MED, V82, P593, DOI 10.1016/0002-9343(87)90105-7; COOPER ER, 1992, PEDIATR AIDS HIV INF, V3, P302; CURLESS RG, 1987, CHILD NERV SYST, V3, P255, DOI 10.1007/BF00274063; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177; DETELS R, 1984, JAMA-J AM MED ASSOC, V251, P1719, DOI 10.1001/jama.251.13.1719; DOREY FJ, 1993, STAT MED, V12, P1589, DOI 10.1002/sim.4780121706; Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010; DREW WL, 1985, ANN INTERN MED, V103, P61, DOI 10.7326/0003-4819-103-1-61; DUDDING L, 1989, J IMMUNOL, V143, P3343; FRENKEL LD, 1990, REV INFECT DIS, V12, pS820; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; Gerard L, 1997, CLIN INFECT DIS, V24, P836, DOI 10.1093/clinids/24.5.836; GERNA G, 1994, J CLIN MICROBIOL, V32, P2709, DOI 10.1128/JCM.32.11.2709-2717.1994; HO DD, 1987, NEW ENGL J MED, V317, P278; JAULT FM, 1994, J VIROL, V68, P959, DOI 10.1128/JVI.68.2.959-973.1994; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P30; Kattan M, 1996, J CLIN EPIDEMIOL, V49, P1285; Kitchen BJ, 1997, PEDIATR INFECT DIS J, V16, P358, DOI 10.1097/00006454-199704000-00005; LANG DJ, 1989, J ACQ IMMUN DEF SYND, V2, P540; LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101; MCKEATING JA, 1990, NATURE, V343, P659, DOI 10.1038/343659a0; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NGUYEN C, 1991, J INFECT DIS, V164, P219, DOI 10.1093/infdis/164.1.219; Nigro G, 1996, AIDS, V10, P1127, DOI 10.1097/00002030-199609000-00011; PASS RF, 1980, PEDIATRICS, V66, P758; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; RAFFI F, 1990, ANN INTERN MED, V112, P234, DOI 10.7326/0003-4819-112-3-234; Rasmussen L, 1997, J INFECT DIS, V176, P1146, DOI 10.1086/514106; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; RINALDO CR, 1980, J INFECT DIS, V141, P488, DOI 10.1093/infdis/141.4.488; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SCHINDLER JM, 1990, KLIN WOCHENSCHR, V68, P237, DOI 10.1007/BF01662723; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shepp DH, 1996, J ACQ IMMUN DEF SYND, V11, P460, DOI 10.1097/00042560-199604150-00006; SKOLNIK PR, 1989, AM J OPHTHALMOL, V107, P361, DOI 10.1016/0002-9394(89)90659-4; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1991, J ACQ IMMUN DEF SYND, V4, pS47; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003	53	177	185	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					77	84		10.1056/NEJM199907083410203	http://dx.doi.org/10.1056/NEJM199907083410203			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395631	Green Accepted			2022-12-01	WOS:000081316200003
J	Cranford, RE				Cranford, RE			Policy should be balanced with concern for the family	BRITISH MEDICAL JOURNAL			English	Article									Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA	Hennepin County Medical Center	Cranford, RE (corresponding author), Hennepin Cty Med Ctr, Dept Neurol, 701 Pk Ave, Minneapolis, MN 55415 USA.							Youngner S., 1999, DEFINITION DEATH CON	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1754	1755						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428563				2022-12-01	WOS:000081216900040
J	Hamiche, A; Sandaltzopoulos, R; Gdula, DA; Wu, C				Hamiche, A; Sandaltzopoulos, R; Gdula, DA; Wu, C			ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF	CELL			English	Article							NUCLEOSOME CORE PARTICLE; YEAST SWI/SNF COMPLEX; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; MULTISUBUNIT COMPLEX; GENE-PRODUCTS; DNA; BINDING; ISWI; MOBILITY	Drosophila NURF is an ATP-dependent chromatin remodeling complex that contains ISWI, a member of the SW12/SNF2 family of ATPases. We demonstrate that NURF catalyzes the bidirectional redistribution of mononucleosomes reconstituted on hsp70 promoter DNA. In the presence of NURF, nucleosomes adopt one predominant position from an ensemble of possible locations within minutes. Movements occur in cis, with no transfer to competing DNA. Migrating intermediates trapped by fro III digestion reveal progressive nucleosome motion in increments of several base pairs. All four core histones are retained quantitatively during this process, indicating that the general integrity of the histone octamer is maintained. We suggest that NURF remodels nucleosomes by transiently decreasing the activation energy for short-range sliding of the histone octamer.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.							Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GLOTOV BO, 1982, BIOCHIM BIOPHYS ACTA, V696, P275, DOI 10.1016/0167-4781(82)90058-6; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; ITO T, 1999, IN PRESS GENES DEV; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Sandaltzopoulos R, 1999, METHOD ENZYMOL, V304, P757; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Travers A, 1997, BIOPOLYMERS, V44, P423, DOI 10.1002/(SICI)1097-0282(1997)44:4<423::AID-BIP6>3.0.CO;2-M; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; van Holde K.E., 1989, CHROMATIN; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEISCHET WO, 1978, NUCLEIC ACIDS RES, V5, P139, DOI 10.1093/nar/5.1.139; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu C, 1998, COLD SPRING HARB SYM, V63, P525, DOI 10.1101/sqb.1998.63.525; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	75	277	281	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					833	842		10.1016/S0092-8674(00)80796-5	http://dx.doi.org/10.1016/S0092-8674(00)80796-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399912	Bronze			2022-12-01	WOS:000081162800005
J	de Medina, EOR; Algra, A				de Medina, EOR; Algra, A			Digoxin in the treatment of paroxysmal atrial fibrillation	LANCET			English	Editorial Material							SINUS RHYTHM; PLACEBO		Univ Utrecht, Med Ctr, Heart Lung Inst, Dept Cardiol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Neurol, Utrecht, Netherlands; Univ Med Ctr, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	de Medina, EOR (corresponding author), Univ Utrecht, Med Ctr, Heart Lung Inst, Dept Cardiol, NL-3508 GA Utrecht, Netherlands.							ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; BEASLEY R, 1985, BRIT MED J, V290, P9, DOI 10.1136/bmj.290.6461.9; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Jordaens L, 1997, EUR HEART J, V18, P643; Karki K, 1997, EUR HEART J, V18, P649; Levy S, 1998, EUR HEART J, V19, P1294, DOI 10.1053/euhj.1998.1050; Murgatroyd FD, 1999, CIRCULATION, V99, P2765, DOI 10.1161/01.CIR.99.21.2765; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622	10	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					882	883						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489943				2022-12-01	WOS:000082511800006
J	Liebl, U; Lipowski, G; Negrerie, M; Lambry, JC; Martin, JL; Vos, MH				Liebl, U; Lipowski, G; Negrerie, M; Lambry, JC; Martin, JL; Vos, MH			Coherent reaction dynamics in a bacterial cytochrome c oxidase	NATURE			English	Article							PARACOCCUS-DENITRIFICANS; REACTION CENTERS; VIBRATIONAL COHERENCE; ELECTRON-TRANSFER; HEME-PROTEINS; PRIMARY EVENT; SPECTROSCOPY; ACTIVATION; ABSORPTION; PROGRAM	Biological reactions in protein complexes involve structural dynamics spanning many orders of magnitude in time. In standard descriptions of catalysis by enzymes, the transition state between reactant and product is reached by thermal, stochastic motion. In the ultrashort time domain, however, the protein moiety and cofactor motions leading to altered conformations can be coherent rather than stochastic in nature(1-4). Such coherent motions may play a key role in controlling the accessibility of the transition state and explain the high efficiency of the reaction. Here we present evidence for coherent population transfer to the product state during an ultrafast reaction catalysed by a key enzyme in aerobic organisms. Using the enzyme cytochrome c oxidase aa(3) from the bacterium Paracoccus denitrificans, we have studied haem dynamics during the photo-initiated ultrafast transfer of carbon monoxide from haem a(3) to CuB by femtosecond spectroscopy. The ground state of the unliganded a(3) species is populated in a stepwise manner in time, indicating that the reaction is mainly governed by coherent vibrations (47 cm(-1)). The reaction coordinate involves conformational relaxation of the haem group and we suggest that ligand transfer also contributes.	Ecole Polytech, ENSTA, Lab Opt Appl, INSERM,U451, F-91761 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	Vos, MH (corresponding author), Ecole Polytech, ENSTA, Lab Opt Appl, INSERM,U451, F-91761 Palaiseau, France.		Negrerie, Michel/L-2283-2018	Negrerie, Michel/0000-0001-9918-031X; Lambry, Jean-Christophe/0000-0001-8264-0391; Vos, Marten/0000-0003-0493-4831				Asher S, 1981, Methods Enzymol, V76, P371; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAGCHI B, 1990, J PHYS CHEM-US, V94, P9, DOI 10.1021/j100364a004; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHAMPION PM, 1998, P 16 INT C RAM SPECT, P73; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; FRANZEN S, 1994, NAT STRUCT BIOL, V1, P230, DOI 10.1038/nsb0494-230; GEORGIADIS KE, 1994, BIOCHEMISTRY-US, V33, P9245, DOI 10.1021/bi00197a028; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMON DD, 1993, BIOCHEMISTRY-US, V32, P11953, DOI 10.1021/bi00096a002; LI XY, 1992, CHEM PHYS LETT, V188, P16, DOI 10.1016/0009-2614(92)85081-K; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; Martin J. L., 1984, ULTRAFAST PHENOMENA, VIV, P447; MARTIN JL, 1994, METHOD ENZYMOL, V232, P416; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rischel C, 1998, P NATL ACAD SCI USA, V95, P12306, DOI 10.1073/pnas.95.21.12306; Schelvis JPM, 1997, J AM CHEM SOC, V119, P8409, DOI 10.1021/ja964133p; STOUTLAND PO, 1991, J PHYS CHEM-US, V95, P6406, DOI 10.1021/j100170a004; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; VOS MH, 1991, P NATL ACAD SCI USA, V88, P8885, DOI 10.1073/pnas.88.20.8885; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; Vos MH, 1998, CHEM PHYS, V233, P179, DOI 10.1016/S0301-0104(97)00355-8; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; ZHU LY, 1994, SCIENCE, V266, P629, DOI 10.1126/science.7939716	30	90	91	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					181	184		10.1038/43699	http://dx.doi.org/10.1038/43699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490029				2022-12-01	WOS:000082458800058
J	Brearley, AJ				Brearley, AJ			Origin of graphitic carbon and pentlandite in matrix olivines in the Allende meteorite	SCIENCE			English	Article							DARK INCLUSIONS; SOLAR NEBULA; AQUEOUS ALTERATION; FAYALITIC OLIVINE; CHONDRITES; PHYLLOSILICATES; RIMS	Matrix olivines in the Allende carbonaceous chondrite are believed to have formed by condensation processes in the primitive solar nebula. However, transmission electron microscope observations of numerous matrix olivines show that they contain abundant, previously unrecognized, nanometer-sized inclusions of pentlandite and poorly graphitized carbon. Neither of these phases would have been stable at the high-temperature conditions required to condense iron-rich olivine in the solar nebula. The presence of these inclusions is consistent with formation of the olivines by parent body processes that involved overgrowth of fine-grained organic materials and sulfides in the precursor matrix materials.	Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA	University of New Mexico	Brearley, AJ (corresponding author), Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA.			Brearley, Adrian/0000-0002-7364-8815				AKAI J, 1988, GEOCHIM COSMOCHIM AC, V52, P1593, DOI 10.1016/0016-7037(88)90228-1; AKAI J, 1994, ANTARCT METEORITES, V7, P94; ASH RD, 1999, LUNAR PLANET SCI, V30; ASHWORTH JR, 1975, EARTH PLANET SC LETT, V27, P43, DOI 10.1016/0012-821X(75)90158-2; Brearley A.J., 1996, CHONDRULES PROTOPLAN, P137; Brearley AJ, 1997, SCIENCE, V276, P1103, DOI 10.1126/science.276.5315.1103; BREARLEY AJ, 1990, GEOCHIM COSMOCHIM AC, V54, P831, DOI 10.1016/0016-7037(90)90377-W; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; BUSECK PR, 1988, ORG GEOCHEM, V12, P221, DOI 10.1016/0146-6380(88)90260-4; Cassen P., 1996, CHONDRULES PROTOPLAN, P21; CLAYTON RN, 1997, WORKSH PAR BOD NEB 1, P10; Cronin J.R., 1988, METEORITES EARLY SOL, P819; DURAND B, 1980, KEROGENS; Fischbach D. B., 1971, CHEM PHYS CARBON, V7, P1; FRANKLIN RE, 1951, ACTA CRYSTALLOGR, V4, P253, DOI 10.1107/S0365110X51000842; GREEN HW, 1971, SCIENCE, V172, P936, DOI 10.1126/science.172.3986.936; HYATSU R, 1980, SCIENCE, V208, P1515; Jarosewich E., 1987, SMITHSONIAN CONTRIB, V27, P1; KOJIMA T, 1995, METEORITICS, V30, P529; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; Krot AN, 1997, METEORIT PLANET SCI, V32, P31, DOI 10.1111/j.1945-5100.1997.tb01238.x; KULLERUD G, 1963, CARNEGIE I WASHINGTO, V62, P175; LARIMER JW, 1967, GEOCHIM COSMOCHIM AC, V31, P1239, DOI 10.1016/S0016-7037(67)80014-0; Lauretta DS, 1998, METEORIT PLANET SCI, V33, P821, DOI 10.1111/j.1945-5100.1998.tb01689.x; MACPHERSON GJ, 1985, GEOCHIM COSMOCHIM AC, V49, P2267, DOI 10.1016/0016-7037(85)90227-3; PALME H, 1990, EARTH PLANET SC LETT, V101, P180, DOI 10.1016/0012-821X(90)90152-N; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; SMITH PPK, 1981, SCIENCE, V212, P322, DOI 10.1126/science.11536554; SWART PK, 1982, J GEOPHYS RES, V87, pA283, DOI 10.1029/JB087iS01p0A283; TORIUMI M, 1989, EARTH PLANET SC LETT, V92, P265, DOI 10.1016/0012-821X(89)90051-4; Weisberg MK, 1998, METEORIT PLANET SCI, V33, P1087, DOI 10.1111/j.1945-5100.1998.tb01714.x; Young ED, 1998, SCIENCE, V282, P452, DOI 10.1126/science.282.5388.452	32	77	77	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1380	1382		10.1126/science.285.5432.1380	http://dx.doi.org/10.1126/science.285.5432.1380			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464092				2022-12-01	WOS:000082233500036
J	Minowa, O; Ikeda, K; Sugitani, Y; Oshima, T; Nakai, S; Katori, Y; Suzuki, M; Furukawa, M; Kawase, T; Zheng, Y; Ogura, M; Asada, Y; Watanabe, K; Yamanaka, H; Gotoh, S; Nishi-Takeshima, M; Sugimoto, T; Kikuchi, T; Takasaka, T; Noda, T				Minowa, O; Ikeda, K; Sugitani, Y; Oshima, T; Nakai, S; Katori, Y; Suzuki, M; Furukawa, M; Kawase, T; Zheng, Y; Ogura, M; Asada, Y; Watanabe, K; Yamanaka, H; Gotoh, S; Nishi-Takeshima, M; Sugimoto, T; Kikuchi, T; Takasaka, T; Noda, T			Altered cochlear fibrocytes in a mouse model of DFN3 nonsyndromic deafness	SCIENCE			English	Article							FACTOR BRN-2; DIFFERENTIATION; HYPOTHALAMUS; MUTATIONS; SURVIVAL	DFN3, an X chromosome-linked nonsyndromic mixed deafness, is caused by mutations in the BRN-4 gene, which encodes a POU transcription factor. Brn-4-deficient mice were created and found to exhibit profound deafness, No gross morphological changes were observed in the conductive ossicles or cochlea, although there was a dramatic reduction in endocochlear potential. Electron microscopy revealed severe ultrastructural alterations in cochlear spiral Ligament fibrocytes. The findings suggest that these fibrocytes, which are mesenchymal in origin and for which a role in potassium ion homeostasis has been postulated, may play a critical role in auditory function.	Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; Tohoku Univ, Sch Med, Dept Otorhinolaryngol, Aoba Ku, Sendai, Miyagi 9808574, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138655, Japan; Kansai Med Univ, Dept Anat, Moriguchi, Osaka 5708506, Japan	Japanese Foundation for Cancer Research; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University; University of Tokyo; Kansai Medical University	Noda, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Minowa, Osamu/AAM-1238-2020; Noda, Tetsuo/B-1667-2016	Watanabe, Kenichi/0000-0002-5269-146X				Avraham KB, 1998, NAT MED, V4, P1238, DOI 10.1038/3215; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; DAVIS H, 1965, COLD SPRING HARB SYM, V30, P181, DOI 10.1101/SQB.1965.030.01.020; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; HONRUBIA V, 1969, J ACOUST SOC AM, V46, P388, DOI 10.1121/1.1911701; Katori Y, 1996, CELL TISSUE RES, V284, P473, DOI 10.1007/s004410050608; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NANCE W E, 1971, Birth Defects Original Article Series, V7, P64; Phippard D, 1998, HEARING RES, V120, P77, DOI 10.1016/S0378-5955(98)00059-8; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHULTE BA, 1989, J HISTOCHEM CYTOCHEM, V37, P127, DOI 10.1177/37.2.2536055; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; SPICER SS, 1991, HEARING RES, V56, P53, DOI 10.1016/0378-5955(91)90153-Z; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	18	159	164	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1408	1411		10.1126/science.285.5432.1408	http://dx.doi.org/10.1126/science.285.5432.1408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464101				2022-12-01	WOS:000082233500045
J	Zhu, HT; Kavsak, P; Abdollah, S; Wrana, JL; Thomsen, GH				Zhu, HT; Kavsak, P; Abdollah, S; Wrana, JL; Thomsen, GH			A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation	NATURE			English	Article							TGF-BETA SUPERFAMILY; PROTEIN LIGASE; SIGNALING PATHWAYS; XENOPUS EMBRYO; C2 DOMAIN; DEGRADATION; RECEPTOR; ENCODES; SYSTEM; ACTS	The TGF-beta superfamily of proteins regulates many different biological processes, including cell growth, differentiation and embryonic pattern formation(1-3). TGF-beta-like factors signal across cell membranes through complexes of transmembrane receptors known as type I and type II serine/threonine-kinase receptors, which in turn activate the SMAD signalling pathway(4,5). On the inside of the cell membrane, a receptor-regulated class of SMADs are phosphorylated by the type-I-receptor kinase. In this way, receptors for different factors are able to pass on specific signals along the pathway: for example, receptors for bone morphogenetic protein (BMP) target SMADs 1, 5 and 8, whereas receptors for activin and TGF-beta target SMADs 2 and 3. Phosphorylation of receptor-regulated SMADs induces their association with Smad4, the 'common-partner' SMAD, and stimulates accumulation of this complex in the nucleus, where it regulates transcriptional responses. Here we describe Smurf1, a new member of the Hect family of E3 ubiquitin ligases. Smurf1 selectively interacts with receptor-regulated SMADs specific for the BMP pathway in order to trigger their ubiquitination and degradation, and hence their inactivation. In the amphibian Xenopus laevis, Smurf1 messenger RNA is localized to the animal pole of the egg; in Xenopus embryos, ectopic Smurf1 inhibits the transmission of BMP signals and thereby affects pattern formation. Smurf1 also enhances cellular responsiveness to the Smad2 (activin/TGF-beta) pathway. Thus, targeted ubipuitination of SMADs may serve to control both embryonic development and a wide variety of cellular responses to TGF-beta signals.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1X8, Canada	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Thomsen, GH (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		zhu, HAITAO/GVL-0589-2022; Wrana, Jeffrey/F-8857-2013; Kavsak, Pete/K-8089-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032429] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD032429, R01 HD032429-04, R01 HD032429-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Candia AF, 1997, DEVELOPMENT, V124, P4467; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson PA, 1997, DEVELOPMENT, V124, P3177	31	644	701	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					687	693		10.1038/23293	http://dx.doi.org/10.1038/23293			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458166				2022-12-01	WOS:000082032900059
J	Bell, AC; West, AG; Felsenfeld, G				Bell, AC; West, AG; Felsenfeld, G			The protein CTCF is required for the enhancer blocking activity of vertebrate insulators	CELL			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER PROTEIN; HAIRY-WING PROTEIN; BETA-GLOBIN LOCUS; C-MYC GENE; DROSOPHILA-MELANOGASTER; CHROMATIN INSULATOR; TRANSCRIPTIONAL ACTIVITY; CHROMOSOMAL DOMAINS; PROMOTER	An insulator is a DNA sequence that can act as a barrier to the influences of neighboring cis-acting elements, preventing gene activation, for example, when located between an enhancer and a promoter. We have identified a 42 bp fragment of the chicken beta-globin insulator that is both necessary and sufficient for enhancer blocking activity in human cells. We show that this sequence is the binding site for CTCF, a previously identified eleven-zinc finger DNA-binding protein that is highly conserved in vertebrates. CTCF sites are present in all of the vertebrate enhancer-blocking elements we have examined. We suggest that directional enhancer blocking by CTCF is a conserved component of gene regulation in vertebrates.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Felsenfeld, G (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			West, Adam/0000-0003-3502-7804				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DORSETT D, 1993, GENETICS, V134, P1135; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; Gdula DA, 1997, GENETICS, V145, P153; Georgiev P, 1996, GENETICS, V142, P425; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; LABHART P, 1987, NUCLEIC ACIDS RES, V15, P3623, DOI 10.1093/nar/15.8.3623; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Ohtsuki S, 1998, GENE DEV, V12, P3325, DOI 10.1101/gad.12.21.3325; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; Robinett CC, 1997, MOL CELL BIOL, V17, P2866, DOI 10.1128/MCB.17.5.2866; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X; Zhong XP, 1997, P NATL ACAD SCI USA, V94, P5219, DOI 10.1073/pnas.94.10.5219; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195	38	826	881	0	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					387	396		10.1016/S0092-8674(00)81967-4	http://dx.doi.org/10.1016/S0092-8674(00)81967-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458613	Bronze			2022-12-01	WOS:000081950300013
J	Koh, YH; Popova, E; Thomas, U; Griffith, LC; Budnik, V				Koh, YH; Popova, E; Thomas, U; Griffith, LC; Budnik, V			Regulation of DLG localization at synapses by CaMKII-dependent phosphorylation	CELL			English	Article							TUMOR-SUPPRESSOR GENE; LONG-TERM POTENTIATION; PROTEIN-KINASE-II; SYNAPTIC BOUTON STRUCTURE; FASCICLIN-II; FUNCTIONAL COMPONENTS; POSTSYNAPTIC DENSITY; ADHESION MOLECULE; K+ CHANNELS; IN-VIVO	Discs large (DLG) mediates the clustering of synaptic molecules. Here we demonstrate that synaptic localization of DLG itself is regulated by CaMKII. We show that DLG and CaMKII colocalize at synapses and exist in the same protein complex. Constitutively activated CaMKII phenocopied structural abnormalities of dig mutant synapses and dramatically increased extra-junctional DLG. Decreased CaMKII activity caused opposite alterations. In vitro, CaMKII phosphorylated a DLG fragment with a stoichiometry close to one. Moreover, expression of site-directed dig mutants that blocked or mimicked phosphorylation had effects similar to those observed upon inhibiting or constitutively activating CaMKII. We propose that CaMKII-dependent DLG phosphorylation regulates the association of DLG with the synaptic complex during development and plasticity, thus providing a link between synaptic activity and structure.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Brandeis Univ, Volen Ctr Complex Syst, Dept Biol, Waltham, MA 02454 USA	University of Massachusetts System; University of Massachusetts Amherst; Brandeis University	Budnik, V (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	vbudnik@bio.umass.edu		Griffith, Leslie/0000-0003-3164-9876	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001786, R01NS030072] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM54408, R01 GM054408] Funding Source: Medline; NINDS NIH HHS [R01 NS30072, KO4 NS01786, R01 NS030072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAND AH, 1993, DEVELOPMENT, V118, P401; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; BUDNIK V, 1990, J NEUROSCI, V10, P3754; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; Davis GW, 1998, CURR OPIN NEUROBIOL, V8, P149, DOI 10.1016/S0959-4388(98)80018-4; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; GORCZYCA M, 1993, J NEUROSCI, V13, P3692; Gramates LS, 1999, INT REV NEUROBIOL, V43, P93, DOI 10.1016/S0074-7742(08)60542-5; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; Guan B, 1996, CURR BIOL, V6, P695, DOI 10.1016/S0960-9822(09)00451-5; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jin R, 1998, J NEUROSCI, V18, P8955; KENNEDY M, 1997, TRENDS NEUROSCI, V20, P103; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; Wang Z, 1998, J NEUROCHEM, V71, P378; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	56	196	200	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					353	363		10.1016/S0092-8674(00)81964-9	http://dx.doi.org/10.1016/S0092-8674(00)81964-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458610	Green Accepted, Bronze			2022-12-01	WOS:000081950300010
J	Freedman, AL; Johnson, MP; Smith, CA; Gonzalez, R; Evans, MI				Freedman, AL; Johnson, MP; Smith, CA; Gonzalez, R; Evans, MI			Long-term outcome in children after antenatal intervention for obstructive uropathies	LANCET			English	Article							POSTERIOR URETHRAL VALVES; CONGENITAL HYDRONEPHROSIS INUTERO; FETAL RENAL-FUNCTION; PRUNE BELLY SYNDROME; PULMONARY HYPOPLASIA; GROWTH; BLADDER; OLIGOHYDRAMNIOS; BIOCHEMISTRY; THERAPY	Background Antenatal intervention has been done for fetal obstructive uropathy far over a decade, yet little is known about long-term outcomes. To assess the long-term implications of fetal intervention, we reviewed the outcomes of children who underwent vesicoamniotic shunt placement. Methods We reviewed the clinical outcomes of 14 children who underwent vesicoamniotic shunt placement at our institution and who survived beyond 2 years of age. Findings In 1987-96, 34 patients underwent vesicoamniotic shunt placement. 13 died and 21 survived, of whom 17 are now more than 2 years old. Three survivors were lost to follow-up. Mean age at follow-up was 54.3 months (range 25-114). Final diagnoses included prune belly syndrome (seven cases), posterior urethral valves (four), urethral atresia (one), vesicoureteral reflux (one), and megacystis (one). Height was below the 25th percentile in 12 (86%) with seven (50%) below the 5th percentile. Five (36%) had renal failure and had successful transplantation, three (21%) have renal insufficiency, and six (43%) have normal renal function. Seven (50%) are acceptably continent, five (36%) have not yet begun toilet-training, and two (14%) are incontinent. Three of four children with valves needed bladder augmentation. Interpretation Antenatal intervention may help those fetuses with the most severe forms of obstructive uropathy, usually associated with a fatal neonatal course. intervention achieves outcomes similar to less severe cases that are usually diagnosed postnatally.	Childrens Hosp Michigan, Dept Paediat Urol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynaecol, Detroit, MI USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Mol Med & Geriatr, Detroit, MI USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Pathol, Detroit, MI USA	Children's Hospital of Michigan; Wayne State University; Wayne State University; Wayne State University	Freedman, AL (corresponding author), 100 UCLA Med Plaza,Suite 690, Los Angeles, CA 90095 USA.							BAUER SB, 1979, J UROLOGY, V121, P769, DOI 10.1016/S0022-5347(17)56985-2; CAMPAIOLA JM, 1985, J UROLOGY, V134, P708, DOI 10.1016/S0022-5347(17)47400-3; CONNOR JP, 1990, J UROLOGY, V144, P1209, DOI 10.1016/S0022-5347(17)39695-7; CROMBLEHOLME TM, 1990, AM J OBSTET GYNECOL, V162, P1239, DOI 10.1016/0002-9378(90)90026-4; ELDER JS, 1990, J UROLOGY, V144, P574, DOI 10.1016/S0022-5347(17)39526-5; ELDER JS, 1987, LANCET, V2, P1007; FREEDMAN AL, 1997, J UROLOGY, V157, pA10; GEARY DF, 1986, J UROLOGY, V135, P324, DOI 10.1016/S0022-5347(17)45627-8; GLICK PL, 1985, J PEDIATR SURG, V20, P376, DOI 10.1016/S0022-3468(85)80223-2; GLICK PL, 1984, J PEDIATR SURG, V19, P649, DOI 10.1016/S0022-3468(84)80348-6; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1983, J PEDIATR SURG, V18, P247, DOI 10.1016/S0022-3468(83)80094-3; JOHNSON MP, 1994, AM J OBSTET GYNECOL, V170, P1770; JOHNSON MP, 1995, AM J OBSTET GYNECOL, V173, P59, DOI 10.1016/0002-9378(95)90170-1; KRUEGER RP, 1980, UROL CLIN N AM, V7, P265; LIPITZ S, 1993, AM J OBSTET GYNECOL, V168, P174, DOI 10.1016/S0002-9378(12)90909-6; MANDELBROT L, 1991, J PERINAT MED, V19, P283; MANNING FA, 1986, NEW ENGL J MED, V315, P336, DOI 10.1056/NEJM198607313150532; MERGUERIAN PA, 1992, J UROLOGY, V148, P1499, DOI 10.1016/S0022-5347(17)36949-5; Mitchell M., 1982, DIAL PEDIAT UROL, V5, P8; MULLER F, 1993, OBSTET GYNECOL, V82, P813; NICOLAIDES KH, 1992, AM J OBSTET GYNECOL, V166, P932, DOI 10.1016/0002-9378(92)91367-J; PETERS CA, 1991, J UROLOGY, V146, P597, DOI 10.1016/S0022-5347(17)37865-5; PETERS CA, 1990, J UROLOGY, V144, P122, DOI 10.1016/S0022-5347(17)39388-6; PETERS CA, 1991, J UROLOGY, V146, P1178, DOI 10.1016/S0022-5347(17)38035-7; REINBERG Y, 1992, J UROLOGY, V148, P125, DOI 10.1016/S0022-5347(17)36532-1; REINBERG Y, 1992, J UROLOGY, V148, P532, DOI 10.1016/S0022-5347(17)36645-4; REINBERG Y, 1991, J UROLOGY, V145, P1017, DOI 10.1016/S0022-5347(17)38518-X; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; WARSHAW BL, 1985, J UROLOGY, V133, P240, DOI 10.1016/S0022-5347(17)48899-9	31	128	131	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					374	377		10.1016/S0140-6736(98)11006-1	http://dx.doi.org/10.1016/S0140-6736(98)11006-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437866				2022-12-01	WOS:000081764900012
J	Mackenzie, A; Hallam, N; Mitchell, E; Beattie, T				Mackenzie, A; Hallam, N; Mitchell, E; Beattie, T			Near patient testing for respiratory syncytial virus in paediatric accident and emergency: prospective pilot study	BRITISH MEDICAL JOURNAL			English	Article							INFECTIONS; DIAGNOSIS		City Hosp Edinburgh, Reg Clin Virol Lab, Edinburgh EH10 5SB, Midlothian, Scotland; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland		Hallam, N (corresponding author), City Hosp Edinburgh, Reg Clin Virol Lab, Edinburgh EH10 5SB, Midlothian, Scotland.							*JOINT WORK GROUP, 1999, GUID NEAR PAT POINT; Langley JM, 1997, PEDIATRICS, V100, P943, DOI 10.1542/peds.100.6.943; TODD SJ, 1995, J CLIN MICROBIOL, V33, P1650, DOI 10.1128/JCM.33.6.1650-1651.1995; Wendt C H, 1995, Semin Respir Infect, V10, P224; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					289	290		10.1136/bmj.319.7205.289	http://dx.doi.org/10.1136/bmj.319.7205.289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426738	Bronze, Green Published			2022-12-01	WOS:000081909100022
J	Wijnhoven, BPL; Pignatelli, M				Wijnhoven, BPL; Pignatelli, M			E-cadherin-catenin: more than a "sticky" molecular complex	LANCET			English	Editorial Material							ALPHA-CATENIN; BETA-CATENIN; EXPRESSION; CANCER		Univ Bristol, Bristol Royal Infirm, Dept Pathol & Microbiol, Div Histopathol, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol	Wijnhoven, BPL (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Pathol & Microbiol, Div Histopathol, Bristol BS2 8HW, Avon, England.		Wijnhoven, Bas/AAF-4838-2020; Pignatelli, Massimo/ABA-2672-2020	Pignatelli, Massimo/0000-0001-9257-3567				Bailey T, 1998, AM J PATHOL, V152, P135; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; GUMBINER BM, 1993, J CELL SCI, P155; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; Krishnadath KK, 1997, J PATHOL, V182, P331; Liu D, 1997, LAB INVEST, V77, P557; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Richmond PJM, 1997, CANCER RES, V57, P3189; Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Valizadeh A, 1997, AM J PATHOL, V150, P1977	15	37	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					356	357		10.1016/S0140-6736(99)90055-7	http://dx.doi.org/10.1016/S0140-6736(99)90055-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437861				2022-12-01	WOS:000081764900006
J	Brustle, O; Jones, KN; Learish, RD; Karram, K; Choudhary, K; Wiestler, OD; Duncan, ID; McKay, RDG				Brustle, O; Jones, KN; Learish, RD; Karram, K; Choudhary, K; Wiestler, OD; Duncan, ID; McKay, RDG			Embryonic stem cell-derived glial precursors: A source of myelinating transplants	SCIENCE			English	Article							IN-VITRO DIFFERENTIATION; CENTRAL-NERVOUS-SYSTEM; NEURAL PRECURSORS; TARGETED MUTATION; PROGENITOR CELLS; NEURONS; BRAIN; ESTABLISHMENT; ASTROCYTE; LETHALITY	Self-renewing, totipotent embryonic stem (ES) cells may provide a virtually unlimited donor source for transplantation. A protocol that permits the in vitro generation of precursors for oligodendrocytes and astrocytes from ES cells was devised. Transplantation in a rat model of a human myelin disease shows that these ES cell-derived precursors interact with host neurons and efficiently myelinate axons in brain and spinal cord. Thus, ES cells can serve as a valuable source of cell type-specific somatic precursors for neural transplantation.	Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA	University of Bonn; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Wisconsin System; University of Wisconsin Madison	Brustle, O (corresponding author), Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.				NINDS NIH HHS [NS33710] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033710] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BLAKEMORE WF, 1995, BRAIN PATHOL, V5, P443, DOI 10.1111/j.1750-3639.1995.tb00623.x; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; BRUSTLE O, UNPUB; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Finley MFA, 1996, J NEUROSCI, V16, P1056; FISHELL G, 1995, DEVELOPMENT, V121, P803; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Hammang JP, 1997, EXP NEUROL, V147, P84, DOI 10.1006/exnr.1997.6592; HODES ME, 1993, DEV NEUROSCI-BASEL, V15, P383, DOI 10.1159/000111361; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LACHAPELLE F, 1995, BRAIN PATHOL, V5, P289, DOI 10.1111/j.1750-3639.1995.tb00606.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	32	734	849	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					754	756		10.1126/science.285.5428.754	http://dx.doi.org/10.1126/science.285.5428.754			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427001				2022-12-01	WOS:000081765100060
J	Norris, JD; Paige, LA; Christensen, DJ; Chang, CY; Huacani, MR; Fan, DJ; Hamilton, PT; Fowlkes, DM; McDonnell, DP				Norris, JD; Paige, LA; Christensen, DJ; Chang, CY; Huacani, MR; Fan, DJ; Hamilton, PT; Fowlkes, DM; McDonnell, DP			Peptide antagonists of the human estrogen receptor	SCIENCE			English	Article							HUMAN PROGESTERONE; ANTIESTROGENS; TAMOXIFEN; IDENTIFICATION; ACTIVATION; YEAST	Estrogen receptor a transcriptional activity is regulated by distinct conformational states that are the result of ligand binding. Phage display was used to identify peptides that interact specifically with either estradiol- or tamoxifen-activated estrogen receptor alpha. When these peptides were coexpressed with estrogen receptor alpha in cells, they functioned as ligand-specific antagonists, indicating that estradiol-agonist and tamoxifen-partial agonist activities do not occur by the same mechanism. The ability to regulate estrogen receptor a transcriptional activity by targeting sites outside of the ligand-binding pocket has implications for the development of estrogen receptor a antagonists for the treatment of tamoxifen-refractory breast cancers.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Novalon Pharmaceut Corp, Durham, NC 27703 USA	Duke University	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Norris, John/0000-0001-6553-8053; Hamilton, Paul/0000-0003-4028-424X	NIDDK NIH HHS [DK48807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048807, R37DK048807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang C. H., UNPUB; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; NORRIS JR, UNPUB; Osborne CK, 1996, SCI MED, V3, P32; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	15	307	342	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					744	746		10.1126/science.285.5428.744	http://dx.doi.org/10.1126/science.285.5428.744			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426998				2022-12-01	WOS:000081765100057
J	Verkhovsky, MI; Jasaitis, A; Verkhovskaya, ML; Morgan, JE; Wikstrom, M				Verkhovsky, MI; Jasaitis, A; Verkhovskaya, ML; Morgan, JE; Wikstrom, M			Proton translocation by cytochrome c oxidase	NATURE			English	Article							PARACOCCUS-DENITRIFICANS; OXYGEN; PUMP	Cell respiration in mitochondria and some bacteria is catalysed by cytochrome c oxidase, which reduces O-2 to water, coupled with translocation of four protons across the mitochondrial or bacterial membrane. The enzyme's catalytic cycle consists of a reductive phase, in which the oxidized enzyme receives electrons from cytochrome c, and an oxidative phase, in which the reduced enzyme is oxidized by O-2. Previous studies indicated that proton translocation is coupled energetically only to the oxidative phase, but this has been challenged. Here, with the purified enzyme inlaid in liposomes, we report time-resolved measurements of membrane potential, which show that hall: of the electrical charges due to proton-pumping actually cross the membrane during reduction after a preceding oxidative phase. pH measurements confirm that proton translocation also occurs during reduction, but only when immediately preceded by an oxidative phase. We conclude that all the energy for proton translocation is conserved in the enzyme during its oxidation by O-2. One half of it is utilized for proton-pumping during oxidation, but the other half is unlatched for this purpose only during re-reduction of the enzyme.	Univ Helsinki, Inst Biomed Sci, Dept Med Chem, Helsinki Bioenerget Grp, FIN-00014 Helsinki, Finland; Univ Helsinki, Bioctr Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Wikstrom, M (corresponding author), Univ Helsinki, Inst Biomed Sci, Dept Med Chem, Helsinki Bioenerget Grp, POB 8, FIN-00014 Helsinki, Finland.		Wikstrom, Marten KF/A-4403-2008	Verkhovskaya, Marina/0000-0001-8950-5256				ARMSTRONG F, 1983, BIOCHIM BIOPHYS ACTA, V722, P61, DOI 10.1016/0005-2728(83)90157-3; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; DRACHEV LA, 1974, NATURE, V249, P321, DOI 10.1038/249321a0; Gennis RB, 1998, P NATL ACAD SCI USA, V95, P12747, DOI 10.1073/pnas.95.22.12747; Hinkle P, 1970, J Bioenerg, V1, P45, DOI 10.1007/BF01516088; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1101, P188, DOI 10.1016/0005-2728(92)90221-M; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P436, DOI 10.1021/bi00216a019; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; SLATER EC, 1953, NATURE, V172, P975, DOI 10.1038/172975a0; SOLIOZ M, 1982, J BIOL CHEM, V257, P1579; VERKHOVSKY MI, IN PRESS BIOCH BIOPH; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6	17	192	196	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					480	483		10.1038/22813	http://dx.doi.org/10.1038/22813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440381				2022-12-01	WOS:000081715000058
J	Cormack, BP; Ghori, N; Falkow, S				Cormack, BP; Ghori, N; Falkow, S			An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ANTIFUNGAL SUSCEPTIBILITY; ALBICANS GENE; RECEPTORS; EXPRESSION; VIRULENCE; INFECTION; PROTEINS; CLONING; VECTORS	Candida glabrata is an important fungal pathogen of humans that is responsible for about 15 percent of mucosal and systemic candidiasis. Candida glabrata adhered avidly to human epithelial cells in culture. By means of a genetic approach and a strategy allowing parallel screening of mutants, it was possible to clone a lectin from a Candida species. Deletion of this adhesin reduced adherence of C. glabrata to human epithelial cells by 95 percent. The adhesin, encoded by the EPA1 gene, is likely a glucan-cross-linked cell-wall protein and binds to host-cell carbohydrate, specifically recognizing asialo-lactosyl-containing carbohydrates.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Prot Design Labs, Fremont, CA 94555 USA	Stanford University	Cormack, BP (corresponding author), Johns Hopkins Med Inst, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	bcormack@jhmi.edu						Calderone R A, 1993, Arch Med Res, V24, P275; Cameron BJ, 1996, INFECT IMMUN, V64, P891, DOI 10.1128/IAI.64.3.891-896.1996; CLEMONS KV, 1994, J INFECT DIS, V169, P859, DOI 10.1093/infdis/169.4.859; Cormack BP, 1999, GENETICS, V151, P979; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P637; Fidel PL, 1996, J INFECT DIS, V173, P425, DOI 10.1093/infdis/173.2.425; FONZI WA, 1993, GENETICS, V134, P717; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gaur NK, 1997, INFECT IMMUN, V65, P5289, DOI 10.1128/IAI.65.12.5289-5294.1997; *GENB, AF149048 GENB; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; JIMENEZLUCHO V, 1990, INFECT IMMUN, V58, P2085, DOI 10.1128/IAI.58.7.2085-2090.1990; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nguyen MH, 1996, AM J MED, V100, P617, DOI 10.1016/S0002-9343(95)00010-0; PASCOPELLA L, 1995, INFECT IMMUN, V63, P4329, DOI 10.1128/IAI.63.11.4329-4335.1995; PENDRAK ML, 1995, FEMS MICROBIOL LETT, V129, P103, DOI 10.1111/j.1574-6968.1995.tb07566.x; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V33, P217, DOI 10.1016/S0732-8893(98)00160-6; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P121, DOI 10.1016/S0732-8893(97)00192-2; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P289, DOI 10.1016/S0732-8893(97)00245-9; SCHABERG DR, 1991, AM J MED S3B, V91, P725; Schuman P, 1998, CLIN INFECT DIS, V27, P1161, DOI 10.1086/514979; Sherman F., 1986, METHODS YEAST GENETI; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STGEME JW, 1994, INFECT IMMUN, V62, P3881, DOI 10.1128/IAI.62.9.3881-3889.1994; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; TEUNISSEN AWRH, 1993, YEAST, V9, P423, DOI 10.1002/yea.320090413; TOSH FD, 1992, INFECT IMMUN, V60, P4734, DOI 10.1128/IAI.60.11.4734-4739.1992; WATARI J, 1994, YEAST, V10, P211, DOI 10.1002/yea.320100208; WHELAN WL, 1987, CRC CR REV MICROBIOL, V14, P99, DOI 10.3109/10408418709104437; YU L, 1994, INFECT IMMUN, V62, P2843, DOI 10.1128/IAI.62.7.2843-2848.1994; YU L, 1994, INFECT IMMUN, V62, P5213, DOI 10.1128/IAI.62.12.5213-5219.1994	35	287	296	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					578	582		10.1126/science.285.5427.578	http://dx.doi.org/10.1126/science.285.5427.578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417386				2022-12-01	WOS:000081609500036
J	Sternlicht, MD; Lochter, A; Sympson, CJ; Huey, B; Rougler, JP; Gray, JW; Pinkel, D; Bissell, MJ; Werb, Z				Sternlicht, MD; Lochter, A; Sympson, CJ; Huey, B; Rougler, JP; Gray, JW; Pinkel, D; Bissell, MJ; Werb, Z			The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis	CELL			English	Article							TRANSGENIC MICE; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; GENE-EXPRESSION; BREAST-CANCER; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; JUVENILE POLYPOSIS; TUMOR PROGRESSION; STROMELYSIN-1	Matrix metalloproteinases (MMPs) are invariably upregulated in the stromal compartment of epithelial cancers and appear to promote invasion and metastasis. Here we report that phenotypically normal mammary epithelial cells with tetracycline-regulated expression of MMP3/stromelysin-1 (Str1) form epithelial glandular structures in vivo without Str1 but form invasive mesenchymal-like tumors with Str1. Once initiated, the tumors become independent of continued Str1 expression. Str1 also promotes spontaneous premalignant changes and malignant conversion in mammary glands of transgenic mice. These changes are blocked by coexpression of a TIMP1 transgene. The premalignant and malignant lesions have stereotyped genomic changes unlike those seen in other murine mammary cancer models. These data indicate that Str1 influences tumor initiation and alters neoplastic risk.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, Canc Genet Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Sternlicht, MD (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.				NCI NIH HHS [CA57621, R01 CA064786-04A1, R01 CA057621, R01 CA064786, CA72006, P01 CA072006, P01 CA072006-020003, R01 CA057621-07, R37 CA064786, CA64786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064786, R01CA057621, P01CA072006, R37CA064786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLPH S, 1987, CYTOGENET CELL GENET, V44, P65, DOI 10.1159/000132345; Ahmad A, 1998, AM J PATHOL, V152, P721; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Bachman KE, 1999, CANCER RES, V59, P798; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Birchmeier C, 1996, ACTA ANAT, V156, P217; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Chin JR, 1997, DEVELOPMENT, V124, P1519; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DEOME KB, 1959, CANCER RES, V19, P515; DOMAGALA W, 1990, AM J PATHOL, V136, P219; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FISHER ER, 1975, CANCER, V36, P1, DOI 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GACK S, 1994, J BIOL CHEM, V269, P10363; GILLES C, 1996, BREAST J, V2, P83; Hay ED, 1995, ACTA ANAT, V154, P8; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hsieh CJ, 1998, CANCER RES, V58, P3942; Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; Kim KS, 1998, EXP CELL RES, V245, P79, DOI 10.1006/excr.1998.4238; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lund LR, 1996, DEVELOPMENT, V122, P181; Martorana AM, 1998, CANCER RES, V58, P4970; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; Mehindate K, 1996, LAB INVEST, V75, P529; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Noe V, 1999, J CELL SCI, V112, P127; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Ritland SR, 1997, CANCER RES, V57, P3520; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; Rutter JL, 1998, CANCER RES, V58, P5321; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Squartini F, 1994, IARC Sci Publ, P47; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sun DZ, 1998, INT J DEV BIOL, V42, P733; SUNDARRAJ N, 1992, CELL TISSUE RES, V267, P347, DOI 10.1007/BF00302973; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; SYMPSON CJ, 1996, J CELL BIOL, V132; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; TISTY TD, 1998, CURR OPIN CELL BIOL, V10, P647; WARGOTZ ES, 1989, HUM PATHOL, V20, P628, DOI 10.1016/0046-8177(89)90149-4; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055	62	711	728	3	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					137	146		10.1016/S0092-8674(00)81009-0	http://dx.doi.org/10.1016/S0092-8674(00)81009-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428026	Bronze, Green Accepted			2022-12-01	WOS:000081632300004
J	Hochman, JS; Tamis, JE; Thompson, TD; Weaver, WD; White, HD; Van de Werf, F; Aylward, P; Topol, EJ; Califf, RM				Hochman, JS; Tamis, JE; Thompson, TD; Weaver, WD; White, HD; Van de Werf, F; Aylward, P; Topol, EJ; Califf, RM		Global Use Strategies Open Occluded Coronary Ar	Sex, clinical presentation, and outcome in patients with acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; INTERVENTION REGISTRY; GENDER DIFFERENCES; HEART-DISEASE; RISK-FACTORS; SHORT-TERM; WOMEN; MEN; MORTALITY	Background Studies have reported that women with acute myocardial infarction have in-hospital and long-term outcomes that are worse than those of men. Methods To assess sex-based differences in presentation and outcome, we examined data from the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb study, which enrolled 12,142 patients (3662 women and 8480 men) with acute coronary syndromes, including infarction with ST-segment elevation, infarction with no ST-segment elevation, and unstable angina. Results Overall, the women were older than the men and had significantly higher rates of diabetes, hypertension, and prior congestive heart failure. They had significantly lower rates of prior myocardial infarction and were less likely ever to have smoked. A smaller percentage of women than men had infarction with ST elevation (27.2 percent vs. 37.0 percent, P<0.001), and of the patients who presented with no ST elevation (those with myocardial infarction or unstable angina), fewer women than men had myocardial infarction (36.6 percent vs. 47.6 percent, P<0.001). Women had more complications than men during hospitalization and a higher mortality rate at 30 days (6.0 percent vs. 4.0 percent, P<0.001) but had similar rates of reinfarction at 30 days after presentation. However, there was a significant interaction between sex and the type of coronary syndrome at presentation (P=0.001). After stratification according to coronary syndrome and adjustment for base-line variables, there was a nonsignificant trend toward an increased risk of death or reinfarction among women as compared with men only in the group with infarction and ST elevation (odds ratio, 1.27; 95 percent confidence interval, 0.98 to 1.63; P=0.07). Among patients with unstable angina, female sex was associated with an independent protective effect (odds ratio for infarction or death, 0.65; 95 percent confidence interval, 0.49 to 0.87; P=0.003). Conclusions Women and men with acute coronary syndromes had different clinical profiles, presentation, and outcomes. These differences could not be entirely accounted for by differences in base-line characteristics and may reflect pathophysiologic and anatomical differences between men and women. (N Engl J Med 1999;341:226-32.) (C) 1999, Massachusetts Medical Society.	St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA; Columbia Univ, New York, NY USA; Duke Clin Res Inst, Durham, NC USA; Henry Ford Heart & Vasc Inst, Detroit, MI USA; Green Lane Hosp, Auckland 3, New Zealand; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Flinders Med Ctr, Adelaide, SA, Australia; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Duke University; Henry Ford Health System; KU Leuven; University Hospital Leuven; Flinders Medical Centre; Cleveland Clinic Foundation	Hochman, JS (corresponding author), St Lukes Roosevelt Hosp Ctr, 1111 Amsterdam Ave, New York, NY 10025 USA.			Aylward, Philip/0000-0002-5358-8552; Hochman, Judith/0000-0002-5889-5981				BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BEHAR S, 1994, AM J CARDIOL, V73, P438, DOI 10.1016/0002-9149(94)90672-6; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; Cucuianu M., 1993, Revue Roumaine de Medecine Interne, V31, P183; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HARRELL FE, 1996, TRANSCAN S FUNCTION; HE J, 1994, AM J EPIDEMIOL, V139, P693, DOI 10.1093/oxfordjournals.aje.a117059; Hochman JS, 1997, J AM COLL CARDIOL, V30, P141, DOI 10.1016/S0735-1097(97)00107-1; HOCHMAN JS, IN PRESS AM HEART J; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; STEGNAR M, 1993, THROMB RES, V69, P81, DOI 10.1016/0049-3848(93)90005-9; STEGNAR M, 1993, THROMB RES, V72, P173, DOI 10.1016/0049-3848(93)90219-E; STONE GW, 1995, AM J CARDIOL, V75, P987, DOI 10.1016/S0002-9149(99)80709-7; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Tracy R P, 1992, Ann Epidemiol, V2, P509; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; VACEK JL, 1993, AM HEART J, V126, P521, DOI 10.1016/0002-8703(93)90399-T; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097	40	608	639	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					226	232		10.1056/NEJM199907223410402	http://dx.doi.org/10.1056/NEJM199907223410402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413734				2022-12-01	WOS:000081528800002
J	Moroney, JT; Tang, MX; Berglund, L; Small, S; Merchant, C; Bell, K; Stern, Y; Mayeux, R				Moroney, JT; Tang, MX; Berglund, L; Small, S; Merchant, C; Bell, K; Stern, Y; Mayeux, R			Low-density lipoprotein cholesterol and the risk of dementia with stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTHERN MANHATTAN STROKE; CARDIOVASCULAR-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; VASCULAR DEMENTIA; ISCHEMIC STROKE; E POLYMORPHISM; HEART-DISEASE; POPULATION; INFARCTION	Context Next to Alzheimer disease; vascular dementia is the second most common form of dementia in the elderly, yet few specific risk factors have been identified. Objective To investigate the relationship of plasma lipids and lipoproteins to dementia with stroke. Design and Setting Prospective longitudinal community-based study over a 7-year period (1991-1998). Participants A total of 1111 nondemented participants (mean [SD] age, 75.0 [5.9] years) were followed up for an average of 2.1 years (range, 1-7.8 years). Main Outcome Measure Incident dementia with stroke according to standardized criteria, by baseline levels of total plasma cholesterol and triglycerides, low-density lipoprotein (LDL)cholesterol, LDL levels corrected for lipoprotein(a), high-density lipoprotein cholesterol, lipoprotein(a), and apolipoprotein E genotype. Results Two hundred eighty-six (25.7%) of the 1111 subjects developed dementia during follow-up; 61 (21.3%) were classified as having dementia with stroke and 225 (78.7%) as having probable Alzheimer disease. Levels of LDC cholesterol were significantly associated with an increased risk of dementia with stroke. Compared with the lowest quartile, the highest quartile of LDL cholesterol was associated with an approximately 3-fold increase in risk of dementia with stroke, adjusting for vascular risk factors and demographic variables (relative risk [RR], 3.1; 95% confidence interval [CI], 1.5-6.1). Levels of LDL corrected for lipoprotein(a) were an even stronger predictor of dementia with stroke in the adjusted multivariate analysis. Compared with the lowest quartile, the RR of dementia with stroke for the highest quartile of lipoprotein(a)-corrected LDL cholesterol was 4.1 (95% CI, 1.8-9.6) after adjusting for vascular factors and demographic variables. Lipid or lipoprotein levels were not associated with the development of Alzheimer disease in-our cohort. Conclusions Elevated levels of LDL cholesterol were associated with the risk of dementia with stroke in elderly patients. Further study is needed to determine whether treatment of elevated LDL cholesterol levels will reduce the risk of dementia with stroke.	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Mayeux, R (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Mayeux, Richard/E-9788-2013	Mayeux, Richard/0000-0001-6519-9696; Berglund, Lars/0000-0001-6705-1791; Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07232, AG 10963] Funding Source: Medline; NINDS NIH HHS [K08 NS 02051] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fujiwara Y, 1997, J Atheroscler Thromb, V4, P90; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; HIXSON J, 1991, J LIPID RES, V31, P545; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; Kalmijn S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/oxfordjournals.aje.a009029; Kalmijn S, 1996, STROKE, V27, P2230, DOI 10.1161/01.STR.27.12.2230; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; NAUCK M, 1995, CLIN CHEM, V41, P1761; Pablos-Mendez A, 1997, ARTERIOSCL THROM VAS, V17, P3534, DOI 10.1161/01.ATV.17.12.3534; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; SACCO RL, 1994, NEUROLOGY, V44, P626, DOI 10.1212/WNL.44.4.626; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.1997.03540340047031; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/WNL.42.6.1185; TATEMICHI TK, 1995, J NEUROL NEUROSUR PS, V58, P633, DOI 10.1136/jnnp.58.5.633; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; Tuck CH, 1997, ARTERIOSCL THROM VAS, V17, P1822, DOI 10.1161/01.ATV.17.9.1822; *US BUR CENS, 1991, CENS POP HOUS SUMM T; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416	40	152	161	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					254	260		10.1001/jama.282.3.254	http://dx.doi.org/10.1001/jama.282.3.254			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422994	Bronze, Green Published			2022-12-01	WOS:000081504400031
J	Shao, ZH; Raible, F; Mollaaghababa, R; Guyon, JR; Wu, CT; Bender, W; Kingston, RE				Shao, ZH; Raible, F; Mollaaghababa, R; Guyon, JR; Wu, CT; Bender, W; Kingston, RE			Stabilization of chromatin structure by PRC1, a polycomb complex	CELL			English	Article							POLYMERASE-II TRANSCRIPTION; DROSOPHILA BITHORAX COMPLEX; CHROMOSOME-BINDING-SITES; HOMEOTIC GENE-EXPRESSION; GROUP PROTEINS; CAENORHABDITIS-ELEGANS; MEDIATED REPRESSION; GROUP PRODUCTS; MELANOGASTER; DOMAIN	The Polycomb group (PcG) genes are required for maintenance of homeotic gene repression during development. Mutations in these genes can be suppressed by mutations in genes of the SWI/SNF family. We have purified a complex, termed PRC1 (Polycomb repressive complex 1), that contains the products of the PcG genes Polycomb, Posterior sex combs, polyhomeotic, Sex combs on midleg, and several other proteins. Preincubation of PRC1 with nucleosomal arrays blocked the ability of these arrays to be remodeled by SWI/SNF. Addition of PRC1 to arrays at the same time as SWI/SNF did not block remodeling. Thus, PRC1 and SWI/SNF might compete with each other for the nucleosomal template. Several different types of repressive complexes, including deacetylases, interact with histone tails. In contrast, PRC1 was active on nucleosomal arrays formed with tailless histones.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Raible, Florian/G-6019-2011	Raible, Florian/0000-0002-4515-6485				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHIANG A, 1995, DEVELOPMENT, V121, P1681; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GINDHART JG, 1995, GENETICS, V139, P797; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hodgson JW, 1997, MECH DEVELOP, V66, P69, DOI 10.1016/S0925-4773(97)00091-9; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KOGIE C, 1999, BIOCHEMISTRY-US, V38, P2514; Korf I, 1998, DEVELOPMENT, V125, P2469; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; LONIE A, 1994, DEVELOPMENT, V120, P2629; MARTIN EC, 1993, DEVELOPMENT, V117, P641; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHLOSSHERR J, 1994, MOL GEN GENET, V243, P453; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tie F, 1998, DEVELOPMENT, V125, P3483; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU CT, 1995, GENETICS, V140, P139; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	53	647	665	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					37	46		10.1016/S0092-8674(00)80604-2	http://dx.doi.org/10.1016/S0092-8674(00)80604-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412979	Bronze			2022-12-01	WOS:000081451000006
J	Gong, JG; Costanzo, A; Yang, HQ; Melino, G; Kaelin, WG; Levrero, M; Wang, JYJ				Gong, JG; Costanzo, A; Yang, HQ; Melino, G; Kaelin, WG; Levrero, M; Wang, JYJ			The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage	NATURE			English	Article							MISMATCH REPAIR DEFICIENCY; FLOW-CYTOMETRY; CELLS; PROTEIN; P53; RADIATION; STRESS; MICE	Cancer chemotherapeutic agents such as cisplatin exert their cytotoxic effect by inducing DNA damage and activating programmed cell death (apoptosis), The tumour-suppressor protein p53 is an important activator of apoptosis. Although p53-deficient cancer cells are less responsive to chemotherapy, their resistance is not complete, which suggests that other apoptotic pathways may exist. A p53-related gene, p73, which encodes several proteins as a result of alternative splicing(1,2), can also induce apoptosis(3). Here we show that the amount of p73 protein in the cell is increased by cisplatin. This induction of p73 is not seen in cells unable to carry out mismatch repair and in which the nuclear enzyme c-Abl tyrosine kinase is not activated by cisplatin, The half-life of p73 is prolonged by cisplatin and by co-expression with c-Abl tyrosine kinase; the apoptosis-inducing function of p73 is also enhanced by the c-Abl kinase, Mouse embryo fibroblasts deficient in mismatch repair or in c-Abl do not upregulate p73 and are more resistant to killing by cisplatin. Our results indicate that c-Abl and p73 are components ofa mismatch-repair-dependent apoptosis pathway which contributes to cisplatin-induced cytotoxicity.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, IRCCS, Ist Dermopatico Immacolata,Biochem Lab, I-00133 Rome, Italy; Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sapienza University Rome; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875; MELINO, GERRY/0000-0001-9428-5972	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, R37 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BOYER JC, 1995, CANCER RES, V55, P6063; Buermeyer AB, 1999, CANCER RES, V59, P538; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FINK D, 1995, CANCER RES, V57, P1841; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Nehme A, 1997, CANCER RES, V57, P3253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	22	800	823	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					806	809						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391249				2022-12-01	WOS:000081101600059
J	Kannus, P; Niemi, S; Parkkari, J; Palvanen, M; Vuori, I; Jarvinen, M				Kannus, P; Niemi, S; Parkkari, J; Palvanen, M; Vuori, I; Jarvinen, M			Hip fractures in Finland between 1970 and 1997 and predictions for the future	LANCET			English	Article							POSTMENOPAUSAL WOMEN; PROXIMAL FEMUR; EPIDEMIOLOGY; TRENDS; AGE; ENGLAND; RATES	Background Hip fractures in elderly people are common worldwide, and the predicted ageing of populations is increasing the burden of these fractures on health-care systems. However, prediction of the true increases in number of patients needing treatment requires exact knowledge of whether the number of hip fractures is rising more rapidly than can be accounted for by demographic changes alone. We aimed to make such a prediction for people aged 50 years or more in Finland. Methods All patients aged 50 years or more, who were admitted to hospitals in Finland during 1970-97 for primary treatment of first hip fracture were selected from the National Hospital Discharge Register. The age-specific and age-adjusted fracture incidences were expressed as the number of patients per 100 000 individuals per year, and predicton of the number, and incidence of hip fractures in Finland (population 5 million) until the year 2030 was calculated with a regression model. Findings The number of hip fractures in Finnish people aged 50 or more rose during the study period, from 1857 in 1970 to 7122 in 1997. The corresponding fracture incidence (per 100 000 people) increased from 163 to 438. The age-adjusted incidence of hip fractures also showed a steady increase from 1970 to 1997. in women, from 292 to 467, and in men, from 112 to 233. If this trend continues, the number of hip fractures in Finland will be almost three-fold higher in the year 2030 than in 1997. Interpretation The number of hip fractures in elderly Finnish men and women is increasing at a rate that cannot be explained merely by demographic changes. The precise reasons for this are not known, but deterioration in age-adjusted bone-mineral density and strength, with accompanying increase in the age-adjusted incidence of injurious falls of the elderly, could partly account for the development.	UKK Inst Hlth Promot Res, FIN-33500 Tampere, Finland; Tampere Res Ctr Sports Med, Tampere, Finland; Accid & Trauma Res Ctr, Tampere, Finland; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Surg, Tampere, Finland	UKK Institute; Tampere University; Tampere University; Tampere University Hospital	Kannus, P (corresponding author), UKK Inst Hlth Promot Res, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.	klpeka@uta.fi						BOEREBOOM FTJ, 1992, OSTEOPOROSIS INT, V2, P279, DOI 10.1007/BF01623183; BOYCE WJ, 1985, LANCET, V1, P150; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; EISKJAER S, 1992, ACTA ORTHOP SCAND, V63, P293, DOI 10.3109/17453679209154785; Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; FENTONLEWIS A, 1981, BRIT MED J, V283, P1217; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; HOFFENBERG R, 1989, J ROY COLL PHYS LOND, V23, P8; HONKNEN R, 1990, HOSP DUE INJURIES FI; Jaglal SB, 1996, CAN J SURG, V39, P105; Kanis JA, 1993, OSTEOPOROSIS INT S1, V3, P10; Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756-3282(95)00381-9; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; LAU EMC, 1990, INT J EPIDEMIOL, V19, P1119, DOI 10.1093/ije/19.4.1119; LEE CM, 1993, ACTA ORTHOP SCAND, V64, P178, DOI 10.3109/17453679308994565; LEVY AR, 1995, AM J EPIDEMIOL, V142, P428, DOI 10.1093/oxfordjournals.aje.a117651; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; MARTIN AD, 1991, CLIN ORTHOP RELAT R, P111; Melton LJ, 1996, BONE, V18, pS121, DOI 10.1016/8756-3282(95)00492-0; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; OBRANT KJ, 1989, CALCIFIED TISSUE INT, V44, P157, DOI 10.1007/BF02556558; *OFF STAT FINL, 1998, STRUCT POP VIT STAT; *OFF STAT FINL, 1997, POP PROJ 1997 2030; PARKKARI J, 1994, CALCIFIED TISSUE INT, V55, P342, DOI 10.1007/BF00299311; SALMELA R, 1987, HOSPITAL, V79, P780; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; Thorngren K G, 1994, Disabil Rehabil, V16, P119; WALLACE WA, 1983, LANCET, V1, P1413	30	236	240	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					802	805		10.1016/S0140-6736(98)04235-4	http://dx.doi.org/10.1016/S0140-6736(98)04235-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459962				2022-12-01	WOS:000079089100012
J	Davies, EK; Peters, AD; Keightley, PD				Davies, EK; Peters, AD; Keightley, PD			High frequency of cryptic deleterious mutations in Caenorhabditis elegans	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; AMBER SUPPRESSORS; SELECTION; RATES; RISK	Deleterious mutations with very small phenotypic effects could be important for several evolutionary phenomena, but the extent of their contribution has been unknown. Fitness effects of induced mutations in Lines of Caenorhabditis elegans were measured using a system for which the number of deleterious point mutations in the DNA can be estimated. In fitness assays, only about 4 percent of the deleterious mutations fixed in each Line were detectable. The remaining 96 percent, though cryptic, are significant for mutation Load and, potentially, for the evolution of sex.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Keightley, PD (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	p.keightley@ed.ac.uk						ANDERSON P, 1995, CAENORHABDITIS ELEGA, P31; BARNES TM, 1995, GENETICS, V141, P159; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; BEJSOVEC A, 1988, GENE DEV, V2, P1307, DOI 10.1101/gad.2.10.1307; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; EIDE D, 1985, GENETICS, V109, P67; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Fry JD, 1999, P NATL ACAD SCI USA, V96, P574, DOI 10.1073/pnas.96.2.574; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; HODGKIN J, 1985, GENETICS, V111, P287; Keightley PD, 1997, P NATL ACAD SCI USA, V94, P3823, DOI 10.1073/pnas.94.8.3823; Keightley PD, 1998, CURR BIOL, V8, pR235, DOI 10.1016/S0960-9822(98)70148-4; Keightley PD, 1996, GENETICS, V144, P1993; Keightley PD, 1998, GENETICS, V148, P753; KONDO K, 1990, J MOL BIOL, V215, P7, DOI 10.1016/S0022-2836(05)80090-7; KONDRASHOV AS, 1995, J THEOR BIOL, V175, P583, DOI 10.1006/jtbi.1995.0167; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1994, P ROY SOC B-BIOL SCI, V258, P221, DOI 10.1098/rspb.1994.0166; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.1111/j.1558-5646.1994.tb02188.x, 10.2307/2410240]; Nakamura Y, 1999, NUCLEIC ACIDS RES, V27, P292, DOI 10.1093/nar/27.1.292; ROSENBLUTH RE, 1983, MUTAT RES, V110, P39, DOI 10.1016/0027-5107(83)90016-7; Shabalina SA, 1997, P NATL ACAD SCI USA, V94, P13034, DOI 10.1073/pnas.94.24.13034; SHABALINA SA, IN PRESS GENET RES; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; Vassilieva LL, 1999, GENETICS, V151, P119; WATERSTON RH, 1981, GENETICS, V97, P307	30	110	112	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1748	1751		10.1126/science.285.5434.1748	http://dx.doi.org/10.1126/science.285.5434.1748			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481013				2022-12-01	WOS:000082472600039
J	Broccoli, V; Boncinelli, E; Wurst, W				Broccoli, V; Boncinelli, E; Wurst, W			The caudal limit of Otx2 expression positions the isthmic organizer	NATURE			English	Article							MIDBRAIN-HINDBRAIN BOUNDARY; NERVOUS-SYSTEM; ROSTRAL BRAIN; MOUSE; GENES; PHENOTYPE; FGF8; ENGRAILED-1; RHOMBOMERES; INDUCTION	The homeobox gene Otx2 is expressed in the anterior neural tube with a sharp limit at the midbrain/hindbrain junction (the isthmic organizer)(1). Otx2 inactivation experiments have shown that this gene is essential for the development of its expression domain(2). Here we investigate whether the caudal limit of Otx2 expression is instrumental in positioning the isthmic organizer and in specifying midbrain versus hindbrain fate, by ectopically expressing Otx2 in the presumptive anterior hindbrain using a knock-in strategy into the En1 locus. Transgenic offspring display a cerebellar ataxia. Morphological and histological studies of adult transgenic brains reveal that most of the anterior cerebellar vermis is missing whereas the inferior colliculus is complementarily enlarged. During early neural pattern formation expression of the midbrain markers Wnt1 and Ephrin-A5, the isthmic organizer markers Pax2 and Fgf-8 and the hindbrain marker Gbx2 are shifted caudally in the presumptive hindbrain territory. These findings show that the caudal limit of Otx2 expression is sufficient for positioning the isthmic organizer and encoding caudal midbrain fate within the mid/hindbrain domain.	GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Neuherberg, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Hosp San Raffaele, DIBIT, I-20132 Milan, Italy	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Wurst, W (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Broccoli, Vania/K-3464-2016	Broccoli, Vania/0000-0003-4050-0926; Wurst, Wolfgang/0000-0003-4422-7410				Acampora D, 1999, TRENDS NEUROSCI, V22, P116, DOI 10.1016/S0166-2236(98)01387-3; Acampora D, 1997, DEVELOPMENT, V124, P3639; ANG SL, 1994, DEVELOPMENT, V120, P2979; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lun K, 1998, DEVELOPMENT, V125, P3049; Mallamaci A, 1996, MECH DEVELOP, V58, P165, DOI 10.1016/S0925-4773(96)00571-0; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; Martinez S, 1999, DEVELOPMENT, V126, P1189; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Millet S, 1996, DEVELOPMENT, V122, P3785; Reifers F, 1998, DEVELOPMENT, V125, P2381; Schwarz M, 1997, P NATL ACAD SCI USA, V94, P14518, DOI 10.1073/pnas.94.26.14518; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wassilew S, 1997, ANTIVIR CHEM CHEMOTH, V8, P3, DOI 10.1177/09563202970080S602; WURST W, 1994, DEVELOPMENT, V120, P2065	30	245	245	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					164	168		10.1038/43670	http://dx.doi.org/10.1038/43670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490025				2022-12-01	WOS:000082458800054
J	Greengold, NL				Greengold, NL			Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					716	717		10.1001/jama.282.8.716	http://dx.doi.org/10.1001/jama.282.8.716			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463694				2022-12-01	WOS:000082118800001
J	Margolis, D				Margolis, D			Neuroscience 2000: A new era of discovery	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					318	320		10.7326/0003-4819-131-4-199908170-00102	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454964				2022-12-01	WOS:000082012500025
J	Plenz, D; Kital, ST				Plenz, D; Kital, ST			A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus	NATURE			English	Article							INTRACELLULAR ANALYSIS; FUNCTIONAL-ANATOMY; PARKINSONS-DISEASE; NEURONAL-ACTIVITY; MPTP MODEL; RAT; MONKEY; DISINHIBITION; STIMULATION; LESION	The subthalamic nucleus of the basal ganglia (STN) is important for normal movement(1,2) as well as in movement disorders(3-5). Lesioning(6) or deep-brain stimulation(7,8) of the STN can alleviate resting tremor in Parkinson's disease. The STN5 and its target nuclei(9,10) display synchronized oscillatory burst discharge at low frequencies, some of which correlate with tremor, but the mechanism underlying this synchronized bursting is unknown. Here we show that the excitatory STN and inhibitory, external globus pallidus (GPe) form a feedback system that engages in synchronized bursting. In mature organotypic cortex-striatum-STN-GPe cultures, neurons in the STN and GPe spontaneously produce synchronized oscillating bursts at 0.4, 0.8 and 1.8 Hz. Pallidal lesion abolishes this bursting, whereas cortical lesion favours bursting at 0.8 Hz. Pallidal bursts, although weaker than STN bursts, were required for synchronized oscillatory burst generation by recruitment of subthalmic rebound excitation. We propose that the STN and GPe constitute a central pacemaker modulated by striatal inhibition of GPe neurons. This pacemaker could be responsible for synchronized oscillatory activity in the normal and pathological basal ganglia.	Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Plenz, D (corresponding author), Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA.							ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALDRIDGE JW, 1991, BRAIN RES, V543, P123; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Chesselet MF, 1996, TRENDS NEUROSCI, V19, P417; CHEVALIER G, 1990, TRENDS NEUROSCI, V13, P277, DOI 10.1016/0166-2236(90)90109-N; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; DELONG MR, 1971, J NEUROPHYSIOL, V34, P414, DOI 10.1152/jn.1971.34.3.414; FILION M, 1979, BRAIN RES, V178, P425, DOI 10.1016/0006-8993(79)90704-2; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hurtado JM, 1999, P NATL ACAD SCI USA, V96, P1674, DOI 10.1073/pnas.96.4.1674; KITA H, 1992, BRAIN RES, V589, P84, DOI 10.1016/0006-8993(92)91164-A; KITA H, 1983, BRAIN RES, V264, P255, DOI 10.1016/0006-8993(83)90823-5; KITAI ST, 1981, BRAIN RES, V214, P411, DOI 10.1016/0006-8993(81)91204-X; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; MATSUMURA M, 1992, J NEUROPHYSIOL, V67, P1615, DOI 10.1152/jn.1992.67.6.1615; NAKANISHI H, 1987, BRAIN RES, V437, P35, DOI 10.1016/0006-8993(87)91524-1; NINI A, 1995, J NEUROPHYSIOL, V74, P1800, DOI 10.1152/jn.1995.74.4.1800; PAN HS, 1988, SYNAPSE, V2, P650, DOI 10.1002/syn.890020612; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; Plenz D, 1998, J COMP NEUROL, V397, P437, DOI 10.1002/(SICI)1096-9861(19980810)397:4<437::AID-CNE1>3.0.CO;2-2; Rodriguez MC, 1998, MOVEMENT DISORD, V13, P111; Ruskin DN, 1999, J NEUROPHYSIOL, V81, P2046, DOI 10.1152/jn.1999.81.5.2046; Shink E, 1996, NEUROSCIENCE, V73, P335, DOI 10.1016/0306-4522(96)00022-X; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P494, DOI 10.1152/jn.1994.72.2.494; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; WURTZ RH, 1986, PROG BRAIN RES, V64, P175	30	528	536	2	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					677	682		10.1038/23281	http://dx.doi.org/10.1038/23281			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458164				2022-12-01	WOS:000082032900057
J	Liu, JJ; Lindquist, S				Liu, JJ; Lindquist, S			Oligopeptide-repeat expansions modulate 'protein-only' inheritance in yeast	NATURE			English	Article							HUMAN PRION PROTEIN; DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROPAGATION; PSI; DETERMINANT; TRANSLATION; TERMINATION; HYPOTHESIS	The yeast [PSI+] element represents a new type of genetic inheritance, in which changes in phenotype are transmitted by a 'protein only' mechanism(1-3) reminiscent of the 'protein-only' transmission of mammalian prion diseases(1,4). The underlying molecular mechanisms for both are poorly understood and it is not clear how similar they might be. Sup35, the [PSI+] protein determinant, and PrP, the mammalian prion determinant, have different functions, different cellular locations and no sequence similarity; however, each contains five imperfect oligopeptide repeats-PQGGYQQYN in Sup35 and PHGGGWGQ in PrP5,6. Repeat expansions in PrP produce spontaneous prion diseases(7,8). Here we show that replacing the wild-type SUP35 gene with a repeat-expansion mutation induces new [PSI+] elements, the first mutation of its type among these newly described elements of inheritance. In vitro, fully denatured repeat-expansion peptides can adopt conformations rich in beta-sheets and form higher-order structures much more rapidly than wild-type peptides. Our results provide insight into the nature of the conformational changes underlying protein-based mechanisms of inheritance and suggest a link between this process and those producing neurodegenerative prion diseases in mammals.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave,MC1028, Chicago, IL 60637 USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Goldmann W, 1998, J GEN VIROL, V79, P3173, DOI 10.1099/0022-1317-79-12-3173; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; SERIO TR, IN PRESS METHODS ENZ; SIKORSKI RS, 1989, GENETICS, V122, P19; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	29	176	180	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					573	576		10.1038/23048	http://dx.doi.org/10.1038/23048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448860				2022-12-01	WOS:000081854800058
J	Stoddard, PK				Stoddard, PK			Predation enhances complexity in the evolution of electric fish signals	NATURE			English	Article							ORDER GYMNOTIFORMES; ELECTRORECEPTION; LEPIDOPTERA; COURTSHIP; ARCTIIDAE	Theories of sexual selection assume that predation is a restrictive, simplifying force in the evolution of animal display characters' and many empirical studies have shown that predation opposes excessive elaboration of sexually selected traits(2). In an unexpected turnaround, I show here that predation pressure on neotropical, weakly electric fish (order Gymnotiformes) seems to have selected for greater signal complexity, by favouring characters that have enabled further signal elaboration by sexual selection. Most gymnotiform fish demonstrate adaptations that lower detectability of their electrolocation/communication signals by key predators. A second wave phase added to the ancestral monophasic signal shifts the emitted spectrum above the most sensitive frequencies of electroreceptive predators. By using playback trials with the predatory electric eel (Electrophorus electricus), I show that these biphasic signals are less detectable than the primitive monophasic signals. But sexually mature males of many species in the family Hypopomidae extend the duration of the second phase of their electric signal pulses(3) and further amplify this sexual dimorphism nightly during the peak hours of reproduction(4). Thus a signal element that evolved for crypsis has itself been modified by sexual selection.	Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA	State University System of Florida; Florida International University	Stoddard, PK (corresponding author), Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA.	stoddard@fiu.edu	Stoddard, Philip K/AAY-4188-2020					Albert JS, 1996, COPEIA, P85; ALVESGOMES JA, 1995, MOL BIOL EVOL, V12, P298; Andersson Malte, 1994; BENNETT LA, 1971, J RES CRIME DELINQ, V8, P1, DOI 10.1177/002242787100800101; BENNETT MV, 1961, ANN NY ACAD SCI, V94, P458, DOI 10.1111/j.1749-6632.1961.tb35555.x; BULLOCK TH, 1982, ANNU REV NEUROSCI, V5, P121, DOI 10.1146/annurev.ne.05.030182.001005; Crampton William G. R., 1998, Anais da Academia Brasileira de Ciencias, V70, P805; Darwin C., 1871, DESCENT MAN SELECTIO; DUNNING BB, 1973, THESIS U MINNESOTA; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.1111/j.1558-5646.1964.tb01674.x; Franchina CR, 1998, J COMP PHYSIOL A, V183, P759, DOI 10.1007/s003590050299; HAGEDORN M, 1988, COPEIA, P324; Hopkins C.D., 1986, P527; HOPKINS CD, 1990, BRAIN BEHAV EVOLUT, V35, P350, DOI 10.1159/000115880; HOPKINS CD, 1978, BEHAV ECOL SOCIOBIOL, V3, P113, DOI 10.1007/BF00294985; HOPKINS CD, 1976, J COMP PHYSIOL, V111, P171, DOI 10.1007/BF00605531; KIRSCHBAUM F, 1995, ELECT FISHES HIST BE, P267; LISSMANN HW, 1958, J EXP BIOL, V35, P156; MCCREERY DB, 1977, J COMP PHYSIOL, V113, P317, DOI 10.1007/BF00620405; MERRON GS, 1993, J FISH BIOL, V43, P575; MILLER RR, 1966, COPEIA, P773, DOI 10.2307/1441406; Moller P., 1995, ELECT FISHES HIST BE; PETERS RC, 1972, J COMP PHYSIOL, V79, P29, DOI 10.1007/BF00693616; REID S, 1983, REV UNELLEZ CIENC TE, V0001, P00013; SANDERFORD MV, 1995, J INSECT BEHAV, V8, P19, DOI 10.1007/BF01990967; SHUMWAY CA, 1988, J COMP PHYSIOL A, V163, P465, DOI 10.1007/BF00604901; Simmons RB, 1996, J INSECT BEHAV, V9, P909, DOI 10.1007/BF02208978; SULLIVAN JP, 1997, THESIS DUKE U; Szabo T., 1974, P59; WESTBY GWM, 1988, BEHAV ECOL SOCIOBIOL, V22, P341	30	128	134	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					254	256		10.1038/22301	http://dx.doi.org/10.1038/22301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421365				2022-12-01	WOS:000081503800041
J	Johnson, RE; Kondratick, CM; Prakash, S; Prakash, L				Johnson, RE; Kondratick, CM; Prakash, S; Prakash, L			hRAD30 mutations in the variant form of xeroderma pigmentosum	SCIENCE			English	Article							ESCHERICHIA-COLI DINB; POSTREPLICATION REPAIR; EXCISION-REPAIR; DNA-SYNTHESIS; REPLICATION; SENSITIVITY; HOMOLOG; BYPASS; DIMER; CELLS	Xeroderma pigmentosum (XP) is an autosomal recessive disease characterized by a high incidence of skin cancers. Yeast RAD30 encodes a DNA polymerase involved in the error-free bypass of ultraviolet (UV) damage. Here it is shown that XP variant (XP-V) cell lines harbor nonsense or frameshift mutations in hRAD30, the human counterpart of yeast RAD30. Of the eight mutations identified, seven would result in a severely truncated hRad30 protein. These results indicate that defects in hRAD30 cause XP-V, and they suggest that error-free replication of UV lesions by hRad30 plays an important role in minimizing the incidence of sunlight-induced skin cancers.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER JC, 1990, CANCER RES, V50, P2593; CLEAVER JE, 1980, CARCINOGENESIS, V1, P647, DOI 10.1093/carcin/1.8.647; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CLEAVER JE, 1981, CYTOGENET CELL GENET, V31, P188, DOI 10.1159/000131646; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Friedberg EC, 1995, DNA REPAIR MUTAGENES; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KONDRATICK CM, UNPUB; KRAEMER KH, 1994, J INVEST DERMATOL, V103, pS96, DOI 10.1111/1523-1747.ep12399329; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Roush AA, 1998, MOL GEN GENET, V257, P686; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Svoboda DL, 1998, CANCER RES, V58, P2445; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276	17	657	669	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					263	265		10.1126/science.285.5425.263	http://dx.doi.org/10.1126/science.285.5425.263			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398605				2022-12-01	WOS:000081346000045
J	Benedetti, JK; Zeh, J; Corey, L				Benedetti, JK; Zeh, J; Corey, L			Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time	ANNALS OF INTERNAL MEDICINE			English	Article						herpes genitalis; virus activation; recurrence; time factors; antiviral agents	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL ACYCLOVIR; SUPPRESSION; ANTIBODIES; THERAPY; TYPE-2; WOMEN; POPULATIONS; RECURRENCES	Background: Visits to physicians for genital herpes simplex virus (HSV) infection continue to increase. Most patients with symptomatic infections have recurrences, but no studies of the long-term clinical course of genital herpes are available. Objective: To determine whether the frequency of HSV recurrences decreases over time. Design: Observational cohort study. Setting: University-based research clinic. Patients: 664 persons with genital herpes followed for at least 14 months. Measurements: Patients were classified as having initial or recurrent HSV-1 or HSV-2 infection. Patient-reported recurrences and observed recurrences were recorded in a database; more than 12 000 recurrences were analyzed. Results: Median recurrence rates in the first year of follow-up were one and five per year in patients with newly acquired HSV-1 and HSV-2 infection, respectively; second-year rates were significantly lower in both groups. Patients presenting with recurrent HSV-2 infection had higher rates of recurrence in the first and second years and no significant decrease; significant decreases were detected with longer follow-up. One third of all patients experienced a decrease of two or more recurrences per year between years 1 and 2. Patients infected with HSV-2 who were followed for more than 4 years had a median decrease of two recurrences between years 1 and 5. However, 25% of these patients had an increase of at least one recurrence in year 5, illustrating the variability among HSV-infected persons. Decreases overtime among patients who never received suppressive therapy were similar to decreases during untreated periods in patients who received suppressive therapy. Conclusions: Herpes simplex virus type 2 infection continues to be a chronic remitting illness. Over time, however, clinically significant reductions occur in a majority of patients. Physicians may wish to periodically assess the need for continued treatment with daily suppressive antiviral chemotherapy.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), 1100 Fairview Ave N D3-100,Box 19024, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30619, AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731, R01AI030619] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1998, LAB DIAGNOSIS VIRAL, P489; BASSETT I, 1994, MED J AUSTRALIA, V160, P697, DOI 10.5694/j.1326-5377.1994.tb125907.x; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; BENEDETTI JK, 1995, AM J MED, V98, P237, DOI 10.1016/S0002-9343(99)80369-6; CATOTTI DN, 1993, SEX TRANSM DIS, V20, P77, DOI 10.1097/00007435-199303000-00004; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P20; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; COREY L, 1999, SEXUALLY TRANSMITTED, P285; Cowan FM, 1996, J INFECT DIS, V174, P470, DOI 10.1093/infdis/174.3.470; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; FIFE KH, 1994, J INFECT DIS, V169, P1338, DOI 10.1093/infdis/169.6.1338; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; GARLAND SM, 1995, J VIROL METHODS, V55, P285, DOI 10.1016/0166-0934(95)00061-9; HARGER JH, 1986, OBSTET GYNECOL, V67, P637, DOI 10.1097/00006250-198605000-00007; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; KNOX SR, 1982, SEX TRANSM DIS, V9, P15, DOI 10.1097/00007435-198201000-00003; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MATTISON HR, 1988, AM J MED, V85, P20; Mertz GJ, 1997, ARCH INTERN MED, V157, P343, DOI 10.1001/archinte.157.3.343; MINDEL A, 1988, LANCET, V1, P926; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; NILSEN AE, 1982, LANCET, V2, P571; Oliver L, 1995, Arch Fam Med, V4, P228, DOI 10.1001/archfami.4.3.228; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; Velleman P.F., 1981, APPL BASICS COMPUTIN; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Weinberg Adriana, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P285	33	126	131	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					14	+		10.7326/0003-4819-131-1-199907060-00004	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391810				2022-12-01	WOS:000081345200003
J	Stirrat, GM				Stirrat, GM			Choice of treatment for menorrhagia	LANCET			English	Editorial Material							INTRAUTERINE SYSTEM; HYSTERECTOMY		St Michaels Hosp, Dept Obstet & Gynaecol, Bristol BS2 8EG, Avon, England		Stirrat, GM (corresponding author), St Michaels Hosp, Dept Obstet & Gynaecol, Bristol BS2 8EG, Avon, England.							Crossman DC, 1997, QJM-MON J ASSOC PHYS, V90, P157, DOI 10.1093/qjmed/90.3.157; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Garry R, 1997, BRIT J OBSTET GYNAEC, V104, P1329, DOI 10.1111/j.1471-0528.1997.tb10998.x; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; Higham JM, 1999, EUR J OBSTET GYN R B, V82, P73, DOI 10.1016/S0301-2115(98)00224-3; Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x; KILLETSEN N, 1998, GYNECOL ENDOSC, V7, P61; LAHTEENMAKI, 1998, BMJ, V316, P1122; Lilford RJ, 1997, BRIT MED J, V314, P160, DOI 10.1136/bmj.314.7075.160; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL; *U LEEDS, 1995, EFF HLTH CAR, V9, P1	11	25	33	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2175	2176		10.1016/S0140-6736(99)00132-4	http://dx.doi.org/10.1016/S0140-6736(99)00132-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392977				2022-12-01	WOS:000081091300005
J	Opie, LH				Opie, LH			Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium?	LANCET			English	Editorial Material							INFARCTION; MAGNESIUM		Univ Cape Town, Sch Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa	University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Sch Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa.							Antman EM, 1996, CARDIOVASC DRUG THER, V10, P297; Apstein CS, 1997, CIRCULATION, V96, P1074, DOI 10.1161/01.CIR.96.4.1074; Apstein CS, 1998, CIRCULATION, V98, P2223, DOI 10.1161/01.CIR.98.21.2223; CEREMUZYNSKI L, 1997, EUR HEART J, V18, pP1054; DEVILLALOBOS DH, 1995, LANCET, V345, P1552; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; FATHORDOUBADI F, 1997, CIRCULATION, V96, P1074; GD Lopaschuk, 1998, METABOLIC APPROACHES, P44; JONASSEN AK, UNPUB; King LM, 1998, CARDIOVASC RES, V39, P381, DOI 10.1016/S0008-6363(98)00100-X; LAZAR HL, 1997, J THORACIC CARDIOVAS, V113, P345; Malmberg K, 1996, EUR HEART J, V17, P1337; OLDFIELD GS, 1986, J THORAC CARDIOV SUR, V91, P874; OPIE LH, 1995, LANCET, V345, P1520, DOI 10.1016/S0140-6736(95)91080-8; SHECHTER M, 1995, AM J CARDIOL, V75, P321, DOI 10.1016/S0002-9149(99)80546-3; SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8; STANLEY AW, 1975, AM J CARDIOL, V36, P929, DOI 10.1016/0002-9149(75)90085-5; Young LH, 1997, CIRCULATION, V95, P415	18	28	30	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					768	769		10.1016/S0140-6736(98)00385-7	http://dx.doi.org/10.1016/S0140-6736(98)00385-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459953				2022-12-01	WOS:000079089100003
J	Naidoo, N; Song, W; Hunter-Ensor, M; Sehgal, A				Naidoo, N; Song, W; Hunter-Ensor, M; Sehgal, A			A role for the proteasome in the light response of the timeless clock protein	SCIENCE			English	Article							DROSOPHILA CLOCK; CIRCADIAN CLOCK; IN-VIVO; DEGRADATION; KINASE; PERIOD; PROTEOLYSIS; INHIBITORS; MECHANISM; GENE	The cyclic expression of the period (PER) and timeless (TIM) proteins is critical for the molecular circadian feedback Loop in Drosophila. The entrainment by Light of the circadian clock is mediated by a reduction in TIM Levels. To elucidate the mechanism of this process, the sensitivity of TIM regulation by Light was tested in an in vitro assay with inhibitors of candidate proteolytic pathways. The data suggested that TIM is degraded through a ubiquitin-proteasome mechanism. In addition, in cultures from third-instar Larvae, TIM degradation was blocked specifically by inhibitors of proteasome activity. Degradation appeared to be preceded by tyrosine phosphorylation. Finally, TIM was ubiquitinated in response to Light in cultured cells.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Sehgal, A (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA.			Naidoo, Navindhra/0000-0001-9142-3751; Song, Wei/0000-0001-6531-8317; Naidoo, Nirinjini/0000-0002-7463-2559				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHEN Y, 1998, CELL, V13, P364; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; HARDIN PE, 1999, HDB BEHAV STATE CONT, P61; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaneko M, 1997, J NEUROSCI, V17, P6745; KOBAYASHI E, 1989, J ANTIBIOT, V42, P1470, DOI 10.7164/antibiotics.42.1470; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; MYERS MP, 1996, SCIENCE, V271, P1740; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yang XM, 1998, J IRON STEEL RES INT, V5, P21; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	35	220	223	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1737	1741		10.1126/science.285.5434.1737	http://dx.doi.org/10.1126/science.285.5434.1737			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481010				2022-12-01	WOS:000082472600036
J	Ottemann, KM; Xiao, WZ; Shin, YK; Koshland, DE				Ottemann, KM; Xiao, WZ; Shin, YK; Koshland, DE			A piston model for transmembrane signaling of the aspartate receptor	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; SINGLE CYTOPLASMIC DOMAIN; DISULFIDE CROSS-LINKING; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SENSORY RECEPTOR; SPIN LABELS; TRANSDUCTION; CHEMORECEPTOR; ADAPTATION	To characterize the mechanism by which receptors propagate conformational changes across membranes, nitroxide spin labels were attached at strategic positions in the bacterial aspartate receptor. By collecting the electron paramagnetic resonance spectra of these labeled receptors in the presence and absence of the Ligand aspartate, ligand binding was shown to generate an similar to 1 angstrom intrasubunit piston-type movement of one transmembrane helix downward relative to the other transmembrane helix. The receptor-associated phosphorylation cascade proteins CheA and CheW did not alter the ligand-induced movement. Because the piston movement is very small, the ability of receptors to produce Large outcomes in response to stimuli is caused by the ability of the receptor-coupled enzymes to detect small changes in the conformation of the receptor.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Shin, YK (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.			Ottemann, Karen/0000-0001-6265-7401; xiao, wenzhong/0000-0003-4944-6380	NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [GM51290] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009765, R01DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051290, R01GM051290] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; CHEN X, 1997, BIOCHEM, V39, P11858; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; OGAWA S, 1967, P NATL ACAD SCI USA, V58, P719; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; REIDEL H, 1986, NATURE, V324, P68; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	46	228	229	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1751	1754		10.1126/science.285.5434.1751	http://dx.doi.org/10.1126/science.285.5434.1751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481014				2022-12-01	WOS:000082472600040
J	Thurman, D; Guerrero, J				Thurman, D; Guerrero, J			Trends in hospitalization associated with traumatic brain injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE-PAYMENT SYSTEM; HEAD-INJURY; ACCURACY	Context Traumatic brain injury (TBI) is associated with more than 50 000 deaths in the United States each year, and recent observations suggest a substantial decline in TBI-related hospitalizations and deaths. Objective To analyze long-term trends in TBI-related hospitalization in the United States. Design, Setting, and Participants Analysis of existing data from 1980 through 1995 from the National Hospital Discharge Survey, an annual survey representing the US general population. The number of participating hospitals ranged from 400 to 494. Main Outcome Measures Annual rates of TBI-related hospitalization, stratified by age, sex, severity of injury, and outcome. Results The annual number of TBI cases identified from the sample during the study : period ranged from 1611 to 3129. Overall rates of hospitalization for TBI declined an estimated 51 %, from 199 to 98 per 100 000 per year. When analyzed by severity of injury, mild TBIs declined most during this period, from 130 to 51 hospitalizations per 100 000 per year (61 % decline; P<.001 compared with intermediate and severe TBI); The decline was greatest among those aged 5-14 years (-66%) and least among those. aged 65 years or older (-9%). The ratio of male to female rates showed little variation during the study period (ratio, 1.8; 95% confidence interval [CI], 1.6-2.0), as did the in-hospital mortality rate (mean, 5.3 per 100 000; 95% CI, 3.6-7.1). Conclusions Changes in hospital practices may be a major factor in the declining rates of TBI-related hospital admissions. These practices increasingly appear to exclude persons with less severe TBI from hospital admission and shift: their care to outpatient settings.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Thurman, D (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Mailstop F-41,4770 Buford Hwy NE, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062				*ASS ADV AUT MED, 1990, ABBR INJ SCAL; ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Burt C W, 1998, Vital Health Stat 13, P1; *CDCP, 1997, DAT FIL DOC NAT HOSP; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; *CTR INJ RES POL J, 1997, ICDMAP90 SOTW; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; Graves E J, 1997, Vital Health Stat 13, P1; Gronwall D., 1989, MILD HEAD INJURY, P153; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; KISH L, 1965, SURVEY SAMPLING, P206; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; *NAT CTR HLTH STAT, 1997, DAT FIL DOC NAT HOSP; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Ruff R. M., 1989, MILD HEAD INJURY, P176; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THURMAN DJ, IN PRESS J HEAD TRAU; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DHHS, 1989, FED INT HEAD INJ TAS; *US DHHS, 1996, INT CLASS DIS	24	370	379	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					954	957		10.1001/jama.282.10.954	http://dx.doi.org/10.1001/jama.282.10.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485680	Bronze			2022-12-01	WOS:000082335900033
J	Sugase, Y; Yamane, S; Ueno, S; Kawano, K				Sugase, Y; Yamane, S; Ueno, S; Kawano, K			Global and fine information coded by single neurons in the temporal visual cortex	NATURE			English	Article							INFEROTEMPORAL CORTEX; POLYSENSORY AREA; MACAQUE MONKEY; RHESUS-MONKEY; RESPONSES; SULCUS; FACE; CONNECTIONS; IDENTITY	When we see a person's face, we can easily recognize their species, individual identity and emotional state. How does the brain represent such complex information? A substantial number of neurons in the macaque temporal cortex respond to faces(1-12) However, the neuronal mechanisms underlying the processing of complex information are not yet clear. Here we recorded the activity of single neurons in the temporal cortex of macaque monkeys while presenting visual stimuli consisting of geometric shapes, and monkey and human faces with various expressions. Information theory was used to investigate how well the neuronal responses could categorize the stimuli. We found that single neurons conveyed two different scales of facial information in their firing patterns, starting at different latencies. Global information, categorizing stimuli as monkey faces, human faces or shapes, was conveyed in the earliest part of the responses. Fine information about identity or expression was conveyed later, beginning on average 51 ms after global information. We speculate that global information could be used as a 'header' to prepare destination areas for receiving more detailed information.	Electrotech Lab, Tsukuba, Ibaraki 3058568, Japan; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Sugase, Y (corresponding author), Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan.		sugase-miyamoto, yasuko/N-2769-2016	sugase-miyamoto, yasuko/0000-0003-3097-3789				AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; AMARI SI, 1977, BIOL CYBERN, V26, P175, DOI 10.1007/BF00365229; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; Ellis HD, 1986, NEUROPSYCHOLOGY FACE, P1; Golomb D, 1997, NEURAL COMPUT, V9, P649, DOI 10.1162/neco.1997.9.3.649; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; HECAEN H, 1962, INTERHEMISPHER RELAT, P215; HELLER J, 1995, J COMPUT NEUROSCI, V2, P175, DOI 10.1007/BF00961433; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; Lavenex P., 1998, Society for Neuroscience Abstracts, V24, P1905; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MIKAMI A, 1994, BEHAV BRAIN RES, V60, P1, DOI 10.1016/0166-4328(94)90057-4; NAKAMURA K, 1994, J NEUROPHYSIOL, V71, P1206, DOI 10.1152/jn.1994.71.3.1206; NAKAMURA K, 1992, J NEUROPHYSIOL, V67, P1447, DOI 10.1152/jn.1992.67.6.1447; ORAM MW, 1992, J NEUROPHYSIOL, V68, P70, DOI 10.1152/jn.1992.68.1.70; Oram MW, 1996, J NEUROPHYSIOL, V76, P109, DOI 10.1152/jn.1996.76.1.109; Panzeri S, 1996, NETWORK-COMP NEURAL, V7, P87, DOI [10.1088/0954-898X/7/1/006, 10.1080/0954898X.1996.11978656]; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Sugase Y., 1998, Society for Neuroscience Abstracts, V24, P899; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	28	553	562	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					869	873		10.1038/23703	http://dx.doi.org/10.1038/23703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476965				2022-12-01	WOS:000082233200045
J	Yin, XM; Wang, K; Gross, A; Zhao, YG; Zinkel, S; Klocke, B; Roth, KA; Korsmeyer, SJ				Yin, XM; Wang, K; Gross, A; Zhao, YG; Zinkel, S; Klocke, B; Roth, KA; Korsmeyer, SJ			Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis	NATURE			English	Article							CYTOCHROME-C; CELL-DEATH; PROTEASE; PATHWAYS; ANTIBODY; FAMILY; REQUIREMENT; ACTIVATION; CASPASE-9; INDUCTION	The protein Bid is a participant in the pathway that leads to cell death (apoptosis), mediating the release of cytochrome c from mitochondria in response to signals from 'death' receptors known as TNFR1/Fas on the cell surface(1-7). It is a member of the pro-apoptotic Bcl-2 familys and is activated as a result of its cleavage by caspase 8, one of a family of proteolytic cell-death proteins. To investigate the role of Bid in vivo, we have generated mice deficient for Bid. We find that when these mice are injected with an antibody directed against Fas, they nearly all survive, whereas wild-type mice die from hepatocellular apoptosis and haemorrhagic necrosis. About half of the Bid-deficient animals had no apparent liver injury and showed no evidence of activation of the effector caspases 3 and 7, although the initiator caspase 8 had been activated. Other Bid-deficient mice survived with only moderate damage: all three caspases (8 and 37) were activated but their cell nuclei were intact and no mitochondrial cytochrome c was released. We also investigated the effects of Bid deficiency in cultured cells treated with anti-pas antibody (hepatocytes and thymocytes) or with TNF-alpha. (fibroblasts). In these Bid(-/-) cells, mitochondrial dysfunction was delayed, cytochrome c was not released, effector caspase activity was reduced and the cleavage of apoptosis substrates was altered. This loss-of-function model indicates that Bid is a critical substrate in vivo for signalling by death-receptor agonists, which mediates a mitochondrial amplification loop that is essential for the apoptosis of selected cells.	Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Korsmeyer, SJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA.			Roth, Kevin/0000-0002-0643-995X; zinkel, sandra/0000-0002-2818-9795				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, GENOMICS, V53, P235, DOI 10.1006/geno.1998.5489; XUESONG L, 1997, CELL, V89, P175; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	30	831	858	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					886	891		10.1038/23730	http://dx.doi.org/10.1038/23730			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476969				2022-12-01	WOS:000082233200049
J	Cuckle, H				Cuckle, H			Maternal age-standardisation of prevalence of Down's syndrome	LANCET			English	Editorial Material									Univ Leeds, Sch Med, Ctr Reprod Growth, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Cuckle, H (corresponding author), Univ Leeds, Sch Med, Ctr Reprod Growth, Leeds LS2 9NZ, W Yorkshire, England.							Carothers AD, 1999, J MED GENET, V36, P386; Cuckle HS, 1999, PRENATAL DIAG, V19, P505, DOI 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO;2-6; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; HOOK EB, 1994, SCREENING DOWNS SYND, P1; James RS, 1998, EUR J HUM GENET, V6, P207, DOI 10.1038/sj.ejhg.5200178; Mutton D, 1998, BRIT MED J, V317, P922; *OFF POP CENS SURV, 1990, BIRTH STAT SER FM1, P17; Penrose LS, 1933, J GENET, V27, P219, DOI 10.1007/BF02984413	8	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					529	530		10.1016/S0140-6736(99)00174-9	http://dx.doi.org/10.1016/S0140-6736(99)00174-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470692				2022-12-01	WOS:000081991000005
J	Deuerling, E; Schulze-Specking, A; Tomoyasu, T; Mogk, A; Bukau, B				Deuerling, E; Schulze-Specking, A; Tomoyasu, T; Mogk, A; Bukau, B			Trigger factor and DnaK cooperate in folding of newly synthesized proteins	NATURE			English	Article							HEAT-SHOCK GENE; ESCHERICHIA-COLI; RECOGNITION; CHAPERONES; ISOMERASE; MUTATIONS	The role of molecular chaperones in assisting the folding of newly synthesized proteins in the cytosol is poorly understood. In Escherichia coli, GroEL assists folding of only a minority of proteins(1) and the Hsp70 homologue DnaK is not essential for protein folding or cell viability at intermediate growth temperatures(2). The major protein associated with nascent polypeptides is ribosome-bound trigger factor(3,4), which displays chaperone and prolyl isomerase activities in vitro(3,5,6). Here we show that Delta tig::kan mutants lacking trigger factor have no defects in growth or protein folding. However, combined Delta tig::kan and Delta dnaK mutations cause synthetic lethality. Depletion of DnaK in the Delta tig::kan mutant results in massive aggregation of cytosolic proteins. In Delta tig::kan cells, an increased amount of newly synthesized proteins associated transiently with DnaK. These findings show in vivo activity for a ribosome-associated chaperone, trigger factor, in general protein folding, and functional cooperation of this protein with a cytosolic Hsp70. Trigger factor and DnaK cooperate to promote proper folding of a variety of E. coli proteins, but neither is essential for folding and viability at intermediate growth temperatures.	Inst Biochem & Mol Biol, D-79104 Freiburg, Germany		Bukau, B (corresponding author), Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.			Bukau, Bernd/0000-0003-0521-7199				BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993	15	392	399	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					693	696		10.1038/23301	http://dx.doi.org/10.1038/23301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458167	Green Published			2022-12-01	WOS:000082032900060
J	Hosfield, DJ; Guan, Y; Haas, BJ; Cunningham, RP; Tainer, JA				Hosfield, DJ; Guan, Y; Haas, BJ; Cunningham, RP; Tainer, JA			Structure of the DNA repair enzyme endonuclease IV and its DNA complex: Double-nucleotide flipping at abasic sites and three-metal-ion catalysis	CELL			English	Article							BASE EXCISION-REPAIR; MAJOR APURINIC ENDONUCLEASE; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; BACILLUS-CEREUS; EXONUCLEASE-III; SUBSTRATE-ANALOG; POLYMERASE-BETA; STRANDED-DNA	Endonuclease IV is the archetype for a conserved apurinic/apyrimidinic (AP) endonuclease family that primes DNA repair synthesis by cleaving the DNA backbone 5' of AP sites. The crystal structures of Endonuclease IV and its AP-DNA complex at 1.02 and 1.55 Angstrom resolution reveal how an alpha(8)beta(8) TIM barrel fold can bind dsDNA. Enzyme loops intercalate side chains at the abasic site, compress the DNA backbone, bend the DNA similar to 90 degrees, and promote double-nucleotide flipping to sequester the extrahelical AP site in an enzyme pocket that excludes undamaged nucleotides. These structures suggest three Zn2+ ions directly participate in phosphodiester bond cleavage and prompt hypotheses that double-nucleotide flipping and sharp bending by AP endonucleases provide exquisite damage specificity while aiding subsequent base excision repair pathway progression.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; SUNY Albany, Dept Biol Sci, Ctr Biochem & Biophys, Albany, NY 12222 USA	Scripps Research Institute; Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Tainer, JA (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NIGMS NIH HHS [GM46312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Demple B, 1997, ENVIRON HEALTH PERSP, V105, P931, DOI 10.2307/3433306; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Friedberg EC, 1995, DNA REPAIR MUTAGENES; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haas BJ, 1999, J BACTERIOL, V181, P2834, DOI 10.1128/JB.181.9.2834-2839.1999; HANSEN S, 1992, J MOL BIOL, V225, P543, DOI 10.1016/0022-2836(92)90938-G; HANSEN S, 1993, J MOL BIOL, V234, P179, DOI 10.1006/jmbi.1993.1572; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Krokan HE, 1997, BIOCHEM J, V325, P1; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; Masson JY, 1996, GENE, V179, P291, DOI 10.1016/S0378-1119(96)00375-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOL CD, 1998, NUCL ACID M, V12, P29; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Ramotar D, 1997, BIOCHEM CELL BIOL, V75, P327, DOI 10.1139/bcb-75-4-327; Ramotar D, 1998, BBA-GENE STRUCT EXPR, V1396, P15, DOI 10.1016/S0167-4781(97)00160-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Romier C, 1998, PROTEINS, V32, P414, DOI 10.1002/(SICI)1097-0134(19980901)32:4<414::AID-PROT2>3.3.CO;2-5; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SAPORITO SM, 1988, J BACTERIOL, V170, P5141, DOI 10.1128/jb.170.11.5141-5145.1988; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SHELDRICK GM, 1997, HIGH RESOLUTION STRU; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WEISS B, 1976, J BIOL CHEM, V251, P1896; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	60	242	246	2	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					397	408		10.1016/S0092-8674(00)81968-6	http://dx.doi.org/10.1016/S0092-8674(00)81968-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458614	Bronze			2022-12-01	WOS:000081950300014
J	Busch, MA; Bomblies, K; Weigel, D				Busch, MA; Bomblies, K; Weigel, D			Activation of a floral homeotic gene in Arabidopsis	SCIENCE			English	Article							FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; MERISTEM IDENTITY; EXPRESSION; LEAFY; PLANTS; ANTIRRHINUM; FLORICAULA; TRANSCRIPTION; MORPHOGENESIS	The patterned expression of floral homeotic genes in Arabidopsis depends on the earlier action of meristem-identity genes such as LEAFY, which encodes a transcription factor that determines whether a meristem will generate flowers instead of Leaves and shoots. The LEAFY protein, which is expressed throughout the flower, participates in the activation of homeotic genes, which are expressed in specific regions of the flower. Analysis of a LEAFY-responsive enhancer in the homeotic gene AGAMOUS indicates that direct interaction of LEAFY with this enhancer is required for its activity in plants. Thus, LEAFY is a direct upstream regulator of floral homeotic genes.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Bomblies, Kirsten/0000-0002-2434-3863				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Busch M., UNPUB; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; HANTKE SS, 1995, DEVELOPMENT, V121, P27; Hofer J, 1997, CURR BIOL, V7, P581, DOI 10.1016/S0960-9822(06)00257-0; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; LIU ZC, 1995, DEVELOPMENT, V121, P975; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; McSteen PCM, 1998, DEVELOPMENT, V125, P2359; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Motte P, 1998, DEVELOPMENT, V125, P71; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PARCY F, UNPUB; Riechmann JL, 1997, BIOL CHEM, V378, P1079; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Souer E, 1998, DEVELOPMENT, V125, P733; Southerton SG, 1998, PLANT MOL BIOL, V37, P897, DOI 10.1023/A:1006056014079; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	36	289	335	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					585	587		10.1126/science.285.5427.585	http://dx.doi.org/10.1126/science.285.5427.585			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417388				2022-12-01	WOS:000081609500038
J	Socolovsky, M; Fallon, AEJ; Wang, S; Brugnara, C; Lodish, HF				Socolovsky, M; Fallon, AEJ; Wang, S; Brugnara, C; Lodish, HF			Fetal anemia and apoptosis of red cell progenitors in Stat5a(-/-)5b(-/-) mice: A direct role for Stat5 in Bcl-X-L induction	CELL			English	Article							GENE-EXPRESSION; ERYTHROID PROGENITORS; ERYTHROPOIETIN RECEPTOR; SEQUENCE SIMILARITY; FORMING-UNITS; S-PHASE; PROLIFERATION; ACTIVATION; DEATH; DIFFERENTIATION	The erythropoietin receptor (EpoR) is essential for production of red blood cells; a principal function of EpoR is to rescue committed erythroid progenitors from apoptosis. Stat5 is rapidly activated following EpoR stimulation, but its function in erythropoiesis has been unclear since adult Stat5a(-/-)5b(-/-) mice have normal steady-state hematocrit. Here we show that Stat5 is essential for the high erythropoietic rate during fetal development. Stat5a(-/-)5b(-/-) embryos are severely anemic; erythroid progenitors are present in low numbers, show higher levels of apoptosis, and are less responsive to Epo. These findings are explained by a crucial role for Stat5 in EpoR's antiapoptotic signaling: it mediates the immediate-early induction of Bcl-X-L in erythroid cells through direct binding to the Bcl-X promoter.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Socolovsky, Merav/0000-0001-6747-7960	NHLBI NIH HHS [HL 32262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; CROIZAT H, 1990, BLOOD, V75, P1006; Erslev AF, 1995, WILLIAMS HEMATOLOGY, P441; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; GREGORY T, 1999, IN PRESS BLOOD; Grillot DAM, 1997, J IMMUNOL, V158, P4750; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LANDSCHULZ KT, 1992, BLOOD, V79, P2749; LIN EY, 1993, J IMMUNOL, V151, P1979; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Palis J, 1998, BLOOD REV, V12, P106, DOI 10.1016/S0268-960X(98)90022-4; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RUSSELL ELIZABETH S., 1966, P351; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	42	592	605	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					181	191		10.1016/S0092-8674(00)81013-2	http://dx.doi.org/10.1016/S0092-8674(00)81013-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428030	Bronze			2022-12-01	WOS:000081632300008
J	Uhlmann, F; Lottspeich, F; Nasmyth, K				Uhlmann, F; Lottspeich, F; Nasmyth, K			Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; FISSION YEAST; BUDDING YEAST; CELL-CYCLE; STRUCTURAL MAINTENANCE; CUT2 PROTEOLYSIS; CHROMOSOMES; PROTEINS	Cohesion between sister chromatids is established during DNA replication and depends on a multiprotein complex called cohesin. Attachment of sister kinetochores to the mitotic spindle during mitosis generates forces that would immediately split sister chromatids were it not opposed by cohesion. Cohesion is essential for the alignment of chromosomes in metaphase but must be abolished for sister separation to start during anaphase. In the budding yeast Saccharomyces cerevisiae, loss of sister-chromatid cohesion depends on a separating protein (separin) called Esp 1 and is accompanied by dissociation from the chromosomes of the cohesion subunit Scc1. Here we show that Esp1 causes the dissooiation of Scc1 from chromosomes by stimulating its cleavage by proteolysis. A mutant Scc1 is described that is resistant to Esp1-dependent cleavage and which blocks both sister-chromatid separation and the dissociation of Scc1 from chromosomes. The evolutionary conservation of separins indicates that the proteolytic cleavage of cohesion proteins might be a general mechanism for triggering anaphase.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Nasmyth, Kim/0000-0001-7030-4403; Uhlmann, Frank/0000-0002-3527-6619				Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; ECKERSKORN C, 1993, ELECTROPHORESIS, V14, P831, DOI 10.1002/elps.11501401133; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LIN Y, 1992, GENETICS, V132, P75; LOSADA A, 1998, GENE DEV, V12, P1003; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Rose M, 1990, LAB COURSE MANUAL ME; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99	37	740	754	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					37	42		10.1038/21831	http://dx.doi.org/10.1038/21831			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403247				2022-12-01	WOS:000081255700042
J	Wan, JJ; Poo, MM				Wan, JJ; Poo, MM			Activity-induced potentiation of developing neuromuscular synapses	SCIENCE			English	Article							LONG-TERM POTENTIATION; CALCIUM-RELEASE CHANNEL; HETEROSYNAPTIC SUPPRESSION; SARCOPLASMIC-RETICULUM; SYNAPTIC TRANSMISSION; SILENT SYNAPSES; SKELETAL-MUSCLE; DEPRESSION; CALMODULIN; PROTEIN	Electrical activity plays a critical role in shaping the structure and function of synaptic connections in the nervous system. In Xenopus nerve-muscle cultures, a brief burst of action potentials in the presynaptic neuron induced a persistent potentiation of neuromuscular synapses that exhibit immature synaptic functions. Induction of potentiation required an elevation of postsynaptic Ca2+ and expression of potentiation appeared to involve an increased probability of transmitter secretion from the presynaptic nerve terminal. Thus, activity-dependent persistent synaptic enhancement may reflect properties characteristic of immature synaptic connections, and bursting activity in developing spinal neurons may promote functional maturation of the neuromuscular synapse.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CHOW I, 1985, J NEUROSCI, V5, P1076; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; EVERS J, 1989, J NEUROSCI, V9, P1523; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KIDOKORO Y, 1982, P NATL ACAD SCI-BIOL, V79, P6727, DOI 10.1073/pnas.79.21.6727; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KULLBERG RW, 1977, DEV BIOL, V60, P101, DOI 10.1016/0012-1606(77)90113-0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LANDMESSER LT, 1984, J PHYSIOL-LONDON, V347, P189, DOI 10.1113/jphysiol.1984.sp015061; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Donovan MJ, 1998, ANN NY ACAD SCI, V860, P130; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; Tabti N, 1998, CULTURING NERVE CELL, P237; WAN J, UNPUB; XIE Z, 1986, P NATL ACAD SCI USA, V83, P4069; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	35	30	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1725	1728		10.1126/science.285.5434.1725	http://dx.doi.org/10.1126/science.285.5434.1725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481007				2022-12-01	WOS:000082472600033
J	Powell, JW; Barber-Foss, KD				Powell, JW; Barber-Foss, KD			Traumatic brain injury in high school athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOTBALL PLAYERS; CONCUSSION	Context The potential seriousness of mild traumatic brain injury (MTBI) is increasingly recognized; however, information on the frequency of MTBI among high school athletes is limited. Objective To identify the type, frequency, and severity of MTBI in selected high school sports activities. Design Observational cohort study.. Setting and Participants Two hundred forty-six certified athletic trainers recorded injury and exposure data for high school varsity athletes participating in boys' football, wrestling, baseball and field hockey, girls' volleyball and softball, boys' and girls' basketball, and boys' and girls' soccer at 235 US high schools during 1 or more of the 1995-1997 academic years. Main Outcome Measures Rates of reported MTBI, defined as a head-injured player who was removed from participation and evaluated by an athletic trainer or physician prior to returning to participation. National incidence figures for MTBI also were estimated. Results Of 23 566 reported injuries in the 10 sports during the 3-year study period, 1219 (5.5 %) were MTBIs. Of the MTBIs, football accounted for 773 (63.4%) of cases; wrestling, 128 (10.5%); girls' soccer, 76 (6.2%); boys' soccer, 69 (5.7%); girls' basketball, 63 (5.2%); boys' basketball, 51 (4.2%); softball, 25 (2.1%); baseball, 15 (1.2%); field hockey, 13 (1.1%); and volleyball, 6 (0.5%). The injury rates per 100 player-seasons were 3.66 for football, 1.58 for wrestling, 1.14 for girls' soccer, 1.04 for girls' basketball, 0.92 for boys' soccer, 0.75 for boys' basketball, 0.46 for softball, 0.46 for field hockey, 0.23 for baseball, and 0.14 for volleyball. The median time lost from participation for all MTBIs was 3 days. There were 6 cases of subdural hematoma and intracranial injury reported in football. Based on these data, an estimated 62 816 cases of MTBI occur annually among high school varsity athletes participating in these sports, with football accounting for about 63 % of cases. Conclusions Rates of MTBI vary among sports and none of the 10 popular high school sports we studied is without the occurrence of an MTBI. Continued involvement of high school sports sponsors, researchers, medical professionals, coaches, and sports participants is essential to help minimize the risk of MTBI.	Med Sports Syst, Iowa City, IA USA		Powell, JW (corresponding author), Michigan State Univ, Dept Kinesiol, IM Sports Circle, E Lansing, MI 48824 USA.							Barth J.T., 1989, MILD HEAD INJURY, P257; BUCKLEY WE, 1985, THESIS PENNSYLVANIA; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; CLARKE KS, 1979, MED SCI SPORTS EXERC, V2, P138; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; GAHLINGER PM, 1993, RATRES2 VERSION 1 4C; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; Kleinbaum D.G., 1982, EPIDEMIOLOGIC RES PR, P1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *NAT ATHL TRAIN AS, 1991, P MILD BRAIN INJ NAT; *NAT CTR ED STAT, 1994, US DHEW NCES PUBL; Powell JW, 1999, J ATHL TRAINING, V34, P277; POWELL JW, 1988, AM J SPORTS MED S, V16, P134; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1	21	408	413	0	59	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					958	963		10.1001/jama.282.10.958	http://dx.doi.org/10.1001/jama.282.10.958			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485681				2022-12-01	WOS:000082335900034
J	Chen, CC; Luo, CL; Wang, SJ; Chern, CM; Fuh, JL; Lin, SH; Hu, HH				Chen, CC; Luo, CL; Wang, SJ; Chern, CM; Fuh, JL; Lin, SH; Hu, HH			Colour doppler imaging for diagnosis of intracranial hypotension	LANCET			English	Article							BLOOD-FLOW; ENHANCEMENT; HEADACHES; ANATOMY; ORBIT	Background Measurement of CSF pressure is the only known way to confirm the diagnosis of intracranial hypotension. We aimed to assess colour doppler flow imaging (CDFI) for measurement of blood flow of the superior ophthalmic vein for the diagnosis of intracranial hypotension. Methods We enrolled 25 consecutive patients with orthostatic headache who had clinical features of intracranial hypotension. We defined low-pressure headache as cerebrospinal-fluid pressure below 60 mm H2O. We used CDFI to measure the diameter and maximum flow velocity of the superior ophthalmic vein in all patients. Magnetic resonance imaging of the brain and lumbar puncture with measurement of cerebrospinal-fluid pressure within 24 h were also done after sonographic examination. The control group comprised 13 healthy individuals of a similar age; in addition, those patients who had orthostatic headache without low pressure served as a control group for the patients. Findings Of the 25 patients recruited for this study, 13 satisfied the criteria for low-pressure headache. The remaining 12 patients with normal cerebrospinal-fluid pressure had transformed migraine (five patients) or chronic tension-type headache (seven patients), and therefore served as the control group for the patients. The mean diameter of the superior ophthalmic vein was substantially larger in the patients with intracranial hypotension (3.9 [SD 0.2] mm) than in the healthy controls (2.6 [0.4] mm) and the controls from the patients' group (2.7 [0.2] mm) (p<0.0001). The mean maximum flow velocity was significantly higher in the intracranial-hypotension group (17.0 [SD 3.4] cm/s) than in the healthy controls (7.9 [1.1] cm/s) and the other patients (7.3 [1.7] cm/s) (p<0.0001). Seven patients with intracranial hypotension were reassessed after treatment with epidural blood patch. After this treatment the clinical symptoms were relieved and there was a striking reversal of the superior ophthalmic vein flow. Interpretation CDFI to measure blood flow of the superior ophthalmic vein provides a practical, simple, and non-invasive diagnostic method for suspected intracranial hypotension.	Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Anesthesiol, Taipei, Taiwan	National Yang Ming Chiao Tung University	Hu, HH (corresponding author), Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan.			Fuh, Jong-Ling/0000-0001-9135-3351				Benzon HT, 1996, ANESTHESIOLOGY, V85, P920, DOI 10.1097/00000542-199610000-00029; Blank SC, 1997, CLIN NEUROL NEUROSUR, V99, P199, DOI 10.1016/S0303-8467(97)00015-2; CARRIE LES, 1993, BRIT J ANAESTH, V71, P179, DOI 10.1093/bja/71.2.179; Costa VP, 1997, J CLIN ULTRASOUND, V25, P448, DOI 10.1002/(SICI)1097-0096(199710)25:8<448::AID-JCU7>3.0.CO;2-J; ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264; Ettl A, 1997, OPHTHALMOLOGY, V104, P869, DOI 10.1016/S0161-6420(97)30219-X; FISHMAN RA, 1993, NEUROLOGY, V43, P609, DOI 10.1212/WNL.43.3_Part_1.609; Fishman RA, 1992, CEREBROSPINAL FLUID, P71; GUILIONI M, 1988, NEUROSURGERY, V22, P807; HIRASHITA M, 1992, EUR J APPL PHYSIOL, V64, P92, DOI 10.1007/BF00376447; HU HH, 1993, STROKE, V24, P1196, DOI 10.1161/01.STR.24.8.1196; Khanna RK, 1997, J NEUROSURG, V86, P893, DOI 10.3171/jns.1997.86.5.0893; Klotzsch C, 1996, NEURORADIOLOGY, V38, P555; LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036; MOKRI B, 1995, NEUROLOGY, V45, P1801, DOI 10.1212/WNL.45.10.1801; Mokri B, 1997, MAYO CLIN PROC, V72, P400, DOI 10.4065/72.5.400; Mokri B, 1998, NEUROLOGY, V51, P786, DOI 10.1212/WNL.51.3.786; POMERANZ S, 1993, ACTA NEUROCHIR, V122, P113, DOI 10.1007/BF01446996; Schievink WI, 1996, J NEUROSURG, V84, P598, DOI 10.3171/jns.1996.84.4.0598; Silberstein SD, 1996, NEUROLOGY, V47, P871, DOI 10.1212/WNL.47.4.871; Spektor S, 1997, NEUROSURGERY, V40, P532, DOI 10.1097/00006123-199703000-00022	21	31	32	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					826	829						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485725				2022-12-01	WOS:000082400700012
J	Tang, YP; Shimizu, E; Dube, GR; Rampon, C; Kerchner, GA; Zhuo, M; Liu, GS; Tsien, JZ				Tang, YP; Shimizu, E; Dube, GR; Rampon, C; Kerchner, GA; Zhuo, M; Liu, GS; Tsien, JZ			Genetic enhancement of learning and memory in mice	NATURE			English	Article							LONG-TERM POTENTIATION; HETEROMERIC NMDA RECEPTORS; SYNAPTIC PLASTICITY; GLUTAMATE RECEPTORS; VISUAL-CORTEX; HIPPOCAMPUS; BRAIN; FEAR; ANTAGONIST; AMYGDALA	Hebb's rule (1949) states that learning and memory are based on modifications of synaptic strength among neurons that are simultaneously active. This implies that enhanced synaptic coincidence detection would lead to better learning and memory. If the NMDA (N-methyl-D-aspartate) receptor, a synaptic coincidence detector(1-4), acts as a graded switch for memory formation, enhanced signal detection by NMDA receptors should enhance learning and memory. Here we show that overexpression of NMDA receptor 2B (NR2B) in the forebrains of transgenic mice leads to enhanced activation of NMDA receptors, facilitating synaptic potentiation in response to stimulation at 10-100 Hz. These mice exhibit superior ability in learning and memory in various behavioural tasks, showing that NR2B is critical in gating the age-dependent threshold for plasticity and memory formation. NMDA-receptor-dependent modifications of synaptic efficacy, therefore, represent a unifying mechanism for associative learning and memory. Our results suggest that genetic enhancement of mental and cognitive attributes such as intelligence and memory in mammals is feasible.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; MIT, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurobiol, St Louis, MO 63110 USA	Princeton University; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); Washington University (WUSTL)	Tsien, JZ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Tang, Ya-Ping/A-1035-2011; Zhuo, Min/A-2072-2008; Shimizu, Eiji/K-4637-2017	Zhuo, Min/0000-0001-9062-3241; Shimizu, Eiji/0000-0002-6741-9338; rampon, claire/0000-0001-8551-8682				Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; DAVIS M, 1987, PSYCHOL LEARNING MEM; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FALLS WA, 1992, J NEUROSCI, V12, P854; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; KONISHI M, 1989, NEURON, V3, P541, DOI 10.1016/0896-6273(89)90264-X; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Morris RG, 1982, NATURE, V2, P681; Mumby DG, 1996, BEHAV NEUROSCI, V110, P266, DOI 10.1037/0735-7044.110.2.266; MYHRER T, 1988, BEHAV NEUROSCI, V102, P356, DOI 10.1037/0735-7044.102.3.356; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Okabe S, 1998, J NEUROSCI, V18, P4177; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Reed JM, 1997, BEHAV NEUROSCI, V111, P667, DOI 10.1037/0735-7044.111.4.667; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Stevens CF, 1998, CURR BIOL, V8, pR151, DOI 10.1016/S0960-9822(98)70097-1; STUBLI U, 1996, J NEUROSCI, V16, P853; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7	30	1434	1541	3	190	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					63	69		10.1038/43432	http://dx.doi.org/10.1038/43432			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485705				2022-12-01	WOS:000082374400041
J	Clemons, WM; May, JLC; Wimberly, BT; McCutcheon, JP; Capel, MS; Ramakrishnan, V				Clemons, WM; May, JLC; Wimberly, BT; McCutcheon, JP; Capel, MS; Ramakrishnan, V			Structure of a bacterial 30S ribosomal subunit at 5.5 angstrom resolution	NATURE			English	Article							RNA-BINDING-SITE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; PROTEIN S15; CRYSTAL-STRUCTURE; BACILLUS-STEAROTHERMOPHILUS; NMR-SPECTROSCOPY; CROSS-LINKING; MESSENGER-RNA; 16S RNA	The 30S ribosomal subunit binds messenger RNA and the anticodon stem-loop of transfer RNA during protein synthesis. A crystallographic analysis of the structure of the subunit from the bacterium Thermos thermophilus is presented, At a resolution of 5.5 Angstrom, the phosphate backbone of the ribosomal RNA is visible, as are the cu-helices of the ribosomal proteins, enabling double-helical regions of RNA to be identified throughout the subunit, all seven of the small-subunit proteins of known crystal structure to be positioned in the electron density map, and the fold of the entire central domain of the small-subunit ribosomal RNA to be determined.	MRC, Mol Biol Lab, Structural Studies Div, Cambridge CB2 2QH, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84103 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	MRC Laboratory Molecular Biology; Utah System of Higher Education; University of Utah; United States Department of Energy (DOE); Brookhaven National Laboratory	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Structural Studies Div, Hills Rd, Cambridge CB2 2QH, England.		Clemons, William M/D-1026-2009	Clemons, William M/0000-0002-0021-889X; Ramakrishnan, V/0000-0002-4699-2194; McCutcheon, John/0000-0002-5489-6039	NIGMS NIH HHS [F31 GM019384] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM019384] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agafonov DE, 1997, P NATL ACAD SCI USA, V94, P12892, DOI 10.1073/pnas.94.24.12892; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Alberts B, 1995, MOL BIOL CELL; ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; ALLEN G, 1979, J BIOL CHEM, V254, P9800; ATMADJA J, 1986, NUCLEIC ACIDS RES, V14, P659, DOI 10.1093/nar/14.2.659; Batey RT, 1996, J MOL BIOL, V261, P536, DOI 10.1006/jmbi.1996.0481; Berglund H, 1997, NAT STRUCT BIOL, V4, P20, DOI 10.1038/nsb0197-20; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; Davies C, 1996, STRUCTURE, V4, P1093, DOI 10.1016/S0969-2126(96)00115-3; GREGORY RJ, 1984, J MOL BIOL, V178, P287, DOI 10.1016/0022-2836(84)90145-1; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; Jaishree TN, 1996, BIOCHEMISTRY-US, V35, P2845, DOI 10.1021/bi951062i; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kalurachchi K, 1997, P NATL ACAD SCI USA, V94, P2139, DOI 10.1073/pnas.94.6.2139; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Lee KS, 1997, J MOL BIOL, V269, P732, DOI 10.1006/jmbi.1997.1092; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Markus MA, 1998, EMBO J, V17, P4559, DOI 10.1093/emboj/17.16.4559; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Moine H, 1997, RNA, V3, P255; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Nevskaya N, 1998, J MOL BIOL, V279, P233, DOI 10.1006/jmbi.1998.1758; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POWERS T, 1995, RNA, V1, P194; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; RAMAKRISHNAN VR, 1981, J MOL BIOL, V153, P739, DOI 10.1016/0022-2836(81)90416-2; Serganov AA, 1996, RNA, V2, P1124; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRAKHANOV SD, 1987, FEBS LETT, V220, P319, DOI 10.1016/0014-5793(87)80838-4; UNGEWICKELL E, 1975, EUR J BIOCHEM, V51, P165, DOI 10.1111/j.1432-1033.1975.tb03917.x; Urlaub H, 1997, J BIOL CHEM, V272, P14547, DOI 10.1074/jbc.272.23.14547; VANACKEN U, 1975, MOL GEN GENET, V140, P61, DOI 10.1007/BF00268989; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WINBERLY BT, 1997, STRUCTURE, V5, P1187; WITTMANNLIEBOLD B, 1978, FEBS LETT, V95, P91, DOI 10.1016/0014-5793(78)80059-3; WU H, 1994, NUCLEIC ACIDS RES, V22, P1687, DOI 10.1093/nar/22.9.1687; YONATH A, 1988, J MOL BIOL, V203, P831, DOI 10.1016/0022-2836(88)90216-1; Yonath A, 1998, ACTA CRYSTALLOGR A, V54, P945, DOI 10.1107/S010876739800991X; YUSUPOV MM, 1988, FEBS LETT, V238, P113, DOI 10.1016/0014-5793(88)80237-0	50	305	328	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					833	840		10.1038/23631	http://dx.doi.org/10.1038/23631			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476960				2022-12-01	WOS:000082233200035
J	Forrester, WC; Dell, M; Perens, E; Garriga, G				Forrester, WC; Dell, M; Perens, E; Garriga, G			A C-elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NEUROMUSCULAR-JUNCTION; GENES; MIGRATION; LINEAGE; FAMILY; MUSK	Ror kinases are a family of orphan receptors with tyrosine kinase activity that are related to muscle specific kinase (MuSK), a receptor tyrosine kinase that assembles acetylcholine receptors at the neuromuscular junction(1,2). Although the functions of Ror kinases are unknown, similarities between Ror and MuSK kinases have led to speculation that Ror kinases regulate synaptic development. Here we show that the Caenorhabditis elegans gene cam-1 encodes a member of the Ror kinase family that guides migrating cells and orients the polarity of asymmetric cell divisions and axon outgrowth. We find that tyrosine kinase activity is required for some of the functions of CAM-1, but not for its role in cell migration. CAM-1 is expressed in cells that require its function, and acts cell autonomously in migrating neurons. Overexpression and loss of cam-1 function result in reciprocal cell-migration phenotypes, indicating that levels of CAM-1 influence the final positions of migrating cells. Our results raise the possibility that Ror kinases regulate cell motility and asymmetric cell division in organisms as diverse as nematodes and mammals.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Garriga, G (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.			Perens, Elliot/0000-0003-3377-7708				Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Forrester WC, 1997, DEVELOPMENT, V124, P1831; Forrester WC, 1998, GENETICS, V148, P151; HANKS SK, 1988, SCIENCE, V241, P47; Hawkins N, 1998, GENE DEV, V12, P3625, DOI 10.1101/gad.12.23.3625; HEDECOCK EM, 1995, GENETICS, V141, P989; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HERMAN RK, 1984, GENETICS, V108, P165; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	25	130	135	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					881	885		10.1038/23722	http://dx.doi.org/10.1038/23722			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476968				2022-12-01	WOS:000082233200048
J	Miotti, PG; Taha, TET; Kumwenda, NI; Broadhead, R; Mtimavalye, LAR; Van der Hoeven, L; Chiphangwi, JD; Liomba, G; Biggar, RJ				Miotti, PG; Taha, TET; Kumwenda, NI; Broadhead, R; Mtimavalye, LAR; Van der Hoeven, L; Chiphangwi, JD; Liomba, G; Biggar, RJ			HIV transmission through breastfeeding - A study in Malawi	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; BREAST-MILK; POSTNATAL TRANSMISSION; HIV-1-INFECTED WOMEN; P24 ANTIGEN; MOTHER; TYPE-1; INFECTION; COHORT	Context Understanding the risk of human immunodeficiency virus (HIV) transmission through breastfeeding is essential for advising HIV-infected mothers and formulating public health policy recommendations. Objective To measure the frequency, timing, and risk factors of HIV transmission through breast milk. Design Prospective cohort study conducted between 1994 and 1997, with follow-up of infants through 24 months of age. Setting Postnatal clinic of tertiary care hospital, Blantyre, Malawi. Participants A total of 672 infants (HIV-negative at birth) born to HIV-infected women who had not received antiretroviral drugs during or after pregnancy. Main Outcome Measure Incidence of HIV in breastfed infants by age and maternal and infant risk factors for HIV transmission, using proportional hazard models to derive risk ratios (RRs) and 95% confidence intervals (Cls). Results Forty-seven children became HIV-infected while breastfeeding but none after breastfeeding had stopped. The cumulative infection rate while breastfeeding, from month 1 to the end of months 5, 11, 17, and 23, was 3.5%, 7.0%, 8.9%, and 10.3 %, respectively. Incidence per month was 0.7% during age 1 to 5 months, 0.6% during age 6 to 11 months, and 0.3% during age 12 to 17 months (P = .01 for trend). The only factors significantly associated with low risk of postnatal HIV transmission in a multivariate model were high maternal parity (RR, 0.23; 95% CI, 0.09-0.56) and older maternal age (RR, 0.44; 95% CI, 0.23-0.84), Conclusions Our data suggest that the risk of HIV infection is highest in the early months of breastfeeding, which should be considered in formulating breastfeeding policy recommendations.	Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Malawi Coll Med, Blantyre, Malawi; NCI, NIH, Bethesda, MD USA	Johns Hopkins University; University of Malawi; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miotti, PG (corresponding author), NIAID, Div Aids, NIH, Room 4109,6700 B Rockledge Dr,MSC 7626, Bethesda, MD 20892 USA.	pm122m@nih.gov	Kumwenda, Newton/ADL-6890-2022	Kumwenda, Newton/0000-0003-2622-4339; Taha, Taha/0000-0001-9814-4894	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173, Z01AI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-35173-117] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Biggar RJ, 1997, J ACQ IMMUN DEF SYND, V14, P368, DOI 10.1097/00042560-199704010-00010; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; BULTERYS M, 1995, AIDS, V9, P93; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Guay LA, 1996, PEDIATRICS, V98, P438; John GC, 1996, EPIDEMIOL REV, V18, P149, DOI 10.1093/oxfordjournals.epirev.a017922; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; LAWRENCE R, 1994, BREASTFEEDING GUIDE, P28; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Lewis P, 1998, J INFECT DIS, V177, P34, DOI 10.1086/513816; NAGELKERKE NJD, 1995, J ACQ IMMUN DEF SYND, V8, P176; NDUATI RW, 1995, J INFECT DIS, V172, P1461, DOI 10.1093/infdis/172.6.1461; NDUATI RW, 1994, LANCET, V344, P1432, DOI 10.1016/S0140-6736(94)90596-7; NDUATI RW, 1998, 12 WORLD AIDS C JUN; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; RUFF AJ, 1994, J ACQ IMMUN DEF SYND, V7, P68; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Southern S O, 1998, J Hum Virol, V1, P328; Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; *UNICEF UNAIDS WHO, 1998, HIV INF FEED IMPL GU; VANDEPERRE P, 1993, LANCET, V341, P914, DOI 10.1016/0140-6736(93)91210-D; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VandePerre P, 1997, LANCET, V350, P221, DOI 10.1016/S0140-6736(05)62390-2	33	232	241	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					744	749		10.1001/jama.282.8.744	http://dx.doi.org/10.1001/jama.282.8.744			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463709	Bronze			2022-12-01	WOS:000082118800025
J	Sauer, FG; Futterer, K; Pinkner, JS; Dodson, KW; Hultgren, SJ; Waksman, G				Sauer, FG; Futterer, K; Pinkner, JS; Dodson, KW; Hultgren, SJ; Waksman, G			Structural basis of chaperone function and pilus biogenesis	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; PAPD CHAPERONE; SUBUNIT RECOGNITION; OUTER-MEMBRANE; PROTEIN; CRYSTALLOGRAPHY; ASSOCIATION; SUPERFAMILY; REFINEMENT; URINARY	Many Gram-negative pathogens assemble architecturally and functionally diverse adhesive pill on their surfaces by the chaperone-usher pathway, Immunoglobulin-like periplasmic chaperones escort pilus subunits to the usher, a large protein complex that facilitates the translocation and assembly of subunits across the outer membrane. The crystal structure of the PapD-PapK chaperone-subunit complex, determined at 2.4 angstrom resolution, reveals that the chaperone functions by donating its G(1) beta strand to complete the immunoglobulin-like fold of the subunit via a mechanism termed donor strand complementation. The structure of the PapD-PapK complex also suggests that during pilus biogenesis, every subunit completes the immunoglobulin-like fold of its neighboring subunit via a mechanism termed donor strand exchange.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Futterer, Klaus/0000-0001-7445-5372	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NIGMS NIH HHS [R01GM54033] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1996, ACTA CRYSTALLOGR D, V52, P32; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Bullitt E, 1996, P NATL ACAD SCI USA, V93, P12890, DOI 10.1073/pnas.93.23.12890; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1996, ESCHERICHIA COLI SAL, P2730; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P23; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; STRIKER R, 1995, MOL MICROBIOL, V16, P1021, DOI 10.1111/j.1365-2958.1995.tb02327.x; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146	36	326	340	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1058	1061		10.1126/science.285.5430.1058	http://dx.doi.org/10.1126/science.285.5430.1058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446050				2022-12-01	WOS:000082033100043
J	Yu, W; Nagaoka, H; Jankovic, M; Misulovin, Z; Suh, HY; Rolink, A; Melchers, F; Meffre, E; Nussenzweig, MC				Yu, W; Nagaoka, H; Jankovic, M; Misulovin, Z; Suh, HY; Rolink, A; Melchers, F; Meffre, E; Nussenzweig, MC			Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization	NATURE			English	Article							V(D)J RECOMBINATION; TRANSGENIC MICE; BONE-MARROW; RECEPTOR; GENE; LYMPHOCYTES; TOLERANCE; ANTIBODY; MOUSE; ELIMINATION	Models of B-cell-development in the immune system suggest that only those immature B cells in the bone marrow that undergo receptor editing express V(D)J-recombination-activating genes (RAGs)(1-3). Here we investigate the regulation of RAG expression in transgenic mice carrying a bacterial artificial chromosome that encodes a green fluorescent. protein reporter instead of RAG2 (ref. 4). We find that the reporter is expressed in all immature B cells in the bone marrow and spleen. Endogenous RAG messenger RNA is expressed in immature beeps in bone marrow and spleen and decreases by two orders of magnitude as they acquire higher levels of surface immunoglobulin M (IgM). Once RAG expression is stopped it is not re-induced during immune responses. Our findings may help to reconcile a series of apparently contradictory observations, and suggest a new model for the mechanisms that regulate allelic exclusion, receptor editing and tolerance.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Inst Mol Genet & Genet Engn, YU-11001 Belgrade, Yugoslavia; Basel Inst Immunol, CH-4005 Basel, Switzerland	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@rockvax.rockfeller.edu	Nussenzweig, Michel/AAE-7292-2019					ALLMAN DM, 1992, J IMMUNOL, V149, P2533; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; STORB U, 1995, IMMUNOGLOBULIN GENES, P345; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859	30	318	323	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					682	687		10.1038/23287	http://dx.doi.org/10.1038/23287			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458165				2022-12-01	WOS:000082032900058
J	Kidd, FL; Isaac, JTR				Kidd, FL; Isaac, JTR			Developmental and activity-dependent regulation of kainate receptors at thalamocortical synapses	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL INTERNEURONS; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; CRITICAL PERIOD; AMPA RECEPTORS; ACTIVATION; NEURONS; CORTEX; RECTIFICATION	Most of the fast excitatory synaptic transmission in the mammalian brain is mediated by ionotrophic glutamate receptors, of which there are three subtypes: AMPA (alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate), NMDA (N-methyl-D-aspartate) and kainate. Although kainate-receptor subunits (GluR5-7, KA1 and 2) are widely expressed in the mammalian central nervous system(1,2), little is known about their function. The development of pharmacological agents that distinguish between AMPA and kainate receptors has now allowed the functions of kainate receptors to be investigated(3,4). The modulation of synaptic transmission by kainate receptors(5-7) and their synaptic activation(8-14) in a variety of brain regions have been reported. The expression of kainate receptor subunits is developmentally regulated(1,2) but their role in plasticity and development is unknown. Here we show that developing thalamocortical synapses express postsynaptic kainate receptors as well as AMPA receptors; however, the two receptor subtypes do not colocalize. During the critical period for experience-dependent plasticity, the kainate-receptor contribution to transmission decreases; a similar decrease occurs when long-term potentiation is induced in vitro. This indicates that during development there is activity-dependent regulation of the expression of kainate receptors at thalamocortical synapses.	Univ Bristol, MRC, Ctr Synapt Plast, Dept Anat, Bristol BS8 1TD, Avon, England	University of Bristol	Isaac, JTR (corresponding author), Univ Bristol, MRC, Ctr Synapt Plast, Dept Anat, Bristol BS8 1TD, Avon, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DeVries SH, 1999, NATURE, V397, P157, DOI 10.1038/16462; Feldman DE, 1998, NEURON, V21, P347, DOI 10.1016/S0896-6273(00)80544-9; FOX K, 1995, NEURON, V15, P485, DOI 10.1016/0896-6273(95)90136-1; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; Li P, 1999, NATURE, V397, P161, DOI 10.1038/16469; Paternain AV, 1998, NEUROPHARMACOLOGY, V37, P1249, DOI 10.1016/S0028-3908(98)00098-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Rozov A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/j.1469-7793.1998.361bh.x; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Washburn MS, 1997, J NEUROSCI, V17, P9393; WILDING TJ, 1995, MOL PHARMACOL, V47, P582	30	187	189	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					569	573		10.1038/23040	http://dx.doi.org/10.1038/23040			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448859				2022-12-01	WOS:000081854800057
J	Cook, PJ; Lawrence, BA; Ludwig, J; Miller, TR				Cook, PJ; Lawrence, BA; Ludwig, J; Miller, TR			The medical costs of gunshot injuries in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIREARM-RELATED INJURIES; WOUNDS; HOSPITALIZATION; CHARGES	Context The cost of treating gunshot injuries imposes a financial burden on society. Estimates of such costs are relevant to evaluation of gun violence reduction programs and may help guide reimbursement policies. Objectives To develop reliable US estimates of the medical costs of treating gunshot injuries and to present national estimates for the sources of payment for treating these injuries. Design and Setting Cost analysis using E-coded discharge data from hospitals in Maryland for 1994-1995 and New York for 1994 and from emergency departments in South Carolina for 1997, Other sources of data included the National Electronic Injury Surveillance System for 1994 incidence of nonfatal gun injuries, the National Spinal Cord Injury Statistical Center database for 1988-1992 estimates of lifetime medical costs of gun injuries, and the 1994 Vital Statistics census for incidence of fatal gun injuries. Main Outcome Measures Estimated national acute-care and follow-up treatment costs and payment sources for gunshot injuries. Results At a mean medical cost per injury of about $17 000, the 134 445 (95% confidence interval [CI], 109 465-159 425) gunshot injuries in the United States in 1994 produced $2.3 billion (95% CI, $2.1 billion-$2.5 billion) in lifetime medical costs (in 1994 dollars, using a 3% real discount rate), of which $1.1 billion (49%) was paid by US taxpayers. Gunshot injuries due to assaults accounted for 74% of total costs. Conclusions Gunshot injury costs represent a substantial burden to the medical care system. Nearly half this cost is borne by US taxpayers.	Duke Univ, Sanford Inst Publ Policy, Durham, NC 27708 USA; Natl Publ Serv Res Inst, Landoven, MD USA; Georgetown Univ, Georgetown Publ Policy Inst, Washington, DC USA	Duke University; Georgetown University	Cook, PJ (corresponding author), Duke Univ, Sanford Inst Publ Policy, Durham, NC 27708 USA.			Cook, Philip/0000-0001-5094-9052; Miller, Ted/0000-0002-0958-2639				ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRICK M, 1992, STAT EVALUATION COST; *BUR CENS, 1998, 1994 VIT STAT CENS D, P109; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; DISCHINGER PC, 1992, AM PUBL HLTH ASS NOV; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lipscomb J, 1996, COST EFFECTIVENESS H, P214; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HLTH AFF MILLWOOD, V12, P17; Miller TR, 1997, ACCIDENT ANAL PREV, V29, P329, DOI 10.1016/S0001-4575(97)00007-9; MILLER TR, 1989, ACCIDENT ANAL PREV, V21, P303, DOI 10.1016/0001-4575(89)90022-5; MILLER TR, 1995, DATABOOK NONFATAL IN; Miller TR, 1996, TXB PENETRATING TRAU, P49; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; MORABITO D, 1989, REPORT CALIFORNIA DE; *NAT CTR HLTH CAR, 1992, NAT HOSP DISCH SURV; *NAT HIGHW TRANSP, 1983, EC COSTS SOC MOT VEH; Roberts RR, 1999, JAMA-J AM MED ASSOC, V281, P644, DOI 10.1001/jama.281.7.644; U. S. Bureau of the Census, 1996, STAT ABSTR US 1996; Vassar MJ, 1996, JAMA-J AM MED ASSOC, V275, P1734, DOI 10.1001/jama.275.22.1734; WEBSTER DW, 1992, ARCH SURG-CHICAGO, V127, P694; WEISSMAN JS, 1992, HEALTH AFFAIR, V11, P148, DOI 10.1377/hlthaff.11.2.148; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; [No title captured]	26	104	104	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					447	454		10.1001/jama.282.5.447	http://dx.doi.org/10.1001/jama.282.5.447			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442660	Bronze			2022-12-01	WOS:000081784900021
J	Watanabe, Y; Nurse, P				Watanabe, Y; Nurse, P			Cohesin Rec8 is required for reductional chromosome segregation at meiosis	NATURE			English	Article							SISTER-CHROMATID COHESION; YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; ANAPHASE TRANSITION; GENE; RECOMBINATION; CENTROMERES; METAPHASE; NUCLEAR; RAD21	When cells exit from mitotic cell division, their sister chromatids lose cohesion and separate to opposite poles of the dividing cell, resulting in equational chromosome segregation. In contrast, the reductional segregation of the first stage of meiotic cell division (meiosis I) requires that sister chromatids remain associated through their centromeres and move together to the same pole. Centromeric cohesion is lost as cells exit from meiosis II and sister chromatids can then separate(1-4). The fission yeast cohesin protein Reed is specific to and required for meiosis(5-8). Here we show that Rec8 appears in the centromeres and adjacent chromosome arms during the pre-meiotic S phase. Centromeric Red persists throughout meiosis I and disappears at anaphase of meiosis II. When the rec8 gene is deleted, sister chromatids separate at meiosis I, resulting in equational rather than reductional chromosome segregation. We propose that the persistence of Rec8 at centromeres during meiosis I maintains sister-chromatid cohesion, and that its presence in the centromere-adjacent regions orients the kinetochores so that sister chromatids move to the same pole. This results in the reductional pattern of chromosome segregation necessary to reduce a diploid zygote to haploid gametes.	Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan.	ywatanab@ims.u-tokyo.ac.jp		Watanabe, Yoshinori/0000-0002-5488-4812				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; KISHIDA M, 1994, CURR GENET, V25, P497, DOI 10.1007/BF00351668; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NAKASEKO Y, 1984, J BACTERIOL, V157, P334, DOI 10.1128/JB.157.1.334-336.1984; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4	29	417	433	4	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					461	464		10.1038/22774	http://dx.doi.org/10.1038/22774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440376				2022-12-01	WOS:000081715000053
J	Bhopal, R; Unwin, N; White, M; Yallop, J; Walker, L; Alberti, KGMM; Harland, J; Patel, S; Ahmad, N; Turner, C; Watson, B; Kaur, D; Kulkarni, A; Laker, M; Tavridou, A				Bhopal, R; Unwin, N; White, M; Yallop, J; Walker, L; Alberti, KGMM; Harland, J; Patel, S; Ahmad, N; Turner, C; Watson, B; Kaur, D; Kulkarni, A; Laker, M; Tavridou, A			Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK; MYOCARDIAL-INFARCTION; INSULIN RESISTANCE; ARTERY DISEASE; SOUTH ASIANS; PREVALENCE; BRADFORD; GLUCOSE; OBESITY; CHINESE	Objective To compare coronary risk factors and disease prevalence among Indians, Pakistanis, and Bangladeshis, and in all South Asians (these three groups together) with Europeans. Design Cross sectional survey. Setting Newcastle upon Tyne. Participants 259 Indian, 305 Pakistani, 120 Bangladeshi, and 825 European men and women aged 25-74 years. Main outcome measures Social and economic circumstances, lifestyle, self reported symptoms and diseases, blood pressure, electrocardiogram, and anthropometric, haematological, and biochemical measurements. Results There were differences in social and economic circumstances, lifestyles, anthropometric measures and disease both bet tween Indians, Pakistanis, and Bangladeshis and between all South Asians and Europeans. Bangladeshis and Pakistanis were the poorest groups. For most risk factors, the Bangladeshis (particularly men) fared the worst: smoking was most common (57%) in that group, and Bangladeshis had the highest concentrations of triglycerides (2.04 mmol/l) and fasting blood glucose (6.6 mmol/l) and the lowest concentration of high density lipoprotein cholesterol (0.97 mmol/l). Blood pressure, however, was lowest in Bangladeshis. Bangladeshis were the shortest(men 164 cm tall v 170 cm for Indians and 174 cm for Europeans). A higher proportion of Pakistani and Bangladeshi men had diabetes (22.4% and 26.6% respectively) than Indians (15.2%). Comparisons of all South Asians with Europeans hid some important differences, but South Asians were still disadvantaged in a wide range of risk factors. Findings in women were similar. Conclusion Risk of coronary heart disease is not uniform among South Asians, and there are important differences between Indians, Pakistanis, and Bangladeshis for many coronary risk factors. The belief that, except for insulin resistance, South Asians have lo lower levels of coronary risk factors than Europeans is incorrect, and may have arisen fi om combining ethnic subgroups and examining a narrow range of factors.	Univ Newcastle Upon Tyne, Sch Med, Div Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Med, Wellcome Labs, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Epidemiol & Publ Hlth, Wellcome Labs, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Clin Biochem, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Bhopal, R (corresponding author), Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland.		White, Martin J. R./G-2410-2010	Unwin, Nigel/0000-0002-1368-1648; Patel, Sheila/0000-0002-0626-1899	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acheson D., 1998, INDEPENDENT INQUIRY; [Anonymous], 1992, STAT PACK SOC SCI SP; ARMITAGE P, 1994, STAT METHODS MED RES, P436; Balarajan R, 1996, HLTH TRENDS, V28, P45; Barker D. J. P., 1994, MOTHERS BABIES DIS L; *BEDF SCI, 1993, OPER MAN MIN MICR SM; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; Bhopal R, 1996, BRIT MED J, V312, P375; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; BURRIN JM, 1985, ANN CLIN BIOCHEM, V22, P327, DOI 10.1177/000456328502200401; Church J., 1996, SOCIAL FOCUS ETHNIC; COLDMAN AJ, 1988, J EPIDEMIOL COMMUN H, V42, P390, DOI 10.1136/jech.42.4.390; Coleman D, 1996, DEMOGRAPHIC CHARACTE; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOWLER PBS, 1985, LANCET, V2, P1363; GUPTA S, 1995, BRIT MED J, V311, P1035, DOI 10.1136/bmj.311.7012.1035; Harland JO, 1997, J EPIDEMIOL COMMUN H, V51, P636, DOI 10.1136/jech.51.6.636; HARRINGTON B, 1993, NEWCASTLE HLTH LIFES; HUGHES LO, 1989, BRIT MED J, V299, P537, DOI 10.1136/bmj.299.6698.537; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; KARN V, 1996, EMPLOYMENT ED HOUSIN; KNIGHT T, 1993, J EPIDEMIOL COMMUN H, V47, P89, DOI 10.1136/jech.47.2.89; KNIGHT TM, 1992, BRIT HEART J, V67, P343; MARMOT MG, 1984, STUDIES MED POPULATI; MCKEIGUE P, 1994, CORONARY HEART DIS S; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; Mendall MA, 1998, BRIT MED J, V316, P953, DOI 10.1136/bmj.316.7136.953; Modood T., 1997, ETHNIC MINORITIES BR; NATH BS, 1988, LANCET, V2, P39, DOI 10.1016/S0140-6736(88)92962-5; NAZROO JY, 1997, HLTH BRITAINS ETHNIC; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PEACH C, 1996, ETHNIC MINORITY POPU; PETRIE JC, 1990, RECOMMENDATIONS BLOO; Prineas R.J., 1982, MINNESOTA CODE MANUA; RAMAIYA KL, 1991, BRIT MED J, V303, P271, DOI 10.1136/bmj.303.6797.271; RATCLIFE P, 1996, SOCIAL GEOGRAPHY ETH; Rose G.A., 1982, CARDIOVASCULAR SURVE; Rudat K., 1994, BLACK MINORITY ETHNI; SHAUKAT N, 1994, POSTGRAD MED J, V70, P315, DOI 10.1136/pgmj.70.823.315; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160; *WHO MONICA PROJ, 1988, WORLD HLTH STAT Q, V41, P115; WILLIAMS R, 1993, J EPIDEMIOL COMMUN H, V47, P96, DOI 10.1136/jech.47.2.96; WILLIAMS R, 1994, INT J EPIDEMIOL, V23, P28, DOI 10.1093/ije/23.1.28	48	407	408	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					215	+		10.1136/bmj.319.7204.215	http://dx.doi.org/10.1136/bmj.319.7204.215			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417082	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000081720300021
J	Bader, M; Muse, W; Ballou, DP; Gassner, C; Bardwell, JCA				Bader, M; Muse, W; Ballou, DP; Gassner, C; Bardwell, JCA			Oxidative protein folding is driven by the electron transport system	CELL			English	Article							DISULFIDE BOND FORMATION; AEROBIC RESPIRATORY-CHAIN; BD TERMINAL OXIDASE; ESCHERICHIA-COLI; FORMATION INVIVO; IN-VIVO; ENDOPLASMIC-RETICULUM; DSBA; PURIFICATION; PATHWAY	Disulfide bond formation is catalyzed in vivo by DsbA and DsbB. Here we reconstitute this oxidative folding system using purified components. We have found the sources of oxidative power for protein folding and show how disulfide bond formation is linked to cellular metabolism. We find that disulfide bond formation and the electron transport chain are directly coupled. DsbB uses quinones as electron accepters, allowing various choices for electron transport to support disulfide bond formation. Electrons flow via cytochrome bo oxidase to oxygen under aerobic conditions or via cytochrome bd oxidase under partially anaerobic conditions. Under truly anaerobic conditions, menaquinone shuttles electrons to alternate final electron accepters such as fumarate. This flexibility reflects the vital nature of the disulfide catalytic system.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	dballou@umich.edu, David P/A-1298-2007					Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1999, NAT CELL BIOL, V1, pE57, DOI 10.1038/11025; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BELIN P, 1994, MOL GEN GENET, V242, P23, DOI 10.1007/BF00277344; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BULL C, 1981, J BIOL CHEM, V256, P2673; COTTER PA, 1990, J BACTERIOL, V172, P6333, DOI 10.1128/jb.172.11.6333-6338.1990; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Hennecke J, 1997, J BIOL CHEM, V272, P189; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KITA K, 1984, J BIOL CHEM, V259, P3368; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rumbley JN, 1997, BBA-PROTEIN STRUCT M, V1340, P131, DOI 10.1016/S0167-4838(97)00036-8; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zeng H, 1998, J BACTERIOL, V180, P3681, DOI 10.1128/JB.180.14.3681-3685.1998	34	308	321	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					217	227		10.1016/S0092-8674(00)81016-8	http://dx.doi.org/10.1016/S0092-8674(00)81016-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428033	Bronze			2022-12-01	WOS:000081632300011
J	Higgins, LM; Frankel, G; Connerton, I; Goncalves, NS; Dougan, G; MacDonald, TT				Higgins, LM; Frankel, G; Connerton, I; Goncalves, NS; Dougan, G; MacDonald, TT			Role of bacterial intimin in colonic hyperplasia and inflammation	SCIENCE			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; CELL-BINDING DOMAIN; EPITHELIAL-CELLS; T-CELLS; MICE; PROTEIN; RESPONSES; SIGNALS; DISEASE; GENE	Enteropathogenic Escherichia coli (EPEC) cells adhere to gut epithelial cells through intimin alpha: the ligand for a bacterially derived epithelial transmembrane protein called the translocated intimin receptor, Citrobacter rodentium colonizes the mouse colon in a similar fashion and uses a different intimin: intimin beta. Intimin alpha was found to costimulate submitogenic signals through the T cell receptor. Dead intimin beta(+) C. rodentium, intimin a-transfected C. rodentium or E. coli strain K12, and EPEC induced mucosal hyperplasia identical to that caused by C. rodentium live infection, as well as a massive T helper cell-type 1 immune response in the colonic mucosa, Mutation of cysteine-937 of intimin to alanine reduced costimulatory activity in vitro and prevented immunopathology in vivo. The mucosal changes elicited by C. rodentium were interferon-gamma-dependent. Immunopathology induced by intimin enables the bacteria to promote conditions that are favorable for increased microbial colonization.	St Bartholomews & Royal London Sch Med & Dent, Dept Paediat Gastroenterol, London EC1A 7BE, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; Univ Nottingham, Sch Biol Sci, Div Food Sci, Loughborough LE12 5RD, Leics, England	University of London; Queen Mary University London; Imperial College London; University of Nottingham	Higgins, LM (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Paediat Gastroenterol, London EC1A 7BE, England.			Connerton, Ian/0000-0001-8652-8938; Higgins, Lisa/0000-0003-2672-1490	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADUROBIE J, 1998, J CLIN MICROBIOL, V36, P662; Bajaj-Elliott M, 1998, J CLIN INVEST, V102, P1473, DOI 10.1172/JCI2792; Brandtzaeg P, 1998, CHEM IMMUNOL, V71, P1; DONNENBERG MS, 1993, J BACTERIOL, V175, P4670, DOI 10.1128/JB.175.15.4670-4680.1993; Ebert EC, 1996, CELL IMMUNOL, V167, P108, DOI 10.1006/cimm.1996.0013; Eckmann L, 1996, J IMMUNOL, V156, P2894; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Higgins LM, 1999, INFECT IMMUN, V67, P3031, DOI 10.1128/IAI.67.6.3031-3039.1999; HIGGINS LM, UNPUB; Hobbie S, 1997, J IMMUNOL, V159, P5550; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lai LC, 1997, INFECT IMMUN, V65, P2211, DOI 10.1128/IAI.65.6.2211-2217.1997; Leach MW, 1996, AM J PATHOL, V148, P1503; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; SPITZ J, 1995, AM J PHYSIOL-GASTR L, V268, pG374, DOI 10.1152/ajpgi.1995.268.2.G374	24	120	120	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					588	591		10.1126/science.285.5427.588	http://dx.doi.org/10.1126/science.285.5427.588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417389				2022-12-01	WOS:000081609500039
J	Lee, J; Ishihara, A; Oxford, G; Johnson, B; Jacobson, K				Lee, J; Ishihara, A; Oxford, G; Johnson, B; Jacobson, K			Regulation of cell movement is mediated by stretch-activated calcium channels	NATURE			English	Article							KERATOCYTES; LOCOMOTION; TRANSLOCATION; MICROFILAMENT; MECHANISM; ADHESIONS; MIGRATION; DYNAMICS; TENSION; RELEASE	Intracellular calcium regulates many of the molecular processes that are essential for cell movement(1). It is required for the production of actomyosin-based contractile forces(2-4) the regulation of the structure and dynamics of the actin cytoskeleton(5,6), and the formation and disassembly of cell-substratum adhesions(7,8). Calcium also serves as a second messenger in many biochemical signal-transduction pathways(7). However, despite the pivotal role of calcium in motile processes; it is not clear how calcium regulates overall cell movement. Here we show that transient increases in intracellular calcium, [Ca2+](i), during the locomotion of fish epithelial keratocytes, occur more frequently in cells that become temporarily 'stuck' to the substratum or when subjected to mechanical stretching. We find that calcium transients arise from the activation of stretch-activated calcium channels, which triggers an influx of extracellular calcium. In addition, the subsequent increase in [Ca2+](i) is involved in detachment of the rear cell margin. Thus, we have defined a mechanism by which cells can detect and transduce mechanical forces into biochemical signals that can modulate locomotion.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Mol & Cell Physiol, Chapel Hill, NC 27599 USA; Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Connecticut	Lee, J (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA.							Anderson KI, 1996, J CELL BIOL, V134, P1209, DOI 10.1083/jcb.134.5.1209; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; GALBRAITH CG, 1997, MOL BIOL CELL S, V8, P385; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; HARTWIG JH, 1988, CELL MOTIL CYTOSKEL, V10, P117, DOI 10.1002/cm.970100116; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ishihara A, 1997, BIOTECHNIQUES, V23, P268, DOI 10.2144/97232st01; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; Lee J, 1997, J CELL SCI, V110, P2833; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; Palecek SP, 1998, J CELL SCI, V111, P929; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; REES DA, 1989, CELL MOTIL CYTOSKEL, V13, P112, DOI 10.1002/cm.970130206; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SACKIN H, 1996, MOL BIOL MEMBRANE TR, P201; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STROHMEIER R, 1984, EXP CELL RES, V154, P412, DOI 10.1016/0014-4827(84)90165-4; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0	30	304	317	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					382	386		10.1038/22578	http://dx.doi.org/10.1038/22578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432119				2022-12-01	WOS:000081590000055
J	Otto, CM; Lind, BK; Kitzman, DW; Gersh, BJ; Siscovick, DS				Otto, CM; Lind, BK; Kitzman, DW; Gersh, BJ; Siscovick, DS		Cardiovascular Hlth Study	Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL CORONARY-ARTERIES; DOPPLER-ECHOCARDIOGRAPHY; NATURAL-HISTORY; ANGINA-PECTORIS; EARLY LESION; STENOSIS; PROGRESSION; ADULTS; DISEASE; EXPRESSION	Background Although aortic-valve stenosis is clearly associated with adverse cardiovascular outcomes, it is unclear whether valve sclerosis increases the risk of cardiovascular events. Methods We assessed echocardiograms obtained at base line from 5621 men and women 65 years of age or older who were enrolled in a population-based prospective study, On echocardiography, the aortic valve was normal in 70 percent (3919 subjects), sclerotic without outflow obstruction in 29 percent (1610), and stenotic in 2 percent (92), The subjects were followed for a mean of 5.0 years to assess the risk of death from any cause and of death from cardiovascular causes. Cardiovascular morbidity was defined as new episodes of myocardial infarction, angina pectoris, congestive heart failure, or stroke. Results There was a stepwise increase in deaths from any cause (P for trend, <0.001) and deaths from cardiovascular causes (P for trend, <0.001) with increasing aortic-valve abnormality; the respective rates were 14.9 and 6.1 percent in the group with normal aortic valves, 21.9 and 10.1 percent in the group with aortic sclerosis, and 41.3 and 19.6 percent in the group with aortic stenosis, The relative risk of death from cardiovascular causes among subjects without coronary heart disease at base line was 1.66 (95 percent confidence interval, 1.23 to 2.23) for those with sclerotic valves as compared with those with normal valves, after adjustment for age and sex. The relative risk remained elevated after further adjustment for clinical factors associated with sclerosis (relative risk, 1.52; 95 percent confidence interval, 1.12 to 2.05), The relative risk of myocardial infarction was 1.40 (95 percent confidence interval, 1.07 to 1.83) among subjects with aortic sclerosis, as compared with those with normal aortic valves. Conclusions Aortic sclerosis is common in the elderly and is associated with an increase of approximately 50 percent in the risk of death from cardiovascular causes and the risk of myocardial infarction, even in the absence of hemodynamically significant obstruction of left ventricular outflow. (N Engl J Med 1999;341:142-7) (C) 1999, Massachusetts Medical Society.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Wake Forest Univ, Sch Med, Div Cardiol, Winston Salem, NC USA; Mayo Clin, Div Cardiol, Rochester, MN USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Mayo Clinic	Otto, CM (corresponding author), Univ Washington, Div Cardiol, Box 356422, Seattle, WA 98195 USA.			Otto, Catherine/0000-0002-0527-9392	NHLBI NIH HHS [N01-HC85081, N01-HC85079, N01-HC85080] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085081, N01HC085080, N01HC085079] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARONOW WS, 1987, AM J CARDIOL, V59, P998, DOI 10.1016/0002-9149(87)91144-1; Boon A, 1997, HEART, V78, P472, DOI 10.1136/hrt.78.5.472; BRENER SJ, 1995, J AM COLL CARDIOL, V25, P305, DOI 10.1016/0735-1097(94)00406-G; CHIZNER MA, 1980, AM HEART J, V99, P419, DOI 10.1016/0002-8703(80)90375-0; DEUTSCHER S, 1984, J CHRON DIS, V37, P407, DOI 10.1016/0021-9681(84)90108-5; FAGGIANO P, 1992, AM J CARDIOL, V70, P229, DOI 10.1016/0002-9149(92)91280-H; FRANK S, 1973, BRIT HEART J, V35, P41; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; GARDIN JM, 1992, J AM SOC ECHOCARDIOG, V5, P550; GEORGESON S, 1990, J AM COLL CARDIOL, V15, P751, DOI 10.1016/0735-1097(90)90271-P; GOTOH T, 1995, AM J CARDIOL, V76, P928, DOI 10.1016/S0002-9149(99)80263-X; HOAGLAND PM, 1985, AM J CARDIOL, V55, P744, DOI 10.1016/0002-9149(85)90149-3; HORSTKOTTE D, 1988, EUR HEART J, V9, P57, DOI 10.1093/eurheartj/9.suppl_E.57; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Julius BK, 1997, CIRCULATION, V95, P892; Kaufmann P, 1996, J AM COLL CARDIOL, V28, P745, DOI 10.1016/0735-1097(96)00194-5; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; MARCUS ML, 1982, NEW ENGL J MED, V307, P1362, DOI 10.1056/NEJM198211253072202; MOHLER ER, 1991, CLIN CARDIOL, V14, P995, DOI 10.1002/clc.4960141210; NADELL R, 1983, J AM COLL CARDIOL, V2, P258, DOI 10.1016/S0735-1097(83)80161-2; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523; OKEEFE JH, 1987, MAYO CLIN PROC, V62, P986, DOI 10.1016/S0025-6196(12)65068-X; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OLSSON M, 1994, J AM COLL CARDIOL, V24, P1664, DOI 10.1016/0735-1097(94)90172-4; Omran H, 1996, HEART, V75, P377, DOI 10.1136/hrt.75.4.377; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Otto CM, 1997, CIRCULATION, V95, P2262, DOI 10.1161/01.CIR.95.9.2262; OTTO CM, 1989, J AM COLL CARDIOL, V13, P545, DOI 10.1016/0735-1097(89)90590-1; PETER M, 1993, CHEST, V103, P1715, DOI 10.1378/chest.103.6.1715; PETROPOULAKIS PN, 1995, CIRCULATION, V92, P1437, DOI 10.1161/01.CIR.92.6.1437; ROGER VL, 1990, AM HEART J, V119, P331, DOI 10.1016/S0002-8703(05)80024-9; Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3; TEERLINK JR, 1997, CIRCULATION S1, V96, P82; TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307	36	916	960	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					142	147		10.1056/NEJM199907153410302	http://dx.doi.org/10.1056/NEJM199907153410302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403851				2022-12-01	WOS:000081413800002
J	Geisler, WS				Geisler, WS			Motion streaks provide a spatial code for motion direction	NATURE			English	Article							VISUAL AREA MT; HUMAN-VISION; ORIENTATION; SELECTIVITY; PATTERNS; NEURONS; MACAQUE; CORTEX; MODEL	Although many neurons in the primary visual cortex (V1) of primates are direction selective(1), they provide ambiguous information about the direction of motion of a stimulus(2,3), There is evidence that one of the ways in which the visual system resolves this ambiguity is by computing, from the responses of V1 neurons, velocity components in two or more spatial orientations and then combining these velocity components(2-9). Here I consider another potential neural mechanism for determining motion direction. When a localized image feature moves fast enough, it should become smeared in space owing to temporal integration in the visual system, creating a spatial signal-a 'motion streak'-oriented in the direction of the motion. The orientation masking and adaptation experiments reported here show that these spatial signals for motion direction exist in the human visual system for feature speeds above about 1 feature width per 100 ms. Computer simulations show that this psychophysical finding is consistent with the known response properties of V1 neurons, and that these spatial signals, when appropriately processed, are sufficient to determine motion direction in natural images.	Univ Texas, Dept Psychol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Geisler, WS (corresponding author), Univ Texas, Dept Psychol, Austin, TX 78712 USA.			Geisler, Wilson/0000-0003-4630-6614				ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ANDERSON CH, 1990, NATURE, V343, P419, DOI 10.1038/343419b0; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; Burr DC, 1997, P ROY SOC B-BIOL SCI, V264, P431, DOI 10.1098/rspb.1997.0061; DERRINGTON A, 1991, VISION RES, V31, P139, DOI 10.1016/0042-6989(91)90081-F; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; Geisler WS, 1997, VISUAL NEUROSCI, V14, P897, DOI 10.1017/S0952523800011627; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MARR D, 1981, PROC R SOC SER B-BIO, V211, P151, DOI 10.1098/rspb.1981.0001; MORGAN MJ, 1989, NATURE, V340, P385, DOI 10.1038/340385a0; RAMACHAN.VS, 1974, PERCEPTION, V3, P97, DOI 10.1068/p030097; Simoncelli EP, 1998, VISION RES, V38, P743, DOI 10.1016/S0042-6989(97)00183-1; Smith A. T., 1994, VISUAL DETECTION MOT; STONE LS, 1990, VISION RES, V30, P1049, DOI 10.1016/0042-6989(90)90114-Z; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322	17	244	246	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					65	69		10.1038/21886	http://dx.doi.org/10.1038/21886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403249				2022-12-01	WOS:000081255700051
J	Yuan, ZM; Shioya, H; Ishiko, T; Sun, XG; Gu, JJ; Huang, YY; Lu, H; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Shioya, H; Ishiko, T; Sun, XG; Gu, JJ; Huang, YY; Lu, H; Kharbanda, S; Weichselbaum, R; Kufe, D			P73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage	NATURE			English	Article							PROTEIN; P53; ACTIVATION; RADIATION; AGENTS; GROWTH	The protein p73 is a structural and functional homologue of the p53 tumour-suppressor protein but, unlike p53, it is not induced in response to DNA damage(1,2). The tyrosine kinase c-Abl is activated by certain DNA-damaging agents(3) and contributes to the induction of programmed cell death (apoptosis) by p53-dependent and p53-independent mechanisms(4). Here we show that c-Abl binds to p73 in cells, interacting through its SH3 domain with the carboxy-terminal homo-oligomerization domain of p73, c-Abl phosphorylates p73 on a tyrosine residue at position 99 both in vitro and in cells that have been exposed to ionizing radiation. Our results show that c-Abl stimulates p73-mediated transactivation and apoptosis. This regulation of p73 by c-Abl in response to PNA damage is also demonstrated by a failure of ionizing-radiation-induced apoptosis after disruption of the c-Abl-p73 interaction. These findings show that p73 is regulated by a c-Abl-dependent mechanism and that p73 participates in the apoptotic response to DNA damage.	Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oregon Health & Science University; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Biol, 665 Huntington Ave, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu		Huang, Ying/0000-0003-1145-3606				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo CM, 1996, J BIOL CHEM, V271, P4497; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhu JH, 1998, CANCER RES, V58, P5061	21	519	530	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					814	817		10.1038/21704	http://dx.doi.org/10.1038/21704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391251				2022-12-01	WOS:000081101600061
J	Lidegaard, O				Lidegaard, O			Commentary: Oral contraceptives and myocardial infarction: reassuring new findings	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark	University of Copenhagen; Herlev & Gentofte Hospital	Lidegaard, O (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1583	1584						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428552				2022-12-01	WOS:000080913100020
J	Diwan, VK; Thorson, A				Diwan, VK; Thorson, A			Sex, gender, and tuberculosis	LANCET			English	Article									Nord Sch Publ Hlth, S-40242 Gothenburg, Sweden		Diwan, VK (corresponding author), Nord Sch Publ Hlth, Box 12133, S-40242 Gothenburg, Sweden.			Thorson, Anna/0000-0002-8703-6561				DIWAN VK, 1998, GENDER TUBERCULOSIS; Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96; KUMARESAN JA, 1996, GLOBAL BURDEN DIS RI; Kurasawa T, 1990, Kekkaku, V65, P47; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; SHAABAN MA, 1990, EUR RESPIR J, V3, P187; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	7	98	104	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1000	1001		10.1016/S0140-6736(99)01318-5	http://dx.doi.org/10.1016/S0140-6736(99)01318-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459926				2022-12-01	WOS:000079421600047
J	Sherff, CM; Carew, TJ				Sherff, CM; Carew, TJ			Coincident induction of long-term facilitation in Aplysia: Cooperativity between cell bodies and remote synapses	SCIENCE			English	Article							LOCAL PROTEIN-SYNTHESIS; SENSORY NEURONS; LATE-PHASE; SYNAPTIC FACILITATION; MACROMOLECULAR-SYNTHESIS; CRITICAL PERIOD; POTENTIATION; PLASTICITY; REQUIREMENT; EXPRESSION	Induction of Long-term synaptic changes at one synapse can facilitate the induction of Long-term plasticity at another synapse. Evidence is presented here that if Aplysia sensory neuron somata and their remote motor neuron synapses are simultaneously exposed to serotonin pulses insufficient to induce Long-term facilitation (LTF) at either site along, processes activated at these sites interact to induce LTF. This coincident induction of LTF requires that (i) the synaptic pulse occur within a brief temporal window of the somatic pulse, and (ii) Local protein synthesis occur immediately at the synapse, followed by delayed protein synthesis at the soma.	Yale Univ, Dept Psychol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Sherff, CM (corresponding author), Yale Univ, Dept Psychol, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH012004] Funding Source: NIH RePORTER; NIMH NIH HHS [F32-MH12004, R01MH-14-1083] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARNBRON RT, 1992, J NEUROSCI, V12, P2813; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLEARY LJ, 1993, J NEUROPHYSIOL, V70, P1767, DOI 10.1152/jn.1993.70.5.1767; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GLANZMAN DL, 1994, J NEUROBIOL, V25, P666, DOI 10.1002/neu.480250608; GUNSTREAM JD, 1995, J NEUROSCI, V15, P439; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JAFFE DB, 1994, J NEUROPHYSIOL, V72, P471, DOI 10.1152/jn.1994.72.1.471; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; Mauelshagen J, 1996, J NEUROSCI, V16, P7099; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; TRUDEAU LE, 1995, J NEUROSCI, V15, P1275; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; XU YL, 1995, J NEUROPHYSIOL, V73, P1313, DOI 10.1152/jn.1995.73.3.1313; Zhang F, 1997, SCIENCE, V275, P1318, DOI 10.1126/science.275.5304.1318	29	72	73	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1911	1914		10.1126/science.285.5435.1911	http://dx.doi.org/10.1126/science.285.5435.1911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489370				2022-12-01	WOS:000082638300050
J	McKenzie, R; Conner, B; Bodeker, G				McKenzie, R; Conner, B; Bodeker, G			Increased summertime UV radiation in New Zealand in response to ozone loss	SCIENCE			English	Article							ULTRAVIOLET-RADIATION; IRRADIANCE; SURFACE	Long-term decreases in summertime ozone over Lauder, New Zealand (45 degrees S), are shown to have Led to substantial increases in peak ultraviolet (UV) radiation intensities. In the summer of 1998-99, the peak sunburning UV radiation was about 12 percent more than in the first years of the decade. Larger increases were seen for DNA-damaging UV radiation and plant-damaging UV radiation, whereas UV-A (315 to 400 nanometers) radiation, which is insensitive to ozone, showed no increase, in agreement with model calculations. These results provide strong evidence of human-induced increases in UV radiation, in a region where baseline levels of UV radiation were already relatively high.	Natl Inst Water & Atmospher Res, NIWA Lauder, Cent Otago, New Zealand	National Institute of Water & Atmospheric Research (NIWA) - New Zealand	McKenzie, R (corresponding author), Natl Inst Water & Atmospher Res, NIWA Lauder, PB 50061 Omakau, Cent Otago, New Zealand.			McKenzie, Richard Lloyd/0000-0002-4484-7057; Bodeker, Gregory/0000-0003-1094-5852				ALBRITTON DL, 1998, SCI ASSESSMENT OZONE; BULLIARD JL, 1996, NZ PUBLIC HLTH REP, V3, P73; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; Connor BJ, 1999, GEOPHYS RES LETT, V26, P189, DOI 10.1029/1998GL900250; FORGAN BW, 1997, MISCELLANEOUS SERIES, V49, P51; MADRONICH S, 1995, AMBIO, V24, P143; McKenzie R, 1996, WEATHER CLIM, V16, P17; MCKENZIE RL, 1992, APPL OPTICS, V31, P6501, DOI 10.1364/AO.31.006501; McKenzie RL, 1998, J GEOPHYS RES-ATMOS, V103, P28785, DOI 10.1029/98JD02704; MCKENZIE RL, 1994, OZONE TROPOSPHERE ST, P627; McKinlay AF., 1987, EXCERPTA MED INT C S, V744, P83; Relethford JH, 1998, AM J PHYS ANTHROPOL, V107, P223, DOI 10.1002/(SICI)1096-8644(199810)107:2<223::AID-AJPA9>3.0.CO;2-V; SECKMEYER G, 1992, NATURE, V359, P135, DOI 10.1038/359135a0; SECKMEYER G, 1995, GEOPHYS RES LETT, V22, P1889, DOI 10.1029/95GL01352; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Shindell DT, 1998, NATURE, V392, P589, DOI 10.1038/33385; STAMNES K, 1991, APPL OPTICS, V30, P4418, DOI 10.1364/AO.30.004418; *UN ENV PROGR UNEP, 1998, ENV EFF OZ DEPL 1998; WMO, 1995, SCI ASS OZ DEPL 1994; *WMO, 1994, WMO M EXP UVB MEAS D	20	264	280	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1709	1711		10.1126/science.285.5434.1709	http://dx.doi.org/10.1126/science.285.5434.1709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481002				2022-12-01	WOS:000082472600028
J	Henney, JE				Henney, JE			New type 2 diabetes drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-01	WOS:000082335900005
J	Kleiman, FE; Manley, JL				Kleiman, FE; Manley, JL			Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50	SCIENCE			English	Article							PRE-MESSENGER-RNA; POLYMERASE-II; POLY(A) POLYMERASE; SPECIFICITY FACTOR; IN-VITRO; 3'-END CLEAVAGE; BINDING DOMAIN; GLOBIN GENE; DNA-DAMAGE; BRCA1	Polyadenylation of messenger RNA precursors requires a complex protein machinery that is closely integrated with the even more complex transcriptional apparatus. Here a polyadenylation factor, CstF-50 (cleavage stimulation factor), is shown to interact in vitro and in intact cells with a nuclear protein of previously unknown function, BRCA1-associated RING domain protein (BARD1). The BARD1-CstF-50 interaction inhibits polyadenylation in vitro. BARD1, like CstF-50, also interacts with RNA polymerase II. These results indicate that BARD1-mediated inhibition of polyadenylation may prevent inappropriate RNA processing during transcription, perhaps at sites of DNA repair, and they reveal an unanticipated integration of diverse nuclear events.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jlm2@columbia.edu		Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28983] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beyer K, 1997, J BIOL CHEM, V272, P26769, DOI 10.1074/jbc.272.42.26769; Chen J., COMMUNICATION; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1997, J BIOL CHEM, V272, P29636, DOI 10.1074/jbc.272.47.29636; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KLEIMAN FE, UNPUB; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907	44	139	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1576	1579		10.1126/science.285.5433.1576	http://dx.doi.org/10.1126/science.285.5433.1576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477523				2022-12-01	WOS:000082359500068
J	Hopker, VH; Shewan, D; Tessier-Lavigne, M; Poo, MM; Holt, C				Hopker, VH; Shewan, D; Tessier-Lavigne, M; Poo, MM; Holt, C			Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1	NATURE			English	Article							FIBRONECTIN RECEPTOR COMPLEX; AXON GUIDANCE; CYCLIC-AMP; CELLS; OUTGROWTH; RETINA; ADULT; DCC	Growing axons are guided by both diffusible and substrate-bound factors(1-3). Growth cones of retinal neurons exhibit chemoattractive turning towards the diffusible factor netrin-1 in vitro(4) and are guided into the optic nerve head (ONH) by localized netrin-1 (ref. 5). Here we report that, in Xenopus, laminin-1 from the extracellular matrix (ECM), converts netrin-mediated attraction into repulsion. A soluble peptide fragment of laminin-1 (YIGSR) mimics this laminin-induced conversion. Low levels of cyclic AMP in growth cones also lead to the conversion of netrin-induced attraction into repulsion(6), and we show that the amount of cAMP decreases in the presence of laminin-1 or YIGSR, suggesting a possible mechanism for laminin's effect. At the netrin-1-rich ONH, where axons turn sharply to leave the eye, laminin-1 is confined to the retinal surface. Repulsion from the region in which laminin and netrin are coexpressed may help to drive axons into the region where only netrin is present, providing a mechanism for their escape from the retinal surface. Consistent with this idea, YIGSR peptides applied to the developing retina cause axons to be misdirected at the ONH. These findings indicate that ECM molecules not only promote axon outgrowth, but also modify the behaviour of growth cones in response to diffusible guidance cues.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Cambridge; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Holt, C (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Holt, Christine Elizabeth/0000-0003-2829-121X				Ardini E, 1997, J BIOL CHEM, V272, P2342; Bates CA, 1996, BRAIN RES, V714, P65, DOI 10.1016/0006-8993(95)01468-3; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cb.07.110191.001001; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; DECURTIS I, 1993, DEVELOPMENT, V118, P377; Deiner MS, 1997, NEURON, V19, P575, DOI 10.1016/S0896-6273(00)80373-6; Hanson MG, 1998, J NEUROSCI, V18, P7361; HARRIS WA, 1985, J NEUROSCI RES, V13, P101, DOI 10.1002/jnr.490130108; HAUZENBERGER D, 1994, J IMMUNOL, V153, P960; HOLT CE, 1989, J NEUROSCI, V9, P3123; LIESI P, 1988, DEV BIOL, V130, P774, DOI 10.1016/0012-1606(88)90366-1; LILIENBAUM A, 1995, MOL CELL NEUROSCI, V6, P139, DOI 10.1006/mcne.1995.1013; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SONG HJ, 1997, NATURE, V389, P413; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; WEEKS BS, 1991, AM J PHYSIOL, V261, pF688, DOI 10.1152/ajprenal.1991.261.4.F688; Wiemelt AP, 1997, J BIOL CHEM, V272, P31489, DOI 10.1074/jbc.272.50.31489	30	392	393	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					69	73		10.1038/43441	http://dx.doi.org/10.1038/43441			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485706				2022-12-01	WOS:000082374400042
J	Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL				Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL			Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy	NATURE			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; DIFFERENTIATION; METABOLISM; MOUSE; FAT	Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a paucity of adipose (fat) tissue which is evident at birth and is accompanied by a severe resistance to insulin, leading to hyperinsulinaemia, hyperglycaemia and enlarged fatty liver(1). We have developed a mouse model that mimics these features of CGL(2): the syndrome occurs in transgenic mice expressing a truncated version of a nuclear protein known as nSREBP-1c (for sterol-regulatory-element-binding protein-1c) under the control of the adipose-specific aP2 enhancer. Adipose tissue from these mice was markedly deficient in messenger RNAs encoding several fat-specific proteins, including leptin(2), a fat-derived hormone that regulates food intake and energy metabolism(3). Here we show that insulin resistance in our lipodystrophic mice can be overcome by a continuous systemic infusion of low doses of recombinant leptin, an effect that is not mimicked by chronic food restriction. Our results support the idea that leptin modulates insulin sensitivity and glucose disposal independently of its effect on food intake, and that leptin deficiency accounts for the insulin resistance found in CGL.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.	mbrowl@mednet.swmed.edu; jgolds@mednet.swmed.edu		Ikemoto, Shinji/0000-0002-2291-2735				Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Pardini VC, 1998, J CLIN ENDOCR METAB, V83, P503, DOI 10.1210/jc.83.2.503; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	775	812	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1999	401	6748					73	76		10.1038/43448	http://dx.doi.org/10.1038/43448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485707				2022-12-01	WOS:000082374400043
J	Weber-Ban, EU; Reid, BG; Miranker, AD; Horwich, AL				Weber-Ban, EU; Reid, BG; Miranker, AD; Horwich, AL			Global unfolding of a substrate protein by the Hsp100 chaperone ClpA	NATURE			English	Article							REGULATORY SUBUNITS; TAGGING SYSTEM; PROTEASES; BINDING; FAMILY; DEGRADATION	The bacterial protein ClpA, a member of the Hsp100 chaperone family, forms hexameric rings that bind to the free ends of the double-ring serine protease ClpP (refs 1, 2). ClpA directs the ATP-dependent degradation of substrate proteins bearing specific sequences(3-5), much as the 19S ATPase 'cap' of eukaryotic proteasomes functions in the degradation of ubiquitinated proteins(6-8). In isolation, ClpA and its relative ClpX can mediate the disassembly of oligomeric proteinsg(9,10); another similar eukaryotic protein, Hsp104, can dissociate low-order aggregates(11). ClpA has been proposed to destabilize protein structure, allowing passage of proteolysis substrates through a central channel into the ClpP proteolytic cylinder(12-14). Here we test the action of ClpA on a stable monomeric protein, the green fluorescent protein GFP, onto which has been added an Il-amino-acid carboxy-terminal recognition peptide, which is responsible for recruiting truncated proteins to ClpAP for degradation(5,15). Fluorescence studies both with and without a 'trap' version of the chaperonin GroEL, which binds non-native forms of GFP(16), and hydrogen-exchange experiments directly demonstrate that ClpA can unfold stable, native proteins in the presence of ATP.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Horwich, AL (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, 295 Congress Ave, New Haven, CT 06510 USA.			Weber-Ban, Eilika/0000-0002-5773-9274				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Wang JM, 1997, CELL, V91, P447, DOI 10.1016/S0092-8674(00)80431-6; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	20	353	357	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					90	93		10.1038/43481	http://dx.doi.org/10.1038/43481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485712				2022-12-01	WOS:000082374400048
J	Knoll, AH				Knoll, AH			Paleontology - A new molecular window on early life	SCIENCE			English	Editorial Material							ATMOSPHERIC OXYGEN; EARLY EVOLUTION; PALEOSOLS; GA		Harvard Univ, Bot Museum, Cambridge, MA 02138 USA	Harvard University	Knoll, AH (corresponding author), Harvard Univ, Bot Museum, Cambridge, MA 02138 USA.	aknoll@oeb.harvard.edu						Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; Buick R, 1998, AAPG BULL, V82, P50; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Golubic S, 1995, LETHAIA, V28, P285, DOI 10.1111/j.1502-3931.1995.tb01817.x; Hayes J.M., 1994, EARLY LIFE EARTH, V84, P220; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Ohmoto H, 1996, GEOLOGY, V24, P1135, DOI 10.1130/0091-7613(1996)024<1135:EIPGPF>2.3.CO;2; OURLSSON G, 1987, MICROBIOL, V41, P301; Peters K.E., 1993, BIOMARKER GUIDE, V1st; Rasmussen B, 1999, GEOLOGY, V27, P115, DOI 10.1130/0091-7613(1999)027<0115:RSOTAA>2.3.CO;2; Rye R, 1998, AM J SCI, V298, P621, DOI 10.2475/ajs.298.8.621; Schopf JW, 1994, EARLY LIFE EARTH, P193; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	16	54	59	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1025	1026		10.1126/science.285.5430.1025	http://dx.doi.org/10.1126/science.285.5430.1025			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10475845				2022-12-01	WOS:000082033100032
J	Huang, CC; Wang, ST; Chang, YC; Lin, KP; Wu, PL				Huang, CC; Wang, ST; Chang, YC; Lin, KP; Wu, PL			Measurement of the urinary lactate : creatinine ratio for the early identification of newborn infants at risk for hypoxic-ischemic encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROSPINAL-FLUID; BIRTH ASPHYXIA; PERINATAL ASPHYXIA; MAGNETIC-RESONANCE; TERM INFANTS; ORGANIC-ACID; EXCRETION; PROGNOSIS; SYSTEM; BRAIN	Background Newborn infants with perinatal asphyxia are prone to the development of hypoxic-ischemic encephalopathy. There are no reliable methods For identifying infants at risk for this disorder. Methods We measured the ratio of lactate to creatinine in urine by proton nuclear magnetic resonance spectroscopy within 6 hours and again 48 to 72 hours after birth in 58 normal infants and 40 infants with asphyxia. The results were correlated with the subsequent presence or absence of hypoxic-ischemic encephalopathy. Results Hypoxic-ischemic encephalopathy did not develop in any of the normal newborns but did develop in 16 of the 40 newborns with asphyxia. Within six hours after birth, the mean (+/-SD) ratio of urinary lactate to creatinine was 16.75+/-27.38 in the infants who subsequently had hypoxic-ischemic encephalopathy, as compared with 0.09+/-0.02 in the normal infants (P<0.001) and 0.19+/-0.12 in the infants with asphyxia in whom hypoxic-ischemic encephalopathy did not develop (P<0.001). A ratio of 0.64 or higher within six hours after birth had a sensitivity of 94 percent and a specificity of 100 percent for predicting the development of hypoxic-ischemic encephalopathy. The sensitivity and specificity of measurements obtained 48 to 72 hours after birth were much lower. The mean ratio of urinary lactate to creatinine was significantly higher in the infants who had adverse outcomes at one year (25.36+/-32.02) than in the infants with favorable outcomes (0.63+/-1.50) (P<0.001). Conclusions Measurement of the urinary lactate:creatinine ratio soon after birth may help identify infants at high risk for hypoxic-ischemic encephalopathy. (N Engl J Med 1999;341:328-35.) (C) 1999, Massachusetts Medical Society.	Natl Cheng Kung Univ, Med Ctr, Dept Pediat, Tainan 704, Taiwan; Natl Cheng Kung Univ, Med Ctr, Dept Publ Hlth, Tainan 704, Taiwan; Natl Cheng Kung Univ, Dept Chem, Tainan 704, Taiwan; Kaohsiung Chang Gung Childrens Hosp, Dept Pediat, Kaohsiung, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chang Gung Memorial Hospital	Huang, CC (corresponding author), Natl Cheng Kung Univ, Med Ctr, Dept Pediat, 138 Sheng Li Rd, Tainan 704, Taiwan.			Huang, Chao-Ching/0000-0003-2799-7181				AMICLTISON C, 1986, NEUROLOGICAL ASSESSM; BLENNOW M, 1995, PEDIATR RES, V37, P260, DOI 10.1203/00006450-199503000-00002; Carter BS, 1998, J PEDIATR-US, V132, P619, DOI 10.1016/S0022-3476(98)70349-X; Cheung PY, 1996, ARCH DIS CHILD-FETAL, V74, pF47, DOI 10.1136/fn.74.1.F47; DAWES GS, 1968, J PHYSIOL-LONDON, V195, P55, DOI 10.1113/jphysiol.1968.sp008446; DEPRAETER C, 1991, PEDIATRICS, V88, P1204; Ekert P, 1997, J PEDIATR-US, V131, P613, DOI 10.1016/S0022-3476(97)70072-6; FERNANDES J, 1976, CLIN CHIM ACTA, V66, P345, DOI 10.1016/0009-8981(76)90233-3; GARCIA J, 1984, J PEDIATR-US, V104, P268, DOI 10.1016/S0022-3476(84)81010-0; HAGBERG H, 1993, ACTA PAEDIATR, V82, P925, DOI 10.1111/j.1651-2227.1993.tb12601.x; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; Huang CC, 1998, RADIOLOGY, V209, P49, DOI 10.1148/radiology.209.1.9769811; ILES RA, 1986, CLIN CHIM ACTA, V161, P173, DOI 10.1016/0009-8981(86)90211-1; Johnston MV, 1998, ANN NEUROL, V44, P155, DOI 10.1002/ana.410440202; Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803; MA S, 1995, APPL BIOCHEM BIOTECH, V53, P37, DOI 10.1007/BF02783480; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; MCCORMICK K, 1985, AM J MED GENET, V22, P291, DOI 10.1002/ajmg.1320220211; NICHOLSON JK, 1989, PROG NUCL MAG RES SP, V21, P449, DOI 10.1016/0079-6565(89)80008-1; PERLMAN JM, 1988, J PEDIATR-US, V113, P875; Perlman JM, 1996, PEDIATRICS, V97, P456; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; RUTH V, 1988, J PEDIATR-US, V113, P880, DOI 10.1016/S0022-3476(88)80024-6; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Savman K, 1998, PEDIATR RES, V43, P746; SIEGEL MJ, 1984, RADIOLOGY, V152, P395, DOI 10.1148/radiology.152.2.6739805; THORNBERG E, 1995, ARCH DIS CHILD-FETAL, V72, pF39, DOI 10.1136/fn.72.1.F39; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; VOLPE JJ, 1995, NEUROLOGY NEWBORN, P221; Walker V, 1996, PEDIATR RES, V40, P309, DOI 10.1203/00006450-199608000-00020; WALKER V, 1992, BIOL NEONATE, V61, P162; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Zuppi C, 1997, CLIN CHIM ACTA, V265, P85, DOI 10.1016/S0009-8981(97)00110-1	33	80	81	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					328	335		10.1056/NEJM199907293410504	http://dx.doi.org/10.1056/NEJM199907293410504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423467				2022-12-01	WOS:000081666900004
J	Fisher, RS; Blum, D				Fisher, RS; Blum, D			Epilepsy surgery where there is dual pathology	LANCET			English	Editorial Material							TEMPORAL-LOBE EPILEPSY; RESECTION; LOBECTOMY; SEIZURES; EXTENT		St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Fisher, RS (corresponding author), St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA.			Fisher, Robert/0000-0003-0287-613X				Arruda F, 1996, ANN NEUROL, V40, P446, DOI 10.1002/ana.410400314; AWAD IA, 1991, NEUROSURGERY, V28, P510, DOI 10.1227/00006123-199104000-00005; CASCINO GD, 1993, EPILEPSY RES, V14, P175, DOI 10.1016/0920-1211(93)90022-Y; FRIED I, 1992, J NEUROSURG, V76, P735, DOI 10.3171/jns.1992.76.5.0735; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOLDENSOHN ES, 1984, EPILEPSIA, V25, pS156, DOI 10.1111/j.1528-1157.1984.tb05648.x; Li LM, 1999, BRAIN, V122, P799, DOI 10.1093/brain/122.5.799; MATHERN GW, 1995, EPILEPSY RES, V21, P133, DOI 10.1016/0920-1211(95)00014-2; NAYEL MH, 1991, NEUROSURGERY, V29, P55, DOI 10.1227/00006123-199107000-00009; O'Brien TJ, 1999, ANN NEUROL, V45, P526, DOI 10.1002/1531-8249(199904)45:4<526::AID-ANA17>3.0.CO;2-N; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019	12	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					267	268		10.1016/S0140-6736(99)00180-4	http://dx.doi.org/10.1016/S0140-6736(99)00180-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440297				2022-12-01	WOS:000081646000003
J	Sigwart, U				Sigwart, U			Prevention of restenosis after stenting	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; IMPLANTATION; PLACEMENT		Royal Brompton Hosp, Dept Invas Cardiol, London SW3 6NP, England	Royal Brompton Hospital	Sigwart, U (corresponding author), Royal Brompton Hosp, Dept Invas Cardiol, London SW3 6NP, England.							CAMPBELL EJ, 1999, AM SOC ARTIF INT ORG, V40, pM853; Chronos NAF, 1998, CIRCULATION, V98, P189; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Hanekamp CEE, 1999, CIRCULATION, V99, P1015, DOI 10.1161/01.CIR.99.8.1015; HINOHARA T, 1992, J AM COLL CARDIOL, V20, P623, DOI 10.1016/0735-1097(92)90017-H; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Prati F, 1999, CIRCULATION, V99, P1011, DOI 10.1161/01.CIR.99.8.1011; ROSENSCHEIN U, 1996, ENDOLUMINAL STENTING; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; WAKSMAN R, 1995, CIRCULATION, V91, P1553	12	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					269	270		10.1016/S0140-6736(99)00137-3	http://dx.doi.org/10.1016/S0140-6736(99)00137-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440299				2022-12-01	WOS:000081646000005
J	Wagner, D; Sablowski, RWM; Meyerowitz, EM				Wagner, D; Sablowski, RWM; Meyerowitz, EM			Transcriptional activation of APETALA1 by LEAFY	SCIENCE			English	Article							FLORAL HOMEOTIC GENES; FLOWER DEVELOPMENT; MERISTEM IDENTITY; ARABIDOPSIS; INITIATION; EXPRESSION	Plants produce new appendages reiteratively from groups of stem cells called shoot apical meristems. LEAFY (LFY) and APETALA1 (AP1) are pivotal for the switch to the reproductive phase, where instead of leaves the shoot apical meristem produces flowers. Use of steroid-inducible activation of LFY demonstrated that early expression of AP1 is a result of transcriptional induction by LFY. This AP1 induction is independent of protein synthesis and occurs specifically in the tissues and at the developmental stage in which floral fate is assumed. Later expression of AP1 appears to be only indirectly affected by LFY.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009; Wagner, Doris/F-1811-2013	Wagner, Doris/0000-0003-4656-2490; Sablowski, Robert/0000-0002-1732-2909				Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; Hempel FD, 1998, PLANT CELL, V10, P1663, DOI 10.1105/tpc.10.10.1663; Hempel FD, 1997, DEVELOPMENT, V124, P3845; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; Liljegren SJ, 1996, CURR OPIN CELL BIOL, V8, P865, DOI 10.1016/S0955-0674(96)80089-5; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Sablowski RWM, 1998, CELL, V92, P93, DOI 10.1016/S0092-8674(00)80902-2; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Tilly JJ, 1998, DEVELOPMENT, V125, P1647; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	24	334	375	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					582	584		10.1126/science.285.5427.582	http://dx.doi.org/10.1126/science.285.5427.582			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417387				2022-12-01	WOS:000081609500037
J	Saito, Y; Nothacker, HP; Wang, ZW; Lin, SHS; Leslie, F; Civelli, O				Saito, Y; Nothacker, HP; Wang, ZW; Lin, SHS; Leslie, F; Civelli, O			Molecular characterization of the melanin-concentrating-hormone receptor	NATURE			English	Article							ALPHA-MSH; RAT; NEUROPEPTIDE; PROTEIN; BRAIN; GENE; HYPOTHALAMUS; PEPTIDE; ENCODES; SYSTEM	Orphan G-protein-coupled receptors (GPCRs) are cloned proteins with structural characteristics common to the GPCRs but that bind unidentified ligands. Orphan GPCRs have been used as targets to identify novel transmitter molecules(1). Here we describe the isolation from brain extracts and the characterization of the natural ligand of a particular orphan GPCR (SLC-1) that is sequentially homologous to the somatostatin receptors(2,3). We show that the natural ligand of this receptor is the neuropeptide melanin-concentrating hormone (MCH)(4), MCH is a cyclic peptide that regulates a variety of functions in the mammalian brain, in particular feeding behaviour(5,6). We demonstrate that nanomolar concentrations of MCH strongly activate SLC-1-related pathways through G alpha(i) and/or G alpha(q) proteins. We have analysed the tissue localization of the MCH receptor and find that it is expressed in several brain regions, in particular those involved in olfactory learning and reinforcement mechanisms, indicating that therapies targeting the MCH receptor should act on the neuronal regulation of food consumption.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Civelli, O (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.		Civelli, Olivier/A-8392-2012					BAKER BI, 1993, ANN NY ACAD SCI, V680, P279, DOI 10.1111/j.1749-6632.1993.tb19690.x; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; deLecea L, 1996, NATURE, V381, P242, DOI 10.1038/381242a0; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Gonzalez MI, 1996, PEPTIDES, V17, P171, DOI 10.1016/0196-9781(95)02092-6; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; JEZOVA D, 1992, ENDOCRINOLOGY, V130, P1024, DOI 10.1210/en.130.2.1024; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; KOLAKOWSKI LF, 1996, FEBS LETT, V398, P255; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; LAKAYE B, 1997, BIOCHIM BIOPHYS ACTA, V1401, P216; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MILLER CL, 1993, PEPTIDES, V14, P1; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1997, J NEUROSCI RES, V48, P397, DOI 10.1002/(SICI)1097-4547(19970601)48:5<397::AID-JNR2>3.0.CO;2-9; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sanchez M, 1997, PEPTIDES, V18, P393, DOI 10.1016/S0196-9781(96)00327-0; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SKOFITSCH G, 1985, BRAIN RES B, V15; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; Winzer-Serhan UH, 1999, BRAIN RES PROTOC, V3, P229, DOI 10.1016/S1385-299X(98)00043-9	30	431	466	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					265	269		10.1038/22321	http://dx.doi.org/10.1038/22321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421368				2022-12-01	WOS:000081503800044
J	Galitski, T; Saldanha, AJ; Styles, CA; Lander, ES; Fink, GR				Galitski, T; Saldanha, AJ; Styles, CA; Lander, ES; Fink, GR			Ploidy regulation of gene expression	SCIENCE			English	Article							CELL-SURFACE FLOCCULIN; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMOSOMES; GROWTH; FLO11	Microarray-based gene expression analysis identified genes showing ploidy-dependent expression in isogenic Saccharomyces cerevisiae strains that varied in ploidy from haploid to tetraploid. These genes were induced or repressed in proportion to the number of chromosome sets, regardless of the mating type. Ploidy-dependent repression of some G(1) cyclins can explain the greater cell size associated with higher ploidies, and suggests ploidy-dependent modifications of cell cycle progression. Moreover, ploidy regulation of the FLO11 gene had direct consequences for yeast development.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Fink, GR (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	fink@wi.mit.edu			NIGMS NIH HHS [GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNER SH, 1984, PROG EXP TUMOR RES, V27, P67; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Futcher B, 1996, YEAST, V12, P1635; Guo M, 1996, GENETICS, V142, P1349; Henikoff S, 1998, CELL, V93, P329, DOI 10.1016/S0092-8674(00)81161-7; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MORTIMER RK, 1958, RADIAT RES, V9, P312, DOI 10.2307/3570795; NAGL W, 1978, ENDOPOLYPLOIDY POLYL; Nelson MA, 1996, TRENDS GENET, V12, P69, DOI 10.1016/0168-9525(96)81403-X; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Royzman I, 1998, GENES CELLS, V3, P767, DOI 10.1046/j.1365-2443.1998.00232.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	26	510	545	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					251	254		10.1126/science.285.5425.251	http://dx.doi.org/10.1126/science.285.5425.251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398601				2022-12-01	WOS:000081346000041
J	Klein, F; Mahr, P; Galova, M; Buonomo, SBC; Michaelis, C; Nairz, K; Nasmyth, K				Klein, F; Mahr, P; Galova, M; Buonomo, SBC; Michaelis, C; Nairz, K; Nasmyth, K			A central role for cohesions in sister chromatid cohesion, formation of axial elements, and recombination during yeast meiosis	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX PROTEINS; SINGLE-DIVISION MEIOSIS; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOME SEGREGATION; TOPOISOMERASE-II; DNA-REPLICATION; BUDDING YEAST	A multisubunit complex, called cohesin, containing Smc1p, Smc3p, Scc1p, and Scc3p, is required for sister chromatid cohesion in mitotic cells. We show here that Smc3p and a meiotic version of Scc1p called Rec8p are required for cohesion between sister chromatids, for formation of axial elements, for reciprocal recombination, and for preventing hyperresection of double-strand breaks during meiosis. Both Rec8p and Smc3p colocalize with chromosome cores independently of synapsis during prophase I and largely disappear from chromosome arms after pachytene but persist in the neighborhood of centromeres until the onset of anaphase II. The eukaryotic cell's cohesion apparatus is required both for the repair of recombinogenic lesions and for chromosome segregation and therefore appears to lie at the heart of the meiotic process.	Univ Vienna, Inst Bot, A-1030 Vienna, Austria; IMP Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Klein, F (corresponding author), Univ Vienna, Inst Bot, Rennweg 14, A-1030 Vienna, Austria.	fklein@s1.botanik.univvie.ac.at		Klein, Franz/0000-0001-7204-1432; Nasmyth, Kim/0000-0001-7030-4403; Buonomo, Sara/0000-0002-0177-2884				Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hayashi A, 1998, GENES CELLS, V3, P587, DOI 10.1046/j.1365-2443.1998.00215.x; Heo SJ, 1998, MOL GEN GENET, V257, P149, DOI 10.1007/s004380050634; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HUGERAT Y, 1993, GENETICS, V135, P297; Jin QW, 1998, J CELL BIOL, V141, P21, DOI 10.1083/jcb.141.1.21; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KLAPHOLZ S, 1980, GENETICS, V96, P567; KLAPHOLZ S, 1980, GENETICS, V96, P589; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LAMMERS JHM, 1995, CHROMOSOMA, V104, P154, DOI 10.1007/s004120050103; Li YF, 1997, MOL MICROBIOL, V23, P869, DOI 10.1046/j.1365-2958.1997.2691632.x; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; MOSES MJ, 1958, J BIOPHYS BIOCHEM CY, V4, P633, DOI 10.1083/jcb.4.5.633; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Prinz S, 1997, GENETICS, V146, P781; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Schalk JAC, 1998, CHROMOSOMA, V107, P540, DOI 10.1007/s004120050340; Schmekel K, 1996, EXP CELL RES, V226, P20, DOI 10.1006/excr.1996.0198; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; UHLMANN F, 1999, IN PRESS NATURE; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x	58	559	578	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					91	103		10.1016/S0092-8674(00)80609-1	http://dx.doi.org/10.1016/S0092-8674(00)80609-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412984	Bronze			2022-12-01	WOS:000081451000011
J	Sahara, S; Aoto, M; Eguchi, Y; Imamoto, N; Yoneda, Y; Tsujimoto, Y				Sahara, S; Aoto, M; Eguchi, Y; Imamoto, N; Yoneda, Y; Tsujimoto, Y			Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation	NATURE			English	Article							CASPASE-ACTIVATED DNASE; LAMIN-A; IMPORT; CELLS; FRAGMENTATION; COMPLEX	Apoptosis is defined by several unique morphological nuclear changes, such as chromatin condensation and nuclear fragmentation(1). These changes are triggered by the activation of a family of cysteine proteases called caspases(2,3), and caspase-activated DNase (CAD/DPP40)(4,5) and Iamin protease (caspase-6)(6,7) have been implicated in some of these changes. CAD/DFF40 induces chromatin condensation in purified nuclei, but distinct caspase-activated factor(s) may be responsible for chromatin condensations. Here we use an in vitro system to identify a new nuclear factor, designated Acinus, which induces apoptotic chromatin condensation after cleavage by caspase-3 without inducing DNA fragmentation. Immunodepletion experiments showed that Acinus is essential for apoptotic chromatin condensation in vitro, and an antisense study revealed that Acinus is also important in the induction of apoptotic chromatin condensation in cells.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Anat, Osaka 5650871, Japan; Japan Sci & Technol Corp JST, CREST, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, 202 Yamadaoka, Osaka 5650871, Japan.		Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	26	345	353	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					168	173		10.1038/43678	http://dx.doi.org/10.1038/43678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490026				2022-12-01	WOS:000082458800055
J	Horton, R				Horton, R			Future of European cardiology: continentally isolated or globally integrated?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							Chockalingam A, 1999, IMPENDING GLOBAL PAN; de Luna AB, 1999, J AM COLL CARDIOL, V33, P1427; De Luna AB, 1999, EUR HEART J, V20, P562, DOI 10.1053/euhj.1998.1392; Fuster V, 1999, CIRCULATION, V99, P1132, DOI 10.1161/01.CIR.99.9.1132; Institute of Medicine, 1998, CONTR CARD DIS DEV C; King SB, 1998, J AM COLL CARDIOL, V32, P2100; Lechat P, 1999, LANCET, V353, P9; Masera G, 1998, LANCET, V352, P1923, DOI 10.1016/S0140-6736(98)07077-9; Ryden L, 1999, EUR HEART J, V20, P319; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0	10	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					791	792						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485717				2022-12-01	WOS:000082400700004
J	Boekema, EJ; van Breemen, JFL; Brisson, A; Ubbink-Kok, T; Konings, WN; Lolkema, JS				Boekema, EJ; van Breemen, JFL; Brisson, A; Ubbink-Kok, T; Konings, WN; Lolkema, JS			Biological motors - Connecting stalks in V-type ATPase	NATURE			English	Article							ROTATIONAL CATALYSIS; ELECTRON-MICROSCOPY; SYNTHASE		Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands	University of Groningen	Boekema, EJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands.		Konings, Wilhelmus N./C-7063-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOYER PD, 1995, FASEB J, V9, P559, DOI 10.1096/fasebj.9.7.7737466; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	10	76	76	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					37	38		10.1038/43369	http://dx.doi.org/10.1038/43369			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485704	Green Published			2022-12-01	WOS:000082374400031
J	Sinha, A; Sazawal, S; Kumar, R; Sood, S; Reddaiah, VP; Singh, B; Rao, M; Naficy, A; Clemens, JD; Bhan, MK				Sinha, A; Sazawal, S; Kumar, R; Sood, S; Reddaiah, VP; Singh, B; Rao, M; Naficy, A; Clemens, JD; Bhan, MK			Typhoid fever in children aged less than 5 years	LANCET			English	Article							VI-CAPSULAR POLYSACCHARIDE; SALMONELLA-TYPHI; VACCINE; YOUNGER	Background Calculation of the incidence of typhoid fever during preschool years is important to define the optimum age of immunisation and the choice of vaccines for public-health programmes in developing countries. Hospital-based studies have suggested that children younger than 5 years do not need vaccination against typhoid fever, but this view needs to be re-examined in community-based longitudinal studies. We undertook a prospective follow-up study of residents of a low-income urban area of Delhi, India, with active surveillance for case detection. Methods A baseline census was undertaken in 1995, Between Nov 1, 1995, and Oct 31, 1996, we visited 8172 residents of 1820 households in Kalkaji, Delhi, twice weekly to detect febrile cases. Blood samples were obtained from febrile patients, and those who tested positive for Salmonella typhi were treated with ciprofloxacin, Findings 63 culture-positive typhoid fever cases were detected. Of these, 28 (44%) were in children aged under 5 years. The incidence rate of typhoid per 1000 person-years was 27.3 at age under 5 years, 11.7 at 5-19 years, and 1.1 between 19 and 40 years. The difference in the incidence of typhoid fever between those under 5 years and those aged 5-19 years (15.6 per 1000 person-years [95% CI 4.7-26.5]), and those aged 19-40 years (26.2 [16.0-36.3]) was significant (p<0.001 for both). The difference between the incidence of typhoid at 5-19 years and the incidence at 19-40 years was also significant (10.6 [6.3-14.8], p<0.001). Morbidity in those under 5 and in older people was similar in terms of duration of fever, signs and symptoms, and need for hospital admission. Interpretation Our findings challenge the common view that typhoid fever is a disorder of school-age children and of adults. Typhoid is a common and significant cause of morbidity between 1 and 5 years of age. The optimum age of typhoid immunisation and the choice of vaccines needs to be reassessed.	All India Inst Med Sci, Dept Pediat, Div Paediat Gastroenterol, Adv Ctr Diarrhoeal Dis Res,Indian Council Med Res, New Delhi 110029, India; All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India; All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; NICHHD, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Council of Medical Research (ICMR); All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bhan, MK (corresponding author), All India Inst Med Sci, Dept Pediat, Div Paediat Gastroenterol, Adv Ctr Diarrhoeal Dis Res,Indian Council Med Res, New Delhi 110029, India.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002528] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; ARORA R K, 1992, Indian Pediatrics, V29, P61; CHUTTANI CS, 1972, INT J EPIDEMIOL, V1, P39, DOI 10.1093/ije/1.1.39; EDELMAN R, 1986, REV INFECT DIS, V8, P329; FERRECCIO C, 1984, J PEDIATR-US, V104, P899, DOI 10.1016/S0022-3476(84)80492-8; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; Gupta A, 1994, Indian J Pediatr, V61, P321, DOI 10.1007/BF02751884; HACKETT J, 1990, VACCINE, V8, P5, DOI 10.1016/0264-410X(90)90169-M; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; KAPOOR J P, 1985, Indian Pediatrics, V22, P811; KLUGMAN KP, 1987, LANCET, V2, P1165; LEVINE MM, 1997, NEW GENERATION VACCI, P437; LEVINE MM, 1994, VACCINES, P601; MAHLE WT, 1993, PEDIATR INFECT DIS J, V12, P627, DOI 10.1097/00006454-199308000-00001; MIDDELKAMP J N, 1965, Med Times, V93, P956; MISHRA S, 1991, Indian Pediatrics, V28, P1171; MULLIGAN TO, 1971, BRIT MED J, V4, P665, DOI 10.1136/bmj.4.5788.665; PATNAIK KC, 1967, INDIAN J MED RES, V55, P228; PLOTKIN SA, 1995, ARCH INTERN MED, V155, P2293, DOI 10.1001/archinte.155.21.2293; Sen S K, 1972, Indian J Pediatr, V39, P354, DOI 10.1007/BF02753167; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; SMITH PG, 1991, METHODS FIELDS TRIAL, P292	22	285	291	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					734	737		10.1016/S0140-6736(98)09001-1	http://dx.doi.org/10.1016/S0140-6736(98)09001-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475185				2022-12-01	WOS:000082233000013
J	Engels, EA; Rosenberg, PS; O'Brien, TR; Goedert, JJ				Engels, EA; Rosenberg, PS; O'Brien, TR; Goedert, JJ		Multicenter Hemophilia Cohort Study	Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: A measure of current immune suppression	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA LEVELS; ANTIRETROVIRAL THERAPY; LYMPHOCYTE COUNTS; TYPE-1 INFECTION; PROGNOSTIC VALUE; IN-VIVO; AIDS; MACROPHAGES; PROGRESSION	Background: For patients infected with HIV, plasma HIV viral load in early disease predicts long-term prognosis. However, the implications of viral load measurements late in HIV disease are uncertain. Objective: To evaluate the relation between plasma HIV viral load and subsequent risk for disease progression in patients with late-stage HIV disease. Design: Retrospective cohort study. Setting: 16 treatment centers for patients with hemophilia. Patients: 389 patients with hemophilia and late-stage HIV disease (CD4 count < 200 cells/mm(3)). Measurements: Plasma HIV viral load was measured at baseline. Patients were followed for AIDS-related illnesses (primary outcome) and, specifically, Pneumocystis carinii pneumonia (secondary outcome). Results: HIV viral load strongly predicted AIDS-related illness. For patients with viral loads less than 4.00 log(10) copies/mL, the 1-year actuarial risk was 0% and the 5-year risk was 25%. For patients with viral loads of at least 6.00 log(10) copies/mL, the 1-year actuarial risk was 42% and the 5-year risk was 78%. A linear relation existed between viral load a nd risk for AIDS-related illness (hazard ratio, 2.37 per log(10) copies/mL; P < 0.001). In addition, viral load most strongly predicted risk for illness immediately after viral load testing; this predictive relation attenuated over time (P = 0.002). These findings changed little after adjustment for CD4 cell counts that were updated during follow-up. In the first year after viral load was measured, it predicted occurrence of P, carinii pneumonia (hazard ratio, 4.69 per log(10) copies/mL; P < 0.001). Conclusions: In patients with hemophilia and late-stage HIV disease, viral load predicts disease progression independently of CD4 cell counts. Because viral load most strongly predicts progression immediately after load is measured, it seems to reflect the current level of immunosuppression.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20822 USA; NCI, Biostat Branch, Div Canc Epidemiol & Genet, Rockville, MD 20822 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Engels, EA (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 8005, Rockville, MD 20822 USA.	engelse@exchange.nih.gov		Rosenberg, Philip/0000-0001-6349-9126	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010115, N01CP033002] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-33002] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHATURVEDI S, 1995, J INFECT DIS, V171, P320, DOI 10.1093/infdis/171.2.320; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Council of State and Territorial Epidemiologists, 1987, MMWR MORB MORTAL S1, V36, p1S; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P52; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; FLETCHER MA, 1987, DIAGN CLIN IMMUNOL, V5, P69; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GalettoLacour A, 1996, J INFECT DIS, V173, P1388, DOI 10.1093/infdis/173.6.1388; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HARRISON TS, 1995, J INFECT DIS, V172, P665, DOI 10.1093/infdis/172.3.665; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P22; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; KLEIN JP, 1997, KSURVIVAL ANAL TECHN, P83; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; KRONER BL, 1994, J ACQ IMMUN DEF SYND, V7, P279; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011; LYLES R, 1999, 6 C RETR OPP INF 31; Maas JJ, 1998, J INFECT DIS, V178, P1024, DOI 10.1086/515655; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; MURDER J, 1994, J CLIN MICROBIOL, V32, P292; O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155, DOI 10.1097/00042560-199806010-00007; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Read C, 1983, ENCY STAT SCI, V3, P86; SHIRATSUCHI H, 1994, J CLIN INVEST, V93, P885, DOI 10.1172/JCI117044; TOLLERUD DJ, 1991, J CLIN LAB ANAL, V5, P255; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; WAGNER RP, 1992, AM REV RESPIR DIS, V146, P1434, DOI 10.1164/ajrccm/146.6.1434	36	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					256	+		10.7326/0003-4819-131-4-199908170-00004	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454946				2022-12-01	WOS:000082012500003
J	Javedan, SP; Dickman, CA				Javedan, SP; Dickman, CA			Cause of adjacent-segment disease after spinal fusion	LANCET			English	Editorial Material							ANTERIOR; INSTRUMENTATION		Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA	Barrow Neurological Institute	Javedan, SP (corresponding author), Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.							AOTA Y, 1995, J SPINAL DISORD, V8, P464, DOI 10.1097/00024720-199512000-00006; Cunningham BW, 1997, SPINE, V22, P2655, DOI 10.1097/00007632-199711150-00014; Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163; FRYMOYER J W, 1978, Spine, V3, P1, DOI 10.1097/00007632-197803000-00001; GOFFIN J, 1995, J SPINAL DISORD, V8, P500; Hilibrand AS, 1997, SPINE, V22, P1574, DOI 10.1097/00007632-199707150-00009; Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009; LEE CK, 1981, SPINE, V6, P118, DOI 10.1097/00007632-198103000-00002; LUNSFORD LD, 1980, J NEUROSURG, V53, P1, DOI 10.3171/jns.1980.53.1.0001; PENTA M, 1995, SPINE, V20, P743, DOI 10.1097/00007632-199503150-00018; ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223; Shono Y, 1998, SPINE, V23, P1550, DOI 10.1097/00007632-199807150-00009; WHITEHILL R, 1987, SPINE, V12, P959, DOI 10.1097/00007632-198712000-00001; Wimmer C, 1997, ACTA ORTHOP SCAND, V68, P269, DOI 10.3109/17453679708996699; Wu W, 1996, ACTA RADIOL, V37, P614; YANG SW, 1986, SPINE, V11, P937	16	36	41	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					530	531		10.1016/S0140-6736(99)00201-9	http://dx.doi.org/10.1016/S0140-6736(99)00201-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470693				2022-12-01	WOS:000081991000006
J	Di Sebastiano, P; Fink, T; di Mola, FF; Weihe, E; Innocenti, P; Friess, H; Buchler, MW				Di Sebastiano, P; Fink, T; di Mola, FF; Weihe, E; Innocenti, P; Friess, H; Buchler, MW			Neuroimmune appendicitis	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; VASOACTIVE INTESTINAL POLYPEPTIDE; GROWTH-ASSOCIATED PROTEIN-43; RECEPTOR-BINDING SITES; CHRONIC-PANCREATITIS; SUBSTANCE-P; ULCERATIVE-COLITIS; CROHNS-DISEASE; NERVE-FIBERS; INNERVATION	Background 15-25% of appendices removed from patients with suspected appendicitis appear normal on histological examination. The cause of pain in such patients is unknown. Since the content of neuropeptides seems to be altered in chronic inflammation, we investigated possible changes in peptidergic innervation for substance P (SP), vasoactive intestinal peptide (VIP), and growth-associated protein-43 (GAP-43). Methods Appendices classified as showing acute appendicitis, non-acute appendicitis (clinical signs of acute appendicitis, but histologically not inflamed), or normal were processed for SP, VIP, and GAP-43 immunocytochemistry. The density of SP immunostaining was assessed by digitised morphometry. Findings 31 appendix specimens were studied (16 acute, 15 non-acute). 16 specimens were used as controls. Expression of GAP-43 was increased in the non-acute appendices. We observed larger amounts of SP-immunoreactive and VIP-immunoreactive nerves in the mucosal layer of the appendix in patients with non-acute appendicitis than in controls and patients with acute appendicitis (mean % area SP-immunoreactive 0.0496 [SD 0.0113] non-acute, 0.0221 [0.0049] acute, 0.0229 [0.0068] controls). In addition, a close spatial relation between SP-immunoreactive and VIP-immunoreactive nerve fibres and lymphoid cells was detected in the outer zone of lymph follicles. Interpretation Neuroproliferation in the appendix, in association with an increase in neurotransmitters SP and VIP, may be involved in the pathophysiology of acute right abdominal pain in the absence of an acute inflammation of the appendix. Our data, together with increasing knowledge about the way in which the nervous system and immune cells interact, suggest that neuroimmune appendicitis is a distinct pathological entity.	Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, CH-3010 Bern, Switzerland; Univ G DAnnunzio, Surg Unit, Chieti, Italy; Univ Mainz, Inst Legal Med, D-6500 Mainz, Germany; Univ Marburg, Dept Anat & Cell Biol, D-35032 Marburg, Germany	University of Bern; G d'Annunzio University of Chieti-Pescara; Johannes Gutenberg University of Mainz; Philipps University Marburg	Buchler, MW (corresponding author), Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, CH-3010 Bern, Switzerland.		di Mola, Fabio Francesco/J-3082-2018; di sebastiano, pierluigi/I-9851-2018	di Mola, Fabio Francesco/0000-0001-9877-2946; di sebastiano, pierluigi/0000-0002-9386-8241				AUBOCK L, 1982, J PATHOL, V136, P217, DOI 10.1002/path.1711360305; BISHOP AE, 1980, GASTROENTEROLOGY, V79, P853; BUCHLER M, 1992, PANCREAS, V7, P183; CHONG MS, 1992, EUR J NEUROSCI, V4, P883, DOI 10.1111/j.1460-9568.1992.tb00115.x; DiSebastiano P, 1997, GASTROENTEROLOGY, V112, P1648, DOI 10.1016/S0016-5085(97)70047-7; DISEBASTIANO P, 1995, DIGEST DIS SCI, V4, P333; FINK T, 1994, NEUROSCIENCE, V63, P249, DOI 10.1016/0306-4522(94)90020-5; GOLDIN E, 1989, DIGEST DIS SCI, V34, P754, DOI 10.1007/BF01540348; HORSCH D, 1993, J COMP NEUROL, V335, P381, DOI 10.1002/cne.903350308; KUBOTA Y, 1992, GASTROENTEROLOGY, V102, P1242; LAU WY, 1986, SURG GYNECOL OBSTET, V162, P256; LEMBECK F, 1985, SUBSTANCE P METABOLI, P137; MAGGI CA, 1990, NEUROSCIENCE, V39, P833, DOI 10.1016/0306-4522(90)90266-7; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MANTYH PW, 1989, PEPTIDES, V10, P627, DOI 10.1016/0196-9781(89)90154-X; MANTYH PW, 1988, NEUROSCIENCE, V25, P817, DOI 10.1016/0306-4522(88)90038-3; MASSON P, 1921, PARIS, V173, P262; MEYERMARCOTTY W, 1986, LANGENBECK ARCH CHIR, V369, P187, DOI 10.1007/BF01274349; MIETTINEN P, 1995, ANN CHIR GYNAECOL FE, V84, P267; OLSEN BS, 1987, HISTOPATHOLOGY, V11, P843, DOI 10.1111/j.1365-2559.1987.tb01887.x; OMORAIN C, 1984, GUT, V25, P57, DOI 10.1136/gut.25.1.57; PERNOW B, 1985, SUBSTANCE P METABOLI, P187; SAMELSON SL, 1987, ARCH SURG-CHICAGO, V122, P691; SHAW PAV, 1990, HISTOPATHOLOGY, V17, P117, DOI 10.1111/j.1365-2559.1990.tb00681.x; SJOLUND K, 1983, GUT, V24, P724, DOI 10.1136/gut.24.8.724; STEAD RH, 1990, J PATHOL, V161, P209, DOI 10.1002/path.1711610307; Wang Y, 1996, LANCET, V347, P1076, DOI 10.1016/S0140-6736(96)90279-2; WEIHE E, 1988, AGENTS ACTIONS, V25, P255, DOI 10.1007/BF01965027; WEIHE E, 1991, ANN NY ACAD SCI, V632, P283, DOI 10.1111/j.1749-6632.1991.tb33116.x; 1987, LANCET, V1, P198	30	97	98	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					461	466		10.1016/S0140-6736(98)10463-4	http://dx.doi.org/10.1016/S0140-6736(98)10463-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465170				2022-12-01	WOS:000081896100010
J	Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER				Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER			Analysis of questions asked by family doctors regarding patient care	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; INFORMATION NEEDS; CLINICAL QUESTIONS; PHYSICIANS	Objectives To characterise the information needs of: family doctors by collecting the questions they asked about patient care during consultations and to classify these in ways that would be useful to developers of knowledge bases. Design Observational study in which investigators visited doctors for two half days and collected their questions. Taxonomies were developed to characterise the clinical topic and generic type of information sought for each question. Setting Eastern Iowa. Participants Random sample of 103 family doctors. Main outcome measures Number of questions posed, pursued, and answered; topic and generic type of information sought for each question; time spent pursuing answers; information resources used. Results Participants asked a total of 1101 questions. Questions about drug prescribing obstetrics and gynaecology, and adult infectious disease were most common and comprised 36% of all questions. The taxonomy of generic questions included 69 categories; the three most common types, comprising 24% of all questions, were "What is the cause of symptom X?" "What is the dose of drug X?" and "How should I manage disease or finding X?" Answers to most questions (702, 64%) were not immediately pursued, but, of those pursued, most (318, 80%) were answered. Doctors spent an average of less than 2 minutes pursuing an answer, and they used readily available print and human resources. Only two questions led to a formal literature search. Conclusions Family doctors in this study did not pursue answers to most of their questions. Questions about patient care can be organised into a limited number of generic types, which could help guide the efforts of knowledge base developers.	Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA; Amer Coll Phys, Amer Soc Internal Med, Philadelphia, PA USA; Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA; Moses Cone Hosp Family Med Residency, Greensboro, NC USA; Univ Iowa, Student Hlth Serv, Iowa City, IA USA	University of Iowa; American College of Physicians; Michigan State University; Moses Cone Memorial Hospital; University of Iowa	Ely, JW (corresponding author), Univ Iowa, Coll Med, Dept Family Med, 200 Hawkins Dr,01291-D PFP, Iowa City, IA 52242 USA.		Bergus, George/AAS-9522-2021	Levy, Barcey/0000-0002-3315-4116				Chambliss ML, 1996, J FAM PRACTICE, V43, P140; CIMINO JJ, 1993, B MED LIBR ASSOC, V81, P195; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; EBELL MH, 1998, MD COMPUTING, V15, P189; ELY JW, 1992, J FAM PRACTICE, V35, P265; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; GORMAN PN, 1994, B MED LIBR ASSOC, V82, P140; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Haug JD, 1997, B MED LIBR ASSOC, V85, P223; HUTH EJ, 1994, ANN INTERN MED, V120, P889, DOI 10.7326/0003-4819-120-10-199405150-00012; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; REYNOLDS RD, 1995, J FAM PRACTICE, V41, P583; Sackett D.L., 1997, EVIDENCE BASED MED P; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Shaughnessy AF, 1998, J FAM PRACTICE, V47, P425; Smith R, 1996, BRIT MED J, V313, P1062; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; VERHOEVEN AAH, 1995, B MED LIBR ASSOC, V83, P85; WILSON SR, 1989, USE CRITICAL INCIDEN; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	23	338	343	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					358	361		10.1136/bmj.319.7206.358	http://dx.doi.org/10.1136/bmj.319.7206.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435959	Bronze, Green Published			2022-12-01	WOS:000082001700021
J	Tesmer, JJG; Sunahara, RK; Johnson, RA; Gosselin, G; Gilman, AG; Sprang, SR				Tesmer, JJG; Sunahara, RK; Johnson, RA; Gosselin, G; Gilman, AG; Sprang, SR			Two-metal-ion catalysis in adenylyl cyclase	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; DNA-POLYMERASE-BETA; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; GUANYLYL CYCLASES; CYTOSOLIC DOMAINS; RNA-POLYMERASE; MECHANISM; BINDING; COMPLEX	Adenylyl cyclase (AC) converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate, a ubiquitous second messenger that regulates many cellular functions. Recent structural studies have revealed much about the structure and function of mammalian AC but have not fully defined its active site or catalytic mechanism. Four crystal structures were determined of the catalytic domains of AC in complex with two different ATP analogs and various divalent metal ions. These structures provide a model for the enzyme-substrate complex and conclusively demonstrate that two metal ions bind in the active site. The similarity of the active site of AC to those of DNA polymerases suggests that the enzymes catalyze phosphoryl transfer by the same two-metal-ion mechanism and likely have evolved from a common ancestor.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, Chim Bioorgan Lab, F-34095 Montpellier 5, France	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Universite de Montpellier	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371, R01DK038828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46371, DK38828] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COOPER DMF, 1998, ADV 2 MESSENGER PHOS, V32; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; LESLIE AGW, 1997, MOSFLM 5 50 IMAGE PL; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; PADMAJA N, 1991, B CHEM SOC JPN, V64, P1359, DOI 10.1246/bcsj.64.1359; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SHELDRICK WS, 1978, ACTA CRYSTALLOGR B, V34, P2324, DOI 10.1107/S0567740878008067; SHOSHANI I, UNPUB; SLABY I, 1984, BIOCHEM BIOPH RES CO, V122, P1410, DOI 10.1016/0006-291X(84)91248-8; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUNAHAVA I, UNPUB; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; VARUGHESE KI, 1982, J AM CHEM SOC, V104, P3398, DOI 10.1021/ja00376a026; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	45	268	276	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					756	760		10.1126/science.285.5428.756	http://dx.doi.org/10.1126/science.285.5428.756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427002				2022-12-01	WOS:000081765100061
J	Ballard, JO				Ballard, JO			Anticoagulant-induced thrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; INDUCED SKIN NECROSIS; WARFARIN		Penn State Univ, Milton S Hershey Med Ctr, Geisinger Hlth Syst,Coll Med, Sect Hematol Oncol H046, Hershey, PA 17033 USA	Geisinger Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ballard, JO (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Geisinger Hlth Syst,Coll Med, Sect Hematol Oncol H046, POB 850, Hershey, PA 17033 USA.							BAUER KA, 1987, BLOOD, V70, P343; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; FIORE L, 1995, WILLIAMS HEMATOLOGY, P1562; Greinacher A, 1999, CIRCULATION, V99, P73, DOI 10.1161/01.CIR.99.1.73; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P554; Sallah S, 1997, THROMB HAEMOSTASIS, V78, P785; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Warkentin TE, 1997, ANN INTERN MED, V127, P804, DOI 10.7326/0003-4819-127-9-199711010-00005; Warkentin TE, 1996, AM J MED, V101, P502, DOI 10.1016/S0002-9343(96)00258-6; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1	11	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					310	312		10.1001/jama.282.4.310	http://dx.doi.org/10.1001/jama.282.4.310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432014				2022-12-01	WOS:000081596800003
J	Boulton, M; Beck, E; Walters, S; Miller, D				Boulton, M; Beck, E; Walters, S; Miller, D			General practice and the care of children with HIV infection: 6 month prospective interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; PRACTITIONERS; INVOLVEMENT; VIEWS; WOMEN; AIDS	Objectives To describe the use of primary care services by children infected with HIV and to explore the attitudes of their parents to the role of general practitioners in their children's care. Design A 6 month prospective study. Quantitative analysis of "contact diaries" kept by parents; qualitative analysis of face to face interviews with parents. Participants Parents of children receiving care at a regional referral centre in London. Results Twenty four families (80% response rate) were recruited to the study. In 19 families the mother was black African. Half the children had been diagnosed with symptomatic HIV infection, half with AIDS. All the children were registered with a general practitioner who knew of the child's HIV infection. In five families there had initially been tensions in their relationship with their general practitioner but by the time of the study all but one family had established at least an "acceptable" relationship Children with symptomatic HIV infection saw their general practitioner a mean of 7.5 times per patient year; for children with AIDS the figure was 5.8. Parents regarded the paediatric HIV team at the hospital as their primary source of medical care. Three factors constrained their use of general practice: their own anxieties about distinguishing "normal" symptoms from those related to HIV infection; their view that. their general practitioner did not feel competent to treat HIV infected children; and their concerns about maintaining confidentiality in the surgery. Conclusions Parents remain oriented towards. the paediatric HIV team as their primary source of medical care and use general practice largely for routine prescriptions for their children. Any further development of the general practitioner's role will need to build on existing relationships with specialist providers and take account of parents' concerns.	Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England	Imperial College London; Imperial College London	Boulton, M (corresponding author), Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England.	m.boulton@ic.ac.uk	BOULTON, Mary/X-9056-2019	BOULTON, Mary/0000-0002-2247-8318				BECK EJ, 1997, HOSP COMMUNITY SERVI; BOULTON M, 1997, EXPERIENCE FAMILIES; CLARKE AE, 1993, FAM PRACT, V10, P8, DOI 10.1093/fampra/10.1.8; *COMM DIS SURV CTR, 1998, COMMUN DIS REP CDR W, V8, P386; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; Huby G, 1998, AIDS CARE, V10, pS83, DOI 10.1080/09540129850124398; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, J ROY COLL GEN PRACT, V39, P280; Madge S, 1998, BRIT J GEN PRACT, V48, P1329; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Shaw M, 1996, BRIT MED J, V312, P1463, DOI 10.1136/bmj.312.7044.1463; SHELDON J, 1993, FAM PRACT, V10, P396, DOI 10.1093/fampra/10.4.396; SINGH S, 1993, BRIT J GEN PRACT, V43, P182; Smith S, 1996, BRIT MED J, V312, P416, DOI 10.1136/bmj.312.7028.416	16	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					232	235		10.1136/bmj.319.7204.232	http://dx.doi.org/10.1136/bmj.319.7204.232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417088	Bronze, Green Published			2022-12-01	WOS:000081720300027
J	van Heemst, D; James, F; Poggeler, S; Berteaux-Lecellier, V; Zickler, D				van Heemst, D; James, F; Poggeler, S; Berteaux-Lecellier, V; Zickler, D			Spo76p is a conserved chromosome morphogenesis protein that links the mitotic and meiotic programs	CELL			English	Article							SISTER-CHROMATID COHESION; SORDARIA-MACROSPORA; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEX; MATING-TYPE; MEIOSIS; RECOMBINATION; GENE; ORGANIZATION; CONDENSATION	Spo76p is conserved and related to the fungal proteins Pds5p and BIMD and the human AS3 prostate proliferative shutoff-associated protein. Spo76p localizes to mitotic and meiotic chromosomes, except at metaphase(s) and anaphase(s). During meiotic prophase, Spo76p assembles into strong lines in correlation with axial element formation. As inferred from spo76-1 mutant phenotypes, Spo76p is required for sister chromatid cohesiveness, chromosome axis morphogenesis, and chromatin condensation during critical transitions at mitotic prometaphase and meiotic midprophase. Spo76p is also required for meiotic interhomolog recombination, likely at postinitiation stage(s). We propose that a disruptive force coordinately promotes chromosomal axial compaction and destabilization of sister connections and that Spo76p restrains and channels the effects of this force into appropriate morphogenetic mitotic and meiotic outcomes.	Univ Paris Sud, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France; Ruhr Univ Bochum, Lehrstuhl Allgemeine Bot, D-44780 Bochum, Germany	UDICE-French Research Universities; Universite Paris Saclay; Ruhr University Bochum	van Heemst, D (corresponding author), Univ Paris Sud, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France.	zickler@igmors.u-psud.fr	Berteaux-Lecellier, Veronique/O-4767-2018; BERTEAUX-LECELLIER, Veronique/P-6456-2019	Berteaux-Lecellier, Veronique/0000-0003-2152-6231; BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231	NIGMS NIH HHS [R37 GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; Bickel SE, 1997, GENETICS, V146, P1319; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAWE RK, 1994, CELL, V76, P901, DOI 10.1016/0092-8674(94)90364-6; DENISON SH, 1993, GENETICS, V134, P1085; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Geck P, 1999, J STEROID BIOCHEM, V68, P41, DOI 10.1016/S0960-0760(98)00165-4; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Holt CL, 1996, GENETICS, V142, P777; HUYNH AD, 1986, CURR GENET, V10, P545, DOI 10.1007/BF00447389; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LECELLIER G, 1994, CURR GENET, V25, P122, DOI 10.1007/BF00309536; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; MOREAU PJF, 1985, MOL GEN GENET, V198, P189, DOI 10.1007/BF00382995; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; OSIEWACZ HD, 1994, CURR GENET, V26, P87, DOI 10.1007/BF00326309; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Poggeler S, 1997, GENETICS, V147, P567; PUKKILA PJ, 1995, CAN J BOT, V73, pS215; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SLONIMSKI PP, 1993, YEAST, V9, P941, DOI 10.1002/yea.320090902; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; THOMPSONCOFFE C, 1994, DEV BIOL, V165, P257, DOI 10.1006/dbio.1994.1251; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; TURCQ B, 1990, CURR GENET, V17, P297, DOI 10.1007/BF00314876; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619; ZICKLER D, 1992, GENETICS, V132, P135	45	104	106	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					261	271		10.1016/S0092-8674(00)81020-X	http://dx.doi.org/10.1016/S0092-8674(00)81020-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428037	Bronze			2022-12-01	WOS:000081632300015
J	Ely, EW; Evans, GW; Haponik, EF				Ely, EW; Evans, GW; Haponik, EF			Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	95th International Conference of the American-Thoracic-Society	APR 23-29, 1999	SAN DIEGO, CA	Amer Thorac Soc		respiration, artificial; age factors; intensive care units; outcome and process assessment (health care); health resources	ILL HOSPITALIZED ADULTS; NEW-YORK-STATE; RESPIRATORY-FAILURE; AGE; MORTALITY; SURVIVAL; SUPPORT; IMPACT; LIFE; PREFERENCES	Background: It has been argued that life support for the elderly should be limited to conserve resources. As this population increases, so will the importance of evaluating appropriate use of mechanical ventilation in this group. Objective: To determine whether age has an independent effect on the outcomes of patients treated with mechanical ventilation after admission to an intensive care unit (ICU). Design: Prospective cohort study. Setting: University-based tertiary care medical center. Patients: 63 patients 75 years of age or older and 237 patients younger than 75 years of age enrolled from medical and coronary ICUs. Measurements: In-hospital mortality rate, duration of mechanical ventilation, lengths of stay in the ICU and in the hospital, and cost of care. Results: Median duration of mechanical ventilation was 4.2 days (interquartile range, 2.1 to 9.3 days) for patients 75 years of age or older and 6.4 days (interquartile range, 3.4 to 11.4 days) for patients younger than 75 years of age (P = 0.14). When the length of time required to "pass" a daily screening test of weaning variables was used as an indicator of recovery from respiratory failure, elderly patients passed earlier than younger patients (risk ratio, 1.58 [95% CI, 1.13 to 2.22]; P = 0.03). The cost of ICU care was lower for older ($12 822 [CI, $9821 to $26 313] than for younger ($19 316 [CI, $9699 to $39 950]) patients (P = 0.03). Median hospital costs tended to be lower in the older group ($21 292 compared with $29 049; P = 0.17). After adjustment for ethnicity, sex, and severity of illness in a multivariate logistic regression analysis, patient age of 75 years or older was predictive of 1 less day on the ventilator (CI, -2.8 to 1.2 days). Lengths of stay in the ICU (beta-coefficient, -0.5 days [CI, -3.0 to 2.7 days]) and in the hospital (beta-coefficient, 0.3 days [CI, -3.7 to 5.5 days]) did not differ for persons 75 years of age or older after these adjustments (P > 0.1). Intensive care unit and hospital costs, however, were lower for elderly persons (P = 0.02). The in-hospital mortality rate was 38.1% among elderly patients and 38.8% among younger patients (P > 0.2); Cox proportional hazards analysis confirmed that survival did not differ between the two groups (relative risk for older patients, 0.82 [CI, 0.52 to 1.29]). Conclusions: After adjustment for severity of illness, elderly patients spent similar time on mechanical ventilation and in the ICU and hospital but had a lower cost of care than younger patients. These outcomes are not explained by differences in mortality rate and suggest that mechanical ventilation should not be restricted in elderly patients with respiratory failure on the basis of chronologic age.	Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA	Vanderbilt University; Wake Forest University	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, 913 Oxford House, Nashville, TN 37232 USA.		Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172				Baltussen R, 1996, HEALTH ECON, V5, P227, DOI 10.1002/(SICI)1099-1050(199605)5:3<227::AID-HEC198>3.3.CO;2-P; Barrett-Connor E, 1998, JAMA-J AM MED ASSOC, V279, P622, DOI 10.1001/jama.279.8.622; Blouin AS, 1996, J NURS ADMIN, V26, P3, DOI 10.1097/00005110-199611000-00001; BOULT C, 1993, J AM GERIATR SOC, V41, P811, DOI 10.1111/j.1532-5415.1993.tb06175.x; Campion EW, 1998, NEW ENGL J MED, V338, P1064, DOI 10.1056/NEJM199804093381512; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DARDAINE V, 1995, AGING-CLIN EXP RES, V7, P221, DOI 10.1007/BF03324339; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; ELPERN EH, 1989, CHEST, V96, P1120, DOI 10.1378/chest.96.5.1120; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Fried TR, 1996, J GEN INTERN MED, V11, P257, DOI 10.1007/BF02598264; Giugliano RP, 1998, ARCH INTERN MED, V158, P1113, DOI 10.1001/archinte.158.10.1113; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; GRACEY DR, 1992, CHEST, V101, P211, DOI 10.1378/chest.101.1.211; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HEUSER MD, 1992, ARCH INTERN MED, V152, P1683, DOI 10.1001/archinte.152.8.1683; Hobbs FB, 1995, 65 PLUS US; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kurek CJ, 1998, CHEST, V114, P214, DOI 10.1378/chest.114.1.214; Kurek CJ, 1997, CRIT CARE MED, V25, P983, DOI 10.1097/00003246-199706000-00015; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, P295; PAPADAKIS MA, 1993, WESTERN J MED, V159, P659; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; STAUFFER JL, 1993, CHEST, V104, P1222, DOI 10.1378/chest.104.4.1222; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; SWINBURNE AJ, 1993, ARCH INTERN MED, V153, P1657, DOI 10.1001/archinte.153.14.1657; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; WITEK TJ, 1985, ARCH INTERN MED, V145, P235, DOI 10.1001/archinte.145.2.235; Yuen E J, 1995, Am J Med Qual, V10, P76, DOI 10.1177/0885713X9501000203; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	54	132	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					96	+		10.7326/0003-4819-131-2-199907200-00004	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	217QD	10419447				2022-12-01	WOS:000081509700003
J	Peng, JR; Richards, DE; Hartley, NM; Murphy, GP; Devos, KM; Flintham, JE; Beales, J; Fish, LJ; Worland, AJ; Pelica, F; Sudhakar, D; Christou, P; Snape, JW; Gale, MD; Harberd, NP				Peng, JR; Richards, DE; Hartley, NM; Murphy, GP; Devos, KM; Flintham, JE; Beales, J; Fish, LJ; Worland, AJ; Pelica, F; Sudhakar, D; Christou, P; Snape, JW; Gale, MD; Harberd, NP			'Green revolution' genes encode mutant gibberellin response modulators	NATURE			English	Article							WHEAT; MAIZE; TRANSDUCTION; EVOLUTION; DWARFISM; GENETICS; ALLELES; PATHWAY; DNA; SH2	World wheat grain yields increased substantially in the 1960s and 1970s because farmers rapidly adopted the new varieties and cultivation methods of the so-called 'green revolution(1-4). The new varieties are shorter, increase grain yield at the expense of straw biomass, and are more resistant to damage by wind and rain(3,4). These wheats are short because they respond abnormally to the plant growth hormone gibberellin, This reduced response to gibberellin is conferred by mutant dwarfing alleles at one of two Reduced height-1 (Rht-B1 and Rht-D1) loci(4,5), Here we show that Rht-B1/Rht-D1 and maize dwarf-8 (d8)(6,7) are orthologues of the Arabidopsis Gibberellin Insensitive (GAI) gene(8,9). These genes encode proteins that resemble nuclear transcription factors and contain an SH2-like(10) domain, indicating that phosphotyrosine may participate in gibberellin signalling. Six different orthologous dwarfing mutant alleles encode proteins that are altered in a conserved amino-terminal gibberellin signalling domain, Transgenic rice plants containing a mutant GAI allele give reduced responses to gibberellin and are dwarfed, indicating that mutant GAI orthologues could be used to increase yield in a wide range of crop species.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Harberd, NP (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk,Colney Lane, Norwich NR4 7UH, Norfolk, England.	harberd@bbsrc.ac.uk	Christou, Paul/C-8645-2011; Devos, Katrien M/B-1380-2014	Christou, Paul/0000-0001-6358-7396; Peng, Jinrong/0000-0002-0793-4848; Snape, john/0000-0002-9241-3931	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000583] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Borner A, 1996, EUPHYTICA, V89, P69, DOI 10.1007/BF00015721; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Conway G., 1997, DOUBLY GREEN REVOLUT; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVOS KM, 1995, THEOR APPL GENET, V91, P282, DOI 10.1007/BF00220890; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Dyson T, 1996, POPULATION FOOD GLOB; Evans L.T., 1993, CROP EVOLUTION ADAPT; FUJIOKA S, 1988, P NATL ACAD SCI USA, V85, P9031, DOI 10.1073/pnas.85.23.9031; Futterer J, 1996, PLANT MOL BIOL, V32, P159, DOI 10.1007/BF00039382; Gale M. D., 1985, Progress in plant breeding - 1, P1; GALE MD, 1976, HEREDITY, V37, P283, DOI 10.1038/hdy.1976.88; HARBERD NP, 1989, GENETICS, V121, P827; HOOLEY R, 1994, PLANT MOL BIOL, V26, P1529, DOI 10.1007/BF00016489; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KURATA N, 1994, NAT GENET, V8, P365, DOI 10.1038/ng1294-365; MOORE G, 1995, CURR BIOL, V5, P737, DOI 10.1016/S0960-9822(95)00148-5; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, PLANT PHYSIOL, V119, P1199, DOI 10.1104/pp.119.4.1199; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Schumacher K, 1999, P NATL ACAD SCI USA, V96, P290, DOI 10.1073/pnas.96.1.290; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Sudhakar D, 1998, TRANSGENIC RES, V7, P289, DOI 10.1023/A:1008870012568; Webb SE, 1998, PHYTOCHEMISTRY, V47, P671, DOI 10.1016/S0031-9422(97)00684-5; WINKLER RG, 1994, PLANTA, V193, P341, DOI 10.1007/BF00201811; Winkler RG, 1993, MAIZE GENET COOP NEW, V67, P110	30	1376	1656	34	576	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					256	261		10.1038/22307	http://dx.doi.org/10.1038/22307			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421366				2022-12-01	WOS:000081503800042
J	Visscher, K; Schnitzer, MJ; Block, SM				Visscher, K; Schnitzer, MJ; Block, SM			Single kinesin molecules studied with a molecular force clamp	NATURE			English	Article							STOCHASTIC-MODEL; MYOSIN MOLECULE; ATP HYDROLYSIS; OPTICAL TRAPS; MOTOR; MECHANICS; KINETICS; MOVEMENT; MICROTUBULES; STEPS	Kinesin is a two-headed, ATP-driven motor protein that moves processively along microtubules in discrete steps of 8 nm, probably by advancing each of its heads alternately in sequence(1-4). Molecular details of how the chemical energy stored in ATP is coupled to mechanical displacement remain obscure. To shed light on this question, a force clamp was constructed, based on a feedback-driven optical trap capable of maintaining constant loads on single kinesin motors(5). The instrument provides unprecedented resolution of molecular motion and permits mechanochemical studies under controlled external loads. Analysis of records of kinesin motion under variable ATP concentrations and loads revealed several new features. First, kinesin stepping appears to be tightly coupled to ATP hydrolysis over a wide range of forces, with a single hydrolysis per 8-nm mechanical advance. Second, the kinesin stall force depends on the ATP concentration. Third, increased loads reduce the maximum velocity as expected, but also raise the apparent Michaelis-Menten constant. The kinesin cycle therefore contains at least one load-dependent transition affecting the rate at which ATP molecules bind and subsequently commit to hydrolysis, It is likely that at least one other load-dependent rate exists, affecting turnover number. Together, these findings will necessitate revisions to our understanding of how kinesin motors function.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Schnitzer, MJ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HIGUCHI H, 1998, CELL STRUCT FUNCT S, V23, P198; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1995, BIOPHYS J, V68, pS245; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0	32	802	816	0	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					184	189		10.1038/22146	http://dx.doi.org/10.1038/22146			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408448				2022-12-01	WOS:000081324900059
J	Wiesmann, C; Ultsch, MH; Bass, SH; de Vos, AM				Wiesmann, C; Ultsch, MH; Bass, SH; de Vos, AM			Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; TYROSINE KINASE RECEPTORS; LEUCINE-RICH MOTIF; NEUROTROPHIN RECEPTORS; AFFINITY RECEPTOR; NGF; RESOLUTION; SITE; DIFFERENTIATION; SPECIFICITY	Nerve growth factor (NGF) is involved in a variety of processes involving signalling, such as cell differentiation and survival, growth cessation and apoptosis of neurons'. These events are mediated by NGF as a result of binding to its two cell-surface receptors,TrkA and p75 (ref. 2). TrkA is a receptor with tyrosine kinase activity that forms a high-affinity binding site for NGF(3). Of the five domains comprising its extracellular portion, the immunoglobulin-like domain proximal to the membrane (TrkA-d5 domain) is necessary and sufficient for NGF binding(4). Here we present the crystal structure of human NGF in complex with human TrkA-d5 at 2.2 Angstrom resolution. The ligand-receptor interface consists of two patches of similar size. One patch involves the central beta-sheet that forms the core of the homodimeric NGF molecule and the loops at the carboxy-terminal pole of TrkA-d5. The second patch comprises the amino-terminal resudes of NGF, which adopt a helical conformation upon complex formation, packing against the 'ABED' sheet of TrkA-d5. The structure is consistent with results from mutagenesis experiments for all neurotrophins, and indicates that the first patch may constitute a conserved binding motif for all family members, whereas the second patch is specific for the interaction between NGF and TrkA.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	de Vos, AM (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.			Wiesmann, Christian/0000-0002-4092-9880				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DECHANT G, 1997, J NEUROSCI, V17, P5271; GOTZ R, 1994, NATURE, V372, P366; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.3.CO;2-9; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Ryden M, 1997, J BIOL CHEM, V272, P33085, DOI 10.1074/jbc.272.52.33085; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; Urfer R, 1998, J BIOL CHEM, V273, P5829, DOI 10.1074/jbc.273.10.5829; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	30	303	331	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					184	188		10.1038/43705	http://dx.doi.org/10.1038/43705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490030				2022-12-01	WOS:000082458800059
J	Henney, JE				Henney, JE			Endotoxin-like reactions to gentamicin sulfate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-01	WOS:000082335900006
J	Rice, TW				Rice, TW			Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy?	LANCET			English	Editorial Material									Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Rice, TW (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA.							CHRISTIE NA, IN PRESS J THORAC CA; Matsubara T, 1999, BRIT J SURG, V86, P669, DOI 10.1046/j.1365-2168.1999.01067.x; Nigro JJ, 1999, J THORAC CARDIOV SUR, V117, P16, DOI 10.1016/S0022-5223(99)70464-2; Rice TW, 1998, ANN THORAC SURG, V65, P787, DOI 10.1016/S0003-4975(97)01387-8	4	45	47	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					792	794						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485718				2022-12-01	WOS:000082400700005
J	Lin, JY; Qi, R; Aston, C; Jing, JP; Anantharaman, TS; Mishra, B; White, O; Daly, MJ; Minton, KW; Venter, JC; Schwartz, DC				Lin, JY; Qi, R; Aston, C; Jing, JP; Anantharaman, TS; Mishra, B; White, O; Daly, MJ; Minton, KW; Venter, JC; Schwartz, DC			Whole-genome shotgun optical mapping of Deinococcus radiodurans	SCIENCE			English	Article							ORDERED RESTRICTION MAPS; IONIZING-RADIATION; FORCE MICROSCOPY; DNA-MOLECULES; PHYSICAL MAP; CHROMOSOME; RECOMBINATION; SURFACES; REPAIR	A whole-genome restriction map of Deinococcus radiodurans, a radiation-resistant bacterium able to survive up to 15,000 grays of ionizing radiation, was constructed without using DNA Libraries, the polymerase chain reaction, or electrophoresis. Very Large, randomly sheared, genomic DNA fragments were used to construct maps from individual DNA molecules that were assembled into two circular overlapping maps (2.6 and 0.415 megabases), without gaps. A third smaller chromosome (176 kilobases) was identified and characterized. Aberrant nonlinear DNA structures that may define chromosome structure and organization, as well as intermediates in DNA repair, were directly visualized by optical mapping techniques after gamma irradiation.	NYU, Dept Chem, WM Keck Lab Biomol Imaging, New York, NY 10003 USA; NYU, Courant Inst Math Sci, Dept Comp Sci, New York, NY 10012 USA; Inst Genome Res, Rockville, MD 20850 USA; Celera Genom, Rockville, MD 20850 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	New York University; New York University; J. Craig Venter Institute; Uniformed Services University of the Health Sciences - USA	Schwartz, DC (corresponding author), Univ Wisconsin, Ctr Biotechnol, Dept Chem, 425 Henry Mall, Madison, WI 53706 USA.				NHGRI NIH HHS [HG0025-08] Funding Source: Medline; NIGMS NIH HHS [GM 39933] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman TS, 1997, J COMPUT BIOL, V4, P91, DOI 10.1089/cmb.1997.4.91; ANANTHARAMAN TS, IN PRESS 7 INT C INT; ANANTHARAMAN TS, 1998, 760 NEW YORK U COUR; Aston C, 1999, METHOD ENZYMOL, V303, P55; BAUTSCH W, 1997, GENOME MAPPING PRACT, P281; BEDERSON BB, 1998, HUMAN FACTORS WEB DE, P255; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLATTNER FR, UNPUB; CAI WW, 1995, P NATL ACAD SCI USA, V92, P5164, DOI 10.1073/pnas.92.11.5164; Cai WW, 1998, P NATL ACAD SCI USA, V95, P3390, DOI 10.1073/pnas.95.7.3390; Daly MJ, 1997, GENE, V187, P225, DOI 10.1016/S0378-1119(96)00755-X; DALY MJ, 1995, SCIENCE, V270, P1318, DOI 10.1126/science.270.5240.1318; Daly MJ, 1996, J BACTERIOL, V178, P4461, DOI 10.1128/jb.178.15.4461-4471.1996; DALY MJ, 1995, J BACTERIOL, V177, P5505; DALY MM, UNPUB; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HANSEN MT, 1978, J BACTERIOL, V134, P71, DOI 10.1128/JB.134.1.71-75.1978; Jing JP, 1999, GENOME RES, V9, P175; KIKUCHI M, 1994, RADIAT RES, V139, P123, DOI 10.2307/3578742; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAI Z, UNPUB; Lee E, UNPUB; LINK AJ, 1991, GENETICS, V127, P681; LIOUTAS C, 1995, EXP PARASITOL, V80, P349, DOI 10.1006/expr.1995.1045; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; Minton KW, 1996, MUTAT RES-DNA REPAIR, V363, P1, DOI 10.1016/0921-8777(95)00014-3; MINTON KW, 1995, BIOESSAYS, V17, P457, DOI 10.1002/bies.950170514; Reed J, 1998, ANAL BIOCHEM, V259, P80, DOI 10.1006/abio.1998.2640; SAMAD AH, 1995, NATURE, V378, P516, DOI 10.1038/378516a0; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; Schwartz DC, 1997, CURR OPIN BIOTECH, V8, P70, DOI 10.1016/S0958-1669(97)80160-7; Wang WN, 1998, BIOPHYS J, V75, P513, DOI 10.1016/S0006-3495(98)77540-X; WHITE O, UNPUB	35	143	167	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1558	1562		10.1126/science.285.5433.1558	http://dx.doi.org/10.1126/science.285.5433.1558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477518				2022-12-01	WOS:000082359500063
J	Hansen, D; Moller, H; Olsen, J				Hansen, D; Moller, H; Olsen, J			Severe periconceptional life events and the sex ratio in offspring: follow up study based on five national registers	BRITISH MEDICAL JOURNAL			English	Article							BIRTH		John F Kennedy Inst, DK-2600 Glostrup, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark; Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danmarks Grundforskningsfond; Aarhus University	Hansen, D (corresponding author), John F Kennedy Inst, G1 Landevej 7, DK-2600 Glostrup, Denmark.			Moller, Henrik/0000-0001-8200-5929				Fenster L, 1997, J ANDROL, V18, P194; Fukuda M, 1998, HUM REPROD, V13, P2321, DOI 10.1093/humrep/13.8.2321; James WH, 1996, J THEOR BIOL, V180, P271, DOI 10.1006/jtbi.1996.0102; LYSTER WR, 1974, J OBSTET GYN BR COMM, V81, P626; PRATT NC, 1989, J REPROD FERTIL, V87, P736	5	112	113	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					548	549		10.1136/bmj.319.7209.548	http://dx.doi.org/10.1136/bmj.319.7209.548			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463895	Green Published, Bronze			2022-12-01	WOS:000082347200022
J	Dowsing, AT; Yong, EL; Clark, M; McLachlan, RI; de Kretser, DM; Trounson, AO				Dowsing, AT; Yong, EL; Clark, M; McLachlan, RI; de Kretser, DM; Trounson, AO			Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene	LANCET			English	Article							DOMINANT CEREBELLAR-ATAXIA; CAG REPEAT; MEN; CHROMOSOME; DISEASE; SPERM; TRANSACTIVATION; INSENSITIVITY; AZOOSPERMIA; MUTATIONS	Background Androgens acting via the androgen receptor bring about stimulation and maintenance of spermatogenesis. If mutations in the androgen-receptor gene interfere with the receptor's function, this effect may partly account for impaired spermatogenesis. We aimed to find out whether expansion of a trinucleotide repeat in the androgen-receptor gene is associated with male infertility. Methods We analysed 67 coded semen and blood samples from a predominantly white group of male infertility patients and controls. Clinical analyses included cause of infertility, sperm count, and reproductive hormone concentrations. Analysis of trinucleotide (CAG) repeal length and point mutations in the androgen-receptor gene was done by PCR, single-stranded conformational polymorphism, and DNA sequencing. Findings Screening and characterisation of the androgen-receptor gene in 35 patients and 32 controls showed no point mutations in the gene. 30 of the infertile patients had idiopathic azoospermia or oligozoospermia, and these men had significantly longer CAG repeat tracts than controls (mean 23.2 [SE 0.7] vs 20.5 [0.3], p=0.0001). The odds of having CAG repeat lengths of 20 were six-fold higher for fertile men than for men with a spermatogenic disorder. Interpretation Our results indicate a relation between CAG repeat length in the androgen-receptor gene and the risk of defective spermatogenesis. With the use of intracytoplasmic sperm injection, this mutation could be inherited. possibly leading to an increase in male infertility in future generations. Should further elongation of the CAG repeat occur in these future generations, there is an added risk of increased severity of male infertility, and potentially an increased incidence of neurodegenerative disease.	Monash Univ, Monash Med Ctr, Ctr Early Human Dev, Inst Reprod & Dev, Clayton, Vic 3168, Australia; Monash Univ, Monash Med Ctr, Dept Math & Stat, Clayton, Vic 3168, Australia; Monash Univ, Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore, Singapore	Monash University; Monash University; Monash University; Prince Henry's Institute of Medical Research; National University of Singapore	Trounson, AO (corresponding author), Monash Univ, Monash Med Ctr, Ctr Early Human Dev, Inst Reprod & Dev, Level 5,246 Clayton Rd, Clayton, Vic 3168, Australia.			Yong, Eu-Leong/0000-0001-6511-770X; Trounson, Alan/0000-0001-5469-0500				AIMAN J, 1982, J CLIN ENDOCR METAB, V54, P725, DOI 10.1210/jcem-54-4-725; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LIU DY, 1994, HUM REPROD, V9, P1694, DOI 10.1093/oxfordjournals.humrep.a138776; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; McLachlan RI, 1996, J ENDOCRINOL, V148, P1, DOI 10.1677/joe.0.1480001; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PUSCHECK EE, 1994, FERTIL STERIL, V62, P1035; Tincello DG, 1997, MOL HUM REPROD, V3, P941, DOI 10.1093/molehr/3.11.941; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; *WHO, 1987, INT J ANDROL S, V7, P3; *WHO, 1996, 2 WHO LAB MAN EX HUM; YONG EL, 1994, FERTIL STERIL, V61, P856; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	25	217	222	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					640	643		10.1016/S0140-6736(98)08413-X	http://dx.doi.org/10.1016/S0140-6736(98)08413-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466666				2022-12-01	WOS:000082214500013
J	Ni, M; Tepperman, JM; Quail, PH				Ni, M; Tepperman, JM; Quail, PH			Binding of phytochrome B to its nuclear signalling partner PIF3 is reversibly induced by light	NATURE			English	Article							REGULATORY ACTIVITY; TERMINAL-DOMAIN; TRANSDUCTION; PROTEIN	The phytochrome photoreceptor family directs plant gene expression by switching between biologically inactive and active conformers in response to the sequential absorption of red and far-red photons(1,2). Several intermediates that act late in the phytochrome signalling pathway have been identified, but fewer have been identified that act early in the pathway(3,4). We have cloned a nuclear basic helix-loop-helix protein, PIF3, which can bind to non-photoactive carboxy-terminal fragments of phytochromes A and B and functions in phytochrome signalling in vivo(5). Here we show that full-length photoactive phytochrome B binds PIF3 in vitro only upon light-induced conversion to its active form, and that photoconversion back to its inactive form causes dissociation from PIF3. We conclude that photosensory signalling by phytochrome B involves light-induced, conformer-specific recognition of the putative transcriptional regulator PIF3, providing a potential mechanism for direct photoregulation of gene expression.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; USDA ARS, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.		Ni, Maria/GVT-4942-2022					Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; DENG XW, IN PRESS SEMIN CELL; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Quail PH, 1998, PHILOS T R SOC B, V353, P1399, DOI 10.1098/rstb.1998.0294; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; Scheer H., 1984, TECHNIQUES PHOTOMORP, P227, DOI [10.5282/ubm/epub.2167, DOI 10.5282/UBM/EPUB.2167]; SOMERS DE, 1991, PLANT CELL, V3, P1263, DOI 10.1105/tpc.3.12.1263; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Tobin Elaine M., 1994, Seminars in Cell Biology, V5, P335, DOI 10.1006/scel.1994.1040; WAGNER D, 1995, P NATL ACAD SCI USA, V92, P8596, DOI 10.1073/pnas.92.19.8596; Wei N, 1996, PLANT PHYSIOL, V112, P871, DOI 10.1104/pp.112.3.871; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	17	350	388	2	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					781	784		10.1038/23500	http://dx.doi.org/10.1038/23500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466729				2022-12-01	WOS:000082131100054
J	Stahl, EA; Dwyer, G; Mauricio, R; Kreitman, M; Bergelson, J				Stahl, EA; Dwyer, G; Mauricio, R; Kreitman, M; Bergelson, J			Dynamics of disease resistance polymorphism at the Rpm1 locus of Arabidopsis	NATURE			English	Article							MOLECULAR POPULATION-GENETICS; PSEUDOMONAS-SYRINGAE; THALIANA; RECOMBINATION; EPIDEMIOLOGY; PARASITES; SELECTION; GENES	The co-evolutionary 'arms race'(1) is a widely accepted model for the evolution of host-pathogen interactions. This model predicts that variation for disease resistance will be transient, and that host populations generally will be monomorphic at disease-resistance (R-gene) loci. However, plant populations show considerable polymorphism at R-gene loci involved in pathogen recognition(2). Here we have tested the arms-race model in Arabidopsis thaliana by analysing sequences flanking Rpm1, a gene conferring the ability to recognize Pseudomonas pathogens carrying AvrRpm1 or AvrB (ref. 3). We reject the arms-race hypothesis: resistance and susceptibility alleles at this locus have co-existed for millions of years. To account for the age of alleles and the relative levels of polymorphism within allelic classes, we use coalescence theory to model the long-term accumulation of nucleotide-polymorphism in the context of the short-term ecological dynamics of disease resistance. This analysis supports a 'trench warfare' hypothesis, in which advances and retreats of resistance-allele frequency maintain variation for disease resistance as a dynamic polymorphism(4,5).	Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Bergelson, J (corresponding author), Univ Chicago, Comm Genet, Chicago, IL 60637 USA.	jbergels@midway.uchicago.edu	Dwyer, Greg/L-1134-2015	Dwyer, Greg/0000-0002-7387-2075; Bergelson, Joy/0000-0001-7893-7387	NIGMS NIH HHS [R01 GM057994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergelson J, 1998, GENETICS, V148, P1311; Bergelson J, 1996, AM NAT, V148, P536, DOI 10.1086/285938; Caicedo AL, 1999, P NATL ACAD SCI USA, V96, P302, DOI 10.1073/pnas.96.1.302; DAWKINS R, 1979, PROC R SOC SER B-BIO, V205, P489, DOI 10.1098/rspb.1979.0081; Grant MR, 1998, P NATL ACAD SCI USA, V95, P15843, DOI 10.1073/pnas.95.26.15843; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Hamilton W.D., 1982, Life Sciences Research Report, P269; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HIRANO SS, 1990, ANNU REV PHYTOPATHOL, V28, P155, DOI 10.1146/annurev.py.28.090190.001103; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1988, GENETICS, V120, P831; Innan H, 1996, GENETICS, V143, P1761; JAYAKAR S D, 1970, Theoretical Population Biology, V1, P140, DOI 10.1016/0040-5809(70)90032-8; JUDSON OP, 1995, GENET RES, V65, P175, DOI 10.1017/S0016672300033267; Kawabe A, 1997, MOL BIOL EVOL, V14, P1303, DOI 10.1093/oxfordjournals.molbev.a025740; Kimura M., 1983, NEUTRAL THEORY MOL E; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; May R.M., 1985, Linnean Society Symposium Series, P243; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; McDonald JH, 1998, MOL BIOL EVOL, V15, P377, DOI 10.1093/oxfordjournals.molbev.a025934; NEI M, 1986, MOL BIOL EVOL, V3, P418; OKane SL, 1997, NOVON, V7, P323, DOI 10.2307/3391949; Purugganan MD, 1999, GENETICS, V151, P839; Purugganan MD, 1998, P NATL ACAD SCI USA, V95, P8130, DOI 10.1073/pnas.95.14.8130; REDEI GP, 1975, ANNU REV GENET, V9, P111, DOI 10.1146/annurev.ge.09.120175.000551; Rozas J, 1997, COMPUT APPL BIOSCI, V13, P307; Smith JM, 2007, GENET RES, V89, P391, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]; TAJIMA F, 1989, GENETICS, V123, P585; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WOLFE KH, 1989, J MOL EVOL, V29, P208, DOI 10.1007/BF02100204	30	450	462	0	65	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					667	671		10.1038/23260	http://dx.doi.org/10.1038/23260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458161				2022-12-01	WOS:000082032900054
J	Grace, AA				Grace, AA			Brugada syndrome	LANCET			English	Editorial Material							UNEXPLAINED-DEATH-SYNDROME; ST-SEGMENT ELEVATION; BUNDLE-BRANCH BLOCK; VENTRICULAR-FIBRILLATION; HEART-DISEASE; SUDDEN-DEATH; MARKER		Papworth Hosp, Cambridge CB3 8RE, England; Univ Cambridge, Dept Biochem, Sect Cardiovasc Biol, Cambridge CB2 1QW, England	Papworth Hospital; University of Cambridge	Grace, AA (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.							Alings M, 1999, CIRCULATION, V99, P666, DOI 10.1161/01.CIR.99.5.666; Brugada J, 1998, CIRCULATION, V97, P457; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Corrado D, 1996, J AM COLL CARDIOL, V27, P443, DOI 10.1016/0735-1097(95)00485-8; Gussak I, 1999, J AM COLL CARDIOL, V33, P5, DOI 10.1016/S0735-1097(98)00528-2; Kasanuki H, 1997, CIRCULATION, V95, P2277, DOI 10.1161/01.CIR.95.9.2277; Matsuo K, 1999, EUR HEART J, V20, P465, DOI 10.1053/euhj.1998.1332; Nademanee K, 1997, CIRCULATION, V96, P2595, DOI 10.1161/01.CIR.96.8.2595; Priori SG, 1999, EUR HEART J, V20, P174, DOI 10.1053/euhj.1998.1220; Priori SG, 1997, CIRCULATION, V95, P265; SAUMAREZ RC, 1995, CIRCULATION, V92, P2565, DOI 10.1161/01.CIR.92.9.2565; WEVER EFD, 1993, CIRCULATION, V88, P1021, DOI 10.1161/01.CIR.88.3.1021; WONG ML, 1992, TROP GEOGR MED, V44, pS1; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	14	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					445	446		10.1016/S0140-6736(99)90032-6	http://dx.doi.org/10.1016/S0140-6736(99)90032-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465166				2022-12-01	WOS:000081896100006
J	Schlegel, M; Osterwalder, JJ; Galeazzi, RL; Vernazza, PL				Schlegel, M; Osterwalder, JJ; Galeazzi, RL; Vernazza, PL			Comparative efficacy of three mumps vaccines during disease outbreak in eastern Switzerland: cohort study	BRITISH MEDICAL JOURNAL			English	Article							MEASLES; RUBELLA		Inst Clin Microbiol & Immunol, CH-9001 St Gallen, Switzerland; Kantonsspital, Dept Med, CH-9007 St Gallen, Switzerland; Kantonsspital, Emergency Dept, CH-9007 St Gallen, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Vernazza, PL (corresponding author), Inst Clin Microbiol & Immunol, CH-9001 St Gallen, Switzerland.							ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; D'Argenio P, 1998, VACCINE, V16, P818, DOI 10.1016/S0264-410X(97)00270-3; *EXP PROGR IMM, 1993, WKLY EPIDEMIOL REC, V68, P83; Germann D, 1996, SCAND J INFECT DIS, V28, P235, DOI 10.3109/00365549609027163; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					352	353		10.1136/bmj.319.7206.352	http://dx.doi.org/10.1136/bmj.319.7206.352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435956	Bronze, Green Published			2022-12-01	WOS:000082001700019
J	Mazmanian, SK; Liu, G; Hung, TT; Schneewind, O				Mazmanian, SK; Liu, G; Hung, TT; Schneewind, O			Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall	SCIENCE			English	Article							GRAM-POSITIVE BACTERIA; RESISTANCE; EXPRESSION; VANCOMYCIN	Surface proteins of Gram-positive bacteria are linked to the bacterial cell wall by a mechanism that involves cleavage of a conserved Leu-Pro-X-Thr-Gly (LPXTG) motif and that occurs during assembly of the peptidoglycan cell wall. A Staphylococcus aureus mutant defective in the anchoring of surface proteins was isolated and shown to carry a mutation in the srtA gene. Overexpression of srtA increased the rate of surface protein anchoring, and homologs of srtA were found in other pathogenic Gram-positive bacteria. The protein specified by srtA, sortase, may be a useful target for the development of new antimicrobial drugs.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Mazmanian, Sarkis/ABD-7729-2021; Ton-That, Hung/AAB-6155-2020	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NIAID NIH HHS [AI 07323, AI33987] Funding Source: Medline; NIGMS NIH HHS [T32GM07104] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger-Bachi Brigitte, 1994, Trends in Microbiology, V2, P389, DOI 10.1016/0966-842X(94)90617-3; BOOTHBY D, 1971, ANAL BIOCHEM, V44, P645, DOI 10.1016/0003-2697(71)90255-7; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; STROMING.JL, 1973, JOHNS HOPKINS MED J, V133, P63; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; TONTHAT H, IN PRESS J BIOL CHEM; UHLEN M, 1984, J BACTERIOL, V159, P713; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747	20	742	810	0	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					760	763		10.1126/science.285.5428.760	http://dx.doi.org/10.1126/science.285.5428.760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427003				2022-12-01	WOS:000081765100062
J	Cooper, C; Coggon, D				Cooper, C; Coggon, D			Physical activity and knee osteoarthritis	LANCET			English	Editorial Material							RISK		Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England	University of Southampton	Cooper, C (corresponding author), Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.							COOPER C, 1995, J RHEUMATOL S43, V22, P1012; Lane NE, 1996, ANN RHEUM DIS, V55, P682, DOI 10.1136/ard.55.9.682; Maetzel A, 1997, J RHEUMATOL, V24, P1599; McAlindon TE, 1999, AM J MED, V106, P151, DOI 10.1016/S0002-9343(98)00413-6; NEGRET P, 1994, BR J RHEUMATOL, V33, P267; ROOS H, 1994, AM J SPORT MED, V22, P219, DOI 10.1177/036354659402200211; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA	8	17	21	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2177	2178		10.1016/S0140-6736(99)90094-6	http://dx.doi.org/10.1016/S0140-6736(99)90094-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392979				2022-12-01	WOS:000081091300007
J	Peshkin, BN; Lerman, C				Peshkin, BN; Lerman, C			Genetic counselling for hereditary breast cancer	LANCET			English	Editorial Material							OVARIAN CANCER; BRCA1; FAMILIES; PREDISPOSITION; SUSCEPTIBILITY		Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Georgetown University	Peshkin, BN (corresponding author), Georgetown Univ, Med Ctr, Washington, DC 20007 USA.		Lerman, Caryn/AHC-5180-2022					Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; Cull A, 1998, BRIT J CANCER, V77, P830, DOI 10.1038/bjc.1998.135; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; Lerman C, 1998, J CLIN ONCOL, V16, P1650, DOI 10.1200/JCO.1998.16.5.1650; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Patenaude AF, 1996, PSYCHO-ONCOLOGY, V5, P241; Watson M, 1999, BRIT J CANCER, V79, P868, DOI 10.1038/sj.bjc.6690139; Watson M, 1996, PSYCHO-ONCOL, V5, P233	10	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2176	2177		10.1016/S0140-6736(99)90078-8	http://dx.doi.org/10.1016/S0140-6736(99)90078-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392978				2022-12-01	WOS:000081091300006
J	Leitzmann, MF; Rimm, EB; Willett, WC; Spiegelman, D; Grodstein, F; Stampfer, MJ; Colditz, GA; Giovannucci, E				Leitzmann, MF; Rimm, EB; Willett, WC; Spiegelman, D; Grodstein, F; Stampfer, MJ; Colditz, GA; Giovannucci, E			Recreational physical activity and the risk of cholecystectomy in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOGISTIC-REGRESSION; GLUCOSE-TOLERANCE; GALLSTONE DISEASE; REPRODUCIBILITY; CHOLESTEROL; VALIDITY; CHOLELITHIASIS; QUESTIONNAIRE; OBESITY; PIGMENT	Background Physical activity may be an important determinant of the risk of gallstone disease in women, both independently and as a result of its role in maintaining body weight. Methods We prospectively studied recreational physical activity (such as jogging, running, and bicycling) and sedentary behavior (such as spending hours watching television) in relation to the risk of cholecystectomy, a surrogate for symptomatic cholelithiasis, in a cohort of 60,290 women who were 40 to 65 years of age in 1986 and had no history of gallstone disease. As part of the Nurses' Health Study, the women reported on questionnaires mailed to them every two years both their activity level and whether they had undergone cholecystectomy. During a 10-year follow-up period (1986 to 1996), 3257 cases of cholecystectomy were documented. Results Recreational physical activity was inversely related to the risk of cholecystectomy. The multivariate relative risk for women in the highest as compared with the lowest quintile of physical activity was 0.69 (95 percent confidence interval, 0.61 to 0.78). In contrast, sedentary behavior was independently related to an increased risk of cholecystectomy. As compared with women who spent less than 6 hours per week sitting while at work or driving, women who spent 41 to 60 hours per week sitting had a multivariate relative risk of 1.42 (95 percent confidence interval, 1.06 to 1.89), and women who spent more than 60 hours per week sitting while at work or driving had a multivariate relative risk of 2.32 (95 percent confidence interval, 1.26 to 4.26). These associations persisted after we controlled for body weight and weight change. Conclusions In women, recreational physical activity is associated with a decreased risk of cholecystectomy. The association is independent of other risk factors for gallstone disease, such as obesity and recent weight loss. (N Engl J Med 1999;341:777-84.) (C)1999, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; PHS HHS [T45 09856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ANGELICO M, 1988, HEPATOLOGY, V8, P907; Apstein MD, 1996, EUR J CLIN INVEST, V26, P343, DOI 10.1046/j.1365-2362.1996.148287.x; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; DiPietro L, 1998, J AM GERIATR SOC, V46, P875, DOI 10.1111/j.1532-5415.1998.tb02722.x; ELLISON PT, 1986, AM J OBSTET GYNECOL, V154, P100; HOFMANN AF, 1993, AM J SURG, V165, P541, DOI 10.1016/S0002-9610(05)80958-4; KALSER SC, 1993, AM J SURG, V165, P390; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; Leitzmann MF, 1998, ANN INTERN MED, V128, P417, DOI 10.7326/0003-4819-128-6-199803150-00001; Linos A D, 1989, HPB Surg, V1, P221, DOI 10.1155/1989/56539; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; Misciagna G, 1999, AM J CLIN NUTR, V69, P120; OETTLE GJ, 1991, GUT, V32, P941, DOI 10.1136/gut.32.8.941; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; PHILLIPP E, 1992, PEPTIDES, V13, P125, DOI 10.1016/0196-9781(92)90150-2; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3; SARIN SK, 1986, DIGEST DIS SCI, V31, P1041, DOI 10.1007/BF01300256; SEALS DR, 1984, JAMA-J AM MED ASSOC, V252, P645, DOI 10.1001/jama.252.5.645; SOUTHGATE DA, 1969, J SCI FOOD AGR, V20, P331, DOI 10.1002/jsfa.2740200603; TROTMAN BW, 1975, AM J DIG DIS, V20, P735, DOI 10.1007/BF01070831; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS CN, 1980, CAN MED ASSOC J, V122, P664; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390	31	141	147	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					777	784		10.1056/NEJM199909093411101	http://dx.doi.org/10.1056/NEJM199909093411101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477775				2022-12-01	WOS:000082534000001
J	Sharp, D				Sharp, D			An Ideal Husband in the wild(e)?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), The Lancet, London WC1B 3SL, England.							CONNOR S, 1999, INDEPENDENT     0819, P5; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475	2	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					700	700		10.1016/S0140-6736(99)00287-1	http://dx.doi.org/10.1016/S0140-6736(99)00287-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475179				2022-12-01	WOS:000082233000007
J	Lipkin, DP				Lipkin, DP			Sleep-disordered breathing in chronic stable heart failure	LANCET			English	Editorial Material							CHEYNE-STOKES RESPIRATION; SYMPATHETIC ACTIVITY; APNEA		Royal Free Hosp, Dept Cardiol, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lipkin, DP (corresponding author), Royal Free Hosp, Dept Cardiol, London NW3 2PF, England.							ANCOLIISRAEL S, 1994, CHEST, V106, P780, DOI 10.1378/chest.106.3.780; Bradley T D, 1996, J Card Fail, V2, P223, DOI 10.1016/S1071-9164(96)80045-5; Cheyne J, 1818, DUBLIN HOSP REP, V12, p[216, 317]; FINDLEY LJ, 1985, SOUTH MED J, V78, P11, DOI 10.1097/00007611-198501000-00004; JAHAVERI S, 1995, ANN INTERN MED, V122, P487; KAVERI S, 1995, ANN INTERN MED, V122, P487; Lanfranchi PA, 1999, CIRCULATION, V99, P1435, DOI 10.1161/01.CIR.99.11.1435; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; Staniforth AD, 1998, EUR HEART J, V19, P922, DOI 10.1053/euhj.1997.0861; Staniforth AD, 1998, HEART, V79, P394, DOI 10.1136/hrt.79.4.394; STOKES W, 1854, DIS HEART AORTA, P302; Tkacova R, 1997, J AM COLL CARDIOL, V30, P739, DOI 10.1016/S0735-1097(97)00199-X	13	13	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					531	532		10.1016/S0140-6736(99)00138-5	http://dx.doi.org/10.1016/S0140-6736(99)00138-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470694				2022-12-01	WOS:000081991000007
J	Bromberg, JF; Wrzeszczynska, MH; Devgan, G; Zhao, YX; Pestell, RG; Albanese, C; Darnell, JE				Bromberg, JF; Wrzeszczynska, MH; Devgan, G; Zhao, YX; Pestell, RG; Albanese, C; Darnell, JE			Stat3 as an oncogene	CELL			English	Article							TRANSCRIPTIONALLY ACTIVE STAT1; EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; ACUTE-PHASE REACTION; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; INTERFERON-GAMMA; GENE-REGULATION	STATs are latent transcription factors that mediate cytokine- and growth factor-directed transcription. In many human cancers and transformed cell lines, Stat3 is persistently activated, and in cell culture, active Stat3 is either required for transformation, enhances transformation, or blocks apoptosis. We report that substitution of two cysteine residues within the C-terminal loop of the SH2 domain of Stat3 produces a molecule that dimerizes spontaneously, binds to DNA, and activates transcription. The Stat3-C molecule in immortalized fibroblasts causes cellular transformation scored by colony formation in soft agar and tumor formation in nude mice. Thus, the activated Stat3 molecule by itself can mediate cellular transformation and the experiments focus attention on the importance of constitutive Stat3 activation in human tumors.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Rockefeller University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.			Zhao, Yanxiang/0000-0002-9408-9979	NATIONAL CANCER INSTITUTE [R01CA075503, R01CA070897] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75503, R29CA70897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; Besser D, 1999, MOL CELL BIOL, V19, P1401; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cory S, 1999, CANCER RES, V59, p1685S; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Heinrich PC, 1998, Z ERNAHRUNGSWISS, V37, P43; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LODISH H, 1995, MOL CELL BIOL, P1247; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Weber-Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	49	2402	2585	3	157	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					295	303		10.1016/S0092-8674(00)81959-5	http://dx.doi.org/10.1016/S0092-8674(00)81959-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458605	Bronze			2022-12-01	WOS:000081950300005
J	Cotzias, CS; Paterson-Brown, S; Fisk, NM				Cotzias, CS; Paterson-Brown, S; Fisk, NM			Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis	BRITISH MEDICAL JOURNAL			English	Article									Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England.		Fisk, Nicholas M/B-2126-2009	Fisk, Nicholas M/0000-0003-0031-7975				FELDMAN GB, 1992, OBSTET GYNECOL, V79, P547; Hilder L, 1998, BRIT J OBSTET GYNAEC, V105, P169, DOI 10.1111/j.1471-0528.1998.tb10047.x; *STAT OFF, 1996, CONF ENQ STILLB DEAT; THORNTON JG, 1989, J OBSTET GYNAECOL, V9, P283, DOI 10.3109/01443618909151065; YUDKIN PL, 1987, LANCET, V1, P1192	5	83	85	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					287	288		10.1136/bmj.319.7205.287	http://dx.doi.org/10.1136/bmj.319.7205.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426736	Bronze, Green Published			2022-12-01	WOS:000081909100020
J	Annunen, S; Paassilta, P; Lohiniva, J; Perala, M; Pihlajamaa, T; Karppinen, J; Tervonen, O; Kroger, H; Lahde, S; Vanharanta, H; Ryhanen, L; Goring, HHH; Ott, J; Prockop, DJ; Ala-Kokko, L				Annunen, S; Paassilta, P; Lohiniva, J; Perala, M; Pihlajamaa, T; Karppinen, J; Tervonen, O; Kroger, H; Lahde, S; Vanharanta, H; Ryhanen, L; Goring, HHH; Ott, J; Prockop, DJ; Ala-Kokko, L			An allele of COL9A2 associated with intervertebral disc disease	SCIENCE			English	Article							COLLAGEN TYPE-IX; CROSS-LINKING SITES; LINKAGE ANALYSIS; MOLECULAR-CLONING; LUMBAR SPINE; II COLLAGEN; CARTILAGE; DEGENERATION; CHAIN; GENE	Intervertebral disc disease is one of the most common musculoskeletal disorders. A number of environmental and anthropometric risk factors may contribute to it, and recent reports have suggested the importance of genetic factors as well. The COL9A2 gene, which codes for one of the polypeptide chains of collagen IX that is expressed in the intervertebral disc, was screened for sequence variations in individuals with intervertebral disc disease. The analysis identified a putative disease-causing sequence variation that converted a codon for glutamine to one for tryptophan in six out of the 157 individuals but in none of 174 controls. The tryptophan allele cosegregated with the disease phenotype in the four families studied, giving a lod score (Logarithm of odds ratio) for linkage of 4.5, and subsequent linkage disequilibrium analysis conditional on linkage gave an additional lod score of 7.1.	Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Biochem Med, SF-90220 Oulu, Finland; Univ Oulu, Dept Phys Med & Rehabil, SF-90220 Oulu, Finland; Univ Oulu, Dept Diagnost Radiol, SF-90220 Oulu, Finland; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Kuopio, Dept Surg, Kuopio 70211, Finland; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; MCP Hahnemann Univ, Ctr Gene Therapy, Philadelphia, PA 19102 USA	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Eastern Finland; Columbia University; Rockefeller University; Drexel University	Ala-Kokko, L (corresponding author), Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland.	leena.ala-kokko@oulu.fi			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00008] Funding Source: Medline; NIAMS NIH HHS [AR39740] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; Becker A, 1998, HUM HERED, V48, P49, DOI 10.1159/000022781; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BUCKWALTER JA, 1995, SPINE, V20, P1307, DOI 10.1097/00007632-199506000-00022; CHOTAI J, 1984, ANN HUM GENET, V48, P359, DOI 10.1111/j.1469-1809.1984.tb00849.x; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; EYRE DR, 1977, BIOCHIM BIOPHYS ACTA, V492, P29, DOI 10.1016/0005-2795(77)90211-2; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; GORING HHH, UNPUB; GORKING HHH, UNPUB; HELIOVAARA M, 1989, ANN MED, V21, P254, DOI 10.3109/07853898909149202; HELIOVAARA M, 1987, J EPIDEMIOL COMMUN H, V41, P251, DOI 10.1136/jech.41.3.251; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Kainulainen K, 1999, HYPERTENSION, V33, P844, DOI 10.1161/01.HYP.33.3.844; Kielty Cay M., 1993, P103; Kimura T, 1996, INT ORTHOP, V20, P177, DOI 10.1007/s002640050058; Korkko J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATSUI H, 1992, SPINE, V17, P1323, DOI 10.1097/00007632-199211000-00011; MORTON NE, 1955, AM J HUM GENET, V7, P277; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; Nelson C L, 1972, Clin Orthop Relat Res, V88, P142, DOI 10.1097/00003086-197210000-00025; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PERALA M, 1994, J BIOL CHEM, V269, P5064; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; ROKOS I, 1994, MATRIX BIOL, V14, P1, DOI 10.1016/0945-053X(94)90024-8; Scapinelli R, 1993, Acta Orthop Belg, V59, P371; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Terwilliger J., 1994, HDB HUMAN GENETIC LI; TIENARI PJ, 1994, GENOMICS, V19, P320, DOI 10.1006/geno.1994.1064; URBAN JPG, 1993, MUSCULOSKELETAL SOFT-TISSUE AGING: IMPACT ON MOBILITY, P391; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VARLOTTA GP, 1991, J BONE JOINT SURG AM, V73A, P124, DOI 10.2106/00004623-199173010-00016; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Weishaupt D, 1998, RADIOLOGY, V209, P661, DOI 10.1148/radiology.209.3.9844656; WILLIAMSON JA, 1990, GENET EPIDEMIOL, V7, P309, DOI 10.1002/gepi.1370070502; WU JJ, 1992, J BIOL CHEM, V267, P23007	45	241	271	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					409	412		10.1126/science.285.5426.409	http://dx.doi.org/10.1126/science.285.5426.409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411504				2022-12-01	WOS:000081465900055
J	Linthicum, KJ; Anyamba, A; Tucker, CJ; Kelley, PW; Myers, MF; Peters, CJ				Linthicum, KJ; Anyamba, A; Tucker, CJ; Kelley, PW; Myers, MF; Peters, CJ			Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya	SCIENCE			English	Article							DIFFERENCE VEGETATION INDEX; SEA-SURFACE TEMPERATURE; NEAR-INFRARED CHANNELS; DOMESTIC-ANIMALS; EL-NINO; RAINFALL; AVHRR; CALIBRATION; AFRICA; VIRUS	All known Rift Valley fever virus outbreaks in East Africa from 1950 to May 1998, and probably earlier, followed periods of abnormally high rainfall. Analysis of this record and Pacific and Indian Ocean sea surface temperature anomalies, coupled with satellite normalized difference vegetation index data, shows that prediction of Rift Valley fever outbreaks may be made up to 5 months in advance of outbreaks in East Africa. Concurrent near-real-time monitoring with satellite normalized difference vegetation data may identify actual affected areas.	Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Def, Washington, DC 20307 USA; NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Centers for Disease Control & Prevention - USA	Anyamba, A (corresponding author), Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Def, Washington, DC 20307 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Anyamba, Assaf/0000-0003-0932-9585				Anyamba A, 1996, INT J REMOTE SENS, V17, P2533, DOI 10.1080/01431169608949091; CANE MA, 1986, ANNU REV EARTH PL SC, V14, P43, DOI 10.1146/annurev.ea.14.050186.000355; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHAGAS C, 1986, PERSISTENT METEOOCEA, P1; CHE N, 1992, REMOTE SENS ENVIRON, V41, P19, DOI 10.1016/0034-4257(92)90057-Q; Daubney R, 1931, J PATHOL BACTERIOL, V34, P545, DOI 10.1002/path.1700340418; DAVIES FG, 1985, B WORLD HEALTH ORGAN, V63, P941; FARMER G, 1988, J CLIMATOL, V8, P489, DOI 10.1002/joc.3370080505; Glantz M. H, 1991, TELECONNECTIONS LINK, P1; HOLBEN BN, 1990, INT J REMOTE SENS, V11, P1511, DOI 10.1080/01431169008955109; Lauenroth W. K., 1979, Perspectives in grassland ecology., P3; LEHOUEROU HN, 1977, J RANGE MANAGE, V30, P181; Linthicum K.J., 1994, SISTEMA TERRA, V3, P44; LINTHICUM KJ, 1985, J HYG-CAMBRIDGE, V95, P197, DOI 10.1017/S0022172400062434; LINTHICUM KJ, 1987, SCIENCE, V235, P1656, DOI 10.1126/science.3823909; LOGAN TM, 1990, J AM MOSQUITO CONTR, V6, P736; LOGAN TM, 1992, T ROY SOC TROP MED H, V86, P202, DOI 10.1016/0035-9203(92)90571-S; LOGAN TM, 1991, J MED ENTOMOL, V28, P293, DOI 10.1093/jmedent/28.2.293; LOS SO, 1993, INT J REMOTE SENS, V14, P1907, DOI 10.1080/01431169308954011; MALO AR, 1990, J ARID ENVIRON, V19, P1; Myneni RB, 1996, GEOPHYS RES LETT, V23, P729, DOI 10.1029/96GL00266; Nicholls N., 1991, TELECONNECTIONS LINK, P493; Nichols, 1991, TELECONNECTIONS LINK, P309; Nicholson SE, 1997, INT J CLIMATOL, V17, P345, DOI 10.1002/(SICI)1097-0088(19970330)17:4<345::AID-JOC127>3.0.CO;2-3; NICHOLSON SE, 1990, CLIMATIC CHANGE, V17, P209, DOI 10.1007/BF00138369; POPE KO, 1992, REMOTE SENS ENVIRON, V40, P185, DOI 10.1016/0034-4257(92)90002-2; ROPELEWSKI C. F., 1987, MON WEA REV, V115, P2352; TUCKER CJ, 1994, INT J REMOTE SENS, V15, P3547, DOI 10.1080/01431169408954344; TUCKER CJ, IN PRESS AMBIO; VERMOTE E, 1995, INT J REMOTE SENS, V16, P2317, DOI 10.1080/01431169508954561	30	402	419	4	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					397	400		10.1126/science.285.5426.397	http://dx.doi.org/10.1126/science.285.5426.397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411500				2022-12-01	WOS:000081465900051
J	Zou, H; McGarry, TJ; Bernal, T; Kirschner, MW				Zou, H; McGarry, TJ; Bernal, T; Kirschner, MW			Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis	SCIENCE			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ANAPHASE TRANSITION; NUCLEAR DIVISION; BUDDING YEAST; METAPHASE; COMPLEX; MITOSIS; SPINDLE; PDS1P	A vertebrate securin (vSecurin) was identified on the basis of its biochemical analogy to the Pds1p protein of budding yeast and the Cut2p protein of fission yeast. The vSecurin protein bound to a vertebrate homolog of yeast separins Esp1p and Cut1p and was degraded by proteolysis mediated by an anaphase-promoting complex in a manner dependent on a destruction motif. Furthermore, expression of a stable Xenopus securin mutant protein blocked sister-chromatid separation but did not block the embryonic cell cycle. The vSecurin proteins share extensive sequence similarity with each other but show no sequence similarity to either of their yeast counterparts. Human securin is identical to the product of the gene called pituitary tumor-transforming gene (PTTG), which is overexpressed in some tumors and exhibits transforming activity in NIH 3T3 cells. The oncogenic nature of increased expression of vSecurin may result from chromosome gain or loss, produced by errors in chromatid separation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Funabiki H, 1997, EMBO J, V16, P5977, DOI 10.1093/emboj/16.19.5977; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1997, SCIENCE, V277, P973, DOI 10.1126/science.277.5328.973; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZOU H, UNPUB	29	655	691	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					418	422		10.1126/science.285.5426.418	http://dx.doi.org/10.1126/science.285.5426.418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411507				2022-12-01	WOS:000081465900058
J	Kerem, E; Bistritzer, T; Hanukoglu, A; Hofmann, T; Zhou, ZQ; Bennett, W; MacLaughlin, E; Barker, P; Nash, M; Quittell, L; Boucher, R; Knowles, MR				Kerem, E; Bistritzer, T; Hanukoglu, A; Hofmann, T; Zhou, ZQ; Bennett, W; MacLaughlin, E; Barker, P; Nash, M; Quittell, L; Boucher, R; Knowles, MR			Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTIC-FIBROSIS; I PSEUDOHYPOALDOSTERONISM; MUCOCILIARY CLEARANCE; ION-TRANSPORT; GENE; DISEASE; METHACHOLINE; MUTATIONS; CHILDREN; INFANTS	Background Active sodium absorption is the dominant mechanism of ion transport in airway epithelium, but its role in pulmonary physiology and airway host defense is unknown. To address this question, we studied the function of airway epithelial cells and determined the frequency of pulmonary symptoms in patients with systemic pseudohypoaldosteronism, a salt-losing disorder caused by loss-of-function mutations in the genes for the epithelial sodium channel. Methods In nine patients 1.5 to 22 years of age who had systemic pseudohypoaldosteronism, we tested for mutations in the genes for the epithelial sodium channel, estimated the rate of sodium transport in the airway, determined the volume and ion composition of airway surface liquid, reviewed clinical features, collected laboratory data pertinent to pulmonary function, and, in three adults, measured mucociliary clearance. Results The patients with systemic pseudohypoaldosteronism had loss-of-function mutations in the genes for the epithelial sodium-channel subunits, no sodium absorption from airway surfaces, and a volume of airway surface liquid that was more than twice the normal value. The mean (+/-SE) mucociliary transport rate was higher in the 3 adult patients than in 12 normal subjects (2.0+/-0.7 vs. 0.5+/-0.3 percent per minute, P=0.009). Young patients (those five years of age or less) all had recurrent episodes of chest congestion, coughing, and wheezing, but no airway infections with Staphylococcus aureus or Pseudomonas aeruginosa. Older patients (those more than five years of age) had less frequent respiratory symptoms. Conclusions Patients with systemic pseudohypoaldosteronism fail to absorb liquid from airway surfaces; the result is an increased volume of liquid in the airways. These results demonstrate that sodium transport has a role in regulating the volume of liquid on airway surfaces. (N Engl J Med 1999;341: 156-62.) (C) 1999, Massachusetts Medical Society.	Univ N Carolina, Cystic Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Sch Med, Pediat Resp Med & Cyst Fibrosis Ctr, Jerusalem, Israel; Assaf Harofeh Med Ctr, Dept Pediat, IL-70300 Zerifin, Israel; Wolfson Med Ctr, Dept Pediat, Holon, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Univ Giessen, Kinderklin, Giessen, Germany; Univ N Carolina, Ctr Environm Med, Chapel Hill, NC 27599 USA; Univ So Calif, Los Angeles, CA USA; Childrens Hosp Los Angeles, Div Pediat Pulm, Los Angeles, CA 90027 USA; Columbia Presbyterian Med Ctr, Pediat Nephrol Div, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Pediat Pulm Div, New York, NY 10032 USA	University of North Carolina; University of North Carolina Chapel Hill; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Justus Liebig University Giessen; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; Children's Hospital Los Angeles; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Knowles, MR (corresponding author), Univ N Carolina, Cystic Fibrosis Pulm Res & Treatment Ctr, 7011 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	knowles@med.unc.edu	MacLaughlin, Eric J/L-7316-2019; Hanukoglu, Aaron/L-4892-2016	MacLaughlin, Eric J/0000-0002-1460-445X; Hanukoglu, Aaron/0000-0003-1486-6641	NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [P01 HL34322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVITAL A, 1988, J PEDIATR-US, V112, P591, DOI 10.1016/S0022-3476(88)80177-X; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; GERHARDT T, 1985, PEDIATR RES, V19, P1165, DOI 10.1203/00006450-198511000-00010; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; HANUKOGLU A, 1994, J PEDIATR-US, V125, P752, DOI 10.1016/S0022-3476(94)70071-0; HANUKOGLU A, 1991, J CLIN ENDOCR METAB, V73, P936, DOI 10.1210/jcem-73-5-936; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; Knowles MR, 1998, J CLIN INVEST, V101, P285; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LODRUPCARLSEN KC, 1993, EUR RESPIR J, V6, P1496; Marthinsen L, 1998, ACTA PAEDIATR, V87, P472; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; OBERFIELD SE, 1979, J CLIN ENDOCR METAB, V48, P228, DOI 10.1210/jcem-48-2-228; Olivier KN, 1996, AM J RESP CRIT CARE, V154, P217, DOI 10.1164/ajrccm.154.1.8680683; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; SANCHEZ I, 1993, AM REV RESPIR DIS, V147, P705, DOI 10.1164/ajrccm/147.3.705; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith JJ, 1996, CELL, V87, pU25; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; VANDENPLAS Y, 1992, J PEDIATR GASTR NUTR, V14, P467; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; YAGER D, 1989, J APPL PHYSIOL, V66, P2873, DOI 10.1152/jappl.1989.66.6.2873; Zar J., 1996, BIOSTAT ANAL	35	263	278	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					156	162		10.1056/NEJM199907153410304	http://dx.doi.org/10.1056/NEJM199907153410304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403853	Green Published			2022-12-01	WOS:000081413800004
J	Grakoui, A; Bromley, SK; Sumen, C; Davis, MM; Shaw, AS; Allen, PM; Dustin, ML				Grakoui, A; Bromley, SK; Sumen, C; Davis, MM; Shaw, AS; Allen, PM; Dustin, ML			The immunological synapse: A molecular machine controlling T cell activation	SCIENCE			English	Article							II PEPTIDE COMPLEXES; LIPID-LINKED FORM; ANTIGEN-RECEPTOR; PHOTOBLEACHING RECOVERY; SIGNAL-TRANSDUCTION; PLANAR BILAYERS; ADHESION; RECOGNITION; MEMBRANES; AFFINITY	The specialized junction between a T lymphocyte and an antigen-presenting cell, the immunological synapse, consists of a central cluster of T cell receptors surrounded by a ring of adhesion molecules. Immunological synapse formation is now shown to be an active and dynamic mechanism that allows T cells to distinguish potential antigenic Ligands, initially, T cell receptor ligands were engaged in an outermost ring of the nascent synapse. Transport of these complexes into the central cluster was dependent on T cell receptor-ligand interaction kinetics. Finally, formation of a stable central cluster at the heart of the synapse was a determinative event for T cell proliferation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Stanford University	Dustin, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	dustin@immunology.wustl.edu	Dustin, Michael/AAM-4611-2020	Davis, Mark/0000-0001-6868-657X; Dustin, Michael/0000-0003-4983-6389				Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Baldwin KK, 1999, J EXP MED, V189, P13, DOI 10.1084/jem.189.1.13; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; Dustin ML, 1996, J IMMUNOL, V157, P2014; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; GAY D, 1986, J IMMUNOL, V136, P2026; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1989, COLD SH Q B, V54, P657; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; VAFUTUTTI S, 1995, NATURE, V375, P148; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WADE WF, 1989, J CELL BIOL, V109, P3325, DOI 10.1083/jcb.109.6.3325; WADE WF, 1994, INT IMMUNOL, V6, P1457, DOI 10.1093/intimm/6.10.1457; Wang W, 1997, J IMMUNOL, V158, P5797; WEISS A, 1987, J IMMUNOL, V138, P2169; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	47	2440	2541	3	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					221	227		10.1126/science.285.5425.221	http://dx.doi.org/10.1126/science.285.5425.221			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398592				2022-12-01	WOS:000081346000032
J	Dalgaard, LZ; Klar, AJS				Dalgaard, LZ; Klar, AJS			Orientation of DNA replication establishes mating-type switching pattern in S-pombe	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; GENETIC-ANALYSIS; INITIATION; CELLS; TRANSPOSITION; ASYMMETRY; STRANDS; BREAKS	The fission yeast Schizosaccharomyces pombe normally has haploid cells of two mating types, which differ at the chromosomal locus mat1. After two consecutive asymmetric cell divisions, only one in four 'grand-daughter' cells undergoes a 'mating-type switch', in which genetic information is transferred to mat1 from the mat2-P or mat3-M donor loci(1-4). This switching pattern probably results from an imprinting event at mat1 that marks one sister chromatid in a strand-specific manner(3-5), and is related to a site-specific, double-stranded DNA break at mat1(6,7). Here we show that the genetic imprint is a strand-specific, alkali-labile DNA modification at mat1. The DNA break is an artefact, created from the imprint during DNA purification. We also propose and test the model that mat1 is preferentially replicated by a centromere-distal origin(s), so that the strand-specific imprint occurs only during lagging-strand synthesis. Altering the origin of replication, by inverting mat1 or introducing an origin of replication, affects the imprinting and switching efficiencies in predicted ways. Two-dimensional gel analysis confirmed that mat1 is preferentially replicated by a centromere-distal origin(s). Thus, the DNA replication machinery may confer different developmental potential to sister cells.	NCI, Gene Regulat & Chromosome Biol Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Klar, AJS (corresponding author), NCI, Gene Regulat & Chromosome Biol Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA.	klar@mail.ncifcrf.gov		Dalgaard, Jacob/0000-0001-9545-7254				Arcangioli B, 1998, EMBO J, V17, P4503, DOI 10.1093/emboj/17.15.4503; ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BRESCH C, 1968, MOL GEN GENET, V102, P301, DOI 10.1007/BF00433721; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CADDLE MS, 1994, MOL CELL BIOL, V14, P1796, DOI 10.1128/MCB.14.3.1796; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EGEL R, 1987, CURR GENET, V12, P429, DOI 10.1007/BF00434820; Egel R., 1989, MOL BIOL FISSION YEA, P31; GERRING S L, 1991, P57; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KLAR AJS, 1993, COLD SPRING HARB SYM, V58, P457, DOI 10.1101/SQB.1993.058.01.052; Klar AJS, 1998, CIBA F SYMP, V214, P87; KLAR AJS, 1993, CURR OPIN GENET DEV, V3, P745, DOI 10.1016/S0959-437X(05)80093-0; KLAR AJS, 1986, CELL, V46, P725, DOI 10.1016/0092-8674(86)90348-X; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIELSEN O, 1989, EMBO J, V8, P269, DOI 10.1002/j.1460-2075.1989.tb03373.x; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; STYRKARSDOTTIR U, 1993, CURR GENET, V23, P184, DOI 10.1007/BF00352020	24	113	116	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					181	184		10.1038/22139	http://dx.doi.org/10.1038/22139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408447				2022-12-01	WOS:000081324900058
J	Scally, G				Scally, G			Tackling teenage pregnancy in the UK	LANCET			English	Editorial Material									Natl Hlth Serv Execut, Bristol BS34 8SR, Avon, England		Scally, G (corresponding author), Natl Hlth Serv Execut, South West Reg, Bristol BS34 8SR, Avon, England.							Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; *DEP HLTH, 1992, HLTH NAT; JONES EF, 1986, TEENAGE PREGNANCY IN; MCKITTRICK D, 1993, BRIT MED J, V306, P229; Scally G, 1993, Midwives Chron, V106, P232; *SOC EXCL UN, 1999, TEEN PREGN; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; WELLINGS K, 1995, BRIT MED J, V311, P417, DOI 10.1136/bmj.311.7002.417; 1999, DAILY TELEGRAPH 0615, P23	9	3	3	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2178	2178		10.1016/S0140-6736(99)00208-1	http://dx.doi.org/10.1016/S0140-6736(99)00208-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392980				2022-12-01	WOS:000081091300008
J	Gleissberg, V				Gleissberg, V			The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?	LANCET			English	Article									Newham Healthcare NHS Trust, Shrrewsbury Ctr, London E7, England		Gleissberg, V (corresponding author), Newham Healthcare NHS Trust, Shrrewsbury Ctr, Shrewsbury Rd, London E7, England.	ginig@ibm.net						BENNETT DE, 1996, THORAX S3, V51, pSA32; Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3; *DEP HLTH NT WORK, 1996, PREV CONTR TUB UK RE; FARMER F, 1998, BRIT MED J, V317, P671; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; HAYWARD A, 1998, TUBERCULOSIS CONTROL; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; Snider DE, 1998, NEW ENGL J MED, V338, P1689, DOI 10.1056/NEJM199806043382309; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; WHO, 1997, TREATM TUB GUID NAT, V2; *WHO, 1997, ANT DRUG RES WORLD W	12	14	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					998	999		10.1016/S0140-6736(99)01439-7	http://dx.doi.org/10.1016/S0140-6736(99)01439-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459924				2022-12-01	WOS:000079421600045
J	Yerly, S; Kaiser, L; Race, E; Bru, JP; Clavel, F; Perrin, L				Yerly, S; Kaiser, L; Race, E; Bru, JP; Clavel, F; Perrin, L			Transmission of antiretroviral-drug-resistant HIV-1 variants	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITORS; IN-VIVO; ZIDOVUDINE; NEVIRAPINE; THERAPY; SWITZERLAND; PREVALENCE; LAMIVUDINE; INFECTION	Background Resistance of HIV-1 to antiretroviral drugs is the main cause of antiretroviral-treatment failure. We assessed the transmission of drug-resistant variants among individuals with primary HIV-1 infection. Methods Population-based sequencing of the viral reverse transcriptase and protease genes derived from plasma viral RNA was done in 82 consecutive individuals with documented primary HIV-1 infection from January, 1996, to July, 1998. Phenotypic resistance to protease inhibitors was assessed by recombinant virus assay in individuals with two or more mutations associated with resistance to protease inhibitors. Findings Zidovudine-resistance mutations were detected in seven (9%) of 82 individuals. Mutations associated with resistance to other reverse-transcriptase inhibitors (RTls) were detected in two individuals. Primary-resistance mutations associated with protease inhibitors (V82A, L90M) were detected in three (4%) of 70 individuals; two of these had also RTI-resistance mutations. Decreased sensitivity to three or four protease inhibitors was seen in three individuals, one of whom was infected with HIV-1 variants that harboured 12 mutations associated with resistance to multiple RTI and protease inhibitors. Interpretation To introduce the best antiretroviral treatment, resistance testing should be done in recently HIV-1-infected individuals.	Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Infect Dis, AIDS Unit, Geneva, Switzerland; Hop Xavier Bichat, INSERM, Antiviral Res Lab, Paris, France; Annecy Hosp Ctr, Div Infect Dis, Annecy, France	University of Geneva; University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Annecy Genevois	Perrin, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland.	luc.perrin@hcuge.ch		Kaiser, Laurent/0000-0002-0857-2252				Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Eron J, 1998, AIDS, V12, pS13; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; GRANT RM, 1998, ANTIVIR THER S, V3, P108; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; PERRIN L, 1998, 12 WORLD AIDS C GEN; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Schinazi R. F., 1997, International Antiviral News, V5, P129; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998	26	332	342	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					729	733		10.1016/S0140-6736(98)12262-6	http://dx.doi.org/10.1016/S0140-6736(98)12262-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475184				2022-12-01	WOS:000082233000012
J	Meddings, DR; O'Connor, SM				Meddings, DR; O'Connor, SM			Circumstances around weapon injury in Cambodia after departure of a peacekeeping force: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							WAR; EPIDEMIOLOGY; INTERVENTION; HEALTH	Objective To examine the circumstances surrounding weapon injury and combatant status of those injured by weapons. Design Prospective cohort study Setting Northwestern Cambodia after departure of United Nations peacekeeping force, Subjects 863 people admitted to hospital for weapon injuries over 12 months. Main outcome measures Annual incidence of Weapon injury by time period; proportions of injuries inflicted as a result of interfactional combat (combat injuries) and outside such combat (non-combat injuries) by combatant status and weapon type. Results The annual incidence of weapon injuries was higher than the rate observed before the peacekeeping operation. 30%, of weapon injuries occurred in contexts other than inter-factional combat. Most commonly these were firearm injuries inflicted intentionally on civilians, Civilians accounted for 71% of those with non-combat injuries, 42% of those with combat related injuries, and 51% of those with weapon injuries of either type. Conclusions The incidence of weapon injuries remained high when the disarmament component of a peacekeeping operation achieved only limited success. Furthermore, injuries occurring outside the context of interfactional combat accounted for a substantial proportion of all weapon injuries, were experienced disproportionately by civilians, and were most likely to entail the intentional use of a firearm against a civilian.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Div Hlth Operat, CH-1202 Geneva, Switzerland		Meddings, DR (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; *AS WATCH PHYS HUM, 1991, LAND MIN CAMB COW WA; COBEY JC, 1993, JAMA-J AM MED ASSOC, V270, P632, DOI 10.1001/jama.270.5.632; COMNINELLIS N, 1994, TROP DOCT, V24, P1; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Grossman Dave, 1995, KILLING PSYCHOL COST; Klare M. T., 1995, LETHAL COMMERCE GLOB; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; WANG J, 1996, MANAGING ARMS PEACE, P32; WEINBERG J, 1995, SOC SCI MED, V40, P1663, DOI 10.1016/0277-9536(95)00022-Y; Williams P., 1997, SOC SIEGE CRIME VIOL, P11; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	14	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					412	415		10.1136/bmj.319.7207.412	http://dx.doi.org/10.1136/bmj.319.7207.412			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445922	Bronze, Green Published			2022-12-01	WOS:000082098900016
J	Moszynski, P				Moszynski, P			United Nations estimates of HIV prevalence in Zambia under attack	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					338	338		10.1136/bmj.319.7206.338	http://dx.doi.org/10.1136/bmj.319.7206.338			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435948	Green Published			2022-12-01	WOS:000082001700012
J	Zuber, ME; Perron, M; Philpott, A; Bang, A; Harris, WA				Zuber, ME; Perron, M; Philpott, A; Bang, A; Harris, WA			Giant eyes in Xenopus laevis by overexpression of XOptx2	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; HOMEOBOX GENE SIX3; S-PHASE; LENS INDUCTION; DROSOPHILA EYE; NERVOUS-SYSTEM; EYELESS GENE; SINE OCULIS; EXPRESSION; DIFFERENTIATION	Overexpression of XOptx2, a homeodomain-containing transcription factor expressed in the Xenopus embryonic eye field, results in a dramatic increase in eye size. An XOptx2-Engrailed repressor gives a similar phenotype, while an XOptx2-VP16 activator reduces eye size. XOptx2 stimulates bromodeoxyuridine incorporation, and XOptx2-induced eye enlargement is dependent on cellular proliferation. Moreover, retinoblasts transfected with XOptx2 produce clones of cells approximately twice as large as control clones. Pax6, which does not increase eye size alone, acts synergistically with XOptx2. Our results suggest that XOptx2, in combination with other genes expressed in the eye field, is crucially involved in the proliferative state of retinoblasts and thereby the size of the eye.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Dept Oncol, Cambridge CB3 2QQ, England; Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA	University of Cambridge; University of Cambridge; Salk Institute	Harris, WA (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Perron, Muriel/F-6795-2019	Perron, Muriel/0000-0002-1558-8236; Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Casarosa S, 1997, MECH DEVELOP, V61, P187, DOI 10.1016/S0925-4773(96)00640-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; EAGLESON G, 1995, J NEUROBIOL, V28, P146, DOI 10.1002/neu.480280203; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Halder G, 1998, DEVELOPMENT, V125, P2181; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Harris W. A., 1979, SOC NEUROSCI S, V4, P228; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.0.CO;2-E; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Kobayashi M, 1998, DEVELOPMENT, V125, P2973; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Li HS, 1997, DEVELOPMENT, V124, P603; Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649; Lopez-Rios J, 1999, MECH DEVELOP, V83, P155, DOI 10.1016/S0925-4773(99)00017-9; MARDON G, 1994, DEVELOPMENT, V120, P3473; Mariani FV, 1998, DEVELOPMENT, V125, P5019; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Nieuwkoop P.D., 1994, SYSTEMATICAL CHRONOL, DOI 10.1201/9781003064565-29; Oliver G, 1996, MECH DEVELOP, V60, P233, DOI 10.1016/S0925-4773(96)00632-6; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; PITTACK C, 1991, DEVELOPMENT, V113, P577; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROTMANN ECKHARD, 1940, WILHELM ROUX ARCH ENTWICKLUNGSMECH ORGAN, V140, P124, DOI 10.1007/BF00576250; Rotmann Eckhard, 1939, Wilhelm Roux Arch Entwickl Mech Org, V139, P1, DOI 10.1007/BF00576382; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Shen WP, 1997, DEVELOPMENT, V124, P45; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Stone LS, 1930, J EXP ZOOL, V55, P193, DOI 10.1002/jez.1400550112; Toy J, 1999, MECH DEVELOP, V83, P183, DOI 10.1016/S0925-4773(99)00049-0; Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TWITTY V, 1955, ANAL DEV, P402; TWITTY VC, 1940, GROWTH, V4, P109	46	169	169	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					341	352		10.1016/S0092-8674(00)81963-7	http://dx.doi.org/10.1016/S0092-8674(00)81963-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458609	Bronze			2022-12-01	WOS:000081950300009
J	Clancy, CE; Rudy, Y				Clancy, CE; Rudy, Y			Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia	NATURE			English	Article							LONG-QT SYNDROME; DYNAMIC-MODEL; ION CHANNELS; MUTATIONS; HEART; AFTERDEPOLARIZATIONS; MECHANISM; MYOCYTES	Advances in genetics and molecular biology have provided an extensive body of information on the structure and function of the elementary building blocks of living systems. Genetic defects in membrane ion channels can disrupt the delicate balance of dynamic interactions between the ion channels and the cellular environment, leading to altered cell function(1-3). As ion-channel defects are typically studied in isolated expression systems, away from the cellular environment where they function physiologically, a connection between molecular findings and the physiology and pathophysiology of the cell is rarely established. Here we describe a single-channel-based Markovian modelling approach that bridges this gap. We achieve this by determining the cellular arrhythmogenic consequences of a mutation in the cardiac sodium channel that can lead to a clinical arrhythmogenic disorder (the long-QT syndrome) and sudden cardiac death.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rudy, Y (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	yxr@po.cwru.edu	Clancy, Colleen/B-2528-2010					Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; BALSER JR, 1990, BIOPHYS J, V57, P433, DOI 10.1016/S0006-3495(90)82560-1; Barinaga M, 1998, SCIENCE, V281, P32, DOI 10.1126/science.281.5373.32; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Chandra R, 1998, AM J PHYSIOL-HEART C, V274, pH1643, DOI 10.1152/ajpheart.1998.274.5.H1643; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Hanck D. A., 1995, CARDIAC ELECTROPHYSI, P65; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; LUO CH, 1994, CIRC RES, V74, P1097, DOI 10.1161/01.RES.74.6.1097; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; MITSUIYE T, 1995, J PHYSIOL-LONDON, V485, P581, DOI 10.1113/jphysiol.1995.sp020754; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; Wang DW, 1997, J CLIN INVEST, V99, P1714, DOI 10.1172/JCI119335; WELSH MJ, 1995, NATURE, V376, P640, DOI 10.1038/376640a0; YUE DT, 1989, SCIENCE, V244, P349, DOI 10.1126/science.2540529; ZENG J, 1997, BIOMEDICAL ENG; ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140; ZENG JL, 1995, BIOPHYS J, V68, P949, DOI 10.1016/S0006-3495(95)80271-7	21	323	331	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					566	569		10.1038/23034	http://dx.doi.org/10.1038/23034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448858				2022-12-01	WOS:000081854800056
J	Farrell, Z; O'Neill, D				Farrell, Z; O'Neill, D			Towards better screening and assessment of oropharyngeal swallow disorders in the general hospital	LANCET			English	Editorial Material							ASPIRATION; STROKE		Adelaide & Meath Hosp Dublin, Dept Speech & Language Therapy, Dublin 24, Ireland; Adelaide & Meath Hosp Dublin, Dept Age Related Hlth Care, Dublin 24, Ireland	Trinity College Dublin; Trinity College Dublin	Farrell, Z (corresponding author), Adelaide & Meath Hosp Dublin, Dept Speech & Language Therapy, Dublin 24, Ireland.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				*AG HLTH CAR POL R, 1999, 99E023 ACHPR AG HLTH; Bastian Robert W., 1993, Dysphagia, V8, P359, DOI 10.1007/BF01321780; COLLINS DR, 1996, CLIN INTENSIVE CARE, V7, P315; Collins MJ, 1997, STROKE, V28, P1773, DOI 10.1161/01.STR.28.9.1773; DEPIPPO KL, 1994, ARCH PHYS MED REHAB, V75, P1284; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; Leder SB, 1997, DYSPHAGIA, V12, P21, DOI 10.1007/PL00009514; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; Logemann J., 1997, EVALUATION TREATMENT; *SCOTT INT GUID NE, 1997, MAN PAT STROK 3; Selley W. G., 1994, Dysphagia, V9, P162, DOI 10.1007/BF00341260; Smith D., 1997, ROMANI CULTURE IDENT, P7; Smithard DG, 1998, AGE AGEING, V27, P99, DOI 10.1093/ageing/27.2.99; STROUD A, 1997, DYSPHAGIA, V12, P106; ZENNER PM, 1995, DYSPHAGIA, V10, P27, DOI 10.1007/BF00261276	15	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					355	356		10.1016/S0140-6736(98)90085-X	http://dx.doi.org/10.1016/S0140-6736(98)90085-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437860				2022-12-01	WOS:000081764900005
J	Goodman, CA; Coleman, PG; Mills, AJ				Goodman, CA; Coleman, PG; Mills, AJ			Cost-effectiveness of malaria control in sub-Saharan Africa	LANCET			English	Article							CHILDREN; HEALTH; CHEMOPROPHYLAXIS; CHLOROQUINE; STRATEGIES; MORBIDITY; EFFICACY; PROGRAM; WOMEN	Background Information on the cost-effectiveness of malaria control is needed for the WHO Roll Back Malaria campaign, but is sparse. We used mathematical models to calculate cost-effectiveness ratios for the main prevention and treatment interventions in sub-Saharan Africa. Methods We analysed interventions to prevent malaria in childhood (insecticide-treated nets, residual spraying of houses, and chemoprophylaxis) and pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermittent treatment), and to improve malaria treatment (improved compliance, improved availability of second-line and third-line drugs, and changes in first-line drug). We developed models that included probabilistic sensitivity analysis to calculate ranges for the cost per disability-adjusted life year (DALY) averted for each intervention in three economic strata. Data were obtained from published and unpublished sources, and consultations with researchers and programme managers. Findings In a very-low-income country, for insecticide treatment of existing nets, the cost-effectiveness range was US$4-10 per DALY averted; for provision of nets and insecticide treatment $19-85; for residual spraying (two rounds per year) $32-58; for chemoprophylaxis for children $3-12 (assuming an existing delivery system); for intermittent treatment of pregnant women $4-29; and for improvement in case management $1-8. Although some interventions are inexpensive, achieving high coverage with an intervention to prevent childhood malaria would use a high proportion of current health-care expenditure. Interpretation Cost-effective interventions are available. A package of interventions:to decrease the bulk of the malaria burden is not, however, affordable in very-low-income countries. Coverage of the most vulnerable groups in Africa will require substantial assistance from external donors.	London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Goodman, CA (corresponding author), London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England.			Goodman, Catherine/0000-0002-2241-3485; Mills, Anne/0000-0001-9863-9950				[Anonymous], DECADE PROGR MALARIA; Barat LM, 1998, TROP MED INT HEALTH, V3, P535, DOI 10.1046/j.1365-3156.1998.00271.x; Barendregt JJ, 1996, B WORLD HEALTH ORGAN, V74, P439; Bloland PB, 1998, TROP MED INT HEALTH, V3, P543; BRINKMANN U, 1991, TROP MED PARASITOL, V42, P204; Coleman PG, 1999, TROP MED INT HEALTH, V4, P175, DOI 10.1046/j.1365-3156.1999.43382.x; Curtis CF, 1998, PHILOS T ROY SOC B, V353, P1769, DOI 10.1098/rstb.1998.0329; Curtis CF, 1998, TROP MED INT HEALTH, V3, P619, DOI 10.1046/j.1365-3156.1998.00281.x; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Gilson L, 1998, SOC SCI MED, V47, P1891; GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q; GREENWOOD BM, 1988, LANCET, V1, P1121; GULMEZOGLU AM, 1998, COCHRANE COLLABORATI; HILL JA, 1996, APPROACHES MALARIA 1; JAMISON DT, 1993, DIS CONTROL PRIORIRI; LENGELER C, 1998, COCHRANE LIB; *MAN SCI HLTH, 1996, INT DRUG PRIC IND GU; MCDERMOTT JM, 1996, AM J TROP MED HYG S1, V55, P1; MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L; MOLINEAUX L, 1985, HLTH POLICY SOCIAL P, P13; Murray CJL., 1996, GLOBAL BURDEN DIS CO; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7; Phillips MA., 1993, PEEM GUIDELINES SERI, V3; SCHAPIRA A, 1993, PARASITOL TODAY, V9, P168, DOI 10.1016/0169-4758(93)90140-B; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Steketee RW, 1996, AM J TROP MED HYG, V55, P95, DOI 10.4269/ajtmh.1996.55.95; United Nations, 1982, POP STUD-J DEMOG; WERNSDORFER WH, 1988, MALARIA PRINCIPLES P, V2, P1765; *WHO, 1998, ROLL BACK MAL GLOB P; *WHO, 1996, TDRGEN961 WHO; *WHO TDR, 1997, TDR NEWS, V54, P5; *WORLD BANK, 1994, TANZ ROL GOV PUBL EX, V1; World Bank, 1997, WORLD DEV REP STAT C	36	182	183	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					378	385		10.1016/S0140-6736(99)02141-8	http://dx.doi.org/10.1016/S0140-6736(99)02141-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437867				2022-12-01	WOS:000081764900013
J	Adachi-Yamada, T; Fujimura-Kamada, K; Nishida, Y; Matsumoto, K				Adachi-Yamada, T; Fujimura-Kamada, K; Nishida, Y; Matsumoto, K			Distortion of proximodistal information causes JNK-dependent apoptosis in Drosophila wing	NATURE			English	Article							LONG-RANGE ACTION; DECAPENTAPLEGIC GENE; MORPHOGEN GRADIENT; IMAGINAL DISKS; EXPRESSION; MELANOGASTER; SURVIVAL; COMPLEX; AXIS; HID	Distinct and evolutionarily conserved signal-transduction cascades mediate the survival or death of cells during development. The c-Jun amino-terminal kinases (JNKs) of the mitogen-activated protein kinase superfamily are involved in apoptotic signalling in various cultured cells(1), However, the role of the JNK pathway in development is less well understood In Drosophila, Decapentaplegic (Dpp; a homologue of transforming growth factor-beta) and Wingless (Wg; a Wnt homologue) proteins are secretory morphogens that act cooperatively to induce formation of the proximodistal axis of appendages(2-7). Here we show that either decreased Dpp signalling in the distal wing cells or increased Dpp signalling in the proximal wing cells causes apoptosis, Inappropriate levels of Dpp signalling lead to aberrant morphogenesis in the respective wing zones, and these apoptotic zones are also determined by the strength of the Wg signal. Our results indicate that distortion of the positional information determined by Dpp and Wg signalling gradients leads to activation of the JNK apoptotic pathway, and the consequent induction of cell death thereby maintains normal morphogenesis.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Adachi-Yamada, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Tsai, Yu-Chen/B-5852-2008	Kamada, Konomi/0000-0002-2186-8728				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; deCelis JF, 1997, DEVELOPMENT, V124, P1007; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito K, 1997, DEVELOPMENT, V124, P761; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TERRAS V, 1994, SLAVIC E EUR J, V38, P165, DOI 10.2307/308553; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	27	243	245	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					166	169		10.1038/22112	http://dx.doi.org/10.1038/22112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408443				2022-12-01	WOS:000081324900054
J	Katzman, GL; Dagher, AP; Patronas, NJ				Katzman, GL; Dagher, AP; Patronas, NJ			Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR HEALTH; SINUS ABNORMALITIES; PINEAL CYSTS; MRI	Context Previous reports have discussed incidental disease found on brain magnetic resonance imaging (MRI) scans that had been requested for an unrelated clinical concern or symptom, resulting in a selection bias for disease. However, the prevalence of unexpected abnormalities has not been studied in a healthy population. Objective To evaluate the prevalence of incidental findings on brain MRI scans obtained for a healthy, asymptomatic population without selection bias. Design, Setting, and Participants Retrospective analysis of brain MRI scans obtained between May 17, 1996, and July 25, 1997, from 1000 volunteers who participated as control subjects for various research protocols at the National Institutes of Health. All participants (age range, 3-83 years; 54.6% male) were determined to be healthy and asymptomatic by physician examination and participant history. Main Outcome Measure Prevalence of abnormalities on brain MRI by category of finding (no referral necessary, routine referral, urgent referral [within 1 week of study], and immediate referral [within 1 to several days of study]), Results Eighty-two percent of the MRI results were normal, Of the 18% demonstrating incidental abnormal findings, 15.1% required no referral; 1.8%, routine referral; 1.1%, urgent referral; and 0%, immediate referral. In subjects grouped for urgent referral, 2 confirmed primary brain tumors (and a possible but unconfirmed third) were found, demonstrating a prevalence of at least 0.2%. Conclusion Asymptomatic subjects present with a variety of abnormalities, providing valuable information on disease prevalence in a presumed healthy population, A small percentage of these findings require urgent medical attention and/or additional studies.	NIH, Dept Diagnost Radiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Dagher, AP (corresponding author), NIH, Dept Diagnost Radiol, Bldg 10,Room 1C660, Bethesda, MD 20892 USA.							Baum KA, 1996, NEURORADIOLOGY, V38, P755, DOI 10.1007/s002340050342; BRYAN RN, 1994, AM J NEURORADIOL, V15, P1625; Davis FG, 1996, NEUROEPIDEMIOLOGY, V15, P103, DOI 10.1159/000109895; DICOSTANZO A, 1993, J NEUROL NEUROSUR PS, V56, P207, DOI 10.1136/jnnp.56.2.207; HUME AJ, 1984, GREENFIELDS NEUROPAT, P426; Iwabuchi Y, 1997, ARCH OTOLARYNGOL, V123, P602; MALY PV, 1995, NEURORADIOLOGY, V37, P471, DOI 10.1007/BF00600097; MORRIS P, 1997, PRACTICAL NEUROANGIO, P296; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P529; Patel K, 1996, J LARYNGOL OTOL, V110, P649, DOI 10.1017/S0022215100134516; PrestonMartin S, 1996, NEUROL CLIN, V14, P273, DOI 10.1016/S0733-8619(05)70256-5; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Robinson R., 1971, PROGR NEUROLOGICAL S, P133, DOI 10.1159/000391818; Salonen O, 1997, NEURORADIOLOGY, V39, P537, DOI 10.1007/s002340050463; SAWAMURA Y, 1995, NEUROSURGERY, V37, P11, DOI 10.1227/00006123-199507000-00002; Yue NC, 1997, RADIOLOGY, V202, P41, DOI 10.1148/radiology.202.1.8988190	16	371	376	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					36	39		10.1001/jama.282.1.36	http://dx.doi.org/10.1001/jama.282.1.36			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404909	Bronze			2022-12-01	WOS:000081195800026
J	Ishitani, T; Ninomiya-Tsuji, J; Nagai, S; Nishita, M; Meneghini, M; Barker, N; Waterman, M; Bowerman, B; Clevers, H; Shibuya, H; Matsumoto, K				Ishitani, T; Ninomiya-Tsuji, J; Nagai, S; Nishita, M; Meneghini, M; Barker, N; Waterman, M; Bowerman, B; Clevers, H; Shibuya, H; Matsumoto, K			The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF	NATURE			English	Article							XENOPUS-EMBRYOS; DROSOPHILA; GENE; WINGLESS; TRANSDUCTION; ARMADILLO; LEF-1; AXIS; IDENTIFICATION; ACTIVATION	The Wnt signalling pathway regulates many developmental processes through a complex of beta-catenin and the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of high-mobility-group transcription factors(1-5). Wnt stabilizes cytosolic beta-catenin, which then binds to TCF and activates gene transcription. This signalling cascade is conserved in vertebrates, Drosophila and Caenorhabditis elegans. In C. elegans, the proteins MOM-4 and LIT-I regulate Wnt signalling to polarize responding cells during embryogenesis(6). MOM-4 and LIT-1 are homologous to TAK1 (a kinase activated by transforming growth factor-beta) mitogen-activated protein-kinase-kinase kinase (MAP3K)(7) and MAP kinase (MAPK)-related NEMO-like kinase (NLK)(8,9), respectively, in mammalian cells. These results raise the possibility that TAK1 and NLK are also involved in Wnt signalling in mammalian cells. Here we show that TAK1 activation stimulates NLK activity and downregulates transcriptional activation mediated by beta-catenin and TCF. Injection of NLK suppresses the induction of axis duplication by microinjected beta-catenin in Xenopus embryos. NLK phosphorylates TCF/LEF factors and inhibits the interaction of the beta-catenin-TCF complex with DNA. Thus, the TAK1-NLK-MAPK-like pathway negatively regulates the Wnt signalling pathway.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Nagoya University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of Oregon; Utrecht University; Utrecht University Medical Center; University of California System; University of California Irvine	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan.		Ishitani, Tohru/E-9781-2014; Barker, Nick/A-5535-2011; Barker, Nick/AAE-9833-2021; Barker, Nick/AAS-2774-2020	Barker, Nick/0000-0003-3566-4475; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARDIGAN KM, 1997, GENE DEV, V11, P3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	491	521	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					798	802		10.1038/21674	http://dx.doi.org/10.1038/21674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391247				2022-12-01	WOS:000081101600057
J	Barker, DJP				Barker, DJP			Intrauterine nutrition may be important - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							ACHESON ED, 1986, P NUTR SOC, V45, P131, DOI 10.1079/PNS19860047; Barker D.J.P., 1998, MOTHERS BABIES HLTH; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Dwork Deborah, 1987, WAR IS GOOD BABIES O; Fogel R., 1991, NUTR POVERTY	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1477	1478						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419294				2022-12-01	WOS:000080668200030
J	Leggatt, V; Mackay, J; Yates, JRW				Leggatt, V; Mackay, J; Yates, JRW			Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER		E Barnwell Hlth Ctr, Cambridge CB5 8SP, England; Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	Leggatt, V (corresponding author), E Barnwell Hlth Ctr, Cambridge CB5 8SP, England.							Dunlop MG, 1997, BMJ-BRIT MED J, V314, P1882, DOI 10.1136/bmj.314.7098.1882; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Lalloo F, 1998, EUR J CANCER, V34, P937, DOI 10.1016/S0959-8049(98)00005-7; Mackay James, 1997, Cancer Treatment Reviews, V23, pS13, DOI 10.1016/S0305-7372(97)90003-7; Pharoah PDP, 1998, BRIT MED BULL, V54, P823	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					757	758		10.1136/bmj.319.7212.757	http://dx.doi.org/10.1136/bmj.319.7212.757			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488003	Bronze, Green Published			2022-12-01	WOS:000082701500022
J	Selhub, J; Jacques, PF; Rosenberg, IH; Rogers, G; Bowman, BA; Gunter, EW; Wright, JD; Johnson, CL				Selhub, J; Jacques, PF; Rosenberg, IH; Rogers, G; Bowman, BA; Gunter, EW; Wright, JD; Johnson, CL			Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations	ANNALS OF INTERNAL MEDICINE			English	Article							PLASMA TOTAL HOMOCYSTEINE; FOLIC-ACID; COBALAMIN DEFICIENCY; REFERENCE INTERVALS; METHYLMALONIC ACID; ELDERLY POPULATION; VASCULAR-DISEASE; BRITISH MEN; RISK; HYPERHOMOCYSTEINEMIA	Background: The concentration of circulating total homocysteine is a sensitive marker of inadequate folate and vitamin B-12 status. Elevated homocysteine concentrations are associated with an increased risk for vascular disease. Objective: To identify reference ranges for serum total homocysteine concentration in U.S. residents and quantify the contribution of circulating vitamin concentrations to high homocysteine concentrations. Design: Cross-sectional prevalence study. Setting: United States. Patients: A nationally representative sample of 3563 male participants and 4523 female participants 12 years of age or older who participated in the third National Health and Nutrition Examination Survey. Measurements: Reference ranges (5th and 95th percentiles) for the total homocysteine concentration were defined among participants who were folate- and vitamin B-12-replete and had normal creatinine concentrations. A high total homocysteine concentration was defined as one that exceeded the sex-specific 95th percentile for the reference sample (participants 20 to 39 years of age). The population attributable risk percentage was calculated to determine the contribution of low folate (<11 nmol/L) and vitamin B-12 (<185 pmol/L) concentrations to a high homocysteine concentration. Results: Reference ranges for serum total homocysteine concentration increased with age; these ranges were 4.3 to 9.9 mu mol/L for male participants and 3.3 to 7.2 mu mol/L for female participants 12 to 19 years of age and from 5.9 to 15.3 mu mol/L for men and 4.9 to 11.6 mu mol/L for women 60 years of age or older. A high homocysteine concentration was defined as at least 11.4 mu mol/L for male participants and at least 10.4 mu mol/L for female participants. Approximately two thirds of the cases of high homocysteine concentrations were associated with low vitamin concentrations. Conclusions: Upper reference limits for the serum total homocysteine concentration increased with age and were higher for male participants than for female participants at all ages. In most cases, high homocysteine concentrations were associated with low serum vitamin concentrations.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Ctr Dis Control & Prevent, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Environm Hlth Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Tufts University; United States Department of Agriculture (USDA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Selhub, J (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052630] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL52630] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1996, FED REGISTER, V61, P8781; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Bates CJ, 1997, EUR J CLIN NUTR, V51, P691, DOI 10.1038/sj.ejcn.1600468; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; Chambers JM., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Gunter E.W., 1996, LAB PROCEDURES USED; Guttormsen AB, 1997, KIDNEY INT, V52, P495, DOI 10.1038/ki.1997.359; Herbert V, 1999, MODERN NUTR HLTH DIS, P433; Jacques PF, 1999, AM J CLIN NUTR, V69, P482; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Johnson C.L., 1998, VITAL HLTH STAT, V11, P1; Joosten E, 1996, EUR J HAEMATOL, V57, P222; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Mijatovic V, 1998, OBSTET GYNECOL, V91, P432, DOI 10.1016/S0029-7844(97)00704-7; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Rasmussen K, 1996, CLIN CHEM, V42, P630; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; ROSENBERG IH, 1992, AM J CLIN NUTR, V55, P1237; *SAS I INC, 1996, SAS SYST WIND VERS 6; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Selhub J., 1996, PRESENT KNOWLEDGE NU, P206; Shah BV, 1996, SUDAAN USERS MANUAL; *SPSS INC, 1997, SYSTAT 7 0 WIND; *THREE NAT HLTH NU, 1996, REF MAN REP WEIGHT E; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; UBBINK JB, 1995, CLIN CHEM, V41, P1033; *US DEP HHS, 1994, DHHS PUBL PHS; Weir D. G., 1999, MODERN NUTR HLTH DIS, P447; WILCKEN DEL, 1988, METABOLISM, V37, P697, DOI 10.1016/0026-0495(88)90093-5; 1997, MMWR MORB MORTAL WKL, V46, P721	41	302	320	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					331	+		10.7326/0003-4819-131-5-199909070-00003	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475885				2022-12-01	WOS:000082458500002
J	Ferry, LH; Grissino, LM; Runfola, PS				Ferry, LH; Grissino, LM; Runfola, PS			Tobacco dependence curricula in US undergraduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING-CESSATION; UNITED-STATES; STUDENTS; PHYSICIANS; QUIT	Context Tobacco use is the leading preventable cause of death in the United States. And yet only 21% of practicing physicians claim they received adequate training to help their patients stop smoking. Objective To assess the content and extent of tobacco education and intervention skills in US medical schools' curricula. Design A survey with 13 multiple-response items on tobacco education, Survey questions were based on the recommendations of the Agency for Health Care Policy and Research and the National Cancer Institute Expert Panel, The Liaison Committee on Medical Education included 4 of these items in a modified form on the 1997 annual questionnaire. Setting One hundred twenty-six US medical schools. Participants Surveys were obtained from 122 associate deans for medical education (98.6%), Main Outcome Measures Curriculum content in basic science and clinical science, elective or required clinical experience, hours of instruction, and resource materials, Results Inclusion of all 6 tobacco curricula content areas recommended by the National Cancer Institute and the Agency for Health Care Policy and Research was higher in basic science (63/115 [54.8%]) than in clinical science (5/115 [4.4%]). Most medical schools (83/120 [69.2%]) did not require clinical training in smoking cessation techniques, while 23.5% (27/115) offered additional experience as an elective course, Thirty-one percent (32/102) of schools averaged less than 1 hour of instruction per year in smoking cessation techniques during the 4 years of medical school. A minority of schools reported 3 or more hours of clinical smoking cessation instruction in the third (14.7%) and fourth (4.9%) years. Conclusions A majority of US medical school graduates are not adequately trained to treat nicotine dependence. The major deficit is the lack of smoking cessation instruction and evaluation in the clinical years. A model core tobacco curricula that meets national recommendations should be developed and implemented in all US medical schools.	Loma Linda Univ, Sch Med, Dept Prevent Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Publ Hlth, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Ferry, LH (corresponding author), Loma Linda Univ, Sch Med, Dept Prevent Med, Nichol Hall,Room 1516, Loma Linda, CA 92350 USA.							ALLEN SS, 1990, AM J PREV MED, V6, P28, DOI 10.1016/S0749-3797(18)31041-9; *AM AC FAM PHYS, 1987, STOP SMOK KIT; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P854; COULTAS DB, 1994, ACAD MED, V69, pS48, DOI 10.1097/00001888-199410000-00039; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P624, DOI 10.1001/jama.271.8.624; GLYNN TJ, 1993, NIH PUBLICATION; GOLDSTEIN MG, 1989, PROJECT ADEPT CURRIC; HORTON J, 1986, CANCER DETECT PREV, V9, P417; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Richmond R, 1997, ED MED STUDENTS TOBA, P281; Richmond RL, 1998, TOB CONTROL, V7, P247, DOI 10.1136/tc.7.3.247; U. S. Department of Health and Human Services, 1998, HLTH PEOPL 2010 OBJ; [U.S. Department of Health and Human Services Public Health Service Agency], 1996, AHCPR PUBL; U. S. Department of Health and Human Services Public Health Service Office of Disease Prevention and Health Promotion., 1994, CLIN HDB PREV SERV P; *US DEP HHS, 1995, HLTH PEOPL 2000 MIDC; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; VARNER KF, 1996, DIRECTORY AM MED ED	19	154	157	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					825	829		10.1001/jama.282.9.825	http://dx.doi.org/10.1001/jama.282.9.825			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478687	Bronze			2022-12-01	WOS:000082272200006
J	Zolensky, ME; Bodnar, RJ; Gibson, EK; Nyquist, LE; Reese, Y; Shih, CY; Wiesmann, H				Zolensky, ME; Bodnar, RJ; Gibson, EK; Nyquist, LE; Reese, Y; Shih, CY; Wiesmann, H			Asteroidal water within fluid inclusion-bearing halite in an H5 chondrite, Monahans (1998)	SCIENCE			English	Article							CARBONACEOUS CHONDRITES; AQUEOUS ALTERATION; CONSTRAINTS; MINERALOGY; AGE	Crystals of halite and sylvite within the Monahans (1998) H5 chondrite contain aqueous fluid inclusions. The fluids are dominantly sodium chloride-potassium chloride brines. but they also contain divalent cations such as iron, magnesium, or calcium. Two possible origins for the brines are indigenous fluids flowing within the asteroid and exogenous fluids delivered into the asteroid surface from a salt-containing icy object.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Virginia Tech, Dept Geol Sci, Blacksburg, VA 24061 USA; Lockheed Martin Space Operat Co, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Virginia Polytechnic Institute & State University; Lockheed Martin	Zolensky, ME (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mail Code SN2, Houston, TX 77058 USA.		Bodnar, Robert J/A-1916-2009	Zolensky, Michael/0000-0002-3181-1303				BARBER DJ, 1981, GEOCHIM COSMOCHIM AC, V45, P945, DOI 10.1016/0016-7037(81)90120-4; BERKLEY JL, 1978, GEOPHYS RES LETT, V5, P1075, DOI 10.1029/GL005i012p01075; BRIDGES JC, 1998, LUNAR PLANET SCI, V29; Browning L, 1998, METEORIT PLANET SCI, V33, P1213, DOI 10.1111/j.1945-5100.1998.tb01306.x; Chang L, 1996, ROCK FORMING MINER B, V5, P369; DAVIS DW, 1990, GEOCHIM COSMOCHIM AC, V54, P591, DOI 10.1016/0016-7037(90)90355-O; DUFRESNE ER, 1962, GEOCHIM COSMOCHIM AC, V26, P1085, DOI 10.1016/0016-7037(62)90047-9; Fieni C., 1978, METEORITICS, V13, P460; Garner E.L., 1975, LUNAR SCI C P, V6, P1845; GOODING JL, 1991, METEORITICS, V26, P135, DOI 10.1111/j.1945-5100.1991.tb01029.x; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; LANGENAUER M, 1993, EARTH PLANET SC LETT, V120, P431, DOI 10.1016/0012-821X(93)90255-8; LAWLER JP, 1983, ECON GEOL, V78, P527, DOI 10.2113/gsecongeo.78.3.527; McSween H.Y., 1988, METEORITES EARLY SOL, P102; MCSWEEN HY, 1987, GEOCHIM COSMOCHIM AC, V51, P2469, DOI 10.1016/0016-7037(87)90298-5; MERNAGH TP, 1989, GEOCHIM COSMOCHIM AC, V53, P765, DOI 10.1016/0016-7037(89)90022-7; MINSTER JF, 1982, NATURE, V300, P414, DOI 10.1038/300414a0; NASSAU K, 1983, PHYSICS CHEM COLOR; NYQUIST LE, 1990, GEOCHIM COSMOCHIM AC, V54, P2195, DOI 10.1016/0016-7037(90)90045-M; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; Roedder E., 1984, FLUID INCLUSIONS; ROEDDER E, 1968, FLUID INCLUSION RES; RUDNICK RL, 1985, J GEOPHYS RES, V90, pC669, DOI 10.1029/JB090iS02p0C669; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; TARTER JG, 1981, THESIS ARIZONA STATE; WARNER JL, 1983, J GEOPHYS RES, V88, pA731, DOI DOI 10.1029/JB088IS02P0A731); Zolensky M., 1988, METEORITES EARLY SOL, P114; ZOLENSKY ME, 1989, ICARUS, V78, P411, DOI 10.1016/0019-1035(89)90188-7; ZOLENSKY ME, 1999, LUNAR PLANET SCI, V30	29	158	164	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1377	1379		10.1126/science.285.5432.1377	http://dx.doi.org/10.1126/science.285.5432.1377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464091				2022-12-01	WOS:000082233500035
J	Stahl-Hennig, C; Steinman, RM; Tenner-Racz, K; Pope, M; Stolte, N; Matz-Rensing, K; Grobschupff, G; Raschdorff, B; Hunsmann, G; Racz, P				Stahl-Hennig, C; Steinman, RM; Tenner-Racz, K; Pope, M; Stolte, N; Matz-Rensing, K; Grobschupff, G; Raschdorff, B; Hunsmann, G; Racz, P			Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus	SCIENCE			English	Article							DENDRITIC CELLS; IMMUNE-RESPONSES; T-CELLS; HIV-1; REPLICATION; MACAQUES; SIV; PLASMA; SKIN; TRANSMISSION	The early events during infection with an immunodeficiency virus were followed by application of pathogenic simian immunodeficiency virus atraumatically to the tonsils of macaques. Analyses by virologic assays and in situ hybridization revealed that the infection started Locally in the tonsils, a mucosal-associated Lymphoid organ, and quickly spread to other Lymphoid tissues. At day 3, there were few infected cells, but then the number increased rapidly, reaching a high plateau between days 4 and 7. The infection was not detected in the dendritic cell-rich squamous epithelium to which the virus was applied; instead, it was primarily in CD4(+) tonsillar T cells, close to the specialized antigen-transporting epithelium of the tonsillar crypts. Transport of the virus and immune-activating stimuli across this epithelium would allow mucosal Lymphoid tissue to function in the atraumatic transmission of immunodeficiency viruses.	German Primate Ctr, D-37077 Gottingen, Germany; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Deutsches Primatenzentrum (DPZ); Rockefeller University; Bernhard Nocht Institut fur Tropenmedizin	Stahl-Hennig, C (corresponding author), German Primate Ctr, D-37077 Gottingen, Germany.		Abrams, William R/A-5782-2008; Steinman, Ralph/F-7729-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040874, R01AI042129, R01AI040877] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40877, AI 42129, AI 40874] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Frankel SS, 1997, AM J PATHOL, V151, P89; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Ignatius R, 1998, J MED PRIMATOL, V27, P121, DOI 10.1111/j.1600-0684.1998.tb00236.x; Kelsall BL, 1996, J EXP MED, V183, P237, DOI 10.1084/jem.183.1.237; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; Neildez O, 1998, VIROLOGY, V243, P12, DOI 10.1006/viro.1997.9026; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NORLEY SG, 1993, BIOLOGICALS, V21, P251, DOI 10.1006/biol.1993.1082; Ogra P., 1987, IMMUNOLOGY EAR, P63; OWEN RL, 1990, SPRINGER SEMIN IMMUN, V12, P139; Pope M, 1997, AIDS RES HUM RETROV, V13, P819, DOI 10.1089/aid.1997.13.819; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; Ruprecht RM, 1998, AIDS RES HUM RETROV, V14, pS97; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; StahlHennig C, 1996, J GEN VIROL, V77, P2969, DOI 10.1099/0022-1317-77-12-2969; STAHLHENNIG C, 1992, VIROLOGY, V186, P588, DOI 10.1016/0042-6822(92)90025-K; TENNERRACZ K, 1988, AIDS, V2, P299, DOI 10.1097/00002030-198808000-00010; TENNERRACZ K, 1979, LAB INVEST, V41, P106; WINTHER B, 1994, ARCH OTOLARYNGOL, V120, P144; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	32	191	193	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1261	1265		10.1126/science.285.5431.1261	http://dx.doi.org/10.1126/science.285.5431.1261			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455052				2022-12-01	WOS:000082130200042
J	Yao, Y; Ferrer-Montiel, AV; Montal, M; Tsien, RY				Yao, Y; Ferrer-Montiel, AV; Montal, M; Tsien, RY			Activation of store-operated Ca2+ current in Xenopus oocytes requires SNAP-25 but not a diffusible messenger	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; 3T3-L1 ADIPOCYTES; SNARE-COMPLEX; INOSITOL TRISPHOSPHATE; LAEVIS OOCYTES; RHO-GTPASES; G-PROTEIN; INFLUX; MEMBRANE; CELLS	Depletion of Ca2+ stores in Xenopos oocytes activated entry of Ca2+ across the plasma membrane, which was measured as a current I-soc in subsequently formed cell-attached patches. I-soc survived excision into inside-out configuration. If cell-attached patches were formed before store depletion, I-soc was activated outside but not inside the patches. I-soc was potentiated by microinjection of Clostridium C3 transferase, which inhibits Rho GTPase, whereas I-soc was inhibited by expression of wild-type or constitutively active Rho. Activation of I-soc was also inhibited by botulinum neurotoxin A and dominant-negative mutants of SNAP-25 but was unaffected by brefeldin A. These results suggest that oocyte I-soc is dependent not on aqueous diffusible messengers but on SNAP-25, probably via exocytosis of membrane channels or regulatory molecules.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; Calakos N, 1996, PHYSIOL REV, V76, P1; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; Ferrer-Montiel AV, 1998, FEBS LETT, V435, P84, DOI 10.1016/S0014-5793(98)01012-6; FerrerMontiel AV, 1996, J BIOL CHEM, V271, P18322, DOI 10.1074/jbc.271.31.18322; Fomina AF, 1999, J NEUROSCI, V19, P3711; Gregory RB, 1996, BIOCHEM J, V319, P755, DOI 10.1042/bj3190755; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hilgemann Donald W., 1995, P307; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Holda JR, 1998, NEWS PHYSIOL SCI, V13, P157; Huang XH, 1998, MOL ENDOCRINOL, V12, P1060, DOI 10.1210/me.12.7.1060; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Putney JW, 1999, BIOESSAYS, V21, P38; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SOKABE M, 1990, J CELL BIOL, V111, P599, DOI 10.1083/jcb.111.2.599; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandenBerghe N, 1996, BIOCHEM BIOPH RES CO, V229, P430, DOI 10.1006/bbrc.1996.1821; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	57	225	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					475	485		10.1016/S0092-8674(00)81976-5	http://dx.doi.org/10.1016/S0092-8674(00)81976-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481912	Bronze			2022-12-01	WOS:000082174900008
J	Mulholland, K				Mulholland, K			Magnitude of the problem of childhood pneumonia	LANCET			English	Editorial Material							RESPIRATORY-TRACT INFECTIONS; UPPER RIVER DIVISION; GAMBIAN CHILDREN; LOBAR PNEUMONIA; RURAL AREA; ETIOLOGY; MORTALITY; INFANT; BANGLADESH; PATTERN		WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Mulholland, K (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.	mulhollande@who.ch						ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219, DOI 10.1017/S0021932000013390; CHEN LC, 1980, INT J EPIDEMIOL, V9, P25, DOI 10.1093/ije/9.1.25; DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345, DOI 10.1080/02724936.1993.11747669; EVANS JR, 1981, NEW ENGL J MED, V305, P1117, DOI 10.1056/NEJM198111053051904; Falade AG, 1997, ANN TROP PAEDIATR, V17, P315, DOI 10.1080/02724936.1997.11747904; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009; FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GRANT JP, 1996, STATE WORLDS CHILDRE; GRANT P, 1980, STATE WORLDS CHILDRE; GREENWOOD B, 1992, J INFECT DIS, V165, pS26, DOI 10.1093/infdis/165-Supplement_1-S26; GWATKIN DR, 1980, AM J PUBLIC HEALTH, V70, P1286, DOI 10.2105/AJPH.70.12.1286; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; KABIR M, 1995, J BIOSOC SCI, V27, P179, DOI 10.1017/S0021932000022689; Leowski J, 1986, World Health Stat Q, V39, P138; Lewis F L, 1944, Arch Dis Child, V19, P122; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Murray CJL, 1996, GLOBAL HLTH STAT; ORUBULOYE IO, 1975, POP STUD-J DEMOG, V29, P259, DOI 10.2307/2173511; PRESTON SH, 1976, MORTALITY PATTERNS N, P89; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; WARREN KS, 1988, SOC SCI MED, V26, P891, DOI 10.1016/0277-9536(88)90407-8; WHO (World Health Organization), 1978, PRIM HLTH CAR JOINT; World Bank, 1993, INV HLTH WORLD DEV R	29	74	80	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					590	592		10.1016/S0140-6736(98)10238-6	http://dx.doi.org/10.1016/S0140-6736(98)10238-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470718				2022-12-01	WOS:000081991000048
J	Ramamoorthy, S; Blakely, RD				Ramamoorthy, S; Blakely, RD			Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants	SCIENCE			English	Article							PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; IMIPRAMINE BINDING-SITES; TRITIATED IMIPRAMINE; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; STRIATAL SYNAPTOSOMES; FUNCTIONAL REGULATION; SURFACE EXPRESSION; XENOPUS-OOCYTES	Many psychotropic drugs interfere with the reuptake of dopamine, norepinephrine, and serotonin. Transport capacity is regulated by kinase-linked pathways, particularly those involving protein kinase C (PKC), resulting in transporter phosphorylation and sequestration. Phosphorylation and sequestration of the serotonin transporter (SERT) were substantially impacted by ligand occupancy. Ligands that can permeate the transporter, such as serotonin or the amphetamines, prevented PKC-dependent SERT phosphorylation. Nontransported SERT antagonists such as cocaine and antidepressants were permissive for SERT phosphorylation but blocked serotonin effects. PKC-dependent SEPT sequestration was also blocked by serotonin. These findings reveal activity-dependent modulation of neurotransmitter reuptake and identify previously unknown consequences of amphetamine, cocaine, and antidepressant action.	Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA.	randy.blakely@mcmail.vanderbilt.edu			NIDA NIH HHS [DA07390] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; APPARSUNDARAM S, 1996, SOC NEUR ABSTR, V22; Barker Eric L., 1995, P321; BAUMAN AL, 1998, SOC NEUR ABSTR, V24; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649; BERGER UV, 1992, EUR J PHARMACOL, V215, P153, DOI 10.1016/0014-2999(92)90023-W; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bonisch H, 1998, Adv Pharmacol, V42, P183; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Cinquanta M, 1997, NEUROPHARMACOLOGY, V36, P803, DOI 10.1016/S0028-3908(97)00064-6; Cook EH, 1997, MOL PSYCHIATR, V2, P247; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; CORNEZA J, 1991, BIOCHEM J, V275, P435; Crespi D, 1997, BRIT J PHARMACOL, V121, P1735, DOI 10.1038/sj.bjp.0701325; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Fozzard J., 1989, PERIPHERAL ACTIONS 5; FULLER RW, 1994, LIFE SCI, V55, P163, DOI 10.1016/0024-3205(94)00876-0; FULLER RW, 1990, ANN N Y ACAD SCI, V600, P68; Furlong RA, 1998, AM J MED GENET, V81, P58, DOI 10.1002/(SICI)1096-8628(19980207)81:1<58::AID-AJMG11>3.3.CO;2-W; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Huff RA, 1997, J NEUROCHEM, V68, P225; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; Jones SR, 1998, J NEUROSCI, V18, P1979; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Little KY, 1998, AM J PSYCHIAT, V155, P207; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MARCUSSON JO, 1989, PSYCHOPHARMACOLOGY, V99, P17, DOI 10.1007/BF00634446; MELTZER HY, 1981, ARCH GEN PSYCHIAT, V38, P1322; MELTZER HY, 1990, ANN NY ACAD SCI, V600, P486; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Morgan AE, 1997, EUR J PHARMACOL, V331, pR1, DOI 10.1016/S0014-2999(97)01035-2; MYERS CL, 1988, J APPL PHYSIOL, V65, P377, DOI 10.1152/jappl.1988.65.1.377; NEMEROFF CB, 1988, ARCH GEN PSYCHIAT, V45, P919; NISHIO H, 1995, EUR J PHARM-MOLEC PH, V288, P149, DOI 10.1016/0922-4106(95)90189-2; OWENS MJ, 1994, CLIN CHEM, V40, P288; PAUL SM, 1981, ARCH GEN PSYCHIAT, V38, P1315; Pierce RC, 1997, J NEUROSCI, V17, P3254; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; RAMAMOORTHY S, UNPUB; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; ROSS SB, 1964, ACTA PHARMACOL TOX, V21, P226; ROSS SB, 1982, BIOL SEROTONERGIC TR, P160; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Rudnick G, 1998, METHOD ENZYMOL, V296, P233; Sakai N, 1997, J NEUROCHEM, V68, P2618; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; STANLEY M, 1982, SCIENCE, V216, P1337, DOI 10.1126/science.7079769; SULZER D, 1993, J NEUROCHEM, V60, P527, DOI 10.1111/j.1471-4159.1993.tb03181.x; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Weiger WA, 1997, BIOL REV, V72, P61, DOI 10.1017/S0006323196004975; White FJ, 1998, NATURE, V393, P118, DOI 10.1038/30105; Yura A, 1996, BRAIN RES, V738, P96, DOI 10.1016/0006-8993(96)00762-7; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	79	292	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					763	766		10.1126/science.285.5428.763	http://dx.doi.org/10.1126/science.285.5428.763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427004				2022-12-01	WOS:000081765100063
J	Krishnan, B; Dryer, SE; Hardin, PE				Krishnan, B; Dryer, SE; Hardin, PE			Circadian rhythms in olfactory responses of Drosophila melanogaster	NATURE			English	Article							MUTANTS; PHYSIOLOGY; EXPRESSION; CLOCK; LIGHT; FLY	The core mechanism of circadian timekeeping in arthropods and vertebrates consists of feedback loops involving several clock genes, including period (per) and timeless (tim)(1,2). In the fruitfly Drosophila, circadian oscillations in per expression occur in chemosensory cells of the antennae, even when the antennae are excised and maintained in isolated organ culture(3). Here we demonstrate a robust circadian rhythm in Drosophila in electrophysiological responses to two classes of olfactory stimuli. These rhythms are observed in wild-type flies during light-dark cycles and in constant darkness, but are abolished in per or tim null-mutant flies (per(01) and tim(01)) which lack rhythms in adult emergence and locomotor behaviour. Olfactory rhythms are also abolished in the per 7.2:2 transgenic line in which per expression is restricted to the lateral neurons of the optic lobe(4). Because per 7.2:2 flies do not express per in peripheral oscillators, our results provide evidence that peripheral circadian oscillators are necessary for circadian rhythms in olfactory responses. As olfaction is essential for food acquisition, social interactions and predator avoidance in many animals, circadian regulation of olfactory systems could have profound effects on the behaviour of organisms that rely on this sensory modality.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Biol Clocks Program, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Dryer, SE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.		Krishnan, Balaji/C-7572-2009; Krishnan, Balaji/M-9914-2019	Krishnan, Balaji/0000-0003-2074-4165; Hardin, Paul/0000-0002-3370-9011				ALCORTA E, 1991, J NEUROPHYSIOL, V65, P702, DOI 10.1152/jn.1991.65.3.702; Anholt RRH, 1996, GENETICS, V143, P293; AYER RK, 1992, J NEUROBIOL, V23, P965, DOI 10.1002/neu.480230804; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DUBIN AE, 1995, J NEUROBIOL, V28, P214, DOI 10.1002/neu.480280208; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Hardin PE, 1998, CURR OPIN NEUROBIOL, V8, P642, DOI 10.1016/S0959-4388(98)80093-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Qiu J, 1996, MOL CELL BIOL, V16, P4182; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033	16	239	243	2	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					375	378		10.1038/22566	http://dx.doi.org/10.1038/22566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432117				2022-12-01	WOS:000081590000053
J	Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA				Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA			Older persons' preferences for site of terminal care	ANNALS OF INTERNAL MEDICINE			English	Article							PALLIATIVE CARE; DEATH; PLACE; HOME; TEAM; LIFE; END	Background: Little is known about patients' preferences for site of terminal care, Objective: To describe older persons' preferences for home or hospital as the site of terminal care and to explore potential reasons for their preferences. Design: Cross-sectional quantitative and qualitative interviews. Setting: Participants' homes. Patients: Community-dwelling persons 65 years of age or older who were recently hospitalized with congestive heart failure, chronic obstructive pulmonary disease, or pneumonia and were not selected according to life expectancy; 246 patients participated in quantitative interviews and 29 participated in qualitative interviews. Measurements: Preference for site of terminal care and the reasons for that preference. Results: In quantitative interviews, 118 patients (48%) preferred terminal care in the hospital, 106 (43%) preferred home, and 22 (9%) did not know. One third changed their preference when asked about their preference in the event of a nonterminal illness. Reasons for preference identified during qualitative interviews included the desire to be with family members and concerns about burden to family members and their ability to provide necessary care. Concern about long-term care needs resulted in preference for a nursing home when choice was not constrained to home and hospital. Conclusions: Preference for home as the site of care for terminal illness exceeds existing practice. However, the current debate about home versus hospital as the ideal site for end-of-life care may ignore an important issue to older persons-namely, the care of disabilities that precede death.	Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, West Haven, CT 06516 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale Univ, Program Aging, New Haven, CT 06511 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University	Fried, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu						Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gilbar O, 1996, Hosp J, V11, P31, DOI 10.1300/J011v11n01_03; Glaser B. G., 1978, THEORETICAL SENSITIV; GROTHJUNCKER A, 1983, J AM GERIATR SOC, V31, P457, DOI 10.1111/j.1532-5415.1983.tb05116.x; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; MCWHINNEY IR, 1995, CAN MED ASSOC J, V152, P361; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; *NAT CTR HLTH STAT, 1990, VIT STAT US  A, V2; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415	13	108	110	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					109	112		10.7326/0003-4819-131-2-199907200-00006	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419426				2022-12-01	WOS:000081509700005
J	von Kries, R; Koletzko, B; Sauerwald, T; von Mutius, E; Barnert, D; Grunert, V; von Voss, H				von Kries, R; Koletzko, B; Sauerwald, T; von Mutius, E; Barnert, D; Grunert, V; von Voss, H			Breast feeding and obesity: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ENDOCRINE RESPONSES; GROWTH; CHILDHOOD; ADIPOSITY; PROTEIN; INFANTS; NUTRITION; CHILDREN; WEIGHT; ADULTS	Objective To assess the impact of breast feeding on the risk of obesity and risk of being overweight in children at the time of entry to school. Design Cross sectional survey. Setting Bavaria, southern Germany. Methods Routine data were collected on the height and weight of 134 577 children participating in the obligatory health examination at the time of school entry in Bavaria. In a subsample of 13 345 children, early feeding, diet, and lifestyle factors were assessed using responses to a questionnaire completed by parents. Subjects 9357 children aged 5 and 6 who had German nationality. Main outcome measures Being overweight was defined as having a body mass index above the 90th centile and obesity was defined as body mass index above the 97th centile of all enrolled German children. Exclusive breast feeding was defined as the child being fed no food other than breast milk. Results The prevalence of obesity in children who had never been breast fed was 4.5% as compared with 2.8% in breastfed children. A clear dose-response effect was identified for the duration of breast feeding on the prevalence of obesity: the prevalence was 3.8% for 2 months of exclusive breast feeding, 2.3% for 3-5 months, 1.7% for 6-12 months, and 0.8% for more than 12 months. Similar relations were found with the prevalence of being overweight. The protective effect of breast feeding was not attributable to differences in social class or lifestyle. After adjusting for potential confounding factors, breast feeding remained a significant protective factor against the development of obesity (odds ratio 0.75, 95% CI 0.57 to 0.98) and being overweight (0.79, 0.68 to 0.93). Conclusions In industrialised countries promoting prolonged breast feeding may help decrease the prevalence of obesity in childhood. Since obese children have a high risk of becoming obese adults, such preventive measures may eventually result in a reduction in the prevalence of cardiovascular diseases and other diseases related to obesity.	Univ Munich, Inst Social Paediat & Adolescent Med, D-81377 Munich, Germany; Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany	University of Munich; University of Munich	von Kries, R (corresponding author), Univ Munich, Inst Social Paediat & Adolescent Med, Heiglhofstr 63, D-81377 Munich, Germany.			von Mutius, Erika/0000-0002-8893-4515				ABRAHAM S, 1971, HEALTH SERV REP, V86, P273, DOI 10.2307/4594149; BARANOWSKI T, 1990, J DEV BEHAV PEDIATR, V11, P234; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; Deheeger M, 1996, PHYSIOL BEHAV, V59, P403, DOI 10.1016/0031-9384(95)02011-X; Desai M, 1997, BIOL REV, V72, P329, DOI 10.1017/S0006323196005026; Desai M, 1997, AM J PHYSIOL-GASTR L, V272, pG1083, DOI 10.1152/ajpgi.1997.272.5.G1083; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Freedman DS, 1997, PEDIATRICS, V99, P420, DOI 10.1542/peds.99.3.420; GOLDBLOOM R, 1994, CAN MED ASSOC J, V150, P871; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HEINIG MJ, 1993, AM J CLIN NUTR, V58, P152, DOI 10.1093/ajcn/58.2.152; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; LUCAS A, 1980, LANCET, V1, P1267; LUCAS A, 1981, ACTA PAEDIATR SCAND, V70, P195, DOI 10.1111/j.1651-2227.1981.tb05541.x; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; POSKITT EME, 1978, BRIT MED J, V1, P603, DOI 10.1136/bmj.1.6113.603; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; ROLLANDCACHERA MF, 1995, INT J OBESITY, V19, P573; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; RollandCachera MF, 1996, AM J CLIN NUTR, V64, P663, DOI 10.1093/ajcn/64.4.663; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; VONEHRENSTEIN O, 1999, IN PRESS CLIN EXP AL; WHITEHEAD RG, 1995, PEDIATR RES, V37, P239, DOI 10.1203/00006450-199502000-00019; WILKINSON PW, 1977, LANCET, V1, P350	25	540	563	0	47	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					147	150		10.1136/bmj.319.7203.147	http://dx.doi.org/10.1136/bmj.319.7203.147			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406746	Bronze, Green Published			2022-12-01	WOS:000081619300017
J	Jiang, ZY; Swem, LR; Rushing, BG; Devanathan, S; Tollin, G; Bauer, CE				Jiang, ZY; Swem, LR; Rushing, BG; Devanathan, S; Tollin, G; Bauer, CE			Bacterial photoreceptor with similarity to photoactive yellow protein and plant phytochromes	SCIENCE			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOCYCLE INTERMEDIATE; SIGNAL-TRANSDUCTION; HISTIDINE KINASE; QUANTUM YIELD; GENE; CHROMOPHORE; RHODOPSIN; KINETICS	A phytochrome-like protein called Ppr was discovered in the purple photosynthetic bacterium Rhodospirillum centenum, Ppr has a photoactive yellow protein (PYP) amino-terminal domain, a central domain with similarity to phytochrome, and a carboxyl-terminal histidine kinase domain. Reconstitution experiments demonstrate that Ppr covalently attaches the blue light-absorbing chromophore p-hydroxycinnamic acid and that it has a photocycle that is spectrally similar to, but kinetically slower than, that of PYP. Ppr also regulates chalcone synthase gene expression in response to blue light with autophosphorylation inhibited in vitro by blue light. Phylogenetic analysis demonstrates that R. centenum Ppr may be ancestral to cyanobacterial and plant phytochromes.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	Indiana University System; Indiana University Bloomington; University of Arizona	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040941, R29GM040941, R01GM053940, R01GM040941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 40941, R01 GM053940, R01 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Devanathan S, 1997, ARCH BIOCHEM BIOPHYS, V340, P83, DOI 10.1006/abbi.1997.9902; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; *GENB, AF121274 GENB; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang Z., UNPUB; Jiang ZY, 1997, J BACTERIOL, V179, P5720, DOI 10.1128/jb.179.18.5720-5727.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; MARTIN CR, 1993, INT REV CYTOL, V147, P233, DOI 10.1016/S0074-7696(08)60770-6; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Meyer TE, 1998, SCIENCE, V281, P1964; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RAGATZ L, 1995, ARCH MICROBIOL, V163, P1; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Xiong J, 1998, P NATL ACAD SCI USA, V95, P14851, DOI 10.1073/pnas.95.25.14851; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	29	149	155	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					406	409		10.1126/science.285.5426.406	http://dx.doi.org/10.1126/science.285.5426.406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411503				2022-12-01	WOS:000081465900054
J	Chambers, J; Ames, RS; Bergsma, D; Muir, A; Fitzgerald, LR; Hervieu, G; Dytko, GM; Foley, JJ; Martin, J; Liu, WS; Park, J; Ellis, C; Ganguly, S; Konchar, S; Cluderay, J; Leslie, R; Wilson, S; Sarau, HM				Chambers, J; Ames, RS; Bergsma, D; Muir, A; Fitzgerald, LR; Hervieu, G; Dytko, GM; Foley, JJ; Martin, J; Liu, WS; Park, J; Ellis, C; Ganguly, S; Konchar, S; Cluderay, J; Leslie, R; Wilson, S; Sarau, HM			Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1	NATURE			English	Article							RAT-BRAIN; GENE; PEPTIDES; NEUROPEPTIDES; EXPRESSION; CLONING; BINDING; FAMILY; ACID	The underlying causes of obesity are poorly understood but probably involve complex interactions between many neurotransmitter and neuropeptide systems involved in the regulation of food intake and energy balance. Three pieces of evidence indicate that the neuropeptide melanin-concentrating hormone (MCH) is an important component of this system. First, MCH stimulates feeding when injected directly into rat brains(1,2); second, the messenger RNA for the MCH precursor is upregulated in the hypothalamus of genetically obese mice and in fasted animals'; and third, mice lacking MCH eat less and are lean(3). MCH antagonists might, therefore, provide a treatment for obesity. However, the development of such molecules has been hampered because the identity of the MCH receptor has been unknown until now. Here we show that the 353-amino-acid human orphan G-protein-coupled receptor SLC-1 (ref, 4) expressed in HEK293 cells binds MCH with sub-nanomolar affinity, and is stimulated by MCH to mobilize intracellular Ca2+ and reduce forskolin-elevated cyclic AMP levels. We also show that SLC-1 messenger RNA and protein is expressed in the ventromedial and dorsomedial nuclei of the hypothalamus, consistent with a role for SLC-1 in mediating the effects of MCH on feeding.	SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Renal Pharmaceut, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Chambers, J (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, New Frontier Sci Pk,So Way, Harlow CM19 5AW, Essex, England.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; Burgaud JL, 1997, BIOCHEM BIOPH RES CO, V241, P622, DOI 10.1006/bbrc.1997.7849; DROZDZ R, 1995, FEBS LETT, V359, P199, DOI 10.1016/0014-5793(95)00043-9; Fitzgerald LW, 1998, J PHARMACOL EXP THER, V287, P448; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; Hervieu G, 1998, NEUROSCIENCE, V85, P1263, DOI 10.1016/S0306-4522(98)00024-4; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; Kolakowski LF, 1996, FEBS LETT, V398, P253, DOI 10.1016/S0014-5793(96)01160-X; Lakaye B, 1998, BBA-MOL CELL RES, V1401, P216, DOI 10.1016/S0167-4889(97)00135-3; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; Miller CL, 1998, BRAIN RES, V803, P86, DOI 10.1016/S0006-8993(98)00626-X; MORO O, 1993, J BIOL CHEM, V268, P22273; PRESSE F, 1990, MOL ENDOCRINOL, V4, P632, DOI 10.1210/mend-4-4-632; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; Tritos NA, 1998, DIABETES, V47, P1687, DOI 10.2337/diabetes.47.11.1687	25	418	450	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					261	265		10.1038/22313	http://dx.doi.org/10.1038/22313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421367				2022-12-01	WOS:000081503800043
J	Reid, FDA; Cook, DG; Majeed, A				Reid, FDA; Cook, DG; Majeed, A			Explaining variation in hospital admission rates between general practices: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY ADMISSIONS; REFERRAL RATES; EAST LONDON; PRACTITIONERS; DEPRIVATION; PATIENT; ASTHMA	Objectives To quantify the extent of the variation in hospital admission rates between general practices, and to investigate whether this variation can be explained by factors relating to the patient, the hospital, and the general practice. Design Cross sectional analysis of routine data. Setting Merton, Sutton, and Wandsworth Health Authority, which includes areas of inner and outer London. Subjects 209 136 hospital admissions in 1995-6 in patients registered with 120 general practices in the study area. Main outcome measures Hospital admission rate for general practices for overall, emergency, and elective admissions. Results Crude admission rates for general practices displayed a twofold difference between the 10th and the 90th centile for all, emergency, and elective admissions. This difference was only minimally reduced by standardising for age and sex. Sociodemographic patient factors derived from census data accounted for 42% of the variation in overall admission rates; 45% in emergency admission rates; and 25% in elective admission rates. There was a strong positive correlation between factors related to deprivation and emergency, but not elective, admission rates, raising questions about equity of provision of health care. The percentage of each practice's admissions to different local hospitals added significantly to the explanation of variation, while the general practice characteristics considered added very little. Conclusions Hospital admission rates varied greatly between general practices; this was largely explained by differences in patient populations. The lack of significant factors related to general practice is of little help for the direct management of admission rates, although the effect of sociological rather than organisational practice variables should routinely be standardised for differences in patient populations and hospitals used.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England	St Georges University London; St Georges University London	Reid, FDA (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.			Majeed, Azeem/0000-0002-2357-9858; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1993, SPSS WINDOWS BASE SY; ARMITAGE P, 1987, STATISTICAL METHODS, P403; Capewell S, 1996, BRIT MED J, V312, P991; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Crombie D L, 1988, Health Trends, V20, P53; DEMARCO P, 1993, BRIT MED J, V307, P1465, DOI 10.1136/bmj.307.6917.1465; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HippisleyCox J, 1997, BRIT MED J, V314, P1458, DOI 10.1136/bmj.314.7092.1458; MAJEED A, 1996, HLTH TRENDS, V28, P52; Majeed A, 1998, CLIN MANAGE, V7, P160; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; NOONE A, 1989, J ROY COLL GEN PRACT, V39, P404; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; THAKKER Y, 1994, ARCH DIS CHILD, V70, P488, DOI 10.1136/adc.70.6.488; Whynes DK, 1996, FAM PRACT, V13, P174, DOI 10.1093/fampra/13.2.174; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160	24	82	82	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					98	103		10.1136/bmj.319.7202.98	http://dx.doi.org/10.1136/bmj.319.7202.98			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398636	Green Published, Bronze			2022-12-01	WOS:000081438200035
J	Kuroda, MI; Kelley, RL				Kuroda, MI; Kelley, RL			Developmental biology - Sex and repression	SCIENCE			English	Editorial Material							CHROMOSOME DOSAGE COMPENSATION; X-CHROMOSOME; C-ELEGANS; NEMATODE; PROTEIN; HOMOLOG; GENE		Baylor Univ, Howard Hughes Med Inst, Dept Cell Biol, Houston, TX 77030 USA; Baylor Univ, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor University; Howard Hughes Medical Institute; Baylor University	Kuroda, MI (corresponding author), Baylor Univ, Howard Hughes Med Inst, Dept Cell Biol, Houston, TX 77030 USA.							Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; DELONG L, 1993, GENETICS, V133, P875; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579	13	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1787	1788		10.1126/science.284.5421.1787	http://dx.doi.org/10.1126/science.284.5421.1787			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10391797				2022-12-01	WOS:000080809000037
J	Banatvala, N; Peremitin, GG				Banatvala, N; Peremitin, GG			Tuberculosis, Russia, and the Holy Grail	LANCET			English	Article									MERLIN, London W1M 4HW, England; Tomsk Reg TB Dispensary, Tomsk, Russia		Banatvala, N (corresponding author), MERLIN, 14 David Mews, London W1M 4HW, England.			Banatvala, Nick/0000-0001-8130-154X				Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Drobniewski F, 1996, TUBERCLE LUNG DIS, V77, P297, DOI 10.1016/S0962-8479(96)90092-1; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671	3	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					999	1000		10.1016/S0140-6736(99)02059-0	http://dx.doi.org/10.1016/S0140-6736(99)02059-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459925				2022-12-01	WOS:000079421600046
J	Chintu, C; Mwinga, A				Chintu, C; Mwinga, A			An African perspective on the threat of tuberculosis and HIV/AIDS - can despair be turned to hope?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS		Univ Lusaka, Teaching Hosp, UNZA UCLMS TB HIV Res & Training Project, Lusaka, Zambia	University of Zambia	Chintu, C (corresponding author), Univ Lusaka, Teaching Hosp, UNZA UCLMS TB HIV Res & Training Project, Lusaka, Zambia.	cchintu@zamnet.zm						Department for International Development, 1997, WHIT PAP INT DEV; DOLIN P, 1998, GENDER TUBERCULOSIS; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Zumla A, 1998, INT J TUBERC LUNG D, V2, P179	6	27	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					997	997		10.1016/S0140-6736(99)01141-1	http://dx.doi.org/10.1016/S0140-6736(99)01141-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459923				2022-12-01	WOS:000079421600044
J	Kelly, M				Kelly, M		Hlth Population Div Dept Int Dev	A donor's perspective on tuberculosis in international health	LANCET			English	Article									DFID, HPD, London SW1E 5JL, England		Kelly, M (corresponding author), DFID, HPD, 94 Victoria St, London SW1E 5JL, England.							Department for International Development, 1997, EL WORLD POV CHALL 2; *GLOB TUB PROGR, 1998, TUB GLOB SURV; *GLOB TUB PROGR, 1994, FRAM ESS TB CONTR; GWATKIN DR, 1998, 981 WHO TDR ER RD; Styblo K, 1991, TUBERCULOSIS CAN BE, V2, P60	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1006	1006						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459930				2022-12-01	WOS:000079421600051
J	Graham, WJ; Newell, ML				Graham, WJ; Newell, ML			Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; TO-CHILD TRANSMISSION; INFECTION; ZIDOVUDINE; MORBIDITY; HEALTH; IMPACT; TRIAL		Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland; UCL, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	University of Aberdeen; University of London; University College London	Graham, WJ (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Graham, Wendy/0000-0003-1473-5342				ABOUZAHR C, 1998, GLOBAL BURDEN DIS IN, V3, P111; [Anonymous], 1996, UNICEF REVISED 1990; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; BARNETT T, 1992, AIDS AFRICA; Cassels A, 1998, LANCET, V352, P1777, DOI 10.1016/S0140-6736(98)05350-1; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P151; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DABIS F, 1995, AIDS, V9, P204, DOI 10.1097/00002030-199509020-00015; Diczfalusy E, 1994, World Health Forum, V15, P1; *EUR COLL STUD, 1997, BRIT J OBSTET GYNAEC, V105, P704; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; Graham W, 1998, BRIT J OBSTET GYNAEC, V105, P375, DOI 10.1111/j.1471-0528.1998.tb10116.x; GRAHAM WJ, 1992, SOC SCI MED, V35, P967, DOI 10.1016/0277-9536(92)90236-J; Graham WJ, 1998, SOC SCI MED, V47, P1925, DOI 10.1016/S0277-9536(98)00334-7; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HANSLUWKA HE, 1985, SOC SCI MED, V20, P1207, DOI 10.1016/0277-9536(85)90374-0; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; LOWBEER D, 1998, HLTH DIMENSIONS SEX, V3, P297; MAHLER H, 1987, LANCET, V1, P668; Mansergh G, 1998, JAMA-J AM MED ASSOC, V280, P30, DOI 10.1001/jama.280.1.30; Mayaud P, 1998, LANCET, V351, P29; McDonagh M, 1996, HEALTH POLICY PLANN, V11, P1, DOI 10.1093/heapol/11.1.1; Mertens T E, 1995, AIDS, V9 Suppl A, pS259; Murray C. J. L., 1998, GLOBAL BURDEN DIS IN, V3, P1; Newell ML, 1997, AIDS, V11, pS165; OVER M, 1993, 9 INT C AIDS 3 STD W; *PREV MAT MORT NET, 1995, SOC SCI MED, V40, P657; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; Strong MA, 1992, HLTH TRANSITION REV, V2, P215; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; *UNAIDS, 1998, REP GLOB HIV AIDS EP; VILLAR J, 1995, ACTA OBSTET GYNECOL, V76, P1; *WORLD BANK, 1997, CONFR AIDS PUBL PRIO; World Health Organization, 1997, MON REPR HLTH SEL SH; World Health Organization, 1997, COV MAT CAR LIST AV	36	40	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					836	839		10.1016/S0140-6736(98)12374-7	http://dx.doi.org/10.1016/S0140-6736(98)12374-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459980				2022-12-01	WOS:000079089100048
J	Laezza, F; Doherty, JJ; Dingledine, R				Laezza, F; Doherty, JJ; Dingledine, R			Long-term depression in hippocampal interneurons: Joint requirement for pre- and postsynaptic events	SCIENCE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA2+-PERMEABLE AMPA RECEPTORS; GYRUS IN-VITRO; RAT HIPPOCAMPUS; DENTATE GYRUS; POTENTIATION; EXPRESSION; CHANNELS; LOCALIZATION; SUBTYPES	Long-term depression (LTD) is a well-known form of synaptic plasticity of principal neurons in the mammalian brain. Whether such changes occur in interneurons is still controversial. CA3 hippocampal interneurons expressing Ca2+-permeable AMPA receptors exhibited LTD after tetanic stimulation of CA3 excitatory inputs. LTD was independent of NMDA receptors and required both Ca2+-influx through postsynaptic AMPA receptors and activation of presynaptic mGluR7-Like receptors. These results point to the capability of interneurons to undergo plastic changes of synaptic strength through joint activation of pre- and postsynaptic glutamate receptors.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Neurosci, Atlanta, GA 30322 USA	Emory University; Emory University	Dingledine, R (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.		Laezza, Fernanda/L-6019-2016; dingledine, Ray/F-5173-2011; Laezza, Fernanda/X-4076-2019	Laezza, Fernanda/0000-0003-1141-1852; Laezza, Fernanda/0000-0003-1141-1852; Dingledine, Ray/0000-0001-7128-4520				Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bradley SR, 1996, J NEUROSCI, V16, P2044; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONN PJ, COMMUNICATION; Doherty J, 1997, J NEUROPHYSIOL, V77, P393, DOI 10.1152/jn.1997.77.1.393; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang LQ, 1997, NEUROREPORT, V8, P687, DOI 10.1097/00001756-199702100-00022; IINO M, 1994, NEUROSCI LETT, V173, P14, DOI 10.1016/0304-3940(94)90139-2; Isa T, 1996, NEUROREPORT, V7, P689, DOI 10.1097/00001756-199602290-00002; JACKSON H, 1988, TRENDS NEUROSCI, V11, P278, DOI 10.1016/0166-2236(88)90112-9; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Lissin DV, 1999, J NEUROSCI, V19, P1263; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; Maccaferri G, 1996, J NEUROSCI, V16, P5334; Maccaferri G, 1998, SCIENCE, V279, P1368, DOI 10.1126/science.279.5355.1368; MACCAFERRI G, 1995, NEURON, V15, P135; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McMahon LL, 1997, NEURON, V18, P295, DOI 10.1016/S0896-6273(00)80269-X; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P2; Phillips T, 1997, NEUROREPORT, V8, P3349, DOI 10.1097/00001756-199710200-00031; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Tzounopoulos T, 1998, NEURON, V21, P837, DOI 10.1016/S0896-6273(00)80599-1; Vida I, 1998, J PHYSIOL-LONDON, V506, P755, DOI 10.1111/j.1469-7793.1998.755bv.x; Wang Y, 1997, J NEUROPHYSIOL, V77, P812, DOI 10.1152/jn.1997.77.2.812; Washburn MS, 1997, J NEUROSCI, V17, P9393; Washburn MS, 1996, J PHARMACOL EXP THER, V278, P669; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; YOKI M, 1996, SCIENCE, V273, P645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	40	131	135	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1411	1414		10.1126/science.285.5432.1411	http://dx.doi.org/10.1126/science.285.5432.1411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464102				2022-12-01	WOS:000082233500046
J	Paradis, K; Langford, G; Long, ZF; Heneine, W; Sandstrom, P; Switzer, WM; Chapman, LE; Lockey, C; Onions, D; Otto, E				Paradis, K; Langford, G; Long, ZF; Heneine, W; Sandstrom, P; Switzer, WM; Chapman, LE; Lockey, C; Onions, D; Otto, E		XEN 111 Study Grp	Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue	SCIENCE			English	Article							HUMAN-CELLS; NO EVIDENCE; INFECTION; XENOTRANSPLANTATION; CONNECTION; KIDNEYS; SAFETY	Pig organs may offer a solution to the shortage of human donor organs for transplantation, but concerns remain about possible cross-species transmission of porcine endogenous retrovirus (PERV). Samples were collected from 160 patients who had been treated with various Living pig tissues up to 12 years earlier. Reverse transcription-polymerase chain reaction (RT-PCR) and protein immunoblot analyses were performed on serum from all 160 patients. No viremia was detected in any patient. Peripheral blood mononuclear cells from 159 of the patients were analyzed by PCR using PERV-specific primers. No PERV infection was detected in any of the patients from whom sufficient DNA was extracted to allow complete PCR analysis (97 percent of the patients). Persistent microchimerism (presence of donor cells in the recipient) was observed in 23 patients for up to 8.5 years.	Imutran Ltd, Cambridge CB2 2YP, England; Genet Therapy Inc, Gaithersburg, MD 20878 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, HIV & Retrovirol Branch, Atlanta, GA 30333 USA; Q One Biotech Ltd, Glasgow G20 0XA, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, Glasgow G20 0XA, Lanark, Scotland; Circe Biomed, Lexington, KY 40501 USA; Novartis Pharma, Basel, Switzerland; CDC, Atlanta, GA 30333 USA	Novartis; Centers for Disease Control & Prevention - USA; University of Glasgow; Novartis; Centers for Disease Control & Prevention - USA	Paradis, K (corresponding author), Imutran Ltd, POB 399, Cambridge CB2 2YP, England.							ABOUNA GM, 1970, LANCET, V2, P391; Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; BENVENISTE RE, 1975, P NATL ACAD SCI USA, V72, P4090, DOI 10.1073/pnas.72.10.4090; BIGGAR RJ, 1985, LANCET, V2, P520; Breimer ME, 1996, XENOTRANSPLANTATION, V3, P328, DOI 10.1111/j.1399-3089.1996.tb00155.x; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; GRANT RF, 1995, VIROLOGY, V207, P292, DOI 10.1006/viro.1995.1080; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; HOOVER EA, 1991, J AM VET MED ASSOC, V199, P1392; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; Long ZF, 1998, HUM GENE THER, V9, P1165, DOI 10.1089/hum.1998.9.8-1165; Martin U, 1998, LANCET, V352, P692, DOI 10.1016/S0140-6736(98)07144-X; Matthews AL, 1999, TRANSPLANTATION, V67, P939, DOI 10.1097/00007890-199904150-00002; Mullon C, 1999, Expert Opin Investig Drugs, V8, P229, DOI 10.1517/13543784.8.3.229; NIKONOV S, 1991, GRUDN SERDECH SOSUDI, V2, P42; *NUFF COUNC BIOETH, 1996, AN HUM TRANSPL ETH X; Onions D, 1998, TRENDS MICROBIOL, V6, P430, DOI 10.1016/S0966-842X(98)01386-9; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SONG IC, 1966, SURGERY, V59, P576; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Stoye J, 1998, LANCET, V352, P666, DOI 10.1016/S0140-6736(98)22035-6; Switzer WM, 1999, TRANSPLANTATION, V68, P183, DOI 10.1097/00007890-199907270-00003; Takeuchi Y, 1998, J VIROL, V72, P9986, DOI 10.1128/JVI.72.12.9986-9991.1998; WHITE D, 1995, NATURE, V378, P434, DOI 10.1038/378434b0; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; 1997, Patent No. 40167	28	576	618	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1236	1241		10.1126/science.285.5431.1236	http://dx.doi.org/10.1126/science.285.5431.1236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455044				2022-12-01	WOS:000082130200034
J	Weinberg, DS; Newschaffer, CJ; Topham, A				Weinberg, DS; Newschaffer, CJ; Topham, A			Risk for colorectal cancer after gynecologic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							OVARIAN-CANCER; COLON-CANCER; RECTUM; WOMEN; CARE	Background. Studies have suggested that women with previous diagnoses of gynecologic cancer (cervical, endometrial, or ovarian) have an increased risk for colorectal cancer. Objective: To quantify risk for colorectal cancer after gynecologic cancer, both overall and for subgroups defined by age at diagnosis, cancer stage at diagnosis, ethnicity, and duration of follow-up. Design: Retrospective cohort analysis of the Surveillance, Epidemiology, and End Results (SEER) program database from 1974 through 1995. Setting: U.S. cancer registry. Patients: 21 222 patients with cervical cancer, 51 680 patients with endometrial cancer, and 28 832 patients with ovarian cancer. Measurements: Standardized incidence ratios (SIRs) were calculated for each gynecologic cancer site and for subgroups to represent the relative risk for colorectal cancer in women with previously diagnosed gynecologic cancer compared with women without gynecologic cancer. Poisson regression methods adjusting simultaneously for all study variables were used to estimate relative risks for colorectal cancer across subgroups with each gynecologic cancer. Results: Overall, risk for colorectal cancer was elevated among women with previous ovarian cancer (SIR, 1.36 [95% CI, 1.21 to 1.53]). Risk was greatest in women who received a diagnosis before 50 years of age (SIR, 3.67 [CI, 2.74 to 4.80]) but was also elevated in women who received a diagnosis between 50 and 64 years of age (SIR, 1.52 [CI, 1.25 to 1.83]). The risk for colorectal cancer after endometrial cancer was also elevated substantially if endometrial cancer was diagnosed before the age of 50 (SIR, 3.39 [CI, 2.73 to 4.17]). No apparent risk elevation was associated with previous cervical cancer. Conclusions: Previous endometrial or ovarian cancer, particularly when diagnosed at an early age, increases subsequent risk for colorectal cancer. Greater emphasis on colorectal cancer screening in these populations may be necessary.	Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA	Jefferson University	Weinberg, DS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, 480 Main Bldg,132 S 10th St, Philadelphia, PA 19107 USA.	david.weinberg@mail.tju.edu						BERGFELDT K, 1995, ACTA ONCOL, V34, P771, DOI 10.3109/02841869509127185; Boice J D Jr, 1985, Natl Cancer Inst Monogr, V68, P3; BOMAN B, 1999, P AM ASS CANC RES PH, V40, pA278; BRESLOW N, 1986, NATL CANC I MONOGR, V67, P149; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Easton DF, 1996, INT J CANCER, V65, P284, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;284::AID-IJC2&gt;3.0.CO;2-W; Fontana SA, 1997, AM J PUBLIC HEALTH, V87, P1190, DOI 10.2105/AJPH.87.7.1190; HENDERSON B, 1997, CANC MED, V1, P277; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lynch HT, 1998, SEMIN ONCOL, V25, P265; McCredie M, 1997, CANCER EPIDEM BIOMAR, V6, P155; NELSON CL, 1993, GENET EPIDEMIOL, V10, P235, DOI 10.1002/gepi.1370100404; Potter J, 1996, PREVENTION EARLY DET; SANDLER RS, 1983, GASTROENTEROLOGY, V84, P51; *SEER CANC STAT RE, 1993, NIH PUBL; Travis LB, 1996, CANCER RES, V56, P1564; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; ZUMOFF B, 1982, CANCER RES, V42, P3289	20	42	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					189	193		10.7326/0003-4819-131-3-199908030-00005	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428735				2022-12-01	WOS:000081788700004
J	Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS				Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS			Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model	BRITISH MEDICAL JOURNAL			English	Article									Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen NV, Denmark; Gentofte Hosp, Dept Neurol, DK-2900 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Jorgensen, HS (corresponding author), Bispebjerg Hosp, Dept Neurol, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.							Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; JORGENSEN HS, 1994, LANCET, V344, P156; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401	4	32	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					288	289		10.1136/bmj.319.7205.288	http://dx.doi.org/10.1136/bmj.319.7205.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426737	Bronze, Green Published			2022-12-01	WOS:000081909100021
J	Bisgaard, H; Moller, H				Bisgaard, H; Moller, H			Changes in risk of hospital readmission among asthmatic children in Denmark, 1978-93	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Bisgaard, H (corresponding author), Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark.	Bisgaard@RH.DK	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Moller, Henrik/0000-0001-8200-5929	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bisgaard H, 1997, PEDIATR PULM, P27; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Warner JO, 1998, PEDIATR PULM, V25, P1	4	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					229	230		10.1136/bmj.319.7204.229	http://dx.doi.org/10.1136/bmj.319.7204.229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417085	Green Published, Bronze			2022-12-01	WOS:000081720300024
J	Barish, MA; Yucel, EK; Ferrucci, JT				Barish, MA; Yucel, EK; Ferrucci, JT			Current concepts - Magnetic resonance cholangiopancreatography	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; SPIN-ECHO TECHNIQUE; MR-CHOLANGIOPANCREATOGRAPHY; DUCT OBSTRUCTION; PANCREATIC DUCT; CHOLANGIOGRAPHY; CHOLEDOCHOLITHIASIS; DIAGNOSIS; ERCP		Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA	Boston University	Barish, MA (corresponding author), Boston Univ, Med Ctr, Dept Radiol, 1 Boston Med Ctr Pl, Boston, MA 02118 USA.			Barish, Matthew/0000-0002-7521-8878				BARISH MA, 1995, AM J ROENTGENOL, V165, P295, DOI 10.2214/ajr.165.2.7618543; BARON RL, 1983, AM J ROENTGENOL, V140, P1173, DOI 10.2214/ajr.140.6.1173; BILBAO MK, 1976, GASTROENTEROLOGY, V70, P314; Bret PM, 1996, RADIOLOGY, V199, P99, DOI 10.1148/radiology.199.1.8633179; Chan YL, 1996, RADIOLOGY, V200, P85, DOI 10.1148/radiology.200.1.8657949; CRANLEY B, 1989, BRIT J SURG, V67, P869; CRONAN JJ, 1983, RADIOLOGY, V146, P467, DOI 10.1148/radiology.146.2.6849096; CUNNINGHAM JT, 1990, ADV THERAPEUTIC ENDO, P193; David V, 1998, AM J ROENTGENOL, V170, P1055, DOI 10.2214/ajr.170.4.9530058; DOWSETT JF, 1990, GUT, V31, P905, DOI 10.1136/gut.31.8.905; Ernst O, 1997, AM J ROENTGENOL, V168, P1115, DOI 10.2214/ajr.168.4.9124131; Ernst O, 1998, AM J ROENTGENOL, V171, P1027, DOI 10.2214/ajr.171.4.9762990; FORBES A, 1984, GUT, V25, P971, DOI 10.1136/gut.25.9.971; Fulcher AS, 1998, RADIOLOGY, V207, P21, DOI 10.1148/radiology.207.1.9530295; GROSS BH, 1983, RADIOLOGY, V146, P471, DOI 10.1148/radiology.146.2.6849097; Guibaud L, 1998, AM J ROENTGENOL, V170, P27, DOI 10.2214/ajr.170.1.9423592; GUIBAUD L, 1994, AM J ROENTGENOL, V163, P847, DOI 10.2214/ajr.163.4.8092021; GUIBAUD L, 1995, RADIOLOGY, V197, P109, DOI 10.1148/radiology.197.1.7568807; HAMILTON I, 1983, CLIN RADIOL, V34, P543, DOI 10.1016/S0009-9260(83)80156-1; JEFFREY RB, 1983, AM J ROENTGENOL, V140, P1179, DOI 10.2214/ajr.140.6.1179; Koito K, 1998, RADIOLOGY, V208, P231, DOI 10.1148/radiology.208.1.9646818; LAING FC, 1983, RADIOLOGY, V146, P475, DOI 10.1148/radiology.146.2.6849098; Lee MG, 1997, RADIOLOGY, V202, P663, DOI 10.1148/radiology.202.3.9051013; Lehman G A, 1995, Gastrointest Endosc Clin N Am, V5, P145; MACAULAY SE, 1995, RADIOLOGY, V196, P227, DOI 10.1148/radiology.196.1.7784572; Matos C, 1997, RADIOLOGY, V203, P435, DOI 10.1148/radiology.203.2.9114101; Onaya H, 1998, AM J ROENTGENOL, V171, P171, DOI 10.2214/ajr.171.1.9648782; OSNES M, 1986, GUT, V27, P1193, DOI 10.1136/gut.27.10.1193; PAVONE P, 1995, RADIOLOGY, V197, P312; PHILLIPS EH, 1994, SURG CLIN N AM, V74, P931, DOI 10.1016/S0039-6109(16)46395-4; Regan F, 1996, AM J ROENTGENOL, V167, P1441, DOI 10.2214/ajr.167.6.8956574; RIEGER R, 1995, GASTROINTEST ENDOSC, V42, P6, DOI 10.1016/S0016-5107(95)70235-0; SILVIS SE, 1985, BOCKUS GASTROENTEROL, V6, P3569; Soto JA, 1996, RADIOLOGY, V199, P91, DOI 10.1148/radiology.199.1.8633178; SOTO JA, 1995, RADIOLOGY, V196, P459, DOI 10.1148/radiology.196.2.7617861; Soto JA, 1996, GASTROENTEROLOGY, V110, P589, DOI 10.1053/gast.1996.v110.pm8566608; TAKEHARA Y, 1994, RADIOLOGY, V192, P73, DOI 10.1148/radiology.192.1.8208969; THOENI RF, 1990, GASTROINTEST RADIOL, V15, P291, DOI 10.1007/BF01888800; WALLNER BK, 1991, RADIOLOGY, V181, P805, DOI 10.1148/radiology.181.3.1947101; Yamataka A, 1997, J PEDIATR SURG, V32, P1560, DOI 10.1016/S0022-3468(97)90452-8	40	143	149	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					258	264		10.1056/NEJM199907223410407	http://dx.doi.org/10.1056/NEJM199907223410407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413739				2022-12-01	WOS:000081528800007
J	Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF				Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF			Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue - An uncontrolled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lymphoma, mucosa-associated lymphoid tissue; Helicobacter pylori; Helicobacter infections; antibiotics; neoplasm staging	HELICOBACTER-PYLORI INFECTION; MANTLE CELL LYMPHOMA; MALT LYMPHOMA; MALIGNANT-LYMPHOMA; CLASSIFICATION; REGRESSION; ERADICATION; THERAPY; SYSTEM; CURE	Background: Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth. Objective: To determine the response of gastric MALT lymphoma to antibiotic treatment. Design: Prospective, uncontrolled treatment trial. Setting: University hospital referral center and three collaborating university and community hospitals. Patients: 34 patients with stage I or stage II N1 gastric MALT lymphoma. Intervention: Two of three oral antibiotic regimens-1) amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2) tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracycline, 500 mg four times daily, and metronidazole, 500 mg three times daily-were administered sequentially (usually in the order written) for 21 days at baseline and at 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate. Measurements: Complete remission was defined as the absence of histopathologic evidence of lymphoma on endoscopic biopsy. Partial remission was defined as a reduction in endoscopic tumor stage or 50% reduction in the size of large tumors. Results: 34 patients were followed for a mean (+/-SD) of 41 +/- 16 months (range, 18 to 70 months) after antibiotic treatment. Of 28 H. pylori-positive patients, 14 (50% [95% CI, 31% to 69%]) achieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of the 8), and 10 (36% [CI, 19% to 56%]) did not respond to treatment. Treatment failed in all 6 (100% [CI, 54% to 100%]) H. pylori-negative patients. Patients with endoscopic appearance of gastritis (stage I T1 disease) were most likely to achieve complete remission within 18 months. Tumors in the distal stomach were associated with more favorable response than tumors in the proximal stomach. Conclusions: A subset of H. pylori-positive gastric MALT lymphomas, including infiltrative tumors, may respond to antibiotics. The likelihood of: early complete remission seems to be greatest for superficial and distal tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Steinbach, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Box 78,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsteihb@aol.com	Graham, David/AAL-2165-2021	Cabanillas, Fernando/0000-0001-9234-7893; Steinbach, Gideon/0000-0001-7597-0544; Shen, Yu/0000-0002-3899-7868	NCI NIH HHS [R01 CA67540-02, CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067540, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BLACKLEDGE G, 1979, CLIN ONCOL, V5, P209; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; CHAN JKC, 1990, AM J PATHOL, V136, P1153; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; GREINER A, 1994, LAB INVEST, V70, P572; HARRIS NL, 1994, BLOOD, V84, P1361; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; LUTHRA R, 1995, DIAGN MOL PATHOL, V4, P4, DOI 10.1097/00019606-199503000-00003; McLaughlin P, 1996, ANN ONCOL, V7, P211; MONTALBAN C, 1995, ANN ONCOL, V6, P355, DOI 10.1093/oxfordjournals.annonc.a059184; MOUTSOPOULOS HM, 1994, CLIN IMMUNOL IMMUNOP, V72, P162, DOI 10.1006/clin.1994.1123; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NAKAMURA S, 1995, CANCER, V76, P1313, DOI 10.1002/1097-0142(19951015)76:8<1313::AID-CNCR2820760804>3.0.CO;2-1; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; Neubauer A, 1997, JNCI-J NATL CANCER I, V89, P1350, DOI 10.1093/jnci/89.18.1350; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; Sackmann M, 1997, GASTROENTEROLOGY, V113, P1087, DOI 10.1053/gast.1997.v113.pm9322502; SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X; STEINBACH G, 1995, GASTROENTEROLOGY, V108, pA541; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	33	170	178	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					88	+		10.7326/0003-4819-131-2-199907200-00003	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419446				2022-12-01	WOS:000081509700002
J	Duff, SE; Wong, CKM; May, RE				Duff, SE; Wong, CKM; May, RE			Surgeons' and occupational health departments' awareness of guidelines on post-exposure prophylaxis for staff exposed to HIV: telephone survey	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CARE WORKERS; BLOOD; RISK		Frenchay Hosp, Dept Surg, Bristol BS16 1LE, Avon, England		Duff, SE (corresponding author), Royal Hampshire Cty Hosp, Winchester & Eastleigh Healthcare, Dept Surg, Winchester SO22 5DG, Hants, England.		Duff, Sarah E/AAW-3795-2021					Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *DEP HLTH, 1997, GUID POST EXP PROPH; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001	5	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					162	163		10.1136/bmj.319.7203.162	http://dx.doi.org/10.1136/bmj.319.7203.162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406752	Green Published, Bronze			2022-12-01	WOS:000081619300023
J	Morgan, K; Prothero, D; Frankel, S				Morgan, K; Prothero, D; Frankel, S			The rise in emergency admissions - crisis or artefact? Temporal analysis of health services data	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Avon Hlth Author, Bristol BS2 8EE, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							Blatchford O, 1997, BRIT MED J, V315, P1322, DOI 10.1136/bmj.315.7119.1322; Capewell S, 1996, BRIT MED J, V312, P991; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; Kendrick S, 1996, Health Bull (Edinb), V54, P169	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					158	159		10.1136/bmj.319.7203.158	http://dx.doi.org/10.1136/bmj.319.7203.158			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406749	Green Published, Bronze			2022-12-01	WOS:000081619300020
J	Zheng, BH; Larkin, DW; Albrecht, U; Sun, ZS; Sage, M; Eichele, G; Lee, CC; Bradley, A				Zheng, BH; Larkin, DW; Albrecht, U; Sun, ZS; Sage, M; Eichele, G; Lee, CC; Bradley, A			The mPer2 gene encodes a functional component of the mammalian circadian clock	NATURE			English	Article							DROSOPHILA PERIOD GENE; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION; LIGHT; RHYTHMS; TIMELESS; HOMOLOG; PAS; REGULATORS; EXPRESSION	Circadian rhythms are driven by endogenous biological clocks that regulate many biochemical, physiological and behavioural professes in a wide range of life forms'. In mammals, there is a master circadian clock in the suprachiasmatic nucleus of the anterior hypothalamus. Three putative mammalian homologues (mPer1, mPer2 and mPer3) of the Drosophila circadian clock gene period (per) have been identified(2-8). The mPer genes share a conserved PAS domain (a dimerization domain found in Per, Amt and Sim) and show a circadian expression pattern in the suprachiasmatic nucleus. To assess the in vivo function of mPer2, we generated and characterized a deletion mutation in the PAS domain of the mouse mPer2 gene. Here we show that mice homozygous for this mutation display a shorter circadian period followed by a loss of circadian rhythmicity in constant darkness. The mutation also diminishes the oscillating expression of both mPer1 and mPer2 in the suprachiasmatic nucleus, indicating that mPer2 may regulate mPer1 in vivo. These data provide evidence that an mPer gene functions in the circadian clock, and define mPer2 as a component of the mammalian circadian oscillator.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	ching@bcm.tmc.edu	Sun, Zhongsheng/AAS-4883-2020; Albrecht, Urs/A-9831-2011	Sun, Zhongsheng/0000-0002-7640-5026; Albrecht, Urs/0000-0002-0663-8676; Bradley, Allan/0000-0002-2349-8839				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Aschoff J, 1981, HDB BEHAVIORAL NEURO, P3, DOI DOI 10.1007/978-1-4615-6552-9_1; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bracewell R. N., 1986, HARTLEY TRANSFORM; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; IBUKA N, 1977, BRAIN RES, V122, P33, DOI 10.1016/0006-8993(77)90660-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	30	562	575	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					169	173		10.1038/22118	http://dx.doi.org/10.1038/22118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408444				2022-12-01	WOS:000081324900055
J	Langst, G; Bonte, EJ; Corona, DFV; Becker, PB				Langst, G; Bonte, EJ; Corona, DFV; Becker, PB			Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer	CELL			English	Article							REMODELING FACTOR; RNA-POLYMERASE; IN-VITRO; CHROMATIN ACCESSIBILITY; DNA; TRANSCRIPTION; COMPLEX; PROTEIN; YEAST; MOBILITY	The chromatin accessibility complex (CHRAC) belongs to the class of nucleosome remodeling factors that increase the accessibility of nucleosomal DNA in an ATP-dependent manner. We found that CHRAC induces movements of intact histone octamers to neighboring DNA segments without facilitating their displacement to competing DNA or histone chaperones in trans. CHRAC-induced energy-dependent nucleosome sliding may, in principle, explain nucleosome remodeling, nucleosome positioning, and nucleosome spacing reactions known to be catalyzed by CHRAC. The catalytic core of CHRAC, the ATPase ISWI, also mobilized nucleosomes at the expense of energy. However, the directionality of the CHRAC- and ISWI-induced nucleosome movements differed drastically, indicating that the geometry of the native complex modulates the activity of its catalytic core.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Becker, PB (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	becker@embl-heidelberg.de	Corona, Davide F.V./H-8467-2012; Längst, Gernot/G-5287-2015	Längst, Gernot/0000-0002-8232-1179; Becker, Peter/0000-0001-7186-0372				Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Grigoriev M, 1998, MOL CELL, V2, P373, DOI 10.1016/S1097-2765(00)80281-6; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Langst G, 1997, NUCLEIC ACIDS RES, V25, P511, DOI 10.1093/nar/25.3.511; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marilley M, 1996, NUCLEIC ACIDS RES, V24, P2204, DOI 10.1093/nar/24.12.2204; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; RAMSPERGER U, 1995, EMBO J, V14, P3215, DOI 10.1002/j.1460-2075.1995.tb07324.x; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; Varga-Weisz PD, 1999, METHOD ENZYMOL, V304, P742; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Widom J, 1999, METH MOL B, V119, P61; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0	52	288	295	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					843	852		10.1016/S0092-8674(00)80797-7	http://dx.doi.org/10.1016/S0092-8674(00)80797-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399913	hybrid			2022-12-01	WOS:000081162800006
J	Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP				Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP			Ethnic differences in use of hormone replacement therapy: community based survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England	St Georges University London; St Georges University London; St Georges University London	Cook, DG (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Cappuccio, Francesco Paolo/ABF-1094-2020; Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Harris, Tess/0000-0002-8671-1553; Cook, Derek/0000-0002-9723-5759				BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; GRIFFITHS F, 1995, FAM PRACT, V12, P163, DOI 10.1093/fampra/12.2.163; TOBIAS JH, 1994, CLIN SCI, V87, P587, DOI 10.1042/cs0870587	5	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					610	611		10.1136/bmj.319.7210.610	http://dx.doi.org/10.1136/bmj.319.7210.610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473476	Green Published, Bronze			2022-12-01	WOS:000082460300020
J	Ko, AI; Reis, MG; Dourado, CMR; Johnson, WD; Riley, LW				Ko, AI; Reis, MG; Dourado, CMR; Johnson, WD; Riley, LW		Salvador Leptospirosis Study Grp	Urban epidemic of severe leptospirosis in Brazil	LANCET			English	Article							INNER-CITY; ANTIBODIES; ASSAY	Background Leptospirosis has, traditionally, been considered a sporadic rural disease. We describe a large urban outbreak of leptospirosis. Methods Active surveillance for leptospirosis was established in an infectious-disease referral hospital in Salvador, Brazil, between March 10 and Nov 2, 1996. Patients meeting case criteria for severe manifestations of leptospirosis were recruited into the study. The diagnosis was confirmed in the laboratory with the microagglutination test and identification of leptospires in blood or urine. Risk factors for death were examined by multivariate analyses. Findings Surveillance identified 326 cases of which 193 (59%) were laboratory-confirmed (133) or probable (60) cases. Leptospira interrogans serovar copenhageni was isolated from 87% of the cases with positive blood cultures. Most of the cases were adult (mean age 35.9 years [SD 15.9]), and 80% were male. Complications included jaundice (91%), oliguria (35%), and severe anaemia (26%). 50 cases died (case-fatality rate 15%) despite aggressive supportive care including dialysis (in 23%). Altered mental status was the strongest independent predictor of death (odds ratio 9.12 [95% CI 4.28-20.3]), age over 37 years, renal insufficiency, and respiratory insufficiency were also significant predictors of death. Before admission to hospital, 42% were misdiagnosed as having dengue fever in the outpatient clinic; an outbreak of dengue fever was taking place concurrently. Interpretation An epidemic of leptospirosis has become a major urban health problem, associated with high mortality. Diagnostic confusion with dengue fever, another emerging infectious disease with a similar geographic distribution, prevents timely intervention that could minimise mortality.	Brazilian Minist Hlth, Ctr Pesquisas Goncalo Moniz, Fdn Oswaldo Cruz MS, BR-40295001 Salvador, BA, Brazil; Hosp Couto Maia, Secretary Hlth State Bahia, Salvador, BA, Brazil; Cornell Univ Med Coll, Div Int Med & Infect Dis, New York, NY USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Fundacao Oswaldo Cruz; Cornell University; University of California System; University of California Berkeley	Ko, AI (corresponding author), Brazilian Minist Hlth, Ctr Pesquisas Goncalo Moniz, Fdn Oswaldo Cruz MS, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.		Ko, Albert/P-2343-2015	Ko, Albert/0000-0001-9023-2339; Pedreira, Clarissa/0000-0003-1267-3344	FOGARTY INTERNATIONAL CENTER [D43TW000919, D43TW000905, D43TW000018] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW00919, D43 TW00905, D43 TW00018] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		CACCIAPUOTI B, 1994, EUR J EPIDEMIOL, V10, P173, DOI 10.1007/BF01730367; CASTRO JSM, 1997, B EPIDEMIOL SESAB, V5, P2; CHEN Y, 1990, CHUNG HUA SHEN CHING, V23, P226; CHILDS JE, 1992, AM J PUBLIC HEALTH, V82, P597, DOI 10.2105/AJPH.82.4.597; DEMERS RY, 1983, J FAM PRACTICE, V17, P1007; Dupont H, 1997, CLIN INFECT DIS, V25, P720, DOI 10.1086/513767; EDWARDS FA, 1964, MEDICINE, V36, P117; Faine S., 1982, GUIDELINES CONTROL L, V1; Faine S., 1993, LEPTOSPIRA LEPTOSPIR; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; FORWELL MA, 1984, BRIT MED J, V289, P1583, DOI 10.1136/bmj.289.6458.1583; Goncalves A J, 1992, Rev Soc Bras Med Trop, V25, P261; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; Gussenhoven GC, 1997, J CLIN MICROBIOL, V35, P92, DOI 10.1128/JCM.35.1.92-97.1997; KORVER H, 1988, Israel Journal of Veterinary Medicine, V44, P15; LESSA I, 1981, LANCET, V2, P1113, DOI 10.1016/S0140-6736(81)91315-5; MERIEN F, 1992, J CLIN MICROBIOL, V30, P2219; NOGUCHI H, 1924, MONOGRAPHS ROCKEFELL, V20, P1; PARK SK, 1989, AM J TROP MED HYG, V41, P345, DOI 10.4269/ajtmh.1989.41.345; SAKATA EE, 1992, REV I MED TROP, V34, P217, DOI 10.1590/S0036-46651992000300006; Vinetz JM, 1996, ANN INTERN MED, V125, P794, DOI 10.7326/0003-4819-125-10-199611150-00002; Winslow WE, 1997, J CLIN MICROBIOL, V35, P1938, DOI 10.1128/JCM.35.8.1938-1942.1997; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; 1991, ANUARIO ESTATISTICO; 1997, MMWR MORB MORTAL WKL, V46, P577; 1998, RELATORIO GESTAO; 1998, MMWR MORB MORTAL WKL, V47, P585	27	529	559	1	115	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					820	825		10.1016/S0140-6736(99)80012-9	http://dx.doi.org/10.1016/S0140-6736(99)80012-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485724				2022-12-01	WOS:000082400700011
J	Brennand, JK				Brennand, JK			"I wish I'd got my new ears last year, mum"'	LANCET			English	Editorial Material									Perth Royal Infirm, Perth PH1 1NX, Scotland		Brennand, JK (corresponding author), Perth Royal Infirm, Taymount Terrace, Perth PH1 1NX, Scotland.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					676	676		10.1016/S0140-6736(99)04026-X	http://dx.doi.org/10.1016/S0140-6736(99)04026-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466688				2022-12-01	WOS:000082214500048
J	Maiden, MCJ; Spratt, BG				Maiden, MCJ; Spratt, BG			Meningococcal conjugate vaccines: new opportunities and new challenges	LANCET			English	Editorial Material							NEISSERIA-MENINGITIDIS; ET-37 COMPLEX; VACCINATION; CARRIAGE; DISEASE		Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England	University of Oxford	Maiden, MCJ (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3FY, England.		Spratt, Brian G/A-1676-2009; Maiden, Martin C J/C-5055-2014; Maiden, Martin/N-6805-2019	Maiden, Martin C J/0000-0001-6321-5138; Maiden, Martin/0000-0001-6321-5138				CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; Gupta S, 1999, PHILOS T R SOC B, V354, P711, DOI 10.1098/rstb.1999.0424; Kwara A, 1998, TROP MED INT HEALTH, V3, P742, DOI 10.1046/j.1365-3156.1998.00300.x; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Racoosin JA, 1998, JAMA-J AM MED ASSOC, V280, P2094, DOI 10.1001/jama.280.24.2094; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Slack MPE, 1998, PEDIATR INFECT DIS J, V17, pS204, DOI 10.1097/00006454-199809001-00026; Stephens DS, 1999, LANCET, V353, P941, DOI 10.1016/S0140-6736(98)00279-7; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010; VEDROS NA, 1987, EVOLUTION MENINGOCOC, P33; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320	16	87	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					615	616						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466659				2022-12-01	WOS:000082214500006
J	Mahanty, SK; Wang, YM; Farley, FW; Elion, EA				Mahanty, SK; Wang, YM; Farley, FW; Elion, EA			Nuclear shuttling of yeast scaffold Ste5 is required for its recruitment to the plasma membrane and activation of the mating MAPK cascade	CELL			English	Article							PHEROMONE RESPONSE PATHWAY; BETA-GAMMA COMPLEX; SACCHAROMYCES-CEREVISIAE; KINASE CASCADE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TRANSCRIPTION FACTOR; CELL-CYCLE; FUS3; TRANSPORT	Localization of Ste5 to G beta at the plasma membrane is essential for transmission of the pheromone signal to associated MAP kinase cascade enzymes. Here, we show that this crucial localization requires prior shuttling of Ste5 through the nucleus. Ste5 shuttles through the nucleus constitutively during vegetative growth. Pheromone enhances nuclear export of Ste5, and this pool translocates vectorial ly to the cell periphery. Remarkably, Ste5 that cannot transit the nucleus is unable to localize at the periphery and activate the pathway, while Ste5 with enhanced transit through the nucleus has enhanced ability to localize to the periphery and activate the pathway. This novel regulatory scheme may ensure that cytoplasmic Ste5 does not activate downstream kinases in the absence of pheromone and could be applicable to other membrane-recruited signaling proteins.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	elion@bcmp.med.harvard.edu			NIGMS NIH HHS [GM46962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; [Anonymous], 1991, Methods Enzymol, V194, P1; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; Choi KY, 1999, MOL BIOL CELL, V10, P1553, DOI 10.1091/mbc.10.5.1553; CHOI KY, 1994, CELL, V78, P499; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; ELION EA, 1991, COLD SH Q B, V56, P41; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Farley FW, 1999, GENETICS, V151, P1425; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KAISER CA, 1997, MOL CELLULAR BIOL YE, V3, P91; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	57	127	130	1	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					501	512		10.1016/S0092-8674(00)81978-9	http://dx.doi.org/10.1016/S0092-8674(00)81978-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481914	Bronze			2022-12-01	WOS:000082174900010
J	Forsberg, E; Pejler, G; Ringvall, M; Lunderius, C; Tomasini-Johansson, B; Kusche-Gullberg, M; Eriksson, I; Ledin, J; Hellman, L; Kjellen, L				Forsberg, E; Pejler, G; Ringvall, M; Lunderius, C; Tomasini-Johansson, B; Kusche-Gullberg, M; Eriksson, I; Ledin, J; Hellman, L; Kjellen, L			Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme	NATURE			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; SERINE PROTEASES; SULFATE; MOUSE; BIOSYNTHESIS; EXPRESSION; PROTEOGLYCANS; DROSOPHILA	Heparin is a sulphated polysaccharide, synthesized exclusively by connective-tissue-type mast cells(1) and stored in the secretory granules in complex with histamine and various mast-cell proteases(2). Although heparin has long been used as an antithrombotic drug, endogenous heparin is not present in the blood, so it cannot have a physiological role in regulating blood coagulation. The biosynthesis of heparin involves a series of enzymatic reactions, including sulphation at various positions(1,3). The initial modification step, catalysed by the enzyme glucosaminyl N-deacetylase/N-sulphotransferase-2, NDST-2 (refs 4-7), is essential for the subsequent reactions. Here we report that mice carrying a targeted disruption of the gene encoding NDST-2 are unable to synthesize sulphated heparin. These NDST-2-deficient mice are viable and fertile but have fewer connective-tissue-type mast cells; these cells have an altered morphology and contain severely reduced amounts of histamine and mast-cell proteases. Our results indicate that one site of physiological action for heparin could be inside connective-tissue-type mast cells, where its absence results in severe defects in the secretory granules.	Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Cell & Mol Biol, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University; Uppsala University	Kjellen, L (corresponding author), Swedish Univ Agr Sci, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.		Kusche-Gullberg, Marion/P-4466-2016; Kjellen, Lena/F-1362-2011	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ledin, Johan/0000-0002-7319-7735				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PASSLER R, 1995, GENE DEV, V9, P1896; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458	25	392	396	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					773	776		10.1038/23488	http://dx.doi.org/10.1038/23488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466727				2022-12-01	WOS:000082131100052
J	Connelly, MT; Ferrari, N; Hagen, N; Inui, TS				Connelly, MT; Ferrari, N; Hagen, N; Inui, TS			Patient-identified needs for hormone replacement therapy counseling: A qualitative study	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN	Background: Numerous medical organizations, including the American College of Physicians, have recommended that women be counseled about postmenopausal hormone replacement therapy (HRT). Patients' perspectives on their counseling needs, however, have not been integrated into most counseling guides. Objective: To use patient self-reports to identify needs for HRT counseling. Design: Individual, in-depth patient interviews. Setting: Managed care organization. Patients: 26 women who had received an initial prescription for HRT. Measurements: Qualitative, consensus review of the content of interview transcripts. Results: On average, women reported 15 factors (range, 6 to 24 factors) as critical to their decision-making process. Although most women cited their physician's opinion (96%), reports in the media (81%), and experiences and opinions of friends (77%) as critical to their decisions about HRT, counseling recommendations address none of these concerns. Conclusions: Many women in a managed care organization who accepted a prescription for HRT identified counseling needs that are not included in widely used HRT guidelines.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Hlth Publicat Grp, Boston, MA 02215 USA; Brown & Toland Phys Serv Org, San Francisco, CA 94109 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Connelly, MT (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 203, Boston, MA 02215 USA.				AHRQ HHS [1F32HS00107-01] Funding Source: Medline; BHP HRSA HHS [2T32PE11001-06, 5T32PE11001-07] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		*AM COLL OBST GYN, 1998, AM COLL OBST GYN ED, V247, P1; Barry MJ, 1997, DIS MANAGE CLIN OUTC, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; Chan ECY, 1998, AM J MED, V105, P266, DOI 10.1016/S0002-9343(98)00257-5; CRABTREE BF, 1992, DOING QUALITATIVE RE, P41; Daley J, 1999, ANN INTERN MED, V130, P602, DOI 10.7326/0003-4819-130-7-199904060-00021; FEASLEY J, 1996, HLTH OUTCOMES OLDER; GRADY D, 1992, ANN INTERN MED, V117, P1038; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; Liao L, 1996, J GEN INTERN MED, V11, P373, DOI 10.1007/BF02600051; LIVINGSTON WW, 1994, J GEN INTERN MED, V9, P385, DOI 10.1007/BF02629518; MANSFIELD PK, 1998, HEALTH CARE WOMEN IN, V18, P55; Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459; O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Saver BG, 1997, AM J PREV MED, V13, P358, DOI 10.1016/S0749-3797(18)30155-7; Seto TB, 1996, J GEN INTERN MED, V11, P197, DOI 10.1007/BF02642475; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P829	18	37	37	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					265	268		10.7326/0003-4819-131-4-199908170-00005	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454947				2022-12-01	WOS:000082012500004
J	Silvian, LF; Wang, JM; Steitz, TA				Silvian, LF; Wang, JM; Steitz, TA			Insights into editing from an Ile-tRNA synthetase structure with tRNA(Ile) and mupirocin	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; DNA-POLYMERASE-I; ESCHERICHIA-COLI; KLENOW FRAGMENT; AMINOACYLATION; REFINEMENT; MECHANISM; SITES; GENE	Isoleucyl-transfer RNA (tRNA) synthetase (IleRS) joins Ire to tRNA(Ile) at its synthetic active site and hydrolyzes incorrectly acylated amino acids at its editing active site. The 2.2 angstrom resolution crystal structure of Staphylococcus aureus IleRS complexed with tRNA(Ile) and Mupirocin shows the acceptor strand of the tRNA(Ile) in the continuously stacked, A-form conformation with the 3' terminal nucleotide in the editing active site. To position the 3' terminus in the synthetic active site, the acceptor strand must adopt the hairpinned conformation seen in tRNA(Gln) complexed with its synthetase, The amino acid editing activity of the IleRS may result from the incorrect products shuttling between the synthetic and editing active sites, which is reminiscent of the editing mechanism of DNA polymerases.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Silvian, LF (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		Steitz, Thomas A./C-6559-2009	Silvian, Laura/0000-0002-5299-5201	NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FRIEDMAN AM, 1994, AM CRYST ASS ANN M A; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; HECK JD, 1988, J BIOL CHEM, V263, P868; JONES TA, 1994, O MANUAL; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SILVIAN LF, UNPUB; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WANG JC, UNPUB	28	343	357	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1074	1077		10.1126/science.285.5430.1074	http://dx.doi.org/10.1126/science.285.5430.1074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446055				2022-12-01	WOS:000082033100048
J	Veenstra, DL; Saint, S; Sullivan, SD				Veenstra, DL; Saint, S; Sullivan, SD			Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-STREAM INFECTION; PROSPECTIVE RANDOMIZED TRIAL; PULMONARY-ARTERY CATHETERS; CRITICALLY ILL PATIENTS; BACTERIAL-COLONIZATION; INTENSIVE-CARE; SILVER-SULFADIAZINE; MORTALITY; SEPSIS; CHLORHEXIDINE	Context A recent randomized controlled trial and meta-analysis indicated that central venous catheters impregnated with an antiseptic combination of chlorhexidine and silver sulfadiazine are efficacious in reducing the incidence of catheter-related bloodstream infection (CR-BSI); however, the ultimate clinical and economic consequences of their use have not been formally evaluated. Objective To estimate the incremental clinical and economic outcomes associated with the use of antiseptic-impregnated vs standard catheters. Design Decision analytic model using data from randomized controlled trials, meta-analyses, and case-control studies, as well as safety data from the US Food and Drug Administration. Setting and Patients A hypothetical cohort of hospitalized patients at high risk for catheter-related infections leg, patients in intensive care units, immunosuppressed patients, and patients receiving total parenteral nutrition) requiring use of a central venous catheter. Intervention Short-term use (2-10 days) of chlorhexidine-silver sulfadiazine-impregnated multilumen central venous catheters and nonimpregnated catheters. Main Outcome Measures Expected incidence of CR-BSI and death attributable to antiseptic-impregnated and standard catheter use; direct medical costs for both types of catheters. Results In the base-case analysis, use of antiseptic-impregnated catheters resulted in a decrease in the incidence of CR-BSI of 2.2% (5.2% for standard vs 3.0% for antiseptic-impregnated catheters), a decrease in the incidence of death of 0.33% (0.78% for standard vs 0.45% for antiseptic-impregnated), and a decrease in costs of $196 per catheter used ($532 for standard vs $336 for antiseptic-impregnated). The decrease in CR-BSI ranged from 1.2% to 3.4%, the decrease in death ranged from 0.09% to 0.78%, and the costs saved ranged from $68 to $391 in a multivariate sensitivity analysis. Conclusion Our analyses suggest that use of chlorhexidine-silver sulfadiazine-impregnated central venous catheters in patients at high risk for catheter-related infections reduces the incidence of CR-BSI and death and provides significant saving in costs. Use of these catheters should be considered as part of a comprehensive nosocomial infection control program.	Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; Univ Washington, Sch Pharm, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle	Veenstra, DL (corresponding author), Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, POB 357630, Seattle, WA 98195 USA.		Saint, Sanjay/AAF-5126-2019		AHRQ HHS [HS/HL08368-01A1, HS07834-03S1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Appavu S. K., 1994, Chest, V106, p176S; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; Bach A, 1996, J ANTIMICROB CHEMOTH, V37, P315, DOI 10.1093/jac/37.2.315; Bach A, 1995, ZBL BAKT-INT J MED M, V283, P208; BACH A, 1994, ANESTHESIOLOGY, V81, pA261; BOOTH FVM, 1996, CRIT CARE MED S1, V24, pA45; *BUR LAB STAT, 1998, CONS PRIC IND MED CA; *CDCP, 1996, EPI INF COMP PROGR V; Ciresi DL, 1996, AM SURGEON, V62, P641; Civetta JM, 1996, CRIT CARE MED, V24, P1660, DOI 10.1097/00003246-199610000-00010; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; Collin GR, 1999, CHEST, V115, P1632, DOI 10.1378/chest.115.6.1632; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; *CTR DEV RAD HLTH, 1998, POT HYP REACT CHLORH; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Drummond MF., 2015, METHODS EC EVALUATIO; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; George SJ, 1997, EUR J ANAESTH, V14, P428, DOI 10.1046/j.1365-2346.1997.00168.x; GILLUM BS, 1998, VITAL HLTH STAT, V13, P133; Hannan M, 1996, CLIN INTENSIVE CARE, V7, P56; Hasaniya NWMA, 1996, CHEST, V109, P1030, DOI 10.1378/chest.109.4.1030; Heard SO, 1998, ARCH INTERN MED, V158, P81, DOI 10.1001/archinte.158.1.81; *HLTH CAR FIN ADM, 1998, PROSP PAYM SYST STAN; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Logghe C, 1997, J HOSP INFECT, V37, P145, DOI 10.1016/S0195-6701(97)90184-5; Maki Dennis G., 1994, P155; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, CRIT CARE MED, V22, P1729; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; MODAK SM, 1992, COMPLICATION SURG, V11, P23; Naglie G, 1997, MED DECIS MAKING, V17, P136, DOI 10.1177/0272989X9701700203; NYSTROM B, 1994, INFECT CONT HOSP EP, V15, P435; Oda T, 1997, ANESTHESIOLOGY, V87, P1242, DOI 10.1097/00000542-199711000-00031; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pearson ML, 1997, ANN INTERN MED, V127, P304, DOI 10.7326/0003-4819-127-4-199708150-00009; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Pittet D, 1994, JAMA-J AM MED ASSOC, V272, P1819; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; Ramsay J, 1994, CRIT CARE MED, V22, pA115; SMITH RL, 1991, CHEST, V100, P164, DOI 10.1378/chest.100.1.164; Tennenberg S, 1997, ARCH SURG-CHICAGO, V132, P1348; Torrance GW., 1996, COST EFFECTIVENESS H, P54; TRAZZERA S, 1995, CRIT CARE MED, V23, pA152; vanHeerden PV, 1996, ANAESTH INTENS CARE, V24, P330, DOI 10.1177/0310057X9602400305; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; *WHO, 1997, INF EXCH SYST	57	194	202	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					554	560		10.1001/jama.282.6.554	http://dx.doi.org/10.1001/jama.282.6.554			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450717				2022-12-01	WOS:000081919100029
J	Lin, L; Faraco, J; Li, R; Kadotani, H; Rogers, W; Lin, XY; Qiu, XH; de Jong, PJ; Nishino, S; Mignot, E				Lin, L; Faraco, J; Li, R; Kadotani, H; Rogers, W; Lin, XY; Qiu, XH; de Jong, PJ; Nishino, S; Mignot, E			The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene	CELL			English	Article							RNA SPLICE JUNCTIONS; MESSENGER-RNA; DROSOPHILA PERIOD; SEQUENCE; CATAPLEXY; SYSTEMS; SUSCEPTIBILITY; HYPOTHALAMUS; CHROMOSOMES; EXPRESSION	Narcolepsy is a disabling sleep disorder affecting humans and animals. It is characterized by daytime sleepiness, cataplexy, and striking transitions from wakefulness into rapid eye movement (REM) sleep. In this study, we used positional cloning to identify an autosomal recessive mutation responsible for this sleep disorder in a well-established canine model. We have determined that canine narcolepsy is caused by disruption of the hypocretin (orexin) receptor 2 gene (Hcrtr2). This result identifies hypocretins as major sleep-modulating neurotransmitters and opens novel potential therapeutic approaches for narcoleptic patients.	Stanford Univ, Sch Med, Dept Psychiat, Ctr Narcolepsy, Stanford, CA 94305 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Stanford University; Roswell Park Cancer Institute	Mignot, E (corresponding author), Stanford Univ, Sch Med, Dept Psychiat, Ctr Narcolepsy, Stanford, CA 94305 USA.		Kadotani, Hiroshi/A-7908-2015	Kadotani, Hiroshi/0000-0001-7474-3315	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS023724, R01NS033797, P50NS023724, R37NS033797] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59601] Funding Source: Medline; NINDS NIH HHS [NS23724, NS33797] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ALDRICH MS, 1993, PROG NEUROBIOL, V41, P533, DOI 10.1016/0301-0082(93)90042-Q; ALDRICH MS, 1989, NEUROLOGY, V39, P1505, DOI 10.1212/WNL.39.11.1505; Baker TL, 1985, BRAIN MECH SLEEP, P199; Barch MJ, 1997, AGT CYTOGENETICS LAB; Beck B, 1999, BIOCHEM BIOPH RES CO, V258, P119, DOI 10.1006/bbrc.1999.0605; Borbely AA, 1994, PRINCIPLES PRACTICE, P309; Broberger C, 1998, J COMP NEUROL, V402, P460; Cederberg R, 1998, VET REC, V142, P31, DOI 10.1136/vr.142.2.31; COLTMAN DW, 1994, NUCLEIC ACIDS RES, V22, P2726, DOI 10.1093/nar/22.14.2726; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dement VV, 1994, PRINCIPLES PRACTICE, P3; Dutra AS, 1996, CYTOGENET CELL GENET, V74, P113, DOI 10.1159/000134395; Edwards CMB, 1999, J ENDOCRINOL, V160, pR7, DOI 10.1677/joe.0.160R007; FOUTZ AS, 1979, SLEEP, V1, P413; Francisco LV, 1996, MAMM GENOME, V7, P359, DOI 10.1007/s003359900104; Green E D, 1991, PCR Methods Appl, V1, P77; Honda Y., 1990, HDB SLEEP DISORDERS, P217; Horvath TL, 1999, J NEUROSCI, V19, P1072; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Ida T, 1999, BRAIN RES, V821, P526, DOI 10.1016/S0006-8993(99)01131-2; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kastin AJ, 1999, J PHARMACOL EXP THER, V289, P219; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; KILDUFF TS, 1986, SLEEP, V9, P102, DOI 10.1093/sleep/9.1.102; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li R, 1999, GENOMICS, V58, P9, DOI 10.1006/geno.1999.5772; Lin L, 1997, TISSUE ANTIGENS, V50, P507, DOI 10.1111/j.1399-0039.1997.tb02907.x; Lubkin M, 1998, BIOCHEM BIOPH RES CO, V253, P241, DOI 10.1006/bbrc.1998.9750; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MATSUKI K, 1992, LANCET, V339, P1052, DOI 10.1016/0140-6736(92)90571-J; McGrory J, 1999, CLIN GENET, V55, P118, DOI 10.1034/j.1399-0004.1999.550208.x; MIGNOT E, 1993, PSYCHOPHARMACOLOGY, V113, P76, DOI 10.1007/BF02244337; MIGNOT E, 1995, ADV NEUROIMMUNOL, V5, P23, DOI 10.1016/0960-5428(94)00043-N; MIGNOT E, 1993, J NEUROSCI, V13, P1057; MIGNOT E, 1994, SLEEP, V17, pS60, DOI 10.1093/sleep/17.suppl_8.S60; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; MIGNOT E, 1991, P NATL ACAD SCI USA, V88, P3475, DOI 10.1073/pnas.88.8.3475; MIGNOT E, 1994, SLEEP, V17, pS68, DOI 10.1093/sleep/17.suppl_8.S68; MILLER JD, 1990, BRAIN RES, V509, P169, DOI 10.1016/0006-8993(90)90328-9; MINNICK MF, 1992, GENE, V110, P235, DOI 10.1016/0378-1119(92)90654-8; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; Moore RY, 1998, CHRONOBIOL INT, V15, P475, DOI 10.3109/07420529808998703; Moriguchi T, 1999, NEUROSCI LETT, V264, P101, DOI 10.1016/S0304-3940(99)00177-9; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; Neff MW, 1999, GENETICS, V151, P803; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; OSTRANDER EA, 1995, MAMM GENOME, V6, P192, DOI 10.1007/BF00293011; Ott J., 1991, ANAL HUMAN GENETIC L; Peyron C, 1998, J NEUROSCI, V18, P9996; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; Reid MS, 1996, BRAIN RES, V733, P83, DOI 10.1016/S0006-8993(96)00541-0; Riehl J, 1998, EXP NEUROL, V152, P292, DOI 10.1006/exnr.1998.6847; Ryder EJ, 1999, ANIM GENET, V30, P63, DOI 10.1046/j.1365-2052.1999.00424.x; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Sweet DC, 1999, BRAIN RES, V821, P535, DOI 10.1016/S0006-8993(99)01136-1; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; van den Pol AN, 1999, J NEUROSCI, V19, P3171; Wakefield MJ, 1996, MAMM GENOME, V7, P715, DOI 10.1007/s003359900221; Yamamoto Y, 1999, MOL BRAIN RES, V65, P14, DOI 10.1016/S0169-328X(98)00320-9	73	1878	1977	5	162	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					365	376		10.1016/S0092-8674(00)81965-0	http://dx.doi.org/10.1016/S0092-8674(00)81965-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458611	Bronze			2022-12-01	WOS:000081950300011
J	Skuse, D				Skuse, D			Survival after being born too soon, but at what cost?	LANCET			English	Editorial Material							LOW-BIRTH-WEIGHT; EARLY INTERVENTION; PREMATURE-INFANTS; RISK-FACTORS; AGE; ADJUSTMENT; OUTCOMES; CHILDREN; SCHOOL		Inst Child Hlth, Behav Sci Unit, London WC1N 1EH, England	University of London; University College London	Skuse, D (corresponding author), Inst Child Hlth, Behav Sci Unit, 30 Guilford St, London WC1N 1EH, England.							BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BLAIR C, 1995, AM J MENT RETARD, V99, P542; Breslau N, 1996, BIOL PSYCHIAT, V40, P389, DOI 10.1016/0006-3223(95)00399-1; Finnstrom O, 1998, ACTA PAEDIATR, V87, P1055, DOI 10.1080/080352598750031374; FORFAR JO, 1994, DEV MED CHILD NEUROL, V36, P1037; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; HILLE ETM, 1994, J PEDIATR-US, V125, P426, DOI 10.1016/S0022-3476(05)83290-1; Horwood LJ, 1998, ARCH DIS CHILD-FETAL, V79, pF12, DOI 10.1136/fn.79.1.F12; Kaufman A.S., 2014, KAUFMAN TEST ED ACHI; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; McCarton CM, 1997, JAMA-J AM MED ASSOC, V277, P126, DOI 10.1001/jama.277.2.126; PERLMAN M, 1995, J PEDIATR-US, V126, P75, DOI 10.1016/S0022-3476(95)70507-4; Schendel DE, 1997, AM J EPIDEMIOL, V146, P740; Sykes DH, 1997, J CHILD PSYCHOL PSYC, V38, P315, DOI 10.1111/j.1469-7610.1997.tb01516.x; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201	15	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					354	355		10.1016/S0140-6736(99)00150-6	http://dx.doi.org/10.1016/S0140-6736(99)00150-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437859				2022-12-01	WOS:000081764900004
J	Carmeliet, P; Lampugnani, MG; Moons, L; Breviario, F; Compernolle, V; Bono, F; Balconi, G; Spagnuolo, R; Oosthuyse, B; Dewerchin, M; Zanetti, A; Angellilo, A; Mattot, V; Nuyens, D; Lutgens, E; Clotman, F; de Ruiter, MC; Gittenberger-de Groot, A; Poelmann, R; Lupu, F; Herbert, JM; Collen, D; Dejana, E				Carmeliet, P; Lampugnani, MG; Moons, L; Breviario, F; Compernolle, V; Bono, F; Balconi, G; Spagnuolo, R; Oosthuyse, B; Dewerchin, M; Zanetti, A; Angellilo, A; Mattot, V; Nuyens, D; Lutgens, E; Clotman, F; de Ruiter, MC; Gittenberger-de Groot, A; Poelmann, R; Lupu, F; Herbert, JM; Collen, D; Dejana, E			Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis	CELL			English	Article							BLOOD-VESSEL DEVELOPMENT; GROWTH-FACTOR RECEPTOR; CELL-CELL CONTACTS; BETA-CATENIN; N-CADHERIN; NEURONAL APOPTOSIS; EMBRYOS LACKING; IN-VITRO; EXPRESSION; ACTIVATION	Vascular endothelial cadherin, VE-cadherin, mediates adhesion between endothelial cells and may affect vascular morphogenesis via intracellular signaling, but the nature of these signals remains unknown. Here, targeted inactivation (VEC-/-) or truncation of the beta-catenin-binding cytosolic domain (VECdelta C/delta C) Of the VE-cadherin gene was found not to affect assembly of endothelial cells in vascular plexi, but to impair their subsequent remodeling and maturation, causing lethality at 9.5 days of gestation. Deficiency or truncation of VE-cadherin induced endothelial apoptosis and abolished transmission of the endothelial survival signal by VEGF-A to Akt kinase and Bc12 via reduced complex formation with VEGF receptor-2, beta-catenin, and phosphoinositide 3 (PI3)-kinase. Thus, VE-cadherin/beta-catenin signaling controls endothelial survival.	Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Sanofi Rech, Dept Haematol, F-31036 Toulouse, France; Leiden Univ, Med Ctr, Dept Anat & Embryol, Leiden, Netherlands; Thrombosis Res Inst, Vasc Biol Lab, Weston Expt Res Ctr, London SW3 6LR, England; Univ Insubria, Dept Clin & Biol Sci, Sch Med, Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Sanofi-Aventis; Sanofi France; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Thrombosis Research Institute; University of Insubria	Carmeliet, P (corresponding author), Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.		Lupu, Florea/AAV-3257-2021; Lutgens, Esther/E-2919-2010; Carmeliet, Peter/AAQ-5140-2020; adriana, zanetti/ABA-1189-2020; Lupu, Florea/C-3162-2009	Lupu, Florea/0000-0003-1249-9278; Lutgens, Esther/0000-0002-2609-5744; Carmeliet, Peter/0000-0001-7961-1821; adriana, zanetti/0000-0002-5825-9707; Lupu, Florea/0000-0003-1249-9278; Nuyens, Dieter/0000-0001-9390-3273; Angelillo-Scherrer, Anne/0000-0003-2872-4863; Lampugnani, Maria Grazia/0000-0002-4802-7064; Moons, Lieve (Godelieve)/0000-0003-0186-1411; DEJANA, ELISABETTA/0000-0002-0007-0426				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; CORADA M, 1999, IN PRESS P NATL ACAD; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Esser S, 1998, J CELL SCI, V111, P1853; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hogers B, 1999, CARDIOVASC RES, V41, P87, DOI 10.1016/S0008-6363(98)00218-1; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; Kemler R, 1992, Semin Cell Biol, V3, P149; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; MCCLANAHAN T, 1993, BLOOD, V81, P2903; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieset JE, 1997, J CELL SCI, V110, P1013; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; SALOMON D, 1992, J CELL SCI, V102, P7; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; vanMaeleFabry G, 1997, INT J DEV BIOL, V41, P365; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	40	979	1013	2	46	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					147	157		10.1016/S0092-8674(00)81010-7	http://dx.doi.org/10.1016/S0092-8674(00)81010-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428027	Bronze			2022-12-01	WOS:000081632300005
J	Finnerty, GT; Roberts, LSE; Connors, BW				Finnerty, GT; Roberts, LSE; Connors, BW			Sensory experience modifies the short-term dynamics of neocortical synapses	NATURE			English	Article							RAT VISUAL-CORTEX; PYRAMIDAL NEURONS; BARREL CORTEX; POSTSYNAPTIC POTENTIALS; CORTICAL PLASTICITY; RELEASE PROBABILITY; SYNAPTIC PLASTICITY; REORGANIZATION; DEPRESSION; MOUSE	Many representations of sensory stimuli in the neocortex are arranged as topographic maps. These cortical maps are not fixed, but show experience-dependent plasticity(1,2). For instance, sensory deprivation causes the cortical area representing the deprived sensory input to shrink, and neighbouring spared representations to enlarge, in somatosensory(3), auditory(4) or visual cortex(5). In adolescent and adult animals, changes in cortical maps are most noticeable in the supragranular layers at the junction of deprived and spared cortex(6-9). However, the cellular mechanisms of this experience-dependent plasticity are unclear. Long-term potentiation and depression have been implicated(10-12), but have not been proven to be necessary or sufficient for cortical map reorganization. Short-term synaptic dynamics have not been considered. We developed a brain slice preparation involving rat whisker barrel cortex in vitro. Here we report that sensory deprivation alters short-term synaptic dynamics in both vertical and horizontal excitatory pathways within the supragranular cortex. Moreover, modifications of horizontal pathways amplify changes in the vertical inputs. Our findings help to explain the functional cortical reorganization that follows persistent changes of sensory experience.	Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brown University	Connors, BW (corresponding author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.		Finnerty, Gerald/E-5292-2010; Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ARMSTRONGJAMES M, 1994, J NEUROSCI, V14, P6978; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Cash S, 1998, J NEUROSCI, V18, P10; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; FOX K, 1992, J NEUROSCI, V12, P1826; Garraghty PE, 1996, J COMP NEUROL, V367, P319, DOI 10.1002/(SICI)1096-9861(19960401)367:2<319::AID-CNE12>3.0.CO;2-L; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; Glazewski S, 1996, J NEUROPHYSIOL, V75, P1714, DOI 10.1152/jn.1996.75.4.1714; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MASON A, 1991, J NEUROSCI, V11, P72; MCCASLAND JS, 1988, J COMP NEUROL, V278, P555, DOI 10.1002/cne.902780407; Merzbacher L., 1910, Z F R GESAMTE NEUROL, V3, P1, DOI [10.1007/BF02893591, DOI 10.1007/BF02893591]; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; VOLGUSHEV M, 1995, EUR J NEUROSCI, V7, P1751, DOI 10.1111/j.1460-9568.1995.tb00695.x; WELKER C, 1974, J COMP NEUROL, V158, P437, DOI 10.1002/cne.901580405	29	207	208	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					367	371		10.1038/22553	http://dx.doi.org/10.1038/22553			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432115				2022-12-01	WOS:000081590000051
J	Wu, W; Wong, K; Chen, JH; Jiang, ZH; Dupuls, S; Wu, JY; Rao, Y				Wu, W; Wong, K; Chen, JH; Jiang, ZH; Dupuls, S; Wu, JY; Rao, Y			Directional guidance of neuronal migration in the olfactory system by the protein Slit	NATURE			English	Article							SUBVENTRICULAR ZONE CELLS; NEURAL CREST MIGRATION; FETAL MONKEY NEOCORTEX; POLYSIALIC ACID; NERVOUS-SYSTEM; AXON GUIDANCE; GENE ENCODES; C-ELEGANS; GLIA; PRECURSORS	Although cell migration is crucial for neural development, molecular mechanisms guiding neuronal migration have remained unclear. Here we report that the secreted protein Slit repels neuronal precursors migrating from the anterior subventricular zone in the telencephalon to the olfactory bulb. Our results provide a direct demonstration of a molecular cue whose concentration gradient guides the direction of migrating neurons. They also support a common guidance mechanism for axon projection and neuronal migration and suggest that Slit may provide a molecular tool with potential therapeutic applications in controlling and directing cell migration.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Shanghai Res Ctr Life Sci, Mol Neurobiol Lab, Shanghai, Peoples R China; Chinese Acad Sci, Natl Inst Neurosci, Shanghai, Peoples R China	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.		Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03, R01 EY014576] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, R01 GM070967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2; Getchell TV., 1991, SMELL TASTE HLTH DIS, P19; Gordon N, 1996, DEV MED CHILD NEUROL, V38, P1131; GRAY GE, 1990, EXPERIENTIA, V46, P929, DOI 10.1007/BF01939386; Hardesty I, 1904, AM J ANAT, V3, P229, DOI 10.1002/aja.1000030303; HATTEN ME, 1984, J CELL BIOL, V98, P193, DOI 10.1083/jcb.98.1.193; HATTEN ME, 1981, J CELL BIOL, V90, P622, DOI 10.1083/jcb.90.3.622; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HINDS JW, 1968, J COMP NEUROL, V134, P305, DOI 10.1002/cne.901340305; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Norman M, 1995, CONGENITAL MALFORMAT; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; TILNEY FREDERICK, 1933, BULL NEUROL INST NEW YORK, V3, P252; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZHU Y, IN PRESS NEURON; Zigova T, 1996, DEV BIOL, V173, P459, DOI 10.1006/dbio.1996.0040	50	451	505	3	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					331	336		10.1038/22477	http://dx.doi.org/10.1038/22477			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432110	Green Accepted			2022-12-01	WOS:000081590000040
J	Orphanides, G; Wu, WH; Lane, WS; Hampsey, M; Reinberg, D				Orphanides, G; Wu, WH; Lane, WS; Hampsey, M; Reinberg, D			The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins	NATURE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CELL-PROLIFERATION; HISTONE OCTAMER; IN-VITRO; YEAST; CDC68; REPRESSION; MUTATIONS; BINDING	The regulation of gene expression depends critically upon chromatin structure(1). Transcription of protein-coding genes can be reconstituted on naked DNA with only the general transcription factors and RNA polymerase II (ref. 2), This minimal system cannot transcribe DNA packaged into chromatin, indicating that accessory factors may facilitate access to DNA. Two classes of accessory factor, ATP-dependent chromatin-remodelling enzymes(3) and histone acetyltransferases(4), facilitate transcription initiation from chromatin templates. FACT (for facilitates chromatin transcription) is a chromatin-specific elongation factor required for transcription of chromatin templates in vitro(5,6) Here we show that FACT comprises a new human homologue of the Saccharomyces cerevisiae Spt16/Cdc68 protein and the high-mobility group-1-like protein structure-specific recognition protein-1. Yeast SPT16/CDC68 is an essential gene that has been implicated in transcription and cell-cycle regulation. Consistent with our biochemical analysis of FACT, we provide evidence that Spt16/Cdc68 is involved in transcript elongation in vivo. Moreover, FACT specifically interacts with nucleosomes and histone H2A/H2B dimers, indicating that it may work by promoting nucleosome disassembly upon transcription. In support of this model, we show that FACT activity is abrogated by covalently crosslinking nucleasomal histones.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Reinberg, Danny/0000-0003-4288-2016				BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Evans DRH, 1998, GENETICS, V150, P1393; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; PRENDERGAST JA, 1990, GENETICS, V124, P81; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XU QL, 1995, MOL CELL BIOL, V15, P6025	29	425	433	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					284	288		10.1038/22350	http://dx.doi.org/10.1038/22350			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421373				2022-12-01	WOS:000081503800049
J	Choy, E; Chiu, VK; Silletti, J; Feoktistov, M; Morimoto, T; Michaelson, D; Ivanov, IE; Philips, MR				Choy, E; Chiu, VK; Silletti, J; Feoktistov, M; Morimoto, T; Michaelson, D; Ivanov, IE; Philips, MR			Endomembrane trafficking of Ras: The CAAX motif targets proteins to the ER and Golgi	CELL			English	Article							PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; MURINE SARCOMA-VIRUS; PLASMA-MEMBRANE; LOCALIZATION; GENE; CELLS; PALMITOYLATION; PURIFICATION; PROTEOLYSIS	We show that Nras is transiently localized in the Golgi prior to the plasma membrane (PM). Moreover, green fluorescent protein (GFP)-tagged Nras illuminated motile, peri-Golgi vesicles, and prolonged BFA treatment blocked PM expression. GFP-Hras colocalized with GFP-Nras, but GFP-Kras4B revealed less Golgi and no vesicular fluorescence. Whereas a secondary membrane targeting signal was required for PM expression, the CAAX motif alone was necessary and sufficient to target proteins to the endomembrane where they were methylated, a modification required for efficient membrane association. Thus, prenylated CAAX proteins do not associate directly with the PM but instead associate with the endomembrane and are subsequently transported to the PM, a process that requires a secondary targeting motif.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Philips, MR (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.			Mark, Philips/0000-0002-1179-8156	NCRR NIH HHS [M01 RR00096] Funding Source: Medline; NIAID NIH HHS [R01 AI036224, AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036224, R29AI036224] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FLECK A, 1962, BIOCHIM BIOPHYS ACTA, V55, P571; FLEISCHER B, 1969, J CELL BIOL, V43, P59, DOI 10.1083/jcb.43.1.59; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GRAND RJA, 1987, ONCOGENE, V1, P305; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; PHILIPS MR, 1995, METHOD ENZYMOL, V256, P49; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; Willumsen BM, 1996, ONCOGENE, V13, P1901	36	599	606	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					69	80		10.1016/S0092-8674(00)80607-8	http://dx.doi.org/10.1016/S0092-8674(00)80607-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412982	Bronze			2022-12-01	WOS:000081451000009
J	Sym, M; Robinson, N; Kenyon, C				Sym, M; Robinson, N; Kenyon, C			MIG-13 positions migrating cells along the anteroposterior body axis of C. elegans	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYO; ACTIVITY GRADIENT; GENE-EXPRESSION; NERVOUS-SYSTEM; AXON OUTGROWTH; MESSENGER-RNA; LDL-RECEPTOR; PROTEINS	The C. elegans Q neuroblasts and their descendants migrate along the anteroposterior (A/P) body axis to positions that are not associated with any obvious landmarks. We find that a novel protein, MIG-13, is required to position these cells correctly. MIG-13 is a transmembrane protein whose expression is restricted to the anterior and central body regions by Hox gene activity. MIG-13 functions non-cell autonomously within these regions to promote migration toward the anterior: loss of mig-13 activity shifts the Q descendants toward the posterior, whereas increasing the level of MIG-13 shifts them anteriorly in a dose-dependent manner. Our findings suggest that MIG-13 is a component of a global A/P migration system, and that the level of MIG-13 determines where along the body axis these migrating cells stop.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.							BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Battye R, 1999, DEVELOPMENT, V126, P2475; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRENNER S, 1974, GENETICS, V77, P71; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Burdine RD, 1998, DEVELOPMENT, V125, P1083; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; Harris J, 1996, DEVELOPMENT, V122, P3117; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1995, GENETICS, V141, P989; HUNTER CP, 1995, NATURE, V377, P229, DOI 10.1038/377229a0; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Maloof JN, 1999, DEVELOPMENT, V126, P37; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; MITANI S, 1993, DEVELOPMENT, V119, P773; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SALSER SJ, 1995, THESIS U CALIFORNIA; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wightman B, 1996, DEVELOPMENT, V122, P671; Wolf FW, 1998, NEURON, V20, P655, DOI 10.1016/S0896-6273(00)81006-5; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	50	57	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					25	36		10.1016/S0092-8674(00)80603-0	http://dx.doi.org/10.1016/S0092-8674(00)80603-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412978	Bronze			2022-12-01	WOS:000081451000005
J	Culleton, BF; Larson, MG; Kannel, WB; Levy, D				Culleton, BF; Larson, MG; Kannel, WB; Levy, D			Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study	ANNALS OF INTERNAL MEDICINE			English	Article						uric acid; cardiovascular diseases; outcome assessment (health care); diuretics; risk factors	DIABETES-MELLITUS; FOLLOW-UP; HYPERTENSIVE PATIENTS; GLUCOSE-TOLERANCE; XANTHINE-OXIDASE; FREE-RADICALS; HYPERURICEMIA; WOMEN; POPULATION; INSULIN	Background: Hyperuricemia is associated with risk for cardiovascular disease and death. However, the role of uric acid independent of established risk factors is uncertain. Objective: To examine the relation of serum uric acid level to incident coronary heart disease, death from cardiovascular disease, and death from all causes. Design: Community-based, prospective observational study. Setting: Framingham, Massachusetts. Patients: 6763 Framingham Heart Study participants (mean age, 47 years). Measurements: Serum uric acid level at baseline (1971 to 1976); event rates per 1000 person-years by sex-specific uric acid quintile. Results: During 117 376 person-years of follow-up, 617 coronary heart disease events, 429 cardiovascular disease deaths, and 1460 deaths from all causes occurred. In men, after adjustment for age, elevated serum uric acid level was not associated with increased risk for an adverse outcome. In women, after adjustment for age, uric acid level was predictive of coronary heart disease (P = 0.002), death from cardiovascular disease (P = 0.009), and death from all causes (P = 0.03). After additional adjustment for cardiovascular disease risk factors, uric acid level was no longer associated with coronary heart disease, death from cardiovascular disease, or death from ail causes. in a stepwise Cox model, diuretic use was identified as the covariate responsible for rendering serum uric acid a statistically nonsignificant predictor of outcomes. Conclusions: These findings indicate that uric acid does not have a causal role in the development of coronary heart disease, death from cardiovascular disease, or death from all causes. Any apparent association with these outcomes is probably due to the association of uric acid level with other risk factors.	Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Framingham Heart Study, Framingham, MA 01702 USA	Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levy, D (corresponding author), NHLBI, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.	Dan@fram.nhlbi.nih.gov	Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; Alderman MH, 1998, J HYPERTENS, V16, pS5; ALDERMAN MH, 1998, AM J HYPERTENS, V11, P16; Anker SD, 1997, HEART, V78, P39, DOI 10.1136/hrt.78.1.39; [Anonymous], 1981, LANCET, V2, P539; ASHRAF M, 1993, J SUBMICR CYTOL PATH, V25, P193; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BENGTSSON C, 1988, ACTA MED SCAND, V224, P549; BOLLI R, 1988, J AM COLL CARDIOL, V12, P239, DOI 10.1016/0735-1097(88)90381-6; BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; CAPPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354, DOI 10.1001/jama.270.3.354; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY LV, 1964, CLIN CHEM, V10, P838; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; EMMERSON BT, 1979, AUST NZ J MED, V9, P451, DOI 10.1111/j.1445-5994.1979.tb04180.x; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; FRIEDL HP, 1990, AM J PATHOL, V136, P491; GALVAN AQ, 1995, AM J PHYSIOL-ENDOC M, V268, pE1, DOI 10.1152/ajpendo.1995.268.1.E1; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; GINSBERG MH, 1977, J CLIN INVEST, V60, P999, DOI 10.1172/JCI108880; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HAYABUCHI Y, 1993, EUR J PEDIATR, V152, P873, DOI 10.1007/BF01957519; HUIZER T, 1989, J MOL CELL CARDIOL, V21, P691, DOI 10.1016/0022-2828(89)90610-X; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KEIL U, 1988, ACTA MED SCAND, P119; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Lehto S, 1998, STROKE, V29, P635, DOI 10.1161/01.STR.29.3.635; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LEWIS PJ, 1976, LANCET, V1, P564; Leyva F, 1997, EUR HEART J, V18, P858; Liese AD, 1998, CIRCULATION, V97, P822; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MONTOR SG, 1987, EUR J PHARMACOL, V140, P203, DOI 10.1016/0014-2999(87)90806-5; MURPHY MB, 1982, LANCET, V2, P1293; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; PORTER KB, 1992, OBSTET GYNECOL, V79, P394, DOI 10.1097/00006250-199203000-00014; *PROGR COOP RES GR, 1985, PREV MED, V14, P312; Rathmann W, 1998, ANN EPIDEMIOL, V8, P250, DOI 10.1016/S1047-2797(97)00204-4; REAVEN GM, 1994, J INTERN MED, V236, P13; REUNANEN A, 1982, ACTA MED SCAND, P49; Sahebjami H, 1998, CHEST, V113, P1604, DOI 10.1378/chest.113.6.1604; *SAS STAT SOFTW, 1996, CHANG ENH REL 6 11 C; SAUGSTAD OD, 1975, PEDIATR RES, V9, P158, DOI 10.1203/00006450-197504000-00002; SHURTLEFF D, 1974, FRAMINGHAM STUDY, P17; Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617; STETTEN D, 1959, SCIENCE, V129, P1737, DOI 10.1126/science.129.3365.1737; VasquezVivar J, 1996, BIOCHEM J, V314, P869, DOI 10.1042/bj3140869; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; 1997, ARCH INTERN MED, V157, P2413	57	927	1004	4	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					7	+		10.7326/0003-4819-131-1-199907060-00003	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391820				2022-12-01	WOS:000081345200002
J	Hayashi, T; Tsumura, K; Suematsu, C; Okada, K; Fujii, S; Endo, G				Hayashi, T; Tsumura, K; Suematsu, C; Okada, K; Fujii, S; Endo, G			Walking to work and the risk for hypertension in men: The Osaka Health Survey	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; walking; exercise; middle age; cardiovascular disease	CORONARY HEART-DISEASE; TIME PHYSICAL-ACTIVITY; BLOOD-PRESSURE; COLLEGE ALUMNI; OLDER WOMEN; ATTACK RISK; EXERCISE; TREAT; TRIAL; DEATH	Background: It is not known whether physical activity is effective in reducing the risk for hypertension. Objective: To investigate the association of the duration of the walk to work and leisure-time physical activity with the risk for hypertension. Design: Prospective cohort study. Setting: Work site in Osaka, Japan. Participants: 6017 Japanese men 35 to 60 years of age with systolic blood pressure less than 140 mm Hg, diastolic blood pressure less than 90 mm Hg, normal glucose intolerance, and no history of hypertension or diabetes at baseline. Measurements: Data on physical activity were obtained by using questionnaires. Blood pressure was measured by using a standard technique; a value of at least 160/95 mm Hg was used to diagnose hypertension. Results: During 59 784 person-years of follow-up, 626 cases of hypertension were confirmed. The duration of the walk to work was associated with a reduction in the risk for incident hypertension; multivariate-adjusted relative risks were 1.00 for a walk of 10 minutes or less (reference category), 0.88 (95% CI, 0.75 to 1.04) for an 11- to 20-minute walk, and 0.71 (CI, 0.52 to 0.97) for a walk of 21 minutes or more (P for trend = 0.02). For every 26.3 men who walk more than 20 minutes to work, one case of hypertension will be prevented. Conclusions: Walking to work and other types of physical activity decreased the risk for hypertension in Japanese men. Regular exercise can prevent hypertension.	Osaka City Univ, Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, Osaka 5458585, Japan; Osaka Gas Co Ltd, Med Ctr Employees Hlth, Nishi Ku, Osaka 5500023, Japan; Environm & Publ Hlth Bur, Kita Ku, Osaka 5300005, Japan	Osaka Metropolitan University; Osaka Gas Co., Ltd.	Hayashi, T (corresponding author), Osaka City Univ, Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.		Hayashi, Tomoshige/N-8508-2015					Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ARROLL B, 1992, J CLIN EPIDEMIOL, V45, P439, DOI 10.1016/0895-4356(92)90093-3; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; FAGARD R, 1990, HYPERTENSION PATHOPH, P1985; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; KINGWELL BA, 1993, MED J AUSTRALIA, V158, P234, DOI 10.5694/j.1326-5377.1993.tb121740.x; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LEON AS, 1985, MED CLIN N AM, V69, P3, DOI 10.1016/S0025-7125(16)31055-0; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; PAFFENBARGER RS, 1991, ANN MED, V23, P319, DOI 10.3109/07853899109148067; PAFFENBARGER RS, 1995, AM J EPIDEMIOL, V142, P889, DOI 10.1093/oxfordjournals.aje.a117736; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; REAVEN PD, 1991, CIRCULATION, V83, P559, DOI 10.1161/01.CIR.83.2.559; SEALS DR, 1991, HYPERTENSION, V18, P583, DOI 10.1161/01.HYP.18.5.583; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WASHBURN RA, 1987, PREV MED, V16, P636, DOI 10.1016/0091-7435(87)90047-8; WILLIAMS RR, 1991, HYPERTENSION, V18, P29, DOI 10.1161/01.HYP.18.3_Suppl.I29; World Health Organization, 1978, WHO TECH REP SER, P7; ZANCHETTI A, 1993, HYPERTENSION, V22, P392	28	148	158	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					21	+		10.7326/0003-4819-131-1-199907060-00005	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391811				2022-12-01	WOS:000081345200004
J	Roose, J; Huls, G; van Beest, M; Moerer, P; van der Horn, K; Goldschmeding, R; Logtenberg, T; Clevers, H				Roose, J; Huls, G; van Beest, M; Moerer, P; van der Horn, K; Goldschmeding, R; Logtenberg, T; Clevers, H			Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1	SCIENCE			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; COLORECTAL-CANCER; AXIS FORMATION; FUNCTIONAL INTERACTION; XENOPUS EMBRYOS; TRANSCRIPTION; GENE; ASSOCIATION; ACTIVATION	Mutations in APC or beta-catenin inappropriately activate the transcription factor Tcf4, thereby transforming intestinal epithelial cells. Here it is shown that one of the target genes of Tcf4 in epithelial cells is Tcf1, The most abundant Tcf1 isoforms Lack a beta-catenin interaction domain. Tcf1(-/-) mice develop adenomas in the gut and mammary glands. Introduction of a mutant APC allele into these mice substantially increases the number of these adenomas. Tcf1 may act as a feedback repressor of beta-catenin-Tcf4 target genes and thus may cooperate with APC to suppress malignant transformation of epithelial cells.	Univ Utrecht, Med Ctr, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Clevers, H (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol, POB 85500, NL-3508 GA Utrecht, Netherlands.	h.clevers@lab.azu.nl	Goldschmeding, Roel/I-1723-2014					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BAKRER N, 1999, AM J PATHOL, V154, P29; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JEN J, 1994, CANCER RES, V54, P5523; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mayer K, 1997, INT J CANCER, V72, P625, DOI 10.1002/(SICI)1097-0215(19970807)72:4<625::AID-IJC13>3.0.CO;2-A; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schilham MW, 1998, J IMMUNOL, V161, P3984; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANBEEST M, UNPUB; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	391	416	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1923	1926		10.1126/science.285.5435.1923	http://dx.doi.org/10.1126/science.285.5435.1923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489374				2022-12-01	WOS:000082638300054
J	Henney, JE				Henney, JE			Approval of TMJ prosthesis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-01	WOS:000082335900007
J	Redelmeier, DA; Tibshirani, RJ				Redelmeier, DA; Tibshirani, RJ			Why cars in the next lane seem to go faster	NATURE			English	Article							PERCEPTION		Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Stanford University; Stanford University	Redelmeier, DA (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Angrilli A, 1997, PERCEPT PSYCHOPHYS, V59, P972, DOI 10.3758/BF03205512; Feller V, 1984, INTRO PROBABILITY TH; GILOVICH T, 1985, COGNITIVE PSYCHOL, V17, P295, DOI 10.1016/0010-0285(85)90010-6; Helbing D, 1998, NATURE, V396, P738, DOI 10.1038/25499; LARSON RC, 1987, OPER RES, V35, P895, DOI 10.1287/opre.35.6.895; Snowden RJ, 1998, NATURE, V392, P450, DOI 10.1038/33049; TVERSKY A, 1991, Q J ECON, V106, P1039, DOI 10.2307/2937956; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; *US BUR CENS, 1997, STAT ABSTR US 1996; Walton D, 1998, ACCIDENT ANAL PREV, V30, P821, DOI 10.1016/S0001-4575(98)00035-9	10	12	12	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					35	35		10.1038/43360	http://dx.doi.org/10.1038/43360			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	232MK	10485702	Bronze			2022-12-01	WOS:000082374400028
J	Funa, N; Ohnishi, Y; Fujii, I; Shibuya, M; Ebizuka, Y; Horinouchi, S				Funa, N; Ohnishi, Y; Fujii, I; Shibuya, M; Ebizuka, Y; Horinouchi, S			A new pathway for polyketide synthesis in microorganisms	NATURE			English	Article							STREPTOMYCES-GRISEUS; CHALCONE SYNTHASE; GENE; BIOSYNTHESIS; ANTIBIOTICS; VANCOMYCIN; SEQUENCE; SITE	Chalcone synthases, which biosynthesize chalcones (the starting materials for many flavonoids(1,2)), have been believed to be specific to plants. However, the rppA gene from the Gram-positive, soil-living filamentous bacterium Streptomyces griseus encodes a 372-amino-acid protein that shows significant similarity to chalcone synthases'. Several rppA-like genes are known, but their functions and catalytic properties have not been described. Here we show that a homodimer of RppA catalyses polyketide synthesis: it selects malonyl-coenzyme-A as the starter, carries out four successive extensions and releases the resulting pentaketide to cyclize to 1,3,6,8-tetrahydroxynaphthalene (THN). Site-directed mutagenesis revealed that, as in other chalcone synthases(4,5), a cysteine residue is essential for enzyme activity. Disruption of the chromosomal rppA gene in S. griseus abolished melanin production in hyphae, resulting in 'albino' mycelium. THN was readily oxidized to form 2,5,7-trihydroxy-1,4-naphthoquinone(flaviolin), which then randomly polymerized to form various coloured compounds. THN formed by RppA appears to be an intermediate in the biosynthetic pathways for not only melanins but also various secondary metabolites containing a naphthoquinone ring. Therefore, RppA is a chalcone-synthase-related synthase that synthesizes polyketides and is found in the Streptomyces and other bacteria.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.			Ohnishi, Yasuo/0000-0001-7633-9236				Ando N, 1997, MICROBIOL-UK, V143, P2715, DOI 10.1099/00221287-143-8-2715; Bangera MG, 1996, MOL PLANT MICROBE IN, V9, P83, DOI 10.1094/MPMI-9-0083; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BELL AA, 1986, ANNU REV PHYTOPATHOL, V24, P411, DOI 10.1146/annurev.py.24.090186.002211; BLANCO G, 1993, GENE, V130, P107, DOI 10.1016/0378-1119(93)90352-4; DIMROTH P, 1976, EUR J BIOCHEM, V68, P591, DOI 10.1111/j.1432-1033.1976.tb10847.x; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; FUNAYAMA S, 1990, J ORG CHEM, V55, P1132, DOI 10.1021/jo00291a003; HAMMOND SJ, 1982, J CHEM SOC CHEM COMM, P344, DOI 10.1039/c39820000344; Hopwood D. A., 1985, GENETIC MANIPULATION; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LANZ T, 1991, J BIOL CHEM, V266, P9971; Maniatis T., 1982, MOL CLONING LAB MANU; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; PATHIRANA C, 1992, TETRAHEDRON LETT, V33, P7663, DOI 10.1016/0040-4039(93)88010-G; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Schroder J., 1999, COMPREHENSIVE NATURA, V1, P749, DOI DOI 10.1016/b978-0-08-091283-7.00029-1; SHIN-YA K, 1990, Tetrahedron Letters, V31, P6025, DOI 10.1016/S0040-4039(00)98019-5; SHIOMI K, 1986, J ANTIBIOT, V39, P494, DOI 10.7164/antibiotics.39.494; TAKANO Y, 1995, MOL GEN GENET, V249, P162, DOI 10.1007/BF00290362; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; UEDA K, 1995, J ANTIBIOT, V48, P638, DOI 10.7164/antibiotics.48.638; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658	28	230	250	6	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					897	899		10.1038/23748	http://dx.doi.org/10.1038/23748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476972				2022-12-01	WOS:000082233200052
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Folding to green	SCIENCE			English	Article									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Peters, R (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1229	1229		10.1126/science.285.5431.1229	http://dx.doi.org/10.1126/science.285.5431.1229			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10484733				2022-12-01	WOS:000082130200032
J	Kim, KK; Yokota, H; Kim, SH				Kim, KK; Yokota, H; Kim, SH			Four-helical-bundle structure of the cytoplasmic domain of a serine chemotaxis receptor	NATURE			English	Article							DISULFIDE CROSS-LINKING; LIGAND-BINDING DOMAIN; ASPARTATE RECEPTOR; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; ALPHA-HELIX; CHEMORECEPTOR; MODEL; DIMER; MUTAGENESIS	The bacterial chemotaxis receptors are transmembrane receptors with a simple signalling pathway which has elements relevant to the general understanding of signal recognition and transduction across membranes, how signals are relayed between molecules in a pathway, and how adaptation to a persistent signal is achieved(1). In contrast to many mammalian receptors which signal by oligomerizing upon ligand binding(2), the chemotaxis receptors are dimeric even in the absence of their ligands, and their signalling does not depend on a monomer-dimer equilibrium(3). Bacterial chemotaxis receptors are composed of a ligand-binding domain, a transmembrane domain consisting of two helices TM1 and TM2, and a cytoplasmic domain. All known bacterial chemotaxis receptors have a highly conserved cytoplasmic domain, which unites signals from different ligand domains into a single signalling pathway to flagella motors. Here we report the crystal structure of the cytoplasmic domain of a serine chemotaxis receptor of Escherichia coli, which reveals a 200 Angstrom-long coiled-coil of two antiparallel helices connected by a 'U-turn'. Two of these domains form a long, supercoiled, four-helical bundle in the cytoplasmic portion of the receptor.	Univ Calif Berkeley, Melvin Calvin Lab 220, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Phys Biosci Div, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Melvin Calvin Lab 220, Berkeley, CA 94720 USA.	shkim@LBL.gov						AMES P, 1988, COLD SPRING HARB SYM, V53, P59, DOI 10.1101/SQB.1988.053.01.010; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bass RB, 1998, J BIOL CHEM, V273, P25006, DOI 10.1074/jbc.273.39.25006; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BRUNGER AT, 1993, X PLOR VERSION 3 1; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1994, PROTEIN SCI, V3, P159; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	30	381	386	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1999	400	6746					787	792		10.1038/23512	http://dx.doi.org/10.1038/23512			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466731				2022-12-01	WOS:000082131100056
J	Lenski, RE; Ofria, C; Collier, TC; Adami, C				Lenski, RE; Ofria, C; Collier, TC; Adami, C			Genome complexity, robustness and genetic interactions in digital organisms	NATURE			English	Article							DELETERIOUS MUTATIONS; EVOLUTION; FITNESS; POPULATIONS; ADAPTATION	Digital organisms are computer programs that self-replicate, mutate and adapt by natural selection(1-3). They offer an opportunity to test generalizations about living systems that may extend beyond the organic life that biologists usually study. Here we have generated two classes of digital organism: simple programs selected solely for rapid replication, and complex programs selected to perform mathematical operations that accelerate replication through a set of defined 'metabolic' rewards., To examine the differences in their genetic architecture, we introduced millions of single and multiple mutations into each organism and measured the effects on the organism's fitness. The complex organisms are more robust than the simple ones with respect to the average effects of single mutations. Interactions among mutations are common and usually yield higher fitness than predicted from the component mutations assuming multiplicative effects; such interactions are especially important in the complex organisms. Frequent interactions among mutations have also been seen in bacteria, fungi and fruitflies(4-6). Our findings support the view that interactions are a general feature of genetic systems(7-9).	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; CALTECH, Kellogg Radiat Lab, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA	Michigan State University; California Institute of Technology; University of California System; University of California Los Angeles	Lenski, RE (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.	lenski@pilot.msu.edu; chalres@krl.caltech.edu	Adami, Christoph/A-5181-2009; Adami, Chris/A-9675-2011	Adami, Chris/0000-0002-2915-9504; Lenski, Richard/0000-0002-1064-8375; Ofria, Charles/0000-0003-2924-1732				ADAMI C, 1995, PHYSICA D, V80, P154, DOI 10.1016/0167-2789(95)90073-X; Adami C., 1998, INTRO ARTIFICIAL LIF; Burch CL, 1999, GENETICS, V151, P921; Clark AG, 1997, GENETICS, V147, P157; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; deVisser JAGM, 1997, EVOLUTION, V51, P1499, DOI 10.1111/j.1558-5646.1997.tb01473.x; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Frank Steven A., 1996, P451; Henry, 1992, ADAPTATION NATURAL A; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; KAUFFMAN S, 1987, J THEOR BIOL, V128, P11, DOI 10.1016/S0022-5193(87)80029-2; Kauffman S.A., 1993, ORIGINS ORDER; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Koza J.R, 1997, GENETIC PROGRAMMING; KOZA JR, 1998, EVOLUTIONARY ROBOTIC, P37; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Maynard-Smith J., 1978, MODELS ECOLOGY; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; PAQUIN CE, 1983, NATURE, V306, P368, DOI 10.1038/306368a0; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; RAY T., 1992, ARTIF LIFE, P371, DOI DOI 10.1016/S0040-4039(01)97473-8; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SMITH JM, 1992, NATURE, V355, P772; SOKAL RR, 1994, BIOMETRY; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Turner PE, 1999, NATURE, V398, P441, DOI 10.1038/18913; Wright S., 1977, EXPT RESULTS EVOLUTI	29	197	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					661	664		10.1038/23245	http://dx.doi.org/10.1038/23245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458160				2022-12-01	WOS:000082032900052
J	Ehresman, K; Lynfield, R; Danila, R; Black, S; Shinefield, H; Fireman, B; Cordova, S				Ehresman, K; Lynfield, R; Danila, R; Black, S; Shinefield, H; Fireman, B; Cordova, S			Intussusception among recipients of rotavirus vaccine - United States, 1998-1999 (Reprinted from MMWR, vol 48, pg 577, 1999)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									Minnesota Dept Hlth, Minneapolis, MN 55414 USA; Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA; US FDA, Div Biostat & Epidemiol, Rockville, MD 20857 USA; Natl Ctr Infect Dis, Viral Gastroenteritis Sect, Resp & Enter Viruses Br, Atlanta, GA USA; Natl Ctr Infect Dis, Off Director, Div Viral & Rickettsial Dis, Atlanta, GA USA; CDC, Vaccine Safety Datalink Team, Atlanta, GA 30333 USA; CDC, Stat Anal Br, Data Management Div, Atlanta, GA 30333 USA; CDC, Vaccine Safety & Dev Activ, Atlanta, GA 30333 USA; CDC, Child Vaccine Prevent Dis Br, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA	Minnesota Department of Health (MHD); Kaiser Permanente; US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Ehresman, K (corresponding author), Minnesota Dept Hlth, Minneapolis, MN 55414 USA.							Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577	1	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					520	521						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450702				2022-12-01	WOS:000081919100010
J	Mole, SE				Mole, SE			Batten's disease: eight genes and still counting?	LANCET			English	Editorial Material							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; MUTATIONS		UCL Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6JJ, England	University of London; University College London; UCL Medical School	Mole, SE (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6JJ, England.		Mole, Sara/C-2024-2008	Mole, Sara/0000-0003-4385-4957				BERKOVIC SF, 1988, BRAIN, V111, P27, DOI 10.1093/brain/111.1.27; CAMP LA, 1993, J BIOL CHEM, V268, P22566; Das AK, 1998, J CLIN INVEST, V102, P361, DOI 10.1172/JCI3112; Goebel H, 1999, NEURONAL CEROID LIPO; Greene NDE, 1999, MOL GENET METAB, V66, P309, DOI 10.1006/mgme.1999.2828; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; LU JY, 1996, P NATL ACAD SCI USA, V93, P1046; Mitchison HM, 1998, HUM MOL GENET, V7, P291, DOI 10.1093/hmg/7.2.291; MOLE SE, IN PRESS HUM MUTAT; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Ranta S, 1997, GENOME RES, V7, P887, DOI 10.1101/gr.7.9.887; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; Wheeler RB, 1999, MOL GENET METAB, V66, P337, DOI 10.1006/mgme.1999.2804	19	45	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					443	445		10.1016/S0140-6736(99)00173-7	http://dx.doi.org/10.1016/S0140-6736(99)00173-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465165				2022-12-01	WOS:000081896100005
J	Chen, CH; von Kessler, DP; Park, WJ; Beachy, PA				Chen, CH; von Kessler, DP; Park, WJ; Beachy, PA			Nuclear trafficking of cubitus interruptus in the transcriptional regulation of hedgehog target gene expression	CELL			English	Article							KINESIN-RELATED PROTEIN; SIGNAL-TRANSDUCTION; DROSOPHILA EMBRYOS; KINASE-A; WINGLESS; PROTEOLYSIS; PATHWAYS; COMPLEX; PHOSPHORYLATION; PROTEASOME	Transcriptional activation of Hedgehog (Hh) target genes requires Cubitus interruptus, a 155 kDa cytoplasmic zinc finger protein (Ci155), which in the absence of Hh signaling is processed to form a nuclear repressor (Ci75). We show that Hh signaling reduces phosphorylation of Ci155, and this reduction in turn appears to decrease processing. Blocking processing with proteasome inhibitors or altered Ci proteins, however, is insufficient for activation of Hh targets. We find that Hh signaling increases the rate of Ci155 nuclear import, resulting in significant nuclear accumulation. Even in the absence of signaling, nuclear accumulation of Ci155 suffices for significant induction of Hh targets, and active nuclear export of Ci155 is an essential mechanism for maintenance of the unstimulated state.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FORBES AJ, 1993, DEVELOPMENT, P115; Hepker J, 1997, DEVELOPMENT, V124, P549; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; ZHANG J, 1991, J BIOL CHEM, V266, P2290	35	213	219	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					305	316		10.1016/S0092-8674(00)81960-1	http://dx.doi.org/10.1016/S0092-8674(00)81960-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458606	Bronze			2022-12-01	WOS:000081950300006
J	Miyashita-Lin, EM; Hevner, R; Wassarman, KM; Martinez, S; Rubenstein, JLR				Miyashita-Lin, EM; Hevner, R; Wassarman, KM; Martinez, S; Rubenstein, JLR			Early neocortical regionalization in the absence of thalamic innervation	SCIENCE			English	Article							CEREBRAL-CORTEX; NERVOUS-SYSTEM; CALRETININ IMMUNOREACTIVITY; EXPRESSION PATTERN; CORTICAL AREAS; MUTANT MICE; FOREBRAIN; GENE; RAT; SPECIFICATION	There is a Long-standing controversy regarding the mechanisms that generate the functional subdivisions of the cerebral neocortex. One model proposes that thalamic axonal input specifies these subdivisions; the competing model postulates that patterning mechanisms intrinsic to the dorsal telencephalon generate neocortical regions. Gbx-2 mutant mice, whose thalamic differentiation is disrupted, were investigated. Despite the Lack of cortical innervation by thalamic axons, neocortical region-specific gene expression (Cadherin-6, EphA-7, Id-2, and RZR-beta) developed normally. This provides evidence that patterning mechanisms intrinsic to the neocortex specify the basic organization of its functional subdivisions.	Univ Calif San Francisco, Sch Med, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA; Univ Miguel Hernandez, Univ Murcia, Inst Neurosci, Fac Med,Dept Morphol Sci, Alicante, Spain	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidad Miguel Hernandez de Elche; University of Murcia	Rubenstein, JLR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926	NIMH NIH HHS [R01 MH49428-01, R01 MH51561-01A1] Funding Source: Medline; NINDS NIH HHS [NS34661-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049428, R01MH051561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034661] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acampora D, 1997, DEVELOPMENT, V124, P3639; ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BULFONE A, 1993, J NEUROSCI, V13, P3155; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P5212, DOI 10.1210/en.136.11.5212; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; FONSECA M, 1995, J COMP NEUROL, V361, P177, DOI 10.1002/cne.903610114; FRANZ T, 1994, ACTA ANAT, V150, P38; Frassoni C, 1998, NEUROSCIENCE, V83, P1203, DOI 10.1016/S0306-4522(97)00443-0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; GITTON Y, IN PRESS CEREB; Golden JA, 1999, P NATL ACAD SCI USA, V96, P2439, DOI 10.1073/pnas.96.5.2439; Grove EA, 1998, DEVELOPMENT, V125, P2315; HEVNER RF, UNPUB; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9; MIYASHITALIN EM, UNPUB; Monaghan AP, 1997, NATURE, V390, P515, DOI 10.1038/37364; MORI T, 1995, MOL BRAIN RES, V34, P154, DOI 10.1016/0169-328X(95)00154-K; Nothias F, 1998, CURR BIOL, V8, P459, DOI 10.1016/S0960-9822(98)70189-7; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; Pellegrini M, 1996, DEVELOPMENT, V122, P3893; Qiu MS, 1996, DEV BIOL, V178, P174, DOI 10.1006/dbio.1996.0207; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; RUBENSTEIN JLR, IN PRESS CEREB CORTE; Schaeren-Wiemers N, 1997, EUR J NEUROSCI, V9, P2687, DOI 10.1111/j.1460-9568.1997.tb01698.x; Stoykova A, 1996, DEVELOPMENT, V122, P3453; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yoshida M, 1997, DEVELOPMENT, V124, P101	36	264	269	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					906	909		10.1126/science.285.5429.906	http://dx.doi.org/10.1126/science.285.5429.906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436162				2022-12-01	WOS:000081860900054
J	Bowman, S; Lawson, D; Basham, D; Brown, D; Chillingworth, T; Churcher, CM; Craig, A; Davies, RM; Devlin, K; Feltwell, T; Gentles, S; Gwilliam, R; Hamlin, N; Harris, D; Holroyd, S; Hornsby, T; Horrocks, P; Jagels, K; Jassal, B; Kyes, S; McLean, J; Moule, S; Mungall, K; Murphy, L; Oliver, K; Quail, MA; Rajandream, MA; Rutter, S; Skelton, J; Squares, R; Squares, S; Sulston, JE; Whitehead, S; Woodward, JR; Newbold, C; Barrell, BG				Bowman, S; Lawson, D; Basham, D; Brown, D; Chillingworth, T; Churcher, CM; Craig, A; Davies, RM; Devlin, K; Feltwell, T; Gentles, S; Gwilliam, R; Hamlin, N; Harris, D; Holroyd, S; Hornsby, T; Horrocks, P; Jagels, K; Jassal, B; Kyes, S; McLean, J; Moule, S; Mungall, K; Murphy, L; Oliver, K; Quail, MA; Rajandream, MA; Rutter, S; Skelton, J; Squares, R; Squares, S; Sulston, JE; Whitehead, S; Woodward, JR; Newbold, C; Barrell, BG			The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum	NATURE			English	Article							MALARIA; GENE; DNA; GENOME; CENTROMERE; DOMAINS; CONSTRUCTION; EXPRESSION; LIBRARIES; PROTEINS	Analysis of Plasmodium falciparum chromosome 3, and comparison with chromosome 2, highlights novel features of chromosome organization and gene structure. The sub-telomeric regions of chromosome 3 show a conserved order of features, including repetitive DNA sequences, members of multigene families involved in pathogenesis and antigenic variation, a number of conserved pseudogenes, and several genes of unknown function. A putative centromere has been identified that has a core region of about 2 kilobases with an extremely high (adenine + thymidine) composition and arrays of tandem repeats. We have predicted 215 protein-coding genes and two transfer RNA genes In the 1,060,106-base-pair chromosome sequence. The predicted protein-coding genes can be divided into three main classes: 52.6% are not spliced, 45.1% have a large exon with short additional 5' or 3' exons, and 2.3% have a multiple exon structure more typical of higher eukaryotes.	Sanger Ctr, Pathogen Sequencing Unit, Hinxton CB10 1SA, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	Wellcome Trust Sanger Institute; University of Oxford	Bowman, S (corresponding author), Sanger Ctr, Pathogen Sequencing Unit, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	sharen@sanger.ac.uk	Quail, michael/ABE-6131-2020; Horrocks, Paul/C-2615-2009	Horrocks, Paul/0000-0003-3981-0732; Murphy, Lee/0000-0001-6467-7449; Davies, Robert/0000-0002-9983-1378; Craig, Alister/0000-0003-0914-6164; Jassal, Bijay/0000-0002-5039-5405; Newbold, Chris/0000-0002-9274-3789; Lawson, Daniel/0000-0001-7765-983X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aston C, 1999, TRENDS BIOTECHNOL, V17, P297, DOI 10.1016/S0167-7799(99)01326-8; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; Berriman M, 1998, BIOCHEM J, V334, P437, DOI 10.1042/bj3340437; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARCY B, 1997, MOL BIOCHEM PARASIT, V68, P221; Cheng Q, 1998, MOL BIOCHEM PARASIT, V97, P161, DOI 10.1016/S0166-6851(98)00144-3; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEBRUIN D, 1994, P NATL ACAD SCI USA, V91, P619, DOI 10.1073/pnas.91.2.619; ENEA V, 1984, SCIENCE, V225, P628, DOI 10.1126/science.6204384; Fischer K, 1997, MOL CELL BIOL, V17, P3679, DOI 10.1128/MCB.17.7.3679; Garcia A, 1999, PARASITOL TODAY, V15, P90, DOI 10.1016/S0169-4758(99)01393-9; Gardiner K, 1995, SOMAT CELL MOLEC GEN, V21, P399, DOI 10.1007/BF02310207; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Hoffman SL, 1997, NATURE, V387, P647, DOI 10.1038/42571; HOLT DC, IN PRESS INT J PARAS; Horrocks P, 1998, MOL BIOCHEM PARASIT, V95, P171, DOI 10.1016/S0166-6851(98)00110-8; KYES S, IN PRESS P NATL ACAD; LANZER M, 1992, EMBO J, V11, P1949, DOI 10.1002/j.1460-2075.1992.tb05248.x; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; Soldati D, 1999, PARASITOL TODAY, V15, P5, DOI 10.1016/S0169-4758(98)01363-5; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Thompson JK, 1997, MOL BIOCHEM PARASIT, V90, P537, DOI 10.1016/S0166-6851(97)00203-X; Thompson JK, 1997, MOL BIOCHEM PARASIT, V87, P49, DOI 10.1016/S0166-6851(97)00041-8; TRIGLIA T, 1991, MOL BIOCHEM PARASIT, V44, P207, DOI 10.1016/0166-6851(91)90006-R; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; VAUDIN M, 1995, NUCLEIC ACIDS RES, V23, P670, DOI 10.1093/nar/23.4.670; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; World Health Organization, 1993, GLOB STRAT MAL CONTR	45	269	297	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					532	538		10.1038/22964	http://dx.doi.org/10.1038/22964			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448855				2022-12-01	WOS:000081854800046
J	Rosner, F				Rosner, F			Can an amulet cure leukemia?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		PREUSS J, 1993, BIBLICAL TALMUDIC ME, P146; Rosner F, 1999, MT SINAI J MED, V66, P102; ZIMMELS HJ, 1952, MAGICIANS THEOLOGIAN, P135	3	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					307	307		10.1001/jama.282.4.307	http://dx.doi.org/10.1001/jama.282.4.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432013				2022-12-01	WOS:000081596800001
J	Pauker, SG; Rothberg, M				Pauker, SG; Rothberg, M			Commentary: Resist jumping to conclusions	BRITISH MEDICAL JOURNAL			English	Editorial Material									New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Pauker, SG (corresponding author), New England Med Ctr, Box 302,750 Washington St, Boston, MA 02111 USA.							CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; GOLDRATT F, 1992, GOAL; Levy SB, 1992, ANTIBIOTIC PARADOX M; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; 1999, ALLIANCE PRUDENT USE	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1616	1617						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428553				2022-12-01	WOS:000080913100038
J	Fattori, R; Nienaber, CA; Descovich, B; Ambrosetto, P; Reggiani, LB; Pepe, G; Kaufmann, U; Negrini, N; von Kodolitsch, Y; Gensini, GF				Fattori, R; Nienaber, CA; Descovich, B; Ambrosetto, P; Reggiani, LB; Pepe, G; Kaufmann, U; Negrini, N; von Kodolitsch, Y; Gensini, GF			Importance of dural ectasia in phenotypic assessment of Marfan's syndrome	LANCET			English	Article							FIBRILLIN-1 FBN1; MUTATIONS	Background Early identification of Marfan's syndrome is fundamental in the prevention of aortic dilatation, but the wide phenotypic expression of the disorder makes the clinical diagnosis very difficult. Dural ectasia has been classified as a major diagnostic criterion; however, its prevalence is not known. We aimed to identify the true prevalence of dural ectasia in Marfan's syndrome, and to investigate its relation to aortic pathology. Methods A magnetic-resonance-imaging (MRI) study of the thoracic aorta and of the lumbosacral spine was done in an inclusive series of 83 patients with Marfan's syndrome to assess the presence and degree of dural ectasia and aortic involvement; 12 patients were younger than 18 years. 100 individuals who underwent MRI of the lumbar spine for routine clinical indications represented the control group; none of them had any potential causes for dural ectasia. Findings Dural ectasia was identified in 76 (92%) patients and none of the control group. The severity of dural ectasia was related to age; the mean (SD) age of patients with mild dural ectasia was 26 years (14) whereas that of those with severe disease (meningocele) was 36 years (9) (p=0.038). 11 of 12 patients younger than 18 years had dural ectasia. No association was found between aortic dilatation and dural ectasia. Interpretation Dural ectasia is a highly characteristic sign of Marian's syndrome, even at an early age.	Univ Hosp S Orsola, Inst Radiol, Bologna, Italy; Univ Hosp S Orsola, Neurol Inst, Bologna, Italy; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, Div Cardiol, D-20246 Hamburg, Germany; Univ Roma Tor Vergata, Dept Internal Med, Clin Biochem Sect, I-00173 Rome, Italy; Univ Hosp Careggi, Dept Internal Med & Cardiol, Florence, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University of Hamburg; University of Rome Tor Vergata; University of Florence; Azienda Ospedaliero Universitaria Careggi	Fattori, R (corresponding author), Osped S Orsola Malpighi, Ist Radiol Radiol 3, Via Massarenti 9, I-40100 Bologna, Italy.	ross@med.unibo.it	Fattori, Rossella/L-1017-2016; Pepe, Guglielmina/K-8013-2016; Bacchi Reggiani, Maria Letizia/O-2311-2014	Pepe, Guglielmina/0000-0001-9825-6618; Bacchi Reggiani, Maria Letizia/0000-0003-3985-1542				[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.0.CO;2-R; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DUNCAN RW, 1995, SPINE, V20, P1197, DOI 10.1097/00007632-199505150-00016; ELDADAH ZA, 1995, J CLIN INVEST, V95, P874, DOI 10.1172/JCI117737; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; Legget ME, 1996, HEART, V75, P389, DOI 10.1136/hrt.75.4.389; Milewicz DM, 1996, CIRCULATION, V94, P2708, DOI 10.1161/01.CIR.94.11.2708; MITCHELL GE, 1967, RADIOLOGY, V89, P67, DOI 10.1148/89.1.67; NELSON JD, 1958, BRIT J RADIOL, V31, P561, DOI 10.1259/0007-1285-31-370-561; PEPIN MG, 1992, AM J HUM GENET, V5, pA44; PYERITZ RE, 1988, AM J HUM GENET, V43, P726; PYERITZ RE, 1993, AM J MED GENET, V47, P127, DOI 10.1002/ajmg.1320470131; RAFTOPOULOS C, 1993, ACTA CHIR BELG, P1; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; SMITH MD, 1993, J BONE JOINT SURG AM, V75A, P1067, DOI 10.2106/00004623-199307000-00013; SONIER CB, 1993, J NEURORADIOLOGY, V20, P292; SOULEN RL, 1987, RADIOLOGY, V165, P697, DOI 10.1148/radiology.165.3.3685348; STERN WE, 1988, J NEUROSURG, V69, P221, DOI 10.3171/jns.1988.69.2.0221; ZANHKA KG, 1989, J AM COLL CARDIOL  S, V13, pA119	23	144	145	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					910	913		10.1016/S0140-6736(98)12448-0	http://dx.doi.org/10.1016/S0140-6736(98)12448-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489951				2022-12-01	WOS:000082511800014
J	Schmidt, A; Wolde, M; Thiele, C; Fest, W; Kratzin, H; Podtelejnikov, AV; Witke, W; Huttner, WB; Soling, HD				Schmidt, A; Wolde, M; Thiele, C; Fest, W; Kratzin, H; Podtelejnikov, AV; Witke, W; Huttner, WB; Soling, HD			Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid	NATURE			English	Article							ACYL-COENZYME-A; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; PHOSPHOLIPID-METABOLISM; TRANSPORT VESICLES; BINDING PARTNERS; PROTEIN; DYNAMIN; ENDOCYTOSIS; DOMAIN	Endophilin I is a presynaptic protein of unknown function that binds to dynamin, a GTPase that is implicated in endocytosis and recycling of synaptic vesicles. Here we show that endophilin I is essential for the formation of synaptic-like microvesicles (SLMVs) from the plasma membrane. Endophilin I exhibits lysophosphatidic acid acyl transferase (LPAAT) activity, and endophilin-I-mediated SLMV formation requires the transfer of the unsaturated fatty acid arachidonate to lysophosphatidic acid, converting it to phosphatidic acid. A deletion mutant lacking the SH3 domain through which endophilin I interacts with dynamin still exhibits LPAAT activity but no longer mediates SLMV formation. These results indicate that endophilin I may induce negative membrane curvature by converting an inverted-cone-shaped lipid to a cone-shaped lipid in the cytoplasmic leaflet of the bilayer. We propose that, through this action, endophilin I works with dynamin to mediate synaptic vesicle invagination from the plasma membrane and fission.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Heidelberg Univ, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Gottingen, Dept Clin Biochem, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg; Max Planck Society; University of Gottingen; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Huttner, WB (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 110, D-01307 Dresden, Germany.	whuttner@sun0.urz.uni-heidelberg.de; hsoelin@gwdg.de	Podtelejnikov, Alexandre/B-6120-2017; Huttner, Wieland B./P-4080-2018	Podtelejnikov, Alexandre/0000-0002-8124-6584; Schmidt, Anne/0000-0002-8326-0937				Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; DUZGUNES N, 1995, NATO ADV SCI INST SE, V91, P97; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; Kates M., 1986, TECHNIQUES LIPIDOLOG; Kirchhausen T, 1999, NATURE, V398, P470, DOI 10.1038/18989; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; LIPOWSKY R, 1993, BIOPHYS J, V64, P1133, DOI 10.1016/S0006-3495(93)81479-6; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MORRIS SA, 1995, CURR BIOL, V5, P113, DOI 10.1016/S0960-9822(95)00028-5; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SOLING HD, 1989, ADV ENZYME REGUL, V28, P35, DOI 10.1016/0065-2571(89)90062-9; SOLING HD, 1989, J BIOL CHEM, V264, P10643; SOLING HD, 1987, J BIOL CHEM, V262, P16786; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	49	436	457	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					133	141		10.1038/43613	http://dx.doi.org/10.1038/43613			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490020				2022-12-01	WOS:000082458800045
J	Katan, MB				Katan, MB			Functional foods	LANCET			English	Editorial Material									Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands; Agr Univ Wageningen, Div Human Nutr & Epidemiol, NL-6703 HD Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Katan, MB (corresponding author), Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands.							Bellisle F, 1998, BRIT J NUTR, V80, pS173, DOI 10.1079/BJN19980109; Diplock AT, 1999, BRIT J NUTR, V81, pS1, DOI 10.1017/S0007114599000471; Levin A, 1999, ANN INTERN MED, V131, P161, DOI 10.7326/0003-4819-131-2-199907200-00101; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559	6	14	15	4	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1999	354	9181					794	794						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485719				2022-12-01	WOS:000082400700006
J	Fernandez, G; Effern, A; Grunwald, T; Pezer, N; Lehnertz, K; Dumpelmann, M; Van Roost, D; Elger, CE				Fernandez, G; Effern, A; Grunwald, T; Pezer, N; Lehnertz, K; Dumpelmann, M; Van Roost, D; Elger, CE			Real-time tracking of memory formation in the human rhinal cortex and hippocampus	SCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; EVENT-RELATED POTENTIALS; EPISODIC MEMORY; ANTIEPILEPTIC DRUGS; SEMANTIC MEMORY; BRAIN ACTIVITY; SYSTEM; WORDS; ORGANIZATION; RECOGNITION	A fundamental question about human memory is which brain structures are involved, and when, in transforming experiences into memories. This experiment sought to identify neural correlates of memory formation with the use of intracerebral electrodes implanted in the brains of patients with temporal Lobe epilepsy. Event-related potentials (ERPs) were recorded directly from the medial temporal Lobe (MTL) as the patients studied single words. ERPs elicited by words subsequently recalled in a memory test were contrasted with ERPs elicited by unrecalled words. Memory formation was associated with distinct but interrelated ERP differences within the rhinal cortex and the hippocampus, which arose after about 300 and 500 milliseconds, respectively. These findings suggest that declarative memory formation is dissociable into subprocesses and sequentially organized within the MTL.	Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany; Univ Bonn, Dept Radiat & Nucl Phys, D-53105 Bonn, Germany; Univ Bonn, Dept Neurosurg, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Fernandez, G (corresponding author), Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany.		Duempelmann, Matthias/K-2583-2012; Fernandez, Guillen/B-3771-2009	Duempelmann, Matthias/0000-0002-1476-7777; Fernandez, Guillen/0000-0002-5522-0604; Lehnertz, Klaus/0000-0002-5529-8559				AGGLETON JP, IN PRESS BEHAV BRAIN; Akaho R, 1996, PSYCHIAT CLIN NEUROS, V50, P61, DOI 10.1111/j.1440-1819.1996.tb01665.x; Amaral DG, 1990, HUMAN NERVOUS SYSTEM, P711; Baayen R. H., 1993, CELEX LEXICAL DATABA; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Chen YJ, 1996, EPILEPSIA, V37, P81, DOI 10.1111/j.1528-1157.1996.tb00516.x; Cohen, 1993, MEMORY AMNESIA HIPPO, DOI 10.1136/jnnp.58.1.128-a; Dolan RJ, 1999, HIPPOCAMPUS, V9, P25, DOI 10.1002/(SICI)1098-1063(1999)9:1<25::AID-HIPO3>3.0.CO;2-4; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Elger CE, 1997, NEUROPSYCHOLOGIA, V35, P657, DOI 10.1016/S0028-3932(96)00110-8; Fernandez G, 1998, PSYCHOPHYSIOLOGY, V35, P709, DOI 10.1017/S0048577298970500; Fernandez G, 1999, HIPPOCAMPUS, V9, P35, DOI 10.1002/(SICI)1098-1063(1999)9:1<35::AID-HIPO4>3.0.CO;2-Z; Fernandez G, 1998, J NEUROSCI, V18, P1841; Gleissner U, 1997, NEUROREPORT, V8, P2893, DOI 10.1097/00001756-199709080-00018; Gregg V., 1976, RECALL RECOGNITION, P183; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; HEIT G, 1988, NATURE, V333, P773, DOI 10.1038/333773a0; Henke K, 1999, P NATL ACAD SCI USA, V96, P5884, DOI 10.1073/pnas.96.10.5884; JACKSON GD, 1996, MRI NEUROANATOMY; JONESGOTMAN M, 1991, EPILEPSY SURG, P469; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; KLEE M, 1977, J NEUROPHYSIOL, V40, P647, DOI 10.1152/jn.1977.40.3.647; KUTAS M, 1997, COGNITIVE NEUROSCIEN, P197; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; NEVILLE HJ, 1986, J MEM LANG, V25, P75, DOI 10.1016/0749-596X(86)90022-7; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; PALLER KA, 1992, ELECTROEN CLIN NEURO, V84, P269, DOI 10.1016/0168-5597(92)90008-Y; PALLER KA, 1990, J EXP PSYCHOL LEARN, V16, P1021, DOI 10.1037/0278-7393.16.6.1021; Panagopoulos GR, 1997, ACTA NEUROL SCAND, V96, P62; Picton T, 1995, HDB NEUROPSYCHOLOGY, V10, P3; RINGO JL, 1995, J NEUROPHYSIOL, V73, P1712, DOI 10.1152/jn.1995.73.4.1712; RUGG MD, 1995, NEUROPSYCHOLOGIA, V33, P471, DOI 10.1016/0028-3932(94)00132-9; Rugg MD, 1998, HUM BRAIN MAPP, V6, P394, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<394::AID-HBM12>3.3.CO;2-G; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; SUZUKI WA, 1994, J NEUROSCI, V14, P1856, DOI 10.1523/JNEUROSCI.14-03-01856.1994; Tulving E., 1972, ORGAN MEM, V1, P381, DOI DOI 10.1017/S0140525X00047257; UNDERWOO.BJ, 1969, PSYCHOL REV, V76, P559, DOI 10.1037/h0028143; Van Roost D, 1998, NEUROSURGERY, V43, P819, DOI 10.1097/00006123-199810000-00058; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	51	243	245	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1582	1585		10.1126/science.285.5433.1582	http://dx.doi.org/10.1126/science.285.5433.1582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477525				2022-12-01	WOS:000082359500070
J	Jana, N; Vasishta, K; Saha, SC; Ghosh, K				Jana, N; Vasishta, K; Saha, SC; Ghosh, K			Obstetrical outcomes among women with extrapulmonary tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY TUBERCULOSIS; PREGNANCY	Background The prevalence of tuberculosis, especially extrapulmonary tuberculosis, is increasing worldwide. Because information on the outcome of pregnancy among women with extrapulmonary tuberculosis is limited, we studied the course of pregnancy and labor and the perinatal outcome in these women and their infants. Methods From 1983 to 1993, we followed 33 pregnant women who had extrapulmonary tuberculosis (12 with tuberculous lymphadenitis and 9 with intestinal, 7 with skeletal, 2 with renal, 2 with meningeal, and 1 with endometrial tuberculosis) through their deliveries. Of the 33, 29 received antituberculosis treatment during pregnancy. The antenatal complications, intrapartum events, and perinatal outcomes were compared with those among 132 healthy pregnant women without tuberculosis who were matched for age, parity, and socioeconomic status. Results Tuberculous lymphadenitis did not affect the course of pregnancy or labor or the perinatal outcome. However, as compared with the control women, the 21 women with tubercular involvement of other extrapulmonary sites had higher rates of antenatal hospitalization (24 percent vs. 2 percent, P< 0.001), infants with low Apgar scores (less than or equal to 6) soon after birth (19 percent vs. 3 percent, P=0.01), and low-birth-weight (<2500 g) infants (33 percent vs. 11 percent, P=0.01). Conclusions Extrapulmonary tuberculosis that is confined to the lymph nodes has no effect on obstetrical outcomes, but tuberculosis at other extrapulmonary sites does adversely affect the outcome of pregnancy. (N Engl J Med 1999;341:645-9.) (C) 1999, Massachusetts Medical Society.	Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India; Mem Hosp, Dept Obstet & Gynaecol, Darlington, Durham, England; W Middlesex Univ Hosp, Dept Obstet & Gynaecol, Isleworth, Middx, England	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Imperial College London	Vasishta, K (corresponding author), Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India.		JANA, NARAYAN/AAE-5437-2020					BROOKS JH, 1986, BRIT J OBSTET GYNAEC, V93, P1009, DOI 10.1111/j.1471-0528.1986.tb08027.x; CASPER GR, 1995, AUST NZ J OBSTET GYN, V35, P398, DOI 10.1111/j.1479-828X.1995.tb02151.x; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P1083; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DAVIES PDO, 1993, THORAX, V48, P193, DOI 10.1136/thx.48.3.193; DWYER DE, 1987, AUST NZ J MED, V17, P507, DOI 10.1111/j.1445-5994.1987.tb00110.x; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GOVENDER S, 1989, S AFR MED J, V75, P190; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7; KINGDOM JCP, 1989, BRIT J OBSTET GYNAEC, V96, P233, DOI 10.1111/j.1471-0528.1989.tb01668.x; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LAU SK, 1991, J LARYNGOL OTOL, V105, P558, DOI 10.1017/S0022215100116603; MARGONO F, 1994, OBSTET GYNECOL, V83, P911, DOI 10.1097/00006250-199406000-00001; SCHAEFER G, 1954, AM J OBSTET GYNECOL, V67, P605, DOI 10.1016/0002-9378(54)90050-2; SIMPSON ML, 1989, ORTHOPAEDIC INFECT D, P205; SNIDER DE, 1980, AM REV RESPIR DIS, V122, P65; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TULI SM, 1991, TUBERCULOSIS SKELETA, P162; VARMA TR, 1991, INT J GYNECOL OBSTET, V35, P1, DOI 10.1016/0020-7292(91)90056-B; *WHO, 1993, TREATM TUB GUID NAT, P3; 1985, INDIAN J TUBERC, V32, P115	22	76	80	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					645	649		10.1056/NEJM199908263410903	http://dx.doi.org/10.1056/NEJM199908263410903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460815				2022-12-01	WOS:000082192500003
J	Ma, WY; Korngreen, A; Uzlaner, N; Priel, Z; Silberberg, SD				Ma, WY; Korngreen, A; Uzlaner, N; Priel, Z; Silberberg, SD			Extracellular sodium regulates airway ciliary motility by inhibiting a P2X receptor	NATURE			English	Article							HYPERTONIC SALINE AEROSOL; CYSTIC-FIBROSIS; MUCOCILIARY CLEARANCE; SURFACE LIQUID; HUMAN LUNG; EPITHELIA; INHALATION; INCREASES; HEALTHY; FLUID	The mucociliary system is responsible for clearing inhaled particles and pathogens from the airways, This important task is performed by the beating of cilia and the consequent movement of mucus from the lungs to the upper airways(1,2). Because ciliary motility is enhanced by elevated intracellular calcium concentrations, inhibition of calcium influx could lead to disease by jeopardizing mucociliary clearance. Several hormones and neurotransmitters stimulate ciliary motility, one of the most potent of which is extracellular ATP (ATP(0))(1), which acts by releasing calcium ions from internal stores and by activating calcium influx(3-5). Here we show that, in airway ciliated cells, extracellular sodium ions (Na-0(+)) specifically and competitively inhibit an ATP. gated channel that is permeable to calcium ions, and thereby attenuate ATP(0)-induced ciliary motility, Our finding points to a physiological role for Na-0(+) in ciliary function, and indicates that mucociliary clearance might be improved in respiratory disorders such as chronic bronchitis and cystic fibrosis by decreasing the sodium concentration of the airway surface fluid in which the cilia are bathed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Silberberg, SD (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.		Silberberg, Shai/ABA-2778-2020	Korngreen, Alon/0000-0002-2036-6160				Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Boitano S, 1997, AM J PHYSIOL-LUNG C, V272, pL1189, DOI 10.1152/ajplung.1997.272.6.L1189; Daviskas E, 1997, EUR RESPIR J, V10, P2449, DOI 10.1183/09031936.97.10112449; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.3.CO;2-R; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hull J, 1998, AM J RESP CRIT CARE, V157, P10, DOI 10.1164/ajrccm.157.1.9703045; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; SILBERBERG A, 1990, BIORHEOLOGY, V27, P295; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Uzlaner N, 1999, J PHYSIOL-LONDON, V516, P179, DOI 10.1111/j.1469-7793.1999.179aa.x; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	24	64	68	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					894	897		10.1038/23743	http://dx.doi.org/10.1038/23743			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476971				2022-12-01	WOS:000082233200051
J	Moreno, E; Morata, G				Moreno, E; Morata, G			Caudal is the Hox gene that specifies the most posterior Drosophile segment	NATURE			English	Article							PROXIMAL-DISTAL AXIS; BRACHYURY GENE; HOMEOBOX GENES; GENITAL DISC; PROTEIN; MELANOGASTER; HEDGEHOG; EXPRESSION; ENCODES; ORGANIZATION	The homeobox gene caudal (can) has a maternal embryonic function that establishes the antero-posterior body axis of Drosophila(1,2). It also has a conserved(2,4) late embryonic and imaginal function(1) related to the development of the posterior body region. Here we report the developmental role of can in adult Drosophila, It is required for the normal development of the analia structures, which derive from the most posterior body segment. In the absence of cad function, the analia develop like the immediately anterior segment (male genitalia), following the transformation rule of the canonical Hox genes(5), We also show that cad can induce ectopic analia development if expressed in the head or wing. We propose that cad is the Hox gene that determines the development of the fly's most posterior segment. cad acts in combination with the Hedgehog (Hh) pathway(6) to specify the different components of the analia: the activities of cad and of the Hh pathway induce Distal-less expression that, together with cad, promote external analia development. In the absence of the Hh pathway, cad induces internal analia development, probably by activating the brachyenteron and even-skipped genes.	UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Morata, G (corresponding author), UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain.		Moreno, Eduardo/D-7262-2011	Morata, Gines/0000-0003-3274-5173; moreno, eduardo/0000-0001-5040-452X				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; Casares F, 1997, DEV GENES EVOL, V207, P216, DOI 10.1007/s004270050110; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; EPPER F, 1983, ROUX ARCH DEV BIOL, V192, P270, DOI 10.1007/BF00848659; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Gorfinkiel N, 1997, GENE DEV, V11, P2259, DOI 10.1101/gad.11.17.2259; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MURAKAMI R, 1995, ROUX ARCH DEV BIOL, V205, P89, DOI 10.1007/BF00188847; NOTHIGER R, 1977, ROUX ARCH DEV BIOL, V181, P367, DOI 10.1007/BF00848062; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; Sanchez L, 1997, DEV GENES EVOL, V207, P229, DOI 10.1007/s004270050111; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SINGER JB, 1996, DEVELOPMENT, V122, P3703; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wu LH, 1998, DEVELOPMENT, V125, P2433	28	111	114	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					873	877		10.1038/23709	http://dx.doi.org/10.1038/23709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476966				2022-12-01	WOS:000082233200046
J	Wang, SL; Hawkins, CJ; Yoo, SJ; Muller, HAJ; Hay, BA				Wang, SL; Hawkins, CJ; Yoo, SJ; Muller, HAJ; Hay, BA			The Drosophila caspase inhibitor DIAP1 is essential for cell survival and is negatively regulated by HID	CELL			English	Article							REAPER-INDUCED APOPTOSIS; BACULOVIRUS INHIBITOR; NURSE CELLS; DEATH; GENE; PROTEINS; GRIM; MELANOGASTER; EXPRESSION; PROTEASES	Drosophila Reaper (RPR), Head Involution Defective (HID), and GRIM induce caspase-dependent cell death and physically interact with the cell death inhibitor DIAP1. Here we show that HID blocks DIAP1's ability to inhibit caspase activity and provide evidence suggesting that RPR and GRIM can act similarly. Based on these results, we propose that RPR, HID, and GRIM promote apoptosis by disrupting productive IAP-caspase interactions and that DIAP1 is required to block apoptosis-inducing caspase activity. Supporting this hypothesis, we show that elimination of DIAP1 function results in global early embryonic cell death and a large increase in DIAP1-inhibitable caspase activity and that DIAP1 is still required for cell survival when expression of rpr, hid, and grim is eliminated.	CALTECH, Div Biol MC156 29, Pasadena, CA 91125 USA; Univ Dusseldorf, Genet Inst, D-40225 Dusseldorf, Germany	California Institute of Technology; Heinrich Heine University Dusseldorf	Muller, HAJ (corresponding author), CALTECH, Div Biol MC156 29, Pasadena, CA 91125 USA.		Muller, Hans-Arno/Q-2864-2019; Hawkins, Christine/B-8769-2011; Müller, Hans-Arno/G-5753-2012	Muller, Hans-Arno/0000-0002-7525-6874; Hawkins, Christine/0000-0001-8120-1071; Müller, Hans-Arno/0000-0002-7525-6874	NIGMS NIH HHS [GM057422-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Cavaliere V, 1998, DEV GENES EVOL, V208, P106, DOI 10.1007/s004270050160; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	49	417	432	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					453	463		10.1016/S0092-8674(00)81974-1	http://dx.doi.org/10.1016/S0092-8674(00)81974-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481910	Bronze			2022-12-01	WOS:000082174900006
J	Luo, RZT; Beniac, DR; Fernandes, A; Yip, CC; Ottensmeyer, FP				Luo, RZT; Beniac, DR; Fernandes, A; Yip, CC; Ottensmeyer, FP			Quaternary structure of the insulin-insulin receptor complex	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; BINDING; DOMAIN; IMAGES; FAMILY; SITE	The three-dimensional (3D) structure of the intrinsically dimeric insulin receptor bound to its ligand, insulin, was determined by electron cryomicroscopy. Gold-labeled insulin served to locate the insulin-binding domain. The 3D structure was then fitted with available known high-resolution domain substructures to obtain a detailed contiguous model for this heterotetrameric transmembrane receptor. The 3D reconstruction indicates that the two alpha subunits jointly participate in insulin binding and that the kinase domains in the two beta subunits are in a juxtaposition that permits autophosphorylation of tyrosine residues in the first step of insulin receptor activation.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Yip, CC (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CHRISTENSEN C, 1998, J BIOL CHEM, V273, P17780; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEMEYTS P, 1993, EXP CLIN ENDOCRINOL, V101, P17; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EGERTON RF, 1996, ELECT ENERGY LOSS SP, P145; FABRY M, 1992, J BIOL CHEM, V267, P8950; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; FARROW NA, 1993, ULTRAMICROSCOPY, V52, P141, DOI 10.1016/0304-3991(93)90185-Z; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GEIGER R, 1971, Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, V352, P1487, DOI 10.1515/bchm2.1971.352.2.1487; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Mulhern TD, 1998, TRENDS BIOCHEM SCI, V23, P465, DOI 10.1016/S0968-0004(98)01288-2; MURRAYRUST J, 1992, BIOESSAYS, V14, P325, DOI 10.1002/bies.950140507; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SCHAFFER L, 1993, EXP CLIN ENDOCRINOL, V101, P7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Smith GD, 1996, PROTEIN SCI, V5, P1502, DOI 10.1002/pro.5560050806; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; UILRICH A, 1990, CELL, V61, P203; WHITE MF, 1994, J BIOL CHEM, V269, P1; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105	28	106	113	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1077	1080		10.1126/science.285.5430.1077	http://dx.doi.org/10.1126/science.285.5430.1077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446056				2022-12-01	WOS:000082033100049
J	Sassone-Corsi, P; Mizzen, CA; Cheung, P; Crosio, C; Monaco, L; Jacquot, S; Hanauer, A; Allis, CD				Sassone-Corsi, P; Mizzen, CA; Cheung, P; Crosio, C; Monaco, L; Jacquot, S; Hanauer, A; Allis, CD			Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3	SCIENCE			English	Article							MITOTIC CHROMOSOME CONDENSATION; PROTEIN; TRANSCRIPTION; PP90(RSK); KINASES; SIGNAL; CBP; MAP; ACETYLTRANSFERASE; HYPERACETYLATION	During the immediate-early response of mammalian cells to mitogens, histone H3 is rapidly and transiently phosphorylated by one or more unidentified kinases. Rsk-2, a member of the pp90(rsk) family of kinases implicated in growth control, was required for epidermal growth factor (EGF)-stimulated phosphorylation of H3. RSK-2 mutations in humans are Linked to Coffin-Lowry syndrome (CLS). Fibroblasts derived from a CLS patient failed to exhibit EGF-stimulated phosphorylation of H3, although H3 was phosphorylated during mitosis. Introduction of the wild-type RSK-2 gene restored EGF-stimulated phosphorylation of H3 in CLS cells. In addition, disruption of the RSK-2 gene by homologous recombination in murine embryonic stem cells abolished EGF-stimulated phosphorylation of H3. H3 appears to be a direct or indirect target of Rsk-2, suggesting that chromatin remodeling might contribute to mitogen-activated protein kinase-regulated gene expression.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Strasbourg, France; Univ Virginia, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Virginia	Sassone-Corsi, P (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Strasbourg, France.		Sassone-Corsi, Paolo/H-6182-2011; Monaco, Lucia/A-4031-2010		NIGMS NIH HHS [GM40922] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALLIS CD, UNPUB; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHADEE DN, IN PRESS J BIOL CHEM; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Dierich A, 1997, METHODS IN DEVELOPMENTAL TOXICOLOGY AND BIOLOGY, P111; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; SASSONECORSI P, UNPUB; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wolffe AP, 1997, BIOCHEM SOC T, V25, P354, DOI 10.1042/bst0250354; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	29	405	418	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					886	891		10.1126/science.285.5429.886	http://dx.doi.org/10.1126/science.285.5429.886			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436156				2022-12-01	WOS:000081860900048
J	Winzeler, EA; Shoemaker, DD; Astromoff, A; Liang, H; Anderson, K; Andre, B; Bangham, R; Benito, R; Boeke, JD; Bussey, H; Chu, AM; Connelly, C; Davis, K; Dietrich, F; Dow, SW; EL Bakkoury, M; Foury, F; Friend, SH; Gentalen, E; Giaever, G; Hegemann, JH; Jones, T; Laub, M; Liao, H; Liebundguth, N; Lockhart, DJ; Lucau-Danila, A; Lussier, M; M'Rabet, N; Menard, P; Mittmann, M; Pai, C; Rebischung, C; Revuelta, JL; Riles, L; Roberts, CJ; Ross-MacDonald, P; Scherens, B; Snyder, M; Sookhai-Mahadeo, S; Storms, RK; Veronneau, S; Voet, M; Volckaert, G; Ward, TR; Wysocki, R; Yen, GS; Yu, KX; Zimmermann, K; Philippsen, P; Johnston, M; Davis, RW				Winzeler, EA; Shoemaker, DD; Astromoff, A; Liang, H; Anderson, K; Andre, B; Bangham, R; Benito, R; Boeke, JD; Bussey, H; Chu, AM; Connelly, C; Davis, K; Dietrich, F; Dow, SW; EL Bakkoury, M; Foury, F; Friend, SH; Gentalen, E; Giaever, G; Hegemann, JH; Jones, T; Laub, M; Liao, H; Liebundguth, N; Lockhart, DJ; Lucau-Danila, A; Lussier, M; M'Rabet, N; Menard, P; Mittmann, M; Pai, C; Rebischung, C; Revuelta, JL; Riles, L; Roberts, CJ; Ross-MacDonald, P; Scherens, B; Snyder, M; Sookhai-Mahadeo, S; Storms, RK; Veronneau, S; Voet, M; Volckaert, G; Ward, TR; Wysocki, R; Yen, GS; Yu, KX; Zimmermann, K; Philippsen, P; Johnston, M; Davis, RW			Functional characterization of the S-cerevisiae genome by gene deletion and parallel analysis	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; YEAST GENOME; DNA-SEQUENCE; PROTEIN; IDENTIFICATION; DISRUPTION; EXPRESSION; LOCALIZATION; REDUCTASE	The functions of many open reading frames (ORFs) identified in genome-sequencing projects are unknown. New, whole-genome approaches are required to systematically determine their function. A total of 6925 Saccharomyces cerevisiae strains were constructed, by a high-throughput strategy, each with a precise deletion of one of 2026 ORFs (more than one-third of the ORFs in the genome). Of the deleted ORFs, 17 percent were essential for viability in rich medium. The phenotypes of more than 500 deletion strains were assayed in parallel. Of the deletion strains, 40 percent showed quantitative growth defects in either rich or minimal medium.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Rosetta Inpharmat Inc, Kirkland, WA 98034 USA; Free Univ Brussels, Lab Physiol Cellulaire & Genet Levures, Brussels, Belgium; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Salamanca, Dipartimento Microbiol & Genet, Edificio Dept 323, CSIC, E-37007 Salamanca, Spain; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Basel, Biozentrum, Dept Mol Microbiol, CH-4003 Basel, Switzerland; ULB, IRMW, B-1070 Brussels, Belgium; Catholic Univ Louvain, FYSA, B-1348 Louvain, Belgium; Affymetrix, Santa Clara, CA 95051 USA; Inst Microbiol, D-40225 Dusseldorf, Germany; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium	Stanford University; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Yale University; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Johns Hopkins University; McGill University; University of Basel; Universite Libre de Bruxelles; Universite Catholique Louvain; Affymetrix; Washington University (WUSTL); KU Leuven	Davis, RW (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	dbowe@cmgm.stanford.edu	BENITO, ROCIO/B-4271-2017; André, Bruno/D-1725-2010; Storms, Reginald/B-2405-2013; Johnston, Mark/R-6156-2019; Winzeler, Elizabeth/AAP-6752-2020; Revuelta, Jose Luis/ABG-1502-2020; Johnston, Mark/K-3543-2019; Zhang, Ning/F-1387-2014; Revuelta, Jose L/C-2324-2012; Lucau-Danila, Anca/AAE-7674-2021	BENITO, ROCIO/0000-0001-9781-4198; Winzeler, Elizabeth/0000-0002-4049-2113; Revuelta, Jose Luis/0000-0001-7838-5308; Johnston, Mark/0000-0002-4932-7229; Revuelta, Jose L/0000-0001-7838-5308; LUCAU-DANILA, Anca/0000-0002-9379-6241; Snyder, Michael/0000-0003-0784-7987; Gentalen, Erik/0000-0002-7982-2431; Wysocki, Robert/0000-0002-3274-2629; Menard, Patrice/0000-0001-8844-3727	NHGRI NIH HHS [HG00185-02, HG01633, HG01627] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001627, R01HG001633] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Baganz F, 1998, YEAST, V14, P1417, DOI 10.1002/(SICI)1097-0061(199811)14:15<1417::AID-YEA334>3.0.CO;2-N; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brachmann CB, 1998, YEAST, V14, P115; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CHOW TYK, 1992, J CELL SCI, V101, P709; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; KASAHARA S, 1994, J BACTERIOL, V176, P1488, DOI 10.1128/jb.176.5.1488-1499.1994; LASHKARI DA, 1995, P NATL ACAD SCI USA, V92, P7912, DOI 10.1073/pnas.92.17.7912; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; NIEDENTHAL R, IN PRESS YEAST; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Rad MR, 1997, YEAST, V13, P281; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Storms RK, 1997, GENOME, V40, P151, DOI 10.1139/g97-022; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.0.CO;2-K; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	37	3047	3189	4	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					901	906		10.1126/science.285.5429.901	http://dx.doi.org/10.1126/science.285.5429.901			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436161				2022-12-01	WOS:000081860900053
J	Yoshida, H; Shiratori, Y; Moriyama, M; Arakawa, Y; Ide, T; Sata, M; Inoue, O; Yano, M; Tanaka, M; Fujiyama, S; Nishiguchi, S; Kuroki, T; Imazeki, F; Yokosuka, O; Kinoyama, S; Yamada, G; Omata, M				Yoshida, H; Shiratori, Y; Moriyama, M; Arakawa, Y; Ide, T; Sata, M; Inoue, O; Yano, M; Tanaka, M; Fujiyama, S; Nishiguchi, S; Kuroki, T; Imazeki, F; Yokosuka, O; Kinoyama, S; Yamada, G; Omata, M		IHIT Study Grp	Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; carcinoma, hepatocellular; interferon; liver cirrhosis; alanine aminotransferase	POLYMERASE CHAIN-REACTION; PLACEBO-CONTROLLED TRIAL; NON-B-HEPATITIS; VIRUS-RNA; NON-A; SUSTAINED RESPONSE; LIVER-DISEASE; ALFA THERAPY; DOUBLE-BLIND; EFFICACY	Background: Previous studies on the effect of interferon therapy on the incidence of hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk factor for hepatocellular carcinoma. Objective: To evaluate the effect of interferon therapy on incidence of hepatocellular carcinoma, adjusting for risk factors, including the degree of liver fibrosis. Design: Retrospective cohort study. Setting: Seven university hospitals and one regional core hospital in Japan. Patients: 2890 patients with chronic hepatitis C who had undergone liver biopsy since 1986. Of these patients, 2400 received interferon and 490 were untreated. Measurements: The degree of liver fibrosis was assessed from stage F0 (no fibrosis) to stage F4 (cirrhosis). Response to interferon was determined virologically and biochemically. Screening for development of hepatocellular carcinoma was performed periodically during an average follow-up of 4.3 years. Effect of interferon therapy on the risk for hepatocellular carcinoma was analyzed by using Cox proportional hazards regression. Results: Hepatocellular carcinoma developed in 89 interferon-treated patients and in 59 untreated patients. Among untreated patients, the annual incidence of hepatocellular carcinoma increased with the degree of liver fibrosis, from 0.5% among patients with stage F0 or F1 fibrosis to 7.9% among patients with stage F4 fibrosis. The cumulative incidence in treated and untreated patients differed significantly for patients with stage F2 fibrosis (P = 0.0128) and for those with stage F3 fibrosis (P = 0.0011). In multivariate analysis, interferon therapy was associated with a reduced risk for hepatocellular carcinoma (adjusted risk ratio, 0.516 [95% CI, 0.358 to 0.742]; P < 0.001), especially among patients with sustained virologic response (risk ratio, 0.197 [CI, 0.099 to 0.392]), among those with persistently normal serum alanine aminotransferase levels (risk ratio, 0.197 [CI, 0.104 to 0.375]), and among those with alanine aminotransferase levels less than two times the upper limit of normal (risk ratio, 0.358 [CI, 0.206 to 0.622]). Conclusions: Interferon therapy significantly reduces the risk for hepatocellular carcinoma, especially among virologic or biochemical responders.	Univ Tokyo, Dept Gastroenterol, Tokyo 1138655, Japan; Univ Tokyo, Dept Gastroenterol, Tokyo 113, Japan; Nihon Univ, Dept Internal Med 3, Tokyo 173, Japan; Kurume Univ, Dept Internal Med 2, Fukuoka 830, Japan; Nagasaki Chuo Natl Hosp, Dept Clin Res, Nagasaki 856, Japan; Kumamoto Univ, Dept Internal Med 3, Kumamoto 860, Japan; Osaka City Univ, Dept Internal Med 3, Osaka 545, Japan; Chiba Univ, Dept Internal Med 1, Chiba 260, Japan; Kawasaki Med Sch, Ctr Liver, Okayama 700, Japan	University of Tokyo; University of Tokyo; Nihon University; Kurume University; Kumamoto University; Osaka Metropolitan University; Chiba University; Kawasaki Medical School	Yoshida, H (corresponding author), Univ Tokyo, Dept Gastroenterol, Hongo 7-3-1, Tokyo 1138655, Japan.	yoshida-2im@h.u-tokyo.ac.jp						Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; DIBISCEGLIE AM, 1995, SEMIN LIVER DIS, V15, P64, DOI 10.1055/s-2007-1007263; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1016/0270-9139(93)90500-M; KATO Y, 1994, CANCER, V74, P2234, DOI 10.1002/1097-0142(19941015)74:8<2234::AID-CNCR2820740805>3.0.CO;2-6; KAWANO SI, 1994, J GASTROEN HEPATOL, V9, P217, DOI 10.1111/j.1440-1746.1994.tb01712.x; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OMATA M, 1991, DIGEST DIS SCI, V36, P1217, DOI 10.1007/BF01307512; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1996, HEPATOLOGY, V24, P778; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Shiratori Y, 1997, GASTROENTEROLOGY, V113, P558, DOI 10.1053/gast.1997.v113.pm9247476; Shiratori Y, 1996, J GASTROEN HEPATOL, V11, P705, DOI 10.1111/j.1440-1746.1996.tb00318.x; Silini E, 1996, GASTROENTEROLOGY, V111, P199, DOI 10.1053/gast.1996.v111.pm8698200; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; TAKANO S, 1995, HEPATOLOGY, V21, P650; TAKEDA T, 1993, GASTROENTEROL JPN, V28, P104, DOI 10.1007/BF02989218; TANAKA E, 1995, J GASTROEN HEPATOL, V10, P538, DOI 10.1111/j.1440-1746.1995.tb01344.x; TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7; Tarao K, 1997, CANCER, V79, P688, DOI 10.1002/(SICI)1097-0142(19970215)79:4<688::AID-CNCR5>3.0.CO;2-A; YAMADA G, 1993, GUT, V34, pS133, DOI 10.1136/gut.34.2_Suppl.S133; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; YOKOSUKA O, 1995, GUT, V37, P721, DOI 10.1136/gut.37.5.721; Yoshida H, 1996, RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, P543	36	900	931	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					174	+		10.7326/0003-4819-131-3-199908030-00003	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428733				2022-12-01	WOS:000081788700002
J	Kondrashov, AS; Kondrashov, FA				Kondrashov, AS; Kondrashov, FA			Interactions among quantitative traits in the course of sympatric speciation	NATURE			English	Article							SEXUAL SELECTION; LAKE-VICTORIA; MODEL; EVOLUTION; CICHLIDS; BARBS	Sympatric speciation, the origin of two or more species from a single local population, has almost certainly been involved in formation of several species flocks(1-4), and may be fairly common in nature(5). The most straightforward scenario for sympatric speciation requires disruptive selection favouring two substantially different phenotypes, and consists of the evolution of reproductive isolation between them followed by the elimination of all intermediate phenotypes(6). Here we use the hypergeometric phenotypic model(7-10) to show that sympatric speciation is possible even when fitness and mate choice depend on different quantitative traits, so that speciation must involve formation of covariance between these traits. The increase in the number of variable loci affecting fitness facilitates sympatric speciation, whereas the increase in the number of variable loci affecting mate choice has the opposite effect. These predictions may enable more cases of sympatric speciation to be identified.	Simons Rock Coll, Great Barrington, MA 01230 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Kondrashov, FA (corresponding author), Simons Rock Coll, 84 Alford Rd, Great Barrington, MA 01230 USA.		Kondrashov, Fyodor Alexeevich/H-6331-2015	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694				AXELROD HR, 1996, MOST COMPLETE COLORE; BARTON NH, 1992, EVOLUTION, V46, P551, DOI 10.2307/2409871; Berrebi P, 1998, BIOL J LINN SOC, V64, P369; Darwin C., 1859, ORIGIN SPECIES MEANS; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Galis F, 1998, TRENDS ECOL EVOL, V13, P1, DOI 10.1016/S0169-5347(97)01239-1; Johnson TC, 1996, SCIENCE, V273, P1091, DOI 10.1126/science.273.5278.1091; KARLIN S, 1975, THEOR POPUL BIOL, V7, P364, DOI 10.1016/0040-5809(75)90025-8; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; KONDRASHOV AS, 1986, THEOR POPUL BIOL, V29, P1, DOI 10.1016/0040-5809(86)90002-X; KONDRASHOV AS, 1986, BIOL J LINN SOC, V27, P201, DOI 10.1111/j.1095-8312.1986.tb01734.x; KONDRASHOV AS, 1984, GENETIKA+, V20, P408; Kondrashov AS, 1998, ENDLESS FORMS, P90; Lewontin RC., 1966, SYST ZOOL, V15, P141, DOI [10.2307/2411632, DOI 10.2307/2411632]; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; Mina MV, 1996, J FISH BIOL, V48, P383, DOI 10.1006/jfbi.1996.0040; RICE WR, 1984, EVOLUTION, V38, P1251, DOI 10.1111/j.1558-5646.1984.tb05647.x; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Ritchie MG, 1998, ENDLESS FORMS, P291; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Seehausen O, 1998, BEHAV ECOL SOCIOBIOL, V42, P1, DOI 10.1007/s002650050405; Shpak M, 1999, EVOLUTION, V53, P600, DOI 10.1111/j.1558-5646.1999.tb03794.x; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093; van Doorn GS, 1998, P ROY SOC B-BIOL SCI, V265, P1915, DOI 10.1098/rspb.1998.0520; Wallace A.R., 1989, DARWINISM	27	418	431	0	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					351	354		10.1038/22514	http://dx.doi.org/10.1038/22514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432111				2022-12-01	WOS:000081590000046
J	Ghose, RP; Hall, PM; Bravo, EL				Ghose, RP; Hall, PM; Bravo, EL			Medical management of aldosterone-producing adenomas	ANNALS OF INTERNAL MEDICINE			English	Article						aldosterone; adenoma; hypertension; potassium; aldosteronism	DIAGNOSIS	Background: No data are available on the long-term medical management of aldosterone-producing adenomas. Objective: To demonstrate the efficacy of medical management of aldosterone-producing adenomas in terms of blood pressure and serum potassium concentration and to discuss morbidity associated with medical management. Design: Retrospective cohort study. Setting: Large tertiary care referral center. Patients: 24 patients with documented aldosterone-producing adenomas who were treated medically for at least 5 years. Measurements: Aldosterone excretion rate, plasma renin activity, and size and location of adenomas (by computed tomography). Blood pressure and serum electrolytes were measured at the time of diagnosis and last follow-up. Results: From the time of diagnosis to the time of last follow-up, systolic blood pressure decreased from 175 mm Hg to 129 mm Hg (95% CI for difference, 37.1 to 53.8 mm Hg) and diastolic blood pressure decreased from 106 mm Hg to 79 mm Hg (CI for difference, 20.8 to 33.9 mm Hg). Serum potassium concentration increased from 3.0 mmol/L to 4.3 mmol/L (CI for difference, 1.1 to 1.5 mmol/L). Conclusions: Medical management of aldosterone-producing adenomas is a viable option for controlling blood pressure and serum potassium concentration.	Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hall, PM (corresponding author), Cleveland Clin Fdn, Dept Hypertens & Nephrol, 9500 Euclid Ave,Desk A101, Cleveland, OH 44195 USA.	hallpm@ccf.org						BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1993, CLEV CLIN J MED, V60, P379; BRAVO EL, 1988, HYPERTENSION, V11, P207; CONN JN, 1965, J LAB CLIN MED, V45, P3; LITCHFIELD WR, 1995, ENDOCRIN METAB CLIN, V24, P593, DOI 10.1016/S0889-8529(18)30033-1; Lo CY, 1996, ANN SURG, V224, P125, DOI 10.1097/00000658-199608000-00003; Quarmby CJ, 1995, S AFR MED J, V85, P1353; YOUNG WF, 1990, MAYO CLIN PROC, V65, P96, DOI 10.1016/S0025-6196(12)62114-4	8	88	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					105	+		10.7326/0003-4819-131-2-199907200-00005	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419425				2022-12-01	WOS:000081509700004
J	Caceres, M; Ranz, JM; Barbadilla, A; Long, M; Ruiz, A				Caceres, M; Ranz, JM; Barbadilla, A; Long, M; Ruiz, A			Generation of a widespread Drosophila inversion by a transposable element	SCIENCE			English	Article							EVOLUTIONARY HISTORY; MOLECULAR CHARACTERIZATION; CHROMOSOME REARRANGEMENTS; BODY-SIZE; MELANOGASTER; BUZZATII; POPULATIONS; HOBO; RECOMBINATION; BREAKPOINTS	Although polymorphic inversions in Drosophila are very common, the origin of these chromosomal rearrangements is unclear. The breakpoints of the cosmopolitan inversion 2j of D. buzzatii were cloned and sequenced. Both breakpoints contain large insertions corresponding to a transposable element. It appears that the two pairs of target site duplications generated upon insertion were exchanged during the inversion event, and that the inversion arose by ectopic recombination between two copies of the transposon that were in opposite orientations. This is apparently the mechanism by which transposable elements generate natural inversions in Drosophila.	Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	Autonomous University of Barcelona; University of Chicago	Caceres, M (corresponding author), Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.		Barbadilla, Antonio/A-6915-2017; jose, ranz/A-5432-2008; Ruiz, Alfredo/ABH-2402-2020; Cáceres, Mario/A-6379-2009	Barbadilla, Antonio/0000-0002-0374-1475; Cáceres, Mario/0000-0002-7736-3251				BARKER JSF, 1994, GENETICA, V92, P165, DOI 10.1007/BF00132535; Betran E, 1998, EVOLUTION, V52, P144, DOI [10.2307/2410929, 10.1111/j.1558-5646.1998.tb05147.x]; BRAND S, 1993, NUCLEIC ACIDS RES, V21, P3699, DOI 10.1093/nar/21.16.3699; BUSSEAU I, 1989, MOL GEN GENET, V218, P222, DOI 10.1007/BF00331272; CAPY P, 1998, DYNAMICS EVOLUTION T; CIRERA S, 1995, GENETICS, V139, P321; Daveran-Mingot ML, 1998, J BACTERIOL, V180, P4834, DOI 10.1128/JB.180.18.4834-4842.1998; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; Eggleston WB, 1996, GENETICS, V144, P647; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1984, GENETICS, V107, P657; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FONTDEVILA A, 1981, EVOLUTION, V35, P148, DOI 10.1111/j.1558-5646.1981.tb04867.x; HASSON E, 1995, J EVOLUTION BIOL, V8, P369, DOI 10.1046/j.1420-9101.1995.8030369.x; KOMODA Y, 1991, GENETICS, V129, P639; Krimbas C.B., 1992, DROSOPHILA INVERSION; Ladeveze V, 1998, P ROY SOC B-BIOL SCI, V265, P1157, DOI 10.1098/rspb.1998.0412; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LIM JK, 1994, BIOESSAYS, V16, P269, DOI 10.1002/bies.950160410; LYTTLE TW, 1992, GENETICA, V86, P113, DOI 10.1007/BF00133715; MARIN I, 1995, MOL GEN GENET, V248, P423, DOI 10.1007/BF02191642; Mathiopoulos KD, 1998, P NATL ACAD SCI USA, V95, P12444, DOI 10.1073/pnas.95.21.12444; MONTGOMERY EA, 1991, GENETICS, V129, P1085; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; NAYLOR JA, 1995, HUM MOL GENET, V4, P1217, DOI 10.1093/hmg/4.7.1217; Nei M., 1987, MOL EVOLUTIONARY GEN; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; Powell J.R., 1997, PROGR PROSPECTS EVOL; Ranz JM, 1999, CHROMOSOMA, V108, P32; Ranz JM, 1997, GENETICS, V145, P281; ROEDER GS, 1983, MOBILE GENETIC ELEME, P299; Rost A.K., 1995, QUANTITATION MRNA PO, P93; RUIZ A, 1991, GENETICS, V128, P739; RUIZ A, 1993, HEREDITY, V70, P582, DOI 10.1038/hdy.1993.85; Ruiz A., 1984, Genetica Iberica, V36, P13; SAWRUK E, 1990, FEBS LETT, V273, P177, DOI 10.1016/0014-5793(90)81078-3; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; STRECK RD, 1986, EMBO J, V5, P3615, DOI 10.1002/j.1460-2075.1986.tb04690.x; TAKASUISHIKAWA E, 1992, MOL GEN GENET, V232, P17, DOI 10.1007/BF00299132; WESLEY CS, 1994, P NATL ACAD SCI USA, V91, P3132, DOI 10.1073/pnas.91.8.3132; WOJTAS KM, 1992, GENETICS, V132, P789	44	163	166	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					415	418		10.1126/science.285.5426.415	http://dx.doi.org/10.1126/science.285.5426.415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411506				2022-12-01	WOS:000081465900057
J	Drickamer, MA				Drickamer, MA			Commentary: Honesty is the best policy	BRITISH MEDICAL JOURNAL			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06504 USA	Yale University	Drickamer, MA (corresponding author), Yale Univ, Sch Med, 20 York St, New Haven, CT 06504 USA.							Hall MA, 1998, ANN INTERN MED, V128, P395, DOI 10.7326/0003-4819-128-5-199803010-00009; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1618	1618						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428555				2022-12-01	WOS:000080913100040
J	Pym, AS; Cole, ST				Pym, AS; Cole, ST			PostDOTS, postgenomics: the next century of tuberculosis control	LANCET			English	Article							VACCINE		Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France; Univ Liverpool, Wellcome Trust Trop Ctr, Liverpool L69 3BX, Merseyside, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Liverpool	Cole, ST (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, 28 Rue Dr Roux, F-75724 Paris 15, France.			Pym, Alexander/0000-0002-6260-8180				BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; India Single-lesion Multicentre Trial Group, 1997, Indian Journal of Leprosy, V69, P121; Jacobs GG, 1997, TUBERCLE LUNG DIS, V78, P159, DOI 10.1016/S0962-8479(97)90022-8; Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; Murray PJ, 1996, P NATL ACAD SCI USA, V93, P934, DOI 10.1073/pnas.93.2.934; Pelicic V, 1998, MOL MICROBIOL, V28, P413, DOI 10.1046/j.1365-2958.1998.00807.x; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STRAUS SJE, 1998, SCIENCE, V276, P707; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; *WHO GLOB TUB PROG, 1998, WHOTB98237; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1004	1005		10.1016/S0140-6736(99)02118-2	http://dx.doi.org/10.1016/S0140-6736(99)02118-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459929				2022-12-01	WOS:000079421600050
J	Tobin, EH				Tobin, EH			Prosthetic joint infections: controversies and clues	LANCET			English	Editorial Material							ULTRACLEAN AIR		Albany Med Coll, Div Infect Dis, Albany, NY 12208 USA	Albany Medical College	Tobin, EH (corresponding author), Albany Med Coll, Div Infect Dis, Albany, NY 12208 USA.							BACKE HA, 1996, CLIN ORTHOP RELAT R, V331, P125; BARRACK RL, 1997, CLIN ORTHOP RELAT R, V345, P8; Berbari EF, 1998, CLIN INFECT DIS, V27, P1247, DOI 10.1086/514991; BLASER J, 1995, ANTIMICROB AGENTS CH, V39, P1134, DOI 10.1128/AAC.39.5.1134; Christensen Gordon D., 1994, P45; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DUNCAN CP, 1994, J BONE JOINT SURG AM, V76A, P1742, DOI 10.2106/00004623-199411000-00020; Lachiewicz PF, 1996, J BONE JOINT SURG AM, V78A, P749, DOI 10.2106/00004623-199605000-00015; LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10; NORDEN C, 1994, INFECT BONES JOINTS, P291; Proctor Richard A., 1994, P79; Segreti J, 1998, CLIN INFECT DIS, V27, P711, DOI 10.1086/514951; STECKELBERGJM, 1994, INFECT ASS INDWELLIN, P259; TAYLOR GJS, 1993, J BONE JOINT SURG BR, V75, P503, DOI 10.1302/0301-620X.75B3.8496233; Tunney MM, 1998, J BONE JOINT SURG BR, V80B, P568, DOI 10.1302/0301-620X.80B4.8473; Zimmerli W, 1998, JAMA-J AM MED ASSOC, V279, P1537, DOI 10.1001/jama.279.19.1537	16	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					770	771		10.1016/S0140-6736(99)00071-9	http://dx.doi.org/10.1016/S0140-6736(99)00071-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459955				2022-12-01	WOS:000079089100005
J	Haucke, V; De Camilli, P				Haucke, V; De Camilli, P			AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic motifs	SCIENCE			English	Article							COATED VESICLE FORMATION; SORTING SIGNALS; SYNAPTIC VESICLES; RECEPTOR; MEMBRANE; PROTEINS; BINDING; DOMAIN; COMPLEXES; LIPOSOMES	Clathrin-mediated endocytosis is initiated by the recruitment of the clathrin adaptor protein AP-2 to the plasma membrane where the membrane protein synaptotagmin is thought to act as a docking site. AP-2 also interacts with endocytic motifs present in other cargo proteins. Peptides with a tyrosine-based endocytic motif stimulated binding of AP-2 to synaptotagmin and enhanced AP-2 recruitment to the plasma membrane of neuronal and non-neuronal cells. This suggests a mechanism by which nucleation of clathrin-coated pits is stimulated by the loading of cargo proteins.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36252] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R41NS036252, R42NS036252] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JACOBSON BS, 1977, SCIENCE, V195, P302, DOI 10.1126/science.831278; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P1651; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	145	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1268	1271		10.1126/science.285.5431.1268	http://dx.doi.org/10.1126/science.285.5431.1268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455054				2022-12-01	WOS:000082130200044
J	Korschen, HG; Beyermann, M; Muller, F; Heck, M; Vantler, M; Koch, KW; Kellner, R; Wolfrum, U; Bode, C; Hofmann, KP; Kaupp, UB				Korschen, HG; Beyermann, M; Muller, F; Heck, M; Vantler, M; Koch, KW; Kellner, R; Wolfrum, U; Bode, C; Hofmann, KP; Kaupp, UB			Interaction of glutamic-acid-rich proteins with the cGMP signalling pathway in rod photoreceptors	NATURE			English	Article							GATED CHANNEL; OUTER SEGMENTS; BETA-SUBUNIT; LOCALIZATION; CALMODULIN; CELLS; PHOTOTRANSDUCTION; MEMBRANE; DOMAIN; LIGHT	The assembly of signalling molecules into macromolecular complexes (transducisomes) provides specificity, sensitivity and speed in intracellular signalling pathways(1,2). Rod photoreceptors in the eye contain an unusual set of glutamic-acid-rich proteins (GARPs) of unknown function(3-7). GARPs exist as two soluble forms, GARP1 and GARP2, and as a large cytoplasmic domain (GARP' part) of the beta-subunit of the cyclic GMP-gated channel(3-7). Here we identify GARPs as multivalent proteins that interact with the key players of cGMP signalling, phosphodiesterase and guanylate cyclase, and with a retina-specific ATP-binding cassette transporter (ABCR)(8,9), through four, short, repetitive sequences. In electron micrographs, GARPs are restricted to the rim region and incisures of discs in dose proximity to the guanylate cyclase and ABCR, whereas the phosphodiesterase is randomly distributed. GARP2, the most abundant splice form, associates more strongly with light-activated than with inactive phosphodiesterase, and GARP2 potently inhibits phosphodiesterase activity. Thus, the GARPs organize a dynamic protein complex near the disc rim that may control cGMP turnover and possibly other light-dependent processes. Because there are no similar GARPs in cones, we propose that GARPs may prevent unnecessary cGMP turnover during daylight, when rods are held in saturation by the relatively high light levels.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10998 Berlin, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Karlsruhe, Inst Zool, D-76128 Karlsruhe, Germany	Helmholtz Association; Research Center Julich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	A.eckert@fz-juelich.de	Koch, Karl-Wilhelm/C-9551-2015; Mueller, Frank/I-7196-2013	Koch, Karl-Wilhelm/0000-0003-1501-0044; Mueller, Frank/0000-0001-7264-1227				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ARDELL MD, 1995, GENOMICS, V28, P32, DOI 10.1006/geno.1995.1102; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; Eckmiller MS, 1998, ACTA ANAT, V162, P133; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KOCH KW, 1992, SIGNAL TRANSDUCTION, P259; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PEDLER CMH, 1967, VISION RES, V7, P829, DOI 10.1016/0042-6989(67)90003-X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; Schrem A, 1999, J BIOL CHEM, V274, P6244, DOI 10.1074/jbc.274.10.6244; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.0.CO;2-G; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	29	105	108	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1999	400	6746					761	766		10.1038/23468	http://dx.doi.org/10.1038/23468			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466724				2022-12-01	WOS:000082131100049
J	Young, LJ; Nilsen, R; Waymire, KG; MacGregor, GR; Insel, TR				Young, LJ; Nilsen, R; Waymire, KG; MacGregor, GR; Insel, TR			Increased affiliative response to vasopressin in mice expressing the V-1a receptor from a monogamous vole	NATURE			English	Article							MICROTUS-OCHROGASTER; PRAIRIE VOLES; SPECIES-DIFFERENCES; PATERNAL BEHAVIOR; COHABITATION; INNERVATION; HAMSTERS; BRAIN; GENE	Arginine vasopressin influences male reproductive and social behaviours in several vertebrate taxa(1) through its actions at the V-1a receptor in the brain, The neuroanatomical distribution of vasopressin V-1a receptors varies greatly between species with different forms of social organization(2,3). Here we show that centrally administered arginine vasopressin increases affiliative behaviour in the highly social, monogamous prairie vole, but not in the relatively asocial, promiscuous montana vole. Molecular analyses indicate that gene duplication and/or changes in promoter structure of the prairie vole receptor gene may contribute to the species differences in vasopressin-receptor expression. We further show that mice that are transgenic for the prairie vole receptor gene have a neuroanatomical pattern of receptor binding that is similar to that of the prairie vole, and exhibit increased affiliative behaviour after injection with arginine vasopressin. These data indicate that the pattern of V-1a-receptor gene expression in the brain may be functionally associated with species-typical social behaviours in male vertebrates.	Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; Emory Univ, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University; Emory University	Young, LJ (corresponding author), Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.							BAMSHAD M, 1994, PHYSIOL BEHAV, V56, P751, DOI 10.1016/0031-9384(94)90238-0; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BESTERMEREDITH JK, IN PRESS HORM BEHAV; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; FERRIS CF, 1988, PHYSIOL BEHAV, V44, P235, DOI 10.1016/0031-9384(88)90144-8; Ferris CF, 1997, J NEUROSCI, V17, P4331; INSEL TR, 1994, J NEUROSCI, V14, P5381; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Meloni R, 1998, HUM MOL GENET, V7, P423, DOI 10.1093/hmg/7.3.423; MOORE FL, 1983, PEPTIDES, V4, P97, DOI 10.1016/0196-9781(83)90173-0; RITTERS LV, 1997, ANN NY ACAD SCI, V807, P478; SHAPIRO LE, 1990, J COMP PSYCHOL, V104, P268, DOI 10.1037/0735-7036.104.3.268; WANG ZX, 1994, BRAIN RES, V650, P212, DOI 10.1016/0006-8993(94)91784-1; WANG ZX, 1994, P NATL ACAD SCI USA, V91, P400, DOI 10.1073/pnas.91.1.400; WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0; Young LJ, 1998, TRENDS NEUROSCI, V21, P71, DOI 10.1016/S0166-2236(97)01167-3; Young LJ, 1997, BEHAV NEUROSCI, V111, P599, DOI 10.1037/0735-7044.111.3.599	18	362	377	0	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					766	768		10.1038/23475	http://dx.doi.org/10.1038/23475			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466725				2022-12-01	WOS:000082131100050
J	Burkle, FM				Burkle, FM			Fortnightly review - Lessons learnt and future expectations of complex emergencies	BRITISH MEDICAL JOURNAL			English	Review							PUBLIC-HEALTH; WAR		Univ Hawaii, John A Burns Sch Med, Ctr Excellence Disaster Med & Humanitarian Assist, WHO,Collaborating Ctr, Honolulu, HI 96826 USA	University of Hawaii System; World Health Organization	Burkle, FM (corresponding author), Univ Hawaii, John A Burns Sch Med, Ctr Excellence Disaster Med & Humanitarian Assist, WHO,Collaborating Ctr, Honolulu, HI 96826 USA.		Burkle, Frederick/AAE-5423-2020					[Anonymous], 1997, REFUGEE HLTH APPROAC; BLECHMAN BM, 1994, TRAINING PEACEKEEPIN, P1; Borton J, 1996, DISASTERS, V20, P305, DOI 10.1111/j.1467-7717.1996.tb01046.x; BRADSHAW AL, 1998, INT ENV SECURITY REG; BURKHOLDER BT, 1995, LANCET, V346, P1012, DOI 10.1016/S0140-6736(95)91694-6; Burkle F M Jr, 1995, Prehosp Disaster Med, V10, P48; BURKLE FM, 1999, HUMANITARIAN CRISES, P293; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; *DIV EM HUM ACT, 1999, APPL HLTH RES EM SET; Garshnek V, 1998, SPACE POLICY, V14, P223, DOI 10.1016/S0265-9646(98)00023-X; *INT FED RED CROSS, 1997, WORLD DIS REP 1997; KANE H, 1995, WORLDWATCH       JUN, P18; MINEAR L, 1991, HUMANITARIANISM WAR; *NAT DEF COUNC FDN, 1998, NAT DEF COUNC FDN WO; Palmer CA, 1998, DISASTERS, V22, P236, DOI 10.1111/1467-7717.00089; Perrin P., 1996, HDB WAR PUBLIC HLTH; *PUBL BROADC SYST, 1997, ALL THINGS CONS CULT; *REPR HLTH REF CON, 1998, REF REPR HLTH CAR NE; *SPHER PROJ, 1998, HUM CHART MIN STAND, pCH6; THAROOR S, 1998, WASHINGTON POST 0216, P34; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; *UN HIGH COMM REF, 1999, STAT WORLDS REF HUM; ZWI A, 1991, HEALTH POLICY PLANN, V6, P203, DOI 10.1093/heapol/6.3.203; 1998, ECONOMIST       0502, P21	25	48	49	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					422	426		10.1136/bmj.319.7207.422	http://dx.doi.org/10.1136/bmj.319.7207.422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445925	Green Published			2022-12-01	WOS:000082098900020
J	Sakakibara, H; Kojima, H; Sakai, Y; Katayama, E; Oiwa, K				Sakakibara, H; Kojima, H; Sakai, Y; Katayama, E; Oiwa, K			Inner-arm dynein c of Chlamydomonas flagella is a single-headed processive motor	NATURE			English	Article							KINESIN MOLECULES; MICROTUBULES; PROTEINS; PURIFICATION; MICROSCOPY; MOVEMENT; MUTANTS; TUBULIN; DOMAIN; ASSAY	Axonemal dyneins are force-generating ATPases that produce movement of eukaryotic cilia and flagella(1,2). Several studies indicate that inner-arm dyneins mainly produce bending moments in flagella(3,4) and that these motors have inherent oscillations in force and motility(5-8). Processive motors such as kinesins have high duty ratios of attached to total ATPase cycle (attached plus detached) times(9) compared to sliding motors such as myosin(10). Here we provide evidence that subspecies-c, a single-headed axonemal inner-arm dynein, is processive but has a low duty ratio. Ultrastructurally it is similar to other dyneins(11-14), with a single globular head, long stem and a slender stalk that attaches to microtubules. In vitro studies of microtubules sliding over surfaces coated with subspecies-c at low densities (measured by single-molecule fluorescence) show that a single molecule is sufficient to move a microtubule more than 1 mu m at 0.7 mu m s(-1). When many motors interact the velocity is 5.1 mu m s(-1), fitting a duty ratio of 0.14. Using optical trap nanometry, we show that beads carrying a single subspecies-c motor move processively along the microtubules in 8-nm steps but slip backwards under high loads. These results indicate that dynein subspecies-c functions in a very different way from conventional motor proteins, and has properties that could produce self-oscillation in vivo.	Kansai Adv Res Ctr, Commun Res Lab, Kobe, Hyogo 6512401, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan	National Institute of Information & Communications Technology (NICT) - Japan; University of Tokyo	Oiwa, K (corresponding author), Kansai Adv Res Ctr, Commun Res Lab, Kobe, Hyogo 6512401, Japan.	oiwa@crl.go.jp	Oiwa, Kazuhiro/D-7721-2011	Oiwa, Kazuhiro/0000-0002-1281-113X				AMOS LA, 1989, J CELL SCI, V93, P19; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1987, J MOL BIOL, V194, P481, DOI 10.1016/0022-2836(87)90676-0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; KAGAMI O, 1992, J CELL SCI, V103, P653; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KING SM, 1986, METHOD ENZYMOL, V134, P291; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Oiwa K., 1997, Biophysical Journal, V72, pA180; OIWA K, 1988, CELL STRUCT FUNCT, V13, P193, DOI 10.1247/csf.13.193; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TAKAHASHI K, 1983, J SUBMICR CYTOL PATH, V15, P1; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89	28	149	152	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					586	590		10.1038/23066	http://dx.doi.org/10.1038/23066			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448863				2022-12-01	WOS:000081854800061
J	O'Neill, J				O'Neill, J			A peaceful death	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					327	327		10.1136/bmj.319.7205.327	http://dx.doi.org/10.1136/bmj.319.7205.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426772	Green Published			2022-12-01	WOS:000081909100069
J	Corrie, JET; Brandmeier, BD; Ferguson, RE; Trentham, DR; Kendrick-Jones, I; Hopkins, SC; van der Heide, UA; Goldman, YE; Sabido-David, C; Dale, RE; Criddle, S; Irving, M				Corrie, JET; Brandmeier, BD; Ferguson, RE; Trentham, DR; Kendrick-Jones, I; Hopkins, SC; van der Heide, UA; Goldman, YE; Sabido-David, C; Dale, RE; Criddle, S; Irving, M			Dynamic measurement of myosin light-chain-domain tilt and twist in muscle contraction	NATURE			English	Article							SKELETAL-MUSCLE; FLUORESCENCE POLARIZATION; FORCE GENERATION; STRIATED-MUSCLE; SCALLOP MYOSIN; MOTOR DOMAIN; LEVER-ARM; FIBERS; ORIENTATION; ACTIN	A new method is described for measuring motions of protein domains in their native environment on the physiological timescale. pairs of cysteines are introduced Into the domain at sites chosen from its static structure and are crosslinked by a bifunctional rhodamine. Domain orientation in a reconstituted macromolecular complex is determined by combining fluorescence polarization data from a small number of such labelled cysteine pairs. This approach bridges the gap between in vitro studies of protein structure and cellular studies of protein function and is used here to measure the tilt and twist of the myosin light-chain domain with respect to actin filaments in single muscle cells. The results reveal the structural basis for the lever-arm action of the light-chain domain of the myosin motor during force generation in muscle.	Univ London Kings Coll, Randall Inst, London WC2B 5RL, England; Natl Inst Med Res, London NW7 1AA, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of London; King's College London; MRC National Institute for Medical Research; MRC Laboratory Molecular Biology; University of Pennsylvania	Irving, M (corresponding author), Univ London Kings Coll, Randall Inst, 26-29 Drury Lane, London WC2B 5RL, England.			, Seth/0000-0003-3999-2281	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; Corrie JET, 1998, BIOCONJUGATE CHEM, V9, P160, DOI 10.1021/bc970174e; Dale RE, 1999, BIOPHYS J, V76, P1606, DOI 10.1016/S0006-3495(99)77320-0; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Hopkins SC, 1998, BIOPHYS J, V74, P3093, DOI 10.1016/S0006-3495(98)78016-6; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; JANSCO A, 1994, P NATL ACAD SCI USA, V91, P8762; KABASCH W, 1990, NATURE, V347, P37; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; Ling N, 1996, BIOPHYS J, V70, P1836, DOI 10.1016/S0006-3495(96)79749-7; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOSS RL, 1982, J BIOL CHEM, V257, P8588; OKI M, 1983, TOP STEREOCHEM, V14, P1; PENZKOFER A, 1980, OPT COMMUN, V35, P81, DOI 10.1016/0030-4018(80)90364-8; Press W., 1992, NUMERICAL RECIPES FO, V2; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; Sabido-David C, 1998, BIOPHYS J, V74, P3083, DOI 10.1016/S0006-3495(98)78015-4; Sabido-David C, 1998, J MOL BIOL, V279, P387, DOI 10.1006/jmbi.1998.1771; SIMMONS RM, 1980, NATURE, V286, P626, DOI 10.1038/286626a0; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Warshaw DM, 1998, P NATL ACAD SCI USA, V95, P8034, DOI 10.1073/pnas.95.14.8034; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	44	172	173	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					425	430		10.1038/22704	http://dx.doi.org/10.1038/22704			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440371				2022-12-01	WOS:000081715000043
J	Muers, MF				Muers, MF			Quitting smoking and lungs	LANCET			English	Editorial Material							DECLINE; FEV(1)		Gen Infirm Leeds, Resp Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Muers, MF (corresponding author), Gen Infirm Leeds, Resp Unit, Leeds LS1 3EX, W Yorkshire, England.							ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; CALLUM C, 1998, UK SMOKING EPIDEMIC; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794, DOI 10.1164/arrd.1987.135.4.794; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; Fletcher C, 1976, NATURAL HIST CHRONIC; GOLDING JF, 1995, SMOKING RESP MED, P531; Murray RP, 1998, J CLIN EPIDEMIOL, V51, P1317, DOI 10.1016/S0895-4356(98)00120-6; Raw M, 1998, THORAX, V53, pS1, DOI 10.1136/thx.53.2008.S1; Sherrill DL, 1996, CHEST, V109, P1001, DOI 10.1378/chest.109.4.1001; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; *U YORK NHS CTR RE, 1998, EFFECTIVENESS MATTER, V3, P1; XU X, 1994, EUR RESPIR J, V7, P1056; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345	13	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					177	178		10.1016/S0140-6736(99)90021-1	http://dx.doi.org/10.1016/S0140-6736(99)90021-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421295				2022-12-01	WOS:000081504200005
J	Streeten, DHP				Streeten, DHP			What test for hypothalamic-pituitary-adrenocortical insufficiency?	LANCET			English	Editorial Material							NORMAL CORTISOL RESPONSE; ADRENAL AXIS; CORTICOTROPIN; ACTH; CELLS		SUNY Hlth Sci Ctr, Dept Med, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Streeten, DHP (corresponding author), SUNY Hlth Sci Ctr, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.							Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Agwu JC, 1999, ARCH DIS CHILD, V80, P330, DOI 10.1136/adc.80.4.330; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; Clark PM, 1998, CLIN ENDOCRINOL, V49, P287; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; DONALD RA, 1993, CLIN ENDOCRINOL, V38, P609, DOI 10.1111/j.1365-2265.1993.tb02142.x; LANDON J, 1967, LANCET, V2, P697; LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; RESCHINI E, 1982, J ENDOCRINOL INVEST, V5, P259, DOI 10.1007/BF03348333; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; Streeten DHP, 1999, J CLIN ENDOCR METAB, V84, P835, DOI 10.1210/jc.84.3.835; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371	16	34	39	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					179	180		10.1016/S0140-6736(98)00318-3	http://dx.doi.org/10.1016/S0140-6736(98)00318-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421297				2022-12-01	WOS:000081504200007
J	Payre, F; Vincent, A; Carreno, S				Payre, F; Vincent, A; Carreno, S			Ovo/svb integrates Wingless and DER pathways to control epidermis differentiation	NATURE			English	Article							DROSOPHILA EGF RECEPTOR; OVO GENE; ARMADILLO; EXPRESSION; PROTEIN; ROLES; MORPHOGENESIS; SHAVENBABY; ENCODES; CUTICLE	In Drosophila, as in mammals, epidermal differentiation is controlled by signalling cascades' that include Wnt proteins(2,3) and the ovo/shavenbaby (svb) family of zinc-finger transcription factor(4-6) Ovo/svb is a complex gene with two genetic functions corresponding to separate control regions: ovo is required for female germline development and svb for epidermal morphogenesis(7,8). In the Drosophila embryo, the ventral epidermis consists of the segmental alternance of two major cell types that produce either naked cuticle or cytoplasmic extrusions known as denticles. Wingless signalling specifies smooth cells that produce naked cuticle(9), whereas the activation of the Drosophila epidermal growth factor (EGF) receptor (DER) leads to the production of denticles(10). Here we show that expression of the ovo/svb gene controls the choice between these cell fates. We find that svb is a key selector gene that, cell autonomously, directs cytoskeletal modifications producing the denticle. The DER pathway promotes denticle formation by activating svb expression. Conversely, Wingless promotes the smooth cell fate through the transcriptional repression of svb by the bipartite nuclear factor Armadillo/dTcf. Ou data indicate that transcriptional regulation of svb integrates inputs fi om the Wingless and DER pathways and controls epidermal differentiation.	Ctr Dev Biol, F-31062 Toulouse, France		Payre, F (corresponding author), Ctr Dev Biol, UMR5547,Bat IVR3,118 Route Narbonne, F-31062 Toulouse, France.		Vincent, Alain/AAE-4712-2019	Carreno, Sebastien/0000-0002-5839-2102; PAYRE, Francois/0000-0002-8144-6711				Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Dai X, 1998, GENE DEV, V12, P3452, DOI 10.1101/gad.12.21.3452; Dickinson WJ, 1997, CELL MOTIL CYTOSKEL, V38, P9; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GARFINKEL MD, 1994, MOL CELL BIOL, V14, P6809, DOI 10.1128/MCB.14.10.6809; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Lee T, 1996, DEVELOPMENT, V122, P409; Lu JN, 1998, DEV GENES EVOL, V208, P213, DOI 10.1007/s004270050175; MEVELNINIO M, 1991, EMBO J, V10, P2259, DOI 10.1002/j.1460-2075.1991.tb07762.x; MEVELNINIO M, 1995, MECH DEVELOP, V49, P83, DOI 10.1016/0925-4773(94)00305-7; MevelNinio M, 1996, DEVELOPMENT, V122, P4131; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Pai LM, 1997, DEVELOPMENT, V124, P2255; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Szuts D, 1997, DEVELOPMENT, V124, P3209; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	30	171	177	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					271	275		10.1038/22330	http://dx.doi.org/10.1038/22330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421370				2022-12-01	WOS:000081503800046
J	Moore, PA; Belvedere, O; Orr, A; Pieri, K; LaFleur, DW; Feng, P; Soppet, D; Charters, M; Gentz, R; Parmelee, D; Li, YL; Galperina, O; Giri, J; Roschke, V; Nardelli, B; Carrell, J; Sosnovtseva, S; Greenfield, W; Ruben, SM; Olsen, HS; Fikes, J; Hilbert, DM				Moore, PA; Belvedere, O; Orr, A; Pieri, K; LaFleur, DW; Feng, P; Soppet, D; Charters, M; Gentz, R; Parmelee, D; Li, YL; Galperina, O; Giri, J; Roschke, V; Nardelli, B; Carrell, J; Sosnovtseva, S; Greenfield, W; Ruben, SM; Olsen, HS; Fikes, J; Hilbert, DM			BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator	SCIENCE			English	Article							MOLECULAR-CLONING; CD40 LIGAND; CELL GROWTH; EXPRESSION; DIFFERENTIATION; IMMUNOGLOBULIN; INTERLEUKIN-5; LYMPHOTOXIN; BSF-2; CDNA	The tumor necrosis factor (INF) superfamily of cytokines includes both soluble and membrane-bound proteins that regulate immune responses. A member of the human TNF family, BLyS (B Lymphocyte stimulator), was identified that induced B cell proliferation and immunoglobulin secretion. BLyS expression on human monocytes could be up-regulated by interferon-gamma. Soluble BLyS functioned as a potent B cell growth factor in costimulation assays. Administration of soluble recombinant BLyS to mice disrupted splenic B and T cell zones and resulted in elevated serum immunoglobulin concentrations. The B cell tropism of BLyS is consistent with its receptor expression on B-Lineage cells. The biological profile of BLyS suggests it is involved in monocyte-driven B cell activation.	Human Genome Sci, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Hilbert, DM (corresponding author), Human Genome Sci, 9410 Key W Ave, Rockville, MD 20850 USA.		Carrell, Jeffrey/AAV-7361-2020	Carrell, Jeffrey/0000-0001-7484-4407				AKERSTROM B, 1985, J IMMUNOL, V135, P2589; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1991, ADV EXP MED BIOL, V292, P121; BERTOLINI JN, 1993, EUR J IMMUNOL, V23, P398, DOI 10.1002/eji.1830230215; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRABSTEIN KH, 1993, J IMMUNOL, V150, P3141; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HILBERT DM, 1993, EUR J IMMUNOL, V23, P2412, DOI 10.1002/eji.1830231006; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Lens SMA, 1998, SEMIN IMMUNOL, V10, P491, DOI 10.1006/smim.1998.0154; Metzger DW, 1995, RES IMMUNOL, V146, P499, DOI 10.1016/0923-2494(96)83023-9; MOORE PS, UNPUB; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; Oshima H, 1998, INT IMMUNOL, V10, P517, DOI 10.1093/intimm/10.4.517; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; POUPART P, 1987, EMBO J, V6, P1219, DOI 10.1002/j.1460-2075.1987.tb02357.x; PUNNONEN J, 1994, ALLERGY, V49, P576, DOI 10.1111/j.1398-9995.1994.tb00122.x; RINGDEN O, 1977, SCAND J IMMUNOL, V6, P1159; SIECKMANN DG, 1978, J EXP MED, V147, P814, DOI 10.1084/jem.147.3.814; TAKATSU K, 1987, P NATL ACAD SCI USA, V84, P4234, DOI 10.1073/pnas.84.12.4234; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; vanKooten C, 1997, INT ARCH ALLERGY IMM, V113, P393, DOI 10.1159/000237614; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	29	932	1115	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					260	263		10.1126/science.285.5425.260	http://dx.doi.org/10.1126/science.285.5425.260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398604				2022-12-01	WOS:000081346000044
J	Hindie, E; Urena, P; Jeanguillaume, C; Melliere, D; Berthelot, JM; Menoyo-Calonge, V; Chiappini-Briffa, D; Janin, A; Galle, P				Hindie, E; Urena, P; Jeanguillaume, C; Melliere, D; Berthelot, JM; Menoyo-Calonge, V; Chiappini-Briffa, D; Janin, A; Galle, P			Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism	LANCET			English	Article							CHRONIC-RENAL-FAILURE; TECHNETIUM 99M SESTAMIBI; SURGICAL-TREATMENT; SUBTOTAL PARATHYROIDECTOMY; TC-99M SESTAMIBI; DOUBLE-PHASE; LOCALIZATION; TECHNETIUM-99M-SESTAMIBI; SURGERY; PATHOGENESIS	Background Parathyroidectomy is unsuccessful in 10-30% of uraemic patients operated on for secondary hyperparathyroidism, We investigated the usefulness of preoperative radionuclide imaging, with simultaneous recording of the distribution images of iodine-123 and technetium-99m-labelled sestamibi. Methods 11 patients with secondary hyperparathyroidism underwent prospective imaging and parathyroidectomy. Plasma concentrations of intact parathyroid hormone (PTH) were measured in all patients before and 6 months after subtotal parathyroidectomy. Findings Preoperative scanning showed 42 hot-spots suggesting enlarged parathyroid glands, 45 glands were discovered at surgery, and the parathyroidectomy was deemed successful in ten patients. Among the latter, one patient had a supernumerary parathyroid gland detected by scanning and resected from the left thymus. Another patient showed ectopic uptake corresponding to a large parathyroid gland in the upper mediastinum, and another had a parathyroid gland well above the thyroid. No false-positive scan findings were documented. In the patient for whom parathyroidectomy failed, preoperative scanning suggested five enlarged parathyroid glands, though the surgeon found only four glands, in their normal positions. Hyperparathyroidism persisted (intact PTH 527 ng/L, 6 months after surgery). A second scan confirmed the preoperative scan, showing a fifth parathyroid gland in the middle of the right thyroid lobe. Interpretation Simultaneous recording of Tc-99m-sestamibi and I-123 improved the imaging of parathyroid glands in secondary hyperparathyroidism. The technique can identify ectopic and supernumerary parathyroid glands.	Hop Henri Mondor, Dept Nucl Med & Biophys, F-94010 Creteil, France; Hop Henri Mondor, Dept Endocrine Surg, F-94010 Creteil, France; Clin LOrangerie, Nephrol Unit, Aubervilliers, France; Ctr Henri Kuntziger, Haemodyalysis Unit, Paris, France; Hop St Louis, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Hindie, E (corresponding author), Univ Paris 12, Fac Med, Biophys Lab, 8 Rue Gen Sarrail, F-94000 Creteil, France.	hindie@univ-paris12.fr	JEANGUILLAUME, Christian/A-1070-2008	Jeanguillaume, Christian/0000-0002-8335-4255				AKERSTROM G, 1984, SURGERY, V95, P14; AKERSTROM G, 1992, WORLD J SURG, V16, P562, DOI 10.1007/BF02067321; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; BLAKE DP, 1983, SURG GYNECOL OBSTET, V157, P325; Borley NR, 1996, BRIT J SURG, V83, P989, DOI 10.1002/bjs.1800830734; Chesser AMS, 1997, NEPHROL DIAL TRANSPL, V12, P97, DOI 10.1093/ndt/12.1.97; COAKLEY AJ, 1989, NUCL MED COMMUN, V10, P791, DOI 10.1097/00006231-198911000-00003; DRUEKE TB, 1995, KIDNEY INT, V48, P259, DOI 10.1038/ki.1995.292; FRAKER DL, 1990, WORLD J SURG, V14, P342, DOI 10.1007/BF01658522; Fukagawa M, 1997, SEMIN SURG ONCOL, V13, P73, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<73::AID-SSU2>3.3.CO;2-3; GAGNE ER, 1992, J AM SOC NEPHROL, V3, P1008; GAZ RD, 1987, SURGERY, V102, P949; GIANGRANDE A, 1992, NEPHROL DIAL TRANSPL, V7, P412; Hindie E, 1998, J NUCL MED, V39, P1100; HINDIE E, 1995, J CLIN ENDOCR METAB, V80, P302, DOI 10.1210/jc.80.1.302; Hindie E, 1997, RADIOLOGY, V204, P221, DOI 10.1148/radiology.204.1.9205251; Hines OJ, 1998, J CLIN ENDOCR METAB, V83, P2384, DOI 10.1210/jc.83.7.2384; Jeanguillaume C, 1998, RADIOLOGY, V207, P207, DOI 10.1148/radiology.207.1.9580138; Johnston LB, 1996, J CLIN ENDOCR METAB, V81, P346, DOI 10.1210/jc.81.1.346; KESSLER M, 1991, NEPHROL DIAL TRANSPL, V6, P176, DOI 10.1093/ndt/6.3.176; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; ODOHERTY MJ, 1992, J NUCL MED, V33, P313; Parfitt AM, 1997, KIDNEY INT, V52, P3, DOI 10.1038/ki.1997.297; Piga M, 1996, J NUCL MED, V37, P565; Pons F, 1997, EUR J NUCL MED, V24, P1494, DOI 10.1007/s002590050179; PUNCH JD, 1995, ARCH SURG-CHICAGO, V130, P538; ROTHMUND M, 1988, ANN SURG, V207, P310, DOI 10.1097/00000658-198803000-00014; ROTHMUND M, 1990, WORLD J SURG, V14, P393, DOI 10.1007/BF01658536; RUDBERG C, 1986, SURGERY, V99, P643; RUSSELL CF, 1981, ANN SURG, V193, P805, DOI 10.1097/00000658-198106000-00016; SLATOPOLSKY E, 1994, AM J KIDNEY DIS, V23, P229, DOI 10.1016/S0272-6386(12)80977-2; TAILLEFER R, 1992, J NUCL MED, V33, P1801; TAKAGI H, 1986, WORLD J SURG, V10, P605, DOI 10.1007/BF01655536; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P87, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<87::AID-SSU4>3.0.CO;2-Y; WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272-6386(95)90453-0; WEBER CJ, 1993, SURGERY, V114, P1011; WEI JP, 1992, SURGERY, V112, P1111	38	55	56	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2200	2204		10.1016/S0140-6736(98)09089-8	http://dx.doi.org/10.1016/S0140-6736(98)09089-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392985				2022-12-01	WOS:000081091300013
J	Agami, R; Blandino, G; Oren, M; Shaul, Y				Agami, R; Blandino, G; Oren, M; Shaul, Y			Interaction of c-Abl and p73 alpha and their collaboration to induce apoptosis	NATURE			English	Article							FUNCTIONAL DOMAIN; DNA-DAMAGE; P53; PROTEIN; GENE; IDENTIFICATION; LIBRARIES; LIGANDS; REGION; P73	c-Abl, a non-receptor tyrosine kinase, is activated by agents that damage DNA. This activation results in either arrest of the cell cycle in phase G1 or apoptotic cell death, both of which are dependent on the kinase activity of c-Abl(1). p73, a member of the p53 family of tumour-suppressor proteins(2,3), can also induce apoptosis(3), Here we show that the apoptotic activity of p73 alpha requires the presence of functional, kinase-competent c-Abl. Furthermore, p73 and c-Abl can associate with each other, and this binding is mediated by a PxxP motif in p73 and the SH3 domain of c-Abl. We find that p73 is a substrate of the c-Abl kinase and that the ability of c-Abl to phosphorylate p73 is markedly increased by gamma-irradiation. Moreover, p73 is phosphorylated in vivo in response to ionizing radiation. These findings define a pro-apoptotic signalling pathway involving p73 and c-Abl.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	Ivshaul@weizmann.weizmann.ac.il	Blandino, Giovanni/B-1137-2013; agami, reuven/GOG-8289-2022	Blandino, Giovanni/0000-0002-6970-2241; Oren, Moshe/0000-0003-4311-7172; Agami, Reuven/0000-0002-2848-2473	Telethon [596] Funding Source: Medline	Telethon(Fondazione Telethon)		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Zhu JH, 1998, CANCER RES, V58, P5061	23	489	499	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					809	813						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391250				2022-12-01	WOS:000081101600060
J	Barakat, K; Wilkinson, P; Deaner, A; Fluck, D; Ranjadayalan, K; Timmis, A				Barakat, K; Wilkinson, P; Deaner, A; Fluck, D; Ranjadayalan, K; Timmis, A			How should age affect management of acute myocardial infarction? A prospective cohort study	LANCET			English	Article							THROMBOLYTIC THERAPY; RISK; SURVIVAL; TRIAL	Background About 75% of patients with acute myocardial infarction are older than 70 years, but patients in this age group are commonly treated less vigorously than younger patients. This differential treatment may partly reflect clinicians' misconceptions about the outlook of such patients, and the importance of age in clinical decisions. We examined how age does and should affect the management of patients and risk stratification in acute myocardial infarction. Methods In this prospective cohort study, we recruited 1225 consecutive patients admitted with acute myocardial infarction to a district general hospital in east London. The primary endpoint was death. We used tabulation and regression methods to analyse the association between age group and clinical variables. Findings Patients aged 70 years or older took a longer time to arrive in hospital and were less likely to receive thrombolysis or discharge beta-blockers than patients younger than 60 years: odds ratio 0.63 (95% CI 9.45-0.88) for thrombolysis and 0.25 (0.16-0.37) for beta-blockade, adjusted for sex, diabetes, previous acute myocardial infarction, Q wave infarction, and left-ventricular failure. Left-ventricular failure was the strongest independent predictor of death within 1 year of infarction with a hazard ratio of 4.76 (3.53-6.43), adjusted for age, sex, diabetes, and Q wave infarction. Patients aged 70 years or older without left-ventricular failure had significantly better survival at 1 year after acute myocardial infarction than patients under 60 years with left-ventricular failure. 70.8% (62.2-78.2) of the older patients who survived to hospital discharge were still alive 3 years later. Interpretation Elderly patients with acute myocardial infarction were treated less vigorously than younger patients. The prognosis of acute myocardial infarction, however, was substantially affected by the development of left-ventricular failure and other clinical indices, such that many older patients had a better outlook than younger patients with adverse clinical factors. In planning risk-based management, consideration of age independently of clinical status is inappropriate.	London Chest Hosp, Royal Hosp NHS Trust, Dept Cardiol, London E2 9JX, England; Newman Healthcare Trust, London, England; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England	University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine	Timmis, A (corresponding author), London Chest Hosp, Royal Hosp NHS Trust, Dept Cardiol, London E2 9JX, England.	adam@timmis-lch.demon.co.uk		Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; COLEMAN MP, 1989, 89006 INT AG RES CAN; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HANNAFORD PC, 1994, BRIT MED J, V309, P573, DOI 10.1136/bmj.309.6954.573; HAWKINS CM, 1983, CIRCULATION, V67, P94; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; McMechan SR, 1998, BMJ-BRIT MED J, V317, P1334, DOI 10.1136/bmj.317.7169.1334; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NORRIS RM, 1969, LANCET, V1, P274; *OFF NAT STAT, 1997, MORT STAT DH2, V22; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525	23	103	109	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					955	959		10.1016/S0140-6736(98)07114-1	http://dx.doi.org/10.1016/S0140-6736(98)07114-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459903				2022-12-01	WOS:000079421600009
J	Levashina, EA; Langley, E; Green, C; Gubb, D; Ashburner, M; Hoffmann, JA; Reichhart, JM				Levashina, EA; Langley, E; Green, C; Gubb, D; Ashburner, M; Hoffmann, JA; Reichhart, JM			Constitutive activation of toll-mediated antifungal defense in serpin-deficient Drosophila	SCIENCE			English	Article							DORSAL-VENTRAL PATTERN; SIGNALING PATHWAY; GENE; PROTEIN; PEPTIDE; METCHNIKOWIN; EXPRESSION; POLARITY; EMBRYO	The antifungal defense of Drosophila is controlled by the spaetzle/Toll/cactus gene cassette, Here, a Loss-of-function mutation in the gene encoding a blood serine protease inhibitor, Spn43Ac, was shown to Lead to constitutive expression of the antifungal peptide drosomycin, and this effect was mediated by the spaetzle and Toll gene products. Spaetzle was cleaved by proteolytic enzymes to its active Ligand form shortly after immune challenge, and cleaved Spaetzle was constitutively present in Spn4Ac-deficient flies. Hence, Spn43Ac negatively regulates the Toll signaling pathway, and Toll does not function as a pattern recognition receptor in the Drosophila host defense.	Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Cambridge	Reichhart, JM (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	reichhart@ibmc.u-strasbg.fr	Gubb, David/F-9793-2011	Levashina, Elena/0000-0003-4605-906X				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boswell D. R., 1986, REC ADV CLIN IMMUNOL, V4, P1; BRAND AH, 1993, DEVELOPMENT, V118, P401; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Gerard C, 1998, NATURE, V395, P217, DOI 10.1038/26104; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giebel B, 1997, MECH DEVELOP, V63, P75, DOI 10.1016/S0925-4773(97)00029-4; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEITZLER P, 1993, GENETICS, V135, P105; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Iwanaga S, 1998, J BIOCHEM, V123, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	23	358	374	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1917	1919		10.1126/science.285.5435.1917	http://dx.doi.org/10.1126/science.285.5435.1917			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489372				2022-12-01	WOS:000082638300052
J	Komarov, PG; Komarova, EA; Kondratov, RV; Christov-Tselkov, K; Coon, JS; Chernov, MV; Gudkov, AV				Komarov, PG; Komarova, EA; Kondratov, RV; Christov-Tselkov, K; Coon, JS; Chernov, MV; Gudkov, AV			A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy	SCIENCE			English	Article							HEMATOPOIETIC GROWTH-FACTORS; TUMOR-SUPPRESSOR GENE; IN-VIVO; P53-DEFICIENT MICE; APOPTOSIS; RADIATION; TUMORIGENESIS; IRRADIATION; ACTIVATION; RESISTANCE	Chemotherapy and radiation therapy for cancer often have severe side effects that limit their efficacy. Because these effects are in part determined by p53-mediated apoptosis, temporary suppression of p53 has been suggested as a therapeutic strategy to prevent damage of normal tissues during treatment of p53-deficient tumors. To test this possibility, a small molecule was isolated for its ability to reversibly block p53-dependent transcriptional activation and apoptosis. This compound, pifithrin-alpha, protected mice from the Lethal genotoxic stress associated with anticancer treatment without promoting the formation of tumors. Thus, inhibitors of p53 may be useful dregs for reducing the side effects of cancer therapy and other types of stress associated with p53 induction.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Cleveland Clin Fdn, Res Inst, Cleveland, OH 44195 USA; Quark Biotech, Pleasanton, CA 94566 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Komarov, PG (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.			Kondratov, Roman/0000-0003-3449-745X; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA75179, CA60730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRONCHUD M, 1993, ANTI-CANCER DRUG, V4, P127, DOI 10.1097/00001813-199304000-00002; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Deichman GI, 1998, INT J CANCER, V75, P277, DOI 10.1002/(SICI)1097-0215(19980119)75:2<277::AID-IJC17>3.3.CO;2-H; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Johnston EM, 1998, SEMIN ONCOL, V25, P552; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KOMAROVA EA, UNPUB; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Steele RJC, 1998, BRIT J SURG, V85, P1460; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Westphal CH, 1998, CANCER RES, V58, P5637; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	31	1072	1133	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1733	1737		10.1126/science.285.5434.1733	http://dx.doi.org/10.1126/science.285.5434.1733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481009				2022-12-01	WOS:000082472600035
J	De Stefano, V; Martinelli, I; Mannucci, PM; Paciaroni, K; Chiusolo, P; Casorelli, I; Rossi, E; Leone, G				De Stefano, V; Martinelli, I; Mannucci, PM; Paciaroni, K; Chiusolo, P; Casorelli, I; Rossi, E; Leone, G			The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; INHERITED THROMBOPHILIA; 20210A ALLELE; GLN MUTATION; GENE; THROMBOEMBOLISM; RESISTANCE; PREVALENCE; ARG-506; VARIANT	Background Point mutations in the factor V gene (factor V Leiden) and the prothrombin gene (the substitution of A for G at position 20210) are the most common causes of inherited thrombophilia. Whether or not factor V Leiden increases the risk of recurrent deep venous thrombosis is controversial, and there is no information on the risk of recurrence among carriers of both mutations. Methods We studied a retrospective cohort of 624 patients who were referred for a first episode of deep venous thrombosis. After excluding 212 patients with other inherited or acquired causes of thrombophilia, we compared 112 patients who were heterozygous carriers of factor V Leiden with 17 patients who were heterozygous for both factor V Leiden and the prothrombin mutation and 283 patients who had neither mutation. The relative risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards model. Results Patients who were heterozygous for factor V Leiden alone had a risk of recurrent deep venous thrombosis that was similar to that among patients who had neither mutation (relative risk, 1.1; 95 percent confidence interval, 0.7 to 1.6; P = 0.76). In contrast, patients who were heterozygous for both factor V Leiden and the prothrombin mutation had a higher risk of recurrent thrombosis than did carriers of factor V Leiden alone (relative risk, 2.6; 95 percent confidence interval, 1.3 to 5.1; P = 0.002). When the analysis was restricted to patients with spontaneous recurrences (i.e., ones that occurred in the absence of transient risk factors for venous thrombosis), the risk among carriers of both mutations, as compared with carriers of factor V Leiden alone, remained high (relative risk, 3.7; 95 percent confidence interval, 1.7 to 7.7; P<0.001), particularly if the first event had also been spontaneous (relative risk, 5.4; 95 percent confidence interval, 2.0 to 14.1; P<0.001). In contrast, the risk of recurrence in the presence of transient risk factors was similar among carriers of both mutations and carriers of factor V Leiden alone. Conclusions The risk of recurrent deep venous thrombosis is similar among carriers of factor V Leiden and patients without this mutation. Carriers of both factor V Leiden and the G20210A prothrombin mutation have an increased risk of recurrent deep venous thrombosis after a first episode and are candidates for lifelong anticoagulation. (N Engl J Med 1999;341:801-6.) (C)1999, Massachusetts Medical Society.	Univ Cattolica, Ist Semeiot Med, Dept Hematol, I-00168 Rome, Italy; Univ Milan, Osped Maggiore, Ist Ricovero & Cura Carattere Sci, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	De Stefano, V (corresponding author), Univ Cattolica, Ist Semeiot Med, Dept Hematol, Largo Gemelli 8, I-00168 Rome, Italy.		De Stefano, Valerio/J-3650-2018; Giuseppe Leone, Full Professor/I-9166-2019; CHIUSOLO, PATRIZIA/J-3003-2018; Martinelli, ida/J-2287-2015	De Stefano, Valerio/0000-0002-5178-5827; Giuseppe Leone, Full Professor/0000-0002-7812-5300; CHIUSOLO, PATRIZIA/0000-0002-1355-1587; Martinelli, ida/0000-0001-9218-3622				[Anonymous], 1998, BR J HAEMATOL, V101, P374; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; De Stefano V, 1998, SEMIN THROMB HEMOST, V24, P367, DOI 10.1055/s-2007-996025; De Stefano V, 1998, THROMB HAEMOSTASIS, V80, P342; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Ehrenforth S, 1998, BLOOD, V91, P2209, DOI 10.1182/blood.V91.6.2209; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Eichinger S, 1999, THROMB HAEMOSTASIS, V81, P14; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P1047; Leroyer C, 1998, THROMB HAEMOSTASIS, V80, P49; Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684; Makris M, 1997, THROMB HAEMOSTASIS, V78, P1426; Margaglione M, 1998, ANN INTERN MED, V129, P89, DOI 10.7326/0003-4819-129-2-199807150-00003; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, CIRCULATION, V95, P1777; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; Zoller B, 1998, BLOOD, V91, P2210, DOI 10.1182/blood.V91.6.2210	28	327	341	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					801	806		10.1056/NEJM199909093411104	http://dx.doi.org/10.1056/NEJM199909093411104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477778				2022-12-01	WOS:000082534000004
J	Finnin, MS; Donigian, JR; Cohen, A; Richon, VM; Rifkind, RA; Marks, PA; Breslow, R; Pavletich, NP				Finnin, MS; Donigian, JR; Cohen, A; Richon, VM; Rifkind, RA; Marks, PA; Breslow, R; Pavletich, NP			Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors	NATURE			English	Article							TRANSFORMED-CELL DIFFERENTIATION; TRANSCRIPTIONAL REPRESSION; PROTEINS; INDUCERS	Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression(1). HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers(2,3). HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell. growth(4-6), induce terminal differentiation(4,5) and prevent the formation of tumours in mice models(7,8), and they are effective in the treatment of promyelocytic leukemia(3). Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolieus, that shares 35.2% identity with human HDACl over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.	nikola@xray2.mskcc.org		Finnin, Michael/0000-0003-2794-2703				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cohen L. A., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P108; Davie JR, 1998, J CELL BIOCHEM, P203; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DESAI D, 1999, P AM ASSOC CANC RES, V40, P2396; Fenrick R, 1998, J CELL BIOCHEM, P194; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; SHUTE RE, 1987, J MED CHEM, V30, P71, DOI 10.1021/jm00384a013; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; YOSHIDA T, 1993, CHEM EXPRESS, V8, P17	30	1418	1578	5	215	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					188	193		10.1038/43710	http://dx.doi.org/10.1038/43710			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490031				2022-12-01	WOS:000082458800060
J	Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR				Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR			Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-STREAM INFECTIONS; INSERTED CENTRAL CATHETERS; NOSOCOMIAL INFECTIONS; ACCESS DEVICES; VENOUS ACCESS; RECIPIENTS; POPULATION; PREVENTION; SYSTEM; CANCER	Background: Intravenous therapy in the outpatient and home settings is commonplace for many diseases and nutritional disorders. Few data are available on the rate of and risk factors for bloodstream infection among patients receiving such therapy. Objective: To determine rates of and risk factors for bloodstream infection among patients receiving home infusion therapy. Design: Prospective, observational cohort study. Setting: Cleveland, Ohio, and Toronto, Ontario, Canada. Patients: Patients receiving home infusion therapy through a central or midline catheter. Measurements: Primary laboratory-confirmed bloodstream infection. Results: Among 827 patients (988 catheters), the most common diagnoses were infections other than HIV (67%), cancer (24%), nutritional and digestive disease (17%), heart disease (14%), receipt of bone marrow or solid organ transplants (11%), and HIV infection (7%). Sixty-nine bloodstream infections occurred during 69 532 catheter-days (0.99 infections per 1000 days). In a Cox regression model with time-dependent covariates, independent risk factors for bloodstream infection were recent receipt of a bone marrow transplant (hazard ratio, 5.8 [95% CI, 3.0 to 11.3]), receipt of total parenteral nutrition (hazard ratio, 4.1 [CI, 2.3 to 7.2]), receipt of therapy outside the home (for example, in an outpatient clinic or physician's office) (hazard ratio, 3.6 [CI, 2.2 to 5.9]), use of a multilumen catheter (hazard ratio, 2.8 [CI, 1.7 to 4.7]), and previous bloodstream infection (hazard ratio, 2.5 [CI, 1.5 to 4.2]). Rates of bloodstream infection per 1000 catheter-days varied from 0.16 for patients with none of these 5 risk factors to 6.77 for patients with 3 or more risk factors. Centrally inserted venous catheters were associated with a higher risk than implanted ports were, but the difference was not statistically significant. Conclusion: Bloodstream infections seem to be infrequent among outpatients receiving infusions through central and midline catheters. However, the rate of infection increases with bone marrow transplantation, parenteral nutrition, infusion therapy in a hospital clinic or physician's office, and use of multilumen catheters. Compared with implanted ports or peripherally inserted catheters, centrally inserted venous catheters may confer greater risk for bloodstream infection.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Centers for Disease Control & Prevention - USA; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cleveland Clinic Foundation	Tokars, JI (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA.		mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				CAMPION E, 1998, NEW ENGL J MED, V333, P1213; Cookson ST, 1998, INFECT CONT HOSP EP, V19, P23; DANZIG LE, 1995, JAMA-J AM MED ASSOC, V273, P1862, DOI 10.1001/jama.273.23.1862; Do AN, 1999, J INFECT DIS, V179, P442, DOI 10.1086/314592; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Engelhard D, 1996, TRANSPLANTATION, V61, P430, DOI 10.1097/00007890-199602150-00020; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; HOWELL PB, 1995, CANCER, V75, P1367, DOI 10.1002/1097-0142(19950315)75:6<1367::AID-CNCR2820750620>3.0.CO;2-Z; Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477; Kellerman S, 1996, J PEDIATR-US, V129, P711, DOI 10.1016/S0022-3476(96)70154-3; LAM S, 1994, ARCH INTERN MED, V154, P1833, DOI 10.1001/archinte.154.16.1833; McDonald LC, 1998, INFECT CONT HOSP EP, V19, P772; Ng PK, 1997, MAYO CLIN PROC, V72, P225, DOI 10.4065/72.3.225; PARKER JW, 1995, J BONE JOINT SURG AM, V77A, P572, DOI 10.2106/00004623-199504000-00010; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pittet D, 1997, CLIN INFECT DIS, V24, P1068, DOI 10.1086/513640; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; RAVIGLIONE MC, 1989, AM J MED, V86, P780, DOI 10.1016/0002-9343(89)90473-7; *SAS I INC, 1992, P229 SAS I INC STAT, P434; Serody JS, 1997, INFECT DIS CLIN N AM, V11, P459, DOI 10.1016/S0891-5520(05)70365-2; Stroud L, 1997, INFECT CONT HOSP EP, V18, P479; VLADECK BC, 1994, JAMA-J AM MED ASSOC, V271, P1566	24	107	110	3	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					340	+		10.7326/0003-4819-131-5-199909070-00004	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475886				2022-12-01	WOS:000082458500003
J	Dominici, P; Bellentani, S; Di Biase, AR; Saccoccio, G; Le Rose, A; Masutti, F; Viola, L; Balli, F; Tiribelli, C; Grilli, R; Fusillo, M; Grossi, E				Dominici, P; Bellentani, S; Di Biase, AR; Saccoccio, G; Le Rose, A; Masutti, F; Viola, L; Balli, F; Tiribelli, C; Grilli, R; Fusillo, M; Grossi, E			Familial clustering of Helicobacter pylori infection: population based study	BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL SYMPTOMS; CAMPYLOBACTER-PYLORI; DUODENAL-ULCER; HEALTHY-INDIVIDUALS; IMMUNE-RESPONSE; CHILDREN; GASTRITIS; PREVALENCE; CHILDHOOD; IDENTIFICATION	Objectives To assess the rate of intrafamilial transmission of Helicobacter pylori infection in the general population and the role of a family's social background. Design Population survey. Setting Campogalliano, a town in northern Italy with about 5000 residents. Participants 3289 residents, accounting for 416 families. Main outcome measures Prevalence of H pylori infection assessed by presence of IgG antibodies to H pylori. Results The overall prevalence of H pylori infection was 58%. Children belonging to families with both parents infected had a significantly higher prevalence of H pylori infection (44%) than children from families with only one (30%) or no parents (21%) infected (P < 0.001). Multivariate analyses confirmed that children with both parents positive had double the risk of being infected by H pylori than those from families in which both parents were negative. Family social status was independently related to infection in children, with those from blue collar or farming families showing an increased risk of infection compared with children of white collars workers (odds ratio 2.02, 95% confidence interval 1.16 to 3.49). Conclusions H pylori infection clusters within families belonging to the same population. Social status may also be a risk factor. This suggests either a person to person transmission or a common source of exposure for H pylori infection.	Bracco SpA, Dept Med, I-20134 Milan, Italy; Fondo Studio Malattie Fegato ONLUS, I-34121 Trieste, Italy; Univ Modena & Reggio Emilia, Dept Gynaecol Obstet & Paediat Sci, I-41100 Modena, Italy	Bracco; Universita di Modena e Reggio Emilia	Bellentani, S (corresponding author), Fondo Studi Fegato, Sez Modena, I-41100 Ferrara, Italy.		Grossi, Enzo/AAF-7765-2020; Grilli, Roberto/K-1444-2016; Bellentani, Stefano/L-3600-2019; Grilli, Roberto/AAN-9249-2021; Tiribelli, Claudio/A-4716-2014	Grilli, Roberto/0000-0001-9425-7170; Grilli, Roberto/0000-0001-9425-7170; Tiribelli, Claudio/0000-0001-6596-7595; Bellentani, Stefano/0000-0003-2836-8870				ALFONSO V, 1995, REV ESP ENFERM DIG, V87, P109; ALMOAGEL MA, 1990, AM J GASTROENTEROL, V85, P944; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BEST LM, 1994, J CLIN MICROBIOL, V32, P1193, DOI 10.1128/JCM.32.5.1193-1196.1994; Bonamico M, 1996, ITAL J GASTROENTEROL, V28, P512; CARRICK J, 1989, GUT, V30, P790, DOI 10.1136/gut.30.6.790; CONTINIBALI S, 1988, RIV ITAL PED S1, V14, P87; DASKALOPOULOS G, 1987, GASTROENTEROLOGY, V92, P1363; DEGIACOMA C, 1991, J PEDIATR-US, V119, P205, DOI 10.1016/S0022-3476(05)80728-0; DEGIACOMO C, 1995, ACTA GASTROENTEROL S, P87; DOOLEY CP, 1993, GASTROENTEROL CLIN N, V22, P1; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1526; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FIEDOREK SC, 1991, PEDIATRICS, V88, P578; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; GASBARRINI G, 1995, GUT, V36, P838, DOI 10.1136/gut.36.6.838; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HOSMER DW, 1983, APPL LOGISTIC REGRES; JOHNSTON BJ, 1986, GUT, V27, P11532; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; KATELARIS PH, 1991, ITALIAN J GASTROE S2, V23, P12; LANGENBERG ML, 1984, LANCET, V1, P1348; LIN SK, 1991, ITAL J GASTROENTE S2, V23, P10; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALATY HM, 1994, GUT, V35, P742, DOI 10.1136/gut.35.6.742; MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540; Mendall M A, 1997, Semin Gastrointest Dis, V8, P113; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MITCHELL HM, 1987, LANCET, V2, P681; MITCHELL JD, 1992, AM J GASTROENTEROL, V87, P382; NWOKOLO CU, 1992, GUT, V33, P1323, DOI 10.1136/gut.33.10.1323; ODERDA G, 1991, DIGEST DIS SCI, V36, P572, DOI 10.1007/BF01297021; Palli D, 1997, ALIMENT PHARM THERAP, V11, P719, DOI 10.1046/j.1365-2036.1997.00215.x; TALLEY NJ, 1991, J CLIN MICROBIOL, V29, P1635, DOI 10.1128/JCM.29.8.1635-1639.1991; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1	38	79	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					537	540		10.1136/bmj.319.7209.537	http://dx.doi.org/10.1136/bmj.319.7209.537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463891	Green Published, Bronze			2022-12-01	WOS:000082347200017
J	Ursini, F; Heim, S; Kiess, M; Maiorino, M; Roveri, A; Wissing, J; Flohe, L				Ursini, F; Heim, S; Kiess, M; Maiorino, M; Roveri, A; Wissing, J; Flohe, L			Dual function of the selenoprotein PHGPx during sperm maturation	SCIENCE			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; RAT SPERM; MITOCHONDRIAL CAPSULES; SELENIUM DEFICIENCY; PROTEIN; EXPRESSION; SELENOCYSTEINE; ENZYME; CELLS; CDNA	The selenoprotein phospholipid hydroperoxide glutathione peroxidase (PHGPx) changes its physical characteristics and biological functions during sperm maturation. PHGPx exists as a Soluble peroxidase in spermatids but persists in mature spermatozoa as an enzymatically inactive, oxidatively cross-linked, insoluble protein. in the midpiece of mature spermatozoa, PHGPx protein represents at least 50 percent of the capsule material that embeds the helix of mitochondria. The role of PHGPx as a structural protein may explain the mechanical instability of the mitochondrial midpiece that is observed in selenium deficiency.	Tech Univ Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Natl Res Ctr Biotechnol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; University of Padua	Flohe, L (corresponding author), Tech Univ Braunschweig, Dept Biochem, Mascheroder Weg 1, D-38124 Braunschweig, Germany.		Roveri, Antonella/AAF-3669-2019	Roveri, Antonella/0000-0002-3252-0559				Adham IM, 1996, DNA CELL BIOL, V15, P159, DOI 10.1089/dna.1996.15.159; ANDREESE.JR, 1973, J BACTERIOL, V116, P867, DOI 10.1128/JB.116.2.867-873.1973; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BAUCHE F, 1994, FEBS LETT, V349, P392, DOI 10.1016/0014-5793(94)00709-8; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; CALVIN HI, 1981, GAMETE RES, V4, P139, DOI 10.1002/mrd.1120040208; Cataldo L, 1996, MOL REPROD DEV, V45, P320, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;320::AID-MRD9&gt;3.0.CO;2-U; Fisher HM, 1997, J EXP ZOOL, V277, P390, DOI 10.1002/(SICI)1097-010X(19970401)277:5&lt;390::AID-JEZ5&gt;3.0.CO;2-K; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe Leopold, 1997, P415; Giannattasio A, 1997, J ENDOCRINOL INVEST, V20, P439, DOI 10.1007/BF03347999; Gobom J, 1997, INT J MASS SPECTROM, V169, P153, DOI 10.1016/S0168-1176(97)00216-4; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; Nam Sang-Yoon, 1997, Journal of Reproduction and Development, V43, P227, DOI 10.1262/jrd.43.227; National Research Council (US) Subcommittee on Selenium: 7, 1983, SELENIUM NUTR REVISE; PALLINI V, 1979, J SUBMICR CYTOL PATH, V11, P165; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Sandstrom PA, 1998, FREE RADICAL BIO MED, V24, P1485, DOI 10.1016/S0891-5849(98)00023-9; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SELIGMAN J, 1992, BIOL REPROD, V46, P301, DOI 10.1095/biolreprod46.2.301; SHALGI R, 1989, BIOL REPROD, V40, P1037, DOI 10.1095/biolreprod40.5.1037; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; TURNER DC, 1973, ARCH BIOCHEM BIOPHYS, V154, P366, DOI 10.1016/0003-9861(73)90069-6; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wallace E, 1987, SELENIUM BIOL MED A, P181; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; WU ASH, 1979, BIOL REPROD, V20, P793, DOI 10.1095/biolreprod20.4.793	39	636	680	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1393	1396		10.1126/science.285.5432.1393	http://dx.doi.org/10.1126/science.285.5432.1393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464096				2022-12-01	WOS:000082233500040
J	Gilbert, RE; Tookey, PA				Gilbert, RE; Tookey, PA			Perinatal mortality and morbidity among babies delivered in water: surveillance study and postal survey	BRITISH MEDICAL JOURNAL			English	Article							BIRTHING POOLS; TERM INFANTS; LABOR; ENCEPHALOPATHY; INFECTION	Aim To compare perinatal morbidity and mortality for babies delivered in water with rates for babies delivered conventionally (not in water). Design Surveillance study (of all consultant paediatricians) and postal survey (of all NHS maternity units). Setting British Isles (surveillance study); England and Wales (postal survey). Subjects Babies born in the British Isles between April 1994 and March 1996 who died perinatally or were admitted for special care within 48 hours of birth after delivery in water or after labour in water followed by conventional delivery (surveillance study); babies delivered in water in England and Wales in the same period (postal survey). Main outcome measures Number of deliveries in water in the British Isles that resulted in perinatal death or in admission to special care within 48 hours of birth; and proportions (of such deliveries) of all water births in England and Wales. Results 4032 deliveries (0.6% of all deliveries) in England and Wales occurred in water. Perinatal mortality was 1.2/1000 (95% confidence interval 0.4 to 2.9) live births; 8.4/1000 (5.8 to 11.8) live births were admitted for special care. No deaths were directly attributable to delivery in water, but 2 admissions were for water aspiration. UK reports of mortality and special care admission rates for babies of women considered to be at low risk of complications during delivery who delivered conventionally ranged from 0.8/1000 (0.2 to 4.2) to 4.6/1000 (0.1 to 25) live births and from 9.2 (1.1 to 33) to 64/1000 (58 to 10) live births respectively. Compared with regional data for low risk, spontaneous, normal vaginal deliveries at term, the relative risk for perinatal mortality associated with delivery in water was 0.9 (99% confidence interval 0.2 to 3.6). Conclusions Perinatal mortality is not substantially higher among babies delivered in water than among those born to low risk women who delivered conventionally. The data are compatible with a small increase or decrease in perinatal mortality for babies delivered in water.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Gilbert, RE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gilbert, Ruth/0000-0001-9347-2709				ALDERDICE F, 1995, BRIT MED J, V310, P837, DOI 10.1136/bmj.310.6983.837; ALDERDICE F, 1995, BRIT J MIDWIFERY, V3, P375; Arya R, 1996, ARCH DIS CHILD-FETAL, V75, pF97, DOI 10.1136/fn.75.2.F97; Barron SL, 1996, BRIT MED J, V313, P1306; BARRY CN, 1995, BRIT MED J, V310, P1602, DOI 10.1136/bmj.310.6994.1602b; CAMMU H, 1994, ACTA OBSTET GYN SCAN, V73, P468, DOI 10.3109/00016349409013433; CHURCH LK, 1989, J NURSE-MIDWIFERY, V34, P165, DOI 10.1016/0091-2182(89)90076-1; Cleary R, 1996, BRIT J OBSTET GYNAEC, V103, P223, DOI 10.1111/j.1471-0528.1996.tb09710.x; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; HALL S, 1997, CHILD CARE HLTH DEV, V24, P129; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; Johnson P, 1996, BRIT J OBSTET GYNAEC, V103, P202, DOI 10.1111/j.1471-0528.1996.tb09706.x; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; Middle C, 1995, BRIT J OBSTET GYNAEC, V102, P970, DOI 10.1111/j.1471-0528.1995.tb10904.x; NIKODEM V, 1998, COCHRANE LIB; ODENT M, 1983, LANCET, V2, P1476, DOI 10.1016/S0140-6736(83)90816-4; PAGE L, 1995, MATERNAL CHILD H JAN, P22; Parker PC, 1997, PEDIATRICS, V99, P653, DOI 10.1542/peds.99.4.653a; RAWAL J, 1994, BRIT MED J, V309, P511, DOI 10.1136/bmj.309.6953.511; Roome APCH, 1996, LANCET, V348, P274, DOI 10.1016/S0140-6736(05)65590-0; ROSEVEAR SK, 1993, LANCET, V342, P1048, DOI 10.1016/0140-6736(93)92902-6; Rosser J, 1994, MIDIRS MIDWIFERY DIG, V4, P4; Rush J, 1996, BIRTH-ISS PERINAT C, V23, P136, DOI 10.1111/j.1523-536X.1996.tb00474.x; SCHORN MN, 1993, J NURSE-MIDWIFERY, V38, P336, DOI 10.1016/0091-2182(93)90014-8	24	64	68	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					483	487		10.1136/bmj.319.7208.483	http://dx.doi.org/10.1136/bmj.319.7208.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454400	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000082199600019
J	van Oudenaarden, A; Boxer, SG				van Oudenaarden, A; Boxer, SG			Brownian ratchets: Molecular separations in lipid bilayers supported on patterned arrays	SCIENCE			English	Article							PARTICLES; POLYELECTROLYTES; MACROMOLECULES; MEMBRANES; PROTEINS; MOTION; SIEVE	Brownian ratchets use a time-varying asymmetric potential that can be applied to separate diffusing particles or molecules. A new type of Brownian ratchet, a geometrical Brownian ratchet, has been realized, Charged, fluorescently labeled phospholipids in a two-dimensional fluid bilayer were driven in one direction by an electric field through a two-dimensional periodic array of asymmetric barriers to lateral diffusion fabricated from titanium oxide on silica, Diffusion spreads the phospholipid molecules in the orthogonal direction, and the asymmetric barriers rectify the Brownian motion, causing a directional transport of molecules. The geometrical ratchet can be used as a continuous molecular sieve to separate mixtures of membrane-associated molecules that differ in electrophoretic mobility and diffusion coefficient.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Boxer, SG (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		van Oudenaarden, Alexander/AAA-1705-2019	Boxer, Steven/0000-0001-9167-4286				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Astumian RD, 1998, CHAOS, V8, P533, DOI 10.1063/1.166334; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Derenyi I, 1998, PHYS REV E, V58, P7781, DOI 10.1103/PhysRevE.58.7781; Duke TAJ, 1998, PHYS REV LETT, V80, P1552, DOI 10.1103/PhysRevLett.80.1552; Ertas D, 1998, PHYS REV LETT, V80, P1548, DOI 10.1103/PhysRevLett.80.1548; FAUCHEUX LP, 1995, J CHEM SOC FARADAY T, V91, P3163, DOI 10.1039/ft9959103163; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; FEYNMAN RP, 1966, FEYNMAN LECT PHYSICS, V1; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; Groves JT, 1995, BIOPHYS J, V69, P1972, DOI 10.1016/S0006-3495(95)80067-6; Groves JT, 1998, LANGMUIR, V14, P3347, DOI 10.1021/la9711701; Groves JT, 1997, SCIENCE, V275, P651, DOI 10.1126/science.275.5300.651; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KONIG BW, 1996, LANGMUIR, V12, P1343; KUNG LA, UNPUB; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i; Shimizu S, 1997, SYNTHETIC MET, V85, P1337, DOI 10.1016/S0379-6779(97)80260-3; Slater GW, 1997, PHYS REV LETT, V78, P1170, DOI 10.1103/PhysRevLett.78.1170; Stora T, 1999, ANGEW CHEM INT EDIT, V38, P389, DOI 10.1002/(SICI)1521-3773(19990201)38:3<389::AID-ANIE389>3.0.CO;2-U; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	29	209	212	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1046	1048		10.1126/science.285.5430.1046	http://dx.doi.org/10.1126/science.285.5430.1046			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446046				2022-12-01	WOS:000082033100039
J	Zhong, Q; Chen, CF; Li, S; Chen, YM; Wang, CC; Xiao, J; Chen, PL; Sharp, ZD; Lee, WH				Zhong, Q; Chen, CF; Li, S; Chen, YM; Wang, CC; Xiao, J; Chen, PL; Sharp, ZD; Lee, WH			Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response	SCIENCE			English	Article							BREAST-CANCER; PROTEIN; IDENTIFICATION; REPAIR; RAD50	BRCA1 encodes a tumor suppressor that is mutated in familiar breast and ovarian cancers. Here, it is shown that BRCA1 interacts in vitro and in vivo with hRad50, which forms a complex with hMre11 and p95/nibrin. Upon irradiation, BRCA1 was detected in discrete foci in the nucleus, which colocalize with hRad50. Formation of irradiation-induced foci positive for BRCA1, hRad50, hMre11, or p95 was dramatically reduced in HCC/1937 breast cancer cells carrying a homozygous mutation in BRCA1 but was restored by transfection of wild-type BRCA1. Ectopic expression of wild-type, but not mutated, BRCA1 in these cells rendered them less sensitive to the DNA damage agent, methyl methanesulfonate. These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the hRad50-hMre11-p95 complex.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.		Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X; LI, SHANG/0000-0002-6226-3362; Chen, Chi-Fen/0000-0002-6391-821X	NCI NIH HHS [CA 30195, CA 58183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA030195, P50CA058183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhong Q, 1997, CANCER RES, V57, P4225	15	502	525	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					747	750		10.1126/science.285.5428.747	http://dx.doi.org/10.1126/science.285.5428.747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426999				2022-12-01	WOS:000081765100058
J	Ralph, SG; Rutherford, AJ; Wilson, JD				Ralph, SG; Rutherford, AJ; Wilson, JD			Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study	BRITISH MEDICAL JOURNAL			English	Article							PRETERM DELIVERY; GENITAL-TRACT; PREGNANCY; WOMEN; ENDOMETRITIS; ASSOCIATION; HORMONE; BIRTH	Objectives To assess whether bacterial vaginosis affects the rates of conception and miscarriage in the first trimester. Design Cohort study. Setting Assisted conception unit of a teaching hospital in Leeds. Participants 867 consecutive women undergoing in vitro fertilisation. Interventions Screening for bacterial vaginosis with a Gram stained vaginal smear before egg collection. Main outcome measures The presence of bacterial vaginosis or normal vaginal flora, and the rate of conception and miscarriage in the first trimester. Results 190 of 771 (24.6%) women had bacterial vaginosis. No difference in conception rate was found between those women with bacterial vaginosis and those with normal vaginal flora: 61 women (32.1%) and 146 of 493 women (29.6%) respectively (relative risk 1.08, 95% confidence interval 0.85 to 1.39; odds ratio 1.12, 0.77 to 1.64). However, 22 women (31.6%) with bacterial vaginosis who conceived had a significantly increased risk of miscarriage in the first trimester compared with 27 women (18.5%) with normal vaginal flora (crude relative risk 1.95, 1.11 to 3.42; crude odds ratio: 2.49; 1.21 to 5.12). This increased risk remained significant after adjustment for factors known to increase the rate of miscarriage: increasing maternal age, smoking, history of three or more miscarriages, no precious live birth and polycystic ovaries (adjusted relative risk 2.03, 1.09 to 3.78; adjusted odds ratio 2.67, 1.26 to 5.63). Conclusions Bacterial vaginosis does not affect conception but is associated with an increased risk of miscarriage in the first trimester in women undergoing in vitro fertilisation, independent of other risk factors.	Gen Infirm, Dept Genitourinary Med, Leeds LS1 3EX, W Yorkshire, England; Gen Infirm, Reprod Med Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; Leeds General Infirmary	Wilson, JD (corresponding author), Gen Infirm, Dept Genitourinary Med, Leeds LS1 3EX, W Yorkshire, England.							ASHKENAZI J, 1994, FERTIL STERIL, V61, P526; Curtis P, 1992, HUM REPROD, V7, P625; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HOWE RS, 1988, FERTIL STERIL, V49, P726; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KURKI T, 1992, OBSTET GYNECOL, V80, P173; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; RIDUAN JM, 1993, AM J OBSTET GYNECOL, V169, P175, DOI 10.1016/0002-9378(93)90157-E; RUTHERFORD AJ, 1988, BRIT MED J, V296, P1765, DOI 10.1136/bmj.296.6639.1765; SAUER MV, 1992, AM J OBSTET GYNECOL, V166, P148, DOI 10.1016/0002-9378(92)91850-A; STENMAN UH, 1987, J CLIN ENDOCR METAB, V64, P730, DOI 10.1210/jcem-64-4-730; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	15	164	174	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					220	223		10.1136/bmj.319.7204.220	http://dx.doi.org/10.1136/bmj.319.7204.220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417083	Bronze, Green Published			2022-12-01	WOS:000081720300022
J	Huang, J; Kim, LJ; Mealey, R; Marsh, HC; Zhang, Y; Tenner, AJ; Connolly, ES; Pinsky, DJ				Huang, J; Kim, LJ; Mealey, R; Marsh, HC; Zhang, Y; Tenner, AJ; Connolly, ES; Pinsky, DJ			Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein	SCIENCE			English	Article							FOCAL CEREBRAL-ISCHEMIA; P-SELECTIN; RECEPTOR TYPE-1; NEUTROPHIL ADHESION; ALZHEIMERS-DISEASE; INFARCT VOLUME; BRAIN; REPERFUSION; C1Q; PLATELET	Glycoprotein adhesion receptors such as selectins contribute to tissue injury in stroke. Ischemic neurons strongly expressed C1q, which may target them for complement-mediated attack or C1qRp-mediated clearance. A hybrid molecule was used to simultaneously inhibit both complement activation and selectin-mediated adhesion. The extracellular domain of soluble complement receptor-1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLe(x)) to inhibit complement activation and endothelial-platelet-Leukocyte interactions. sCR1 and sCR1sLe(x) colocalized to ischemic cerebral microvessels and C1q-expressing neurons, inhibited neutrophil and platelet accumulation, and reduced cerebral infarct volumes. Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sCR1 molecule.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Avant Immunotherapeut Inc, Needham, MA 02494 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Columbia University; University of California System; University of California Irvine	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Kim, Louis/F-1781-2011	Marsh, Henry/0000-0001-5637-6013; Huang, Judy/0000-0002-0675-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055397, R01HL059488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035144] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55397, R01 HL59488] Funding Source: Medline; NINDS NIH HHS [R01 NS35144] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; CHAVEZCARTAYA RE, 1995, TRANSPLANTATION, V59, P1047, DOI 10.1097/00007890-199504150-00023; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Diacovo TG, 1996, BLOOD, V88, P146; Frijns CJM, 1997, STROKE, V28, P2214, DOI 10.1161/01.STR.28.11.2214; Fruchterman TM, 1998, SURGERY, V124, P782, DOI 10.1067/msy.1998.91489; FURIE B, 1995, THROMB HAEMOSTASIS, V74, P224; GILLINOV AM, 1993, ANN THORAC SURG, V55, P619, DOI 10.1016/0003-4975(93)90264-I; Haring HP, 1996, STROKE, V27, P1386, DOI 10.1161/01.STR.27.8.1386; HILL J, 1992, J IMMUNOL, V149, P1723; HUANG J, IN PRESS NEUROSURGER; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; KOROTZER AR, 1995, EXP NEUROL, V134, P214, DOI 10.1006/exnr.1995.1051; Kuijper PHM, 1996, BLOOD, V87, P3271, DOI 10.1182/blood.V87.8.3271.bloodjournal8783271; Lazar HL, 1998, ANN THORAC SURG, V65, P973, DOI 10.1016/S0003-4975(98)00021-6; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PEMBERTON M, 1993, J IMMUNOL, V150, P5104; PETRY F, 1991, J IMMUNOL, V147, P3988; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Rittershaus CW, 1999, J BIOL CHEM, V274, P11237, DOI 10.1074/jbc.274.16.11237; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TENNER AJ, 1981, J IMMUNOL, V127, P648; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YOUNG KR, 1991, J IMMUNOL, V146, P3356	32	278	295	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					595	599		10.1126/science.285.5427.595	http://dx.doi.org/10.1126/science.285.5427.595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417391				2022-12-01	WOS:000081609500041
J	Lall, S; Francis-Lang, H; Flament, A; Norvell, A; Schupbach, T; Ish-Horowicz, D				Lall, S; Francis-Lang, H; Flament, A; Norvell, A; Schupbach, T; Ish-Horowicz, D			Squid hnRNP protein promotes apical cytoplasmic transport and localization of Drosophila pair-rule transcripts	CELL			English	Article							MESSENGER-RNA LOCALIZATION; CIS-ACTING SEQUENCES; BINDING PROTEIN; XENOPUS OOCYTES; FUSHI-TARAZU; BICOID RNA; ASYMMETRIC LOCALIZATION; EARLY EMBRYOGENESIS; NUCLEAR EXPORT; GENE	Drosophila melanogaster pair-rule segmentation gene transcripts localize apically of nuclei in blastoderm embryos. This might occur by asymmetric (vectorial) export from one side of the nucleus or by transport within the cytoplasm. We have followed fluorescently labeled pair-rule transcripts postinjection into Drosophila embryos. Naked, microinjected fushi tarazu (ftz) transcripts do not localize in blastoderm embryos, indicating that cytoplasmic mechanisms alone are insufficient for epical targeting. However, prior exposure of ftz to Drosophila or human embryonic nuclear extract leads to rapid, specific, microtubule-dependent transport, arguing against vectorial export. We present evidence that ftz transcript localization involves the Squid (Hrp40) hnRNP protein and that the activity of hnRNP proteins in promoting transcript localization is evolutionarily conserved. We propose that cytoplasmic localization machineries recognize transcripts in the context of nuclear partner proteins.	Imperial Canc Res Fund, Dev Genet Lab, London WC2A 3PX, England; Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	Cancer Research UK; Howard Hughes Medical Institute; Princeton University	Ish-Horowicz, D (corresponding author), Imperial Canc Res Fund, Dev Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England.			Ish-Horowicz, David/0000-0001-5684-7129				AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EDGAR BA, 1986, CELL, V47, P747, DOI 10.1016/0092-8674(86)90517-9; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FOE VE, 1983, J CELL SCI, V61, P31; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Gavis ER, 1996, DEV BIOL, V176, P36, DOI 10.1006/dbio.1996.9996; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Litman P, 1996, DEV BIOL, V176, P86, DOI 10.1006/dbio.1996.9992; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POKRYWKA NJ, 1994, DEV BIOL, V166, P210, DOI 10.1006/dbio.1994.1308; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Wallace CS, 1998, J NEUROSCI, V18, P26; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	61	71	71	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					171	180		10.1016/S0092-8674(00)81012-0	http://dx.doi.org/10.1016/S0092-8674(00)81012-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428029	Bronze			2022-12-01	WOS:000081632300007
J	Vaccarino, V; Parsons, L; Every, NR; Barron, HV; Krumholz, HM				Vaccarino, V; Parsons, L; Every, NR; Barron, HV; Krumholz, HM		Natl Registry Myocardial Infarction 2 Participa	Sex-based differences in early mortality after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; THROMBOLYTIC THERAPY; UNITED-STATES; CASE-FATALITY; SHORT-TERM; INTERVENTION REGISTRY; NATIONAL REGISTRY; DIABETES-MELLITUS; CLINICAL OUTCOMES; BYPASS-SURGERY	Background There is conflicting information about whether short-term mortality after myocardial infarction is higher among women than among men after adjustment for age and other prognostic factors. We hypothesized that younger, but not older, women have higher mortality rates during hospitalization than their male peers. Methods We analyzed data on 384,878 patients (155,565 women and 229,313 men) who were 30 to 89 years of age and who had been enrolled in the National Registry of Myocardial Infarction 2 between June 1994 and January 1998. Patients who had been transferred from or to other hospitals were excluded. Results The overall mortality rate during hospitalization was 16.7 percent among the women and 11.5 percent among the men. Sex-based differences in the rates varied according to age. Among patients less than 50 years of age, the mortality rate for the women was more than twice that for the men. The difference in the rates decreased with increasing age and was no longer significant after the age of 74 (P < 0.001 for the interaction between sex and age). Logistic-regression analysis showed that the odds of death were 11.1 percent greater for women than for men with every five-year decrease in age (95 percent confidence interval, 10.1 to 12.1 percent). Differences in medical history, the clinical severity of the infarction, and early management accounted for only about one third of the difference in the risk. After adjustment for these factors, women still had a higher risk of death for every five years of decreasing age (increase in the odds of death, 7.0 percent; 95 percent confidence interval, 5.9 to 8.1 percent). Conclusions After myocardial infarction, younger women, but not older women, have higher rates of death during hospitalization than men of the same age. The younger the age of the patients, the higher the risk of death among women relative to men. Younger women with myocardial infarction represent a high-risk group deserving of special study. (N Engl J Med 1999;341:217-25.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med Cardiol, New Haven, CT 06520 USA; Univ Washington, Sch Med, Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Field Program, Seattle, WA USA; Univ Washington, Sch Med, Div Cardiol, Cardiovasc Outcomes Res Ctr, Seattle, WA USA; Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA; Genentech Inc, Div Med Affairs, San Francisco, CA 94080 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Yale University; Yale University; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Roche Holding; Genentech; Yale University	Vaccarino, V (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020					ABBOT RD, 1989, JAMA-J AM MED ASSOC, V261, P1884; ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Albert CM, 1996, CIRCULATION, V93, P1170, DOI 10.1161/01.CIR.93.6.1170; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P3249; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Barron HV, 1998, J AM COLL CARDIOL, V32, P360, DOI 10.1016/S0735-1097(98)00225-3; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BERGLUND U, 1988, THROMB HAEMOSTASIS, V60, P21; Breslow NE, 1980, IARC SCI PUBL, VI; BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133; Burke AP, 1998, CIRCULATION, V97, P2110, DOI 10.1161/01.CIR.97.21.2110; Chambless L, 1997, CIRCULATION, V96, P3849; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; CIRAULO DA, 1983, CHEST, V2, P196; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HAMMAR N, 1992, INT J EPIDEMIOL, V21, P1090, DOI 10.1093/ije/21.6.1090; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herman B, 1997, EUR HEART J, V18, P963; HERRINGTON DM, 1997, WOMEN HEART DIS, P243; HEUPLER FA, 1980, AM J CARDIOL, V45, P873, DOI 10.1016/0002-9149(80)90134-4; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KILLIP T, 1967, AM J CARDIOL, V20, P467; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; MARRUGAT J, 1998, NEW ENGL J MED, V338, P8; Maynard C, 1997, ARCH INTERN MED, V157, P1379, DOI 10.1001/archinte.157.12.1379; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MAYNARD C, 1993, CARDIOL ELDER, V1, P121; Nohria Anju, 1998, Cardiology Clinics, V16, P45, DOI 10.1016/S0733-8651(05)70383-0; PETER T, 1978, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1978.tb107829.x; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; Sonke GS, 1996, BRIT MED J, V313, P853; Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Vaccarino V, 1996, J AM GERIATR SOC, V44, P1174, DOI 10.1111/j.1532-5415.1996.tb01366.x; Vaccarino V, 1998, ARCH INTERN MED, V158, P2054, DOI 10.1001/archinte.158.18.2054; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4	63	930	967	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					217	225		10.1056/NEJM199907223410401	http://dx.doi.org/10.1056/NEJM199907223410401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413733				2022-12-01	WOS:000081528800001
J	Wolter, T				Wolter, T			If the fates allow	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Family Hlth Associates, Chippewa Falls, WI 54729 USA		Wolter, T (corresponding author), Family Hlth Associates, 2449 Cty Highway 1, Chippewa Falls, WI 54729 USA.	taran@execpc.com							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					148	149		10.7326/0003-4819-131-2-199907200-00014	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419433				2022-12-01	WOS:000081509700012
J	Mansi, JL; Gogas, H; Bliss, JM; Gazet, JC; Berger, U; Coombes, RC				Mansi, JL; Gogas, H; Bliss, JM; Gazet, JC; Berger, U; Coombes, RC			Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study	LANCET			English	Article							BONE-MARROW MICROMETASTASES; EPITHELIAL MEMBRANE ANTIGEN; MAMMARY-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; PROGNOSTIC-SIGNIFICANCE; MICRO-METASTESES; TUMOR-CELLS; METASTASES	Background Bone-marrow micrometastases have been found in patients with primary breast cancer. We report long-term follow-up of women with primary breast cancer, diagnosed between 1981 and 1986, who had multiple aspirates taken at the time of initial surgery. Methods 350 women with primary breast cancer were examined immunocytochemically with antibody to epithelial membrane antigen. We investigated associations with various prognostic factors as well as the effect of micrometastases on relapse-free survival and overall survival. Findings At median follow-up of 12.5 years, 151 patients had metastatic disease and 136 patients had died from breast cancer. 10-year relapse-free and overall survival were 43.9% (95% CI 33.4-54.7) and 44.9% (34.2-55.9) in patients with micrometastases, and 62.7% (56.5-68.6) and 65.7% (59.4-71.5) in patients without micrometastases at presentation (p<0.001). For relapse-free survival acid overall survival, allowing for tumour size, lymph-node Status, and vascular invasion, the effect of micrometastases decreased and was no longer significant, with a hazard ratio of 1.09 (0.74-1.61) for relapse-free survival and 1.21 (0.84-1.75) for overall survival. Interpretation The presence of bone-marrow micrometastases in patients with primary breast cancer is associated with a shorter relapse-free survival and overall survival, but is not all independent prognostic factor. This immunocytochemical technique may be of value in patients for whom pathological tumour size and lymph-node status are unavailable tie, patients receiving primary medical treatment).	Univ London St Georges Hosp, Dept Med Oncol, London SW17 0QT, England; Inst Canc Res, Surrey, England; Univ London St Georges Hosp, Dept Surg, London SW17 0QT, England; Charing Cross Hosp, Dept Oncol, London, England	St Georges University London; University of London; Institute of Cancer Research - UK; St Georges University London; Imperial College London	Mansi, JL (corresponding author), Univ London St Georges Hosp, Dept Med Oncol, London SW17 0QT, England.			Coombes, Raoul Charles/0000-0002-4811-1100; Bliss, Judith/0000-0001-7957-7424				BERGER U, 1988, AM J CLIN PATHOL, V90, P1; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COTE RJ, 1988, AM J SURG PATHOL, V12, P333, DOI 10.1097/00000478-198805000-00001; COTE RJ, 1991, DIAGN ONCOL, V1, P37; DEARNALEY DP, 1983, J ROY SOC MED, V76, P359, DOI 10.1177/014107688307600506; DEARNALEY DP, 1981, BRIT J CANCER, V44, P85, DOI 10.1038/bjc.1981.152; DIEL IJ, 1992, J CLIN ONCOL, V10, P1534, DOI 10.1200/JCO.1992.10.10.1534; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; ELLIS G, 1989, CANCER, V63, P2509, DOI 10.1002/1097-0142(19890615)63:12<2509::AID-CNCR2820631225>3.0.CO;2-K; Fields KK, 1996, J CLIN ONCOL, V14, P1868, DOI 10.1200/JCO.1996.14.6.1868; HARBECK N, 1994, BRIT J CANCER, V69, P566, DOI 10.1038/bjc.1994.103; HARBECK N, 1990, Journal of Cancer Research and Clinical Oncology, V116, P49; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; MANSI JL, 1988, J UROLOGY, V139, P545, DOI 10.1016/S0022-5347(17)42516-X; MANSI JL, 1989, J CLIN ONCOL, V7, P445, DOI 10.1200/JCO.1989.7.4.445; MANSI JL, 1991, EUR J CANCER, V27, P1552, DOI 10.1016/0277-5379(91)90413-8; MANSI JL, 1987, BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093; PASSOSCOELHO J, 1994, CANCER RES, V54, P2366; PINKUS GS, 1985, HUM PATHOL, V16, P929, DOI 10.1016/S0046-8177(85)80132-5; PORRO G, 1988, CANCER, V61, P2407, DOI 10.1002/1097-0142(19880615)61:12<2407::AID-CNCR2820611202>3.0.CO;2-G; REDDING WH, 1983, LANCET, V2, P1271; SHARP JG, 1992, INT J CELL CLONING, V10, P92, DOI 10.1002/stem.5530100731; THOMAS P, 1987, HUM PATHOL, V18, P728, DOI 10.1016/S0046-8177(87)80244-7; THOR A, 1988, BREAST CANCER RES TR, V11, P133, DOI 10.1007/BF01805837	26	232	244	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					197	202		10.1016/S0140-6736(98)10175-7	http://dx.doi.org/10.1016/S0140-6736(98)10175-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421301				2022-12-01	WOS:000081504200011
J	Yoshizawa, S; Fourmy, D; Puglisi, JD				Yoshizawa, S; Fourmy, D; Puglisi, JD			Recognition of the codon-anticodon helix by ribosomal RNA	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOMES; DEACYLATED TRANSFER-RNA; A-SITE; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; CATALYTIC CORE; MESSENGER-RNA; BINDING-SITES; TRANSLATION; COMPLEX	Translational fidelity is established by ribosomal recognition of the codon-anticodon interaction within the aminoacyl-transfer RNA (tRNA) site (A site) of the ribosome. Experiments are presented that reveal possible contacts between 16S ribosomal RNA and the codon-anticodon complex. Nf methylation of adenine at position 1492 (A1492) and A1493 interfered with A-site tRNA binding. Mutation of A1492 and A1493 to guanine or cytosine also impaired A-site tRNA binding. The deleterious effects of A1492G or A1493G (or both) mutations were compensated by 2' fluorine substitutions in the mRNA codon. The results suggest that the ribosome recognizes the codon-anticodon complex by adenine contacts to the messenger RNA backbone and provide a mechanism for molecular discrimination of correct versus incorrect codon-anticodon pairs.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Puglisi, JD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	puglisi@stanford.edu	Yoshizawa, Satoko/T-8302-2018; fourmy, dominique/J-4766-2014	Yoshizawa, Satoko/0000-0002-9333-8961; fourmy, dominique/0000-0002-2170-3536	NIGMS NIH HHS [GM51266] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051266] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURUP H, 1994, NUCLEIC ACIDS RES, V22, P4963, DOI 10.1093/nar/22.23.4963; Blanchard SC, 1998, BIOCHEMISTRY-US, V37, P7716, DOI 10.1021/bi973125y; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7600, DOI 10.1021/bi00485a009; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; DAVIES J, 1964, P NATL ACAD SCI USA, V51, P883, DOI 10.1073/pnas.51.5.883; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; KARIMI R, 1994, EUR J BIOCHEM, V226, P355, DOI 10.1111/j.1432-1033.1994.tb20059.x; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUTLAND CG, 1992, ANNU REV GENET, V26, P29; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; MCCARTHY BJ, 1965, P NATL ACAD SCI USA, V54, P880, DOI 10.1073/pnas.54.3.880; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Narlikar GJ, 1998, BIOCHEMISTRY-US, V37, P9902, DOI 10.1021/bi980495t; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; POTAPOV AP, 1995, J BIOL CHEM, V270, P17680, DOI 10.1074/jbc.270.30.17680; POWERS T, 1994, TRENDS GENET, V10, P27, DOI 10.1016/0168-9525(94)90016-7; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Recht MI, 1999, J MOL BIOL, V286, P33, DOI 10.1006/jmbi.1998.2446; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Szewczak AA, 1998, NAT STRUCT BIOL, V5, P1037, DOI 10.1038/4146; TAKAHASHI LH, 1989, J AM CHEM SOC, V111, P3368, DOI 10.1021/ja00191a039; VanLoock MS, 1999, J MOL BIOL, V285, P2069, DOI 10.1006/jmbi.1998.2442; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437; YOSHIZAWA S, UNPUB	39	196	206	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1722	1725		10.1126/science.285.5434.1722	http://dx.doi.org/10.1126/science.285.5434.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481006				2022-12-01	WOS:000082472600032
J	Matser, EJT; Kessels, AG; Lezak, MD; Jordan, BD; Troost, J				Matser, EJT; Kessels, AG; Lezak, MD; Jordan, BD; Troost, J			Neuropsychological impairment in amateur soccer players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN INJURY	Context Soccer players incur concussions during matches and training sessions, as well as numerous subconcussive blows to the head from impacts with the soccer ball (headers). The combination of soccer-related concussions and the number of headers may be a risk for chronic traumatic brain injury (CTBI). Objective To determine whether amateur soccer players have evidence of CTBI. Design, Setting, and Participants Cross-sectional study of 33 amateur soccer players and 27 amateur athletes involved in swimming and track (controls) in the Netherlands who underwent interviews and neuropsychological testing. Main Outcome Measures Performance of soccer players vs controls on 16 neuropsychological tests having 27 outcomes. Results Compared with control athletes, amateur soccer players exhibited impaired performance on tests of planning (39% vs 13%; P = .001) and memory (27% vs 7%; P = .004). Among soccer players, 9 (27%) had incurred 1 soccer-related concussion and 7 (23%) had had 2 to 5 concussions during their career. The number of concussions incurred in soccer was inversely related to the neuropsychological performance on 6 of the neuropsychological tests. Conclusions Our results indicate that participation in amateur soccer in general and concussion specifically is associated with impaired performance in memory and planning functions. Due to the worldwide popularity of soccer, these observations may have important public health implications.	St Anna Hosp, Det Neuropsychol & Sports Neurol, NL-5560 AB Geldrop, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Anat, NL-3000 DR Rotterdam, Netherlands; Univ Hosp Maastricht, Res Unit Patient Care, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Burke Rehabil Hosp, Traumat Brain Injury Program, White Plains, NY USA	Erasmus University Rotterdam; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Oregon Health & Science University	Matser, EJT (corresponding author), St Anna Hosp, Det Neuropsychol & Sports Neurol, POB 90, NL-5560 AB Geldrop, Netherlands.							[Anonymous], 1981, WAIS R MANUAL; Army Individual Test Battery, 1944, ARM COMB FITN TEST; Benton AL., 1994, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; CORSELLIS JA, 1976, LANCET, V1, P401; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Deelman B.G., 1980, NEUROPSYCHOLOGIE NED; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lauter J, 1996, BIOMETRICS, V52, P964, DOI 10.2307/2533057; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luteyn, 1966, DUTCH J PSYCHOL, V2, P675; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATSER JT, 1996, GENEESKUNDE SPORT, V29, P66; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Osterrieth P. A., 1944, ARCHIVESPSYCHOLOGIE, V30, P206; Raven J.C., 1960, GUIDE STANDARD PROGR; ROBBERTS AH, 1969, BRAIN DAMAGE BOXERS; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Van De Loo L., 1956, TIJIKSCHRIFT PSYCHOL, V2, P33; VANDERVLUGT H, 1979, LATERALISATIES HERSE; Wechsler D, 1974, WECHSLER MEMORY SCAL; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	28	272	275	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					971	973		10.1001/jama.282.10.971	http://dx.doi.org/10.1001/jama.282.10.971			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485683	Bronze			2022-12-01	WOS:000082335900036
J	Ozes, ON; Mayo, LD; Gustin, JA; Pfeffer, SR; Pfeffer, LM; Donner, DB				Ozes, ON; Mayo, LD; Gustin, JA; Pfeffer, SR; Pfeffer, LM; Donner, DB			NF-kappa B activation by tumour necrosis factor requires the Akt serine-threonine kinase	NATURE			English	Article							SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; IKK-ALPHA; TNF; COMPLEX; PHOSPHORYLATION; 3-KINASE; BETA	Activation of the nuclear transcription factor NF-kappa B by inflammatory cytokines requires the successive action of NF-kappa B-inducing kinase (NIK) and an I kappa B-kinase (IKK) complex composed of IKK alpha and IKK beta(1-5). Here we show that the Akt serine-threonine kinase(6) is involved in the activation of NF-kappa B by tumour necrosis factor (TNF). TNF activates phosphatidylinositol-3-OH kinase (PI(3)K) and its downstream target Akt (protein kinase B). Wortmannin (a PI(3)K inhibitor), dominant-negative PI(3)K or kinase-dead Akt inhibits TNF-mediated NF-kappa B activation. Constitutively active Akt induces NF-kappa B activity and this effect is blocked by dominant-negative NIK. Conversely, NIK activates NF-KB and this is blocked by kinase-dead Akt. Thus, both Akt and NIK are necessary for TNF activation of NF-kappa B. Akt mediates IKKa phosphorylation at threonine 23. Mutation of this amino acid blocks phosphorylation by Akt or TNF and activation of NF-kappa B. These findings indicate that Akt is part of a signalling pathway that is necessary for inducing key immune and inflammatory responses.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Oncol Ctr, Indianapolis, IN 46202 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center	Donner, DB (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.			Pfeffer, Lawrence/0000-0003-2809-1234				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bauerle PA, 1996, CELL, V87, P13; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	20	1827	1882	1	107	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					82	85						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485710				2022-12-01	WOS:000082374400046
J	Bahcall, DO; Kowler, E				Bahcall, DO; Kowler, E			Illusory shifts in visual direction accompany adaptation of saccadic eye movements	NATURE			English	Article							DISPLACEMENT; TARGETS; REPRESENTATION; LOCALIZATION; PERCEPTION	A central problem in human vision is to explain how the visual world remains stable despite the continual displacements of the retinal image produced by rapid saccadic movements of the eyes. Perceived stability has been attributed to 'efferent-copy' signals, representing the saccadic motor commands, that cancel the effects of saccade-related retinal displacements(1-6). Here we show by means of a perceptual illusion, that traditional cancellation theories cannot explain stability. The perceptual illusion was produced by first inducing adaptive changes in saccadic gain (ratio of saccade size to target eccentricity). Following adaptation, subjects experienced an illusory mislocalization in which widely separated targets flashed before and after saccades appeared to be in the same place. The illusion shows that the perceptual system did not take the adaptive changes into account, Perceptual localization is based on signals representing the size of the initially-intended saccade, not the size of the saccade that is ultimately executed, Signals representing intended saccades initiate a visual comparison process used to maintain perceptual stability across saccades and to generate the oculomotor error signals that ensure saccadic accuracy.	Rutgers State Univ, Dept Psychol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kowler, E (corresponding author), Rutgers State Univ, Dept Psychol, Piscataway, NJ 08854 USA.	kowler@rci.rutgers.edu						ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; CARPENTER RHS, 1992, MOVEMENTS EYES; CORNSWEET TN, 1962, AM J PSYCHOL, V75, P485, DOI 10.2307/1419876; CRANE HD, 1978, APPL OPTICS, V17, P691, DOI 10.1364/AO.17.000691; DASSONVILLE P, 1992, VISUAL NEUROSCI, V9, P261, DOI 10.1017/S0952523800010671; Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; DEUBEL H, 1995, VISION RES, V35, P3529, DOI 10.1016/0042-6989(95)00058-M; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; ERKELENS CJ, 1993, EXP BRAIN RES, V93, P157; Frens MA, 1997, BRAIN RES BULL, V43, P473, DOI 10.1016/S0361-9230(97)80001-9; GOLDBERG ME, 1993, INT CONGR SER, V1024, P203; GOODALE MA, 1986, NATURE, V320, P748, DOI 10.1038/320748a0; KOWLER E, 1995, VISION RES, V35, P1741, DOI 10.1016/0042-6989(94)00255-K; LEIGH RJ, 1991, NEUROBIOLOGY EYE MOV, P82; LENNIE P, 1978, NATURE, V275, P766, DOI 10.1038/275766a0; LUDVIGH E, 1952, AMA ARCH OPHTHALMOL, V48, P442; MACKAY DM, 1973, HDB SENSORY PHYSIOLO, V7, P307; MATIN L, 1965, SCIENCE, V148, P1485, DOI 10.1126/science.148.3676.1485; MATIN L, 1972, HDB SENSORY PHYSIOLO, V7, P331; McGowan JW, 1998, VISION RES, V38, P895, DOI 10.1016/S0042-6989(97)00232-0; MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071; MILLER JM, 1981, J EXP PSYCHOL HUMAN, V7, P356, DOI 10.1037/0096-1523.7.2.356; OPTICAN LM, 1985, ADAPTIVE MECH GAZE C, P71; POLA J, 1976, EYE MOVEMENTS PSYCHO, P245; Skavenski A. A., 1990, EYE MOVEMENTS THEIR, P263; SKAVENSKI AA, 1972, PERCEPT PSYCHOPHYS, V11, P287, DOI 10.3758/BF03210380; Sperling G., 1990, EYE MOVEMENTS THEIR, P307; VONHELMHOLTZ H, 1963, TREATISE PHYSL OPTIC, V3; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503	30	81	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					864	866		10.1038/23693	http://dx.doi.org/10.1038/23693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476963				2022-12-01	WOS:000082233200043
J	Coral-Vazquez, R; Cohn, RD; Moore, SA; Hill, JA; Weiss, RM; Davisson, RL; Straub, V; Barresi, R; Bansal, D; Hrstka, RF; Williamson, R; Campbell, KP				Coral-Vazquez, R; Cohn, RD; Moore, SA; Hill, JA; Weiss, RM; Davisson, RL; Straub, V; Barresi, R; Bansal, D; Hrstka, RF; Williamson, R; Campbell, KP			Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy	CELL			English	Article							GLYCOPROTEIN COMPLEX; DILATED CARDIOMYOPATHY; GAMMA-SARCOGLYCAN; DEFICIENT MICE; HEART-FAILURE; MUTATIONS; GENE; NICORANDIL; LGMD2F; ACTIN	To investigate mechanisms in the pathogenesis of cardiomyopathy associated with mutations of the dystrophin-glycoprotein complex, we analyzed genetically engineered mice deficient for either alpha-sarcoglycan (Sgca) or delta-sarcoglycan (Sgcd). We found that only Sgcd null mice developed cardiomyopathy with focal areas of necrosis as the histological hallmark in cardiac and skeletal muscle. Absence of the sarcoglycan-sarcospan (SG-SSPN) complex in skeletal and cardiac membranes was observed in both animal models. Loss of vascular smooth muscle SG-SSPN complex was only detected in Sgcd null mice and associated with irregularities of the coronary vasculature. Administration of a vascular smooth muscle relaxant prevented onset of myocardial necrosis. Our data indicate that disruption of the SG-SSPN complex in vascular smooth muscle perturbs vascular function, which initiates cardiomyopathy and exacerbates muscular dystrophy.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Dept Vet Affairs, Iowa City, IA 52242 USA; Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022; Cohn, Ronald/AAC-5835-2021; Pillay, Nischalan/F-9536-2012	Barresi, Rita/0000-0001-7351-959X; Campbell, Kevin/0000-0003-2066-5889; Moore, Steven/0000-0002-6353-7900; Coral, Ramon/0000-0001-6126-2002; Straub, Volker/0000-0001-9046-3540	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom; NIDDK NIH HHS [DK25295] Funding Source: Medline; Telethon [305/B] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Fondazione Telethon(Fondazione Telethon); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; KASKI JC, 1995, CARDIOVASC DRUG THER, V9, P221, DOI 10.1007/BF00878469; KUKOVETZ WR, 1992, J CARDIOVASC PHARM, V20, pS1, DOI 10.1097/00005344-199206203-00002; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; Melacini P, 1999, MUSCLE NERVE, V22, P473, DOI 10.1002/(SICI)1097-4598(199904)22:4<473::AID-MUS8>3.0.CO;2-5; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Moreira ES, 1998, J MED GENET, V35, P951, DOI 10.1136/jmg.35.11.951; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Sakamoto A, 1999, FEBS LETT, V447, P124, DOI 10.1016/S0014-5793(99)00267-7; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; STRAUB V, 1999, IN PRESS J BIOL CHEM; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3	25	299	309	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					465	474		10.1016/S0092-8674(00)81975-3	http://dx.doi.org/10.1016/S0092-8674(00)81975-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481911	Bronze			2022-12-01	WOS:000082174900007
J	Campbell, JJ; Haraldsen, G; Pan, J; Rottman, J; Qin, S; Ponath, P; Andrew, DP; Warnke, R; Ruffing, N; Kassam, N; Wu, L; Butcher, EC				Campbell, JJ; Haraldsen, G; Pan, J; Rottman, J; Qin, S; Ponath, P; Andrew, DP; Warnke, R; Ruffing, N; Kassam, N; Wu, L; Butcher, EC			The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells	NATURE			English	Article							LYMPHOCYTE-ASSOCIATED ANTIGEN; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; HOMING RECEPTOR; E-SELECTIN; EXPRESSION; PHENOTYPE; SUBSETS; INTERLEUKIN-8; RECRUITMENT	Lymphocytes that are responsible for regional (tissue-specific) immunity home from the blood to the intestines, inflamed skin or other sites through a multistep process involving recognition of vascular endothelial cells and extravasation(1). Chemoattractant cytokine molecules known as chemokines(2) regulate this lymphocyte traffic, in part by triggering arrest (stopping) of lymphocytes rolling on endothelium(3-5). Here we shaw that many systemic memory T cells in blood carry the chemokine receptor CCR4 (ref. 6) and therefore respond to its ligands, the chemokines TARC and MDC. These cells include essentially all skin-homing cells expressing the cutaneous lymphocyte antigen and a subset of other systemic memory lymphocytes; however, intestinal (alpha 4 beta 7(+)) memory and naive T cells respond poorly. Immunohistochemistry reveals anti-TARC reactivity of venules and infiltration of many CCR4(+) lymphocytes in chronically inflamed skin, but not in the gastrointestinal lamina propria. Moreover, TARC induces integrin-dependent adhesion of skin (but not intestinal) memory T cells to the cell-adhesion molecule ICAM-1, and causes their rapid arrest under physiological now. Our results suggest that CCR4 and TARC are important in the recognition of skin vasculature by circulating T cells and in directing lymphocytes that are involved in systemic as opposed to intestinal immunity to their target tissues.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; LeukoSite Inc, Cambridge, MA 02142 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Campbell, JJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Haraldsen, Guttorm/W-4359-2019; Haraldsen, Guttorm/I-2680-2013	Campbell, James/0000-0003-4252-5182; Haraldsen, Guttorm/0000-0002-0064-9665				Anderson A O, 1993, Semin Immunol, V5, P271, DOI 10.1006/smim.1993.1031; Andrew DP, 1998, J IMMUNOL, V161, P5027; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Baekkevold ES, 1999, LAB INVEST, V79, P327; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Mackay CR, 1996, EUR J IMMUNOL, V26, P2433, DOI 10.1002/eji.1830261025; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SILBER A, 1994, J CLIN INVEST, V93, P1554, DOI 10.1172/JCI117134; Teraki Y, 1997, J IMMUNOL, V159, P6018; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Williams MB, 1997, J IMMUNOL, V159, P1746; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	30	674	698	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					776	780		10.1038/23495	http://dx.doi.org/10.1038/23495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466728				2022-12-01	WOS:000082131100053
J	Humphries, DE; Wong, GW; Friend, DS; Gurish, MF; Qiu, WT; Huang, CF; Sharpe, AH; Stevens, RL				Humphries, DE; Wong, GW; Friend, DS; Gurish, MF; Qiu, WT; Huang, CF; Sharpe, AH; Stevens, RL			Heparin is essential for the storage of specific granule proteases in mast cells	NATURE			English	Article							DIPEPTIDYL PEPTIDASE-I; MOLECULAR-CLONING; SERINE PROTEASES; MESSENGER-RNA; MOUSE; GENE; TRANSCRIPTION; EXPRESSION; SUBCLASS; SULFOTRANSFERASE	All mammals produce heparin, a negatively charged glycosaminoglycan that is a major constituent of the secretory granules of mast cells which are found in the peritoneal cavity and most connective tissues. Although heparin is one of the most studied molecules in the body, its physiological function has yet to be determined. Here we describe transgenic mice, generated by disrupting the N-deacetylase/N-sulphotransferase-2 gene(1,2), that cannot express fully sulphated heparin, The mast cells in the skeletal muscle that normally contain heparin lacked metachromatic granules and failed to store appreciable amounts of mouse mast-cell protease (mMCP)-4, mMCP-5 and carboxypeptidase A (mMC-CPA), even though they contained substantial amounts of mMCP-7, We developed mast cells from the bone marrow of the transgenic mice. Although these cultured cells contained high levels of various protease transcripts and had substantial amounts of mMCP-6 protein in their granules, they also failed to express mMCP-5 and mMC-CPA, Our data show that heparin controls, through a post-translational mechanism, the levels of specific cassettes of positively charged proteases inside mast cells.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02130 USA; VA Med Ctr, Boston, MA 02130 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ERIKSSON I, 1994, J BIOL CHEM, V269, P10439; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Gurish MF, 1997, BLOOD, V90, P382; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P16744; Huang CF, 1998, J IMMUNOL, V160, P1910; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1989, BIOSYNTHESIS HEPARIN, P159; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1982, J BIOL CHEM, V257, P253; STEVENS RL, 1986, J IMMUNOL, V137, P291; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054	30	340	347	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					769	772		10.1038/23481	http://dx.doi.org/10.1038/23481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466726				2022-12-01	WOS:000082131100051
J	Bontempi, B; Laurent-Demir, C; Destrade, C; Jaffard, R				Bontempi, B; Laurent-Demir, C; Destrade, C; Jaffard, R			Time-dependent reorganization of brain circuitry underlying long-term memory storage	NATURE			English	Article							POSTERIOR CINGULATE CORTICES; POSITRON EMISSION TOMOGRAPHY; COGNITIVE NEUROSCIENCE; HIPPOCAMPAL-FORMATION; RETROGRADE-AMNESIA; EPISODIC MEMORY; CONSOLIDATION; MICE; PERSPECTIVE; RETRIEVAL	Retrogade amnesia observed following hippocampal lesions in humans and animals is typically temporally graded(1,2), with recent memory being impaired while remote memories remain intact, indicating that the hippocampal formation has a time-limited role in memory storage(3,4). However, this claim remains controversial because studies involving hippocampal lesions tell us nothing about the contribution of the hippocampus to memory storage if this region was present at the time of memory retrieval(5,6). We therefore used non-invasive functional brain imaging using (C-14)2-deoxyglucose uptake to examine how the brain circuitry underlying long-term memory storage is reorganized over time in an intact brain. Regional metabolic activity in the brain was mapped in mice tested at different times for retention of a spatial discrimination task. Here we report that increasing the retention interval from 5 days to 25 days resulted in both decreased hippocampal metabolic activity during retention testing and a loss of correlation between hippocampal metabolic activity and memory performance. Concomitantly, a recruitment of certain cortical areas was observed. These results indicate that there is a time-dependent reorganization of the neuronal circuitry underlying long-term memory storage, in which a transitory interaction between the hippocampal formation and the neocortex would mediate the establishment of long-lived cortical memory representations.	Univ Bordeaux 1, CNRS, UMR 5807, Cognit Neurosci Lab, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bontempi, B (corresponding author), Univ Bordeaux 1, CNRS, UMR 5807, Cognit Neurosci Lab, Ave Fac, F-33405 Talence, France.							Alkire MT, 1998, P NATL ACAD SCI USA, V95, P14506, DOI 10.1073/pnas.95.24.14506; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Bontempi B, 1996, EUR J NEUROSCI, V8, P2348, DOI 10.1111/j.1460-9568.1996.tb01198.x; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; CHO YH, 1993, J NEUROSCI, V13, P1759; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Dudai Y, 1996, NEURON, V17, P367, DOI 10.1016/S0896-6273(00)80168-3; FINCH DM, 1984, EXP NEUROL, V83, P468, DOI 10.1016/0014-4886(84)90116-X; Fink GR, 1996, J NEUROSCI, V16, P4275; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; Knowlton BJ, 1998, CURR OPIN NEUROBIOL, V8, P293, DOI 10.1016/S0959-4388(98)80154-2; LEHMAN A, 1974, ATLAS STEREOTAXIQUE; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCINTOSH AR, 1994, J NEUROPHYSIOL, V72, P1717, DOI 10.1152/jn.1994.72.4.1717; MEUNIER M, 1991, BEHAV BRAIN RES, V44, P133, DOI 10.1016/S0166-4328(05)80018-X; Moscovitch M, 1998, CURR OPIN NEUROBIOL, V8, P297, DOI 10.1016/S0959-4388(98)80155-4; Nyberg L, 1996, J NEUROSCI, V16, P3753; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; Reed JM, 1998, J NEUROSCI, V18, P3943; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SIF J, 1989, NEUROSCI LETT, V101, P223, DOI 10.1016/0304-3940(89)90535-1; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	29	454	458	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					671	675		10.1038/23270	http://dx.doi.org/10.1038/23270			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458162				2022-12-01	WOS:000082032900055
J	Beswich, AJ; Lawley, B; Fraise, AP; Pahor, AL; Brown, NL				Beswich, AJ; Lawley, B; Fraise, AP; Pahor, AL; Brown, NL			Detection of Alloiococcus otitis in mixed bacterial populations from middle-ear effusions of patients with otitis media	LANCET			English	Article							POLYMERASE CHAIN-REACTION; PCR; IDENTIFICATION; PERSISTENT; PATHOGENS; CHILDREN; RNA; DNA	Background Otitis media is a potentially serious disorder, since there is a risk of permanent hearing loss. Culture methods are not useful in characterisation of populations of bacteria in the middle ear. We have used a PCR-based method that does not depend on prior knowledge of the bacteria identified by culture. Methods Middle-ear effusion fluid was obtained from 12 patients with chronic otitis media with effusion. Total DNA was extracted from the samples, and the hypervariable regions of bacterial 16S rRNA genes were amplified by means of broad-range PCR primers. Individual PCR products were segregated by cloning to allow analysis of mixed bacterial populations. Findings Many bacterial species were detected by PCR, whereas with culture-based approaches, no bacterial growth was detected for ten of the 12 patients. The gram-positive bacterium Alloiococcus otitis (A otitidis) was detected by 16S rDNA amplification in six of the twelve samples, but not by culture techniques. Interpretation The method may have general usefulness in characterising bacterial populations at the site of infection and may indicate, from small sample numbers, organisms that are candidates for further investigation.	Univ Birmingham, Sch Biol Sci, Birmingham, W Midlands, England; City Hosp NHS Trust, Hosp Infect Res Lab, Birmingham, W Midlands, England; City Hosp NHS Trust, Dept Otorhinolaryngol, Birmingham, W Midlands, England	University of Birmingham	Beswich, AJ (corresponding author), Hlth & Safety Lab, Broad Lane, Sheffield S3 7HQ, S Yorkshire, England.	alan.beswick@hsl.gov.uk						AGUIRRE M, 1992, INT J SYST BACTERIOL, V42, P79, DOI 10.1099/00207713-42-1-79; ALVAREZ AJ, 1994, APPL ENVIRON MICROB, V60, P374, DOI 10.1128/AEM.60.1.374-376.1994; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; Hinton A, 1996, CLIN OTOLARYNGOL, V21, P158, DOI 10.1111/j.1365-2273.1996.tb01322.x; HOTOMI M, 1993, INT J PEDIATR OTORHI, V27, P119, DOI 10.1016/0165-5876(93)90127-O; HOWIE VM, 1975, AM J DIS CHILD, V129, P679, DOI 10.1001/archpedi.1975.02120430016006; Jero J, 1997, ACTA OTO-LARYNGOL, P22; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; Liederman EM, 1998, ANN OTO RHINOL LARYN, V107, P10; Matar GM, 1998, J CLIN MICROBIOL, V36, P1185, DOI 10.1128/JCM.36.5.1185-1188.1998; Ohtani H, 1998, NEPHROL DIAL TRANSPL, V13, P177, DOI 10.1093/ndt/13.1.177; PICHICHERO ME, 1995, PEDIATR INFECT DIS J, V14, P178, DOI 10.1097/00006454-199503000-00002; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; Saffer M, 1996, ACTA OTO-LARYNGOL, V116, P836, DOI 10.3109/00016489609137936; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Stackebrandt E, 1996, MICROBIAL DIVERSITY IN TIME AND SPACE, P19, DOI 10.1007/978-0-585-34046-3_3; TEBBE CC, 1993, APPL ENVIRON MICROB, V59, P2657, DOI 10.1128/AEM.59.8.2657-2665.1993; Wilbrink B, 1998, ARTHRITIS RHEUM-US, V41, P535, DOI 10.1002/1529-0131(199803)41:3<535::AID-ART20>3.0.CO;2-4	22	39	45	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1999	354	9176					386	389		10.1016/S0140-6736(98)09295-2	http://dx.doi.org/10.1016/S0140-6736(98)09295-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437868				2022-12-01	WOS:000081764900014
J	Caparros-Lefebvre, D; Elbaz, A				Caparros-Lefebvre, D; Elbaz, A		Caribbean Parkinsonism Study Grp	Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study	LANCET			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRESSIVE SUPRANUCLEAR PALSY; DOPAMINE TRANSPORTER; DEMENTIA COMPLEX; ENDOGENOUS AMINE; ANNONA-MURICATA; DISEASE; GUAM; DERIVATIVES; ACCURACY	Background In Europe and North America, Parkinson's disease is the major form of parkinsonism; less than 4% of cases are progressive supranuclear palsy (PSP) and about 20% are atypical parkinsonism. The distribution of these subgroups is different in the French West Indies. We aimed to define the clinical and demographic specificity of these disorders in Guadeloupe and to investigate a postulated link with consumption of herbal tea and fruits from the Annonaceae family (Annona muricata and Annona squamosa), which contain neurotoxic benzyltetrahydroisoquinoline alkaloids. Methods Between September, 1996, and August, 1998, 87 consecutive patients with parkinsonism were referred to the single neurological department in Guadeloupe. After detailed clinical, neurophysiological, cognitive, and neuroradiological assessment, they were classified by generally accepted criteria as having Parkinson's disease, PSP, or atypical parkinsonism. We compared the amount of tropical fruits and herbal tea consumed by the various parkinsonian subgroups and by frequency-matched controls (patients with benign symptoms and no neurodegenerative disease). Findings Of the 87 patients, 22 had Parkinson's disease, 31 had PSP, 30 had atypical parkinsonism, and four had atypical parkinsonism associated with motor neuron disease, 44 of the patients with PSP or atypical parkinsonism were male. The patients with atypical parkinsonism had symmetrical rigidity and bradykinesia, and no levodopa peak-dose dyskinesias. Patients with PSP differed from those with atypical parkinsonism because they had supranuclear vertical down-gaze palsy, severe gait and balance problems, and frontal-lobe syndrome. 29 Patients with PSP reported regular consumption of pawpaw fruit, and 26 drank herbal tea. 30 patients with atypical parkinsonism reported regular consumption of pawpaw fruit, and 24 drank herbal tea. Both of these groups consumed significantly more fruit and herbal tea than patients with Parkinson's disease (fruit: odds ratio 23.6; herbal tea: 28.2); and controls (fruit: 20.7; herbal tea: 6.48). Both of these groups and herbal tea than Interpretation Our study confirms the over-representation of atypical parkinsonism and PSP in patients with parkinsonism in the French West Indies. Chronic exposure to neurotoxic alkaloids could be an important aetiological factor because these compounds induce parkinsonism in animals. A larger epidemiological study, to clarify the link between these fruits with atypical parkinsonism and PSP, is proposed.	CHU Antilles & Guyane, Dept Neurol, F-97159 Pointe A Pitre, Guadeloupe, France; Hop La Pitie Salpetriere, INSERM, U360, F-75013 Paris, France	CHU Guadeloupe; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Caparros-Lefebvre, D (corresponding author), CHU Antilles & Guyane, Dept Neurol, Route de Chauvel, F-97159 Pointe A Pitre, Guadeloupe, France.	lefebvdo@ais.gp	Elbaz, Alexis/F-8952-2017	Elbaz, Alexis/0000-0001-9724-5490				AMARENCO P, 1991, J NEUROL NEUROSUR PS, V54, P1121, DOI 10.1136/jnnp.54.12.1121-a; BOOTH RG, 1989, NEUROSCI LETT, V100, P306, DOI 10.1016/0304-3940(89)90704-0; BRUNETON J, 1993, TECHNIQUE DOCUMENTAT, P707; Cabedo N, 1998, J NAT PROD, V61, P709, DOI 10.1021/np980008a; CHAUDHURI KR, 1996, MOV DISORD S1, V11, P534; Coleman T, 1996, J PHARMACOL EXP THER, V277, P685; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; ELIZAN TS, 1966, ARCH NEUROL-CHICAGO, V14, P356, DOI 10.1001/archneur.1966.00470100012002; ESTEGUY M, 1985, REV NEUROL, V141, P413; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; Hasrat JA, 1997, J PHARM PHARMACOL, V49, P1145, DOI 10.1111/j.2042-7158.1997.tb06058.x; Hasrat JA, 1997, PHYTOMEDICINE, V4, P133, DOI 10.1016/S0944-7113(97)80059-1; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; HOF PR, 1994, ACTA NEUROPATHOL, V88, P397; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JOSEPH H, 1983, THESIS U MONTPELLIER; Kawai H, 1998, J NEUROCHEM, V70, P745; KOTAKE Y, 1995, J NEUROCHEM, V65, P2633; Kotake Y, 1996, NEUROSCI LETT, V217, P69; KOVAR J, 1983, ARCH BIOCHEM BIOPHYS, V221, P271, DOI 10.1016/0003-9861(83)90144-3; LEBOEUF M, 1981, PLANTA MED, V42, P37, DOI 10.1055/s-2007-971543; Litvan I, 1996, NEUROLOGY, V46, P922, DOI 10.1212/WNL.46.4.922; Litvan I, 1998, ARCH NEUROL-CHICAGO, V55, P969, DOI 10.1001/archneur.55.7.969; MARTIN RO, 1967, BIOCHEMISTRY-US, V6, P2355, DOI 10.1021/bi00860a010; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; Nagatsu T, 1997, NEUROSCI RES, V29, P99, DOI 10.1016/S0168-0102(97)00083-7; Okada T, 1998, NEUROSCI RES, V30, P87, DOI 10.1016/S0168-0102(97)00121-1; OYANAGI K, 1994, ACTA NEUROPATHOL, V88, P405; REED D, 1987, AM J EPIDEMIOL, V125, P92, DOI 10.1093/oxfordjournals.aje.a114515; RODGERSJOHNSON P, 1986, NEUROLOGY, V36, P7, DOI 10.1212/WNL.36.1.7; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Uitti R J, 1995, Parkinsonism Relat Disord, V1, P21, DOI 10.1016/1353-8020(95)00004-P; WU YC, 1989, PLANTA MED, P163, DOI 10.1055/s-2006-961913	35	165	172	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					281	286		10.1016/S0140-6736(98)10166-6	http://dx.doi.org/10.1016/S0140-6736(98)10166-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440304				2022-12-01	WOS:000081646000010
J	Bendor, R				Bendor, R			Arthritis and I	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					150	152		10.7326/0003-4819-131-2-199907200-00015	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419434				2022-12-01	WOS:000081509700013
J	Nobbenhuis, MAE; Walboomers, JMM; Helmerhorst, TJM; Rozendaal, L; Remmink, AJ; Risse, EKJ; van der Linden, HC; Voorhorst, FJ; Kenemans, P; Meijer, CJLM				Nobbenhuis, MAE; Walboomers, JMM; Helmerhorst, TJM; Rozendaal, L; Remmink, AJ; Risse, EKJ; van der Linden, HC; Voorhorst, FJ; Kenemans, P; Meijer, CJLM			Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; HIGH-RISK; INFECTION; GENOTYPES; WOMEN; CIN	Background A relation has been established between infection with high-risk types of human papillomavirus and development of cervical cancer. We investigated a role for testing for human papillomavirus as part of cervical-cancer screening. Methods We monitored by cytology, colposcopy, and testing for high-risk human papillomavirus 353 women referred to gynaecologists with mild to moderate and severe dyskaryosis. The median follow-up time was 33 months. At the last visit we took biopsy samples. Our primary endpoint was clinical progression, defined as cervical intraepithelial neoplasia (CIN) 3, covering three or more cervical quadrants on colposcopy, or a cervical-smear result of suspected cervical cancer. Findings 33 women reached clinical progression. All had persistent infection with high-risk human papillomavirus. The cumulative 6-year incidence of clinical progression among these women was 40% (95% CI 21-59). in women with end histology CIN 3, 98 (95%) of 103 had persistent infection with high-risk human papillomavirus from baseline. Among women with mild to moderate dyskaryosis at baseline, a second test for human papillomavirus at 6 months predicted end histology CIN 3 better than a second cervical smear. Interpretation Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of CIN 3. All women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dyskaryosis should be referred only after a second positive test for high-risk human papillomavirus at 6 months.	Univ Hosp Vrije Univ, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Obstet & Gynaecol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands; Univ Rotterdam Hosp, Dept Obstet & Gynecol, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Meijer, CJLM (corresponding author), Univ Hosp Vrije Univ, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.							Anderson MC, 1995, HAINES TAYLOR OBSTET, P292; BAUER HM, 1993, SEX TRANSM DIS, V20, P274, DOI 10.1097/00007435-199309000-00007; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; HELMERHORST TJM, 1987, EUR J OBSTET GYN R B, V24, P221, DOI 10.1016/0028-2243(87)90021-9; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hopman E H, 1998, Obstet Gynecol Surv, V53, P97, DOI 10.1097/00006254-199802000-00021; HOPMAN EH, 1995, GYNECOL ONCOL, V58, P206, DOI 10.1006/gyno.1995.1212; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; KATAJA V, 1992, SEX TRANSM DIS, V19, P154, DOI 10.1097/00007435-199205000-00009; Kjaer SK, 1996, INT J CANCER, V65, P601, DOI 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Meijer CJLM, 1998, HISTOPATHOLOGY, V33, P83, DOI 10.1046/j.1365-2559.1998.00436.x; Meijer CJLM, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P338; NGEANGEL C, 1998, J NATL CANCER I, V90, P43; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; Syrjanen KJ, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P93; VANDERGRAAF Y, 1988, J CLIN EPIDEMIOL, V41, P21, DOI 10.1016/0895-4356(88)90005-4; Vooijs G P, 1987, Ned Tijdschr Geneeskd, V131, P1662; WALBOOMERS JMM, 1999, IN PRESS J PATHOL; WALBOOMERS JMM, 1997, HUMAN PAPILLOMAVIRUS, P341; Wright TC, 1995, BLAUSTEINS PATHOLOGY, P248	30	510	543	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					20	25		10.1016/S0140-6736(98)12490-X	http://dx.doi.org/10.1016/S0140-6736(98)12490-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406360				2022-12-01	WOS:000081243200009
J	Urban, BC; Ferguson, DJP; Pain, A; Willcox, N; Plebanski, M; Austyn, JM; Roberts, DJ				Urban, BC; Ferguson, DJP; Pain, A; Willcox, N; Plebanski, M; Austyn, JM; Roberts, DJ			Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells	NATURE			English	Article							MALARIA-PARASITIZED ERYTHROCYTES; ANTIGENIC VARIATION; RECEPTOR; CYTOADHERENCE; SEQUESTRATION; ASSOCIATION; PHENOTYPES; IMMUNITY; ADHESION; INVITRO	The malaria parasite Plasmodium falciparum is one of the most successful human pathogens. Specific virulence factors remain poorly defined, although the adhesion of infected erythrocytes to the venular endothelium has been associated with some of the syndromes of severe disease(1). Immune responses cannot prevent the development of symptomatic infections throughout life, and clinical immunity to the disease develops only slowly during childhood. An understanding of the obstacles to the development of protective immunity is crucial for developing rational approaches to prevent the disease. Here we show that intact malaria-infected erythrocytes adhere to dendritic cells, inhibit the maturation of dendritic cells and subsequently reduce their capacity to stimulate T cells. These data demonstrate both a novel mechanism by which malaria parasites induce immune dysregulation and a functional role beyond endothelial adhesion for the adhesive phenotypes expressed at the surface of infected erythrocytes.	John Radcliffe Hosp, Oxford Ctr, Inst Mol Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Nuffield Dept Pathol, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Mol Immunol Grp, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Nuffield Dept Surg, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Natl Blood Serv, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford	Roberts, DJ (corresponding author), John Radcliffe Hosp, Oxford Ctr, Inst Mol Med, Oxford OX3 9DU, England.		Urban, Britta/W-6087-2018; Pain, Arnab/L-5766-2015; Plebanski, Magdalena/AAU-3144-2021	Urban, Britta/0000-0002-4197-8393; Pain, Arnab/0000-0002-1755-2819; Ferguson, David/0000-0001-5045-819X; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Austyn J M, 1998, Curr Opin Hematol, V5, P3, DOI 10.1097/00062752-199801000-00002; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Brown K.N., 1993, Parassitologia (Rome), V35, P13; Coppel R L, 1998, Curr Opin Hematol, V5, P132; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOWARD RJ, 1984, CONTEMP TOP IMMUNOBI, V12, P127; HOWARD RJ, 1983, P NATL ACAD SCI-BIOL, V80, P4129, DOI 10.1073/pnas.80.13.4129; LANGRETH SG, 1985, INFECT IMMUN, V47, P760, DOI 10.1128/IAI.47.3.760-766.1985; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; Nagvekar N, 1998, J CLIN INVEST, V101, P2268, DOI 10.1172/JCI2068; Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389; PLEBANSKI M, 1992, IMMUNOLOGY, V75, P86; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHWARZER E, 1994, BRIT J HAEMATOL, V88, P740, DOI 10.1111/j.1365-2141.1994.tb05112.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0; WALSH DS, 1995, CLIN IMMUNOL IMMUNOP, V77, P89, DOI 10.1016/0090-1229(95)90141-8; WILLIAMSON WA, 1978, LANCET, V1, P1328; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	30	470	488	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					73	77		10.1038/21900	http://dx.doi.org/10.1038/21900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403251				2022-12-01	WOS:000081255700053
J	Gulbis, JM; Mann, S; MacKinnon, R				Gulbis, JM; Mann, S; MacKinnon, R			Structure of a voltage-dependent K+ channel beta subunit	CELL			English	Article							KETO REDUCTASE SUPERFAMILY; HUMAN ALDOSE REDUCTASE; 3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE; SHAKER POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; SEQUENCE ALIGNMENTS; ALDEHYDE REDUCTASE; BOVINE BRAIN; INACTIVATION; EXPRESSION	The integral membrane subunits of many voltage-dependent potassium channels are associated with an additional protein known as the beta subunit. One function of beta subunits is to modify K+ channel gating. We have determined the structure of the conserved core of mammalian beta subunits by X-ray crystallography at 2.8 Angstrom resolution. Like the integral membrane component of K+ channels, beta subunits form a fourfold symmetric structure. Each subunit is an oxidoreductase enzyme complete with a nicotinamide cofactor in its active site. Several structural features of the enzyme active site, including its location with respect to the four-fold axis, imply that it may interact directly or indirectly with the K+ channel's voltage sensor. This structure suggests a mechanism for coupling membrane electrical excitability directly to chemistry of the cell.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu			NIGMS NIH HHS [GM47400] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BENNER SA, 1982, EXPERIENTIA, V38, P633, DOI 10.1007/BF02327092; Bennett MJ, 1997, STRUCTURE, V5, P799, DOI 10.1016/S0969-2126(97)00234-7; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; Branden C. I., 2012, INTRO PROTEIN STRUCT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELKABBANI O, 1995, NAT STRUCT BIOL, V2, P687, DOI 10.1038/nsb0895-687; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Hille B., 1992, IONIC CHANNELS EXCIT; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN WD, 1969, GENETICS, V61, P399; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Tang HX, 1996, PLANT CELL, V8, P1545, DOI 10.1105/tpc.8.9.1545; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728	45	239	245	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					943	952		10.1016/S0092-8674(00)80805-3	http://dx.doi.org/10.1016/S0092-8674(00)80805-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399921	Bronze			2022-12-01	WOS:000081162800014
J	Orth, K; Palmer, LE; Bao, ZQ; Stewart, S; Rudolph, AE; Bliska, JB; Dixon, JE				Orth, K; Palmer, LE; Bao, ZQ; Stewart, S; Rudolph, AE; Bliska, JB; Dixon, JE			Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector	SCIENCE			English	Article							NF-KAPPA-B; ALPHA PRODUCTION; CELL-DEATH; BETA; MACROPHAGES; APOPTOSIS; YOPJ; PHOSPHORYLATION; SUPPRESSION; RESISTANCE	The bacterial pathogen Yersinia uses a type III secretion system to inject several virulence factors into target cells. One of the Yersinia virulence factors, YopJ, was shown to bind directly to the superfamily of MAPK (mitogen-activated protein kinase) kinases (MKKs) blocking both phosphorylation and subsequent activation of the MKKs. These results explain the diverse activities of YopJ in inhibiting the extracellular signal-regulated kinase, c-Jun amino-terminal kinase, p38, and nuclear factor kappa B signaling pathways, preventing cytokine synthesis and promoting apoptosis. YopJ-related proteins that are found in a number of bacterial pathogens of animals and plants may function to block MKKs so that host signaling responses can be modulated upon infection.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Ctr Infect Dis, Stony Brook, NY 11794 USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NIAID NIH HHS [AI35175] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035175] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Brubaker R R, 1972, Curr Top Microbiol Immunol, V57, P111; Ciesiolka LD, 1999, MOL PLANT MICROBE IN, V12, P35, DOI 10.1094/MPMI.1999.12.1.35; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; ORTH K, UNPUB; Palmer L. C., UNPUB; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Stewart S, 1999, MOL CELL BIOL, V19, P5523; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1993, MOL PLANT MICROBE IN, V6, P616, DOI 10.1094/MPMI-6-616; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	43	327	338	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1920	1923		10.1126/science.285.5435.1920	http://dx.doi.org/10.1126/science.285.5435.1920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489373				2022-12-01	WOS:000082638300053
J	Collins, MW; Grindel, SH; Lovell, MR; Dede, DE; Moser, DJ; Phalin, BR; Nogle, S; Wasik, M; Cordry, D; Daugherty, MK; Sears, SF; Nicolette, G; Indelicato, P; McKeag, DB				Collins, MW; Grindel, SH; Lovell, MR; Dede, DE; Moser, DJ; Phalin, BR; Nogle, S; Wasik, M; Cordry, D; Daugherty, MK; Sears, SF; Nicolette, G; Indelicato, P; McKeag, DB			Relationship between concussion and neuropsychological performance in college football players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINOR HEAD-INJURY	Context Despite the high prevalence and potentially serious outcomes associated with concussion in athletes, there is little systematic research examining risk factors and short- and long-term outcomes. Objectives To assess the relationship between concussion history and learning disability (LD) and the association of these variables with neuropsychological performance and to evaluate postconcussion recovery in a sample of college football players. Design, Setting, and Participants A total of 393 athletes from 4 university football programs across the United States received preseason baseline evaluations between May 1997 and February 1999. Subjects who had subsequent football-related acute concussions (n = 16) underwent neuropsychological comparison with matched control athletes from within the sample (n = 10). Main Outcome Measures Clinical interview, 8 neuropsychological measures, and concussion symptom scale ratings at baseline and after concussion. Results Of the 393 players, 129 (34%) had experienced 1 previous concussion and 79 (20%) had experienced 2 or more concussions. Multivariate analysis of variance yielded significant main effects for both LD (P<.001) and concussion history (P = .009), resulting in lowered baseline neuropsychological performance. A significant interaction was found between LD and history of multiple concussions and LD on 2 neurol psychological measures (Trail-Making Test, Form B [P = .007] and Symbol Digit Modalities Test [P = .009]), indicating poorer performance for the group with LD and multiple concussions compared with other groups. A discriminant function analysis using neuropsychological testing of athletes 24 hours after acute in-season concussion compared with controls resulted in an overall 89.5% correct classification rate. Conclusions Our study suggests that neuropsychological assessment is a useful indicator of cognitive functioning in athletes and that bath history of multiple concussions and LD are associated with reduced cognitive performance. These variables may be detrimentally synergistic and should receive further study.	Henry Ford Hlth Syst, Div Neuropsychol, Dept Behav Hlth, Detroit, MI 48202 USA; Univ Pittsburgh, Dept Family Practice, Pittsburgh, PA USA; Univ Pittsburgh, Dept Family Med Sports Med, Pittsburgh, PA USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Florida, Coll Med, Dept Orthoped & Rehabil, Gainesville, FL USA; Univ Florida, Dept Community & Family Hlth, Gainesville, FL USA; Univ Florida, Dept Sports Hlth, Gainesville, FL USA; Michigan State Univ, Dept Athlet Training, E Lansing, MI 48824 USA; Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; St Vincents Med Ctr, Dept Sports Med, Erie, PA USA	Henry Ford Health System; Henry Ford Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Michigan State University; Michigan State University	Collins, MW (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, Dept Behav Hlth, 1 Ford Pl 1E, Detroit, MI 48202 USA.			Moser, David/0000-0003-4102-5266; sears, samuel/0000-0002-7863-3591				Barth J.T., 1989, MILD HEAD INJURY, P257; BEARS SR, 1995, J LEARN DISABIL, V27, P315; Bream H., 1996, ATHLETIC THERAPY TOD, V1, P7; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Donders J, 1997, Pediatr Rehabil, V1, P179; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HENDERSON C, 1994, COLL FRESHMEN DISABI; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HURBERT RT, 1994, COMPREHENDING BEHAV; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1994, MILD BRAIN INJURY SP; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 1999, SPORTS RELATED CONCU; Nicolson RI, 1999, LANCET, V353, P1662, DOI 10.1016/S0140-6736(98)09165-X; Powell JW, 1999, SPORTS-RELATED CONCUSSION, P75; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Spreen O, 1998, COMPENDIUM NEUROPSYC; Spreen O, 1995, DEV NEUROPSYCHOLOGY; *STATS, 1995, STAT WIND COMP PROGR; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Torg JS, 1982, ATHLETIC INJURIES HE; [No title captured]	29	584	597	1	80	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					964	970		10.1001/jama.282.10.964	http://dx.doi.org/10.1001/jama.282.10.964			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485682	Bronze			2022-12-01	WOS:000082335900035
J	Bostom, AG; Rosenberg, IH; Silbershatz, H; Jacques, PF; Selhub, J; D'Agostino, RB; Wilson, PWF; Wolf, PA				Bostom, AG; Rosenberg, IH; Silbershatz, H; Jacques, PF; Selhub, J; D'Agostino, RB; Wilson, PWF; Wolf, PA			Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study	ANNALS OF INTERNAL MEDICINE			English	Article							VASCULAR-DISEASE; NATURAL-HISTORY; RISK FACTOR; HYPERHOMOCYSTEINEMIA; SERUM; HOMOCYSTINURIA; ADULTS	Background: Total homocysteine levels are associated with arteriosclerotic outcomes. Objective: To determine whether total homocysteine levels predict incident stroke in elderly persons. Design: Prospective population-based cohort study with 9.9 years of follow-up. Setting: Framingham, Massachusetts. Patients: 1947 Framingham Study participants (1158 women and 789 men; mean age +/- SD, 70 +/- 7 years). Measurements: Baseline total homocysteine levels and 9.9-year stroke incidence. Results: The quartiles of nonfasting total homocysteine levels were as follows: quartile 1, 4.13 to 9.25 mu mol/L; quartile 2, 9.26 to 11.43 mu mol/L; quartite 3, 11.44 to 14.23 mu mol/L; quartile 4, 14.24 to 219.84 mu mol/L. During follow-up, 165 incident strokes occurred. In proportional hazards models adjusted for age, sex, systolic blood pressure, diabetes, smoking, and history of atrial fibrillation and coronary heart disease, relative risk (RR) estimates comparing quartile 1 with the other three quartiles were as follows: quartile 2 compared with quartile 1-RR, 1.32 (95% CI, 0.81 to 2.14); quartile 3 compared with quartile 1-RR, 1.44 (CI, 0.89 to 2.34); quartile 4 compared with quartile 1-RR, 1.82 (CI, 1.14 to 2.91). The linear trend across the quartiles was significant (P < 0.001). Conclusion: Nonfasting total homocysteine levels are an independent risk factor for incident stroke in elderly persons.	Tufts Univ, New England Med Ctr, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Brown Univ, Mem Hosp Rhode Isl, Providence, RI 02912 USA; NHLBI, Framingham Study, Framingham, MA 01701 USA	Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA); Boston University; Brown University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rosenberg, IH (corresponding author), Tufts Univ, New England Med Ctr, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	rosenberg@hnrc.tufts.edu	Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [R01-HL-40423-05, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-17] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Bellamy MF, 1998, CIRCULATION, V98, P1848, DOI 10.1161/01.CIR.98.18.1848; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; KANNEL WB, 1987, FRAMINGHAM STUDY EPI, P1; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479; MUDD SH, 1985, AM J HUM GENET, V37, P1; Omenn GS, 1998, CIRCULATION, V97, P421; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Robins M., 1981, STROKE, V12, pI45; ROLLAND PH, 1995, CIRCULATION, V91, P1161, DOI 10.1161/01.CIR.91.4.1161; UELAND PM, 1993, CLIN CHEM, V39, P1764; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	20	326	340	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					352	355		10.7326/0003-4819-131-5-199909070-00006	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475888				2022-12-01	WOS:000082458500005
J	Kark, JD; Selhub, J; Adler, B; Gofin, J; Abramson, JH; Friedman, G; Rosenberg, IH				Kark, JD; Selhub, J; Adler, B; Gofin, J; Abramson, JH; Friedman, G; Rosenberg, IH			Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM TOTAL HOMOCYSTEINE; REDUCTASE GENE MUTATION; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; RISK FACTOR; HEALTH; HYPERHOMOCYSTEINEMIA; PHYSICIANS; VITAMINS	Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 mu mol/L in 28% of men and 20% of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend), The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths "attributable" to elevated plasma homocysteine level(greater than or equal to 14 mu mol/L) were 12.5% (95% CI, 6.7% to 18.8%)for all deaths, 16.0% (CI, 7.2% to 25.6%) for deaths during the first 5 years of follow-up, and 8.3% (CI, 1.5% to 16.1%) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.	Hadassah Univ Hosp, Dept Social Med, IL-91120 Ein Kerem, Israel; Hebrew Univ Jerusalem, Hadassah Sch Publ Hlth & Community Med, Ein Kerem, Israel; Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Hadassah Univ Hosp, Geriatr Unit, IL-91120 Ein Kerem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tufts University; United States Department of Agriculture (USDA); Hebrew University of Jerusalem	Kark, JD (corresponding author), Hadassah Univ Hosp, Dept Social Med, POB 12000, IL-91120 Ein Kerem, Israel.	jeremyl@vms.huji.ac.il						ABRAMSON JH, 1992, J CLIN EPIDEMIOL, V45, P651, DOI 10.1016/0895-4356(92)90137-C; ABRAMSON JH, 1994, INT J EPIDEMIOL, V23, P98, DOI 10.1093/ije/23.1.98; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Arnadottir M, 1996, SCAND J CLIN LAB INV, V56, P41, DOI 10.3109/00365519609088586; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; Bostom AG, 1997, KIDNEY INT, V52, P10, DOI 10.1038/ki.1997.298; Bostom AG, 1999, ARCH INTERN MED, V159, P1077, DOI 10.1001/archinte.159.10.1077; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, ATHEROSCLEROSIS, V141, P315, DOI 10.1016/S0021-9150(98)00154-3; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DAngelo A, 1997, BLOOD, V90, P1; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Gofin J, 1996, INT J OBESITY, V20, P260; Gofin J, 1995, EUR HEART J, V16, P1988, DOI 10.1093/oxfordjournals.eurheartj.a060858; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Guttormsen AB, 1997, KIDNEY INT, V52, P495, DOI 10.1038/ki.1997.359; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; KAPLAN G, 1988, J GERONTOL, V43, pS114, DOI 10.1093/geronj/43.4.S114; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; Kuller LH, 1998, CIRCULATION, V98, P196, DOI 10.1161/01.CIR.98.3.196; LARUE A, 1979, J GERONTOL, V34, P687, DOI 10.1093/geronj/34.5.687; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; MCCULLY KS, 1969, AM J PATHOL, V56, P111; NEWMAN DJ, 1995, KIDNEY INT, V47, P312, DOI 10.1038/ki.1995.40; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Rose G.A., 1982, CARDIOVASCULAR SURVE; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; *WHO REG OFF EUR, 1996, HIGHL HLTH ISR, P21; Wollesen F, 1999, KIDNEY INT, V55, P1028, DOI 10.1046/j.1523-1755.1999.0550031028.x	43	113	116	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					321	+		10.7326/0003-4819-131-5-199909070-00002	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475884				2022-12-01	WOS:000082458500001
J	Reirden, DH				Reirden, DH			Lessons outside the lecture hall	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA; Connecticut Childrens Med Ctr, Farmington, CT USA	University of Connecticut; Connecticut Children's Medical Center	Reirden, DH (corresponding author), Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					820	821		10.1001/jama.282.9.820	http://dx.doi.org/10.1001/jama.282.9.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478685	hybrid			2022-12-01	WOS:000082272200004
J	Apelqvist, A; Li, H; Sommer, L; Beatus, P; Anderson, DJ; Honjo, T; de Angelis, MH; Lendahl, U; Edlund, H				Apelqvist, A; Li, H; Sommer, L; Beatus, P; Anderson, DJ; Honjo, T; de Angelis, MH; Lendahl, U; Edlund, H			Notch signalling controls pancreatic cell differentiation	NATURE			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTION FACTOR; INSULIN GENE; EXPRESSION; PROGENITOR; NEURONS; NEUROGENESIS; ORIGIN; MICE	The pancreas contains both exocrine and endocrine cells, but the molecular mechanisms controlling the differentiation of these cell types are largely unknown. Despite their endodermal origin, pancreatic endocrine cells share several molecular characteristics with neurons(1-5), and, like neurons in the central nervous system(6,7) differentiating endocrine cells in the pancreas appear in a scattered fashion within a field of progenitor coils(8,9). This indicates that they may be generated by lateral specification through Notch signalling(6,7). Here, to test this idea, we analysed pancreas development in mice genetically altered at several steps in the Notch signalling pathway, Mice deficient for Delta-like gene 1 (Dll1)(10) or the intracellular mediator RBP-JK(11) showed accelerated differentiation of pancreatic endocrine cells. A similar phenotype was observed in mice over-expressing neurogenin 3 (ngn 3)(12) or the intracellular form of Notch3 (ref. 13) (a repressor of Notch signalling). These data provide evidence that ngn3 acts as pro-endocrine gene and that Notch signalling is critical for the decision between the endocrine and progenitor/exocrine fates in the developing pancreas.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; ETH Honggerberg, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; GSF, Inst Mammalian Genet, D-85764 Neuherberg, Germany; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Umea University; Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Kyoto University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet	Edlund, H (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.		Honjo, Tasuku/N-4470-2016; de Angelis, Martin Hrabe/F-5531-2012	de Angelis, Martin Hrabe/0000-0002-7898-2353; Edlund, Helena/0000-0002-3553-7348; Sommer, Lukas/0000-0002-1143-7908; Lendahl, Urban/0000-0001-9543-8141				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.0.CO;2-G; Beatus P, 1999, DEVELOPMENT, V126, P3925; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; FONTAINE J, 1977, J EMBRYOL EXP MORPH, V41, P209; Hogan B., 2014, MANIPULATING MOUSE E; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lewis J, 1996, CURR OPIN NEUROBIOL, V6, P3, DOI 10.1016/S0959-4388(96)80002-X; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MISHIBASHI M, 1995, GENE DEV, V15, P3136; Mitsiadis TA, 1998, DEV BIOL, V204, P420, DOI 10.1006/dbio.1998.9092; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OKA C, 1995, DEVELOPMENT, V121, P3291; Pictet R., 1972, HDB PHYSL, P25; PICTET RL, 1976, SCIENCE, V191, P191, DOI 10.1126/science.1108195; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245	30	911	948	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					877	881		10.1038/23716	http://dx.doi.org/10.1038/23716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476967				2022-12-01	WOS:000082233200047
J	Node, K; Huo, YQ; Ruan, XL; Yang, BC; Spiecker, M; Ley, K; Zeldin, DC; Liao, JK				Node, K; Huo, YQ; Ruan, XL; Yang, BC; Spiecker, M; Ley, K; Zeldin, DC; Liao, JK			Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids	SCIENCE			English	Article							EPOXYEICOSATRIENOIC ACIDS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; EXPRESSION; HEART	The epoxyeicosatrienoic acids (EETs) are products of cytochrome P450 epoxy-genases that have vasodilatory properties similar to that of endothelium-derived hyperpolarizing factor. The cytochrome P450 isoform CYP2J2 was cloned and identified as a potential source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytokine-induced endothelial cell adhesion molecule expression, and EETs prevented leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-kappa B and I kappa B kinase. The inhibitory effects of EETs were independent of their membrane-hyperpolarizing effects, suggesting that these molecules play an important nonvasodilatory role in vascular inflammation.	Brigham & Womens Hosp, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Virginia, Ctr Hlth Sci, Dept Biomed Engn, Charlottesville, VA 22908 USA; NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liao, JK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, 75 Francis St, Boston, MA 02115 USA.		TATSUTA, HARUKI/F-2997-2010; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048743, R01HL052233, R01HL058108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233, R01 HL052233, R01 HL052233-06, P01 HL048743-090008, HL-58108, P01 HL048743-080008, R01 HL052233-05, P01 HL048743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DE CR, 1995, J CLIN INVEST, V96, P60; FARIN FM, 1994, TOXICOL APPL PHARM, V124, P1, DOI 10.1006/taap.1994.1001; Hoebel BG, 1998, CLIN EXP PHARMACOL P, V25, P826, DOI 10.1111/j.1440-1681.1998.tb02162.x; Kozak W, 1998, AM J PHYSIOL-REG I, V275, pR1031, DOI 10.1152/ajpregu.1998.275.4.R1031; LIAO J, UNPUB, P63509; LIN JHC, 1996, ENDOTHELIUM, V4, P219; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; Nakashima T, 1996, AM J PHYSIOL-REG I, V271, pR1274, DOI 10.1152/ajpregu.1996.271.5.R1274; Oltman CL, 1998, CIRC RES, V83, P932; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Rosolowsky M, 1996, BBA-LIPID LIPID MET, V1299, P267, DOI 10.1016/0005-2760(95)00216-2; VANROLLINS M, 1993, J LIPID RES, V34, P1931; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551	20	954	1017	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1276	1279		10.1126/science.285.5431.1276	http://dx.doi.org/10.1126/science.285.5431.1276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455056	Green Accepted			2022-12-01	WOS:000082130200046
J	Littleton, JT; Serano, TL; Rubin, GM; Ganetzky, B; Chapman, ER				Littleton, JT; Serano, TL; Rubin, GM; Ganetzky, B; Chapman, ER			Synaptic function modulated by changes in the ratio of synaptotagmin I and IV	NATURE			English	Article							NEUROTRANSMITTER RELEASE; MUTATIONAL ANALYSIS; BINDING; DOMAIN; DROSOPHILA; VESICLES; PROTEINS; SENSOR; REGION; SNARE	Communication within the nervous system is mediated by Ca2+-triggered fusion of synaptic vesicles with the presynaptic plasma membrane. Genetic and biochemical evidence indicates that synaptotagmin I may function as a Ca2+ sensor in neuronal exocytosis because it can bind Ca2+ and penetrate into lipid bilayers(1-4). Chronic depolarization or seizure activity results in the upregulation of a distinct and unusual isoform of the synaptotagmin family, synaptotagmin IV (ref. 5). We have identified a Drosophila homologue of synaptotagmin IV that is enriched on synaptic vesicles and contains an evolutionarily conserved substitution of aspartate to serine that abolishes its ability to bind membranes in response to Ca2+ influx. Synaptotagmin IV forms hetero-oligomers with synaptotagmin I, resulting in synaptotagmin clusters that cannot effectively penetrate lipid bilayers and are less efficient at coupling Ca2+ to secretion in vivo: upregulation of synaptotagmin IV, but not synaptotagmin I, decreases evoked neurotransmission. These findings indicate that modulating the expression of synaptotagmins with different Ca2+-binding affinities can lead to heteromultimers that can regulate the efficiency of excitation-secretion coupling in vivo and represent a new molecular mechanism for synaptic plasticity.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Littleton, JT (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.			Rubin, Gerald/0000-0001-8762-8703; Chapman, Edwin/0000-0001-9787-8140; Littleton, J. Troy/0000-0001-5576-2887				BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	20	135	139	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					757	760		10.1038/23462	http://dx.doi.org/10.1038/23462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466723				2022-12-01	WOS:000082131100048
J	Liu, L; Wolf, R; Ernst, R; Heisenberg, M				Liu, L; Wolf, R; Ernst, R; Heisenberg, M			Context generalization in Drosophila visual learning requires the mushroom bodies	NATURE			English	Article							FLIGHT ORIENTATION; MELANOGASTER; BRAIN; EXPRESSION; GENE	The world is permanently changing, Laboratory experiments on learning and memory normally minimize this feature of reality, keeping all conditions except the conditioned and unconditioned stimuli as constant as possible(1). In the real world, however, animals need to extract from the universe of sensory signals the actual predictors of salient events by separating them from nonpredictive stimuli (context(2)), In principle, this can be achieved if only those sensory inputs that resemble the reinforcer in their temporal structure are taken as predictors. Here we study visual learning in the fly Drosophila melanogaster, using a flight simulator(3,4), and show that memory retrieval is, indeed, partially context-independent. Moreover, we show that the mushroom bodies, which are required for olfactory(5-7) but not visual or tactile learning(8), effectively support context generalization. In visual learning in Drosophila, it appears that a facilitating effect of context cues for memory retrieval is the default state, whereas making recall context-independent requires additional processing.	Biozentrum, Lehrstuhl Genet, D-97074 Wurzburg, Germany	University of Wurzburg	Heisenberg, M (corresponding author), Biozentrum, Lehrstuhl Genet, D-97074 Wurzburg, Germany.							ASHBURNER M, 1989, LAB MANUAL PROTOCOLL, P254; Barth M, 1997, LEARN MEMORY, V4, P219, DOI 10.1101/lm.4.2.219; BICKEL WK, 1985, J EXP ANAL BEHAV, V44, P245, DOI 10.1901/jeab.1985.44-245; BOUTON ME, 1993, PSYCHOL BULL, V114, P80, DOI 10.1037/0033-2909.114.1.80; BUCHNER E, 1988, CELL TISSUE RES, V253, P357, DOI 10.1007/BF00222292; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Crittenden JR, 1998, LEARN MEMORY, V5, P38; deBelle JS, 1996, P NATL ACAD SCI USA, V93, P9875, DOI 10.1073/pnas.93.18.9875; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; ERBRE J, 1987, ANTHR BRAIN ITS EVOL; ERNST R, IN PRESS VIS RES; Guo A, 1996, LEARN MEMORY, V3, P49, DOI 10.1101/lm.3.1.49; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; Heisenberg M., 1984, STUDIES BRAIN FUNCTI, V12; Ito K, 1998, LEARN MEMORY, V5, P52; Li YS, 1997, J COMP NEUROL, V387, P631; MARTIN JR, 1998, DROSOPHILA MELANOGAS, V5, P179; Pavlov IP, 1927, CONDITIONED REFLEXES; PROKOP A, 1994, DEV BIOL, V161, P321, DOI 10.1006/dbio.1994.1034; Rybak J, 1998, LEARN MEMORY, V5, P133; SCHILDBERGER K, 1984, J COMP PHYSIOL, V154, P71, DOI 10.1007/BF00605392; SCHURMANN FW, 1974, EXP BRAIN RES, V19, P406, DOI 10.1007/BF00234464; Strausfeld NJ, 1998, LEARN MEMORY, V5, P11; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Tarpy R.M., 1997, CONT LEARNING THEORY; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Wolf R, 1998, LEARN MEMORY, V5, P166; WOLF R, 1991, J COMP PHYSIOL A, V169, P699	29	221	224	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					753	756		10.1038/23456	http://dx.doi.org/10.1038/23456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	228HM	10466722				2022-12-01	WOS:000082131100047
J	Brentnall, TA; Bronner, MP; Byrd, DR; Haggitt, PC; Kimmey, MB				Brentnall, TA; Bronner, MP; Byrd, DR; Haggitt, PC; Kimmey, MB			Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							LARGE BOWEL; ADENOCARCINOMA; LESIONS; CARCINOMA	Background: Pancreatic cancer, the fourth most common cause of cancer death in the United States, is hereditary in an estimated 10% of cases. Surveillance of patients with a familial predisposition for pancreatic cancer has not been systematically evaluated. Objective: To develop a surveillance program that can identify and treat patients who have precancerous conditions of the pancreas and a family history of pancreatic cancer. Design: Prospective cohort study. Setting: University medical center. Patients: 14 patients from three kindreds with a history of pancreatic cancer. Interventions: Endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP), spiral computed tomography, and serum carcinoembryonic antigen and CA19-9 analysis were performed in all patients. Four affected patients were tested for the K-ras mutation. Main Outcome Measurement: Pancreatic dysplasia was determined by histologic evaluation. Results: Seven of the 14 patients were believed to have dysplasia on the basis of clinical history and abnormalities on endoscopic ultrasonography and ERCP and were referred for pancreatectomy. All 7 patients had histologic evidence of dysplasia in pancreatectomy specimens. Findings on endoscopic ultrasonography were subtle, nonspecific, and similar to those seen in patients with chronic pancreatitis. Findings on ERCP ranged from mild and focal side-branch duct irregularities and small sacculations to main-duct strictures and grapelike clusters of saccules. Some of these changes are typical of chronic pancreatitis, but others are more distinctive. Spiral computed tomography and serum tumor markers had low sensitivity in the detection of pancreatic dysplasia. Analysis for the K-ras mutation yielded positive results in 3 of 4 patients with dysplasia. Conclusions: Thorough screening of patients with a family history of pancreatic cancer is feasible. Clinical data combined with imaging studies (endoscopic ultrasonography and ERCP) can be used to identify high-risk patients who have dysplasia. The role of molecular genetic testing is uncertain at this time.	Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Brentnall, TA (corresponding author), Univ Washington, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA.	teribr@u.washington.edu						BARBOSA JJD, 1946, SURG GYNECOL OBSTET, V82, P527; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; BRENTNALL TA, 1995, CANCER RES, V55, P4264; BUSARD JM, 1950, ARCH SURG-CHICAGO, V60, P674, DOI 10.1001/archsurg.1950.01250010695003; CUBILLA AL, 1976, CANCER RES, V36, P2690; Enterline H T, 1976, Curr Top Pathol, V63, P95; EVANS JP, 1995, J MED GENET, V32, P330, DOI 10.1136/jmg.32.5.330; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; KLIMSTRA DS, 1994, INT J PANCREATOL, V16, P224; KLOPPEL G, 1980, VIRCHOWS ARCH A, V387, P221, DOI 10.1007/BF00430702; KOZUKA S, 1979, CANCER, V43, P1419, DOI 10.1002/1097-0142(197904)43:4<1418::AID-CNCR2820430431>3.0.CO;2-O; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LONGNECKER DS, 1994, INT J PANCREATOL, V16, P201; Lynch HT, 1996, SEMIN ONCOL, V23, P251; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; POUR P, 1977, AM J PATHOL, V88, P291; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wiersema M J, 1995, Gastrointest Endosc Clin N Am, V5, P487	18	290	301	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					247	+		10.7326/0003-4819-131-4-199908170-00003	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454945				2022-12-01	WOS:000082012500002
J	McBride, HM; Rybin, V; Murphy, C; Giner, A; Teasdale, R; Zerial, M				McBride, HM; Rybin, V; Murphy, C; Giner, A; Teasdale, R; Zerial, M			Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13	CELL			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; SMALL GTPASE RAB5; VESICLE DOCKING; SNARE COMPLEX; AMPA RECEPTORS; PROTEIN; TRANSPORT; ENDOSOME; EXOCYTOSIS; BINDING	SNAREs and Rab GTPases cooperate in vesicle transport through a mechanism yet poorly understood. We now demonstrate that the Rab5 effecters EEA1 and Rabaptin-5/Rabex-5 exist on the membrane in high molecular weight oligomers, which also contain NSF. Oligomeric assembly is modulated by the ATPase activity of NSF. Syntaxin 13, the t-SNARE required for endosome fusion, is transiently incorporated into the large oligomers via direct interactions with EEA1. This interaction is required to drive fusion, since both dominant-negative EEA1 and synthetic peptides encoding the MIE Zn2+ finger hinder the interaction and block fusion. We propose a novel mechanism whereby oligomeric EEA1 and NSF mediate the local activation of syntaxin 13 upon membrane tethering and, by analogy with viral fusion proteins, coordinate the assembly of a fusion pore.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Ioannina, Sch Med, Biol Chem Lab, Ioannina 45110, Greece; Alfred Hosp, Monash Med Sch, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	European Molecular Biology Laboratory (EMBL); Max Planck Society; University of Ioannina; Florey Institute of Neuroscience & Mental Health; Monash University	Zerial, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		McBride, Heidi M/C-1162-2008; Teasdale, Rohan D/B-2538-2009; McBride, Heidi M./ABD-5774-2021; Murphy, Carol/ABE-4282-2021; Teasdale, Rohan/AAD-6698-2019	McBride, Heidi M/0000-0003-4666-2280; Teasdale, Rohan D/0000-0001-7455-5269; McBride, Heidi M./0000-0003-4666-2280; Murphy, Carol/0000-0003-1353-8558; Teasdale, Rohan/0000-0001-7455-5269				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lin JW, 1998, NEURON, V21, P267, DOI 10.1016/S0896-6273(00)80534-6; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Markovic I, 1998, J CELL BIOL, V143, P1155, DOI 10.1083/jcb.143.5.1155; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	64	393	398	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					377	386		10.1016/S0092-8674(00)81966-2	http://dx.doi.org/10.1016/S0092-8674(00)81966-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458612	Bronze			2022-12-01	WOS:000081950300012
J	Neugebauer, R; Hoek, HW; Susser, E				Neugebauer, R; Hoek, HW; Susser, E			Prenatal exposure to wartime famine and development of antisocial personality disorder in early adulthood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUTCH-HUNGER-WINTER; BIRTH COMPLICATIONS; VIOLENT CRIME; FOLLOW-UP; CHILDREN; PREGNANCY; BEHAVIOR; SCHIZOPHRENIA; ADOLESCENCE; STARVATION	Context Several observational epidemiological studies report an association of pregnancy and obstetric complications with development of antisocial personality disorder (ASPD) in offspring. However, the precise nature and timing of the hypothesized biological insults are not known. Objective To test whether severe maternal nutritional deficiency early in gestation is associated with risk for ASPD in offspring. Design and Setting Retrospective cohort study. From October 1944 to May 1945, the German army blockaded food supplies to the Netherlands, subjecting the western Netherlands first to moderate (official food rations, 4200-6300 kJ/d) then to severe (<4200 kJ/d) nutritional deficiency. The north and south were subjected to moderate nutritional deficiency only. Participants Dutch men born in large urban areas in 1944-1946 who were given psychiatric examinations for military induction at age 18 years (N = 100 543) were classified by the degree and timing of their prenatal exposure to nutritional deficiency based on their birthdate and birthplace. Main Outcome Measure Diagnosis of ASPD by psychiatric interview at time of medical examination for military induction, using the International Classification of Diseases, Sixth Revision (ICD-6). Results Men exposed prenatally to severe maternal nutritional deficiency during the first and/or second trimesters of pregnancy exhibited increased risk for ASPD (adjusted odds ratio [OR], 2.5; 95% confidence interval [CI], 1.5-4.2). Third-trimester exposure to severe nutritional deficiency and prenatal exposure to moderate nutritional deficiency were not associated with risk for ASPD. Conclusions Our data suggest that severe nutritional insults to the developing brain in utero may be capable of increasing the risk for antisocial behaviors in offspring. The possible implications of these findings for both developed countries and developing countries, where severe nutritional deficiency is widespread and often exacerbated by war, natural disaster, and forced migration, warrant study.	Columbia Univ, New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, New York, NY 10032 USA; Columbia Univ, GH Sergievsky Ctr, Fac Med, New York, NY 10032 USA; Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Leiden Univ, Parnassia Hague Psychiat Inst, The Hague, Netherlands	Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Leiden University; Leiden University - Excl LUMC; Parnassia Psychiatric Institute	Neugebauer, R (corresponding author), Columbia Univ, New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, Box 53,722 W 168th St, New York, NY 10032 USA.			Hoek, Hans/0000-0001-6353-5465				[Anonymous], 1994, DIAGNOSTIC STAT MANU; Baker R. L., 1984, INFLUENCES HUMAN DEV; BRENNAN P, 1993, DEV TREATMENT CHILDH, P81; BRESLAU N, 1988, J AM ACAD CHILD PSY, V27, P605, DOI 10.1097/00004583-198809000-00015; BROWN AS, 1995, BRIT J PSYCHIAT, V166, P601, DOI 10.1192/bjp.166.5.601; Brown AS, 1997, EPIDEMIOLOGY, V8, P55, DOI 10.1097/00001648-199701000-00009; BUKA S L, 1988, Acta Paediatrica Japonica, V30, P537; BUKA SL, 1993, ARCH GEN PSYCHIAT, V50, P151; Burger G., 1948, MALNUTRITION STARVAT; CARP EAD, 1947, MED PSYCHOL PATHOP 3; COHEN P, 1989, CHILD DEV, V60, P701, DOI 10.2307/1130735; COHLER BJ, 1975, SOC BIOL, V22, P269, DOI 10.1080/19485565.1975.9988176; Elwood J. M., 1992, EPIDEMIOLOGY CONTROL; FIELD T, 1986, DEV PSYCHOBIOL, V21, P1152; GERSHON ES, 1995, ARCH GEN PSYCHIAT, V50, P900; GRAHAM GG, 1993, NEW ENGL J MED, V328, P1058, DOI 10.1056/NEJM199304083281429; GRIGOROIUSERBANESCU M, 1984, INT J BEHAV DEV, V7, P307, DOI 10.1177/016502548400700304; HALVERSON CF, 1976, CHILD DEV, V47, P281; Hoek HW, 1996, AM J PSYCHIAT, V153, P1637; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KANDEL E, 1991, CRIMINOLOGY, V29, P519, DOI 10.1111/j.1745-9125.1991.tb01077.x; KAPLAN HI, 1991, SYNOPSIS PSYCHIAT, P532; KATES RW, 1993, NEW ENGL J MED, V328, P1055, DOI 10.1056/NEJM199304083281428; Kline J.S., 1989, CONCEPTION BIRTH EPI; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; LYONS MJ, 1995, ARCH GEN PSYCHIAT, V52, P906; MCGEE R, 1984, J CHILD PSYCHOL PSYC, V25, P573, DOI 10.1111/j.1469-7610.1984.tb00173.x; MEDNICK SA, 1988, BIOL CONTRIBUTIONS C; Neugebauer R, 1997, AM J PUBLIC HEALTH, V87, P726, DOI 10.2105/AJPH.87.5.726; OLDS H, 1998, JAMA-J AM MED ASSOC, V280, P1238; PAULHUS DL, 1986, J PERS SOC PSYCHOL, V50, P1235, DOI 10.1037/0022-3514.50.6.1235; Pine DS, 1997, AM J PUBLIC HEALTH, V87, P1303, DOI 10.2105/AJPH.87.8.1303; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; Raine A, 1996, ARCH GEN PSYCHIAT, V53, P544; RAINE A, 1988, SOCIAL PSYCHOPHYSIOL, P231; RAINE A, PSYCHOPATHOLOGY CRIM; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Reiss A., 1993, UNDERSTANDING PREVEN; ROBINSON NM, 1965, PEDIATRICS, V35, P425; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; SCRIMSHAW NS, 1907, ANNU REV NUTR, V7, P1; SHAFFER D, 1985, CLIN GUIDE CHILD PSY, P29; SOUTH MA, 1985, TERATOLOGY, V31, P297, DOI 10.1002/tera.1420310216; STEIN Z, 1972, SCIENCE, V178, P708, DOI 10.1126/science.178.4062.708; Stein Z., 1975, FAMINE HUM DEV DUTCH; Susser E, 1998, AM J EPIDEMIOL, V147, P213; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; SZATMARI P, 1990, DEV MED CHILD NEUROL, V32, P954; SZATMARI P, 1986, CAN J PSYCHIAT, V31, P513, DOI 10.1177/070674378603100606; WALDROP MF, 1978, SCIENCE, V199, P536; Wali Sima, 1995, WOMENS RIGHTS HUMAN, P335; WEISSMAN MM, 1996, PSYCHIATRY, P6; *WHO, 1948, MAN INT CLASS DIS IN; ZELDENRUST ELK, 1966, NED TIJDSCHR GENEES, V110, P1737; 1948, MANUAL INT CLASSIFIC	59	235	242	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					455	462		10.1001/jama.282.5.455	http://dx.doi.org/10.1001/jama.282.5.455			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442661				2022-12-01	WOS:000081784900022
J	Lovey, PY; Morabia, A; Bleed, D; Peter, O; Dupuis, G; Petite, J				Lovey, PY; Morabia, A; Bleed, D; Peter, O; Dupuis, G; Petite, J			Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, ILLINOIS	Soc Epidemiol Res			CORONARY HEART-DISEASE; Q-FEVER ENDOCARDITIS; HELICOBACTER-PYLORI SEROPOSITIVITY; ACUTE MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; ATHEROSCLEROTIC PLAQUES; AORTIC-ANEURYSMS; RISK FACTOR; WALLS; TWAR	Objective To evaluate the range of long term vascular manifestations of Coxiella burnetii infection. Design Cohort study in Switzerland of people affected in 1983 by the largest reported outbreak of Q fever and who were followed up 12 rears later. Follow up information about possible vascular disease and endocarditis was obtained through a mailed questionnaire and death certificates. Setting Val de Bagnes, a rural Alpine valley in Switzerland. Participants 2044 (87%) of 2355 people who had serum testing for Coxiella burnetii infection in 1983: 1247 were classed as not hating been infected, 411 were classed as having been acutely infected, and 386 were classed as having been infected before 1983. Main outcome measures Relative risk controlled for age and sex and 12 year risk of vascular diseases and endocarditis among infected participants as compared with those who had never been infected. Results The 12 year risk of endocarditis or venous thromboembolic disease was not increased among those who had been acutely infected. The 12 rear risk of arterial disease was significantly higher among those who had been acutely infected (7%) as compared with those who had never been infected (4%) (relative risk 2.2, 95% confidence interval 1.4 to 3.6). Specifically, there was an increased risk of developing a cerebrovascular accident (relative risk 3.7, 1.6 to 8.4) and cardiac ischaemia (relative risk 1.9, 1.04 to 3.4). 12 year mortality was significantly higher among the 411 people who had been acutely infected in 1983 (9.7%; age adjusted relative risk 1.8, 1.2 to 2.6) when compared with the 1247 participants who had remained serologically negative in 1983 (7.0%) Conclusions Coxiella burnetii infection may cause long term complications including vascular disease.	Univ Hosp Geneva, Dept Internal Med, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland; Hop Valaisans, Inst Cent, Div Infect Dis & Immunol, CH-1951 Sion, Switzerland; Hop Reg, Serv Med Interne, CH-1920 Martigny, Switzerland; Etat Valais, CH-1950 Sion, Switzerland	University of Geneva; University of Geneva	Lovey, PY (corresponding author), Univ Hosp Geneva, Dept Internal Med, Rue Micheli Crest 24, CH-1211 Geneva 14, Switzerland.							BACA OG, 1983, MICROBIOL REV, V47, P127, DOI 10.1128/MMBR.47.2.127-149.1983; Blasi F, 1996, J CLIN MICROBIOL, V34, P2766, DOI 10.1128/JCM.34.11.2766-2769.1996; BROUQUI P, 1993, ARCH INTERN MED, V153, P642, DOI 10.1001/archinte.1993.00410050074010; COYLE PV, 1985, J CLIN PATHOL, V38, P743, DOI 10.1136/jcp.38.7.743; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DUPUIS G, 1985, J CLIN MICROBIOL, V22, P484, DOI 10.1128/JCM.22.4.484-487.1985; DUPUIS G, 1987, INT J EPIDEMIOL, V16, P282, DOI 10.1093/ije/16.2.282; ELLIS ME, 1983, Q J MED, V52, P54; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FERNANDEZGUERRERO ML, 1988, ANN INTERN MED, V108, P209, DOI 10.7326/0003-4819-108-2-209; Folsom AR, 1998, CIRCULATION, V98, P845, DOI 10.1161/01.CIR.98.9.845; GILBERT A, 1889, CR HEBD ACAD SCI, V6, P583; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; HACKSTADT T, 1986, INFECT IMMUN, V52, P337, DOI 10.1128/IAI.52.1.337-340.1986; HALDANE EV, 1983, J INFECT DIS, V148, P978, DOI 10.1093/infdis/148.6.978; HENDRIX LR, 1991, J GEN MICROBIOL, V137, P269, DOI 10.1099/00221287-137-2-269; Juvonen JJ, 1997, J VASC SURG, V25, P499, DOI 10.1016/S0741-5214(97)70260-X; Kuo CC, 1997, J VASC SURG, V26, P29, DOI 10.1016/S0741-5214(97)70143-5; Libby P, 1997, CIRCULATION, V96, P4095; MALLAVIA LP, 1991, EUR J EPIDEMIOL, V7, P213, DOI 10.1007/BF00145669; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570; PETER O, 1985, EUR J CLIN MICROBIOL, V4, P394, DOI 10.1007/BF02148690; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; REIMER LG, 1993, CLIN MICROBIOL REV, V6, P193, DOI 10.1128/CMR.6.3.193-198.1993; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMUEL JE, 1985, INFECT IMMUN, V49, P775, DOI 10.1128/IAI.49.3.775-779.1985; SiegmanIgra Y, 1997, SCAND J INFECT DIS, V29, P41, DOI 10.3109/00365549709008663; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680	30	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					284	286		10.1136/bmj.319.7205.284	http://dx.doi.org/10.1136/bmj.319.7205.284			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426735	Bronze, Green Published			2022-12-01	WOS:000081909100019
J	Brightbill, HD; Libraty, DH; Krutzik, SR; Yang, RB; Belisle, JT; Bleharski, JR; Maitland, M; Norgard, MV; Plevy, SE; Smale, ST; Brennan, PJ; Bloom, BR; Godowski, PJ; Modlin, RL				Brightbill, HD; Libraty, DH; Krutzik, SR; Yang, RB; Belisle, JT; Bleharski, JR; Maitland, M; Norgard, MV; Plevy, SE; Smale, ST; Brennan, PJ; Bloom, BR; Godowski, PJ; Modlin, RL			Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors	SCIENCE			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS INFECTION; SYNTHETIC LIPOPEPTIDE ANALOGS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TREPONEMA-PALLIDUM; BACTERIAL LIPOPROTEIN; LEISHMANIA-MAJOR; INTERFERON-GAMMA	The generation of cell-mediated immunity against many infectious pathogens involves the production of interleukin-12 (IL-12), a key signal of the innate immune system. Yet, for many pathogens, the molecules that induce IL-12 production by macrophages and the mechanisms by which they do so remain undefined. Here it is shown that microbial lipoproteins are potent stimulators of IL-12 production by human macrophages, and that induction is mediated by Toll-like receptors (TLRs). Several lipoproteins stimulated TLR-dependent transcription of inducible nitric oxide synthase and the production of nitric oxide, a powerful microbicidal pathway. Activation of TLRs by microbial lipoproteins may initiate innate defense mechanisms against infectious pathogens.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA; CUNY Mt Sinai Sch Med, Ctr Immunol, New York, NY 10029 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech; Colorado State University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Modlin, Robert L/M-7941-2014; Yang, Ruey-Bing/O-1494-2018; Belisle, John T/B-8944-2017	Modlin, Robert L/0000-0003-4720-031X; Yang, Ruey-Bing/0000-0003-3017-3714; Belisle, John T/0000-0002-2539-2798				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; ASHBRIDGE KR, 1989, NUCLEIC ACIDS RES, V17, P1249, DOI 10.1093/nar/17.3.1249; BESSLER WG, 1977, BIOCHEM BIOPH RES CO, V76, P239, DOI 10.1016/0006-291X(77)90717-3; BESSLER WG, 1985, J IMMUNOL, V135, P1900; BIESERT L, 1987, EUR J BIOCHEM, V162, P651, DOI 10.1111/j.1432-1033.1987.tb10687.x; BRAUN V, 1974, ANNU REV BIOCHEM, V43, P89, DOI 10.1146/annurev.bi.43.070174.000513; BRICKER TM, 1988, INFECT IMMUN, V56, P295, DOI 10.1128/IAI.56.2.295-301.1988; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COOPER AM, 1995, IMMUNOLOGY, V84, P423; de Jong R, 1998, SCIENCE, V280, P1435; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; FLYNN JL, 1995, J IMMUNOL, V155, P2515; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAUSCHILDT S, 1990, EUR J IMMUNOL, V20, P63, DOI 10.1002/eji.1830200110; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Libraty DH, 1997, J CLIN INVEST, V99, P336, DOI 10.1172/JCI119162; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MAILLARD J, 1972, J EXP MED, V136, P185, DOI 10.1084/jem.136.1.185; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; NORGARD MV, 1995, INFECT IMMUN, V63, P1507, DOI 10.1128/IAI.63.4.1507-1515.1995; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIELING PA, 1994, J IMMUNOL, V153, P3639; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Vogel SN, 1999, J IMMUNOL, V162, P5666; WALLIS RS, 1990, P NATL ACAD SCI USA, V87, P3348, DOI 10.1073/pnas.87.9.3348; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; Wooten RM, 1998, J IMMUNOL, V160, P5485; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T; ZHANG M, 1994, J CLIN INVEST, V93, P1733, DOI 10.1172/JCI117157	52	1326	1391	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					732	736		10.1126/science.285.5428.732	http://dx.doi.org/10.1126/science.285.5428.732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426995				2022-12-01	WOS:000081765100054
J	Blat, Y; Kleckner, N				Blat, Y; Kleckner, N			Cohesins bind to preferential sites along yeast chromosome III, with differential regulation along arms versus the centric region	CELL			English	Article							SISTER-CHROMATID COHESION; SMC PROTEIN COMPLEXES; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; NUCLEAR SCAFFOLD; S-PHASE; DYNAMICS; CONDENSATION; MITOSIS; MEIOSIS	Sister chromatid cohesion is mediated by evolutionary conserved chromosomal proteins, termed "cohesins." Using an extension of chromatin immunoprecipitation, we have analyzed the distribution of cohesins Mcd1/Scc1 and Smc1 along yeast chromosome III. Both proteins occur preferentially at the same similar to 23 positions. Sites in a similar to 50 kb region around the centromere give especially intense signals. Prominent centric region binding appears to emerge from a more even distribution, probably by differential loss of cohesins along the chromosome arms. Cohesin binding peaks correspond closely to peaks of high local AT composition, a base composition periodicity of similar to 15 kb that is distinct from the similar to 50 kb periodicity of base composition isochores, consistent with axis association of cohesins. The methodology described can be used to analyze the distribution of any DNA-binding protein and, via microchips, along entire genomes.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Blat, Y (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.				NIGMS NIH HHS [R01-GM44794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Biggins S, 1998, CURR OPIN CELL BIOL, V10, P769, DOI 10.1016/S0955-0674(98)80120-8; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Furuya K, 1998, GENE DEV, V12, P3408, DOI 10.1101/gad.12.21.3408; GASSER SM, 1995, CURR BIOL, V5, P357, DOI 10.1016/S0960-9822(95)00071-6; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1995, J HERED, V86, P330, DOI 10.1093/oxfordjournals.jhered.a111600; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOLEBAJER J, 1958, CHROMOSOMA, V9, P322; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; SAITOH Y, 1993, COLD SPRING HARB SYM, V58, P755, DOI 10.1101/SQB.1993.058.01.083; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUMNER AT, 1991, CHROMOSOMA, V100, P36; SUROSKY RT, 1986, P NATL ACAD SCI USA, V83, P414, DOI 10.1073/pnas.83.2.414; Swedlow JR, 1996, CURR BIOL, V6, P544, DOI 10.1016/S0960-9822(02)00538-9; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	45	330	338	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					249	259		10.1016/S0092-8674(00)81019-3	http://dx.doi.org/10.1016/S0092-8674(00)81019-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428036	Bronze			2022-12-01	WOS:000081632300014
J	Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P				Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P			Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist	NATURE			English	Article							NUCLEUS-ACCUMBENS; RAT; LESIONS; REINFORCEMENT; MODULATION; DEPENDENCE; ACTIVATION; SCHEDULES; ADDICTION; CIRCUITS	Environmental stimuli that are reliably associated with the effects of many abused drugs, especially stimulants such as cocaine, can produce craving and relapse in abstinent human substance abusers(1-4). In animals, such cues can induce and maintain drug-seeking behaviour and also reinstate drug-seeking after extinction(5-7). Reducing the motivational effects of drug-related cues might therefore be useful in the treatment of addiction(3). Converging pharmacological(8,9), human post-mortem(10) and genetic(11) studies implicate the dopamine D-3 receptor(12) in drug addiction. Here we have designed BP 897, the first D-3-receptor-selective agonist, as assessed in vitro with recombinant receptors and in vivo with mice bearing disrupted D-3-receptor genes. BP 897 is a partial agonist in vitro and acts in vivo as either an agonist or an antagonist. We show that BP 897 inhibits cocaine-seeking behaviour that depends upon the presentation of drug-associated cues, without having any intrinsic, primary rewarding effects. Our data indicate that compounds like BP 897 could be used for reducing the drug craving and vulnerability to relapse that are elicited by drug-associated environmental stimuli.	Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Lab Bioprojet, F-75002 Paris, France; Ctr Paul Broca, INSERM, U109, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France; Fac Pharm, CNRS, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch, France	University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Everitt, BJ (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.			Everitt, Barry/0000-0003-4431-6536	Medical Research Council [G9537855] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774; Bordet R, 1997, P NATL ACAD SCI USA, V94, P3363, DOI 10.1073/pnas.94.7.3363; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BEHAV PHARMACOL, V6, P333; Caine SB, 1997, NEUROREPORT, V8, P2373, DOI 10.1097/00001756-199707070-00054; COSTA T, 1992, MOL PHARMACOL, V41, P549; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; Di Ciano P, 1998, EUR J NEUROSCI, V10, P1121, DOI 10.1046/j.1460-9568.1998.00125.x; Duaux E, 1998, MOL PSYCHIATR, V3, P333, DOI 10.1038/sj.mp.4000409; EVERITT B J, 1992, P401; FONTANA DJ, 1993, BRAIN RES, V629, P31, DOI 10.1016/0006-8993(93)90477-5; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Grech DM, 1996, PSYCHOPHARMACOLOGY, V125, P97, DOI 10.1007/BF02249407; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X; OBRIEN CP, 1992, RES P ARNMD, V70, P157; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; PILON C, 1994, EUR J PHARM-MOLEC PH, V268, P129, DOI 10.1016/0922-4106(94)90182-1; PULVIRENTI L, 1994, TRENDS PHARMACOL SCI, V15, P374, DOI 10.1016/0165-6147(94)90158-9; Ridray S, 1998, EUR J NEUROSCI, V10, P1676, DOI 10.1046/j.1460-9568.1998.00173.x; Sautel F, 1995, J PHARMACOL EXP THER, V275, P1239; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Staley JK, 1996, J NEUROSCI, V16, P6100; Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447; Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/s002130050079; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; Xu M, 1999, SYNAPSE, V31, P210, DOI 10.1002/(SICI)1098-2396(19990301)31:3<210::AID-SYN6>3.3.CO;2-S	30	512	535	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					371	375		10.1038/43944	http://dx.doi.org/10.1038/43944			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432116				2022-12-01	WOS:000081590000052
J	Syngal, S; Fox, EA; Li, C; Dovidio, M; Eng, C; Kolodner, RD; Garber, JE				Syngal, S; Fox, EA; Li, C; Dovidio, M; Eng, C; Kolodner, RD; Garber, JE			Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer - Implications for clinical predisposition testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISMATCH REPAIR GENES; COLON-CANCER; MICROSATELLITE INSTABILITY; MLH1 MUTATIONS; HMSH2 MUTATIONS; HNPCC FAMILIES; HMLH1 GENES; HOMOLOG; MSH2; CARCINOMA	Context Genetic testing for cancer predisposition is evolving from purely research applications to affecting clinical management. Objective To determine how often genetic lest results for hereditary nonpolyposis colorectal cancer (HNPCC) can be definitively interpreted and used to guide clinical management. Design Case-series study conducted in 1996 to 1998 in which a complete sequence analysis of hMSH2 and hMLH1 coding sequence and flanking intronic regions was performed. Mutations were categorized as protein truncating and missense. In the case of missense alterations, additional analyses were performed in an effort to assess pathogenicity. Setting and Participants Families were identified by self-referral or health care provider referral to a cancer genetics program. Participants and kindreds were classified into 1 of 4 categories: (1) Amsterdam criteria for HNPCC, (2) modified Amsterdam criteria for HNPCC, (3) young age at onset, or (4) HNPCC-variant. In addition, each proband was classified according to the Bethesda guidelines for identification of individuals with HNPCC. Main Outcome Measure Alterations of hMSH2 and hMLH1 genes. Results Twenty-seven alterations of hMSH2 and hMLH1 were found in 24 of 70 families (34.3 %), Of these, deleterious mutations that could be used with confidence in clinical management were identified in 25.7% (18/70) of families. The rates of definitive results for families fulfilling Amsterdam criteria, modified Amsterdam criteria, young age at onset, HNPCC-variant, and Bethesda guidelines were 27 (39.3%), 13 (18.2%), 12 (16.7%), 11 (15.8%), and 21 (30.4%), respectively. The prevalence of missense mutations, genetic heterogeneity of the syndrome, and limited availability of validated functional assays present a challenge in the interpretation of genetic test results of HNPCC families. Conclusions The identification of pathogenic mutations in a significant subset of families for whom the results may have marked clinical importance makes genetic testing an important option for HNPCC and HNPCC-like kindreds. However, for the majority of individuals in whom sequence analysis of hMSH2 and hMLH1 does not give a definitive result, intensive follow-up is still warranted.	Dana Farber Canc Inst, Dept Populat Sci, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Ludwig Inst Canc Res, La Jolla, CA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research	Garber, JE (corresponding author), Dana Farber Canc Inst, Dept Populat Sci, 44 Binney St,Smith 208, Boston, MA 02115 USA.	judy_garber@dfci.harvard.edu		Eng, Charis/0000-0002-3693-5145				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bellacosa A, 1996, AM J MED GENET, V62, P353, DOI 10.1002/(SICI)1096-8628(19960424)62:4<353::AID-AJMG7>3.0.CO;2-S; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Cotton RGH, 1998, HUM MUTAT, V12, P1, DOI 10.1002/(SICI)1098-1004(1998)12:1<1::AID-HUMU1>3.0.CO;2-M; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROGGATT NJ, 1995, LANCET, V345, P727, DOI 10.1016/S0140-6736(95)90900-1; Froggatt NJ, 1996, EUR J CANCER, V32A, P178, DOI 10.1016/0959-8049(95)00464-5; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Hackman P, 1997, NAT GENET, V17, P135, DOI 10.1038/ng1097-135; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1; Holtzman NA., 1998, PROMOTING SAFE EFFEC; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; KOLBERG R, 1994, J NIH RES, V6, P37; KOLODNER RD, 1995, CANCER RES, V55, P242; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; Maliaka YK, 1996, HUM GENET, V97, P251, DOI 10.1007/BF02265276; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MARY JL, 1994, HUM MOL GENET, V3, P2067; MAUILLON JL, 1996, CANCER RES, V56, P242; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Offit K, 1998, CLINICAL CANCER GENETICS, P1; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135; Risinger JI, 1996, CANCER, V77, P1836, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1836::AID-CNCR12>3.0.CO;2-0; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; TANNERGARD P, 1995, CANCER RES, V55, P6092; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; WATSON P, 1994, AM J MED, V96, P516, DOI 10.1016/0002-9343(94)90091-4; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	53	97	110	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					247	253		10.1001/jama.282.3.247	http://dx.doi.org/10.1001/jama.282.3.247			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422993				2022-12-01	WOS:000081504400030
J	Evans, JMM; Newton, RW; Ruta, DA; MacDonald, TM; Stevenson, RJ; Morris, AD				Evans, JMM; Newton, RW; Ruta, DA; MacDonald, TM; Stevenson, RJ; Morris, AD			Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; POPULATION; MELLITUS; IMPACT	Objectives To investigate patterns of self monitoring of blood glucose concentration in diabetic patients who use insulin and to determine whether frequency of self monitoring is related to glycaemic control. Setting Diabetes database, Tayside, Scotland. Subjects Patients resident in Tayside in 1993-5 who were using insulin and were registered on the database and diagnosed with insulin dependent (type 1) or non-insulin dependent (type 2) diabetes before 1993. Main outcome measures Number of glucose monitoring reagent strips dispensed (reagent strip uptake) derived from records of prescriptions. First recorded haemoglobin A(1c), concentration in the study period, and reagent strips dispensed in the previous 6 months. Results Among 807 patients with type 1 diabetes, 128 (16%) did not redeem any prescriptions for glucose monitoring reagent strips in the 3 year study period. Only 161 (20%) redeemed prescriptions for enough reagent strips to test glucose daily. The corresponding figures for the 790 patients with type 2 diabetes who used insulin were 162 (21%; no strips) and 131 (17%; daily tests). Reagent strip uptake was influenced both by age and by deprivation category. There was a direct relation between uptake and glycaemic control for 258 patients (with recorded haemoglobin A(1c) concentrations) with type 1 diabetes. In a linear regression model the decrease in haemoglobin A(1c) concentration for every extra 180 reagent strips dispensed was 0.7%. For the 290 patients with type 2 diabetes who used insulin there was no such relation. Conclusions Self monitoring of blood glucose concentration is associated with improved glycaemic control in patients with type 1 diabetes. Regular self monitoring in patients with type 1 and type 2 diabetes is uncommon.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Evans, JMM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Med Monitoring Unit, Dundee DD1 9SY, Scotland.	josie@memo.dundee.ac.uk	Morris, Andrew D/C-2837-2009; Ruta, Danny A/E-4472-2013	MacDonald, Thomas/0000-0001-5189-6669; Ruta, Danny/0000-0002-2024-3267	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, DIABETES CARE, V10, P95; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BELMONTE MM, 1988, DIABETES CARE, V11, P484, DOI 10.2337/diacare.11.6.484; *BRIT MED ASS, 1998, BRIT NAT FORM, V35; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; DANEMAN D, 1985, DIABETES CARE, V8, P1, DOI 10.2337/diacare.8.1.1; DCCT Research Group, 1989, NEW ENGL J MED, V329, P977; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Gallichan M, 1997, BRIT MED J, V314, P964, DOI 10.1136/bmj.314.7085.964; GILL GV, 1989, PRACTICAL DIABETES, V6, P77; GORDON D, 1991, DIABETIC MED, V8, P679, DOI 10.1111/j.1464-5491.1991.tb01677.x; HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116; *INF STAT DIV, 1996, SCOTT HLTH STAT 1996; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; MOLITCH ME, 1994, DIABETES CARE, V17, P81; Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; Morris AD, 1997, DIABETES CARE, V20, P1363, DOI 10.2337/diacare.20.9.1363; Morris AD, 1998, DIABETES CARE, V21, P738, DOI 10.2337/diacare.21.5.738; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; PATRICK AW, 1994, DIABETIC MED, V11, P62, DOI 10.1111/j.1464-5491.1994.tb00231.x; Ray NF, 1998, DIABETES CARE, V21, P296; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233	24	179	182	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					83	86		10.1136/bmj.319.7202.83	http://dx.doi.org/10.1136/bmj.319.7202.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398627	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000081438200023
J	Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD				Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD			Are we really dying for a tan?	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; VITAMIN-D; EXPOSURE; SUNLIGHT; POPULATION; MORTALITY; MELANOMA		Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England	University of Bristol	Ness, AR (corresponding author), Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England.		Ness, Andy R/M-7612-2013; Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Ness, Andy R/0000-0003-3548-9523; Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ARTHEY S, 1995, SOC SCI MED, V40, P265, DOI 10.1016/0277-9536(94)E0063-X; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; Bridgwood A, 1996, HLTH ENGLAND 1995 WH; CARTER S, 1997, TOURISM HLTH; CHEW KSY, 1995, SOC SCI MED, V40, P223, DOI 10.1016/0277-9536(94)E0070-9; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; Finkel E, 1998, LANCET, V351, P1866, DOI 10.1016/S0140-6736(05)78819-X; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Freedman DM, 1997, BRIT MED J, V314, P1451, DOI 10.1136/bmj.314.7092.1451; Grimes DS, 1996, QJM-INT J MED, V89, P579; Haines A, 1997, BRIT MED J, V315, P870, DOI 10.1136/bmj.315.7112.870; HUTTON D, 1998, VOGUE            MAY, P114; KHAW KT, 1995, LANCET, V345, P337, DOI 10.1016/S0140-6736(95)90336-4; LUND B, 1978, HORM METAB RES, V10, P553, DOI 10.1055/s-0028-1093390; MARKS R, 1995, ARCH DERMATOL, V131, P415, DOI 10.1001/archderm.131.4.415; McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005; MELIA J, 1995, HLTH HYG, V16, P153; *OFF NAT STAT, 1997, MORT STAT CAUS ENGL; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; *SECR STAT HLTH, 1992, HLTH NAT; Utiger RD, 1998, NEW ENGL J MED, V338, P828, DOI 10.1056/NEJM199803193381209; VIK T, 1979, BMJ-BRIT MED J, V2, P176, DOI 10.1136/bmj.2.6183.176; WEHR TA, 1989, AM J PSYCHIAT, V146, P829; West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714	25	42	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					114	116		10.1136/bmj.319.7202.114	http://dx.doi.org/10.1136/bmj.319.7202.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398641	Green Published			2022-12-01	WOS:000081438200040
J	Maser, P; Sutterlin, C; Kralli, A; Kaminsky, R				Maser, P; Sutterlin, C; Kralli, A; Kaminsky, R			A nucleoside transporter from Trypanosoma brucei involved in drug resistance	SCIENCE			English	Article							UNUSUAL ADENOSINE TRANSPORTER; MOLECULAR-CLONING	Drug resistance of pathogens is an increasing problem whose underlying mechanisms are not fully understood, Cellular uptake of the major drugs against Trypanosoma brucei spp,, the causative agents of sleeping sickness, is thought to occur through an unusual, so far unidentified adenosine transporter, Saccharomyces cerevisiae was used in a functional screen to clone a gene (TbAT1) from Trypanosoma brucei brucei that encodes a nucleoside transporter. When expressed in yeast, TbAT1 enabled adenosine uptake and conferred susceptibility to melaminophenyl arsenicals. Drug-resistant trypanosomes harbor a defective TbAT1 variant. The molecular identification of the entry route of trypanocides opens the way to approaches for diagnosis and treatment of drug-resistant sleeping sickness.	Swiss Trop Inst, CH-4002 Basel, Switzerland; Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Kaminsky, R (corresponding author), Novartis CRA, CH-1566 St Aubin, Switzerland.			Maser, Pascal/0000-0003-3122-1941				Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; BARRETT MP, 1995, MOL BIOCHEM PARASIT, V73, P223, DOI 10.1016/0166-6851(95)00120-P; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FROMMEL TO, 1987, MOL BIOCHEM PARASIT, V26, P183, DOI 10.1016/0166-6851(87)90142-3; FULTON JD, 1955, ANN TROP MED PARASIT, V49, P377; GIBSON WC, 1983, T ROY SOC TROP MED H, V77, P114, DOI 10.1016/0035-9203(83)90033-0; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; Maser P, 1997, RRD ANTIMICROB AG CH, V2, P113; MASER P, UNPUB; MazhariTabrizi R, 1996, BIOCHEM J, V316, P853, DOI 10.1042/bj3160853; POSPICHAL H, 1994, ACTA TROP, V58, P187, DOI 10.1016/0001-706X(94)90013-2; Tye CK, 1998, BIOORG MED CHEM LETT, V8, P811, DOI 10.1016/S0960-894X(98)00095-X; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; YORKE WARRINGTON, 1931, Annals of Tropical Medicine and Parasitology, V25, P351	20	221	228	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					242	244		10.1126/science.285.5425.242	http://dx.doi.org/10.1126/science.285.5425.242			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398598				2022-12-01	WOS:000081346000038
J	Sartori, C; Allemann, Y; Trueb, L; Delabays, A; Nicod, P; Scherrer, U				Sartori, C; Allemann, Y; Trueb, L; Delabays, A; Nicod, P; Scherrer, U			Augmented vasoreactivity in adult life associated with perinatal vascular insult	LANCET			English	Article							PERSISTENT PULMONARY-HYPERTENSION; NITRIC-OXIDE; HYPOXIA; VASOCONSTRICTION; RESISTANCE; NEWBORN	Background Adverse environmental events occurring early in life have received little attention as predictors of disease in the later stages of life. At birth, the transition from gas exchange by the placenta to gas exchange by the lungs requires dramatic changes in the pulmonary circulation, which during this period is particularly vulnerable to noxious stimuli. We measured pulmonary-artery pressure responses to high-altitude exposure, a stimulus that causes pronounced pulmonary vasoconstriction, in young adults who had had transient perinatal hypoxic pulmonary hypertension and in controls of similar age and sex distribution. Methods Review of neonatal-care records at the Lausanne University Hospital for Children identified 15 individuals who met the eligibility criteria (birth at greater than or equal to 34 weeks of gestation, persistence of hypoxaemia during ventilation with oxygen during the first week of life, and persistence of fetal circulation), Ten of these individuals agreed to take part; the control group was ten volunteers without any history of perinatal complications. Systolic pulmonary-artery pressure (by echocardiography) and arterial oxygen saturation were measured at baseline and at high altitude (4559 m). Findings The mean increase in pulmonary-artery pressure at high altitude was significantly greater (p=0.01) in the participants who had had perinatal pulmonary hypertension (from 26.2 mm Hg [SD 2.1] to 62.3 mm Hg [7.3]) than in the controls (from 25.8 mm Hg [2.3] to 49.7 mm Hg [11.3]). The fall in arterial oxygen saturation was similar in the two groups. Interpretation These findings suggest that a transient perinatal insult to the pulmonary circulation leaves a persistent and potentially fatal imprint, which when activated in adult life predisposes to a pathological response. Survivors of perinatal pulmonary hypertension may be at risk of developing this disorder in later life.	CHU Vaudois, Dept Internal Med, CH-1011 Lausanne, Switzerland; CHU Vaudois, Div Cardiol, CH-1011 Lausanne, Switzerland; Univ Hosp, Dept Cariol, Bern, Switzerland; Univ Lausanne, Inst Physiol, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bern; University Hospital of Bern; University of Lausanne	Scherrer, U (corresponding author), CHU Vaudois, Dept Internal Med, BH 10-642, CH-1011 Lausanne, Switzerland.	Urs.Scherrer@chuv.hospvd.ch		Sartori, Claudio/0000-0002-8172-3002				Barker D. J. P., 1994, MOTHERS BABIES DIS L; Blitzer ML, 1996, J AM COLL CARDIOL, V28, P591, DOI 10.1016/0735-1097(96)00218-5; CASLIN A, 1991, J PATHOL, V163, P133, DOI 10.1002/path.1711630209; DOLLBERG S, 1995, PEDIATR RES, V37, P31, DOI 10.1203/00006450-199501000-00007; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; HAKIM TS, 1990, CAN J PHYSIOL PHARM, V68, P419, DOI 10.1139/y90-059; HAMPL V, 1990, AM REV RESPIR DIS, V142, P619, DOI 10.1164/ajrccm/142.3.619; HAWORTH SG, 1988, CHEST, V3, pS133; MORIN FC, 1995, AM J RESP CRIT CARE, V151, P2010, DOI 10.1164/ajrccm.151.6.7767553; PERRELLA MA, 1992, AM J PHYSIOL, V263, pR45, DOI 10.1152/ajpregu.1992.263.1.R45; RABINOVITCH M, 1981, AM J PHYSIOL, V240, pH62, DOI 10.1152/ajpheart.1981.240.1.H62; Sartori C, 1997, Cardiologia, V42, P559; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Smith A. P. L., 1997, European Respiratory Journal Supplement, V10, p433S; STENMARK KR, 1988, CHEST, V3, pS127; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; VENDER RL, 1996, CHEST, V106, P206	17	127	130	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2205	2207		10.1016/S0140-6736(98)08352-4	http://dx.doi.org/10.1016/S0140-6736(98)08352-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392986				2022-12-01	WOS:000081091300014
J	Park, DH; Somers, DE; Kim, YS; Choy, YH; Lim, HK; Soh, MS; Kim, HJ; Kay, SA; Nam, HG				Park, DH; Somers, DE; Kim, YS; Choy, YH; Lim, HK; Soh, MS; Kim, HJ; Kay, SA; Nam, HG			Control of circadian rhythms and photoperiodic flowering by the Arabidopsis GIGANTEA gene	SCIENCE			English	Article							CDNA CLONE; CLOCK; THALIANA; TRANSCRIPTION; PERIOD; DROSOPHILA; MUTANT; PLANTS; ENTRAINMENT; EXPRESSION	Photoperiodic responses in plants include flowering that is day-length-dependent. Mutations in the Arabidopsis thaliana GIGANTEA (GI) gene cause photoperiod-insensitive flowering and alteration of circadian rhythms. The GI gene encodes a protein containing six putative transmembrane domains. Circadian expression patterns of the GI gene and the clock-associated genes, LHY and CCA1, are altered in gi mutants, showing that GI is required for maintaining circadian amplitude and appropriate period length of these genes. The gi-1 mutation also affects Light signaling to the clock, which suggests that GI participates in a feedback loop of the plant circadian system.	Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92307 USA; Scripps Res Inst, Natl Sci Fdn, Ctr Biol Timing, La Jolla, CA 92307 USA	Pohang University of Science & Technology (POSTECH); Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute	Nam, HG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea.		Somers, David E/A-9209-2010; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; SOH, MOON-SOO/0000-0002-4430-516X	NIGMS NIH HHS [GM56006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Amasino RM, 1996, CURR OPIN GENET DEV, V6, P480, DOI 10.1016/S0959-437X(96)80071-2; ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Carre IA, 1996, SEMIN CELL DEV BIOL, V7, P775, DOI 10.1006/scdb.1996.0095; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Green RM, 1999, P NATL ACAD SCI USA, V96, P4176, DOI 10.1073/pnas.96.7.4176; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; Kim YS, 1998, PLANT MOL BIOL, V37, P955, DOI 10.1023/A:1006030617502; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Kwak JM, 1997, PLANTA, V201, P245, DOI 10.1007/s004250050063; Lumsden P. J., 1998, BIOL RHYTHMS PHOTOPE; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Redei G. P., 1974, STADLER S, V6, P135; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Somers DE, 1998, DEVELOPMENT, V125, P485; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Thomas B., 1996, PHOTOPERIODISM PLANT; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; WHITELAM GC, 1998, ARABIDOPSIS ANN PLAN, V1, P331; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	36	451	479	5	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1579	1582		10.1126/science.285.5433.1579	http://dx.doi.org/10.1126/science.285.5433.1579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477524				2022-12-01	WOS:000082359500069
J	Olynyk, JK; Cullen, DJ; Aquilia, S; Rossi, E; Summerville, L; Powell, LW				Olynyk, JK; Cullen, DJ; Aquilia, S; Rossi, E; Summerville, L; Powell, LW			A population-based study of the clinical expression of the hemochromatosis gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; MUTATION ANALYSIS; EARLY DIAGNOSIS; TRANSFERRIN; SATURATION; PREDICTION; PREVALENCE; FIBROSIS; HFE	Background and Methods Hereditary hemochromatosis is associated with homozygosity for the C282Y mutation in the hemochromatosis (HFE) gene on chromosome 6, elevated serum transferrin saturation, and excess iron deposits throughout the body. To assess the prevalence and clinical expression of the HFE gene, we conducted a population-based study in Busselton, Australia. In 1994, we obtained blood samples for the determination of serum transferrin saturation and ferritin levels and the presence or absence of the C282Y mutation and the H63D mutation (which may contribute to increased hepatic iron levels) in 3011 unrelated white adults. We evaluated all subjects who had persistently elevated transferrin-saturation values (45 percent or higher) or were homozygous for the C282Y mutation. We recommended liver biopsy for subjects with serum ferritin levels of 300 ng per milliliter or higher. The subjects were followed for up to four years. Results Sixteen of the subjects (0.5 percent) were homozygous for the C282Y mutation, and 424 (14.1 percent) were heterozygous. The serum transferrin saturation was 45 percent or higher in 15 of the 16 who were homozygous; in 1 subject it was 43 percent. Four of the homozygous subjects had previously been given a diagnosis of hemochromatosis, and 12 had not. Seven of these 12 patients had elevated serum ferritin levels in 1994; 6 of the 7 had further increases in 1998, and 1 had a decrease, although the value remained elevated. The serum ferritin levels in the four other homozygous patients remained in the normal range. Eleven of the 16 homozygous subjects underwent liver biopsy; 3 had hepatic fibrosis, and 1, who had a history of excessive alcohol consumption, had cirrhosis and mild microvesicular steatosis. Eight of the 16 homozygous subjects had clinical findings that were consistent with the presence of hereditary hemochromatosis, such as hepatomegaly, skin pigmentation, and arthritis. Conclusions In a population of white adults of northern European ancestry, 0.5 percent were homozygous for the C282Y mutation in the HFE gene. However, only half of those who were homozygous had clinical features of hemochromatosis, and one quarter had serum ferritin levels that remained normal over a four-year period. (N Engl J Med 1999;341:718-24.) (C)1999, Massachusetts Medical Society.	Univ Western Australia, Dept Med, Fremantle, WA 6959, Australia; Fremantle Hosp, Dept Gastroenterol, Fremantle, WA, Australia; Busselton Populat Med Res Fdn, Perth, WA, Australia; Queen Elizabeth II Med Ctr, Pathctr, Nedlands, WA, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; Univ Queensland, Brisbane, Qld, Australia	University of Western Australia; University of Western Australia; University of Western Australia; QIMR Berghofer Medical Research Institute; University of Queensland	Olynyk, JK (corresponding author), Univ Western Australia, Dept Med, POB 480, Fremantle, WA 6959, Australia.	jolynyk@cyllene.uwa.edu.au		Olynyk, John/0000-0003-0417-3411				Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; Adams PC, 1997, HEPATOLOGY, V26, P986, DOI 10.1002/hep.510260428; Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; BASSETT ML, 1988, ANN NY ACAD SCI, V526, P274, DOI 10.1111/j.1749-6632.1988.tb55512.x; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; BEILBY J, 1992, CLIN CHEM, V38, P2078; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; Cardoso EMP, 1998, J INTERN MED, V243, P203; Carella M, 1997, AM J HUM GENET, V60, P828; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Cullen LM, 1997, BLOOD, V90, P4236, DOI 10.1182/blood.V90.10.4236; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; JEFFREY GP, IN PRESS NAT GENET; Knuiman MW, 1997, J EPIDEMIOL COMMUN H, V51, P515, DOI 10.1136/jech.51.5.515; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; McLaren CE, 1998, GASTROENTEROLOGY, V114, P543, DOI 10.1016/S0016-5085(98)70538-4; Mendler MH, 1998, HEPATOLOGY, V28, p419A; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Moirand R, 1999, GASTROENTEROLOGY, V116, P372, DOI 10.1016/S0016-5085(99)70134-4; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; OLYNYK JK, 1994, POSTGRAD MED, V96, P151, DOI 10.1080/00325481.1994.11945914; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; Powell W.L., 1994, IRON METABOLISM HLTH; Robson KJH, 1997, GUT, V41, P841; Rossi E, 1999, J GASTROEN HEPATOL, V14, P427, DOI 10.1046/j.1440-1746.1999.01884.x; SEARLE J, 1994, PATHOLOGY LIVER, P224; SINGERSAM J, 1989, AMPL FOR PCR US; Snedecor GW, 1967, STAT METHODS; Welborn T A, 1968, Med J Aust, V2, P778	36	565	577	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					718	724		10.1056/NEJM199909023411002	http://dx.doi.org/10.1056/NEJM199909023411002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471457	Green Published			2022-12-01	WOS:000082291900002
J	Harton, JA; Cressman, DE; Chin, KC; Der, CJ; Ting, JPY				Harton, JA; Cressman, DE; Chin, KC; Der, CJ; Ting, JPY			GTP binding by class II transactivator: Role in nuclear import	SCIENCE			English	Article							BARE LYMPHOCYTE SYNDROME; NUCLEOTIDE-BINDING; RAS P21; PROTEIN; CIITA; EXPRESSION; GENES; MHC; ACTIVATION; DEFICIENCY	Class II transactivator (CIITA) is a global transcriptional coactivator of human Leukocyte antigen-D (HLA-D) genes. CIITA contains motifs similar to guanosine triphosphate (CTP)-binding proteins. This report shows that CIITA binds GTP, and mutations in these motifs decrease its GTP-binding and transactivation activity. Substitution of these motifs with analogous sequences from Ras restores CIITA function. CIITA exhibits little GTPase activity, yet mutations in CIITA that confer GTPase activity reduce transcriptional activity. GTP binding by CIITA correlates with nuclear import. Thus, unlike other GTP-binding proteins, CIITA is involved in transcriptional activation that uses GTP binding to facilitate its own nuclear import.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.		Harton, Jonathan A/AAW-5283-2021; Harton, Jonathan/F-2848-2010	Harton, Jonathan A/0000-0002-0350-1877; Harton, Jonathan/0000-0002-0350-1877; Der, Channing/0000-0002-7751-2747	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029564, R01AI045580] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29564, AI45580, AI41751] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; COLLART FR, 1987, MOL CELL BIOL, V7, P3328, DOI 10.1128/MCB.7.9.3328; Crespo J. A., 1963, Revista del Museo arg Cienc nat Bernadino Rivadavia (Ecol), V1, P1; CRESSMAN DE, UNPUB; DAYTON JS, 1994, J IMMUNOL, V152, P984; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Foster R, 1996, MOL CELL BIOL, V16, P2689; Gu JJ, 1997, J BIOL CHEM, V272, P4458, DOI 10.1074/jbc.272.7.4458; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; HART PA, 1990, ONCOGENE, V5, P1099; HARTON JJ, UNPUB; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MONROE JG, 1983, J IMMUNOL, V130, P626; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	48	85	87	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1402	1405		10.1126/science.285.5432.1402	http://dx.doi.org/10.1126/science.285.5432.1402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464099				2022-12-01	WOS:000082233500043
J	Mochizuki, N; Ohba, Y; Kiyokawa, E; Kurata, T; Murakami, T; Ozaki, T; Kitabatake, A; Nagashima, K; Matsuda, M				Mochizuki, N; Ohba, Y; Kiyokawa, E; Kurata, T; Murakami, T; Ozaki, T; Kitabatake, A; Nagashima, K; Matsuda, M			Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i)	NATURE			English	Article							PROTEIN-KINASE ACTIVATION; RAS-DEPENDENT ACTIVATION; MAP KINASE; FIBROBLASTS; TRANSFORMATION; RECEPTORS; SUBUNITS; P21(RAS); GENE	Many receptors for neuropeptides and hormones are coupled with the heterotrimeric G(i) protein, which activates the p42/44 mitogen-activated protein kinase (ERK/MAPE;) cascade through both the alpha- and beta gamma-subunits of G(i) (refs 1-3). The beta gamma-subunit activates the ERK/MAPK cascade through tyrosine kinase(4-6). Constitutively active G alpha(i2) (gip2) isolated from adrenal and ovarian tumours(7,8) transforms Rat-1 fibroblasts and also activates the ERK/MAPK cascade by an unknown mechanism(9,10). The ERK/MAPK pathway is activated by Ras, and is inhibited when the low-molecular-mass GTP-binding protein Rap1 antagonizes pas function(11). Here we show that a novel isoform of Rap1 GTPase-activating protein, called rap1GAPII, binds specifically to the alpha-subunits of the G(i) family of heterotrimeric G-proteins. Stimulation of the G(i)-coupled m2-muscarinic receptor translocates rap1GAPII from the cytosol to the membrane and decreases the amount of GTP-bound Rap1. This decrease in GTP-bound Rap1 activates ERK/MAPK. Thus, the alpha-subunit of G(i) activates the Ras-ERK/MAPK mitogenic pathway by membrane recruitment of rap1GAPII and reduction of GTP-bound Rap1.	Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan; Hokkaido Univ, Sch Med, Dept Cardiovasc Med, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Hokkaido University; Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan.		Ohba, Yusuke/E-7944-2011	Matsuda, Michiyuki/0000-0002-5876-9969				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PIZON V, 1994, J CELL SCI, V107, P1661; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	25	193	197	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					891	894		10.1038/23738	http://dx.doi.org/10.1038/23738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476970				2022-12-01	WOS:000082233200050
J	Glass, TA; de Leon, CM; Marottoli, RA; Berkman, LF				Glass, TA; de Leon, CM; Marottoli, RA; Berkman, LF			Population based study of social and productive activities as predictors of survival among elderly Americans	BRITISH MEDICAL JOURNAL			English	Article							TIME PHYSICAL-ACTIVITY; ALL-CAUSE MORTALITY; MIDDLE-AGED MEN; CARDIOVASCULAR-DISEASE; PLASMA-FIBRINOGEN; COLLEGE ALUMNI; OLDER ADULTS; RISK-FACTORS; HEALTH; DETERMINANTS	Objectives To examine any association between social, productive, and physical activity and 13 year survival in older people. Design Prospective cohort study with annual mortality follow up. Activity and other measures were assessed by structured interviews at baseline in the participants' homes. Proportional hazards models were used to model survival from time of initial interview. Setting City of New Haven, Connecticut, United States. Participants 2761 men and women from a random population sample of 2812 people aged 65 and older. Main outcome measure Mortality from all causes during 13 years of follow up. Results All three types of activity were independently associated with survival after age, sex, race/ethnicity, marital status, income, body mass index; smoking functional disability and history of cancer, diabetes, stroke, and myocardial infarction were controlled for. Conclusions Social and productive activities that involve little or no enhancement, of fitness lower the risk of all cause mortality as much as fitness activities do. This suggests that in addition to increased cardiopulmonary fitness, activity may confer survival benefits through psychosocial pathways. Social and productive activities that require less physical exertion may complement exercise programmes and may constitute alternative interventions for frail elderly people.	Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Rush Presbyterian St Lukes Med Ctr, Rush Inst Healthy Aging, Chicago, IL 60612 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06504 USA	Harvard University; Harvard T.H. Chan School of Public Health; Rush University; Yale University	Glass, TA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA.			Glass, Thomas/0000-0003-4399-612X	NATIONAL INSTITUTE ON AGING [R29AG010170, N01AG002105, R01AG011042] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02105, R01-AG-11042, R29-AG-10170] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADELMANN PK, 1994, J GERONTOL, V49, pS277, DOI 10.1093/geronj/49.6.S277; BERKMAN L, 1979, AM J EPIDEMIOL, V2, P186; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; Bygren LO, 1996, BRIT MED J, V313, P1577, DOI 10.1136/bmj.313.7072.1577; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; GOLDBERG L, 1985, MED CLIN N AM, V69, P41; HELMERT U, 1994, INT J EPIDEMIOL, V23, P285, DOI 10.1093/ije/23.2.285; HERBERT TB, 1994, PSYCHOSOM MED, V56, P337, DOI 10.1097/00006842-199407000-00009; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; KANNEL WB, 1986, AM HEART J, V112, P820, DOI 10.1016/0002-8703(86)90480-1; Kaplan GA, 1996, AM J EPIDEMIOL, V144, P793, DOI 10.1093/oxfordjournals.aje.a009003; KAPLAN GA, 1988, AM J EPIDEMIOL, V128, P370, DOI 10.1093/oxfordjournals.aje.a114977; LaVange L M, 1996, Stat Methods Med Res, V5, P311, DOI 10.1177/096228029600500306; Mendes de Leon CF, 1996, J GERONTOL PSYCHOL S, V51, P183; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; ORTHGOMER K, 1993, PSYCHOSOM MED, V55, P37, DOI 10.1097/00006842-199301000-00007; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PHILLIPS DP, 1988, LANCET, V2, P728; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; ROSENGREN A, 1993, BRIT MED J, V306, P243, DOI 10.1136/bmj.306.6872.243; Rowe JW, 1997, SCIENCE, V278, P367, DOI 10.1126/science.278.5337.367; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; WELIN L, 1992, J EPIDEMIOL COMMUN H, V46, P127, DOI 10.1136/jech.46.2.127; YAMANOUCHI K, 1992, J APPL PHYSIOL, V73, P2241, DOI 10.1152/jappl.1992.73.6.2241; YATES EF, 1988, EMERGENT THEORIES AG, P90; ZIMMER Z, 1995, GERONTOLOGIST, V35, P463, DOI 10.1093/geront/35.4.463	33	558	565	1	38	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					478	483		10.1136/bmj.319.7208.478	http://dx.doi.org/10.1136/bmj.319.7208.478			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454399	Bronze, Green Published			2022-12-01	WOS:000082199600018
J	Koff, RS				Koff, RS			Advances in the treatment of chronic viral hepatitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERFERON; COMBINATION; RIBAVIRIN		MetroWest Med Ctr, Dept Med, Framingham, MA 01702 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Koff, RS (corresponding author), MetroWest Med Ctr, Dept Med, 115 Lincoln St, Framingham, MA 01702 USA.							Bonkovsky HL, 1999, HEPATOLOGY, V29, P264, DOI 10.1002/hep.510290124; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Heathcote EJL, 1998, HEPATOLOGY, V27, P1136, DOI 10.1002/hep.510270431; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Malaguarnera M, 1996, PHARMACOTHERAPY, V16, P609; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; Wong JB, 1998, JAMA-J AM MED ASSOC, V280, P2088, DOI 10.1001/jama.280.24.2088	12	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					511	512		10.1001/jama.282.6.511	http://dx.doi.org/10.1001/jama.282.6.511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450697				2022-12-01	WOS:000081919100001
J	Kanzaki, M; Nagasawa, M; Kojima, I; Sato, C; Naruse, K; Sokabe, M; Iida, H				Kanzaki, M; Nagasawa, M; Kojima, I; Sato, C; Naruse, K; Sokabe, M; Iida, H			Molecular identification of a eukaryotic, stretch-activated nonselective cation channel	SCIENCE			English	Article							MECHANOSENSITIVE ION-CHANNEL; EPITHELIAL NA+ CHANNEL; BALB/C 3T3 CELLS; PLASMA-MEMBRANE; PROTEIN; CD20; EXPRESSION; INFLUX; GENE	Calcium-permeable, stretch-activated nonselective cation (SA Cat) channels mediate cellular responses to mechanical stimuli. However, genes encoding such channels have not been identified in eukaryotes. The yeast MID1 gene product (Mid1) is required for calcium influx in the yeast Saccharomyces cerevisiae. Functional expression of Midi in Chinese hamster ovary cells conferred sensitivity to mechanical stress that resulted in increases in both calcium conductance and the concentration of cytosolic free calcium. These increases were dependent on the presence of extracellular calcium and were reduced by gadolinium, a blocker of SA Cat channels. Single-channel analyses with cell-attached patches revealed that Midi acts as a calcium-permeable, cation-selective stretch-activated channel with a conductance of 32 picosiemens at 150 millimolar cesium chloride in the pipette. Thus, Midi appears to be a eukaryotic, SA Cat channel.	Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan; Nagoya Univ, Sch Med, Dept Physiol, Aichi 4668550, Japan; Electrotech Lab, Supermol Sci Div, Tsukuba, Ibaraki 3058568, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Cell Biol Lab, Gunma 3718510, Japan	Tokyo Gakugei University; Nagoya University; National Institute of Advanced Industrial Science & Technology (AIST); Gunma University	Iida, H (corresponding author), Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan.	iida@u-gakugei.ac.jp	Kanzaki, Makoto/H-6680-2017; Iida, Hidetoshi/AAO-5506-2020; Sato, Chikara/M-7183-2016; NARUSE, Keiji/B-1620-2011; Sokabe, Masahiro/I-1565-2012	Kanzaki, Makoto/0000-0002-6884-2955; Sato, Chikara/0000-0001-5543-4496; naruse, keiji/0000-0003-4100-6444				Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Drummond HA, 1998, NEURON, V21, P1435, DOI 10.1016/S0896-6273(00)80661-3; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; JACKSON MB, 1992, METHOD ENZYMOL, V207, P729; Kanzaki M, 1997, J BIOL CHEM, V272, P14733, DOI 10.1074/jbc.272.23.14733; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KANZAKI M, UNPUB; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Naruse K, 1998, AM J PHYSIOL-HEART C, V274, pH1532; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; TASAKA Y, UNPUB; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659	27	171	178	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					882	886		10.1126/science.285.5429.882	http://dx.doi.org/10.1126/science.285.5429.882			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436155				2022-12-01	WOS:000081860900047
J	Adams, ME				Adams, ME			Hype about glucosamine	LANCET			English	Editorial Material							INSULIN-RESISTANCE; OSTEOARTHRITIS		Univ Calgary, Dept Rheumat Dis, Calgary, AB T2N 4N1, Canada	University of Calgary	Adams, ME (corresponding author), Univ Calgary, Dept Rheumat Dis, Calgary, AB T2N 4N1, Canada.							ADAMS ME, 1994, OSTEOARTHR CARTILAGE, P45; Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Bassleer C, 1998, OSTEOARTHR CARTILAGE, V6, P427, DOI 10.1053/joca.1998.0146; MALEMUD CJ, 1992, BIOL REGULATION CHON, P295; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MATYAS JR, 1995, ARTHRITIS RHEUM, V38, P420, DOI 10.1002/art.1780380320; McAlindon TE, 1998, ARTHRITIS RHEUM, V41, pS198; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Muller-Fassbender H, 1994, Osteoarthritis Cartilage, V2, P61, DOI 10.1016/S1063-4584(05)80007-X; Noack W, 1994, Osteoarthritis Cartilage, V2, P51, DOI 10.1016/S1063-4584(05)80006-8; POOS MD, 1998, P ASS AM PHYS, V110, P422; *QUACKW, 1999, GLUC ARTHR; REICHELT A, 1994, ARZNEIMITTELFORSCH, V44-1, P75; Roos MD, 1996, AM J PHYSIOL-CELL PH, V270, pC803, DOI 10.1152/ajpcell.1996.270.3.C803; SEMIKAR I, 1986, ARZNEIMITTELFORSGUNG, V36, P729	16	46	48	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					353	354		10.1016/S0140-6736(99)90040-5	http://dx.doi.org/10.1016/S0140-6736(99)90040-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437858				2022-12-01	WOS:000081764900003
J	Nicod, LP				Nicod, LP			Pirfenidone in idiopathic pulmonary fibrosis	LANCET			English	Editorial Material							LUNG FIBROSIS; PREDNISONE		Univ Geneva, Hop Cantonal, Div Pulm, Geneva 14, Switzerland	University of Geneva	Nicod, LP (corresponding author), Univ Geneva, Hop Cantonal, Div Pulm, Geneva 14, Switzerland.		Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X				Cain WC, 1998, INT J IMMUNOPHARMACO, V20, P685, DOI 10.1016/S0192-0561(98)00042-3; Douglas WW, 1998, AM J RESP CRIT CARE, V158, P220, DOI 10.1164/ajrccm.158.1.9709089; GANESH R, 1999, AM J RESP CRIT CARE, V159, P1061; Iyer SN, 1998, EXP LUNG RES, V24, P119, DOI 10.3109/01902149809046058; Kaneko M, 1998, CLIN EXP IMMUNOL, V113, P72, DOI 10.1046/j.1365-2249.1998.00618.x; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Lee BS, 1998, J CLIN ENDOCR METAB, V83, P219, DOI 10.1210/jc.83.1.219; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; MCANULTY RJ, 1995, EXP NEPHROL, V3, P96; MEIERSYDOW J, 1979, PRAX KLIN PNEUMOL, V33, P680; Nicod LP, 1998, DRUGS, V55, P555, DOI 10.2165/00003495-199855040-00006; RAGHU G, 1991, AM REV RESPIR DIS, V144, P191; Stewart JP, 1999, AM J RESP CRIT CARE, V159, P1336, DOI 10.1164/ajrccm.159.4.9807077	13	15	17	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					268	269		10.1016/S0140-6736(99)00178-6	http://dx.doi.org/10.1016/S0140-6736(99)00178-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440298				2022-12-01	WOS:000081646000004
J	Serageldin, I				Serageldin, I			Biotechnology and food security in the 21st century	SCIENCE			English	Editorial Material								Biotechnology can contribute to future food security if it benefits sustainable small-farm agriculture in developing countries. Presently, agrobiotechnology research cites ethical, safety, and intellectual property rights issues. Protection of intellectual property rights encourages private sector investment in agrobiotechnology, but in developing countries the needs of smallholder farmers and environmental conservation are unlikely to attract private funds. Public investment will be needed, and new and imaginative public-private collaboration can make the gene revolution beneficial to developing countries. This is crucial for the well-being of today's hungry people and future generations.	World Bank, Consultat Grp Int Agr Res, Washington, DC 20433 USA; World Bank, Special Programs, Washington, DC 20433 USA	The World Bank; The World Bank	Serageldin, I (corresponding author), World Bank, Consultat Grp Int Agr Res, 1818 H St NW, Washington, DC 20433 USA.							BORGSTROM G, 1973, FOOD PEOPLE DILEMMA; *CGIAR, 1998, SHAP CGIARS FUT SUMM, P52; CONWAY G, 1998, DOUBLY GREEN REVOLUT, P44; Eckholm EP, 1976, LOSING GROUND; Hayenga M., 1998, AGBIOFORUM, V1; HAZELL PBR, 1998, AGR ENV PERSPECTIVES; IFPRI (International Food Policy Research Institute), 1995, DAIR LIV EQ PROGR MA; JOHNSON B, 1999, COMMUNICATION   0326; KENDALL H, 1999, BIOTECHNOLOGY BIOSAF, P1; Leisinger K.M., 1995, 2 INT FOOD POL RES I; PINSTRUPANDERSE.PP, 1997, WORLD FOOD SITUATION; Rifkin Jeremy, 1998, BIOTECH CENTURY; SERAGELDIN I, 1997, RURAL WELL BEING VIS, P43; *UN DEV PROGR, 1998, HUM DEV REP 1998, P19; *UN POP DIV, 1999, WORLD POP PROSP 1998; WRIGHT BD, 1996, 19 INT FOOD POL RES; [No title captured]	17	88	106	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					387	389		10.1126/science.285.5426.387	http://dx.doi.org/10.1126/science.285.5426.387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411497				2022-12-01	WOS:000081465900048
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Tolerating differences	SCIENCE			English	Article																		Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					357	358						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10438301				2022-12-01	WOS:000081465900038
J	Feher, VA; Cavanagh, J				Feher, VA; Cavanagh, J			Millisecond-timescale motions contribute to the function of the bacterial response regulator protein Spo0F	NATURE			English	Article							N-15 NMR RELAXATION; HIGH-RESOLUTION NMR; BACKBONE DYNAMICS; BACILLUS-SUBTILIS; STAPHYLOCOCCAL NUCLEASE; MOLECULAR RECOGNITION; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; DOMAIN; SPECTROSCOPY	Protein backbones and side chains display varying degrees of flexibility, which allows many slightly different but related conformational substates to occur(1). Such fluctuations are known to differ in both timescale and magnitude, from rotation of methyl groups (nanoseconds) to the flipping of buried tyrosine rings (seconds)(2,3), Because many mechanisms for protein function require conformational change, it has been proposed that some of these ground-state fluctuations are related to protein function(4). But exactly which aspects of motion are functionally relevant remains to be determined. Only a few examples so far exist where function can be correlated to structural fluctuations with known magnitude and timescale(5,6). As part of an investigation of the mechanism of action of the Bacillus subtilis response regulator Spo0F, we have explored the relationship between the motional characteristics and protein-protein interactions. Here we use a set of nuclear magnetic resonance N-15 relaxation measurements to determine the relative timescales of Spo0F backbone fluctuations on the picosecond-to-millisecond timescale, We show that regions having motion on the millisecond timescale correlate with residues and surfaces that are known to be critical for protein-protein interactions.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Cavanagh, J (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.	johnc@wadsworth.org						AKKE M, 1994, J MAGN RESON SER B, V104, P298, DOI 10.1006/jmrb.1994.1090; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feher VA, 1998, FEBS LETT, V425, P1, DOI 10.1016/S0014-5793(98)00182-3; Feher VA, 1997, BIOCHEMISTRY-US, V36, P10015, DOI 10.1021/bi970816l; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Gryk MR, 1996, PROTEIN SCI, V5, P1195; Jiang MY, 1997, J BIOL CHEM, V272, P11850, DOI 10.1074/jbc.272.18.11850; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; KAYL E, 1998, NAT STRUCT BIOL, V5, P156; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LEE UK, 1987, B KOR CHEM SOC, V8, P1; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tzeng YL, 1997, J MOL BIOL, V272, P200, DOI 10.1006/jmbi.1997.1226; Tzeng YL, 1998, BIOCHEMISTRY-US, V37, P16538, DOI 10.1021/bi981340o; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; WUTHRICH K, 1975, FEBS LETT, V50, P265, DOI 10.1016/0014-5793(75)80504-7; Wyss DF, 1997, PROTEIN SCI, V6, P534; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	30	196	197	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					289	293		10.1038/22357	http://dx.doi.org/10.1038/22357			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421374				2022-12-01	WOS:000081503800050
J	Atroshi, I; Gummesson, C; Johnssson, R; Ornstein, E; Ranstam, J; Rosen, I				Atroshi, I; Gummesson, C; Johnssson, R; Ornstein, E; Ranstam, J; Rosen, I			Prevalence of carpal tunnel syndrome in a general population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NERVE-CONDUCTION; WORK DISABILITY	Context Carpal tunnel syndrome (CTS) is a cause of pain, numbness, and tingling in the hands and is an important cause of work disability. Although high prevalence rates of CTS in certain occupations have been reported, little is known about its prevalence in the general population. Objective To estimate the prevalence of CTS in a general population. Design General health mail survey sent in February 1997, inquiring about symptoms of pain, numbness, and tingling in any part of the body, followed 2 months later by clinical examination and nerve conduction testing of responders reporting symptoms in the median nerve distribution in the hands, as well as of a sample of those not reporting these symptoms (controls). Setting A region in southern Sweden with a population of 170 000. Participants A sex- and age-stratified sample of 3000 subjects (age range, 25-74 years) was randomly selected from the general population register and sent the survey, with a response rate of 83% (n = 2466; 46% men). Of the symptomatic responders, 81% underwent clinical examination. Main Outcome Measures Population prevalence rates, calculated as the number of symptomatic responders diagnosed on examination as having clinically certain CTS and/or electrophysiological median neuropathy divided by the total number of responders. Results Of the 2466 responders, 354 reported pain, numbness, and/or tingling in the median nerve distribution in the hands (prevalence, 14.4%; 95% confidence interval [CI], 13.0%-15.8%). On clinical examination, 94 symptomatic subjects were diagnosed as having clinically certain CTS (prevalence, 3.8%; 95% CI, 3.1%-4.6%). Nerve conduction testing showed median neuropathy at the carpal tunnel in 120 symptomatic subjects (prevalence, 4.9%; 95% CI, 4.1%-5.8%), Sixty-six symptomatic subjects had clinically and electrophysiologically confirmed CTS (prevalence, 2.7%; 95% CI, 2.1%-3.4%). Of 125 control subjects clinically examined, electrophysiological median neuropathy was found in 23 (18.4%; 95% CI, 12.0%-26.3%). Conclusion Symptoms of pain, numbness, and tingling in the hands are common in the general population. Based on our data, 1 in 5 symptomatic subjects would be expected to have CTS based on clinical examination and electrophysiologic testing.	Hassleholm Kristianstad Hosp, Dept Orthoped, S-29185 Kristianstad, Sweden; Univ Lund, Lund, Sweden; Univ Lund Hosp, Dept Orthoped, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Clin Neurosci, Div Clin Neurophysiol, S-22185 Lund, Sweden; Malmo Univ, Dept Hlth & Soc, Malmo, Sweden	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Malmo University	Atroshi, I (corresponding author), Hassleholm Kristianstad Hosp, Dept Orthoped, S-29185 Kristianstad, Sweden.		Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				Altman DG, 1991, PRACTICAL STAT MED R; Bingham RC, 1996, AM J IND MED, V30, P355, DOI 10.1002/(SICI)1097-0274(199609)30:3<355::AID-AJIM15>3.0.CO;2-V; DAWSON DM, 1993, NEW ENGL J MED, V329, P2013, DOI 10.1056/NEJM199312303292707; DEKROM MCTFM, 1992, J CLIN EPIDEMIOL, V45, P373, DOI 10.1016/0895-4356(92)90038-O; Feuerstein M, 1998, J OCCUP ENVIRON MED, V40, P546, DOI 10.1097/00043764-199806000-00007; HAGBERG M, 1992, SCAND J WORK ENV HEA, V18, P337, DOI 10.5271/sjweh.1564; JABLECKI CK, 1993, MUSCLE NERVE, V16, P1392; Katz JN, 1998, AM J IND MED, V33, P543, DOI 10.1002/(SICI)1097-0274(199806)33:6<543::AID-AJIM4>3.0.CO;2-R; KATZ JN, 1990, ANN INTERN MED, V112, P321, DOI 10.7326/0003-4819-112-5-321; KIMURA J, 1989, ELECTRODIAGNOSIS DIS, P105; Rempel D, 1998, AM J PUBLIC HEALTH, V88, P1447, DOI 10.2105/AJPH.88.10.1447; ROSEN I, 1993, SCAND J PLAST RECONS, V27, P95, DOI 10.3109/02844319309079790; ROSENBERG JH, 1993, NEUROLOGY, V43, P2404; Salerno DF, 1998, MUSCLE NERVE, V21, P999, DOI 10.1002/(SICI)1097-4598(199808)21:8<999::AID-MUS3>3.0.CO;2-0; SILVERSTEIN BA, 1987, AM J IND MED, V11, P343, DOI 10.1002/ajim.4700110310; *STAT SWED, 1999, OFF STAT SWED POP ST; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Werner RA, 1998, AM J IND MED, V33, P374, DOI 10.1002/(SICI)1097-0274(199804)33:4<374::AID-AJIM7>3.0.CO;2-U; Yassi A, 1997, LANCET, V349, P943, DOI 10.1016/S0140-6736(96)07221-2; 1985, LANCET, V1, P854	21	1069	1128	4	47	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					153	158		10.1001/jama.282.2.153	http://dx.doi.org/10.1001/jama.282.2.153			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411196	Bronze			2022-12-01	WOS:000081376800032
J	Henschke, CI; McCauley, DI; Yankelevitz, DF; Naidich, DP; McGuinness, G; Miettinen, OS; Libby, DM; Pasmantier, MW; Koizumi, J; Altorki, NK; Smith, JP				Henschke, CI; McCauley, DI; Yankelevitz, DF; Naidich, DP; McGuinness, G; Miettinen, OS; Libby, DM; Pasmantier, MW; Koizumi, J; Altorki, NK; Smith, JP			Early Lung Cancer Action Project: overall design and findings from baseline screening	LANCET			English	Article							SURGICAL-TREATMENT; PULMONARY NODULE; STAGE-I; SURVIVAL; CT	Background The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) in people at high risk of lung cancer. We report the baseline experience. Methods ELCAP has enrolled 1000 symptom-free volunteers, aged 60 years or older, with at least 10 pack years of cigarette smoking and no previous cancer, who were medically fit to undergo thoracic surgery. After a structured interview and informed consent, chest radiographs and low-dose CT were done for each participant. The diagnostic investigation of screen-detected non-calcified pulmonary nodules was guided by ELCAP recommendations, which included short-term high-resolution CT follow-up for the smallest non-calcified nodules. Findings Non-calcified nodules were detected in 233 (23% [95%; CI 21-26]) participants by low-dose CT at baseline, compared with 68 (7% [5-9]) by chest radiography. Malignant disease was detected in 27 (2.7% [1.8-3.8]) by CT and seven (0.7% [0.3-1.3]) by chest radiography, and stage malignant disease in 23 (2.3% [1.5-3.3]) and four (0.4% [0.1-0.9]), respectively. Of the 27 CT-detected cancers, 26 were resectable. Biopsies were done on 28 of the 233 participants with non-calcified nodules; 27 had malignant non-calcified nodules and one had a benign nodule. Another three individuals underwent biopsy against the ELCAP recommendations; all had benign non-calcified nodules. No participant had thoracotomy for a benign nodule. Interpretation low-dose CT can greatly improve the likelihood of detection of small non-calcified nodules, and thus of lung cancer at an earlier and potentially more curable stage. Although false-positive CT results are common. they can be managed with little use of invasive diagnostic procedures.	New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY USA; NYU Med Ctr, New York, NY 10016 USA; McGill Univ, Montreal, PQ, Canada	Cornell University; NewYork-Presbyterian Hospital; Cornell University; New York University; McGill University	Henschke, CI (corresponding author), New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, 525 E 68th St, New York, NY 10021 USA.			naidich, david/0000-0003-3751-5836; McGuinness, Georgeann/0000-0002-5326-9180	NATIONAL CANCER INSTITUTE [R01CA063393] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-63393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUCKSHEE N, 1999, ALA ATS INT C SAN DI; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COLLINS VP, 1956, AMER J ROENTGENOL RA, V76, P988; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FLEHINGER BJ, 1993, CANCER, V72, P1573, DOI 10.1002/1097-0142(19930901)72:5<1573::AID-CNCR2820720514>3.0.CO;2-9; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FONTANA RS, 1998, INT C PREV EARL DIAG, P15; HENSCHKE CI, 1994, CLIN IMAG, V18, P6; Inoue K, 1998, J THORAC CARDIOV SUR, V116, P407, DOI 10.1016/S0022-5223(98)70006-6; KANEKO M, 1998, INT C PREV EARL DIAG, P144; KANEKO M, IN PRESS CANCER; LAIRD AK, 1965, BRIT J CANCER, V19, P278, DOI 10.1038/bjc.1965.32; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LIBBY DM, 1995, AM J MED, V99, P491, DOI 10.1016/S0002-9343(99)80225-3; MELAMED MR, 1987, SURG CLIN N AM, V67, P909; MIETTINEN OS, IN PRESS CANCER; MIETTINEN OS, 1998, INT C PREV EARL DIAG, P98; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAIDICH DP, 1990, RADIOLOGY, V175, P729, DOI 10.1148/radiology.175.3.2343122; NATHAN MH, 1962, RADIOLOGY, V79, P221, DOI 10.1148/79.2.221; NESBITT JC, 1995, ANN THORAC SURG, V60, P466, DOI 10.1016/0003-4975(95)00169-L; Shah R, 1996, J CARDIOVASC SURG, V37, P169; SOBUE T, 1992, CANCER, V69, P685, DOI 10.1002/1097-0142(19920201)69:3<685::AID-CNCR2820690315>3.0.CO;2-W; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Yankelevitz DF, 1997, CLIN IMAG, V21, P107, DOI 10.1016/S0899-7071(96)00011-3; YANKELEVITZ DF, IN PRESS RADIOLOGY; ZERHOUNI EA, 1986, RADIOLOGY, V160, P319, DOI 10.1148/radiology.160.2.3726107	29	1822	1908	3	120	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					99	105		10.1016/S0140-6736(99)06093-6	http://dx.doi.org/10.1016/S0140-6736(99)06093-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408484				2022-12-01	WOS:000081377100011
J	Megee, PC; Koshland, D				Megee, PC; Koshland, D			A functional assay for centromere-associated sister chromatid cohesion	SCIENCE			English	Article							BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; GENETIC-ANALYSIS; MINICHROMOSOMES; PLASMID	Cohesion of sister chromatids occurs along the entire Length of chromosomes, including the centromere where it plays essential roles in chromosome segregation. Here, minichromosomes in the budding yeast Saccharomyces cerevisiae are exploited to generate a functional assay for DNA sequences involved in cohesion. The centromeric DNA element CDEIII was found to be necessary but not sufficient for cohesion. This element was shown previously to be required for assembly of the kinetochore, the centromere-associated protein complex that attaches chromosomes to the spindle. These observations establish a link between centromere-proximal cohesion and kinetochore assembly.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Koshland, D (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.			Megee, Paul/0000-0002-9397-2161	NIGMS NIH HHS [GM41718] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, J MOL BIOL, V225, P25, DOI 10.1016/0022-2836(92)91023-I; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cellbio.11.1.471; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MEGEE PC, UNPUB; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320	19	63	64	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					254	257		10.1126/science.285.5425.254	http://dx.doi.org/10.1126/science.285.5425.254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398602				2022-12-01	WOS:000081346000042
J	Roder, B; Teder-Salejarvi, W; Sterr, A; Rosler, F; Hillyard, SA; Neville, HJ				Roder, B; Teder-Salejarvi, W; Sterr, A; Rosler, F; Hillyard, SA; Neville, HJ			Improved auditory spatial tuning in blind humans	NATURE			English	Article							CONGENITALLY DEAF ADULTS; SIGHTED SUBJECTS; VISUAL-CORTEX; PLASTICITY; POTENTIALS; ACTIVATION; ATTENTION	Despite reports of improved auditory discrimination capabilities in blind humans(1-3) and visually deprived animals(4), there is no general agreement as to the nature or pervasiveness of such compensatory sensory enhancements(5). Neuroimaging studies have pointed out differences in cerebral organization between blind and sighted humans(6-12), but the relationship between these altered cortical activation patterns and auditory sensory acuity remains unclear. Here we compare behavioural and electrophysiological indices of spatial tuning within central and peripheral auditory space in congenitally blind and normally sighted but blindfolded adults to test the hypothesis (raised by earlier studies of the effects of auditory deprivation on visual processing(13,14)) that the effects of visual deprivation might be more pronounced for processing peripheral sounds. We find that blind participants displayed localization abilities that were superior to those of sighted controls, but only when attending to sounds in peripheral auditory space. Electrophysiological recordings obtained at the same time revealed sharper tuning of early spatial attention mechanisms in the blind subjects. Differences in the scalp distribution of brain electrical activity between the two groups suggest a compensatory reorganization of brain areas in the blind that may contribute to the improved spatial resolution for peripheral sound sources.	Univ Marburg, Dept Psychol, D-35037 Marburg, Germany; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Konstanz, Dept Psychol, D-78457 Constance, Germany; Univ Oregon, Dept Psychol, Eugene, OR 97403 USA	Philipps University Marburg; University of California System; University of California San Diego; University of Konstanz; University of Oregon	Roder, B (corresponding author), Univ Marburg, Dept Psychol, Gutenbergstr 18, D-35037 Marburg, Germany.		Roeder, Brigitte/A-4652-2009					Ashmead DH, 1998, PERCEPTION, V27, P105, DOI 10.1068/p270105; Brainard MS, 1998, J NEUROSCI, V18, P3929; Clark V.P., 1994, HUMAN BRAIN MAPPING, V2, P170, DOI [10.1002/hbm.460020306, DOI 10.1002/HBM.460020306]; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Downing C. J., 1985, ATTENTION PERFORM, P171; Hillyard Steven A., 1995, P665; Huynh H., 1976, J EDUC STATIST, V1, P69, DOI [10.3102/10769986001001069, DOI 10.3102/10769986001001069]; HYVARINEN J, 1981, EXP BRAIN RES, V42, P1; Knudsen EI, 1998, SCIENCE, V279, P1531, DOI 10.1126/science.279.5356.1531; KUJALA T, 1992, ELECTROEN CLIN NEURO, V84, P469, DOI 10.1016/0168-5597(92)90034-9; Lessard N, 1998, NATURE, V395, P278, DOI 10.1038/26228; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; MILLER L, 1992, J VISUAL IMPAIR BLIN, V86, P206; MILLS AW, 1972, FDN MODERN AUDITORY, P303; MONDOR TA, 1995, J EXP PSYCHOL HUMAN, V21, P387, DOI 10.1037/0096-1523.21.2.387; MORRONGIELLO BA, 1994, DEV INTERSENSORY PER, P235; MUCHNIK C, 1991, SCAND AUDIOL, V20, P19, DOI 10.3109/01050399109070785; Naatanen R., 1992, ATTENTION BRAIN FUNC; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; NEVILLE HJ, 1983, BRAIN RES, V266, P127, DOI 10.1016/0006-8993(83)91314-8; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; RAUSCHECKER JP, 1983, EXP BRAIN RES, V50, P63; RICE C, 1970, AM F BLIND RES B, V22, P1, DOI DOI 10.3758/S13414-011-0160-4; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Roder B, 1997, PSYCHOPHYSIOLOGY, V34, P292, DOI 10.1111/j.1469-8986.1997.tb02400.x; ROSLER F, 1993, COGNITIVE BRAIN RES, V1, P145, DOI 10.1016/0926-6410(93)90022-W; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Teder-Salejarvi WA, 1998, PERCEPT PSYCHOPHYS, V60, P1228, DOI 10.3758/BF03206172; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7	30	455	461	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					162	166		10.1038/22106	http://dx.doi.org/10.1038/22106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	214JM	10408442				2022-12-01	WOS:000081324900053
J	Zhang, ZD; Green, BR; Cavalier-Smith, T				Zhang, ZD; Green, BR; Cavalier-Smith, T			Single gene circles in dinoflagellate chloroplast genomes	NATURE			English	Article							DNA-REPLICATION; SEQUENCE; RUBISCO; ORIGIN	Photosynthetic dinoflagellates are important aquatic primary producers and notorious causes of toxic 'red tides: Typical dinoflagellate chloroplasts differ from all other plastids in having a combination of three envelope membranes' and peridinin-chlorophyll ale light-harvesting pigments'. Despite evidence of a dinoflagellete satellite DNA containing chloroplast genes(3), previous attempts to obtain chloroplast gene sequences have been uniformly unsuccessful. Here we show that the dinoflagellate chloroplast DNA genome structure is unique. Complete sequences of chloroplast ribosomal RNA genes and seven chloroplast protein genes from the dinoflagellate Heterocapsa triquetra reveal that each is located alone on a separate minicircular chromosome:'one gene-one circle: The genes are the most divergent known from chloroplast genomes. Each circle has an unusual tripartite non-coding region (putative replicon origin), which is highly conserved among the nine circles through extensive gene conversion, but is very divergent between species. Several other dinoflagellate species have minicircular chloroplast genes, indicating that this type of genomic organization may have evolved in ancestral peridinean dinoflagellates. Phylogenetic analysis indicates that dinoflagellate chloroplasts are related to chromistan and red algal chloroplasts and supports their origin by Secondary symbiogenesis(4-6)	Univ British Columbia, Canadian Inst Adv Res Evolutionary Biol Programme, Dept Bot, Vancouver, BC V6T 1Z4, Canada	Canadian Institute for Advanced Research (CIFAR); University of British Columbia	Green, BR (corresponding author), Univ British Columbia, Canadian Inst Adv Res Evolutionary Biol Programme, Dept Bot, Vancouver, BC V6T 1Z4, Canada.	brgreen@interchange.ubc.ca	Green, Beverley R./AAJ-5199-2021	Green, Beverley R./0000-0002-4021-9387				Backert S, 1997, TRENDS PLANT SCI, V2, P477, DOI 10.1016/S1360-1385(97)01148-5; BOCZAR BA, 1991, PLANT PHYSIOL, V97, P613, DOI 10.1104/pp.97.2.613; BOORE JL, 1994, GENETICS, V138, P423; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CAVALIERSMITH T, 1995, BIODIVERSITY EVOLUTI, P75; DODGE J D, 1975, Phycologia, V14, P253, DOI 10.2216/i0031-8884-14-4-253.1; Douglas SE, 1999, J MOL EVOL, V48, P236, DOI 10.1007/PL00006462; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; JACOBS JD, 1992, MOL GEN GENET, V233, P302, DOI 10.1007/BF00587592; JEFFREY SW, 1975, J PHYCOL, V11, P374, DOI 10.1111/j.1529-8817.1975.tb02799.x; La Claire JW, 1998, CURR GENET, V34, P204, DOI 10.1007/s002940050387; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; MORSE D, 1995, SCIENCE, V268, P1622, DOI 10.1126/science.7777861; Palmer J.D., 1998, MOL SYSTEMATICS PLAN, P375, DOI [10.1007/978-1-4615-5419-6_13, DOI 10.1007/978-1-4615-5419-6_13]; Rowan R, 1996, PLANT CELL, V8, P539, DOI 10.1105/tpc.8.3.539; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Saunders GW, 1997, PLANT SYST EVOL, P237; SCHLUNEGGER B, 1984, CURR GENET, V8, P629, DOI 10.1007/BF00395709; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WU M, 1986, P NATL ACAD SCI USA, V83, P6761, DOI 10.1073/pnas.83.18.6761	25	267	288	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					155	159		10.1038/22099	http://dx.doi.org/10.1038/22099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408440				2022-12-01	WOS:000081324900051
J	Brown, SL; Hansen, SL; Langone, JJ				Brown, SL; Hansen, SL; Langone, JJ			Role of serology in the diagnosis of Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFICIENCY TESTING PROGRAM; BORRELIA-BURGDORFERI; OVERDIAGNOSIS; LABORATORIES; VACCINATION; ANTIBODY	Numerous concerns regarding the potential for misdiagnosis of Lyme disease using commercial assays have been voiced by the US Food and Drug Administration (FDA). We attempted to clarify the clinical value of serologic testing for Lyme disease using the results of commonly marketed assays for detecting antibody to Borrelia burgdorferi, the organism that causes Lyme disease, We reviewed published studies on B burgdorferi test performance published through 1998, package insert labeling from FDA-cleared test kits for B burgdorferi, and Lyme Disease Survey Set LY-A from the College of American Pathologists. We assessed the sensitivity and specificity of commercial serologic tests (enzyme-linked immunosorbent assay [ELISA], immunofluorescence antibody [IFA], and immunodot) for diagnosis of Lyme disease. To reduce this risk of misdiagnosis, it is important that clinicians understand the performance characteristics and limitations of these tests. These tests, in common use in clinical or commercial laboratories, should be used only to support a clinical diagnosis of Lyme disease, not as the primary basis for making diagnostic or treatment decisions. Serologic testing is not useful early in the course of Lyme disease because of the low sensitivity of tests in early disease. Serologic testing may be more useful in later disease, at which time sensitivity and specificity of the test are improved. Positive or equivocal results on an ELISA, IFA, or immunodot assay requires supplemental testing with a Western blot assay. A negative result on the Western blot or ELISA indicates that there is no serologic evidence of infection by B burgdorferi at the time the sample was drawn.	US FDA, Off Surveillance & Biometr, Div Postmarket Surveillance, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Off Device Evaluat, Div Clin Lab Devices, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Off Sci & Technol, Div Life Sci, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Brown, SL (corresponding author), 1350 Piccard Dr,HFZ-541, Rockville, MD 20850 USA.							AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; Bakken LL, 1997, J CLIN MICROBIOL, V35, P537, DOI 10.1128/JCM.35.3.537-543.1997; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1998, INFECT DIS; DURAY PH, 1997, PATHOLOGY INFECT DIS, V1; *FDA PUBL HLTH ADV, 1999, ASS ANT BORR BURGD L; Fix AD, 1998, JAMA-J AM MED ASSOC, V279, P206, DOI 10.1001/jama.279.3.206; Hofmann H, 1996, INFECTION, V24, P470, DOI 10.1007/BF01713052; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; SCHMITZ JL, 1993, EUR J CLIN MICROBIOL, V12, P419, DOI 10.1007/BF01967435; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; Sigal LH, 1997, ANNU REV IMMUNOL, V15, P63, DOI 10.1146/annurev.immunol.15.1.63; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1995, ADV INTERNAL MED, V40, P69; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Tierno PM, 1996, LAB MED, V27, P542, DOI 10.1093/labmed/27.8.542; Tugwell P, 1997, ANN INTERN MED, V127, P1106, DOI 10.7326/0003-4819-127-12-199712150-00011; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; *US FDA, 1996, FDA ADV PAN M 1996 M, V2; Zhang YQ, 1997, J CLIN MICROBIOL, V35, P233, DOI 10.1128/JCM.35.1.233-238.1997; 1997, MMWR MORB MORTAL WKL, V46, P531	30	82	89	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					62	66		10.1001/jama.282.1.62	http://dx.doi.org/10.1001/jama.282.1.62			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404913				2022-12-01	WOS:000081195800030
J	Lin, YX; Fletcher, CM; Zhou, JX; Allis, CD; Wagner, G				Lin, YX; Fletcher, CM; Zhou, JX; Allis, CD; Wagner, G			Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A	NATURE			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; YEAST GCN5P; IN-VIVO; PROTEIN; ACTIVATION; ACETYLATION; SUPERFAMILY; COMPLEX; CBP	Gene transcription requires the release of inactive DNA from its packaging of histone proteins. Following the discovery of the first transcription-associated histone acetyltransferase, tetrahymena GCN5(1), it was shown that yeast GCN5 is recruited to the promoter and causes hyper-acetylation of histones and transcriptional activation of target genes(2,3), establishing a direct connection between histone acetylation and transcriptional activation. Many other important transcription regulators have been found to have histone acetyltransferase activity, including TAFII230/250, p300/CBP and its associated factor PCAF(4-9). Here we present the solution structure of the catalytic domain of tGCN5 (residues 47-210) in complex with coenzyme A. The structure contains two domains; the amino-terminal domain is similar to those of other GCN5-related N-acetyltransferases(10,11) but the carboxy-terminal domain is not. Coenzyme A binds in a deep hydrophobic pocket between the two domains. Chemical shift changes upon titration with histone H3 peptides indicate a binding site at the domain boundary opposite to the coenzyme A site. The structural data indicate a single-step acetyl-transfer reaction mechanism catalysed by a hydrogen bond to the backbone amide group of leucine 126 and the side-chain carboxyl group of a conserved acidic residue.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; MIT, Harvard Ctr Magnet Resonance, Cambridge, MA 02139 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; University of Virginia	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.			/0000-0002-7002-1275				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LIN Y, UNPUB J AM CHEM SOC; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	21	78	81	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					86	89		10.1038/21922	http://dx.doi.org/10.1038/21922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403255				2022-12-01	WOS:000081255700057
J	Motulsky, AG				Motulsky, AG			If I had a gene test, what would I have and who would I tell?	LANCET			English	Editorial Material							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; POPULATION; MUTATIONS; RISKS		Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Motulsky, AG (corresponding author), Univ Washington, Dept Med, Box 356723, Seattle, WA 98195 USA.							Baron H, 1996, NAT BIOTECHNOL, V14, P1279, DOI 10.1038/nbt1096-1279; Bernstein T, 1994, RADON RENTAL HOUSING; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P95, DOI 10.1006/bcmd.1997.0125; BOTHWELL TH, 1995, METABOLIC MOL BASES; Brodaty H, 1995, ALZ DIS ASSOC DIS, V9, P182; BURKE W, 1998, JAMA-J AM MED ASSOC, V280, P173; Devilee P, 1999, AM J HUM GENET, V64, P943, DOI 10.1086/302350; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Gryfe R, 1999, AM J HUM GENET, V64, P378, DOI 10.1086/302262; Hartge P, 1999, AM J HUM GENET, V64, P963, DOI 10.1086/302320; HERRERA VLM, 1994, J HYPERTENS, V12, pS47; Levy-Lahad E, 1998, J GERIATR PSYCH NEUR, V11, P42, DOI 10.1177/089198879801100202; Lynch HT, 1998, AM J HUM GENET, V62, P1288, DOI 10.1086/301890; MOTULSKY AG, 1992, GENETIC BASIS COMMON, P150; Poirier J, 1999, J PSYCHIATR NEUROSCI, V24, P147; Powell SM, 1998, METH MOL B, V92, P251; Reilly PR, 1998, AM J HUM GENET, V63, P682, DOI 10.1086/302028; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; Sachse C, 1997, AM J HUM GENET, V60, P284; Salomon O, 1999, ARTERIOSCL THROM VAS, V19, P511, DOI 10.1161/01.ATV.19.3.511; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804	24	17	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI35	SI37						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437855				2022-12-01	WOS:000081825900010
J	Jennett, B				Jennett, B			Brain stem death defines death in law	BMJ-BRITISH MEDICAL JOURNAL			English	Article									So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Jennett, B (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.							BLACK D, 1995, J ROY COLL PHYS LOND, V29, P381; *HLTH DEP GREAT BR, 1983, CAD ORG TRANSPL COD; JENNETT B, 1981, BRIT J ANAESTH, V53, P1111, DOI 10.1093/bja/53.11.1111; SPRUNG CL, 1995, CRIT CARE MED, V23, P618, DOI 10.1097/00003246-199504000-00004	4	7	7	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1755	1755						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428564				2022-12-01	WOS:000081216900041
J	Hofmann, MA; Drury, S; Fu, CF; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM				Hofmann, MA; Drury, S; Fu, CF; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM			RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides	CELL			English	Article							GLYCATION END-PRODUCTS; CALCIUM-BINDING PROTEINS; ADHESION MOLECULE-1; ALZHEIMERS-DISEASE; CALGRANULIN-C; DIABETIC COMPLICATIONS; NEURITE OUTGROWTH; SOLUBLE RECEPTOR; OXIDANT STRESS; S100 FAMILY	S100/calgranulin polypeptides are present at sites of inflammation, likely released by inflammatory cells targeted to such loci by a range of environmental cues. We report here that receptor for AGE (RAGE) is a central cell surface receptor for EN-RAGE (extracellular newly identified RAGE-binding protein) and related members of the S100/calgranulin superfamily. Interaction of EN-RAGEs with cellular RAGE on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Blockade of EN-RAGE/RAGE quenches delayed-type hypersensitivity and inflammatory colitis in murine models by arresting activation of central signaling pathways and expression of inflammatory gene mediators. These data highlight a novel paradigm in inflammation and identify roles for EN-RAGEs and RAGE in chronic cellular activation and tissue injury.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Berlex Biosci, Richmond, CA 94804 USA; Univ Tubingen, D-72076 Tubingen, Germany; Univ Mainz, D-55101 Mainz, Germany	Columbia University; Eberhard Karls University of Tubingen; Johannes Gutenberg University of Mainz	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.			Kambham, Neeraja/0000-0003-1136-3686	NHLBI NIH HHS [HL56881, HL60901] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060901, R01HL056881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DUNN CJ, 1993, J PHARMACOL EXP THER, V266, P1691; Geczy C, 1996, BBA-MOL CELL RES, V1313, P246, DOI 10.1016/0167-4889(96)00096-1; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOTTSCH JD, 1997, T AM OPTHALMOL SOC, V14, P111; Hitomi J, 1996, J CELL SCI, V109, P805; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Ilg EC, 1996, BIOCHEM BIOPH RES CO, V225, P146, DOI 10.1006/bbrc.1996.1144; King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuehn Ralf, 1993, Cell, V75, P263; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LI J, 1997, J BIOL CHEM, V271, P16498; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Rammes A, 1997, J BIOL CHEM, V272, P9496; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1998, HORM SIGNAL, V1, P41; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; Yamamura T, 1996, BIOCHEM BIOPH RES CO, V221, P356, DOI 10.1006/bbrc.1996.0600; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	42	1525	1600	4	75	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					889	901		10.1016/S0092-8674(00)80801-6	http://dx.doi.org/10.1016/S0092-8674(00)80801-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399917	Bronze			2022-12-01	WOS:000081162800010
J	Stampfer, M; Rimm, E				Stampfer, M; Rimm, E			Alcohol and other dietary factors may be important - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY HEART-DISEASE; NUT CONSUMPTION; RISK; FOLATE; WOMEN; FIBER; MEN; PREVENTION; COHORT		Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Stampfer, M (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.	meir.stampfer@channing.harvard.edu						DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; HU FB, IN PRESS AM J CLIN N; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; Liu S, 1998, FASEB J, V12, pA260; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Parodi PW, 1997, MED HYPOTHESES, V49, P313, DOI 10.1016/S0306-9877(97)90197-3; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472	14	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	1999	318	7196					1476	1477						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419293				2022-12-01	WOS:000080668200029
J	Ing, AJ; Ngu, MC				Ing, AJ; Ngu, MC			Cough and gastro-oesophageal reflux	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX; DIAGNOSTIC EVALUATION; KEY COMPONENTS; THERAPY; FREQUENCY; SPECTRUM		Concord Hosp, Dept Thorac Med, Concord, NSW, Australia; Concord Hosp, Dept Gastroenterol, Concord, NSW, Australia	Concord Repatriation General Hospital; Concord Repatriation General Hospital	Ing, AJ (corresponding author), Concord Hosp, Dept Thorac Med, Concord, NSW, Australia.			Ing, Alvin/0000-0002-6391-020X				Allen CJ, 1998, THORAX, V53, P963, DOI 10.1136/thx.53.11.963; *AM COLL CHEST PHY, 1998, CHEST, V114, pS133; DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005; GIUDICELLI R, 1990, ANN CHIR, V47, P552; Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9; ING A J, 1992, American Review of Respiratory Disease, V145, pA11; ING AJ, 1994, AM J RESP CRIT CARE, V149, P160, DOI 10.1164/ajrccm.149.1.8111576; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; IRWIN RS, 1989, AM REV RESPIR DIS, V140, P1294, DOI 10.1164/ajrccm/140.5.1294; MEIER JH, 1994, DIGEST DIS SCI, V39, P2127, DOI 10.1007/BF02090360; SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991; WARING JP, 1995, DIGEST DIS SCI, V40, P1093	13	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					944	946		10.1016/S0140-6736(98)00354-7	http://dx.doi.org/10.1016/S0140-6736(98)00354-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459900				2022-12-01	WOS:000079421600006
J	Rollmann, SM; Houck, LD; Feldhoff, RC				Rollmann, SM; Houck, LD; Feldhoff, RC			Proteinaceous pheromone affecting female receptivity in a terrestrial salamander	SCIENCE			English	Article								A 22-kilodalton protein was isolated from the submandibular (mental) gland of the male terrestrial salamander, Plethodon jordani (family: Plethodontidae). This proteinaceous pheromone, termed plethodontid receptivity factor (PRF), was experimentally delivered to the female during courtship and shown to increase female receptivity, In most plethodontid salamanders, ovulation occurs weeks or months after insemination, so the pheromone-induced change in receptivity is the only known function of PRF, The messenger RNAs corresponding to isoforms of PRF were transcribed into complementary DNA, cloned, sequenced, and shown to have homology with cytokines of the interleukin-6 family. Pheromone activity would represent a previously unrecognized function for cytokines.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Univ Louisville, Sch Med, Dept Biochem, Louisville, KY 40292 USA	University of Chicago; Oregon State University; University of Louisville	Rollmann, SM (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57 St, Chicago, IL 60637 USA.	smrollma@midway.uchicago.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNOLD SJ, 1976, Z TIERPSYCHOL, V42, P247; Arnold SJ., 1982, BIOCH ASP EVOL BIOL, P173; ARNOLD SJ, 1972, THESIS U MICHIGAN AN; DUELLMAN WE, 1986, BIOL AMPHIBIANS, pCH2; DULKA JG, 1987, NATURE, V325, P251, DOI 10.1038/325251a0; Feldhoff Richard C., 1999, P117; Houck LD, 1998, COPEIA, P214; HOUCK LD, 1990, ANIM BEHAV, V39, P729, DOI 10.1016/S0003-3472(05)80384-7; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; Meager T., 1998, MOL BIOL CYTOKINES; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; NICOLA NN, 1994, GUIDEBOOK CYTOKINES, P57; SIGNORET JP, 1961, 4 INT C AN REPR ART, P171; SINGER AG, 1986, J BIOL CHEM, V261, P3323	16	157	159	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1907	1909		10.1126/science.285.5435.1907	http://dx.doi.org/10.1126/science.285.5435.1907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489368				2022-12-01	WOS:000082638300048
J	Gong, JP; Xu, J; Bezanilla, M; van Huizen, R; Derin, R; Li, M				Gong, JP; Xu, J; Bezanilla, M; van Huizen, R; Derin, R; Li, M			Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2	SCIENCE			English	Article							ION CHANNELS; TYROSINE KINASE; PROTEIN-KINASES; K+ CHANNELS; MODULATION; SUBUNIT; BINDING; DOMAIN; ALPHA; LOCALIZATION	Targeting of protein modification enzymes is a key biochemical step to achieve specific and effective posttranslational modifications, Two alternatively spliced ZIP1 and ZIP2 proteins are described, which bind to both Kv beta 2 subunits of potassium channel and protein kinase C (PKC) zeta, thereby acting as a physical link in the assembly of PKC zeta-ZIP-potassium channel complexes. ZIP1 and ZIP2 differentially stimulate phosphorylation of Kv beta 2 by PKC zeta. They also interact to form heteromultimers, which allows for a hybrid stimulatory activity to PKC zeta. Finally, ZIP1 and ZIP2 coexist in the same cell type and are elevated differentially by neurotrophic factors. These results provide a mechanism for specificity and regulation of PKC zeta-targeted phosphorylation.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Li, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	minli@jhmi.edu			NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS033324, R01NS033324] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIELEFELDT K, 1994, BIOPHYS J, V66, P1904, DOI 10.1016/S0006-3495(94)80984-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONG JP, UNPUB; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hille B., 1991, IONIC CHANNELS EXCIT; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/S0968-0004(06)80020-4; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; REINHART PH, 1995, J NEUROSCI, V15, P4572; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Xu J, 1998, TRENDS CARDIOVAS MED, V8, P229, DOI 10.1016/S1050-1738(98)00011-5; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Xu J, 1998, METHOD ENZYMOL, V293, P3; Xu J, 1998, P NATL ACAD SCI USA, V95, P1846, DOI 10.1073/pnas.95.4.1846; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	35	111	116	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1565	1569		10.1126/science.285.5433.1565	http://dx.doi.org/10.1126/science.285.5433.1565			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477520				2022-12-01	WOS:000082359500065
J	Coupland, R				Coupland, R			Clinical and legal significance of fragmentation of bullets in relation to size of wounds: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							WAR WOUNDS; CLASSIFICATION; MANAGEMENT; DISRUPTION; BALLISTICS	Objective To examine the relation between fragmentation of bullets and size of wounds clinically and in the context of the Hague Declaration of 1899. Design Retrospective analysis of prospectively collected data on hospital admissions. Setting Hospitals of the International Committee of the Red Cross. Subjects 5215 people wounded by bullets in armed conflicts (5933 wounds). Main outcome measures Grade of wound computed from the Red Cross wound classification and presence of bullet fragments on radiography. Results Of the 347 wounds with fragmentation of bullets, 251 (72%) were large wounds (grade 2 or 3)that is, those with a clinically detectable cavity. Of the 5586 wounds without fragmentation of bullets, 2915 (52.1%) were large wounds. Only 7.9% (251/3166) of large wounds were associated with fragmentation of bullets. Conclusions Fragmentation of bullets is associated with large wounds, but most large wounds do not contain bullet fragments. In addition, bullet fragments may occur in wounds that are not defined as large. Fragmentation of bullets is neither a necessary nor sufficient cause of large wounds, and surgeons should not diagnose extensive tissue damage because of the presence of fragments on radiography Such findings also do not necessarily represent the use of bullets which contravene the law of war. Future legislation should take into account not only the construction of bullets but also their potential to transfer energy to the human body.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, R (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							BOWYER GW, 1995, J TRAUMA, V38, P64, DOI 10.1097/00005373-199501000-00018; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; Coupland R.M., 1991, RED CROSS WOUND CLAS, P18; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1992, LANCET, V339, P35, DOI 10.1016/0140-6736(92)90152-S; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; COUPLAND RM, 1994, RECENT ADV SURG, P121; Coupland RM, 1993, WAR WOUNDS LIMBS SUR; Coupland Robin, 1997, SIRUS PROJECT DETERM; Davis H J, 1897, Br Med J, V2, P1789; FACKLER ML, 1984, J TRAUMA, V24, P35, DOI 10.1097/00005373-198401000-00005; FACKLER ML, 1984, J TRAUMA, V24, P263, DOI 10.1097/00005373-198403000-00014; KNEUBUEHL BP, 1994, EXP M CERT WEAP SYST, P26; KNUDSEN PJT, 1993, INT J LEGAL MED, V106, P61, DOI 10.1007/BF01225042; LINDSEY D, 1980, J TRAUMA, V20, P1068, DOI 10.1097/00005373-198012000-00012; Ogston A, 1898, Br Med J, V2, P813; Ogston Alex, 1899, BMJ, V2, P278; SELLER KG, 1994, WOUND BALLISTICS; SMITH MSO, 1981, HIGH VELOCITY MISSIL; Spencer CG, 1908, GUNSHOT WOUNDS	20	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					403	406		10.1136/bmj.319.7207.403	http://dx.doi.org/10.1136/bmj.319.7207.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445917	Green Published, Bronze			2022-12-01	WOS:000082098900012
J	Coupland, RM; Samnegaard, HO				Coupland, RM; Samnegaard, HO			Effect of type and transfer of conventional weapons on civilian injuries: retrospective analysis of prospective data from Red Cross hospitals	BRITISH MEDICAL JOURNAL			English	Article							ANTIPERSONNEL MINES; LAND MINES; MOZAMBIQUE; MANAGEMENT; HEALTH	Objective To examine the link between different weapons used in modern wars and their potential to injury civilians. Design Retrospective analysis of prospectively collected data about hospital admissions. Setting Hospitals of the International Committee of the Red Cross. Subjects 18 877 people wounded by bullets, fragmentation munitions, or mines. Of these, 2012 had been admitted to the hospital in Kabul within six hours of injury. Main outcome measures Age and sex of wounded people according to cause of injury and whether they were civilians (women and girls, boys under 16 years old, or men of 50 or more). Results 18.7% of those injured by bullets, 34.1% of those injured by fragments, and 30.8% of those injured by mines were civilians. Of those admitted to the Red Cross hospital in Kabul within six hours of injury, 39.1% of those injured by bullets, 60.6% of those injured by fragments, and 55.0% of those injured by mines were civilians. Conclusions The proportion of civilians injured differs between weapon systems. The higher proportion injured by fragments and mines is explicable in terms of the military efficiency of weapons, the distance between user and victim, and the effect that the kind of weapon has on the psychology of the user.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, RM (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; Bowyer GW, 1997, ANN ROY COLL SURG, V79, P175; CARFIELD RM, 1991, JAMA-J AM MED ASSOC, V226, P688; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Coupland RM, 1996, LANCET, V347, P450, DOI 10.1016/S0140-6736(96)90017-3; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; Grossman Dave, 1995, KILLING PSYCHOL COST; *INT COMM RED CROS, 1996, MED PROF EFF WEAP S; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; Prokosch E., 1995, TECHNOLOGY KILLING; SELLIER KG, 1994, WOUND BALLISTICS; Sidel VW, 1995, BRIT MED J, V311, P1677, DOI 10.1136/bmj.311.7021.1677	14	29	33	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					410	412		10.1136/bmj.319.7207.410	http://dx.doi.org/10.1136/bmj.319.7207.410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445921	Bronze, Green Published			2022-12-01	WOS:000082098900015
J	Andretic, R; Chaney, S; Hirsh, J				Andretic, R; Chaney, S; Hirsh, J			Requirement of circadian genes for cocaine sensitization in Drosophila	SCIENCE			English	Article							CLOCK GENE; BEHAVIORAL SENSITIZATION; PERIOD PROTEIN; DOUBLE-TIME; MELANOGASTER; ADDICTION; MUTANTS; RHYTHMS; TRANSCRIPTION; RESPONSES	The circadian clock consists of a feedback loop in which clock genes are rhythmically expressed, giving rise to cycling Levels of RNA and proteins. Four of the five circadian genes identified to date influence responsiveness to free-base cocaine in the fruit fly, Drosophila melanogaster, Sensitization to repeated cocaine exposures, a phenomenon also seen in humans and animal models and associated with enhanced drug craving, is eliminated in flies mutant for period, clock, cycle, and doubletime, but not in flies lacking the gene timeless. Flies that do not sensitize owing to lack of these genes do not show the induction of tyrosine decarboxylase normally seen after cocaine exposure. These findings indicate unexpected roles for these genes in regulating cocaine sensitization and indicate that they function as regulators of tyrosine decarboxylase.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA	University of Virginia	Hirsh, J (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22903 USA.		Andretic, Rozi/M-5666-2013; Jansen, Heiko T./A-5770-2008	Andretic, Rozi/0000-0003-0375-0520; Jansen, Heiko T./0000-0003-0178-396X; Chaney, Sarah/0000-0002-4734-7576	NIDA NIH HHS [DA05942] Funding Source: Medline; NIGMS NIH HHS [GM/DA 27318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRETIC R, UNPUB; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; GOODMAN A, 1990, PHARMACOL BASIS THER, P417; Hamblen MJ, 1998, GENETICS, V149, P165; HENRY DJ, 1995, J NEUROSCI, V15, P6287; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; MCCLUNG C, IN PRESS CURR BIOL; MCCLUNG C, UNPUB; MORSE AC, 1995, PHYSIOL BEHAV, V58, P891, DOI 10.1016/0031-9384(95)00144-8; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1; TOLLIVER BK, 1994, J PHARMACOL EXP THER, V270, P1230; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHITE FJ, 1995, NEUROBIOLOGY COCAINE, P81; Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135	29	214	228	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1066	1068		10.1126/science.285.5430.1066	http://dx.doi.org/10.1126/science.285.5430.1066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446052				2022-12-01	WOS:000082033100045
J	Hill, LL; Ouhtit, A; Loughlin, SM; Kripke, ML; Ananthaswamy, HN; Owen-Schaub, LB				Hill, LL; Ouhtit, A; Loughlin, SM; Kripke, ML; Ananthaswamy, HN; Owen-Schaub, LB			Fas ligand: A sensor for DNA damage critical in skin cancer etiology	SCIENCE			English	Article							P53 MUTATIONS; INDUCED APOPTOSIS; CELL CARCINOMA; MOUSE SKIN; ULTRAVIOLET; LYMPHOCYTES; ACTIVATION; SUNLIGHT; TUMORS; MICE	DNA-damaged cells can either repair the DNA or be eliminated through a homeostatic control mechanism termed "cellular proofreading." Elimination of DNA-damaged cells after ultraviolet radiation (UVR) through sunburn cell (apoptotic keratinocyte) formation is thought to be pivotal for the removal of precancerous skin cells. Sunburn cell formation was found to be dependent on Fas ligand (FasL), a pro-apoptotic protein induced by DNA damage. Chronic exposure to UVR caused 14 of 20 (70 percent) FasL-deficient mice and 1 of 20 (5 percent) wild-type mice to accumulate p53 mutations in the epidermis, Thus, Fast-mediated apoptosis is important for skin homeostasis, suggesting that the dysregulation of Fas-FasL interactions may be central to the development of skin cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Owen-Schaub, LB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	lowensch@mdanderson.org			NCI NIH HHS [CA45623, CA52457] Funding Source: Medline; NIAID NIH HHS [F32 AI09351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hill LL, 1999, J EXP MED, V189, P1285, DOI 10.1084/jem.189.8.1285; HILL LL, UNPUB; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KANJILAL S, 1993, CANCER RES, V53, P2961; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	20	206	207	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					898	900		10.1126/science.285.5429.898	http://dx.doi.org/10.1126/science.285.5429.898			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436160				2022-12-01	WOS:000081860900052
J	Summons, RE; Jahnke, LL; Hope, JM; Logan, GA				Summons, RE; Jahnke, LL; Hope, JM; Logan, GA			2-Methylhopanoids as biomarkers for cyanobacterial oxygenic photosynthesis	NATURE			English	Article							PROKARYOTIC TRITERPENOIDS; METHYLOBACTERIUM-ORGANOPHILUM; HOPANE SERIES; 2-BETA-METHYLHOPANOIDS; LOCALIZATION; BIOSYNTHESIS; ANTIQUITY; ORIGIN	Oxygenic photosynthesis is widely accepted as the most important bioenergetic process happening in Earth's surface environment(1). It is thought to have evolved within the cyanobacterial lineage, but it has been difficult to determine when it began. Evidence based on the occurrence and appearance of stromatolites(2) and microfossils' indicates that phototrophy occurred as long ago as 3,465 Myr although no definite physiological inferences can be he made from these objects. Carbon isotopes and other geological phenomena(4,5) provide clues but are also equivocal, Biomarkers are potentially useful because the three domains of extant life-Bacteria, Archaea and Eukarya-have signature membrane lipids with recalcitrant carbon skeletons. These lipids turn into hydrocarbons in sediments and can be found wherever the record is sufficiently well preserved. Here we show that 2-methylbacteriohopanepolyols occur in a high proportion of cultured cyanobacteria and cyanobacterial mats, Their 2-methylhopane hydrocarbon derivatives are abundant in organic-rich sediments as old as 2,500 Myr. These biomarkers may help constrain the age of the oldest cyanobacteria and the advent of oxygenic photosynthesis. They could also be used to quantify the ecological importance of cyanobacteria through geological time.	Australian Geol Survey Org, Canberra, ACT 2601, Australia; NASA, Ames Res Ctr, Exobiol Biol Branch, Moffett Field, CA 94035 USA	Geoscience Australia; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Summons, RE (corresponding author), Australian Geol Survey Org, GPO Box 378, Canberra, ACT 2601, Australia.		Summons, Roger Everett/AAL-3789-2020					[Anonymous], 1994, EARLY LIFE EARTH; Bauld J., 1984, MBL LECT BIOL, V3, P39; BISSERET P, 1985, EUR J BIOCHEM, V150, P29, DOI 10.1111/j.1432-1033.1985.tb08982.x; Blankenship RE, 1998, TRENDS BIOCHEM SCI, V23, P94, DOI 10.1016/S0968-0004(98)01186-4; BUICK R, 1992, SCIENCE, V255, P74, DOI 10.1126/science.11536492; Buick R, 1998, AAPG BULL, V82, P50; GOLUBIC S, 1994, EARLY LIFE EARTH, P220; Haug GH, 1998, PALEOCEANOGRAPHY, V13, P427, DOI 10.1029/98PA01976; HERMANN D, 1995, THESIS U HAUTE ALSAC; JURGENS UJ, 1992, FEMS MICROBIOL LETT, V92, P285; JW, 1992, PROTEROZOIC BIOSPHER, P81; KENIG F, 1995, GEOCHIM COSMOCHIM AC, V59, P2999, DOI 10.1016/0016-7037(95)00190-5; KNANI M, 1994, MICROBIOL-UK, V140, P2755, DOI 10.1099/00221287-140-10-2755; Llopiz P, 1996, FEMS MICROBIOL LETT, V140, P199; PETERS KE, 1992, BIOMARKER GUIDE INTE; PRICE LC, 1993, GEOCHIM COSMOCHIM AC, V57, P3261, DOI 10.1016/0016-7037(93)90539-9; RENOUX JM, 1985, EUR J BIOCHEM, V151, P405, DOI 10.1111/j.1432-1033.1985.tb09116.x; ROHMER M, 1984, J GEN MICROBIOL, V130, P1137; ROHMER M, 1993, PURE APPL CHEM, V65, P1293, DOI 10.1351/pac199365061293; Schopf J. W., 1992, PROTEROZOIC BIOSPHER; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Simonin P, 1996, EUR J BIOCHEM, V241, P865, DOI 10.1111/j.1432-1033.1996.00865.x; SUMMONS RE, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P182; Summons RE, 1996, CIBA F SYMP, V202, P174; SUMMONS RE, 1990, AM J SCI, V290A, P212; VILCHEZE C, 1994, MICROBIOLOGY, V140, P2794; ZHAO N, 1996, TETRAHEDRON, V52, P2772; ZUNDEL M, 1985, EUR J BIOCHEM, V150, P35, DOI 10.1111/j.1432-1033.1985.tb08984.x	28	678	731	5	124	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					554	557		10.1038/23005	http://dx.doi.org/10.1038/23005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448856				2022-12-01	WOS:000081854800052
J	Ceriani, MF; Darlington, TK; Staknis, D; Mas, P; Petti, AA; Weitz, CJ; Kay, SA				Ceriani, MF; Darlington, TK; Staknis, D; Mas, P; Petti, AA; Weitz, CJ; Kay, SA			Light-dependent sequestration of TIMELESS by CRYPTOCHROME	SCIENCE			English	Article							DROSOPHILA CLOCK GENE; CIRCADIAN CLOCK; PROTEIN; PERIOD; TIM; PHOTORECEPTORS; TRANSCRIPTION; MELANOGASTER; ENTRAINMENT; HOMOLOG	Most organisms have circadian clocks consisting of negative feedback Loops of gene regulation that facilitate adaptation to cycles of light and darkness. In this study, CRYPTOCHROME (CRY), a protein involved in circadian photoperception in Drosophila, is shown to block the function of PERIOD/TIMELESS (PER/TIM) heterodimeric complexes in a light-dependent fashion. TIM degradation does not occur under these conditions: thus, TIM degradation is uncoupled from abrogation of its function by light, CRY and TIM are part of the same complex and directly interact in yeast in a light-dependent fashion. PER/TIM and CRY influence the subcellular distribution of these protein complexes, which reside primarily in the nucleus after the perception of a light signal. Thus, CRY acts as a circadian photoreceptor by directly interacting with core components of the circadian clock.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, NSF, Ctr Biol Timing, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Harvard University; Harvard Medical School	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kay, Steve A/F-6025-2011; Mas, Paloma/B-8215-2016	Kay, Steve A/0000-0002-0402-2878; Mas, Paloma/0000-0002-3780-8041; Ceriani, Maria/0000-0001-8945-3070	NIMH NIH HHS [MH-59943, MH-51573] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573, R01MH059943] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CERIANI MF, UNPUB; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Egan ES, 1999, J NEUROSCI, V19, P3665; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Okano S, 1999, PHOTOCHEM PHOTOBIOL, V69, P108; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; STAKNIS D, UNPUB; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323	36	430	445	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					553	556		10.1126/science.285.5427.553	http://dx.doi.org/10.1126/science.285.5427.553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417378				2022-12-01	WOS:000081609500028
J	Liu, YY; Gao, JH; Liotti, M; Pu, YL; Fox, PT				Liu, YY; Gao, JH; Liotti, M; Pu, YL; Fox, PT			Temporal dissociation of parallel processing in the human subcortical outputs	NATURE			English	Article							BASAL GANGLIA; WORKING-MEMORY; MOTOR CONTROL; HUMAN BRAIN; DATA SETS; CEREBELLUM; CHANNELS	Many tasks require rapid and fine-tuned adjustment of motor performance based on incoming sensory information. This process of sensorimotor adaptation engages two parallel subcortico-cortical neural circuits, involving the cerebellum and basal ganglia, respectively(1-10), How these distributed circuits are functionally coordinated has not been shown in humans. The cerebellum and basal ganglia show very similar convergence of input-output organization(11,12), which presents an ideal neuroimaging model for the study of parallel processing at a systems level(13). Here we used functional magnetic resonance imaging to measure the temporal coherence of brain activity during a tactile discrimination task. We found that, whereas the prefrontal cortex maintained a high level of activation, output activities in the cerebellum and basal ganglia showed different phasic patterns. Moreover, cerebellar activity significantly correlated with the activity of the supplementary motor area but not with that of the primary motor cortex; in contrast, basal ganglia activity was more strongly associated with the activity of the primary motor cortex than with that of the supplementary motor area. These results demonstrate temporally partitioned activity in the cerebellum and basal ganglia, implicating functional independence in the parallel subcortical outputs. This further supports the idea of task-related dynamic reconfiguration of large-scale neural networks(14,15).	Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, YY (corresponding author), Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		anand, amit/A-7222-2009; Fox, Peter/B-4725-2010	Fox, Peter/0000-0002-0465-2028; LIOTTI, MARIO/0000-0003-3375-5488				ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BRESSLER SL, 1995, BRAIN RES REV, V20, P288, DOI 10.1016/0165-0173(94)00016-I; CHURCHLAND PS, 1988, SCIENCE, V242, P741, DOI 10.1126/science.3055294; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; FOX EM, 1995, PAC RIM L POLY J, V4, P1; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; Ghez C, 1991, PRINCIPLES NEURAL SC, P609; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; Hoover JE, 1999, J NEUROSCI, V19, P1446; Houk JC, 1997, PROG BRAIN RES, V114, P543; HOUK JC, 1993, TRENDS NEUROSCI, V16, P27, DOI 10.1016/0166-2236(93)90049-R; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LIU Y, 1998, P INT SOC MAGN RESON, V6, P110; MARSDEN CD, 1982, NEUROLOGY, V32, P514, DOI 10.1212/WNL.32.5.514; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Middleton FA, 1997, PROG BRAIN RES, V114, P553; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; ROLAND PE, 1988, EUR J NEUROSCI, V1, P3; Rouiller Eric M., 1996, P99, DOI 10.1016/B978-012759440-8/50009-8; Van Essen D. C., 1994, LARGE SCALE NEURONAL, P271; Voogd J, 1997, PROG BRAIN RES, V114, P21; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	28	61	65	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					364	367		10.1038/22547	http://dx.doi.org/10.1038/22547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432114				2022-12-01	WOS:000081590000050
J	Batista, AP; Buneo, CA; Snyder, LH; Andersen, RA				Batista, AP; Buneo, CA; Snyder, LH; Andersen, RA			Reach plans in eye-centered coordinates	SCIENCE			English	Article							POSTERIOR PARIETAL CORTEX; PREMOTOR CORTEX; VISUAL SPACE; NEURONAL-ACTIVITY; MACAQUE MONKEY; MOVEMENTS; AREAS; GAZE	The neural events associated with visually guided reaching begin with an image on the retina and end with impulses to the muscles, In between, a reaching plan is formed, This plan could be in the coordinates of the arm, specifying the direction and amplitude of the movement, or it could be in the coordinates of the eye because visual information is initially gathered in this reference frame. In a reach-planning area of the posterior parietal cortex, neural activity was found to be more consistent with an eye-centered than an arm-centered coding of reach targets. Coding of arm movements in an eye-centered reference frame is advantageous because obstacles that affect planning as well as errors in reaching are registered in this reference frame. Also, eye movements are planned in eye coordinates, and the use of similar coordinates for reaching may facilitate hand-eye coordination.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Mail Code 216-76, Pasadena, CA 91125 USA.		Snyder, Lawrence H/A-4593-2017	Batista, Aaron/0000-0002-1719-0061				BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; Boussaoud D, 1998, J NEUROPHYSIOL, V80, P1132, DOI 10.1152/jn.1998.80.3.1132; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P517, DOI 10.1016/0028-3932(91)90008-V; Colby CL, 1998, NEURON, V20, P15, DOI 10.1016/S0896-6273(00)80429-8; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Galletti C, 1997, EUR J NEUROSCI, V9, P410, DOI 10.1111/j.1460-9568.1997.tb01410.x; GEORGOPOULOS AP, 1983, EXP BRAIN RES, V49, P327; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Hein A, 1958, PERCEPT MOTOR SKILL, V8, P87, DOI [DOI 10.2466/PMS.1958.8.3.87, 10.2466/pms.1958.8.3.87]; Henriques DYP, 1998, J NEUROSCI, V18, P1583; Jeannerod M., 1988, NEURAL BEHAV ORG GOA; JOHNSON PB, 1996, CEREB CORTEX, V6, P1047; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; McIntyre J, 1997, J NEUROPHYSIOL, V78, P1601, DOI 10.1152/jn.1997.78.3.1601; Murata A, 1996, J NEUROPHYSIOL, V75, P2180, DOI 10.1152/jn.1996.75.5.2180; Mushiake H, 1997, J NEUROPHYSIOL, V78, P567, DOI 10.1152/jn.1997.78.1.567; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; Sabes PN, 1997, J NEUROSCI, V17, P7119; SCOTT DW, 1985, ANN STAT, V13, P1024, DOI 10.1214/aos/1176349654; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Soechting J F, 1990, J Cogn Neurosci, V2, P32, DOI 10.1162/jocn.1990.2.1.32; Vetter P, 1999, J NEUROPHYSIOL, V81, P935, DOI 10.1152/jn.1999.81.2.935; WALKER MF, 1995, J NEUROPHYSIOL, V73, P1988, DOI 10.1152/jn.1995.73.5.1988; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	32	523	530	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					257	260		10.1126/science.285.5425.257	http://dx.doi.org/10.1126/science.285.5425.257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398603				2022-12-01	WOS:000081346000043
J	Weinberg, JR; Duerden, BI				Weinberg, JR; Duerden, BI			Commentary: A matter of good clinical practice	BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Lab Serv, London NW9 5EQ, England	Public Health England	Duerden, BI (corresponding author), Publ Hlth Lab Serv, London NW9 5EQ, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1617	1618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428554				2022-12-01	WOS:000080913100039
J	Hoppa, GV; Tufts, BR; Greenberg, R; Geissler, PE				Hoppa, GV; Tufts, BR; Greenberg, R; Geissler, PE			Formation of cycloidal features on Europa	SCIENCE			English	Article							TIDAL STRESSES; FRACTURE; SEPARATION; PATTERNS	Cycloidal patterns are widely distributed on the surface of Jupiter's moon Europa. Tensile cracks may have developed such a pattern in response to diurnal variations in tidal stress in Europa's outer ice shell. When the tensile strength of the ice is reached, a crack may occur. Propagating cracks would move across an ever-changing stress field, following a curving path to a place and time where the tensile stress was insufficient to continue the propagation. A few hours Later, when the stress at the end of the crack again exceeded the strength, propagation would continue in a new direction. Thus, one arcuate segment of the cycloidal chain would be produced during each day on Europa. For this model to work, the tensile strength of Europa's ice crust must be Less than 40 kilo-pascals, and there must be a thick fluid Layer below the ice to allow sufficient tidal amplitude.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Hoppa, GV (corresponding author), Univ Arizona, Lunar & Planetary Lab, 1629 E Univ Blvd, Tucson, AZ 85721 USA.							CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; GAMMON PH, 1983, J PHYS CHEM-US, V87, P4025, DOI 10.1021/j100244a004; GOLOMBEK MP, 1990, ICARUS, V83, P441, DOI 10.1016/0019-1035(90)90078-N; Greenberg R, 1998, ICARUS, V135, P64, DOI 10.1006/icar.1998.5986; HEAD JW, IN PRESS J GEOPHYS R; HELFENSTEIN P, 1983, ICARUS, V53, P415, DOI 10.1016/0019-1035(83)90206-3; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; HOPPA GV, 1996, LUNAR PLANET SCI C, V30; KADEL SD, 1998, LUNAR PLANET SCI C, V29; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MALIN MC, 1986, SATELLITES, P689; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; NOLAN M, 1987, B AM ASTRON SOC, V19, P860; OJKANGASGW, 1989, ICARUS, V81, P242; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SMITH RA, 1976, J GLACIOL, V17, P223, DOI DOI 10.3189/S0022143000013563; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; Tufts B. R., 1998, THESIS U ARIZONA TUC; TUFTS BJ, UNPUB; TURTLE EP, 1998, EOS, V79, pS202	24	167	170	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1899	1902		10.1126/science.285.5435.1899	http://dx.doi.org/10.1126/science.285.5435.1899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489365				2022-12-01	WOS:000082638300045
J	Rojas, JR; Trievel, RC; Zhou, JX; Mo, Y; Li, XM; Berger, SL; Allis, CD; Marmorstein, R				Rojas, JR; Trievel, RC; Zhou, JX; Mo, Y; Li, XM; Berger, SL; Allis, CD; Marmorstein, R			Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide	NATURE			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; CRYSTAL-STRUCTURE; IN-VIVO; REFINEMENT; COMPLEXES; PROTEIN; SUPERFAMILY; ACETYLATION; DYNAMICS; ADA	Gene activation is a highly regulated process that requires the coordinated action of proteins to relieve chromatin repression and to promote transcriptional activation. Nuclear histone acetyltransferase (HAT) enzymes provide a mechanistic link between chromatin destabilization and gene activation by acetylating the E-amino group of specific lysine residues within the aminoterminal tails of core histones to facilitate access to DNA by transcriptional activators(1,2). Here we report the high-resolution crystal structure of the HAT domain of Tetrahymena GCN5 (tGCN5) bound with both its physiologically relevant ligands, coenzyme A (CoA) and a histone H3 peptide, and the structures of nascent tGCN5 and a tGCN5/acetyl-CoA complex. Our structural data reveal histone-binding specificity for a random-coil structure Containing a G-K-X-P recognition sequence, and show that CoA is essential for reorienting the enzyme for histone binding. Catalysis appears to involve water-mediated proton extraction from the substrate lysine by a glutamic acid general base and a backbone amide that stabilizes the transition-state reaction intermediate. Comparison with related N-acetyltransferases indicates a conserved structural framework for CoA binding and catalysis, and structural variability in regions associated with substrate-specific binding.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Rochester	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.		li, xinmin/C-6173-2011	Berger, Shelley/0000-0001-5398-4400				Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR MANUAL VERSION; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; FUREY W, 1995, METHOD ENZYMOL, P590; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Leslie A.G.W., 1992, CCP4 ESF EACMB NEWSL; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	29	225	230	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					93	98		10.1038/43487	http://dx.doi.org/10.1038/43487			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485713				2022-12-01	WOS:000082374400049
J	Lenormand, T; Bourguet, D; Guillemaud, T; Raymond, M				Lenormand, T; Bourguet, D; Guillemaud, T; Raymond, M			Tracking the evolution of insecticide resistance in the mosquito Culex pipiens	NATURE			English	Article							GENE FLOW; HYBRID ZONE; SELECTION; MODEL; CLINE	The evolution of pesticide resistance provides some of the most striking examples of darwinian evolution occurring over a human life span. Identification of resistance alleles opens an outstanding framework in which to study the evolution of adaptive mutations from the beginning of pesticide application(1-3), the evolution of interactions between alleles (dominance(4)) or between loci (epistasis(5,6)). Here we shaw that resistance alleles can also be used as markers to dissect population processes at a microevolutionary scale. We have focused on the antagonistic roles of selection and migration involved in the dynamics of local adaptation with reference to allelic frequencies at two resistance loci in the mosquito Culex pipiens, We find that their frequencies follow an annual cycle of large amplitude (25%), and we precisely unravel the seasonal variation of migration and selection underlying this cycle. Our results provide a firm basis on which to devise an insecticide treatment strategy that will better control the evolution of resistance genes and the growth of mosquito populations.	Univ Montpellier 2, Inst Sci Evolut, Lab Genet & Environm, UMR 5554, F-34095 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Lenormand, T (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.		Raymond, Michel/C-9049-2015; guillemaud, thomas/B-4899-2012; Lenormand, Thomas/A-5328-2012	guillemaud, thomas/0000-0003-0451-1644; Lenormand, Thomas/0000-0001-8930-5393; Bourguet, Denis/0000-0002-2109-5323; Raymond, Michel/0000-0002-1714-6984				ANDERSON DR, 1994, ECOLOGY, V75, P1780, DOI 10.2307/1939637; BARTON NH, 1989, NATURE, V341, P497, DOI 10.1038/341497a0; BARTON NH, 1982, EVOLUTION, V36, P863, DOI 10.1111/j.1558-5646.1982.tb05452.x; Bourguet D, 1997, GENETICS, V147, P1225; Chevillon C, 1997, GENET RES, V70, P195, DOI 10.1017/S0016672397003029; Cook LM, 1999, P ROY SOC B-BIOL SCI, V266, P293, DOI 10.1098/rspb.1999.0636; Davies AG, 1996, GENETICS, V143, P1321; Guillemaud T, 1998, EVOLUTION, V52, P443, DOI [10.1111/j.1558-5646.1998.tb01644.x, 10.2307/2411080]; HALDANE JBS, 1948, J GENET, V48, P277, DOI 10.1007/BF02986626; Harrison R.G., 1990, Oxford Surveys in Evolutionary Biology, V7, P69; JAIN SK, 1966, HEREDITY, V21, P407, DOI 10.1038/hdy.1966.42; Kettlewell H. B. D., 1961, Heredity, V16, P403, DOI 10.1038/hdy.1961.49; Lenormand T, 1998, EVOLUTION, V52, P1705, DOI 10.2307/2411343; Lenormand T, 1998, GENETICS, V149, P1383; Lenormand T, 1998, P ROY SOC B-BIOL SCI, V265, P1985, DOI 10.1098/rspb.1998.0529; LENORMAND T, IN PRESS AM NAT; MALLET J, 1990, GENETICS, V124, P921; MALLET J, 1989, TRENDS ECOL EVOL, V4, P336, DOI 10.1016/0169-5347(89)90088-8; MANI GS, 1980, PROC R SOC SER B-BIO, V210, P299, DOI 10.1098/rspb.1980.0135; MAY RM, 1975, AM NAT, V109, P659, DOI 10.1086/283036; McKenzie J., 1996, ECOLOGICAL EVOLUTION; MUTERO A, 1994, P NATL ACAD SCI USA, V91, P5922, DOI 10.1073/pnas.91.13.5922; NAGLAKI T, 1975, GENETICS, V80, P595; Porter AH, 1997, EVOLUTION, V51, P1561, DOI 10.1111/j.1558-5646.1997.tb01479.x; RAYMOND M, 1989, GENETICS, V123, P543; SITES JW, 1995, EVOLUTION, V49, P9, DOI 10.1111/j.1558-5646.1995.tb05955.x; SLATKIN M, 1975, GENETICS, V81, P787; SLATKIN M, 1973, GENETICS, V75, P733; SZYMURA JM, 1986, EVOLUTION, V40, P1141, DOI 10.1111/j.1558-5646.1986.tb05740.x	29	161	166	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					861	864		10.1038/23685	http://dx.doi.org/10.1038/23685			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476962				2022-12-01	WOS:000082233200042
J	Kay, S				Kay, S			Brachial palsies from obstetric procedures	LANCET			English	Editorial Material							PLEXUS INJURIES		St Jamess Univ Hosp, Dept Plast Reconstruct & Hand Surg, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Kay, S (corresponding author), St Jamess Univ Hosp, Dept Plast Reconstruct & Hand Surg, Leeds LS9 7TF, W Yorkshire, England.							Bager B, 1997, ACTA PAEDIATR, V86, P1214, DOI 10.1111/j.1651-2227.1997.tb14849.x; BIRCH R, 1993, J BONE JOINT SURG BR, V75, P346, DOI 10.1302/0301-620X.75B3.8496196; CLARKE HM, 1995, HAND CLIN, V11, P563; GJORUP L, 1966, ACTA NEUROL SCAN S18, V42, P1; Kay SPJ, 1998, BRIT J PLAST SURG, V51, P43, DOI 10.1054/bjps.1997.0166; Mallet J, 1972, REV CHIR ORTHOP S1, V58, P115; Narakas AO., 1987, THE PARALYSED HAND, VEd, P116; Smith B, 1996, BYTE, V21, P145; Tassin GA, 1987, MICRORECONSTRUCTION, P529; TASSIN JL, 1983, THESIS U PARIS 7; Waters PM, 1999, J BONE JOINT SURG AM, V81A, P649, DOI 10.2106/00004623-199905000-00006	11	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					614	615		10.1016/S0140-6736(99)00222-6	http://dx.doi.org/10.1016/S0140-6736(99)00222-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466658				2022-12-01	WOS:000082214500005
J	Tipton, M; Eglin, C; Gennser, M; Golden, F				Tipton, M; Eglin, C; Gennser, M; Golden, F			Immersion deaths and deterioration in swimming performance in cold water	LANCET			English	Article							THERMAL RESPONSES; EXERCISE; LEG	Background General hypothermia (deep body temperature <35 degrees C) has been implicated in immersion-related deaths, but many deaths occur too quickly for it to be involved. We investigated changes in swimming capability in cold water to find out whether such changes could lead to swim failure and drowning. Methods Ten volunteers undertook three self paced breaststroke swims in a variable-speed swimming flume, in water at 25 degrees C, 18 degrees C, and 10 degrees C, for a maximum of 90 min, During each swim, we measured oxygen consumption, rectal temperature, swim speed and angle, and stroke rate and length. Swim failure was defined as being unable to keep feet off the bottom of the flume. Findings All ten swimmers completed 90 min swims at 25 degrees C, eight completed swims at 18 degrees C, and five at 10 degrees C. In 10 degrees C water, one swimmer reached swim failure after 61 min and four were withdrawn before 90 min with rectal temperatures of 35 degrees C when they were close to swim failure. Swimming efficiency and length of stroke decreased more and rate of stroke and swim angle increased more in 10 degrees C water than in warmer water. These variables seemed to characterise impending swim failure. Interpretation Impaired performance and initial cardiorespiratory responses to immersion probably represent the major dangers to immersion victims. Consequently, treatment should be aimed at symptoms resulting from near-drowning rather than severe hypothermia.	Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth PO1 2DT, Hants, England; Natl Def Res Estab, Dept Naval Med, Harsfjarden, Sweden	University of Portsmouth	Tipton, M (corresponding author), Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth PO1 2DT, Hants, England.	michael.tipton@port.ac.uk		Eglin, Clare Mary/0000-0002-3848-6515; Tipton, Michael/0000-0002-7928-8451				DULAC S, 1987, INT J SPORTS MED, V8, P352, DOI 10.1055/s-2008-1025683; GLASER EM, 1951, J PHYSIOL-LONDON, V115, pP14; Golden F, 1981, HYPOTHERMIA ASHORE A; GOLDEN FS, 1987, J PHYSIOL-LONDON, V391, P399, DOI 10.1113/jphysiol.1987.sp016744; GOLDEN FS, 1986, J PHYSIOL-LONDON, V378, pP94; Golden FS, 1997, BRIT J ANAESTH, V79, P214, DOI 10.1093/bja/79.2.214; GOLDEN FSC, 1982, J PHYSIOL-LONDON, V330, pP60; HOLMER I, 1974, ACTA PHYSIOL SCAND, P1; HOLMER I, 1974, J APPL PHYSIOL, V37, P702, DOI 10.1152/jappl.1974.37.5.702; Home Office, 1977, REP WORK PART WAT SA; HUTCHINSON P, 1998, STAYING ALIVE    SPR, P12; KEATINGE WR, 1969, BRIT MED J, V1, P480, DOI 10.1136/bmj.1.5642.480; NADEL ER, 1974, J APPL PHYSIOL, V36, P465, DOI 10.1152/jappl.1974.36.4.465; PUGH LGC, 1967, BRIT MED J, V2, P333, DOI 10.1136/bmj.2.5548.333; *ROSPA, 1988, DROWN UK 1987; *ROYAL COLL PHYS L, 1966, REP COMM ACC HYP; Scheffe H, 1999, ANAL VARIANCE, V72; TIPTON MJ, 1989, CLIN SCI, V77, P581, DOI 10.1042/cs0770581; TONER MM, 1984, J APPL PHYSIOL, V56, P1355, DOI 10.1152/jappl.1984.56.5.1355	19	51	51	0	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					626	629		10.1016/S0140-6736(99)07273-6	http://dx.doi.org/10.1016/S0140-6736(99)07273-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466663				2022-12-01	WOS:000082214500010
J	Hull, CM; Johnson, AD				Hull, CM; Johnson, AD			Identification of a mating type-like locus in the asexual pathogenic yeast Candida albicans	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; SEXUAL DEVELOPMENT; HOMOLOG; FUNGUS	Candida albicans, the most prevalent fungal pathogen in humans, is thought to lack a sexual cycle. A set of C. albicans genes has been identified that corresponds to the master sexual cycle regulators a1, alpha 1, and alpha 2 of the Saccharomyces cerevisiae mating-type (MAT) Locus. The C. albicans genes are arranged in a way that suggests that these genes are part of a mating type-like Locus that is similar to the mating-type Loci of other fungi. In addition to the transcriptional regulators a1, alpha 1, and alpha 2, the C. albicans mating type-like Locus contains several genes not seen in other fungal MAT Loci, including those encoding proteins similar to poly(A) polymerases, oxysterol binding proteins, and phosphatidylinositol kinases.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnson, AD (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre AD, 1995, INT J AVIAT PSYCHOL, V5, P1, DOI 10.1207/s15327108ijap0501_1; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; Casselton LA, 1998, MICROBIOL MOL BIOL R, V62, P55, DOI 10.1128/MMBR.62.1.55-70.1998; Chibana H, 1998, GENETICS, V149, P1739; Coppin E, 1997, MICROBIOL MOL BIOL R, V61, P411, DOI 10.1128/.61.4.411-428.1997; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Diener AC, 1996, GENETICS, V143, P769; FONZI WA, 1993, GENETICS, V134, P717; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; HULL CM, UNPUB; Jin YS, 1999, MOL CELL BIOL, V19, P585; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; Keogh RS, 1998, YEAST, V14, P443, DOI 10.1002/(SICI)1097-0061(19980330)14:5<443::AID-YEA243>3.0.CO;2-L; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; Odds F, 1988, CANDIDA CANDIDOSIS; Raymond M, 1998, MOL MICROBIOL, V27, P587, DOI 10.1046/j.1365-2958.1998.00704.x; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; Sharon A, 1996, MOL GEN GENET, V251, P60, DOI 10.1007/BF02174345; Turgeon BG, 1998, ANNU REV PHYTOPATHOL, V36, P115, DOI 10.1146/annurev.phyto.36.1.115	22	278	319	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1271	1275		10.1126/science.285.5431.1271	http://dx.doi.org/10.1126/science.285.5431.1271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455055				2022-12-01	WOS:000082130200045
J	Teng, E; Squire, LR				Teng, E; Squire, LR			Memory for places learned long ago is intact after hippocampal damage	NATURE			English	Article							TOPOGRAPHIC DISORIENTATION; RETROGRADE-AMNESIA; LESIONS; MONKEYS; HUMANS; RATS	The hippocampus is part of a system of structures in the medial temporal lobe that are essential for memory(1-3). One influential view of hippocampal function emphasizes its role in the acquisition and retrieval of spatial knowledge(4,5). By this view, the hippocampus constructs and stores spatial maps and is therefore essential for learning and remembering places, including those learned about long ago. We tested a profoundly amnesic patient (E.P.), who has virtually complete bilateral damage to the hippocampus and extensive damage to adjacent structures in the medial temporal lobe. We asked him to recall the spatial layout of the region where he grew up, from which he moved away more than 50 years ago. E.P. performed as well as or better than age-matched control subjects who grew up in the same region and also moved away. In contrast, E.P. has no knowledge of his current neighbourhood, to which he moved after he became amnesic. Our results show that the medial temporal lobe is not the permanent repository of spatial maps, and support the view that the hippocampus and other structures in the medial temporal lobe are essential for the formation of long-term declarative memories, both spatial and non-spatial, but not for the retrieval of very remote memories, either spatial or non-spatial(3,6).	Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Squire, LR (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.							Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Batschelet E, 1965, STAT METHODS ANAL PR; BOTTINI G, 1990, NEUROPSYCHOLOGIA, V28, P309, DOI 10.1016/0028-3932(90)90024-I; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Cohen, 1993, MEMORY AMNESIA HIPPO, DOI 10.1136/jnnp.58.1.128-a; dellaRocchetta AI, 1996, CORTEX, V32, P727, DOI 10.1016/S0010-9452(96)80042-6; DERENZI E, 1977, J NEUROL NEUROSUR PS, V40, P498, DOI 10.1136/jnnp.40.5.498; Hamann SB, 1997, BEHAV NEUROSCI, V111, P850, DOI 10.1037/0735-7044.111.4.850; Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Pai MC, 1997, J FORMOS MED ASSOC, V96, P660; PATERSON A, 1945, BRAIN, V68, P188, DOI 10.1093/brain/68.3.188; Reed JM, 1997, BEHAV NEUROSCI, V111, P1163, DOI 10.1037/0735-7044.111.6.1163; Reed JM, 1998, J NEUROSCI, V18, P3943; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Takahashi N, 1997, NEUROLOGY, V49, P464, DOI 10.1212/WNL.49.2.464; Wechsler D., 1997, WECHSLER MEMORY SCAL, V3rd	28	255	259	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					675	677		10.1038/23276	http://dx.doi.org/10.1038/23276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458163				2022-12-01	WOS:000082032900056
J	Kurachi, S; Deyashiki, Y; Takeshita, L; Kurachi, K				Kurachi, S; Deyashiki, Y; Takeshita, L; Kurachi, K			Genetic mechanisms of age regulation of human blood coagulation factor IX	SCIENCE			English	Article							GLASGOW MONICA SURVEY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; ACTIVATION MARKERS; BINDING MOTIF; FACTOR-VIII; ETS-DOMAIN; SEX; L1; EXPRESSION	Blood coagulation capacity increases with age in healthy individuals. Through extensive Longitudinal analyses of human factor IX gene expression in transgenic mice, two essential age-regulatory elements, AE5' and AE3', have been identified. These elements are required and together are sufficient for normal age regulation of factor IX expression. AE5', a PEA-3 related element present in the 5' upstream region of the gene encoding factor IX, is responsible for age-stable expression of the gene. AE3', in the middle of the 3' untranslated region, is responsible for age-associated elevation in messenger RNA Levels. In a concerted manner, AE5' and AE3' recapitulate natural patterns of the advancing age-associated increase in factor IX gene expression.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kurachi, K (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038644, R01HL053713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013283] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53713, HL38644] Funding Source: Medline; NIA NIH HHS [AG13283] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREW M, 1988, BLOOD, V72, P1651; ANDREW M, 1987, BLOOD, V70, P165, DOI 10.1182/blood.V70.1.165.165; ANDREW M, 1992, BLOOD, V80, P1998, DOI 10.1182/blood.V80.8.1998.1998; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CONLON MG, 1994, THROMB HAEMOSTASIS, V72, P551; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1993, P NATL ACAD SCI USA, V90, P6513, DOI 10.1073/pnas.90.14.6513; FISHER RJ, 1991, ONCOGENE, V6, P2249; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HOGAN F, 1994, MANIPULATING MOUSE E; HSU WK, UNPUB; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KONKEL DA, 1978, CELL, V15, P1125, DOI 10.1016/0092-8674(78)90040-5; KURACHI K, 1993, BLOOD COAGUL FIBRIN, V4, P953, DOI 10.1097/00001721-199304060-00013; Kurachi S, 1996, THROMB HAEMOSTASIS, V76, P965; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; KURACHI S, 1998, BIOCHEMICA, V3, P43; KURACHI S, UNPUB; Lowe GDO, 1997, BRIT J HAEMATOL, V97, P775, DOI 10.1046/j.1365-2141.1997.1222936.x; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; RODE JJ, 1996, NAT MED, V2, P293; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAITO H, 1991, DISORDERS HEMOSTASIS, P18; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SWEENEY JD, 1993, AM J CLIN PATHOL, V99, P687, DOI 10.1093/ajcp/99.6.687; Woodward M, 1997, BRIT J HAEMATOL, V97, P785, DOI 10.1046/j.1365-2141.1997.1232935.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAO SN, 1991, THROMB HAEMOSTASIS, V65, P52; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	36	41	45	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					739	743		10.1126/science.285.5428.739	http://dx.doi.org/10.1126/science.285.5428.739			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426997				2022-12-01	WOS:000081765100056
J	Marcotte, EM; Pellegrini, M; Ng, HL; Rice, DW; Yeates, TO; Eisenberg, D				Marcotte, EM; Pellegrini, M; Ng, HL; Rice, DW; Yeates, TO; Eisenberg, D			Detecting protein function and protein-protein interactions from genome sequences	SCIENCE			English	Article							ESCHERICHIA-COLI; DNA; ASSOCIATION; STABILITY; SRC	A computational method is proposed for inferring protein interactions from genome sequences on the basis of the observation that some pairs of interacting proteins have homologs in another organism fused into a single protein chain. Searching sequences from many genomes revealed 6809 such putative protein-protein interactions in Escherichia coli and 45,502 in yeast. Many members of these pairs were confirmed as functionally related; computational filtering further enriches for interactions. Some proteins have links to several other proteins; these coupled links appear to represent functional interactions such as complexes or pathways. Experimentally confirmed interacting pairs are documented in a Database of interacting Proteins.	Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Chem & Biochem, Box 951570, Los Angeles, CA 90095 USA.		Ng, Ho Leung/E-3419-2010	Ng, Ho Leung/0000-0002-6415-1938; Yeates, Todd/0000-0001-5709-9839; Marcotte, Edward/0000-0001-8808-180X; Pellegrini, Matteo/0000-0001-9355-9564; Rice, Danny/0000-0002-1123-4617	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM 31299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1994, MOL BIOL CELL 2, V3rd ed.; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; FIELDS S, 1989, NATURE, V340, P243; HORTON N, 1992, PROTEIN SCI, V1, P169; Lodish H., 1995, MOL CELL BIOL; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P5929, DOI 10.1073/pnas.95.11.5929; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; Tsai CJ, 1996, J MOL BIOL, V260, P604, DOI 10.1006/jmbi.1996.0424; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YEH WK, 1981, J BIOL CHEM, V256, P1565	21	1241	1306	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					751	753		10.1126/science.285.5428.751	http://dx.doi.org/10.1126/science.285.5428.751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427000	Green Submitted			2022-12-01	WOS:000081765100059
J	Chin, L; Tam, A; Pomerantz, J; Wong, M; Holash, J; Bardeesy, N; Shen, Q; O'Hagan, R; Pantginis, J; Zhou, H; Horner, JW; Cordon-Cardo, C; Yancopoulos, GD; DePinho, RA				Chin, L; Tam, A; Pomerantz, J; Wong, M; Holash, J; Bardeesy, N; Shen, Q; O'Hagan, R; Pantginis, J; Zhou, H; Horner, JW; Cordon-Cardo, C; Yancopoulos, GD; DePinho, RA			Essential role for oncogenic Ras in tumour maintenance	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TRANSGENIC MICE; FACTOR EXPRESSION; UP-REGULATION; ANGIOGENESIS; MELANOMA; CELLS; INDUCTION; HYPOXIA	Advanced malignancy in tumours represents the phenotypic endpoint of successive genetic lesions that affect the function and regulation of oncogenes and tumour-suppressor genes(1). The established tumour is maintained through complex and poorly understood host-tumour interactions that guide processes such as angiogenesis and immune sequestration. The many different genetic alterations that accompany tumour genesis raise questions as to whether experimental cancer-promoting mutations remain relevant during tumour maintenance. Here we show thar melanoma genesis and maintenance are strictly dependent upon expression of H-Ras(V12G) in a doxycycline-inducible H-Ras mouse melanoma model null for the tumour suppressor INK4a. Withdrawal of doxycycline and H-Ras(V12G) down-regulation resulted in clinical and histological regression of primary and explanted tumours. The initial stages of regression involved marked apoptosis in the tumour cells and host-derived endothelial cells. Although the regulation of vascular endothelial growth factor (VEGF) was found td be Ras-dependent in vitro, the failure of persistent endogenous and enforced VEGF expression to sustain tumour viability indicates that the tumour-maintaining actions of activated Ras extend beyond the regulation of VEGF expression in vivo. Our results provide genetic evidence that H-Ras(V12G) is important in both the genesis and maintenance of solid tumours.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Albert Einstein Coll Med, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Regeneron	DePinho, RA (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X				Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BIRD IN, 1993, IMMUNOLOGY, V80, P553; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DOHERTY PC, 1994, CIBA F SYMP, V187, P245; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Gause PR, 1997, MOL CARCINOGEN, V20, P78, DOI 10.1002/(SICI)1098-2744(199709)20:1<78::AID-MC9>3.0.CO;2-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Larcher F, 1996, CANCER RES, V56, P5391; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TRAWEEK ST, 1991, AM J CLIN PATHOL, V96, P25, DOI 10.1093/ajcp/96.1.25; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9	25	697	747	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					468	472		10.1038/22788	http://dx.doi.org/10.1038/22788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440378				2022-12-01	WOS:000081715000055
J	Chen, DK; McGeer, A; de Azavedo, JC; Low, DE				Chen, DK; McGeer, A; de Azavedo, JC; Low, DE		Canadian Bacterial Surveillance Network	Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PENICILLIN-RESISTANT PNEUMOCOCCI; ANTIMICROBIAL RESISTANCE; DNA GYRASE; IN-VITRO; CIPROFLOXACIN RESISTANCE; RESPIRATORY PATHOGENS; MULTIRESISTANT CLONE; TOPOISOMERASE-IV; UNITED-STATES; OTITIS-MEDIA	Background Fluoroquinolones are now recommended for the treatment of respiratory tract infections due to Streptococcus pneumoniae, particularly when the isolates are resistant to beta-lactam antibiotics. Although pneumococci with reduced susceptibility to fluoroquinolones have been identified, their prevalence has not been determined in a defined population. Methods We performed susceptibility testing on 7551 isolates of S. pneumoniae obtained from surveillance in Canada in 1988 and from 1993 to 1998. Pneumococci with reduced susceptibility to fluoroquinolones (defined as a minimal inhibitory concentration of ciprofloxacin of at least 4 mu g per milliliter) were further characterized. We also examined antibiotic prescriptions dispensed in Canadian retail pharmacies, Results Between 1988 and 1997 fluoroquinolone prescriptions increased from 0.8 to 5.5 per 100 persons per year. The prevalence of pneumococci with reduced susceptibility to fluoroquinolones increased from 0 percent in 1993 to 1.7 percent in 1997 and 1998 (P=0.01). Among adults, the prevalence increased from 1.5 percent in 1993 and 1994 combined to 2.9 percent in 1997 and 1998 combined. The prevalence was higher in isolates from older patients (2.6 percent among those 65 years of age or older vs. 1.0 percent among those 15 to 64 years of age, P<0.001) and among those from Ontario (1.5 percent, vs. 0.4 percent among those from the rest of Canada; P<0.001). Fluoroquinolone use was greatest among the elderly and in Ontario, The 75 isolates (17 serotypes) of pneumococci with reduced susceptibility to fluoroquinolones were submitted by 40 laboratories in eight provinces. Reduced susceptibility to fluoroquinolones was associated with resistance to penicillin. Conclusions The prevalence of pneumococci with reduced susceptibility to fluoroquinolones is increasing in Canada, probably as a result of selective pressure from the increased use of fluoroquinolones, (N Engl J Med 1999;341:233-9.) (C) 1999 Massachusetts Medical Society.	Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Toronto Hosp, Dept Microbiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Low, DE (corresponding author), Mt Sinai Hosp, Dept Microbiol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020; Low, Donald/B-1726-2012	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137; 				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Ballow CH, 1997, DIAGN MICR INFEC DIS, V29, P173, DOI 10.1016/S0732-8893(97)81807-X; Barry AL, 1996, J ANTIMICROB CHEMOTH, V37, P365, DOI 10.1093/jac/37.2.365; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Brook I, 1996, CLIN INFECT DIS, V22, P143, DOI 10.1093/clinids/22.1.143; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Campbell GD, 1999, CHEST, V115, p14S, DOI 10.1378/chest.115.suppl_1.14S; Chodosh S, 1998, CLIN INFECT DIS, V27, P730, DOI 10.1086/514934; Coffey TJ, 1996, MICROBIOL-UK, V142, P2747, DOI 10.1099/13500872-142-10-2747; DALHOFF A, 1998, 8 INT C INF DIS BOST, P124; Doern GV, 1998, CLIN INFECT DIS, V27, P764, DOI 10.1086/514953; Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208, DOI 10.1128/AAC.40.5.1208; DOUIDAR SM, 1989, REV INFECT DIS, V11, P878; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Fuchs PC, 1997, J ANTIMICROB CHEMOTH, V39, P671, DOI 10.1093/jac/39.5.671; Goldsmith CE, 1998, J ANTIMICROB CHEMOTH, V41, P420, DOI 10.1093/jac/41.3.420; Goldsmith CE, 1997, J ANTIMICROB CHEMOTH, V40, P11, DOI 10.1093/jac/40.suppl_1.11; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; Gruneberg RN, 1996, DIAGN MICR INFEC DIS, V25, P169, DOI 10.1016/S0732-8893(96)00135-6; Hall LMC, 1998, J CLIN PATHOL, V51, P270, DOI 10.1136/jcp.51.4.270; Hooper DC, 1998, ANN INTERN MED, V129, P908, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00015; JANOIR C, 1998, CLIN INFECT DIS   S1, V27, pS54; KAM KM, 1995, ANTIMICROB AGENTS CH, V39, P2667, DOI 10.1128/AAC.39.12.2667; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; LEE BL, 1991, NEW ENGL J MED, V325, P520; LOVGREN M, 1998, CMAJ, V158, P27; MARCHESE A, 1995, J ANTIMICROB CHEMOTH, V36, P833, DOI 10.1093/jac/36.5.833; Mittermayer H, 1996, EUR J CLIN MICROBIOL, V15, P817, DOI 10.1007/BF01701526; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; Munoz R, 1996, ANTIMICROB AGENTS CH, V40, P2252, DOI 10.1128/AAC.40.10.2252; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1991, J CLIN MICROBIOL, V29, P418; *NAT COMM CLIN LAB, 1998, M100SB NCCLS; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Rahal K, 1997, CLIN INFECT DIS, V24, pS169, DOI 10.1093/clinids/24.Supplement_1.S169; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; Richard MP, 1998, J ANTIMICROB CHEMOTH, V41, P207, DOI 10.1093/jac/41.2.207; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Setchanova L, 1995, MICROB DRUG RESIST, V1, P79, DOI 10.1089/mdr.1995.1.79; Simor AE, 1996, ANTIMICROB AGENTS CH, V40, P2190, DOI 10.1128/AAC.40.9.2190; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SREEDHARAN S, 1991, ANTIMICROB AGENTS CH, V35, P2151, DOI 10.1128/AAC.35.10.2151; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; Tankovic J, 1996, ANTIMICROB AGENTS CH, V40, P2505, DOI 10.1128/AAC.40.11.2505; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Thornsberry C, 1997, DIAGN MICR INFEC DIS, V29, P249, DOI 10.1016/S0732-8893(97)00195-8; Wang EEL, 1998, CAN FAM PHYSICIAN, V44, P1881; Wise R, 1996, LANCET, V348, P1660, DOI 10.1016/S0140-6736(05)65724-8; Wise R, 1997, J ANTIMICROB CHEMOTH, V40, P27, DOI 10.1093/jac/40.suppl_1.27; YOSHIDA R, 1995, ANTIMICROB AGENTS CH, V39, P1196, DOI 10.1128/AAC.39.5.1196; Zhao XL, 1997, P NATL ACAD SCI USA, V94, P13991, DOI 10.1073/pnas.94.25.13991	51	843	867	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					233	239		10.1056/NEJM199907223410403	http://dx.doi.org/10.1056/NEJM199907223410403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413735				2022-12-01	WOS:000081528800003
J	Cline, GW; Petersen, KF; Krssak, M; Shen, J; Hundal, RS; Trajanoski, Z; Inzucchi, S; Dresner, A; Rothman, DL; Shulman, GI				Cline, GW; Petersen, KF; Krssak, M; Shen, J; Hundal, RS; Trajanoski, Z; Inzucchi, S; Dresner, A; Rothman, DL; Shulman, GI			Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBCUTANEOUS ADIPOSE-TISSUE; SKELETAL-MUSCLE; SYNTHASE ACTIVITY; HEXOKINASE-II; BETA-CELL; NIDDM; RESISTANCE; MELLITUS; PHOSPHORYLATION; DEFICIENCY	Background Insulin resistance, a major factor in the pathogenesis of type 2 diabetes mellitus, is due mostly to decreased stimulation of glycogen synthesis in muscle by insulin. The primary rate-controlling step responsible for the decrease in muscle glycogen synthesis is not known, although hexokinase activity and glucose transport have been implicated. Methods We used a novel nuclear magnetic resonance approach with carbon-13 and phosphorus-31 to measure intramuscular glucose, glucose-6-phosphate, and glycogen concentrations under hyperglycemic conditions (plasma glucose concentration, approximately 180 mg per deciliter [10 mmol per liter]) and hyperinsulinemic conditions in six patients with type 2 diabetes and seven normal subjects. In vivo microdialysis of muscle tissue was used to determine the gradient between plasma and interstitial-fluid glucose concentrations, and open-flow microperfusion was used to determine the concentrations of insulin in interstitial fluid. Results The time course and concentration of insulin in interstitial fluid were similar in the patients with diabetes and the normal subjects. The rates of whole-body glucose metabolism and muscle glycogen synthesis and the glucose-6-phosphate concentrations in muscle were approximately 80 percent lower in the patients with diabetes than in the normal subjects under conditions of matched plasma insulin concentrations. The mean (+/-SD) intracellular glucose concentration was 2.0+/-8.2 mg per deciliter (0.11+/-0.46 mmol per liter) in the normal subjects. In the patients with diabetes, the intracellular glucose concentration was 4.3+/-4.9 mg per deciliter (0.24+/-0.27 mmol per liter), a value that was 1/25 of what it would be if hexokinase were the rate-controlling enzyme in glucose metabolism. Conclusions Impaired insulin-stimulated glucose transport is responsible for the reduced rate of insulin-stimulated muscle glycogen synthesis in patients with type 2 diabetes mellitus. (N Engl J Med 1999;341:240-6.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Internal Med, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Internal Med, POB 9812, New Haven, CT 06536 USA.		Trajanoski, Zlatko/AAT-6703-2021; Krssak, Martin/AAU-8183-2020; Shulman, Gerald I./P-7176-2019; Inzucchi, Silvio/ABF-4121-2021	Krssak, Martin/0000-0001-9717-803X; Shulman, Gerald I./0000-0003-1529-5668; 	NCRR NIH HHS [MO1 RR-00125] Funding Source: Medline; NIDDK NIH HHS [R01 DK-49230, P30 DK-45735] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK049230] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; CAHILL GF, 1988, NEW ENGL J MED, V318, P1268, DOI 10.1056/NEJM198805123181909; Cline GW, 1999, DIABETES, V48, pA273; Cline GW, 1998, AM J PHYSIOL-ENDOC M, V274, pE381, DOI 10.1152/ajpendo.1998.274.2.E381; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; HAFFNER SM, 1990, METABOLISM, V39, P842, DOI 10.1016/0026-0495(90)90130-5; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; Kelley DE, 1996, J CLIN INVEST, V97, P2705, DOI 10.1172/JCI118724; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; Moberg E, 1997, DIABETOLOGIA, V40, P1320, DOI 10.1007/s001250050827; *NAT DIS DAT GROUP, 1995, NIH PUBL; Nolan JJ, 1997, DIABETES, V46, P994, DOI 10.2337/diabetes.46.6.994; REAVEN GM, 1976, AM J MED, V60, P80, DOI 10.1016/0002-9343(76)90536-2; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Saccomani MP, 1996, AM J PHYSIOL-ENDOC M, V270, pE170, DOI 10.1152/ajpendo.1996.270.1.E170; Shen J, 1996, J MAGN RESON SER B, V112, P131, DOI 10.1006/jmrb.1996.0123; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Trajanoski Z, 1997, DIABETES CARE, V20, P1114, DOI 10.2337/diacare.20.7.1114; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WRIGHT KS, 1988, DIABETES, V37, P436, DOI 10.2337/diabetes.37.4.436; YANG YJ, 1989, J CLIN INVEST, V84, P1620, DOI 10.1172/JCI114339; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	30	464	479	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					240	246		10.1056/NEJM199907223410404	http://dx.doi.org/10.1056/NEJM199907223410404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413736				2022-12-01	WOS:000081528800004
J	Torrance, CJ; Das, R; Allison, MC				Torrance, CJ; Das, R; Allison, MC			Use of chaperones in clinics for genitourinary medicine: survey of consultants	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS		Royal Gwent Hosp, Dept Genitourinary Med, Newport NP9 2UB, Gwent, Wales; Royal Gwent Hosp, Dept Adult Med, Newport NP9 2UB, Gwent, Wales	Royal Gwent Hospital; Royal Gwent Hospital	Allison, MC (corresponding author), Royal Gwent Hosp, Dept Genitourinary Med, Newport NP9 2UB, Gwent, Wales.							JONES RH, 1983, J ROY COLL GEN PRACT, V33, P25; PENN MA, 1992, J FAM PRACTICE, V35, P639; *ROYAL COLL OBST G, 1997, INT EX REP WORK PART; SPEELMAN A, 1993, BRIT MED J, V307, P986, DOI 10.1136/bmj.307.6910.986	4	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					159	160		10.1136/bmj.319.7203.159	http://dx.doi.org/10.1136/bmj.319.7203.159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406750	Bronze, Green Published			2022-12-01	WOS:000081619300021
J	Tsuda, M; Kamimura, K; Nakato, H; Archer, M; Staatz, W; Fox, B; Humphrey, M; Olson, S; Futch, T; Kaluza, V; Siegfried, E; Stam, L; Selleck, SB				Tsuda, M; Kamimura, K; Nakato, H; Archer, M; Staatz, W; Fox, B; Humphrey, M; Olson, S; Futch, T; Kaluza, V; Siegfried, E; Stam, L; Selleck, SB			The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila	NATURE			English	Article							SEGMENT POLARITY GENES; NERVOUS-SYSTEM; EMBRYO; PROTEIN; GLYCOSAMINOGLYCANS; TRANSCRIPTION; MELANOGASTER; BIOSYNTHESIS; EXPRESSION; SECRETION	Wingless (Wg) is a member of the Wnt family of growth factors, secreted proteins that control proliferation and differentiation during development. Studies in Drosophila have shown that responses to Wg require cell-surface heparan sulphate, a glycosaminoglycan component of proteoglycans(1-4). These findings suggest that a cell-surface proteoglycan is a component of a Wg/Wnt receptor complex. We demonstrate here that the protein encoded by the division abnormally delayed (dally) gene is a cell-surface, heparan-sulphate-modified proteoglycan(5,6). dally partial loss-of-function mutations compromise Wg-directed events, and disruption of daily function with RNA interference produces phenotypes comparable to those found with RNA interference of wg or frizzled (fz)/Dfz2 (ref. 7). Ectopic expression of Daily potentiates Wg signalling without altering levels of Wg and can rescue a wg partial loss-of-function mutant, We also show that dally a regulator of Decapentaplegic (DFP) signalling during post-embryonic development, has tissue-specific effects on Wg and Dpp signalling. Daily can therefore differentially influence signalling mediated by two growth factors, and may form a regulatory component of both Wg and Dpp receptor complexes.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Div Neurobiol, Tucson, AZ 85721 USA; Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo, Japan; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Novartis Inc, Res Triangle Pk, NC 27709 USA	University of Arizona; University of Arizona; Tokyo Metropolitan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Novartis	Selleck, SB (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.			Archer, Michael/0000-0002-0304-4039				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Binari RC, 1997, DEVELOPMENT, V124, P2623; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Emerald BS, 1998, DEV GENES EVOL, V208, P504, DOI 10.1007/s004270050209; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INGHAM PW, 1985, GENETICS, V111, P463; INGHAM PW, 1993, DEVELOPMENT, V117, P283; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller HAJ, 1999, DEVELOPMENT, V126, P577; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PEIFER M, 1994, DEVELOPMENT, V120, P369; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	29	333	343	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					276	280		10.1038/22336	http://dx.doi.org/10.1038/22336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421371				2022-12-01	WOS:000081503800047
J	Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG				Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG			Lesson of the week - Managing patients with deliberate self harm who refuse treatment in the accident and emergency department	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England		Hassan, TB (corresponding author), Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England.							*BRIT ASS ACC EM M, 1996, DIR 1996; *BRIT MED ASS, 1993, RIGHTS RESP DOCT; British Medical Association, 1995, ASS MENT CAP GUID DO; HAWTON K, 1996, ATTEMPTED SUICIDE OX; *MED DEF UN, 1996, CONS TREATM; *MEN PROT SOC, 1998, CONS	6	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					107	109		10.1136/bmj.319.7202.107	http://dx.doi.org/10.1136/bmj.319.7202.107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398639	Green Published			2022-12-01	WOS:000081438200038
J	Wang, HC; Bloom, O; Zhang, MH; Vishnubhakat, JM; Ombrellino, M; Che, JT; Frazier, A; Yang, H; Ivanova, S; Borovikova, L; Manogue, KR; Faist, E; Abraham, E; Andersson, J; Andersson, U; Molina, PE; Abumrad, NN; Sama, A; Tracey, KJ				Wang, HC; Bloom, O; Zhang, MH; Vishnubhakat, JM; Ombrellino, M; Che, JT; Frazier, A; Yang, H; Ivanova, S; Borovikova, L; Manogue, KR; Faist, E; Abraham, E; Andersson, J; Andersson, U; Molina, PE; Abumrad, NN; Sama, A; Tracey, KJ			HMG-1 as a late mediator of endotoxin lethality in mice	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; GROUP-1 PROTEIN HMG1; SEPTIC SHOCK; CHROMOSOMAL-PROTEINS; RECEPTOR ANTAGONIST; DEFICIENT MICE; FACTOR-ALPHA; GENE; AMPHOTERIN; CACHECTIN	Endotoxin, a constituent of Gram-negative bacteria, stimulates macrophages to release Large quantities of tumor necrosis factor (TNF) and interleukin-1 (IL-1), which can precipitate tissue injury and lethal shock (endotoxemia). Antagonists of TNF and IL-1 have shown Limited efficacy in clinical trials, possibly because these cytokines are early mediators in pathogenesis, Here a potential Late mediator of Lethality is identified and characterized in a mouse model. High mobility group-1 (HMG-1) protein was found to be released by cultured macrophages more than 8 hours after stimulation with endotoxin, TNF, or IL-1. Mice showed increased serum Levels of HMG-1 from 8 to 32 hours after endotoxin exposure. Delayed administration of antibodies to HMG-1 attenuated endotoxin lethality in mice, and administration of HMG-1 itself was lethal. Septic patients who succumbed to infection had increased serum HMG-1 levels, suggesting that this protein warrants investigation as a therapeutic target.	NYU, Sch Med, N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA; NYU, Sch Med, N Shore Univ Hosp, Dept Surg, Manhasset, NY 11030 USA; Picower Inst Med Res, Manhasset, NY 11030 USA; Univ Munich, Klinikum Grosshadern, Dept Surg, D-8000 Munich, Germany; Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden; Karolinska Inst, Astrid Lindgrens Childrens Hosp, Dept Rheumatol, Stockholm, Sweden	New York University; Northwell Health; North Shore University Hospital; New York University; Northwell Health; North Shore University Hospital; Northwell Health; University of Munich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Karolinska Institutet; Karolinska Institutet	Wang, HC (corresponding author), NYU, Sch Med, N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA.		Wang, Haichao/AAU-2237-2021; Molina, Patricia E./AAK-9814-2021; Andersson, Ulf/ABD-5162-2021; Wang, Haichao/K-6310-2012	Wang, Haichao/0000-0002-0211-9000; Molina, Patricia E./0000-0002-3598-384X; Andersson, Ulf/0000-0003-0316-3860; Wang, Haichao/0000-0002-0211-9000; Tracey, Kevin J/0000-0003-1884-6314; BLOOM, ONA/0000-0002-8340-2392				ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BUSTIN M, 1979, CELL, V16, P181, DOI 10.1016/0092-8674(79)90199-5; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; Ferrari S, 1996, GENOMICS, V35, P367, DOI 10.1006/geno.1996.0369; FERRARI S, 1994, J BIOL CHEM, V269, P28803; FINK MP, 1995, CRIT CARE MED, V23, P989, DOI 10.1097/00003246-199506000-00001; FINK MP, 1990, J SURG RES, V49, P186, DOI 10.1016/0022-4804(90)90260-9; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; KILLION JW, 1986, INFECT IMMUN, V54, P1; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LEE KLD, 1987, NUCLEIC ACIDS RES, V15, P5051, DOI 10.1093/nar/15.13.5051; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOLDAWER LL, 1994, CRIT CARE MED, V22, pS3; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REMICK DG, 1990, AM J PATHOL, V136, P49; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; Tracey KJ, 1999, SHOCK, V11, P224, DOI 10.1097/00024382-199903000-00012; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4; Walker RE, 1996, J INFECT DIS, V174, P63, DOI 10.1093/infdis/174.1.63; WANG H, UNPUB	37	2705	3137	0	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					248	251		10.1126/science.285.5425.248	http://dx.doi.org/10.1126/science.285.5425.248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398600				2022-12-01	WOS:000081346000040
J	Wingrove, JA; O'Farrell, PH				Wingrove, JA; O'Farrell, PH			Nitric oxide contributes to behavioral, cellular, and developmental responses to low oxygen in Drosophila	CELL			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; DEPENDENT PROTEIN-KINASE; GUANYLATE-CYCLASE; RIBONUCLEOTIDE REDUCTASE; RELAXING FACTOR; GENE ENCODES; CELLS; GROWTH; MELANOGASTER; SYNTHASE	A nitric oxide (NO)/cyclic GMP (cGMP) signaling pathway is thought to play an important role in mammalian vasodilation during hypoxia. We show that Drosophila utilizes components of this pathway to respond to hypoxia. Hypoxic exposure rapidly induced exploratory behavior in larvae and arrested the cell cycle. These behavioral and cellular responses were diminished by an inhibitor of NO synthase and by a polymorphism affecting a form of cGMP-dependent protein kinase. Conversely, these responses were induced by ectopic expression of NO synthase. Perturbing components of the NO/cGMP pathway altered both tracheal development and survival during prolonged hypoxia. These results indicate that NO and protein kinase G contribute to Drosophila's ability to respond to oxygen deprivation.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Farrell, PH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM037193, R01 GM037193-10, R01 GM037193-14] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; DEBELLE JS, 1989, GENETICS, V123, P157; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1989, DEVELOPMENT, V107, P1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ishida A, 1997, J BIOL CHEM, V272, P10050; KALDERON D, 1989, J BIOL CHEM, V264, P10738; Kantrow SP, 1997, AM J PHYSIOL-LUNG C, V272, pL1167, DOI 10.1152/ajplung.1997.272.6.L1167; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Manning Gerards, 1993, P609; MEULEMANS A, 1994, NEUROSCI LETT, V171, P89, DOI 10.1016/0304-3940(94)90612-2; Millar Timothy M., 1997, Biochemical Society Transactions, V25, p528S; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Truman JW, 1996, DEVELOPMENT, V122, P3949; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whorton AR, 1997, AM J PHYSIOL-LUNG C, V272, pL1161, DOI 10.1152/ajplung.1997.272.6.L1161; Wildemann B, 1999, J NEUROBIOL, V38, P1, DOI 10.1002/(SICI)1097-4695(199901)38:1<1::AID-NEU1>3.0.CO;2-L; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; [No title captured]	45	206	222	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					105	114		10.1016/S0092-8674(00)80610-8	http://dx.doi.org/10.1016/S0092-8674(00)80610-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412985	Green Accepted, Green Submitted, Bronze			2022-12-01	WOS:000081451000012
J	Mellitzer, G; Xu, QL; Wilkinson, DG				Mellitzer, G; Xu, QL; Wilkinson, DG			Eph receptors and ephrins restrict cell intermingling and communication	NATURE			English	Article							NEURAL CREST MIGRATION; TRANSMEMBRANE LIGANDS; TYROSINE PHOSPHORYLATION; MOLECULAR-BASIS; GAP-JUNCTIONS; CHICK-EMBRYO; ADHESION; PERMEABILITY; RHOMBOMERES; ATTACHMENT	Eph proteins are receptors with tyrosine-kinase activity which, with their ephrin ligands, mediate contact-dependent cell interactions' that are implicated in the repulsion mechanisms that guide migrating cells and neuronal growth cones to specific destinations(2,3). Ephrin-B proteins have conserved cytoplasmic tyrosine residues that are phosphorylated upon interaction with an EphB receptor(4,5), and may transduce signals that regulate a cellular response(6). Because Eph receptors and ephrins have complementary expression in many tissues during embryogenesis(7), bidirectional activation of Eph receptors and ephrin-B proteins could occur at interfaces of their expression domains, for example at segment boundaries in the vertebrate hindbrain, Previous work(8,9) has implicated Eph receptors and ephrin-B proteins in the restriction of cell intermingling between hindbrain segments(10). We therefore analysed whether complementary expression of Eph receptors and ephrins restricts cell intermingling, and whether this requires bidirectional or unidirectional signalling. Here we report that bidirectional but not unidirectional signalling restricts the intermingling of adjacent cell populations, whereas unidirectional activation is sufficient to restrict cell communication through gap junctions. These results reveal that Eph receptors and ephrins regulate two aspects of cell behaviour that can stabilize a distinct identity of adjacent cell populations.	Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research	Wilkinson, DG (corresponding author), Natl Inst Med Res, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.		Georg, Mellitzer/R-4180-2016	Georg, Mellitzer/0000-0003-4467-0789; Wilkinson, David/0000-0001-6757-7080				BAGNALL KM, 1992, ANAT EMBRYOL, V186, P195; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; MARTINEZ S, 1992, DEVELOPMENT, V116, P1069; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; Wizenmann A, 1997, MOL CELL NEUROSCI, V9, P448, DOI 10.1006/mcne.1997.0642; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U	28	396	409	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					77	81		10.1038/21907	http://dx.doi.org/10.1038/21907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403252				2022-12-01	WOS:000081255700054
J	Hing, H; Xiao, J; Harden, N; Lim, L; Zipursky, SL				Hing, H; Xiao, J; Harden, N; Lim, L; Zipursky, SL			Pak functions downstream of dock to regulate photoreceptor axon guidance in Drosophila	CELL			English	Article							SH2/SH3 ADAPTER PROTEIN; GROWTH CONE GUIDANCE; KINASE PAK; ALPHA-PAK; ACTIN; GTPASES; FAMILY; CDC42; RAC; NCK	The SH2/SH3 adaptor protein Dock has been proposed to transduce signals from guidance receptors to the actin cytoskeleton in Drosophila photoreceptor (R cell) growth cones. Here, we demonstrate that Drosophila p21-activated kinase (Pak) is required in a Dock pathway regulating R cell axon guidance and targeting. Dock and Pak colocalize to R cell axons and growth cones, physically interact, and their loss-of-function phenotypes are indistinguishable. Normal patterns of R cell connectivity require Pak's kinase activity and binding sites for both Dock and Cdc42/Rac. A membrane-tethered form of Pak (Pak(myr)) acts as a dominant gain-of-function protein. Retinal expression of Pak(myr) rescues the R cell connectivity phenotype in dock mutants. These data establish Pak as a critical regulator of axon guidance and a downstream effector of Dock in vivo.	Calif State Univ Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Inst Neurol, London WC1N 1PJ, England	California State University System; California State University Los Angeles; Howard Hughes Medical Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London	Zipursky, SL (corresponding author), Calif State Univ Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	zipursky@hhmi.ucla.edu		Zipursky, Stephen/0000-0001-5630-7181				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DELATORRE JR, 1997, CELL, V19, P1211; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Garrity PA, 1999, NEURON, V22, P707, DOI 10.1016/S0896-6273(00)80730-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harden N, 1996, MOL CELL BIOL, V16, P1896; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; Salecker I, 1998, CELL, V95, P587, DOI 10.1016/S0092-8674(00)81627-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Suter DM, 1998, CURR OPIN NEUROBIOL, V8, P106, DOI 10.1016/S0959-4388(98)80014-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	36	244	249	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					853	863		10.1016/S0092-8674(00)80798-9	http://dx.doi.org/10.1016/S0092-8674(00)80798-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399914	Bronze			2022-12-01	WOS:000081162800007
J	Sandham, JD				Sandham, JD			Complications of acute anaemia: caused by low packed-cell volume or by transfusion?	LANCET			English	Editorial Material							POSTOPERATIVE DELIRIUM		Univ Calgary, Reg Div Crit Care, Calgary, AB T2N 2T9, Canada	University of Calgary	Sandham, JD (corresponding author), Univ Calgary, Reg Div Crit Care, Foothills Hosp Site, Calgary, AB T2N 2T9, Canada.							Ely EW, 1999, NEW ENGL J MED, V340, P467, DOI 10.1056/NEJM199902113400610; FREDERICK AM, 1997, ARCH SURG-CHICAGO, V132, P620; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7	6	1	1	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					883	884		10.1016/S0140-6736(99)90268-4	http://dx.doi.org/10.1016/S0140-6736(99)90268-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489944				2022-12-01	WOS:000082511800007
J	Klinke, R; Kral, A; Heid, S; Tillein, J; Hartmann, R				Klinke, R; Kral, A; Heid, S; Tillein, J; Hartmann, R			Recruitment of the auditory cortex in congenitally deaf cats by long-term cochlear electrostimulation	SCIENCE			English	Article							INTRACOCHLEAR ELECTRICAL-STIMULATION; NEURONAL RESPONSES; WHITE CAT; EVOKED-POTENTIALS; CEREBRAL-CORTEX; REPETITION RATE; BRAIN-STEM; PLASTICITY; IMPLANT; NUCLEUS	In congenitally deaf cats, the central auditory system is deprived of acoustic input because of degeneration of the organ of Corti before the onset of hearing. Primary auditory afferents survive and can be stimulated electrically. By means of an intracochlear implant and an accompanying sound processor, congenitally deaf kittens were exposed to sounds and conditioned to respond to tones. After months of exposure to meaningful stimuli, the cortical activity in chronically implanted cats produced field potentials of higher amplitudes, expanded in area, developed Long Latency responses indicative of intracortical information processing, and showed more synaptic efficacy than in naive, unstimulated deaf cats. The activity established by auditory experience resembles activity in hearing animals.	Physiol Inst 3, D-60590 Frankfurt, Germany		Klinke, R (corresponding author), Physiol Inst 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	klinke@em.uni-frankuft.de		Kral, Andrej/0000-0002-7762-4642				AITKIN L, 1990, AUDITORY CORTEX; BAKIN JS, 1990, BRAIN RES, V536, P271, DOI 10.1016/0006-8993(90)90035-A; BLAKEMORE C, 1978, HDB SENSORY PHYSL, V8, P392; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; BUSBY PA, 1993, J ACOUST SOC AM, V93, P1058, DOI 10.1121/1.405554; CHOUARD CH, 1983, ANN NY ACAD SCI, V405, P387, DOI 10.1111/j.1749-6632.1983.tb31653.x; FOX K, 1994, J NEUROSCI, V14, P7665; FREGNAC Y, 1984, PHYSIOL REV, V64, P325, DOI 10.1152/physrev.1984.64.1.325; Hardie NA, 1999, HEARING RES, V128, P147, DOI 10.1016/S0378-5955(98)00209-3; HARTMANN R, 1984, HEARING RES, V13, P47, DOI 10.1016/0378-5955(84)90094-7; Hartmann R, 1997, HEARING RES, V112, P115, DOI 10.1016/S0378-5955(97)00114-7; Heid S, 1997, HEARING RES, V110, P191, DOI 10.1016/S0378-5955(97)00074-9; Heid S, 1998, HEARING RES, V115, P101, DOI 10.1016/S0378-5955(97)00182-2; HOCHMAIR ES, 1979, INT J ARTIF ORGANS, V2, P255; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kral A, 1999, NEUROREPORT, V10, P781, DOI 10.1097/00001756-199903170-00022; Kral A, 1998, HEARING RES, V121, P11, DOI 10.1016/S0378-5955(98)00061-6; KRAUS N, 1993, HEARING RES, V65, P118, DOI 10.1016/0378-5955(93)90206-G; LARSEN SA, 1992, EXP NEUROL, V115, P151, DOI 10.1016/0014-4886(92)90240-Q; LEAKE PA, 1988, HEARING RES, V33, P11, DOI 10.1016/0378-5955(88)90018-4; Mair I W, 1973, Acta Otolaryngol Suppl, V314, P1; MITANI A, 1985, J COMP NEUROL, V235, P430, DOI 10.1002/cne.902350403; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Popelar J, 1995, HEARING RES, V92, P63, DOI 10.1016/0378-5955(95)00199-9; PRIETO JJ, 1994, J COMP NEUROL, V344, P349, DOI 10.1002/cne.903440304; RAGGIO MW, 1994, J NEUROPHYSIOL, V72, P2334, DOI 10.1152/jn.1994.72.5.2334; Rajan R, 1998, AUDIOL NEURO-OTOL, V3, P123, DOI 10.1159/000013786; Rauschecker JP, 1999, TRENDS NEUROSCI, V22, P74, DOI 10.1016/S0166-2236(98)01303-4; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; REBILLARD G, 1980, BRAIN RES, V188, P252, DOI 10.1016/0006-8993(80)90572-7; ROMAND R, 1992, DEV AUDITORY VESTIBU, V2; Ryugo DK, 1998, J COMP NEUROL, V397, P532, DOI 10.1002/(SICI)1096-9861(19980810)397:4<532::AID-CNE6>3.0.CO;2-2; Schreiner CE, 1996, J NEUROPHYSIOL, V75, P1283, DOI 10.1152/jn.1996.75.3.1283; SCHWARTZ IR, 1982, ACTA OTO-LARYNGOL, V93, P9, DOI 10.3109/00016488209130847; Shepherd RK, 1997, ACTA OTO-LARYNGOL, P28; SKUSE SDH, 1993, LANGUAGE DEV EXCEPTI, P29; SNYDER RL, 1991, HEARING RES, V56, P246, DOI 10.1016/0378-5955(91)90175-9; SNYDER RL, 1990, HEARING RES, V50, P7, DOI 10.1016/0378-5955(90)90030-S; VANDENHONERT C, 1984, HEARING RES, V14, P225, DOI 10.1016/0378-5955(84)90052-2; Weinberger NM, 1998, TRENDS COGN SCI, V2, P271, DOI 10.1016/S1364-6613(98)01200-5; WURTH N, 1999, GOTTINGEN NEUROBIO R, V27, P318	41	148	154	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1729	1733		10.1126/science.285.5434.1729	http://dx.doi.org/10.1126/science.285.5434.1729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481008				2022-12-01	WOS:000082472600034
J	Millett, S; Campbell, K; Epstein, DJ; Losos, K; Harris, E; Joyner, AL				Millett, S; Campbell, K; Epstein, DJ; Losos, K; Harris, E; Joyner, AL			A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer	NATURE			English	Article							EXPRESSION; GENE; SPECIFICATION; FOREBRAIN; BRAIN; NEUROECTODERM; INFORMATION; CEREBELLUM; INDUCTION; HINDBRAIN	The mid/hindbrain (MHB) junction can act as an organizer to direct the development of the midbrain and anterior hindbrain(1,2) In mice, Otx2 is expressed in the forebrain and midbrain and Gbx2 is expressed in the anterior hindbrain, with a shared border at the level of the MHB organizer. Here we show that, in Gbx2(-/-) mutants, the earliest phenotype is a posterior expansion of the Otx2 domain during early somite stages. Furthermore, organizer genes are expressed at the shifted Otx2 border, but not in a normal spatial relationship. To test whether Gbx2 is sufficient to position the MHB organizer, we transiently expressed Gbx2 in the caudal Otx2 domain and found that the Otx2 caudal border was indeed shifted rostrally and a normal appearing organizer formed at this new Otx2 border. Transgenic embryos then showed an expanded hindbrain and a reduced midbrain at embryonic day 9.5-10. We propose that formation of a normal MHB organizer depends on a sharp Otx2 caudal border and that Gbx2 is required to position and sharpen this border.	NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol & Physiol & Neurosci, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University; New York University	Joyner, AL (corresponding author), NYU, Sch Med, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.		Campbell, Kenneth/ABC-3570-2021					ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Acampora D, 1997, DEVELOPMENT, V124, P3639; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; ALVARADOMALLART RM, 1993, J NEUROBIOL, V24, P1341, DOI 10.1002/neu.480241007; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Hogan B., 2014, MANIPULATING MOUSE E; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Millen KJ, 1995, DEVELOPMENT, V121, P3935; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; Rhinn M, 1998, DEVELOPMENT, V125, P845; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Toresson H, 1999, DEVELOPMENT, V126, P1317; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wassef M, 1997, PERSPECT DEV NEUROBI, V5, P3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	19	236	236	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					161	164		10.1038/43664	http://dx.doi.org/10.1038/43664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490024				2022-12-01	WOS:000082458800053
J	Seto, AG; Zaug, AJ; Sobel, SG; Wolin, SL; Cech, TR				Seto, AG; Zaug, AJ; Sobel, SG; Wolin, SL; Cech, TR			Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle	NATURE			English	Article							REVERSE-TRANSCRIPTASE; YEAST; PROTEIN; RNA; BINDING; CELLS; IDENTIFICATION; COMPONENTS; SNRNA	Activation of the chromosome end-replicating enzyme telomerase can greatly extend the lifespan of normal human cells' and is associated with most human cancers(2). In all eukaryotes examined, telomerase has an RNA subunit(3), a conserved reverse transcriptase subunit(4) and additional proteins(5,6) but little is known about the assembly of these components. Here we show that the Saccharomyces cerevisiae telomerase RNA(7) has a 5'-2,2,7-trimethyl-guanosine (TMG) cap and a binding site for the Sm proteins, both hallmarks of small nuclear ribonucleoprotein particles (snRNPs) that are involved in nuclear messenger RNA splicing(8,9). Immunoprecipitation of telomerase from yeast extracts shows that Sm proteins are assembled on the RNA and that most or all of the telomerase activity is associated with the Sm-containing complex These data support a model in which telomerase RNA is transcribed by RNA polymerase II (ref. 10) and 7-methylguanosine-capped, binds the seven Sm proteins, becomes TMG-capped and picks up the other protein subunits, We conclude that the functions of snRNPs assembled by this pathway are not restricted to RNA processing, but also include chromosome telomere replication.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Yale University; Howard Hughes Medical Institute; Yale University	Cech, TR (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399	NIGMS NIH HHS [R01 GM048410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048410] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Chapon C, 1997, RNA, V3, P1337; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; ROY J, 1995, MOL CELL BIOL, V15, P445, DOI 10.1128/MCB.15.1.445; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Yu YT, 1999, RNA WORLD, P487; [No title captured]	27	230	237	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					177	180		10.1038/43694	http://dx.doi.org/10.1038/43694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490028				2022-12-01	WOS:000082458800057
J	Ban, N; Nissen, P; Hansen, J; Capel, M; Moore, PB; Steitz, TA				Ban, N; Nissen, P; Hansen, J; Capel, M; Moore, PB; Steitz, TA			Placement of protein and RNA structures into a 5 angstrom-resolution map of the 50S ribosomal subunit	NATURE			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI RIBOSOME; CRYSTAL-STRUCTURE; CROSS-LINKING; 23S RNA; EF-TU; DOMAIN; LOOP; VISUALIZATION; ARRANGEMENT	We have calculated at 5.0 Angstrom resolution an electron-density map of the large 50S ribosomal subunit from the bacterium Haloarcula marismortui by using phases derived from four heavy-atom derivatives, intercrystal density averaging and density-modification procedures. More than 300 base pairs of A-form RNA duplex have been fitted into this map, as have regions of non-A-form duplex, single-stranded segments and tetraloops. The long rods of RNA crisscrossing the subunit arise from the stacking of short, separate double helices, not all of which are A-form, and in many places proteins crosslink two or more of these rods. The polypeptide exit channel was marked by tungsten cluster compounds bound in one heavy-atom-derivatized crystal. We have determined the structure of the translation-factor-binding centre by fitting the crystal structures of the ribosomal proteins L6, L11 and L14, the sarcin-ricin loop RNA, and the RNA sequence that binds L11 into the electron density. We can position either elongation factor a or elongation factor Tu complexed with an aminoacylated transfer RNA and GTP onto the factor-binding centre in a manner that is consistent with results from biochemical and electron microscopy studies.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; United States Department of Energy (DOE); Brookhaven National Laboratory	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009; Nissen, Poul/D-5774-2014	Nissen, Poul/0000-0003-0948-6628				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dallas A, 1997, STRUCTURE, V5, P1639, DOI 10.1016/S0969-2126(97)00311-0; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; LEFFERS H, 1988, J MOL BIOL, V204, P507, DOI 10.1016/0022-2836(88)90351-8; LEFFERS H, 1987, J MOL BIOL, V195, P43, DOI 10.1016/0022-2836(87)90326-3; LILJAS A, 1990, RIBOSOME, P309; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MILLER KD, 1993, J AM HIST, V80, P319, DOI 10.2307/2079816; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Nakagawa A, 1999, EMBO J, V18, P1459, DOI 10.1093/emboj/18.6.1459; NEVSKAYA N, IN PRESS J MOL BIOL; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P52; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SKOLD SE, 1982, EUR J BIOCHEM, V127, P225, DOI 10.1111/j.1432-1033.1982.tb06859.x; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STOEFFLER G, 1986, STRUCTURE FUNCTION G, P28; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	50	341	368	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					841	847		10.1038/23641	http://dx.doi.org/10.1038/23641			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476961				2022-12-01	WOS:000082233200036
J	Yu, W; Misulovin, Z; Suh, H; Hardy, RR; Jankovic, M; Yannoutsos, N; Nussenzweig, MC				Yu, W; Misulovin, Z; Suh, H; Hardy, RR; Jankovic, M; Yannoutsos, N; Nussenzweig, MC			Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 5 ' of RAG2	SCIENCE			English	Article							V(D)J RECOMBINATION; ACTIVATING GENES; IMMUNE-SYSTEM; LIGASE-IV; IN-VIVO; MICE; PROMOTER; REPAIR; TRANSPOSITION; REARRANGEMENT	RAG1 and RAG2 are essential for V(D)J recombination and Lymphocyte development. These genes are thought to encode a transposase derived from a mobile genetic element that was inserted into the vertebrate genome 450 million years ago. The regulation of RAG1 and RAG2 was investigated in vivo with bacterial artificial chromosome (BAC) transgenes containing a fluorescent indicator. Coordinate expression of RAG1 and RAG2 in B and T cells was found to be regulated by distinct genetic elements found on the 5' side of the RAG2 gene. This observation suggests a mechanism by which asymmetrically disposed cis DNA elements could influence the expression of the primordial transposon and thereby capture RAGs for vertebrate evolution.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Howard Hughes Medical Institute; Rockefeller University; Fox Chase Cancer Center	Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.		Nussenzweig, Michel/AAE-7292-2019		NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown ST, 1997, J IMMUNOL, V158, P5071; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fuller K, 1997, MOL IMMUNOL, V34, P939, DOI 10.1016/S0161-5890(97)00000-X; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Henikoff S, 1996, BIOESSAYS, V18, P401, DOI 10.1002/bies.950180510; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kitagawa T, 1996, BLOOD, V88, P3785, DOI 10.1182/blood.V88.10.3785.bloodjournal88103785; Kurioka H, 1996, MOL IMMUNOL, V33, P1059, DOI 10.1016/S0161-5890(96)00062-4; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Lewis SM, 1997, CELL, V88, P159, DOI 10.1016/S0092-8674(00)81833-4; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1992, IMMUNOGENETICS, V35, P97, DOI 10.1007/BF00189518; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WONG Y, IN PRESS NATURE; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; YUESHENG L, 1996, IMMUNITY, V5, P527; ZARRIN AA, 1997, J IMMUNOL, V159, P4381; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	38	116	118	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1080	1084		10.1126/science.285.5430.1080	http://dx.doi.org/10.1126/science.285.5430.1080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446057				2022-12-01	WOS:000082033100050
J	Li, X; Zhang, YL; Clarke, JD; Li, Y; Dong, XN				Li, X; Zhang, YL; Clarke, JD; Li, Y; Dong, XN			Identification and cloning of a negative regulator of systemic acquired resistance, SNlI1, through a screen for suppressors of npr1-1	CELL			English	Article							TOBACCO MOSAIC-VIRUS; SALICYLIC-ACID; RETINOBLASTOMA PROTEIN; DISEASE RESISTANCE; GENE-EXPRESSION; KAPPA-B; ARABIDOPSIS; MUTANT; SIGNAL; TRANSCRIPTION	Systemic acquired resistance (SAR) is a plant immune response induced after a local infection by necrotizing pathogens. The Arabidopsis NPR1 gene is a positive regulator of SAR, essential for transducing the SAR signal salicylic acid (SA). Mutations in the NPR1 gene abolish the SA-induced expression of pathogenesis-related (PR) genes and resistance to pathogens. To identify additional regulators of SAR, we screened for suppressors of npr1-1. In the npr1-1 background, the sni1 (suppressor of npr1-1, inducible 1) mutant shows near wild-type levels of PR1 expression and resistance to pathogens after induction. Restoration of SAR in npr1-1 by the recessive sni1 mutation indicates that wild-type SNI1 may function as a negative regulator of SAR. We cloned the SNI1 gene and found that it encodes a leucine-rich nuclear protein.	Duke Univ, Dept Bot, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA	Duke University	Dong, XN (corresponding author), Duke Univ, Dept Bot, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA.	xdong@duke.edu						BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dellaporta S.L., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; FUNG YKT, 1993, ONCOGENE, V8, P2659; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Glazebrook J, 1996, GENETICS, V143, P973; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEFFERSON RA, 1987, EMBO J, V6, P3901; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NEVINS JR, 1992, SCIENCE, V258, P424; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; RASKIN I, 1989, P NATL ACAD SCI USA, V86, P2214, DOI 10.1073/pnas.86.7.2214; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shah J, 1997, MOL PLANT MICROBE IN, V10, P69, DOI 10.1094/MPMI.1997.10.1.69; Sokal R.R., 1981, BIOMETRY; Stacey MG, 1999, PLANT CELL, V11, P349, DOI 10.1105/tpc.11.3.349; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523	46	190	206	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					329	339		10.1016/S0092-8674(00)81962-5	http://dx.doi.org/10.1016/S0092-8674(00)81962-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458608	Bronze			2022-12-01	WOS:000081950300008
J	de Walle, HEK; van der Pal, KM; de Jong-van den Berg, LTW; Jeeninga, W; Schouten, JSAG; de Rover, CM; Buitendijk, SE; Cornel, MC				de Walle, HEK; van der Pal, KM; de Jong-van den Berg, LTW; Jeeninga, W; Schouten, JSAG; de Rover, CM; Buitendijk, SE; Cornel, MC			Effect of mass media campaign to reduce socioeconomic differences in women's awareness and behaviour concerning use of folic acid: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Netherlands Org Appl Sci Res TNO Prevent & Hlth, NL-2301 CE Leiden, Netherlands; Groningen Inst Drug Studies, NL-9713 AW Groningen, Netherlands; Midden Brabent, Gemeenschappelylie Gezondheids dienst, NL-5003 DA Tilburg, Netherlands; GGD Reg Achterhock, NL-7005 AZ Doetinchem, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; University of Groningen	Cornel, MC (corresponding author), Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands.		Cornel, Martina/AAE-8955-2020; Schouten, Johannes S.A.G./M-9376-2016	Cornel, Martina/0000-0002-5397-5544; Schouten, Johannes S.A.G./0000-0001-6495-7758				de Jong-van den Berg LTW, 1998, EUR J CLIN PHARMACOL, V54, P329, DOI 10.1007/s002280050468; GEERTS A, 1995, VOEDINGSMAGAZINE, V8, P3	2	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					291	292		10.1136/bmj.319.7205.291	http://dx.doi.org/10.1136/bmj.319.7205.291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426740	Green Published, Bronze			2022-12-01	WOS:000081909100024
J	Lloyd, SA; Whitby, FG; Blair, DF; Hill, CP				Lloyd, SA; Whitby, FG; Blair, DF; Hill, CP			Structure of the C-terminal domain of FliG, a component of the rotor in the bacterial flagellar motor	NATURE			English	Article							SALMONELLA-TYPHIMURIUM; TORQUE GENERATION; ESCHERICHIA-COLI; PROTEIN FLIG; BASAL-BODY; COMPLEX; SWITCH; MUTATIONS; ROTATION; RESIDUES	Many motile species of bacteria are propelled by flagella, which are rigid helical filaments turned by rotary motors in the cell membrane(1-3). The motors are powered by the transmembrane gradient of protons or sodium ions. Although bacterial flagella contain many proteins, only three-MotA, MotB and FliG-participate closely in torque generation. MotA, and MotB are ion-conducting membrane proteins that: form the stator of the motor. FliG is a component of the rotor, present in about 25 copies per flagellum. It is composed of an amino-terminal domain that functions in flagellar assembly and a carboxy-terminal domain (FliG-C) that functions specifically in motor rotation. Here we report the crystal structure of FliG-C from the hyperthermophilic eubacterium Thermotoga maritima, Charged residues that are important for function, and which interact with the stator protein MotA(4,5), duster along a prominent ridge on FliG-C. On the basic; of the disposition of these residues, we present a hypothesis for the orientation of FliG-C domains in the flagellar motor, and propose a structural model for the part of the rotor that interacts with the stator.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Blair, DF (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.							BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Braun TF, 1999, J BACTERIOL, V181, P3542, DOI 10.1128/JB.181.11.3542-3551.1999; BRUNGER AT, 1996, XPLOR VERSION 3 843; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FRANCIS NR, 1992, P NATL ACAD SCI USA, V89, P6304, DOI 10.1073/pnas.89.14.6304; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Garza AG, 1996, J MOL BIOL, V258, P270, DOI 10.1006/jmbi.1996.0249; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; JONES CJ, 1990, J MOL BIOL, V212, P377, DOI 10.1016/0022-2836(90)90132-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lloyd SA, 1997, J MOL BIOL, V266, P733, DOI 10.1006/jmbi.1996.0836; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Marykwas DL, 1996, J BACTERIOL, V178, P1289, DOI 10.1128/jb.178.5.1289-1294.1996; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452; Zhou JD, 1997, J MOL BIOL, V273, P428, DOI 10.1006/jmbi.1997.1316; Zhou JD, 1998, P NATL ACAD SCI USA, V95, P6436, DOI 10.1073/pnas.95.11.6436	30	96	97	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					472	475		10.1038/22794	http://dx.doi.org/10.1038/22794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440379				2022-12-01	WOS:000081715000056
J	Price, CSC; Dyer, KA; Coyne, JA				Price, CSC; Dyer, KA; Coyne, JA			Sperm competition between Drosophila males involves both displacement and incapacitation	NATURE			English	Article							FEMALE RECEPTIVITY; MELANOGASTER; EVOLUTION	Females in almost all animal groups copulate with multiple males(1,2). This behaviour allows different males to compete for fertilization(3) and gives females the opportunity to mediate this competition(4). In many animals and most insects, the second male to copulate with a female typically sires most of her offspring(1,5,6). In Drosophila melanogaster, this second-male sperm precedence has long been studied(7-15) but, as in most species, its mechanism has remained unknown. Here we show, using labelled sperm in doubly mated females, that males can both physically displace and incapacitate stored sperm from earlier-mating males. Displacement occurs only if the second male transfers sperm to the female, and in only one of her three sperm-storage organs. Incapacitation can be caused by either fertile or spermless second males, but requires extended intervals between matings. Sperm from different males are not 'stratified' in the storage organs but mix freely. Many animal species may have multiple mechanisms of sperm competition like those observed here, and revealing these mechanisms is necessary to understand the genetic and evolutionary basis of second-male sperm precedence in animals.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Coyne, JA (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	j-coyne@uchicago.edu						[Anonymous], 1998, SPERM COMPETITION SE; [Anonymous], [No title captured]; Birkhead TR., 1992, SPERM COMPETITION BI; Clark AG, 1998, GENETICS, V149, P1487; Clark AG, 1999, SCIENCE, V283, P217, DOI 10.1126/science.283.5399.217; COYNE JA, 1991, GENETICS, V129, P791; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; GILCHRIST AS, 1995, J INSECT PHYSIOL, V41, P1087, DOI 10.1016/0022-1910(95)00068-6; Gromko M.H., 1984, P371; GROMKO MH, 1993, ANIM BEHAV, V45, P253, DOI 10.1006/anbe.1993.1031; GROMKO MH, 1984, EVOLUTION, V38, P1273, DOI 10.1111/j.1558-5646.1984.tb05649.x; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; Imhof M, 1998, MOL ECOL, V7, P915, DOI 10.1046/j.1365-294x.1998.00382.x; INGMANBAKER J, 1980, BIOCHEM GENET, V18, P809, DOI 10.1007/BF00484595; Kaufmann P, 1942, AM NAT, V76, P445, DOI 10.1086/281068; KIEFER BI, 1966, GENETICS, V54, P1441; LEFEVRE G, 1962, GENETICS, V42, P1719; Lobashov ME, 1939, CR ACAD SCI URSS, V23, P827; NCHTSHEIM H, 1927, Z IND ABST VEREB S, V2, P1143; NEWPORT MEA, 1984, EVOLUTION, V38, P1261, DOI 10.1111/j.1558-5646.1984.tb05648.x; Nonidez JF, 1920, BIOL BULL-US, V39, P207, DOI 10.2307/1536488; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; Price CSC, 1997, NATURE, V388, P663, DOI 10.1038/41753; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Santel A, 1997, MECH DEVELOP, V64, P19, DOI 10.1016/S0925-4773(97)00031-2; SCOTT D, 1990, J INSECT PHYSIOL, V36, P451, DOI 10.1016/0022-1910(90)90063-L; SCOTT D, 1993, J INSECT PHYSIOL, V39, P201, DOI 10.1016/0022-1910(93)90089-A; Simmons L.W., 1998, P341, DOI 10.1016/B978-012100543-6/50035-0; Snedecor GW, 1967, STAT METHODS; Sokal R., 2000, BIOMETRY, V3rd ed., P451	30	135	140	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					449	452		10.1038/22755	http://dx.doi.org/10.1038/22755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440373				2022-12-01	WOS:000081715000050
J	Koshiya, N; Smith, JC				Koshiya, N; Smith, JC			Neuronal pacemaker for breathing visualized in vitro	NATURE			English	Article							RESPIRATORY RHYTHM GENERATION; PRE-BOTZINGER COMPLEX; SPINAL-CORD; MEDULLARY SLICES; MAMMALIAN BRAIN; MECHANISMS; CIRCUITRY; NETWORK; MOTOR; RAT	Breathing movements in mammals arise from a rhythmic pattern of neural activity, thought to originate in the pre-Botzinger complex(1) in the lower brainstem. The mechanisms generating the neural rhythm in this region are unknown(2-5). The central question is whether the rhythm is generated by a network of bursting pacemaker neurons coupled by excitatory synapses that synchronize pacemaker activity. Here we visualized the activity of inspiratory pacemaker neurons at single-cell and population levels with calcium-sensitive dye. We developed methods to label these neurons retrogradely with the dye in neonatal rodent brainstem slices that retain the rhythmically active respiratory network We simultaneously used infrared structural imaging to allow patch-damp recording from the identified neurons, After we pharmacologically blocked glutamatergic synaptic transmission, a subpopulation of inspiratory neurons continued to burst rhythmically but asynchronously. The intrinsic bursting frequency of these pacemaker neurons depended on the baseline membrane potential, providing a cellular mechanism for respiratory frequency control. These results provide evidence that the neuronal kernel for rhythm generation consists of a network of synaptically-coupled pacemaker neurons.	NINDS, Cellular & Syst Neurobiol Sect, Neural Control Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Koshiya, N (corresponding author), NINDS, Cellular & Syst Neurobiol Sect, Neural Control Lab, NIH, Bethesda, MD 20892 USA.	koshiya@nih.gov	Koshiya, Naohiro/ABA-8628-2020	Koshiya, Naohiro/0000-0002-2952-8779				BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Butera RJ, 1999, J NEUROPHYSIOL, V82, P398, DOI 10.1152/jn.1999.82.1.398; Butera RJ, 1999, J NEUROPHYSIOL, V82, P382, DOI 10.1152/jn.1999.82.1.382; DODT HU, 1994, TRENDS NEUROSCI, V17, P453, DOI 10.1016/0166-2236(94)90130-9; FETCHO JR, 1995, J NEUROPHYSIOL, V73, P399, DOI 10.1152/jn.1995.73.1.399; FOSKETT JK, 1988, AM J PHYSIOL       S, pC566; FRIEDLANDER ML, 1992, INT J GYNECOL CANCER, V2, P2; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497, DOI 10.1152/jn.1993.70.4.1497; Inou? S., 1997, VIDEO MICROSCOPY FUN; JOHNSON SM, 1994, J NEUROPHYSIOL, V72, P2598, DOI 10.1152/jn.1994.72.6.2598; Koshiya N, 1996, J PHYSIOL-LONDON, V491, P859, DOI 10.1113/jphysiol.1996.sp021263; Koshiya N., 1997, Society for Neuroscience Abstracts, V23, P1252; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; ODONOVAN M, 1994, J NEUROSCI, V14, P6354; Ramirez JM, 1996, CURR OPIN NEUROBIOL, V6, P817, DOI 10.1016/S0959-4388(96)80033-X; Ramirez JM, 1998, J PHYSIOL-LONDON, V507, P895, DOI 10.1111/j.1469-7793.1998.895bs.x; Ramirez JM, 1996, J PHYSIOL-LONDON, V491, P799, DOI 10.1113/jphysiol.1996.sp021258; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Richter D W, 1992, Curr Opin Neurobiol, V2, P788, DOI 10.1016/0959-4388(92)90135-8; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; SCHWARZACHER SW, 1995, J NEUROPHYSIOL, V73, P1452, DOI 10.1152/jn.1995.73.4.1452; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; SMITH JC, 1995, LUNG BIOL HEALTH DIS, V82, P463; SMITH JC, 1997, NEURONS NETWORKS MOT, P97; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; WILSON CG, 1998, SOC NEUR ABSTR, V23, P875	30	352	357	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					360	363		10.1038/22540	http://dx.doi.org/10.1038/22540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432113				2022-12-01	WOS:000081590000049
J	Valmadrid, CT; Klein, R; Moss, SE; Klein, BEK; Cruickshanks, KJ				Valmadrid, CT; Klein, R; Moss, SE; Klein, BEK; Cruickshanks, KJ			Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; US MALE PHYSICIANS; MYOCARDIAL-INFARCTION; INSULIN SENSITIVITY; 4-YEAR INCIDENCE; SHAPED CURVE; BRITISH MEN; CONSUMPTION; WISCONSIN; RETINOPATHY	Context Despite nutrition information and guidelines that advise against depriving diabetic patients of the potential benefit of moderate alcohol intake against cardiovascular events, the association between alcohol consumption and risk of cardiovascular outcomes in diabetic individuals has not been determined. Objective To examine the relationship between alcohol intake and coronary heart disease (CHD) mortality in persons with older-onset diabetes. Design Population-based, prospective cohort study conducted from 1984 through 1996, with a follow-up of up to 12.3 years. Setting and Participants A total of 983 older-onset diabetic individuals (mean [SD] age, 68.6 [11.0] years; 45.2% male; 98.5% white) were interviewed about their past-year intake of alcoholic beverages during the 1984-1986 follow-up examination of a population-based study of diabetic persons in southern Wisconsin. Main Outcome Measure Time to mortality from CHD by category alcohol intake. Results Alcohol use was inversely associated with risk of CHD mortality in older-onset diabetic subjects. The CHD mortality rates for never and former drinkers were 43.9 and 38.5 per 1000 person-years, respectively, while the rates for those with alcohol intakes of less than 2, 2 to 13, and 14 or more g/d were 25.3, 20.8, and 10.0 per 1000 person-years, respectively. Compared with never drinkers and controlling for age, sex, cigarette smoking, glycosylated hemoglobin level, insulin use, plasma C-peptide level, history of angina or myocardial infarction, digoxin use, and the presence and severity of diabetic retinopathy, former drinkers had a relative risk (RR) of 0.69 (95% confidence interval [CI], 0.43-1.12); for those who drank less than 2 g/d (less frequent than 1 drink a week), the RR was 0.54 (95% CI, 0.33-0.90); for 2 to 13 g/d, it was 0.44 (95% CI, 0.23-0.84); and for 14 or more g/d (about 1 drink or more a day), it was 0.21 (95% CI, 0.09-0.48). Further adjustments for blood pressure, body mass index, education, physical activity, diabetes duration, hypertension history, overt nephropathy, peripheral neuropathy, lipid measures, or intake of medications such as aspirin and antihypertensive agents did not change the associations observed. Conclusion Our results suggest an overall beneficial effect of alcohol consumption in decreasing the risk of death due to CHD in people with older-onset diabetes.	Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Klein, R (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,WARF 460, Madison, WI 53705 USA.	kleinr@epi.ophth.wisc.edu			NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059259] Funding Source: NIH RePORTER; NEI NIH HHS [EY03083] Funding Source: Medline; NHLBI NIH HHS [HL59259] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; *AM DIAB ASS, 1998, MED MAN TYP 2 DIAB, P48; Amer Diabet Assoc, 1999, DIABETES CARE, V22, pS42; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; [Anonymous], 1991, Ophthalmology, V98, P823; [Anonymous], 1991, Ophthalmology, V98, P786; Bell DSH, 1996, DIABETES CARE, V19, P509, DOI 10.2337/diacare.19.5.509; Camargo CA, 1997, ANN INTERN MED, V126, P372, DOI 10.7326/0003-4819-126-5-199703010-00005; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1984, ANAL SURVIVAL DATA; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FABER OK, 1978, DIABETES, V27, P170, DOI 10.2337/diab.27.1.S170; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GEISS LS, 1995, DIABETES AM, P233; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; Hein HO, 1996, BRIT MED J, V312, P736, DOI 10.1136/bmj.312.7033.736; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HULLEY SB, 1981, CIRCULATION, V64, P57; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; Kiechl S, 1996, BRIT MED J, V313, P1040; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; Kitamura A, 1998, AM J EPIDEMIOL, V147, P59; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, AM J EPIDEMIOL, V119, P54, DOI 10.1093/oxfordjournals.aje.a113725; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; Malin H, 1983, DHHS PUBLICATION PHS, P490; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MOSS SE, 1988, J CLIN EPIDEMIOL, V41, P645, DOI 10.1016/0895-4356(88)90116-3; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RUBIN R, 1994, ALCOHOL CLIN EXP RES, V18, P105, DOI 10.1111/j.1530-0277.1994.tb00888.x; SHAPER AG, 1988, LANCET, V2, P1267; The hypertension detection and follow-up program. Hypertension detetection and follow-up program cooperative group, 1976, PREV MED, V5, P207; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; *USDA, 1995, NUTR YOUR HLTH DIET, P40; Wannamethee SG, 1997, INT J EPIDEMIOL, V26, P523, DOI 10.1093/ije/26.3.523; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WIEBE DA, 1984, CLIN CHEM, V30, P352; World Health Organization, 1977, INT CLASS DIS	55	117	117	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					239	246		10.1001/jama.282.3.239	http://dx.doi.org/10.1001/jama.282.3.239			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422992	Bronze			2022-12-01	WOS:000081504400029
J	Lin, XH; Perrimon, N				Lin, XH; Perrimon, N			Daily cooperates with Drosophila Frizzled 2 to transduce Wingless signalling	NATURE			English	Article							LONG-RANGE ACTION; EXPRESSION; GENE; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; MORPHOGEN; POLARITY	The Drosophila wingless gene (wg) encodes a protein of the Wnt family and is a critical regulator in many developmental processes(1). Biochemical studies have indicated that heparan sulphate proteoglycans, consisting of a protein core to which heparan sulphate glycosaminoglycans are attached(2), are important for Wg function(3). Here we show that, consistent with these findings, the Drosophila gene sulfateless (sfl), which encodes a homologue of vertebrate heparan sulphate N-deacetylase/N-sulphotransferase (an enzyme needed for the modification of heparan sulphate) is essential for Wg signalling. We have identified the product of division abnormally delayed (dally), a glycosyl-phosphatidyl inositol (GPI)-linked glypican, as a heparan sulphate proteoglycan molecule involved in Wg signalling, Our results indicate that Daily may act as a co-receptor for Wg, and that Daily, together with Drosophila Frizzled 2, modulates both short- and long-range activities of Wg.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CADIGAN KM, 1998, DEVELOPMENT, V125, P3075; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HAECKER U, 1997, DEVELOPMENT, V124, P3565; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PERRIMON N, 1996, GENETICS, V144, P168; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhang J, 1998, DEVELOPMENT, V125, P3075	20	396	401	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					281	284		10.1038/22343	http://dx.doi.org/10.1038/22343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421372				2022-12-01	WOS:000081503800048
J	Cheasty, T; Said, B; Threlfall, EJ				Cheasty, T; Said, B; Threlfall, EJ			V cholerae non-01: Implications for man?	LANCET			English	Editorial Material							VIBRIO-CHOLERAE; EPIDEMIOLOGY; HEMOLYSINS		PHLS Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England		Threlfall, EJ (corresponding author), PHLS Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England.							ALDOVA E, 1968, J INFECT DIS, V118, P25, DOI 10.1093/infdis/118.1.25; ARITA M, 1986, INFECT IMMUN, V52, P45, DOI 10.1128/IAI.52.1.45-49.1986; BOOTH BA, 1986, J INFECT DIS, V154, P183, DOI 10.1093/infdis/154.1.183; DAKIN WPH, 1974, MED J AUSTRALIA, V2, P487, DOI 10.5694/j.1326-5377.1974.tb70935.x; DATTAROY K, 1986, APPL ENVIRON MICROB, V52, P875, DOI 10.1128/AEM.52.4.875-879.1986; KAMAL AM, 1971, J EGYPT PUBLIC HLTH, V46, P125; KAPER JB, 1986, J CLIN MICROBIOL, V23, P652, DOI 10.1128/JCM.23.3.652-654.1986; MORRIS JG, 1990, EPIDEMIOL REV, V12, P179, DOI 10.1093/oxfordjournals.epirev.a036052; MORRIS JG, 1990, J CLIN INVEST, V85, P679; RHODES JB, 1985, J CLIN MICROBIOL, V22, P572, DOI 10.1128/JCM.22.4.572-575.1985; ROBERTS D, 1979, J HYG-CAMBRIDGE, V82, P123, DOI 10.1017/S0022172400025547; SANYAL SC, 1974, J INFECT DIS, V130, P575, DOI 10.1093/infdis/130.6.575; SHIMADA T, 1993, LANCET, V341, P1347; Visser IJR, 1999, VET REC, V144, P451, DOI 10.1136/vr.144.16.451; YAMAMOTO K, 1986, INFECT IMMUN, V51, P927, DOI 10.1128/IAI.51.3.927-931.1986	15	11	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					89	90		10.1016/S0140-6736(99)00151-8	http://dx.doi.org/10.1016/S0140-6736(99)00151-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408479				2022-12-01	WOS:000081377100005
J	Weng, J; Mata, NL; Azarian, SM; Tzekov, RT; Birch, DG; Travis, GH				Weng, J; Mata, NL; Azarian, SM; Tzekov, RT; Birch, DG; Travis, GH			Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; ROD DARK-ADAPTATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; GENE ABCR; RETINITIS-PIGMENTOSA; FUNDUS FLAVIMACULATUS; MACULAR DEGENERATION; FATTY-ACIDS; LIGHT ADAPTATION; OUTER SEGMENTS	Rim protein (RmP) is an ABC transporter of unknown function in rod outer segment discs. The human gene for RmP (ABCR) is affected in several recessive retinal degenerations. Here, we characterize the ocular phenotype in abcr knockout mice. Mice lacking RmP show delayed dark adaptation, increased all-trans-retinaldehyde (all-trans-RAL) following light exposure, elevated phosphatidylethanolamine (PE) in outer segments, accumulation of the protonated Schiff base complex of all-trans-RAL and PE (N-retinylidene-PE), and striking deposition of a major lipofuscin fluorophore (A2-E) in retinal pigment epithelium (RPE). These data suggest that RmP functions as an outwardly directed flippase for N-retinylidene-PE. Delayed dark adaptation is likely due to accumulation in discs of the noncovalent complex between opsin and all-trans-RAL. Finally, ABCR-mediated retinal degeneration may result from "poisoning" of the RPE due to A2-E accumulation, with secondary photoreceptor degeneration due to loss of the RPE support role.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Retina Fdn SW, Dallas, TX 75231 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Retina Foundation of the Southwest	Travis, GH (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	travis@utsw.swmed.edu	Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Birch, David/0000-0002-6594-2897; Tzekov, Radouil/0000-0002-3662-9818				ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1998, HUM GENET, V102, P699, DOI 10.1007/s004390050765; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BERGSMA DR, 1977, NATURE, V265, P66, DOI 10.1038/265066a0; Birch DG, 1995, DEGENERATIVE DISEASES OF THE RETINA, P359; BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN HM, 1992, J CHROMATOGR-BIOMED, V578, P124, DOI 10.1016/0378-4347(92)80234-H; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DAEMEN FJM, 1969, NATURE, V222, P879, DOI 10.1038/222879a0; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAEY JJ, 1995, RETINA-J RET VIT DIS, V15, P399, DOI 10.1097/00006982-199515050-00005; Dogra S, 1999, YEAST, V15, P111, DOI 10.1002/(SICI)1097-0061(19990130)15:2&lt;111::AID-YEA350&gt;3.0.CO;2-E; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416; FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957; FISHMAN GA, 1994, AM J OPHTHALMOL, V118, P362, DOI 10.1016/S0002-9394(14)72961-7; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GRANIT R, 1947, SENSORY MECHANISM RE; GROENENDIJK GWT, 1984, VISION RES, V24, P1623, DOI 10.1016/0042-6989(84)90320-1; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; HOOD DC, 1993, VISUAL NEUROSCI, V10, P857, DOI 10.1017/S0952523800006076; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JIN J, 1994, VISUAL NEUROSCI, V11, P389, DOI 10.1017/S0952523800001735; JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769; Kedzierski W, 1999, J NEUROCHEM, V72, P430, DOI 10.1046/j.1471-4159.1999.0720430.x; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N; KOLB H, 1974, INVEST OPHTH VISUAL, V13, P487; Lee BL, 1999, RETINA VITREOUS MACU, P978; Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Pepperberg DR, 1997, VISUAL NEUROSCI, V14, P73, DOI 10.1017/S0952523800008774; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953; STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; SUZUKI T, 1986, VISION RES, V26, P425, DOI 10.1016/0042-6989(86)90185-9; TAMURA T, 1989, SCIENCE, V245, P755, DOI 10.1126/science.2772634; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	68	677	710	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					13	23		10.1016/S0092-8674(00)80602-9	http://dx.doi.org/10.1016/S0092-8674(00)80602-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412977	Bronze			2022-12-01	WOS:000081451000004
J	Salmon, DA; Haber, M; Gangarosa, EJ; Phillips, L; Smith, NJ; Chen, RT				Salmon, DA; Haber, M; Gangarosa, EJ; Phillips, L; Smith, NJ; Chen, RT			Health consequences of religious and philosophical exemptions from immunization laws - Individual and societal risk of measles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION; OUTBREAK	Context All US states require proof of immunization for school entry. Exemptions are generally offered for medical, religious, or philosophical reasons, but the health consequences of claiming such exemptions are poorly documented. Objectives To quantify the risk of contracting measles among individuals claiming religious and/or philosophical exemptions from immunization (exemptors) compared with vaccinated persons, and to examine the risk that exemptors pose to the nonexempt population. Design, Setting, and Participants Population-based, retrospective cohort study of data from 1985 through 1992, collected by the Measles Surveillance System of the Centers for Disease Control and Prevention, as well as from annual state immunization program reports on prevalence of exemptors and vaccination coverage. The study group was restricted to individuals aged 5 to 19 years. To empirically determine and quantify community risk, a mathematical model was developed that examines the spread of measles through communities with varying proportions of exemptors and vaccinated children. Main Outcome Measures Relative risk of contracting measles for exemptors vs vaccinated individuals based on cohort study data. Community risk of contracting measles derived from a mathematical model. Results On average, exemptors were 35 times more likely to contract measles than were vaccinated persons (95% confidence interval, 34-37), Relative risk varied by age and year. Comparing the incidence among exemptors with that among vaccinated children and adolescents during the years 1985-1992 indicated that the 1989-1991 measles resurgence may have occurred 1 year earlier among exemptors. Mapping of exemptors by county in California indicated that exempt populations tended to be clustered in certain geographic regions. Depending on assumptions of the model about the degree of mixing between exemptors and nonexemptors, an increase or decrease in the number of exemptors would affect the incidence of measles in nonexempt populations. If the number of exemptors doubled, the incidence of measles infection in nonexempt individuals would increase by 5.5%, 18.6%, and 30.8%, respectively, for intergroup mixing ratios of 20%, 40%, and 60%. Conclusions These data suggest the need for systematic review of vaccine-preventable incidents to examine the effect of exemptors, increased surveillance of the number of exemptors and cases among them, and research to determine the reasons why individuals claim exemptions.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Calif Dept Human Serv, Immunizat Branch, Berkeley, CA USA	Centers for Disease Control & Prevention - USA; Emory University; Rollins School Public Health	Salmon, DA (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Room 580,624 N Broadway, Baltimore, MD 21205 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367; salmon, daniel/0000-0002-1035-4422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032042] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI32042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINSON W, 1995, EPIDEMIOLOGY PREVENT; CDC, 1991, MMWR 40, P369; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P414; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, pR3; *CDCP, 1996, STAT IMM REQ 1994 95; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P766; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; ETKIND P, 1992, AM J DIS CHILD, V146, P173, DOI 10.1001/archpedi.1992.02160140039017; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; HABER M, 1991, INT J EPIDEMIOL, V20, P300, DOI 10.1093/ije/20.1.300; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HERSHEY JC, 1994, ORGAN BEHAV HUM DEC, V59, P177, DOI 10.1006/obhd.1994.1055; JACKSON CL, 1969, PUBLIC HEALTH REP, V84, P787, DOI 10.2307/4593678; MELLINGER AK, 1995, PEDIATR INFECT DIS J, V14, P573, DOI 10.1097/00006454-199507000-00004; *NAT HEART LUNG BL, 1998, NIH PUBL, P1; *NAT VAC ADV COMM, 1991, MEASL EP PROBL BARR; NOVOTNY T, 1988, PUBLIC HEALTH REP, V103, P49; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; Plotkin Stanley A., 1994, VACCINES; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; SUTTER RW, 1991, J INFECT DIS, V163, P12, DOI 10.1093/infdis/163.1.12; WHITE FM, 1979, MMWR-MORBID MORTAL W, V28, P345	24	195	197	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					47	53		10.1001/jama.282.1.47	http://dx.doi.org/10.1001/jama.282.1.47			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212BE	10404911				2022-12-01	WOS:000081195800028
J	Bashaw, GJ; Goodman, CS				Bashaw, GJ; Goodman, CS			Chimeric axon guidance receptors: The cytoplasmic domains of slit and netrin receptors specify attraction versus repulsion	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; GENETIC-ANALYSIS; CNS MIDLINE; COLORECTAL-CANCER; SEMAPHORIN-III; MOTOR AXONS; DROSOPHILA; PROTEIN; COMPLEMENTARY	Frazzled (Fra) is the DCC-like Netrin receptor in Drosophila that mediates attraction; Roundabout (Robo) is a Slit receptor that mediates repulsion. Both ligands are expressed at the midline; both receptors have related structures and are often expressed by the same neurons. To determine if attraction versus repulsion is a modular function encoded in the cytoplasmic domain of these receptors, we created chimeras carrying the ectodomain of one receptor and the cytoplasmic domain of the other and tested their function in transgenic Drosophila. Fra-Robo (Fra's ectodomain and Robe's cytoplasmic domain) functions as a repulsive Netrin receptor; neurons expressing Fra-Robo avoid the Netrin-expressing midline and muscles. Robo-Fra (Robo's ectodomain and Fra's cytoplasmic domain) is an attractive Slit receptor; neurons and muscle precursors expressing Robo-Fra are attracted to the Slit-expressing midline.	Univ Calif Berkeley, Dept Cell & Mol Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, CS (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagnard D, 1998, DEVELOPMENT, V125, P5043; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wong JTW, 1997, DEVELOPMENT, V124, P3597	37	161	171	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					917	926		10.1016/S0092-8674(00)80803-X	http://dx.doi.org/10.1016/S0092-8674(00)80803-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399919	Bronze			2022-12-01	WOS:000081162800012
J	Mackenbach, JP; Kunst, AE				Mackenbach, JP; Kunst, AE			Heterogeneity of populations should be taken into account - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Mackenbach, JP (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Kunst, Anton/0000-0002-3313-5273				Cavelaars A E, 1997, J Health Psychol, V2, P353, DOI 10.1177/135910539700200306; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kunst AE, 1999, AM J PUBLIC HEALTH, V89, P47, DOI 10.2105/AJPH.89.1.47; MANCIA G, 1988, AM HEART J, V115, P240, DOI 10.1016/0002-8703(88)90643-6; *WHO, 1997, WHO REG UBL EUR SER, V75	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1478	1479						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419295				2022-12-01	WOS:000080668200031
J	Donald, PR				Donald, PR			Children and tuberculosis: protecting the next generation?	LANCET			English	Article									Univ Stellenbosch, Fac Med, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa	Stellenbosch University	Donald, PR (corresponding author), Univ Stellenbosch, Fac Med, Dept Paediat & Child Hlth, POB 19063, ZA-7505 Tygerberg, South Africa.	aec1@maties.sun.ac.za						BENTLEY FJ, 1954, TUBERCULOSIS CHILDHO, P232; Beyers N, 1996, S AFR MED J, V86, P40; FOURIE PB, 1999, TUBERCULOSIS CHILDRE, P27; FOX W, 1981, Bulletin of the International Union Against Tuberculosis, V56, P135; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; LINCOLN EM, 1951, AM REV TUBERC PULM, V64, P499; MITCHISON DA, 1982, B INT UNION TUBERC, V42, P140; RICH AR, 1951, PATHOGENESIS TUBERCU, P182; SETH V, 1991, TUBERCULOSIS CHILDRE, P1; van Helden PD, 1998, NOVART FDN SYMP, V217, P178, DOI 10.1002/0470846526.ch13	10	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1001	1002		10.1016/S0140-6736(99)02010-3	http://dx.doi.org/10.1016/S0140-6736(99)02010-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459927				2022-12-01	WOS:000079421600048
J	Chen, CS; Patterson, MC; Wheatley, CL; O'Brien, JF; Pagano, RE				Chen, CS; Patterson, MC; Wheatley, CL; O'Brien, JF; Pagano, RE			Broad screening test for sphingolipid-storage diseases	LANCET			English	Article							PLASMA-MEMBRANE; GOLGI-APPARATUS; SPECTRAL PROPERTIES; SKIN FIBROBLASTS; ACCUMULATION; TRANSPORT; ANALOG; CELLS; MUCOLIPIDOSIS; DISORDERS	Background Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods We used a fluorescent analogue of lactosylceramide, called N-{5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl}-D-lactosylsphingosine (BODIPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM(1) gangliosidosis, GM(2) gangliosidosis (Tay-Sachs and Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2% (95% CI 80.4-99.9) and the specificity 90.0% (68.3-98.8). Interpretation This method may be useful as an initial general screen for lipid-storage diseases, and, with modification, could be used for large-scale automated screening of drugs to abrogate lysosomal storage in various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Div Child & Adolescent Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Lab Genet, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Guggenheim 621-C,200 1st St SW, Rochester, MN 55905 USA.		Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Patterson, Marc/0000-0002-1116-126X	NIGMS NIH HHS [GM-22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022942, R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGMON V, 1993, CLIN CHIM ACTA, V218, P139; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BACH G, 1977, AM J HUM GENET, V29, P610; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burkhardt JK, 1997, EUR J CELL BIOL, V73, P10; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; GALJAARD H, 1980, GENETIC METABOLIC DI; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; Hua CT, 1998, CLIN CHEM, V44, P2094; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kopitz J, 1996, AM J MED GENET, V63, P198; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Meikle PJ, 1997, CLIN CHEM, V43, P1325; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, IN PRESS METHODS ENZ; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625	22	108	108	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					901	905		10.1016/S0140-6736(98)10034-X	http://dx.doi.org/10.1016/S0140-6736(98)10034-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489949				2022-12-01	WOS:000082511800012
J	Ghebreyesus, TA; Haile, M; Witten, KH; Getachew, A; Yohannes, AM; Yohannes, M; Teklehaimanot, HD; Lindsay, SW; Byass, P				Ghebreyesus, TA; Haile, M; Witten, KH; Getachew, A; Yohannes, AM; Yohannes, M; Teklehaimanot, HD; Lindsay, SW; Byass, P			Incidence of malaria among children living near dams in northern Ethiopia: community based incidence survey	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY	Objective To assess the impact of construction of microdams on the incidence of malaria in nearby communities in terms of possibly increasing peak incidence and prolonging transmission. Design Four quarterly cycles of malaria incidence surveys, each taking 30 days, undertaken in eight at risk communities close to dams paired with eight control villages at similar altitudes but beyond flight range of mosquitoes. Setting Tigray region in northern Ethiopia at altitudes of 1800 to 2225 m. Subjects About 7000 children under 10 years living in villages within 3 km of microdams and in control villages 8-10 km distant. Main outcome measures Incidence of malaria in both communities. Results Overall incidence of malaria for the villages close to dams was 14.0 episodes/1000 child months at risk compared with 1.9 in the control villages-a sevenfold ratio. Incidence was significantly higher in both communities at altitudes below 1900 m. Conclusions There is a need for attention to be given to health issues in the implementation of ecological and environmental development programmes, specifically for appropriate malaria control measures to counteract the increased risks near these dams.	Tigray Reg Hlth Bur, Dept Malaria Control, Mekelle, Ethiopia; Mekelle Univ Coll, Mekelle, Ethiopia; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Univ Nottingham, Sch Community Hlth Sci, Nottingham NG13 8FD, England	Mekelle University; Durham University; University of Nottingham	Ghebreyesus, TA (corresponding author), Tigray Reg Hlth Bur, Dept Malaria Control, Mekelle, Ethiopia.			Byass, Peter/0000-0001-5474-4361				Alemayehu T., 1998, Parassitologia (Rome), V40, P259; BOUMA MJ, 1994, LANCET, V343, P302, DOI 10.1016/S0140-6736(94)91152-5; BRADLEY DJ, 1998, VECTOR BORNE DIS CON, P29; COOSEMANS M, 1984, ANN SOC BELG MED TR, V64, P135; DEMEILLON B, 1947, PUBLICATIONS S AFRIC, V10, P190; ELGADDAL AA, 1985, J TROP MED HYG, V88, P153; Ghebreyesus TA, 1996, ACTA TROP, V61, P145, DOI 10.1016/0001-706X(95)00107-P; Ghebreyesus TA, 1998, J PUBLIC HEALTH MED, V20, P238, DOI 10.1093/oxfordjournals.pubmed.a024754; Gillies M. T., 1988, Malaria: principles and practice of malariology. Volume 1., P453; Gratz N. G., 1988, Vector-borne disease control in humans through rice agroecosystem management. Proceedings of the Workshop on Research and Training Needs in the Field of Integrated Vector-borne Disease Control in Riceland Agroecosystems of Developing Countries, 9-14 March 1987., P7; Hunter J, 1993, PARASITIC DIS WATER; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; RAMASAMY R, 1992, AM J TROP MED HYG, V47, P547, DOI 10.4269/ajtmh.1992.47.547; STEPHENS J, 1989, METHOD INFORM MED, V28, P155; TEKLEHAIMANOT A, 1986, LANCET, V2, P127	15	143	147	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					663	666		10.1136/bmj.319.7211.663	http://dx.doi.org/10.1136/bmj.319.7211.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480820	Green Published, Bronze			2022-12-01	WOS:000082636800019
J	Roizen, R; Kerr, WC; Fillmore, KM				Roizen, R; Kerr, WC; Fillmore, KM			Cirrhosis mortality and per capita consumption of distilled spirits, United States, 1949-94: trend analysis	BRITISH MEDICAL JOURNAL			English	Article							ALCOHOL; WINE; CONSEQUENCES; IMPACT; RISK; BEER	Objective To describe, evaluate, and suggest interpretations for an observed aggregate level relation between trends in mortality from cirrhosis and per capita consumption of distilled spirits in the United States. Design Trend analysis using data on US cirrhosis mortality and per capita alcohol consumption. Results There is a consistent long term trend relation between mortality from cirrhosis and per capita consumption of distilled spirits in the United States from 1949 to 1994. Two instances of comparatively sharp drops in the consumption of spirits earlier in the 1940s generated mixed results in predicting changes in cirrhosis mortality. Conclusions An aggregate level relation between trends in long term cirrhosis mortality and the consumption of spirits falls considerably short of establishing a direct causal link between the two for individuals. Moreover, two sharp drops in the consumption of spirits generated only mixed results with respect to the short term trend in cirrhosis. Nevertheless, the observed relation between the consumption of spirits and cirrhosis mortality merits further investigation.	Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Roizen, R (corresponding author), Univ Calif San Francisco, Dept Social & Behav Sci, Box 0612, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007034, R01AA009623] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09623, KO1 AA00073, R01 AA07034] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOX EP, 1976, TIME SERIES ANAL FOR; Derr RF, 1996, BIOCHEM ARCH, V12, P277; Edwards G., 1994, ALCOHOL POLICY PUBLI; GODFREY LG, 1988, SPECIFICATION TESTS; Gottman J., 1981, TIME SERIES ANAL COM; GRANT BF, 1985, US ALCOHOL EPIDEMIOL; GRUENEWALD PJ, 1995, J STUD ALCOHOL, V56, P635, DOI 10.15288/jsa.1995.56.635; HARFORD TC, 1979, INT J ADDICT, V14, P197, DOI 10.3109/10826087909060365; HERD D, 1992, ADDICTION, V87, P1113; HILTON ME, 1991, ALCOHOL AM DRINKING, P121; Holder HD, 1997, ADDICTION, V92, P5, DOI 10.1111/j.1360-0443.1997.tb03632.x; HYMAN MM, 1981, J STUD ALCOHOL, V42, P336, DOI 10.15288/jsa.1981.42.336; KLATSKY AL, 1990, BRIT J ADDICT, V85, P1279; Kling W, 1991, J Stud Alcohol, V52, P503; KLING W, 1989, J STUD ALCOHOL, V50, P456, DOI 10.15288/jsa.1989.50.456; LELBACH WK, 1975, MED CONSEQUENCES ALC, V252; LINGEMAN RR, 1970, DONT YOU KNOW THERES, P247; LJUNG GM, 1979, BIOMETRIKA, V66, P265, DOI 10.1093/biomet/66.2.265; LONGNECKER MP, 1981, J STUD ALCOHOL, V42, P791, DOI 10.15288/jsa.1981.42.791; NORSTROM T, 1987, BRIT J ADDICT, V82, P67; PHILLIPS PCB, 1988, BIOMETRIKA, V75, P335, DOI 10.1093/biomet/75.2.335; Pindyck R.S., 1998, ECONOMETRIC MODELS E; *QUANT MICR SOFTW, 1994, E VIEWS US GUID; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; SAADATMAND R, 1997, 45 US DEP HLTH HUM S; SCHMIDT DN, 1991, INT J PANCREATOL, V8, P45; SELZER MI, 1977, J STUD ALCOHOL, V38, P1204; SKOG OJ, 1980, BRIT J ADDICT, V75, P227; SKOG OJ, 1988, ALCOHOL ALCOHOLISM, V22, P193; Smart RG, 1996, J STUD ALCOHOL, V57, P77, DOI 10.15288/jsa.1996.57.77; SMART RG, 1993, ADDICTION, V88, P193, DOI 10.1111/j.1360-0443.1993.tb00802.x; TERRIS M, 1967, AM J PUBLIC HEALTH N, V57, P2076, DOI 10.2105/AJPH.57.12.2076; TURRELL V, 1946, ALCOHOL POLICIES WAR; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; WILLIAMS GD, 1996, APPARENT CAPITA ALCO	36	55	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					666	670A		10.1136/bmj.319.7211.666	http://dx.doi.org/10.1136/bmj.319.7211.666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	237CH	10480821	Green Published, Bronze			2022-12-01	WOS:000082636800020
J	Cubas, P; Vincent, C; Coen, E				Cubas, P; Vincent, C; Coen, E			An epigenetic mutation responsible for natural variation in floral symmetry	NATURE			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; METHYLATION; MERISTEM	Although there have been many molecular studies of morphological mutants generated in the laboratory, it is unclear how these are related to mutants in natural populations, where the constraints of natural selection and breeding structure are quite different. sere we characterize a naturally occurring mutant of Linaria vulgaris, originally described more than 250 years ago by Linnaeus(1-3), in which the fundamental symmetry of the newer is changed from bilateral to radial. We show that the mutant carries a defect in Lcyc, a homologue of the cycloidea gene which controls dorsoventral asymmetry in Antirrhinum(4). The Lcyc gene is extensively methylated and transcriptionally silent in the mutant. This modification is heritable and co-segregates with the mutant phenotype. Occasionally the mutant reverts phenotypically during, somatic development, correlating with demethylation of Lcyc and restoration of gene expression. It is surprising that the first natural morphological mutant to be characterized should trace to methylation, given the rarity of this mutational mechanism in the laboratory. This indicates that epigenetic mutations may play a more significant role in evolution than has hitherto been suspected.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Cubas, Pilar/M-2268-2015; Cubas, Pilar/ABE-8670-2020	Cubas, Pilar/0000-0003-4679-2173; Cubas, Pilar/0000-0003-4679-2173				Almeida J, 1997, DEVELOPMENT, V124, P1387; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRIEGER F. G., 1935, GENETICA, V17, P385, DOI 10.1007/BF01508186; CAMBARERI EB, 1989, SCIENCE, V244, P1571, DOI 10.1126/science.2544994; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; DAS OP, 1994, GENETICS, V136, P1121; DEVRIES H, 1904, SPECIES VARIETIES TH, P459; DOCHERTY Z, 1982, HEREDITY, V49, P349, DOI 10.1038/hdy.1982.108; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; GUSTAFSSON A, 1979, THEOR APPL GENET, V54, P241, DOI 10.1007/BF00281206; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; Jablonka E, 1998, J EVOLUTION BIOL, V11, P159, DOI 10.1007/s000360050073; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; LINNAEUS C, 1749, THESIS UPPSALA; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; SHERMAN M, 1939, Z INDUKT ABSTAMMUNGS, V77, P1; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	24	847	912	5	245	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					157	161		10.1038/43657	http://dx.doi.org/10.1038/43657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490023				2022-12-01	WOS:000082458800052
J	Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF				Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF			In vivo protein transduction: Delivery of a biologically active protein into the mouse	SCIENCE			English	Article							CELLS; DRUGS; BRAIN	Delivery of therapeutic proteins into tissues and across the blood-brain barrier is severely limited by the size and biochemical properties of the proteins. Here it is shown that intraperitoneal injection of the 120-kilodalton beta-galactosidase protein, fused to the protein transduction domain from the human immunodeficiency virus TAT protein, results in-delivery of the biologically active fusion protein to all tissues in mice, including the brain. These results open new possibilities for direct delivery of proteins into patients in the context of protein therapy, as well as for epigenetic experimentation with model organisms.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.							Anderson WF, 1998, NATURE, V392, P25; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Elefanty AG, 1998, P NATL ACAD SCI USA, V95, P11897, DOI 10.1073/pnas.95.20.11897; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Gius DR, 1999, CANCER RES, V59, P2577; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HO AF, UNPUB, P42707; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KRALL WJ, 1992, NEW BIOL, V4, P581; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; RAPOPORT SI, 1972, SCIENCE, V170, P1243; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHELD WM, 1989, REV INFECT DIS S, V7, P1669; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHWARZE S, UNPUB; van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710	22	2083	2472	2	219	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1569	1572		10.1126/science.285.5433.1569	http://dx.doi.org/10.1126/science.285.5433.1569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477521				2022-12-01	WOS:000082359500066
J	Muller, JR; Metha, AB; Krauskopf, J; Lennie, P				Muller, JR; Metha, AB; Krauskopf, J; Lennie, P			Rapid adaptation in visual cortex to the structure of images	SCIENCE			English	Article							CONTRAST GAIN-CONTROL; CAT STRIATE CORTEX; SYNAPTIC DEPRESSION; RECEPTIVE-FIELDS; CORTICAL-NEURONS; SINGLE UNITS; MACAQUE; CELLS; NORMALIZATION; SELECTIVITY	Complex cells in striate cortex of macaque showed a rapid pattern-specific adaptation. Adaptation made cells more sensitive to orientation change near the adapting orientation. It reduced correlations among the responses of populations of cells, thereby increasing the information transmitted by each action potential. These changes were brought about by brief exposures to stationary patterns, on the time scale of a single fixation. Thus, if successive fixations expose neurons' receptive fields to images with similar but not identical structure, adaptation will remove correlations and improve discriminability.	Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA; Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA	University of Rochester; University of Rochester; New York University	Muller, JR (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Fairchild D209, Stanford, CA 94305 USA.		; Metha, Andrew/H-2401-2015	Lennie, Peter/0000-0002-2561-6368; Metha, Andrew/0000-0003-2997-4362	NEI NIH HHS [EY01319, EY04440, EY06638] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001319, R37EY004440, R01EY004440] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BAHILL AT, 1975, INVEST OPHTH VISUAL, V14, P468; BARLOW HB, 1976, VISION RES, V16, P1043, DOI 10.1016/0042-6989(76)90241-8; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; Blakemore C., 2010, VISION CODING EFFICI, P363, DOI 10.1017/cbo9780511626197.034; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; Carandini M, 1997, PHILOS T R SOC B, V352, P1149, DOI 10.1098/rstb.1997.0098; Carandini M, 1997, J NEUROSCI, V17, P8621; CARANDINI M, COMMUNICATION; Chance FS, 1998, J NEUROSCI, V18, P4785; DEANGELIS GC, 1992, J NEUROPHYSIOL, V68, P144, DOI 10.1152/jn.1992.68.1.144; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; GEISLER WS, 1992, VISION RES, V32, P1409, DOI 10.1016/0042-6989(92)90196-P; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GREENLEE MW, 1988, VISION RES, V28, P791, DOI 10.1016/0042-6989(88)90026-0; Hawken MJ, 1996, VISUAL NEUROSCI, V13, P477, DOI 10.1017/S0952523800008154; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; Land MF, 1997, PHILOS T ROY SOC B, V352, P1231, DOI 10.1098/rstb.1997.0105; Lankheet MJM, 1998, VISUAL NEUROSCI, V15, P37, DOI 10.1017/S0952523898151027; LENNIE P, 1990, J NEUROSCI, V10, P649; LENNIE P, 1994, INVEST OPHTH VIS SCI, V35, P1662; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; REGAN D, 1985, J OPT SOC AM A, V2, P147, DOI 10.1364/JOSAA.2.000147; SAUL AB, 1989, VISUAL NEUROSCI, V2, P593, DOI 10.1017/S0952523800003527; SAUL AB, 1989, VISUAL NEUROSCI, V2, P609, DOI 10.1017/S0952523800003539; SCLAR G, 1989, VISION RES, V29, P747, DOI 10.1016/0042-6989(89)90087-4; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SIMONCELLI EP, 1999, ADV NEURAL INFORMATI, V11; TOLHURST DJ, 1980, EXP BRAIN RES, V38, P431; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; Yarbus A. L., 1967, EYE MOVEMENTS VISION	38	343	345	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1405	1408		10.1126/science.285.5432.1405	http://dx.doi.org/10.1126/science.285.5432.1405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464100				2022-12-01	WOS:000082233500044
J	Scott, J				Scott, J			Heart disease - Good cholesterol news	NATURE			English	Editorial Material							ABC		Univ London Imperial Coll Sci Technol & Med, Sch Med, London W12 0NN, England; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England	Imperial College London; Imperial College London	Scott, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Du Cane Rd, London W12 0NN, England.							Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MARCIL M, IN PRESS LANCET; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408	11	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					816	+		10.1038/23584	http://dx.doi.org/10.1038/23584			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476954				2022-12-01	WOS:000082233200019
J	Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH				Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH			Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRIMARY PULMONARY-HYPERTENSION; DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; CHOLESTEROL REDUCTION; PRIMARY PREVENTION; CLINICAL-TRIALS; EVENTS; COMPLICATIONS; DEXFENFLURAMINE; FENFLURAMINE		Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Seattle, WA 98101 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Group Health Cooperative	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Suite 1360,1730 Minor Ave, Seattle, WA 98101 USA.		Kaplan, Robert/A-2526-2011; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060739, R01HL040628, R01HL043201, R29HL040628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40628, HL60739, HL43201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; [Anonymous], 1991, JAMA, V265, P3255; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Curfman GD, 1997, NEW ENGL J MED, V337, P629, DOI 10.1056/NEJM199708283370909; DagogoJack S, 1997, ARCH INTERN MED, V157, P1802, DOI 10.1001/archinte.157.16.1802; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; *FDA, 1999, EV US DRUG LAW; Ferner RE, 1996, BRIT MED J, V313, P1157, DOI 10.1136/bmj.313.7066.1157; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GUYGRAND B, 1989, LANCET, V2, P1142; Imura H, 1998, NEW ENGL J MED, V338, P908, DOI 10.1056/NEJM199803263381311; LIPICKY RJ, 1993, AM J CARDIOL, V22, pA179; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; McCann UD, 1997, JAMA-J AM MED ASSOC, V278, P666, DOI 10.1001/jama.278.8.666; MEINERT CL, 1970, DIABETES, V19, P789; Mitchell P, 1997, LANCET, V350, P1685, DOI 10.1016/S0140-6736(05)64289-4; Nathan DM, 1998, LANCET, V352, P832, DOI 10.1016/S0140-6736(98)22937-0; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; PEDERSEN TR, 1994, LANCET, V344, P1383; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sobel BE, 1997, CIRCULATION, V95, P1661; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Temple Robert J., 1995, P3; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2	41	122	123	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					786	790		10.1001/jama.282.8.786	http://dx.doi.org/10.1001/jama.282.8.786			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463718	Green Published			2022-12-01	WOS:000082118800034
J	Temple, R				Temple, R			Are surrogate markers adequate to assess cardiovascular disease drugs?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; BLOOD-PRESSURE; HYPERTENSION; MORTALITY; FAILURE; MORBIDITY; THERAPIES		US FDA, Ctr Drug Evaluat & Res Policy, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Temple, R (corresponding author), US FDA, Ctr Drug Evaluat & Res Policy, 5600 Fishers Ln,HFD 101, Rockville, MD 20857 USA.	Temple@CDER.fda.gov						Alderman M, 1997, J HYPERTENS, V15, P105; [Anonymous], 1992, Fed Regist, V57, P58942; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; FDA, 1992, FED REGISTER, V57, P13234; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Forker AD, 1996, J CLIN PHARMACOL, V36, P973, DOI 10.1177/009127009603601101; FREIS ED, 1990, HYPERTENSION, V16, P472, DOI 10.1161/01.HYP.16.4.472; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PACKER M, 1993, CIRCULATION S1, V88, P1; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Sobel BE, 1997, CIRCULATION, V95, P1661; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TEMPLE R, 1990, DEV CARDIOVASC MED, P139; TEMPLE R, 1988, P179; TEMPLE R, 1987, CONGESTIVE HEART FAI, P155; Temple Robert J., 1995, P3; *VET ADM COOP STUD, 1967, JAMA-J AM MED ASSOC, V202, P1228; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	30	220	222	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					790	795		10.1001/jama.282.8.790	http://dx.doi.org/10.1001/jama.282.8.790			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463719				2022-12-01	WOS:000082118800035
J	Salonen, JT; Malin, R; Tuomainen, TP; Nyyssonen, K; Lakka, TA; Lehtimaki, T				Salonen, JT; Malin, R; Tuomainen, TP; Nyyssonen, K; Lakka, TA; Lehtimaki, T			Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Univ Kuopio, Res Inst Publ Hlth, Kuopio 70211, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, Kuopio 70211, Finland	University of Eastern Finland; University of Eastern Finland	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, POB 1627, Kuopio 70211, Finland.		Lehtimäki, Terho/AAD-1094-2022	Lehtimäki, Terho/0000-0002-2555-4427; Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; Sanghera DK, 1998, ATHEROSCLEROSIS, V136, P217, DOI 10.1016/S0021-9150(97)00206-2	5	57	58	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					487	488		10.1136/bmj.319.7208.487	http://dx.doi.org/10.1136/bmj.319.7208.487			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454401	Bronze, Green Published			2022-12-01	WOS:000082199600020
J	Westendorp, RGJ; Hottenga, JJ; Slagboom, PE				Westendorp, RGJ; Hottenga, JJ; Slagboom, PE			Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; INTRAVASCULAR COAGULATION; ENDOTOXIN; SEPSIS; POLYMORPHISM; DIAGNOSIS; MORTALITY; PROMOTER; INCREASE; DISEASE	Background Some patients infected with Neisseria meningitidis develop septic shock accompanied by fibrin deposition and microthrombus formation in various organs, whereas others develop bacteraemia or meningitis without septic shock. We investigated whether genetic differences in the fibrinolytic system influence the development of meningococcal septic shock. Methods We investigated 50 patients who survived meningococcal infection, and 131 controls from the same geographical region. Because we had no information on genotypes of patients who died, we also genotyped 183 first-degree relatives of a consecutive series of patients with meningococcal infection for the 4G/5G deletion/insertion polymorphism in the promoter region of the plasminogen-activator-inhibitor-1 gene (PAI-1), The 4G allele is associated with increased gene transcription in cell lines in vitro and with increased PAI-1 concentrations in carriers in vivo. Findings The allele frequencies of 4G and 5G were similar between patients and controls. However, the 4G/4G genotype was present in only 9% of relatives of patients with meningitis compared with 36% of relatives of patients with septic shock. The 5G/5G genotype was more common among relatives of patients with meningitis (31 vs 11%, p=0.001). Patients whose relatives were carriers of the 4G/4G genotype had a six-fold higher risk of developing septic shock than meningitis (odds ratio 5.9 [95% CI 1.9-18.0]) compared with all other genotypes, Interpretation Variation in the PAI-1 gene does not affect the probability of contracting meningococcal infection, but does influence the development of septic shock.	Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; TNO, Gaubius Lab, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research	Westendorp, RGJ (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, CO-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Slagboom, P. Eline/R-4790-2016	Slagboom, P. Eline/0000-0002-2875-4723				ANDERSEN BM, 1987, SCAND J INFECT DIS, V19, P409, DOI 10.3109/00365548709021673; BOHM N, 1982, PATHOL RES PRACT, V174, P92; BRANDTZAEG P, 1990, THROMB RES, V57, P271, DOI 10.1016/0049-3848(90)90326-8; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; MANSFIELD MW, 1995, THROMB HAEMOSTASIS, V74, P1032; Mesters RM, 1996, THROMB HAEMOSTASIS, V75, P902; Mohanty D, 1997, AM J HEMATOL, V54, P23, DOI 10.1002/(SICI)1096-8652(199701)54:1&lt;23::AID-AJH4&gt;3.0.CO;2-6; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Paloma MJ, 1995, THROMB HAEMOSTASIS, V74, P1578; PARAMO JA, 1990, THROMB HAEMOSTASIS, V64, P3; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; VANDEUREN M, 1993, BMJ-BRIT MED J, V306, P1229, DOI 10.1136/bmj.306.6887.1229; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WESTENDORP RGJ, 1992, AM J MED, V92, P577, DOI 10.1016/0002-9343(92)90761-Y; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1996, THROMB HAEMOSTASIS, V75, P899; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6	23	147	152	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					561	563		10.1016/S0140-6736(98)09376-3	http://dx.doi.org/10.1016/S0140-6736(98)09376-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470701				2022-12-01	WOS:000081991000014
J	Yakshinskiy, BV; Madey, TE				Yakshinskiy, BV; Madey, TE			Photon-stimulated desorption as a substantial source of sodium in the lunar atmosphere	NATURE			English	Article							MERCURY; SURFACE; POTASSIUM; ATOMS; EXOSPHERE; DISCOVERY; ORIGIN; IONS; MOON	Mercury and the Moon both have tenuous atmospheres that contain atomic sodium and potassium. These chemicals must be continuously resupplied, as neither body can retain the atoms for more than a few hours (refs 1-6). The mechanisms proposed to explain the resupply include sputtering of the surface by the solar wind(3,4), micrometeorite impacts(5), thermal desorption(6-8) and photon-stimulated desorption(6-10). But there are few data and no general agreement about which processes. dominate(5,10-14). Here we report laboratory studies of photon-stimulated desorption of sodium from Surfaces that simulate lunar silicates. We find that bombardment of such surfaces at temperatures of similar to 250 K by ultraviolet photons (wavelength lambda < 300 nm) causes very efficient desorption of sodium atoms, induced by electronic excitations rather than by thermal processes or momentum transfer. The flux at the lunar surface of ultraviolet photons from the Sun is sufficient to ensure that photon-stimulated desorption of sodium contributes substantially to the Moon's atmosphere. On Mercury, solar heating of the surface implies that thermal desorption(7) will also be an important source of atmospheric sodium.	Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Rutgers State Univ, Surface Modificat Lab, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Madey, TE (corresponding author), Rutgers State Univ, Dept Phys & Astron, POB 849, Piscataway, NJ 08854 USA.							AGEEV VN, 1995, NUCL INSTRUM METH B, V101, P69, DOI 10.1016/0168-583X(95)00286-3; Ageev VN, 1998, PHYS REV B, V58, P2248, DOI 10.1103/PhysRevB.58.2248; FLYNN B, 1995, J GEOPHYS RES-PLANET, V100, P23271, DOI 10.1029/95JE01747; HEATH DF, 1977, SOLAR OUTPUT ITS VAR, P193; Hellsing B, 1997, J CHEM PHYS, V106, P982, DOI 10.1063/1.473177; Hunten DM, 1997, ADV SPACE RES-SERIES, V19, P1551, DOI 10.1016/S0273-1177(97)00368-2; IP WH, 1986, GEOPHYS RES LETT, V13, P423, DOI 10.1029/GL013i005p00423; KIVELSON MG, 1995, INTRO SPACE PHYSICS, V92; KNOTEK ML, 1983, SPRINGER SER CHEM PH, V24, P139; KOZLOWSKI RWH, 1990, GEOPHYS RES LETT, V17, P2253, DOI 10.1029/GL017i012p02253; Madey TE, 1998, J GEOPHYS RES-PLANET, V103, P5873, DOI 10.1029/98JE00230; MASCHHOFF BL, 1991, SURF SCI, V259, P190, DOI 10.1016/0039-6028(91)90537-3; MCGRATH MA, 1986, NATURE, V323, P694, DOI 10.1038/323694a0; MENDILLO M, 1995, NATURE, V377, P404, DOI 10.1038/377404a0; Mendillo M, 1999, ICARUS, V137, P13, DOI 10.1006/icar.1998.6042; MENDILLO M, 1997, ADV SPACE RES, V19, P1557; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1988, SCIENCE, V241, P675, DOI 10.1126/science.241.4866.675; POTTER AE, 1987, ICARUS, V71, P472, DOI 10.1016/0019-1035(87)90041-8; Potter AE, 1998, J GEOPHYS RES-PLANET, V103, P8581, DOI 10.1029/98JE00059; POTTER AE, 1994, GEOPHYS RES LETT, V21, P2263, DOI 10.1029/94GL01702; Sprague AL, 1997, ICARUS, V129, P506, DOI 10.1006/icar.1997.5784; SPRAGUE AL, 1990, SCIENCE, V249, P1140, DOI 10.1126/science.249.4973.1140; SPRAGUE AL, 1992, ICARUS, V96, P7; Verani S, 1998, PLANET SPACE SCI, V46, P1003, DOI 10.1016/S0032-0633(98)00024-5; Wilde M, 1997, SURF SCI, V390, P186, DOI 10.1016/S0039-6028(97)00547-5; XU XP, 1993, SURF SCI, V282, P323, DOI 10.1016/0039-6028(93)90937-F; ZHOU XL, 1991, SURF SCI REP, V13, P73, DOI 10.1016/0167-5729(91)90009-M	29	138	138	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					642	644		10.1038/23204	http://dx.doi.org/10.1038/23204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458159				2022-12-01	WOS:000082032900045
J	Mehta, AD; Rock, RS; Rief, M; Spudich, JA; Mooseker, MS; Cheney, RE				Mehta, AD; Rock, RS; Rief, M; Spudich, JA; Mooseker, MS; Cheney, RE			Myosin-V is a processive actin-based motor	NATURE			English	Article							SINGLE KINESIN MOLECULES; MOVEMENT; FORCE; TRANSPORT; MECHANICS; STEPS; ATP	Class-V myosins, one of 15 known classes of actin-based molecular motors, have been implicated in several forms of organelle transport(1-5), perhaps working with microtubule-based motors such as kinesin(2-4,6). Such movements may require a motor with mechanochemical properties distinct from those of myosin-II, which operates in large ensembles to drive high-speed motility as in muscle contraction(7). Based on its function and biochemistry, it has been suggested that myosin-V may be a processive motor(7,8) like kinesing(9,10). Processivity means that the motor undergoes multiple catalytic cycles and coupled mechanical advances for each diffusional encounter with its track. This allows single motors to support movement of an organelle along its track Here we provide direct evidence that myosin-V is indeed a processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament.	Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	Stanford University; Yale University; University of North Carolina; University of North Carolina Chapel Hill	Mehta, AD (corresponding author), Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA.			Cheney, Richard/0000-0001-6565-7888	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003299] Funding Source: NIH RePORTER; NIDCD NIH HHS [R29 DC003299] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Evans LL, 1998, J CELL SCI, V111, P2055; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Mehta AD, 1998, METHOD ENZYMOL, V298, P436, DOI 10.1016/S0076-6879(98)98039-9; Mehta AD, 1998, ADV STR BIO, V5, P229; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Reck-Peterson SL, 1999, MOL BIOL CELL, V10, P1001, DOI 10.1091/mbc.10.4.1001; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tabb JS, 1998, J CELL SCI, V111, P3221; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	30	648	663	1	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					590	593		10.1038/23072	http://dx.doi.org/10.1038/23072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448864				2022-12-01	WOS:000081854800062
J	Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V				Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V			Virginity examinations in turkey - Role of forensic physicians in controlling female sexuality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYMEN; GIRLS	Context Although the Turkish Medical Association has deemed "virginity examinations" a form of gender-based violence, women in Turkey are often subjected to such examinations by forensic physicians for both legal and social reasons. Little is known about these physicians' role and attitudes in this practice. Objectives To assess forensic physicians' experiences and attitudes regarding virginity examinations in Turkey and suggest potential solutions to the problems identified, Design Cross-sectional self-administered survey. Setting Surveys were completed during the Forensic Science Congress held in Kusadasi in April 1998 as well as in urban academic and medical practice settings between April and October 1998. Participants Of 158 physicians who practice, are formally trained in, or are in training for forensic medicine, 118 completed the survey (response rate, 74.7%). Main Outcome Measures Frequency and circumstances of conducting virginity examinations, opinions regarding beneficial and adverse consequences of these examinations, and recommendations for changing the practice, as measured by a 100-item questionnaire. Results Overall, survey respondents reported conducting 5901 examinations in the previous 12 months; 4045 were conducted because of alleged sexual assault and 1856 for social reasons, Although 68% of forensic physicians indicated that they believed virginity examinations are inappropriate in the absence of an allegation of sexual assault, 45% had conducted examinations for social reasons. The majority of the respondents (93%) agreed that the examinations are psychologically traumatic for the patient. In addition, more than half (58%) reported that at least 50% of patients undergo examinations against their will. Conclusions Nearly half of forensic physicians in Turkey conduct virginity examinations for social reasons despite beliefs that such examinations are inappropriate, traumatic to the patient, and often performed against the patient's will. Physicians' participation in such practices is inconsistent with principles of bioethics and international human rights.	Phys Human Rights, Boston, MA 02116 USA; Columbia Univ, Ctr Populat & Family Hlth, Joseph L Mailman Sch Publ Hlth, Program Forced Migrat & Hlth, New York, NY 10027 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Istanbul, Dept Forens Med, Istanbul, Turkey	Columbia University; University of California System; University of California San Francisco; Istanbul University	Iacopino, V (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.		Fincanci, Sebnem Korur/F-6684-2010; ARICAN, Nadir/G-2778-2012	Fincanci, Sebnem Korur/0000-0003-4484-4961; ARICAN, Nadir/0000-0002-9736-0277				Bandura A., 1990, ORIGINS TERRORISM PS, P161; BERENSON AB, 1992, PEDIATRICS, V89, P387; BERENSON AB, 1994, CURR OPIN OBSTET GYN, V6, P526; BUROSU E, 1992, CUMHURIYET      0509; Copelon Rhonda, 1998, WOMEN WAR READER, P63; Das V, 1996, DAEDALUS, V125, P67; FAHRI I, 1984, TOPLUMUMUZDA KADIN C, P152; Finkel MA, 1994, CHILD ABUSE MED DIAG, P185; GIARDINO AP, 1992, PRACTICAL GUIDE EVAL; GODDARD V, 1987, CULTURAL CONSTRUCTIO; Goodyear-Smith FA, 1998, FORENSIC SCI INT, V94, P147, DOI 10.1016/S0379-0738(98)00053-X; ISLAMI U, 1992, TURKIYE KAD N OLGUSU, P131; MATTHEWS CD, 1994, REPROD FERT DEVELOP, V6, P1; Onderoglu Selda, 1993, Okajimas Folia Anatomica Japonica, V70, P35; ORTNER SB, 1978, FEMINIST STUD, V4, P19; OZBAY F, 1992, TURKIYE KAD N OLGUSU, P151; OZUGURLU K, 1985, EVLILIK RAPORU ALTIN, P46; PETERSON VS, 1998, WOMEN WAR READER, P44; SCHEGEL A, 1991, AM ETHNOL, V18, P719; *SPSS INC, 1998, SPSS BAS 8 0 WIND; Staub E., 1990, PSYCHOL TORTURE, P49; XIAO Z, 1989, FEMINIST STUD, V15, P279; YUKSEL S, 1992, TURKIYE KAD N OLGUSU, P115; 1994, CUMHURIYET      0325; 1999, LOS ANGELES TIM 0106; [No title captured]	26	19	20	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					485	490		10.1001/jama.282.5.485	http://dx.doi.org/10.1001/jama.282.5.485			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442667				2022-12-01	WOS:000081784900029
J	Garfield, R				Garfield, R			Malaria control in Nicaragua: social and political influences on disease transmission and control activities	LANCET			English	Article							HEALTH	Throughout Central America, a traditional malaria control strategy (depending on heavy use of organic pesticides) became less effective during the 1970s. In Nicaragua, an alternative strategy, based on frequent local epidemiological assessments and community participation, was developed in the 1980s. Despite war-related social instability, and continuing vector resistance, this approach was highly successful. By the end of the contra wart there finally existed organisational and ecological conditions that favoured improved malaria control. Yet the expected improvements did not occur. In the 1990s, Nicaragua experienced its worst recorded malaria epidemics. This situation was partly caused by the country's macroeconomic structural adjustment programme. Volunteers now take fewer slides and provide less treatment, malaria control workers are less motivated by the spirit of public service, and some malaria control stations charge for diagnosis or treatment. To "roll back malaria", In Nicaragua at least, will require the roll-back of some erroneous aspects of structural adjustment.	Columbia Univ, Sch Nursing, New York, NY 10032 USA	Columbia University	Garfield, R (corresponding author), Columbia Univ, Sch Nursing, Box 6,630 W 168th St, New York, NY 10032 USA.							BRUCECHWATT LJ, 1966, B WORLD HEALTH ORGAN, V35, P405; BRUCECHWATT LJ, 1983, LANCET, V2, P688; Curtis E, 1998, LANCET, V352, P1622, DOI 10.1016/S0140-6736(98)03248-6; GABALDON A, 1978, AM J TROP MED HYG, V24, P653; GARFIELD R, 1993, JAMA-J AM MED ASSOC, V270, P989, DOI 10.1001/jama.270.8.989; GARFIELD RM, 1983, LANCET, V2, P500; GARFIELD RM, 1987, AM J PUBLIC HEALTH, V77, P615, DOI 10.2105/AJPH.77.5.615; GARFIELD RM, 1984, AM J PUBLIC HEALTH, V74, P1138, DOI 10.2105/AJPH.74.10.1138; GARFIELD RM, 1986, SOC SCI MED, V8, P869; GEORGHIOU GP, 1972, AM J TROP MED HYG, V21, P797, DOI 10.4269/ajtmh.1972.21.797; Harrison Gordon, 1978, MOSQUITOES MALARIA M; MACDONALD G, 1968, B WORLD HEALTH ORGAN, V38, P743; *MIN SAL, 1982, EV IMP MOV NAC ANT N; *PAN AM HLTH ORG, 1985, STAT MAL CONTR PROGR; WERNSDORFER WH, 1980, MALARIA, V1; WHO, 1973, WHO TECH REP SER, V529; *WHO, 1974, WHO TECH REP SER, V537	17	26	27	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					414	418		10.1016/S0140-6736(99)02226-6	http://dx.doi.org/10.1016/S0140-6736(99)02226-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222CB	10437886				2022-12-01	WOS:000081764900044
J	Zygmunt, PM; Petersson, J; Andersson, DA; Chuang, HH; Sorgard, M; Di Marzo, V; Julius, D; Hogestatt, ED				Zygmunt, PM; Petersson, J; Andersson, DA; Chuang, HH; Sorgard, M; Di Marzo, V; Julius, D; Hogestatt, ED			Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide	NATURE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; ISOLATED MESENTERIC-ARTERY; GENE-RELATED PEPTIDE; RAT HEPATIC-ARTERY; CANNABINOID RECEPTOR; CAPSAICIN RECEPTOR; CB1; NEUROTRANSMITTER; ANTAGONIST; INHIBITION	The endogenous cannabinoid receptor agonist anandamide(1) is a powerful vasodilator of isolated vascular preparations(2-4), but its mechanism of action is unclear. Here we show that the vasodilator response to anandamide in isolated arteries is capsaicin-sensitive and accompanied by release of calcitonin-gene-related peptide (CGRP), The selective CGRP-receptor antagonist 8-37 CGRP (ref. 5), but not the cannabinoid CB1 receptor blocker SR141716A (ref. 7), inhibited the vasodilator effect of anandamide, Other endogenous (2-arachidonylglycerol, palmitylethanolamide) and synthetic (HU 210, WIN 55,212-2, CP 55,940) CB1 and CB2 receptor agonists' could not mimic the action of anandamide. The selective 'vanilloid receptor' antagonist capsazepine(6,7) inhibited anandamide-induced vasodilation and release of CGRP. In patch-clamp experiments on cells expressing the cloned vanilloid receptor (VR1)(8), anandamide induced a capsazepine-sensitive current in whale cells and isolated membrane patches. Our results indicate that anandamide induces vasodilation by activating: vanilloid receptors on perivascular sensory nerves and causing release of CGRP. The vanilloid receptor may thus be another molecular target for endogenous anandamide, besides cannabinoid receptors, in the nervous and cardiovascular systems.	Univ Lund, Inst Lab Med, Dept Clin Pharmacol, S-22185 Lund, Sweden; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco Felice, Napoli, Italy	Lund University; University of California System; University of California San Francisco; Consiglio Nazionale delle Ricerche (CNR)	Hogestatt, ED (corresponding author), Univ Lund, Inst Lab Med, Dept Clin Pharmacol, S-22185 Lund, Sweden.		Di Marzo, Vincenzo/AAD-7742-2019; Petersson, Jesper/I-2546-2016; Andersson, David A/C-3435-2008	Di Marzo, Vincenzo/0000-0002-1490-3070; Andersson, David A/0000-0001-7451-8548; Zygmunt, Peter/0000-0002-5102-8199				BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; HAN SP, 1990, BIOCHEM BIOPH RES CO, V168, P786, DOI 10.1016/0006-291X(90)92390-L; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; KAWASAKI H, 1988, NATURE, V335, P164, DOI 10.1038/335164a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Petersson J, 1998, J VASC RES, V35, P285, DOI 10.1159/000025595; Plane F, 1997, BRIT J PHARMACOL, V121, P1509, DOI 10.1038/sj.bjp.0701361; Pratt PF, 1998, AM J PHYSIOL-HEART C, V274, pH375, DOI 10.1152/ajpheart.1998.274.1.H375; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; White R, 1998, BRIT J PHARMACOL, V125, P533, DOI 10.1038/sj.bjp.0702111; White R, 1998, BRIT J PHARMACOL, V125, P689, DOI 10.1038/sj.bjp.0702127; ZYGMENT PM, 1996, BRIT J PHARMACOL, V118, P1149; ZYGMUNT PM, 1994, ACTA PHYSIOL SCAND, V152, P107, DOI 10.1111/j.1748-1716.1994.tb09789.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V122, P1679, DOI 10.1038/sj.bjp.0701601	30	1727	1794	4	92	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					452	457		10.1038/22761	http://dx.doi.org/10.1038/22761			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440374				2022-12-01	WOS:000081715000051
J	Melville, M; Brown, N; Gray, D; Young, T; Hampton, J				Melville, M; Brown, N; Gray, D; Young, T; Hampton, J			Outcome and use of health services four years after admission for acute myocardial infarction: case record follow up study	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Univ Nottingham, Dept Math, British Heart Fdn, Cardiovasc Stat Unit, Nottingham NG7 2RH, England	University of Nottingham; University of Nottingham	Melville, M (corresponding author), Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England.		Young, Tracey A/A-4543-2010	Young, Tracey/0000-0001-8467-0471				*BRIT CARD SOC, 1998, STRAT PLANN CARD SER; DEBONO DP, 1994, J ROY COLL PHYS LOND, V28, P312; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GREENWOOD D, 1995, SOC SCI MED, V40, P639, DOI 10.1016/0277-9536(94)00147-L; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					230	231		10.1136/bmj.319.7204.230	http://dx.doi.org/10.1136/bmj.319.7204.230			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	221HB	10417086	Bronze, Green Published			2022-12-01	WOS:000081720300025
J	Sanson, B; Alexandre, C; Fascetti, N; Vincent, JP				Sanson, B; Alexandre, C; Fascetti, N; Vincent, JP			Engrailed and hedgehog make the range of wingless asymmetric in Drosophila embryos	CELL			English	Article							MORPHOGEN GRADIENT; GENE-EXPRESSION; CELL FATE; EPIDERMIS; PROTEIN; ARMADILLO; EMBRYOGENESIS; BOUNDARIES; SECRETION; INDUCTION	In many instances, remote signaling involves the transport of secreted molecules. Here, we examine the spread of Wingless within the embryonic epidermis of Drosophila. Using two assays for Wingless activity (specification of naked cuticle and repression of rhomboid transcription), we found that Wingless acts at a different range in the anterior and posterior directions. We show that this asymmetry follows in part from differential distribution of the Wingless protein. Transport or stability is reduced within engrailed-expressing cells, and farther posteriorward Wingless movement is blocked at the presumptive segment boundary and perhaps beyond. We demonstrate the role of hedgehog in the formation of this barrier.	Natl Inst Med Res, London NW7 1AA, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; MRC, LMB, Cambridge CB2 2QH, England	MRC National Institute for Medical Research; University of Cambridge; MRC Laboratory Molecular Biology	Vincent, JP (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	jp.vincent@nimr.mrc.ac.uk		Sanson, Benedicte/0000-0002-2782-4195				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; Dierick HA, 1998, DEVELOPMENT, V125, P4729; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; Hepker J, 1997, DEVELOPMENT, V124, P549; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Jowett T., 1997, TISSUE IN SITU HYBRI; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Martinez Arias Alfonso, 1993, P517; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PAYRE F, 1999, IN PRESS NATURE; PFEIFFER S, 1999, IN PRESS SEMIN DEV B; Pignoni F, 1997, DEVELOPMENT, V124, P271; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Szuts D, 1997, DEVELOPMENT, V124, P3209; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	39	67	70	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					207	216		10.1016/S0092-8674(00)81015-6	http://dx.doi.org/10.1016/S0092-8674(00)81015-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428032	Bronze			2022-12-01	WOS:000081632300010
J	Dawson, DW; Volpert, OV; Gillis, P; Crawford, SE; Xu, HJ; Benedict, W; Bouck, NP				Dawson, DW; Volpert, OV; Gillis, P; Crawford, SE; Xu, HJ; Benedict, W; Bouck, NP			Pigment epithelium-derived factor: A potent inhibitor of angiogenesis	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC ACTIVITY; DIABETIC-RETINOPATHY; FACTOR VEGF; NEOVASCULARIZATION; EXPRESSION; OXYGEN; GENE; BETA; IDENTIFICATION	In the absence of disease, the vasculature of the mammalian eye is quiescent, in part because of the action of angiogenic inhibitors that prevent vessels from invading the cornea and vitreous. Here, an inhibitor responsible for the avascularity of these ocular compartments is identified as pigment epithelium-derived factor (PEDF), a protein previously shown to have neurotrophic activity. The amount of inhibitory PEDF produced by retinal cells was positively correlated with oxygen concentrations, suggesting that its loss plays a permissive role in ischemia-driven retinal neovascularization. These results suggest that PEDF may be of therapeutic use, especially in retinopathies where pathological neovascularization compromises vision and leads to blindness.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bouck, NP (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	n-bouck@nwu.edu	Dawson, David/I-5917-2014	Volpert, Olga/0000-0003-1381-5543				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; DAWSON D, UNPUB; DIPAOLO BR, 1995, EXP CELL RES, V220, P178, DOI 10.1006/excr.1995.1304; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J., 1995, MOL BASIS CANC, P206; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gulledge CJ, 1996, ANTICANCER RES, V16, P741; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hayasaka K, 1998, LIFE SCI, V63, P1089, DOI 10.1016/S0024-3205(98)00205-7; HENKIND P, 1978, AM J OPHTHALMOL, V85, P287, DOI 10.1016/S0002-9394(14)77719-0; KAMINSKA GM, 1993, INVEST OPHTH VIS SCI, V34, P222; KLINTWORTH GK, 1991, CORNEAL ANGIOGENESIS; Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; PREIS I, 1977, AM J OPHTHALMOL, V84, P323; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; SCHACHAT A, 1994, RETINA; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; TANAWAKI T, 1995, J NEUROCHEM, V64, P2509; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Vinores SA, 1998, J NEUROIMMUNOL, V89, P43, DOI 10.1016/S0165-5728(98)00075-7; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; XU HJ, 1991, CANCER RES, V51, P4481	36	1260	1384	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					245	248		10.1126/science.285.5425.245	http://dx.doi.org/10.1126/science.285.5425.245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398599				2022-12-01	WOS:000081346000039
J	Carazo-Salas, RE; Guarguaglini, G; Gruss, OJ; Segref, A; Karsenti, E; Mattaj, IW				Carazo-Salas, RE; Guarguaglini, G; Gruss, OJ; Segref, A; Karsenti, E; Mattaj, IW			Generation of GTP-bound Ran by RCC1 is required for chromatin-induced mitotic spindle formation	NATURE			English	Article							XENOPUS EGG EXTRACTS; MICROTUBULE-ASSOCIATED PROTEIN; SELF-ORGANIZATION; RESPECTIVE ROLES; IMPORT; CENTROSOMES; TRANSPORT; RANGAP1; NUCLEUS; MUTANTS	Chromosomes are segregated by two antiparallel arrays of microtubules arranged to form the spindle apparatus. During cell division, the nucleation of cytosolic microtubules is prevented and spindle microtubules nucleate from centrosomes (in mitotic animal cells) or around chromosomes (in plants and some meiotic cells)(1,2). The molecular mechanism by which chromosomes induce local microtubule nucleation in the absence of centrosomes is unknown(3-5), but it can be studied by adding chromatin beads to Xenopus egg extracts(6). The beads nucleate microtubules that eventually reorganize into a bipolar spindle. RCC1, the guanine-nucleotide-exchange factor for the GTPase protein Ran, is a component of chromatin. Using the chromatin bead assay, we show here that the activity of chromosome-associated RCC1 protein is required for spindle formation. Ran itself, when in the GTP-bound state (Ran-GTP), induces microtubule nucleation and spindle-like structures in M-phase extract. We propose that RCC1 generates a high local concentration of Ran-GTP around chromatin which in turn induces the local nucleation of microtubules.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Segref, Alexandra/C-8325-2011	Carazo-Salas, Rafael E/0000-0002-5943-3981; Segref, Alexandra/0000-0001-8095-4469; Mattaj, Iain/0000-0002-5537-8284				Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CLARKE PR, 1995, J CELL SCI, V108, P1217; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DOMINGUEZ JE, 1994, J CELL SCI, V107, P601; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Hyman A, 1998, J CELL SCI, V111, P2077; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LEPAULT J, 1986, METHOD ENZYMOL, V127, P719; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nicolas FJ, 1997, J CELL SCI, V110, P3019; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pu RT, 1997, MOL BIOL CELL, V8, P1955, DOI 10.1091/mbc.8.10.1955; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673	30	386	392	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					178	181		10.1038/22133	http://dx.doi.org/10.1038/22133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408446				2022-12-01	WOS:000081324900057
J	Tomitani, A; Okada, K; Miyashita, H; Matthijs, HCP; Ohno, T; Tanaka, A				Tomitani, A; Okada, K; Miyashita, H; Matthijs, HCP; Ohno, T; Tanaka, A			Chlorophyll b and phycobilins in the common ancestor of cyanobacteria and chloroplasts	NATURE			English	Article							MULTIPLE EVOLUTIONARY ORIGINS; A/B; PROCHLOROPHYTES; PROTEINS; PLANTS; ANTENNA; ALGA	Photosynthetic organisms have a variety of accessory pigments, on which their classification has been based. Despite this variation, it is generally accepted that all chloroplasts are derived from a single cyanobacterial ancestor(1-3). How the pigment diversity has arisen is the key to revealing their evolutionary history. Prochlorophytes are prokaryotes which perform oxygenic photosynthesis using chlorophyll b, like land plants and green algae (Chlorophyta), and were proposed to be the ancestors of chlorophyte chloroplasts(4,5). However, three known prochlorophytes (Prochloron didemni, Prochlorothrix hollandica and Prochlorococcus marinus) have been shown to be not the specific ancestors of chloroplasts, but only diverged members of the cyanobacteria, which contain phycobilins but lack chlorophyll b(6,7). Consequently it has been proposed that the ability to synthesize chlorophyll b developed independently several times in prochlorophytes and in the ancestor of chlorophytes. Here we have isolated the chlorophyll b synthesis genes (chlorophyll a oxygenase)(8) from two prochlorophytes and from major groups of chlorophytes. Phylogenetic analyses show that these genes share a common evolutionary origin. This indicates that the progenitors of oxygenic photosynthetic bacteria, including the ancestor of chloroplasts, had both chlorophyll b and phycobilins.	Kyoto Univ, Grad Sch Sci, Dept Geol & Mineral, Kyoto 6068502, Japan; Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan; Kamaishi Labs, Marine Biotechnol Inst, Kamaishi, Iwate 0260001, Japan; Univ Amsterdam, Dept Microbiol, NL-1018 WS Amsterdam, Netherlands; Kyoto Univ, Kyoto Univ Museum, Kyoto 6068502, Japan	Kyoto University; Hokkaido University; Kyoto University; University of Amsterdam; Kyoto University	Tomitani, A (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Geol & Mineral, Kyoto 6068502, Japan.	tomitani@terra.kueps.kyoto-u.ac.jp	Matthijs, Hans/B-4503-2009; Tanaka, Ayumi/D-9003-2012					Adachi J., 1996, COMPUTER SCI MONOGRA, V28; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; Bhattacharya D, 1998, PLANT PHYSIOL, V116, P9, DOI 10.1104/pp.116.1.9; BHATTACHARYYA A, 1995, PHYS ESSAYS, V8, P3, DOI 10.4006/1.3036517; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; DELWICHE CF, 1997, ORIGINS ALGAE THEIR, P53; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gray J, 1997, CELL, V89, P25, DOI 10.1016/S0092-8674(00)80179-8; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; Hess WR, 1996, P NATL ACAD SCI USA, V93, P11126, DOI 10.1073/pnas.93.20.11126; Kaneko T, 1996, DNA Res, V3, P109; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LEWIN RA, 1975, NATURE, V256, P735, DOI 10.1038/256735a0; LEWIN RA, 1976, NATURE, V261, P697, DOI 10.1038/261697b0; MORDEN CW, 1989, NATURE, V337, P382, DOI 10.1038/337382a0; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; Rudiger W, 1999, NATO ASI 3 HIGH TECH, V64, P185; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Tan S, 1997, PLANT MOL BIOL, V33, P157, DOI 10.1023/A:1005715528297; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URBACH E, 1992, NATURE, V355, P267, DOI 10.1038/355267a0; WOLFE GR, 1994, NATURE, V367, P566, DOI 10.1038/367566a0	25	154	172	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					159	162		10.1038/22101	http://dx.doi.org/10.1038/22101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408441				2022-12-01	WOS:000081324900052
J	Haan, MN; Shemanski, L; Jagust, WJ; Manolio, TA; Kuller, L				Haan, MN; Shemanski, L; Jagust, WJ; Manolio, TA; Kuller, L			The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E EPSILON-4; DEPENDENT DIABETIC-PATIENTS; ALZHEIMERS-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR HEALTH; E GENOTYPE; POPULATION; DEMENTIA; OLDER; ASSOCIATION	Context Cognitive decline in elderly persons is often an early predictor of dementia. Subclinical cardiovascular disease (CVD) and diabetes mellitus may contribute to substantial decline in cognitive function in the elderly. These risks may be modified by gene-environment interactions between apolipoprotein E (APOE) genotype and CVD risk factors or subclinical CVD. Objectives To examine the association between subclinical CVD and decline in cognitive functioning in the elderly and to examine effect modification by the APOE genotype of the association between subclinical disease and cognitive decline. Design The Cardiovascular Health Study, a population-based, prospective cohort study. Setting and Population A total of 5888 randomly selected Medicare-eligible participants from Sacramento County, California; Forsyth County, North Carolina; Washington County, Maryland; and Pittsburgh, Pa, aged 65 years or older, who were recruited in 1989-1990 (n = 5201) and in 1992-1993 (n = 687) and who were followed up for 7 and 5 years, respectively. Main Outcome Measures Change over time in scores on the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test as a function of APOE genotype, subclinical CVD, and diabetes mellitus. Results Seventy percent of participants had no significant decline on the Modified Mini-Mental State Examination. Systolic blood pressure, the ankle-arm brachial index, atherosclerosis of the internal carotid artery, diabetes mellitus, and several diagnoses of prevalent CVD were significantly associated with declines in scores on the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test. The rate of cognitive decline associated with peripheral vascular disease, atherosclerosis of the common and internal carotid arteries, or diabetes mellitus was increased by the presence of any APOE epsilon 4 allele. Conclusions Most healthy elderly people did not experience cognitive decline. Measures of subclinical CVD were modest predictors of cognitive decline. Those with any APOE epsilon 4 allele in combination with atherosclerosis, peripheral vascular disease, or diabetes mellitus were at substantially higher risk of cognitive decline than those without the APOE epsilon 4 allele or subclinical CVD. High levels of atherosclerosis increased cognitive decline independently of APOE genotype.	Univ Calif Davis, Sch Med, Dept Epidemiol & Prevent Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; NHLBI, Dept Epidemiol, Bethesda, MD 20892 USA; NHLBI, Dept Biometry, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Haan, MN (corresponding author), Univ Calif Davis, Sch Med, Dept Epidemiol & Prevent Med, 1 Shields Ave, Davis, CA 95616 USA.	mnhaan@ucdavis.edu	Jagust, William/ABE-6426-2020; Haan, Mary N/Y-9354-2018	Haan, Mary N/0000-0001-9312-4501	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG033751] Funding Source: NIH RePORTER; NIA NIH HHS [R03 AG033751] Funding Source: Medline; NIDDK NIH HHS [R01 DK060753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen JB, 1996, NEUROPSYCHOLOGIA, V34, P459, DOI 10.1016/0028-3932(95)00115-8; APPLEGATE WB, 1994, ARCH INTERN MED, V154, P2154, DOI 10.1001/archinte.154.19.2154; BERES CA, 1981, J GERONTOL, V36, P591, DOI 10.1093/geronj/36.5.591; Berr C, 1996, NEUROSCI LETT, V218, P9, DOI 10.1016/S0304-3940(96)13059-7; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Cattin L, 1997, ARTERIOSCL THROM VAS, V17, P91, DOI 10.1161/01.ATV.17.1.91; Chandra V, 1998, NEUROEPIDEMIOLOGY, V17, P225, DOI 10.1159/000026175; Crawford JG, 1998, MED HYPOTHESES, V50, P25, DOI 10.1016/S0306-9877(98)90173-6; Curb JD, 1999, NEUROLOGY, V52, P971, DOI 10.1212/WNL.52.5.971; Dey J, 1997, DIABETES CARE, V20, P32, DOI 10.2337/diacare.20.1.32; Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Finch CE, 1997, EXP NEUROL, V143, P82, DOI 10.1006/exnr.1996.6339; Fujishima M, 1995, Hypertens Res, V18, P111, DOI 10.1291/hypres.18.111; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; Glynn RJ, 1999, JAMA-J AM MED ASSOC, V281, P438, DOI 10.1001/jama.281.5.438; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; Heckbert SR, 1997, J AM GERIATR SOC, V45, P1423, DOI 10.1111/j.1532-5415.1997.tb03191.x; Helkala EL, 1996, NEUROSCI LETT, V204, P177, DOI 10.1016/0304-3940(96)12348-X; Hyman BT, 1996, ANN NEUROL, V40, P55, DOI 10.1002/ana.410400111; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; KURITA A, 1995, ACTA NEUROL SCAND, V92, P319; Kurita A, 1996, DIABETES CARE, V19, P361, DOI 10.2337/diacare.19.4.361; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Messier C, 1996, BEHAV BRAIN RES, V75, P1, DOI 10.1016/0166-4328(95)00153-0; MOORADIAN AD, 1988, ARCH INTERN MED, V148, P2369, DOI 10.1001/archinte.148.11.2369; MORTEL KF, 1994, ANGIOLOGY, V45, P171, DOI 10.1177/000331979404500301; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; Naor M, 1997, J DIABETES COMPLICAT, V11, P40, DOI 10.1016/1056-8727(95)00106-9; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PEREZMUNOZ M, 1995, ACTAS LUSO ESPANOLES, V24, P332; Perlmuter L C, 1988, J Diabet Complications, V2, P210, DOI 10.1016/S0891-6632(88)80011-4; Phillips NA, 1997, STROKE, V28, P777, DOI 10.1161/01.STR.28.4.777; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; REAVEN GM, 1990, DIABETES CARE, V13, P16, DOI 10.2337/diacare.13.1.16; ROSES AD, 1977, INT PSYCHOLOGERIA S1, V9, P277; RYAN CM, 1993, J CLIN EXP NEUROPSYC, V15, P685, DOI 10.1080/01688639308402589; *SAS I INC, 1999, SAS STAT COMP PROGR; Skoog I, 1998, J NEUROL NEUROSUR PS, V64, P37, DOI 10.1136/jnnp.64.1.37; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Slooter AJC, 1998, ARCH NEUROL-CHICAGO, V55, P964, DOI 10.1001/archneur.55.7.964; Small BJ, 1998, PSYCHOL AGING, V13, P80, DOI 10.1037/0882-7974.13.1.80; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tun P A, 1990, Clin Geriatr Med, V6, P731; UREN RC, 1990, J AM GERIATR SOC, V38, P505, DOI 10.1111/j.1532-5415.1990.tb02398.x; WORRALL G, 1993, J FAM PRACTICE, V36, P639; Worrall GJ, 1996, J DIABETES COMPLICAT, V10, P320, DOI 10.1016/1056-8727(94)00078-6	59	363	369	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					40	46		10.1001/jama.282.1.40	http://dx.doi.org/10.1001/jama.282.1.40			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212BE	10404910				2022-12-01	WOS:000081195800027
J	Heeb, P; Werner, I; Mateman, AC; Kolliker, M; Brinkhof, MWG; Lessells, CM; Richner, H				Heeb, P; Werner, I; Mateman, AC; Kolliker, M; Brinkhof, MWG; Lessells, CM; Richner, H			Ectoparasite infestation and sex-biased local recruitment of hosts	NATURE			English	Article							GREAT-TITS; NATAL DISPERSAL; PARUS-MAJOR; BIRDS; PHILOPATRY; COMPETITION; ADAPTATION; EVOLUTION; SURVIVAL; SYSTEMS	Dispersal patterns of organisms are a fundamental aspect of their ecology, modifying the genetic and social structure of local populations(1-4). Parasites reduce the reproductive success and survival of hosts and thereby exert selection pressure on host life-history traits(4-6), possibly affecting host dispersal(7-9). Here we test experimentally whether infestation by hen fleas, Ceratophyllus gallinae, affects sex-related recruitment of great tit, Parus major, fledglings. Using sex-specific DNA markers, we show that flea infestation led to a higher proportion of male fledglings recruiting in the local population in one year. In infested broods, the proportion of male recruits increased with brood size over a three year period, whereas the proportion of male recruits from uninfested broods decreased with brood size. Natal dispersal distances of recruits from infested nests were shorter than those from uninfested nests(10). To our knowledge, this study provides the first evidence for parasite-mediated host natal dispersal and local recruitment in relation to sex. Current theory needs to consider parasites as potentially important factors shaping life-history traits associated with host dispersal.	Univ Bern, Dept Zool, Ctr Behav & Evolut, CH-3032 Hinterkappelen, Switzerland; Netherlands Inst Ecol, NL-6666 ZG Heteren, Netherlands	University of Bern; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Heeb, P (corresponding author), Univ Bern, Dept Zool, Ctr Behav & Evolut, CH-3032 Hinterkappelen, Switzerland.	philipp.heeb@esh.unibe.ch	Mateman, Christa/C-9380-2012; Richner, Heinz/B-1659-2008; Lessells, C.M./B-3891-2011	Mateman, Christa/0000-0002-9832-5780; Richner, Heinz/0000-0001-7390-0526; van der Heijden, Marianne/0000-0002-0795-3619; Brinkhof, Martin/0000-0002-9319-665X				Belthoff JR, 1998, ANIM BEHAV, V55, P405, DOI 10.1006/anbe.1997.0625; Brown CR, 1995, P ROY SOC B-BIOL SCI, V262, P313, DOI 10.1098/rspb.1995.0211; BROWN CR, 1992, ECOLOGY, V73, P1718, DOI 10.2307/1940023; Christe P, 1996, BEHAV ECOL, V7, P127, DOI 10.1093/beheco/7.2.127; Clarke AL, 1997, OIKOS, V79, P429, DOI 10.2307/3546885; Clayton D.H., 1997, HOST PARASITE EVOLUT; Crawley M. J., 1993, GLIM ECOLOGISTS; Danchin E, 1998, ECOLOGY, V79, P2415, DOI 10.1890/0012-9658(1998)079[2415:CRSABH]2.0.CO;2; DHONDT AA, 1968, BIRD STUDY, V15, P127, DOI 10.1080/00063656809476192; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; GEBHARDTHENRICH SG, 1991, J EVOLUTION BIOL, V4, P341, DOI 10.1046/j.1420-9101.1991.4030341.x; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HAMILTON WD, 1977, NATURE, V269, P578, DOI 10.1038/269578a0; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Heeb P, 1998, P ROY SOC B-BIOL SCI, V265, P51, DOI 10.1098/rspb.1998.0263; Heeb P, 1996, J ANIM ECOL, V65, P474, DOI 10.2307/5782; HEEB P, IN PRESS ECOLOGY; HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442; JOHNSON ML, 1990, ANNU REV ECOL SYST, V21, P449, DOI 10.1146/annurev.es.21.110190.002313; KACELNIK A, 1995, P ROY SOC B-BIOL SCI, V259, P259, DOI 10.1098/rspb.1995.0038; Kaltz O, 1998, HEREDITY, V81, P361, DOI 10.1046/j.1365-2540.1998.00435.x; Lessells CM, 1998, MOL ECOL, V7, P187, DOI 10.1046/j.1365-294x.1998.00331.x; Poulin R, 1996, AM NAT, V147, P287, DOI 10.1086/285851; RICHNER H, 1993, J ANIM ECOL, V62, P703, DOI 10.2307/5390; Richner H, 1998, ZOOL-ANAL COMPLEX SY, V101, P333; SMITH HG, 1989, J ANIM ECOL, V58, P383, DOI 10.2307/4837; SORCI G, 1994, AM NAT, V144, P153, DOI 10.1086/285666; TINBERGEN JM, 1990, J ANIM ECOL, V59, P1113, DOI 10.2307/5035; Verhulst S, 1997, ECOLOGY, V78, P864, DOI 10.1890/0012-9658(1997)078[0864:NDOGTI]2.0.CO;2; WEATHERHEAD PJ, 1994, BEHAV ECOL, V5, P426, DOI 10.1093/beheco/5.4.426	30	65	65	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1999	400	6739					63	65		10.1038/21881	http://dx.doi.org/10.1038/21881			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403248				2022-12-01	WOS:000081255700050
J	Mankoo, BS; Collins, NS; Ashby, P; Grigorieva, E; Pevny, LH; Candia, A; Wright, CVE; Rigby, PWJ; Pachnis, V				Mankoo, BS; Collins, NS; Ashby, P; Grigorieva, E; Pevny, LH; Candia, A; Wright, CVE; Rigby, PWJ; Pachnis, V			Mox2 is a component of the genetic hierarchy controlling limb muscle development	NATURE			English	Article							SKELETAL MYOGENESIS; PAX-3 EXPRESSION; MET RECEPTOR; MOUSE; CELLS; MIGRATION; MYOD; MUSCULATURE; EMBRYOS; DEFINE	The skeletal muscles of the limbs develop from myogenic progenitors that originate in the paraxial mesoderm and migrate into the limb-bud mesenchyme(1). Among the genes known to be important for muscle development in mammalian embryos are those encoding the basic helix-loop-helix (bHLH) myogenic regulatory factors (MRFs; MyoD, Myf5, myogenin and MRF4)(2-4) and Pax3, a paired-type homeobox gene that is critical for the development of limb musculature(5-7). Mox1 and Mox2 are closely related homeobox genes that are expressed in overlapping patterns in the paraxial mesoderm and its derivatives(8,9), Here we show that mice homozygous for a null mutation of Mox2 have a developmental defect of the limb musculature, characterized by an overall reduction in muscle mass and elimination of specific muscles. Mox2 is not needed for the migration of myogenic precursors into the limb bud, but it is essential for normal appendicular muscle formation and for the normal regulation of myogenic genes, as demonstrated by the downregulation of Pax3 and Myf5 but not MyoD in Mox2-deficient limb buds. Our findings show that the MOX2 homeoprotein is an important regulator of vertebrate limb myogenesis.	Natl Inst Med Res, MRC, Div Dev Neurobiol, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Eukaryot Mol Genet, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Vanderbilt Univ Sch Med, Nashville, TN 37232 USA	MRC National Institute for Medical Research; MRC National Institute for Medical Research; MRC National Institute for Medical Research; Vanderbilt University	Pachnis, V (corresponding author), Natl Inst Med Res, MRC, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.	v-pachni@nimr.mrc.ac.uk		Pachnis, Vassilis/0000-0001-9733-7686				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Daston G, 1996, DEVELOPMENT, V122, P1017; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; GOULDING M, 1994, DEVELOPMENT, V120, P957; GRIM M, 1991, ANAT EMBRYOL, V183, P67; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Jacob HJ, 1980, TERATOLOGY LIMBS, P89; JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5; Kardon G, 1998, DEVELOPMENT, V125, P4019; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Wachtler F, 1986, Bibl Anat, P24; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yamamoto M, 1998, DEVELOPMENT, V125, P1325; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	26	143	146	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1999	400	6739					69	73		10.1038/21892	http://dx.doi.org/10.1038/21892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403250				2022-12-01	WOS:000081255700052
J	Pierani, A; Brenner-Morton, S; Chiang, C; Jessell, TM				Pierani, A; Brenner-Morton, S; Chiang, C; Jessell, TM			A sonic hedgehog-independent, retinoid-activated pathway of neurogenesis in the ventral spinal cord	CELL			English	Article							FLOOR PLATE DIFFERENTIATION; MOTOR-NEURON INDUCTION; EXPRESSION PATTERN; PARAXIAL MESODERM; HOMEOBOX GENES; CELL FATE; PAX GENES; MOUSE; SPECIFICATION; IDENTITY	Sonic hedgehog (Shh) is thought to control the generation of motor neurons and interneurons in the ventral CNS. We show here that a Shh-independent pathway of interneuron generation also operates in the ventral spinal cord. Evidence for this parallel pathway emerged from an analysis of the induction of ventral progenitors that express the Dbx homeodomain proteins and of Evx1/2 (V0) and En1 (V1) neurons. Shh signaling is sufficient to induce Dbx cells and V0 and V1 neurons but is not required for their generation in vitro or in vivo. Retinoids appear to mediate this parallel pathway. These findings reveal an unanticipated Shh-independent signaling pathway that controls progenitor cell identity and interneuron diversity in the ventral spinal cord.	Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Columbia University; Howard Hughes Medical Institute; Vanderbilt University	Jessell, TM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA.		Pierani, Alessandra/O-6136-2017	Pierani, Alessandra/0000-0002-4872-4791				Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Burrill JD, 1997, DEVELOPMENT, V124, P4493; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; LEBER SM, 1995, J NEUROSCI, V15, P1236; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LU SW, 1994, MECH DEVELOP, V47, P187, DOI 10.1016/0925-4773(94)90089-2; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lumsden A, 1995, CURR BIOL, V5, P1347, DOI 10.1016/S0960-9822(95)00266-1; Maden M, 1998, DEVELOPMENT, V125, P4133; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1997, J NEUROSCI, V17, P7805; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pituello F, 1999, DEVELOPMENT, V126, P587; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RANGINI Z, 1991, MECH DEVELOP, V35, P13, DOI 10.1016/0925-4773(91)90037-7; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shoji H, 1996, MECH DEVELOP, V56, P25, DOI 10.1016/0925-4773(96)00509-6; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAGNER M, 1992, DEVELOPMENT, V116, P55; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	50	273	276	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					903	915		10.1016/S0092-8674(00)80802-8	http://dx.doi.org/10.1016/S0092-8674(00)80802-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399918	Bronze			2022-12-01	WOS:000081162800011
J	Stephens, DS				Stephens, DS			Uncloaking the meningococcus: dynamics of carriage and disease	LANCET			English	Editorial Material							NEISSERIA-MENINGITIDIS; POPULATION; SPREAD		Emory Univ, Sch Med, Dept Med & Microbiol & Immunol, Atlanta, GA 30303 USA; Vet Affairs Med Ctr, Res Serv, Atlanta, GA 30033 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Stephens, DS (corresponding author), Emory Univ, Sch Med, Dept Med & Microbiol & Immunol, Atlanta, GA 30303 USA.		Stephens, David S/A-8788-2012					ACHTMAN M, 1994, MOL MICROBIOL, V11, P15, DOI 10.1111/j.1365-2958.1994.tb00285.x; Andersen J, 1998, EPIDEMIOL INFECT, V121, P85, DOI 10.1017/S0950268898008930; [Anonymous], 1805, J MED CHIR PHARM; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; Jones GR, 1998, J INFECT DIS, V178, P451, DOI 10.1086/515622; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; NORTH E, 1980, REV INFECT DIS, V2, P811; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998	14	132	139	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					941	942		10.1016/S0140-6736(98)00279-7	http://dx.doi.org/10.1016/S0140-6736(98)00279-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459897				2022-12-01	WOS:000079421600003
